<SEC-DOCUMENT>0001390478-15-000037.txt : 20150806
<SEC-HEADER>0001390478-15-000037.hdr.sgml : 20150806
<ACCEPTANCE-DATETIME>20150806165802
ACCESSION NUMBER:		0001390478-15-000037
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20150630
FILED AS OF DATE:		20150806
DATE AS OF CHANGE:		20150806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		151033921

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gale-20150630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-10Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s93197D1A0E72371FB72AD437B11F592C"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">o</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 001-33958</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Galena Biopharma, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.81481481481482%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="3%"></td><td width="49%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20-8099512</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4640 SW Macadam Ave., Suite 270, Portland, OR 97239</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive office) (Zip code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number: (855)&#160;855-4253</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168; </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act (Check one):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160; </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="3%"></td><td width="40%"></td><td width="26%"></td><td width="1%"></td><td width="3%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10.5pt;"><font style="font-family:Wingdings;font-size:10.5pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10.5pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;No</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">July&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, Galena Biopharma, Inc. had outstanding </font><font style="font-family:inherit;font-size:10pt;">161,715,398</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, $0.0001 par value per share, exclusive of treasury shares.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s33BE504DE82D14AA00B3D437B1745CC2"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-Q &#8212; QUARTER ENDED June 30, 2015</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="5%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="83%"></td><td width="5%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Part</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Item</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">No.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s00C49B496172B38F04E6D437B1A5E84F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s56FEA54E8479C3C38EC0D437B1C72E4F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s56FEA54E8479C3C38EC0D437B1C72E4F">2</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Balance Sheets as of June 30, 2015 (unaudited) and December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sC90E6A605268F307BADDD437A5BD0B60">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and six months ended June 30, 2015 and 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sC1077173CB50A1FC2A4CD437A5D4300E">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statement of Stockholders' Equity (unaudited) for the six months ended June 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s09758894E03B78547A5AD437A5EBEA5F">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2015 and 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sAE40AD9F15996161AC52D437A60565BE">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8AEC0B4BA14B05FE90E0D437B3134990"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8AEC0B4BA14B05FE90E0D437B3134990">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sBECA697BAB6C6D9167CCD437B6FB4995"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9318743E7526458191ED437B6346DBB">25</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s11F3570F85823B11DA36D437B72E44DC"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s11F3570F85823B11DA36D437B72E44DC">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s8B880DF4FAB61F6B1AA2D437B74FDDFC"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8B880DF4FAB61F6B1AA2D437B74FDDFC">37</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s5D178B64068D10861B22D437B782D15F"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Legal Proceedings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s19593798C0173A3E3DB5D437B7A222A8">38</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Risk Factors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s290DE3E2C8E86872E7CFD437B7D4A399">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#s7BFD57B5B5E849522C17D437B7F5DD66"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7BFD57B5B5E849522C17D437B7F5DD66">43</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s7BFD57B5B5E849522C17D437B7F5DD66"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Index to Exhibits</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7BFD57B5B5E849522C17D437B7F5DD66">43</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;" href="#sB4DB23F5BA9DD3E9A7F7D437B8280F44"><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB4DB23F5BA9DD3E9A7F7D437B8280F44">44</a></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EX-31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EX-31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EX-32.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s00C49B496172B38F04E6D437B1A5E84F"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><a name="s56FEA54E8479C3C38EC0D437B1C72E4F"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160; 1. FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sC90E6A605268F307BADDD437A5BD0B60"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,426</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">655</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,399</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,680</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,024</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equipment and furnishings, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Abstral rights, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Zuplenz rights</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deposits and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,923</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,669</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term debt, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,429</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; no shares issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Common stock, $0.0001&#160;par value; 275,000,000&#160;shares authorized, 161,716,381 shares issued and 162,391,381 shares outstanding at June 30, 2015; 200,000,000 shares authorized, 130,146,341&#160;shares issued and 129,471,341 shares&#160;outstanding at December&#160;31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">294,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">256,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(241,678</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(215,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less treasury shares at cost, 675,000 shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,365</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="sC1077173CB50A1FC2A4CD437A5D4300E"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,382</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,331</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,132</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,504</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cost of revenue (excluding amortization of certain acquired intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">347</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">861</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">678</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,878</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,430</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of certain acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,527</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-operating income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(314</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(449</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total non-operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,660</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted-average common shares outstanding: basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">161,383,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">118,083,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">148,647,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,154,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="s09758894E03B78547A5AD437A5EBEA5F"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td width="41%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional Paid-In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">130,146,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">256,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(215,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32,158,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47,413</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants issued in connection with March 2015 common stock offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock in connection with employee stock purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation for directors and employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(26,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">162,391,381</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">294,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(241,678</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="sAE40AD9F15996161AC52D437A60565BE"></a><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Amounts in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="69%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(26,197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(22,477</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustment to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">816</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">461</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(771</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(47</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,415</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(21,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid for acquisition of Zuplenz rights</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid for acquisition of GALE-401 rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid for purchase of equipment and furnishings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net proceeds from issuance of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,070</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from common stock issued in connection with ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Principle payments on long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">45,613</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,739</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents at the beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47,787</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">45,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash received during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid during the periods for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value of warrants issued in connection with common stock recorded as cost of equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Reclassification of warrant liabilities upon exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27,020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">See accompanying notes to condensed consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s8AEC0B4BA14B05FE90E0D437B3134990"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><a name="sB8F1C8403AC3FE6375EBD437A636640E"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.  Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena&#8217;s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax&#8482; (nelipepimut-S) currently in an international, Phase 3 clinical trial. The company&#8217;s commercial drugs include Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film. Collectively, our clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to&#160;improve cancer care,&#160;from direct treatment of the disease to the reduction of its debilitating side-effects.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our targeted cancer immunotherapy approach is based upon preventing recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow.  Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care.  Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have undetected minimal residual disease.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapies utilize immunologically active peptides combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to target, seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system through an intradermal mode of delivery.  We are currently engaged in multiple clinical trials with NeuVax&#8482;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">(nelipepimut-S) and GALE-301, or Folate Binding Protein (FBP), targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a targeted cancer immunotherapy and is being developed for the prevention of cancer recurrence in human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nona-peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may be a predictive factor of Disease Free Survival (DFS) and Overall Survival (OS) - suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to the HLA A2, A3, A24 or A26 proteins on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including undetected occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our global pivotal, fully enrolled, Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">arly-</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">reatment) trial, NeuVax is targeting the 30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of population). NeuVax has also been shown to bind to A24 and A26 which represents an additional 10-15% of the population in the U.S., but importantly, represents up to 70% of the population in Japan. Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor.  These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographic footprint of NeuVax:</font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;E</font><font style="font-family:inherit;font-size:10pt;">arly- </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:inherit;font-size:10pt;">reatment) study has completed enrollment of 758 patients with HER2 1+ and 2+ under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is fully enrolled with trial sites in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">www.neuvax.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative HLA A2/A3/A24/A26 breast cancer patients to study NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; Genentech/Roche) in the adjuvant setting. This trial is partially funded by Genentech/Roche.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with Herceptin. The study will enroll 100 patients who are neoadjuvantly treated node positive and negative HER2 IHC 3+ patients, not achieving a pathological complete response (pCR) or adjuvantly treated node positive HER2 IHC 3+ patients. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program (CDMRP) which is funded through specific requests from individual members of Congress that are part of the Defense Appropriations Act. Funds are "set aside" (obligated) in entirety at the time of assistance agreement award. The grant was awarded under a Breast Cancer Research Program (BCRP) Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Planned: In January 2014, we partnered with Dr.&#160;Reddy&#8217;s Laboratories, Ltd. in India for the commercialization of NeuVax in that region. Dr.&#160;Reddy&#8217;s is responsible for managing a Phase 2 gastric cancer trial of NeuVax in India in patients that express any level of HER2 (1+, 2+, and 3+). The trial  is expected to initiate in 2016. </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-301 (folate binding protein or FBP)</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second immunotherapy product candidate, GALE-301, targets folate binding protein receptor-alpha, a well-validated therapeutic target, which</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. GALE-301 is an immunogenic peptide and can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of an FBP peptide combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. Current treatments for these diseases are principally with chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in May 2015 at the American Society of Clinical Oncology conference and demonstrated the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence, and that the agent was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;immune response. We expect to present a more mature data set from the Phase 2a trial this Fall at the European Society for Medical Oncology European Cancer Congress 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide (Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Shire Pharmaceuticals), an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;">) is hypothesized to reduce the side effects, but preserve efficacy. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;">&#32;of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK (pharmacokinetic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial.  The Phase 2, open label, single arm trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20th Congress. We expect to present a more mature data set from the Phase 2 trial later this year. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401, with the reference drug Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(anagrelide; Shire Pharmaceuticals).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commercial Capabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Abstral</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(fentanyl) Sublingual Tablets</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first commercial product, Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets, is an important treatment option for inadequately controlled breakthrough cancer pain (BTcP), which affects more than 50% of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a convenient sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain in minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. Abstral is manufactured for us by contract manufacturers and we distribute and sell Abstral in the U.S. through our commercial organization. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Zuplenz</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(ondansetron) Oral Soluble Film</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014 we licensed our second commercial product, Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film, from MonoSol Rx, LLC, which we launched on July 29, 2015. Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. It is estimated that up to </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;">&#32;of chemotherapy and up to 80% of radiotherapy patients will experience CINV and RINV, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">3</sub></font><font style="font-family:inherit;font-size:10pt;">&#32;receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Ondansetron is the most widely prescribed drug in this class of anti-emetics, and used broadly across the oncology spectrum. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tables (ODT) with a safety profile equivalent to ondansetron.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology, an oral soluble film that dissolves on the tongue in less than 30 seconds. Zuplenz eliminates the burden of swallowing pills during periods of emesis, may be advantageous for patients with oral irritation, and may increase patient adherence and the patient's ability to keep the medication down without vomiting. MonoSol will exclusively manufacture Zuplenz for us for sale in the U.S. through our commercial organization.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable -</font><font style="font-family:inherit;font-size:10pt;">&#32;The company maintains credit limits for all customers based upon several factors, including but not limited to financial condition and stability, payment history, published credit reports and use of credit references. Management performs analysis to evaluate accounts receivables to ensure recorded amounts reflect estimated net realizable value. An allowance for doubtful accounts is established based on the Company's best estimate of the amount of probable credit losses in the Company's accounts receivable. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, 2014 the allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Inventories are stated at the lower of cost or market value and are determined using the first-in, first-out ("FIFO") method. Inventories consist of work-in-process and finished goods of our commercial products. The company has entered into manufacturing and supply agreements for the manufacture and final packaging of Abstral and Zuplenz finished goods. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company had inventories of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,426,000</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,264,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of work-in-process and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$162,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of finished goods. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the company had inventories of </font><font style="font-family:inherit;font-size:10pt;">$655,000</font><font style="font-family:inherit;font-size:10pt;">&#32;consisting of </font><font style="font-family:inherit;font-size:10pt;">$455,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of work-in-process and </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of finished goods.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">&#32;- The company recognizes revenue from the sale of Abstral. No revenue has been recorded from the sale of Zuplenz as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell Abstral product in the United States to wholesale pharmaceutical distributors and retail pharmacies, or our "customers," subject to rights of return. We recognize Abstral product sales at the time title transfers to our customer, and provide allowances for estimated future product returns, prompt pay discounts, wholesaler discounts, rebates, chargebacks, patient assistance program benefits and other deductions as needed. The company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the company will be required to make adjustments to these allowances in the future.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Returns - The company estimates future returns based on historical return information, as well as information regarding prescription information and sell-through trends, in relation to the estimated amount of product in the sales channels and product expiration dates. The allowance for returns is recorded as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prompt Pay Discounts - As an incentive for prompt payment, the company offers a cash discount to customers, which is generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;of gross sales. The company expects that all customers will comply with the contractual terms to earn the discount. The company records prompt pay discounts as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wholesaler Discounts - The company offers discounts on sales to wholesalers and distributors based on contractually determined rates. The company accrues the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates - The company participates in certain rebate programs, which provide discounted prescriptions to members of certain managed care organizations, group purchasing organizations and specialty pharmacies. Under these rebate programs, the company pays the rebates generally two to three months after the end of the quarter in which prescriptions subject to the rebate are filled. The company estimates and accrues these rebates based on current contract prices, historical and estimated future percentages of product sold to qualifying member pharmacies and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction to revenue in the period that the related revenue is recognized, with a corresponding liability in accrued expenses and other current liabilities.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks - The company provides discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid or Medicare contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the company the difference between the current retail price and the price the entity paid for the product. The company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historic chargeback activity. Chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient Assistance Programs - The company offers discount card programs to eligible patients for Abstral in which those patients receive discounts on their Abstral prescriptions that are reimbursed by the company. The company estimates the total amount that will be recognized based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognizes the discount as a reduction of revenue and as an other current liability (see Note 4) in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:inherit;font-size:10pt;">&#32;For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:inherit;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:inherit;font-size:10pt;">&#32;These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:inherit;font-size:10pt;">&#32;requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was no income tax expense or benefit for the three and six months periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><a name="s4D004929366F5F913218D437A64953FB"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Business Combinations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014 the Company entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film (Zuplenz), an FDA approved product. The transaction was accounted for as a business combination under the acquisition method of accounting based on Accounting Standards Codification 805, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations.</font><font style="font-family:inherit;font-size:10pt;">" Accordingly, the assets acquired and liabilities assumed were recorded at fair value. As of the issuance date of the condensed consolidated financial statements for the quarter ended June 30, 2015, the Company finalized the valuation of the acquired assets and liabilities for the transaction. Specifically, more complete information for credit memos for expiring channel inventory and the anticipated gross-to-net deductions on the replacement inventory was provided in order to finalize the business combination accounting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price consideration and allocation of purchase price:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.39024390243902%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="75%"></td><td width="1%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Acquisition Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase price consideration:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities assumed:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring channel inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset acquired:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above contingent consideration represents a risk adjusted net present value relating to cash payments on achievement of certain milestones.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sD2139894DA65046740BED437A654FAC3"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.  Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company did not transfer any financial instruments into or out of Level 3 classification during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="86%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><a name="sB3C133802200C341BBABD437A67E4B6A"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.  Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="70%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring Zuplenz channel inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient assistance programs and rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory purchases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sB2C4FF77E8D84233BFCFD437A68A9A5E"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.  Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "Loan"). The Loan payment terms include </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12</font><font style="font-family:inherit;font-size:10pt;">&#32;months of interest-only payments at the fixed coupon rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.45%</font><font style="font-family:inherit;font-size:10pt;">, followed by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;cash facility fee and a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;cash final payment and granted to the lenders </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">seven</font><font style="font-family:inherit;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">182,186</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.47</font><font style="font-family:inherit;font-size:10pt;">, which equaled a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">-day average market price of our common stock prior to the date of the grant.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s09F063AB2104F2C3B121D437A68F606D"></a><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Stockholder Derivative Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 23, 2015, U.S. District Court for the District of Oregon heard argument on the defendants&#8217; motion to stay and motion to dismiss.  On February 4, 2015, the District Court granted in part the motion to stay by staying any discovery until the ruling on the motion to dismiss.  On August 5, 2015, the District Court issued its decision by denying in part and granting in part defendants&#8217; motion to dismiss and granting plaintiffs leave to file an amended complaint. The court had stayed the derivative proceeding pending the outcome of the motion to dismiss in the securities class action case. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 4, 2105, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of June 30, 2015, we have not recorded any</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurer for substantially all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By letter dated December 23, 2014, Orexo and we received a Paragraph IV certification notice (Notice Letter) regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by Actavis Laboratories FL, Inc. (Actavis) requesting approval </font><font style="font-family:inherit;font-size:10pt;color:#404040;">to engage in the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">an</font><font style="font-family:inherit;font-size:10pt;color:#282828;">ufacture</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">use </font><font style="font-family:inherit;font-size:10pt;color:#565656;">or sale </font><font style="font-family:inherit;font-size:10pt;color:#404040;">of generic versions of the Abstral sublingual </font><font style="font-family:inherit;font-size:10pt;color:#282828;">t</font><font style="font-family:inherit;font-size:10pt;color:#565656;">a</font><font style="font-family:inherit;font-size:10pt;color:#282828;">blets</font><font style="font-family:inherit;font-size:10pt;color:#565656;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.1 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.2 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">g </font><font style="font-family:inherit;font-size:10pt;color:#404040;">base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">E</font><font style="font-family:inherit;font-size:10pt;color:#282828;">q </font><font style="font-family:inherit;font-size:10pt;color:#404040;">0.3 mg base, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">Eq 0.4 </font><font style="font-family:inherit;font-size:10pt;color:#404040;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.6 mg base and Eq 0.8 mg base. In the Notice Letter, Actavis </font><font style="font-family:inherit;font-size:10pt;">contends that the patents held by Orexo for Abstral that are listed in the Orange Book (U.S. Patents 6,759,059, 6,761,910 and 7,910,132, which cover compositions, formulations and methods of using Abstral and which expire in September 2019) and which are licensed to us under the Orexo License Agreement, are invalid, unenforceable and/or will not be infringed by the manufacture, use, or sale of the product set forth in the ANDA. On February 4, 2015, Orexo filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories Fl, Inc., Andrx Corporation, Actavis, Inc., and Actavis Pharma, Inc.  All of the defendants except Actavis Laboratories FL, Inc. were subsequently dismissed. Actavis has filed an answer and counterclaim. The lawsuit claims infringement of the three patents.  Orexo filed the lawsuit within 45 days from the receipt of the Notice Letter and under the Hatch-Waxman Act, the final FDA approval of Actavis&#8217; ANDA will be stayed up to 30 months from the date of receipt of the Notice Letter.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A scheduling conference was held on July 9, 2015, in the District Court and on July 10, 2015, the District Court issued a pre-trial scheduling order. The parties are now engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated under Orexo License Agreement to pay for </font><font style="font-family:inherit;font-size:10pt;">88%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the legal costs of the patent infringement lawsuit.  We intend to work with Orexo to continue to vigorously enforce intellectual property rights related to the Abstral product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments. </font></div><div style="line-height:120%;text-align:left;padding-left:40px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><a name="s12EA4E4E01BB42958D2CD437A69030B8"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.  Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company has authorized up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company has authorized up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">275,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">&#160;par value per share, for issuance.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:inherit;font-size:10pt;">On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of the company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:inherit;font-size:10pt;">36</font><font style="font-family:inherit;font-size:10pt;">&#32;month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the company's common stock at </font><font style="font-family:inherit;font-size:10pt;">$2.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the company issued </font><font style="font-family:inherit;font-size:10pt;">631,221</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:inherit;font-size:10pt;">2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, excluding the commitment fee shares. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:inherit;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds from the sale of </font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended June 30, 2015 or during the three and six months ended June 30, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:inherit;font-size:10pt;">&#32;- On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">24,358,974</font><font style="font-family:inherit;font-size:10pt;">&#32;units at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$1.56</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$38 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;">&#32;of a share of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.08</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for additional net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:inherit;font-size:10pt;">$40.8 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="84%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><a name="s9F7802E0682C26D8E61FD437A6AC2EBA"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.  Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="21%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="23%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><a name="s9F7802E0682C26D8E61FD437A6AC2EBA"></a><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td width="24%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">182,186</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.47</font><font style="font-family:inherit;font-size:10pt;">, which equaled to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">75.34%</font><font style="font-family:inherit;font-size:10pt;">, expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">seven</font><font style="font-family:inherit;font-size:10pt;">&#32;years, risk-free rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.20%</font><font style="font-family:inherit;font-size:10pt;">, and a dividend rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.00%</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.93</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sFADA75EFA51A034859C2D437A7115049"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.  Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8212; The company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="45%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.14</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company&#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the company&#8217;s options of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#32;with the average vesting term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four years</font><font style="font-family:inherit;font-size:10pt;">&#32;for an average of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six years</font><font style="font-family:inherit;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;for options granted to its employees, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8%</font><font style="font-family:inherit;font-size:10pt;">&#32;for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,582,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.54</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">26,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock were reserved for issuance under the company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">11,411,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,066,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four years</font><font style="font-family:inherit;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="53%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were calculated based on the closing price of the company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&#8217;s common stock and the exercise price of the underlying options.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><a name="sE064192DD08B05AAB01ED437A73B7EC8"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 10. Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="43%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s083CA7BD65D22D91180DD437A748559D"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.  Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="67%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Three and Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sE07E9105E48668CF5A5BD437A74DC918"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.  License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the acquisition of NeuVax</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$200,000</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March&#160;18, 2013, we acquired Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets, a transmucosal immediate-release fentanyl (TIRF) product, for sale and distribution in the United States from Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, and exclusively licensed certain intellectual property from Orexo to use, distribute, market, sell, offer for sale Abstral solely in the United States and to non-exclusively manufacture Abstral for use, distribute, market, sell, offer for sale and import Abstral solely in the United States. Abstral has been approved by the U.S. Food and Drug Administration (FDA).</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our agreement with Orexo, we assumed responsibility for the U.S. commercialization of Abstral and for all regulatory and reporting matters in the U.S. We also agreed to establish and maintain through 2015 (marketing period) a specified minimum commercial field force to market, sell and distribute Abstral and to use commercially reasonable efforts to reach the specified sales milestones. Orexo is entitled to reacquire the U.S. rights to Abstral from us for no consideration if we breach our obligations to establish and maintain the requisite sales force throughout the marketing period. We expect to maintain our sales efforts beyond this date. We officially launched U.S. commercial sales of Abstral in October 2013.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In exchange for the U.S. rights to Abstral, (1)&#160;we paid Orexo </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront, and a&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment in cash in October 2013 upon the approval by the FDA of a specified U.S. manufacturer of Abstral; and (2)&#160;we agreed to pay to Orexo: (a)&#160;three one-time future cash milestone payments based on our net sales of Abstral; and (b)&#160;a low double-digit royalty on future net sales. No further milestone or royalty payments will be due after the date on which all claims of the last remaining licensed patents expire (currently </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">) or become invalidated by a patent office, court, or other governmental agency of competent jurisdiction in a final and non-appealable judgment. In exchange of license, Galena agreed to pay eight-eight percent of the expenses and costs incurred to prosecute any ANDA action..</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014, we entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film, an FDA-approved product for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). In exchange for the U.S. rights to Zuplenz, and in connection with the effectiveness of the license and transfer to us of the New Drug Application (NDA) for Zuplenz, we paid MonoSol a total of </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and shares of our common stock in 2014 and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash in 2015. In addition to these payments, we will pay MonoSol </font><font style="font-family:inherit;font-size:10pt;">$0.25 million</font><font style="font-family:inherit;font-size:10pt;">&#32;within </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;days after MonoSol&#8217;s payment of applicable fees relating to the notice of allowance by the United States Patent and Trademark Office of a U.S. patent with composition claims covering Zuplenz that extend beyond 2028, (ii) future cash milestone payments of up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on our achievement of specified &#8220;net sales&#8221; of Zuplenz in amounts ranging from </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">, and (iii) a low double-digit royalty on future &#8220;net sales.&#8221;</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s33BE504DE82D14AA00B3D437B1745CC2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div></div><br><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the license agreement, we assumed responsibility for the commercialization of Zuplenz and for all regulatory and reporting matters in the U.S. We also agreed in the license and supply agreement to use our best commercial efforts to begin commercializing Zuplenz in the U.S. in accordance with a joint commercialization plan to be established by the company and MonoSol. We also agreed that, until net sales of Zuplenz exceed a specified minimum amount or a competing product has been approved by the FDA and is placed into the market for sale, we will maintain a specified minimum number of field sales force personnel on specified terms.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the license and supply agreement, MonoSol has the exclusive right to supply all of our requirements for Zuplenz, subject to certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sC91B4A91EB5448904289D437A751D66B"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.  Significant Customers and Concentration of Credit Risk</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company is engaged in the business of developing and commercializing pharmaceutical products. As of June 30, 2015, the Company had sales from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;active commercial product, Abstral, available in </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;dosing strengths, and all sales reported are in the United States.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales to the following customers represented </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;or more of net revenue during at least </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;of the periods are presented as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="40%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="70%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to concentrations in our customer base, concentrations also exist with respect to the dispensing pharmacies to which our customers sell Abstral. For example </font><font style="font-family:inherit;font-size:10pt;">47%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">57%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;pharmacies for the three month periods ending June 30, 2015 and 2014, respectively. Additionally, </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">59%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">&#32;pharmacies for the six months periods ending June 30, 2015 and 2014, respectively.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s7EEA1BC9319223DCF807D437A769FD51"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14.  Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company evaluated all events or transactions that occurred after </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><a name="sC9318743E7526458191ED437B6346DBB"></a><div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In this </font><font style="font-family:inherit;font-size:10pt;">section</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, "Galena," &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours&#8221; and &#8220;us&#8221; refer to Galena Biopharma, Inc. and its consolidated subsidiaries, Apthera, Inc., or &#8220;Apthera,&#8221; and Mills Pharmaceuticals, LLC, or "Mills."</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This management&#8217;s discussion and analysis of financial condition as of June 30, 2015 and results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;months ended June 30, 2015 and 2014, respectively, should be read in conjunction with management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 which was filed with the SEC on March 5, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The discussion and analysis below includes certain forward-looking statements related to the commercialization of our products in the U.S., our future financial condition and results of operations and potential for profitability, the sufficiency of our cash resources, our ability to obtain additional equity or debt financing, possible partnering or other strategic opportunities for the development of our products, as well as other statements related to the progress and timing of our product commercialization and development activities, present or future licensing, collaborative or financing arrangements or that otherwise relate to future periods, which are all forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements represent, among other things, the expectations, beliefs, plans and objectives of management and/or assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; and &#8220;expect&#8221; and similar expressions are intended to connote forward-looking statements. All forward-looking statements involve certain risks, including the uncertainties and other factors described in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 that could cause our actual commercialization efforts, development activities, financial condition and results of operations, and business prospects and opportunities to differ materially from these expressed in, or implied by, those forward-looking statements. We caution investors not to place significant reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated) and we undertake no obligation to update or revise forward-looking statements.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><a name="sA08C0BF6F2C6422A2DABD437B656A38B"></a><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology therapeutics that address major unmet medical needs across the full spectrum of cancer care. Galena&#8217;s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax&#8482; (nelipepimut-S) currently in an international, Phase 3 clinical trial. The company&#8217;s commercial drugs include Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film. Collectively, our clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to&#160;improve cancer care,&#160;from direct treatment of the disease to the reduction of its debilitating side-effects.&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:17px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are seeking to build value for shareholders through pursuit of the following objectives:</font></div><div style="line-height:120%;text-align:left;padding-left:17px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Develop novel cancer immunotherapies</font><font style="font-family:inherit;font-size:10pt;">&#32;to address unmet medical needs through the use of peptide based vaccines targeting well-established tumor antigens in the adjuvant, minimum residual disease setting, in high risk patients who are more likely to benefit from treatment via immunotherapy. Our immunotherapy programs currently seek to significantly decrease the risk of disease recurrence in breast, gastric, endometrial and ovarian cancers.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expand our development pipeline</font><font style="font-family:inherit;font-size:10pt;">&#32;by enhancing the potential clinical and geographic footprint of our technologies. We can accomplish this through the initiation of additional clinical trials as well as through acquisition of additional development stage products in related oncology indications.  We also seek to leverage valuable partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Maintain commercial capabilities</font><font style="font-family:inherit;font-size:10pt;">&#32;to sell, market, and distribute oncology related pharmaceutical products in the U.S. through our established commercial infrastructure. This commercial strategy creates the opportunity to generate accretive cash flows to support our development programs, and also provides future leverage to support the potential commercialization of our clinical stage technologies in one of the world's largest economic markets.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The chart below summarizes the current status of our pipeline:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:66px;"><img src="pipeline4302015a01.jpg" style="height:388px;width:640px;"></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><a name="sA08C0BF6F2C6422A2DABD437B656A38B"></a><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our targeted cancer immunotherapy approach is based upon preventing recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow.  Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care.  Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have undetected minimal residual disease.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapies utilize immunologically active peptides combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to target, seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system through a convenient, and a patient friendly intradermal mode of delivery.  We are currently engaged in multiple clinical trials with NeuVax&#8482;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">(nelipepimut-S) and GALE-301, or Folate Binding Protein (FBP), targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a targeted cancer immunotherapy and is being developed for the prevention of cancer recurrence in human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nona-peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may be a predictive factor of Disease Free Survival (DFS) and Overall Survival (OS) - suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to the HLA A2, A3, A24 or A26 proteins on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including undetected occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Breast Cancer</font><font style="font-family:inherit;font-size:10pt;">: According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% of breast cancer patients have tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients - those with HER2 immunohistochemistry (IHC) 3+ disease, or IHC 2+ and fluorescence </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in situ</font><font style="font-family:inherit;font-size:10pt;">&#32;hybridization (FISH) positive - have an approved treatment option available. This leaves the majority of breast cancer patients with low-to-intermediate HER2 IHC 1+/2+ ineligible for targeted therapy and without an effective treatment option to prevent cancer recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our global pivotal, fully enrolled, Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">arly-</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">reatment) trial, NeuVax is targeting the 30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of population). NeuVax has also been shown to bind to A24 and A26 which represents an additional 10-15% of the population in the U.S., but importantly, represents up to 70% of the population in Japan. Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor.  These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><a name="sA08C0BF6F2C6422A2DABD437B656A38B"></a><br><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Gastric Cancer</font><font style="font-family:inherit;font-size:10pt;">: Gastric cancer (also known as stomach cancer) is a disease in which the cells forming the inner lining of the stomach become abnormal and start to divide uncontrollably, forming a cancerous tumor mass. Cancer can develop in any of the five sections of the stomach. Symptoms and outcomes of the disease will vary depending on the location of the cancer. Stomach cancer is one of the leading causes of cancer deaths in several areas of the world, most notably in Asian countries. Annually, almost one million people will be diagnosed worldwide with stomach cancer and over 700,000 will die from the disease. More than 90% of stomach cancers are caused by adenocarcinomas, malignant cancers that originate in glandular tissues. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Overall, only approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographic footprint of NeuVax:</font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;E</font><font style="font-family:inherit;font-size:10pt;">arly- </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:inherit;font-size:10pt;">reatment) study has completed enrollment of 758 patients with HER2 1+ and 2+ under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is fully enrolled with trial sites in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">www.neuvax.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative HLA A2/A3/A24/A26 breast cancer patients to study NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; Genentech/Roche) in the adjuvant setting. This trial is partially funded by Genentech/Roche.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with Herceptin. The study will enroll 100 patients who are neoadjuvantly treated node positive and negative HER2 IHC 3+ patients, not achieving a pathological complete response (pCR) or adjuvantly treated node positive HER2 IHC 3+ patients. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program (CDMRP) which is funded through specific requests from individual members of Congress that are part of the Defense Appropriations Act. Funds are "set aside" (obligated) in entirety at the time of assistance agreement award. The grant was awarded under a Breast Cancer Research Program (BCRP) Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Planned: In January 2014, we partnered with Dr.&#160;Reddy&#8217;s Laboratories, Ltd. in India for the commercialization of NeuVax in that region. Dr.&#160;Reddy&#8217;s is responsible for managing a Phase 2 gastric cancer trial of NeuVax in India in patients that express any level of HER2 (1+, 2+, and 3+). The trial  is expected to initiate in 2016. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-301 (folate binding protein or FBP)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second immunotherapy product candidate, GALE-301, targets folate binding protein receptor-alpha, a well-validated therapeutic target, which</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. GALE-301 is an immunogenic peptide and can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of an FBP peptide combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. Current treatments for these diseases are principally with chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in May 2015 at the American Society of Clinical Oncology conference and demonstrated the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence, and that the agent was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;immune response. We expect to present a more mature data set from the Phase 2a trial this Fall at the European Society for Medical Oncology European Cancer Congress 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><a name="sA08C0BF6F2C6422A2DABD437B656A38B"></a><br><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ovarian and Endometrial Cancer</font><font style="font-family:inherit;font-size:10pt;">: Ovarian cancer occurs in more than 22,000 patients per year in the U.S. and is the most lethal gynecologic cancer. Despite the incidence of ovarian cancer being only approximately 10% of that of breast cancer, the number of patients who die from ovarian cancer is nearly 50% that of breast cancer. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease. For their treatment, these patients typically have their tumors surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While most patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse, and once the disease recurs, the treatment options and successes drop dramatically. Endometrial cancer is the most common gynecologic cancer and occurs in more than 46,000 women with more than 8,000 deaths in the U.S. annually. There are two basic types of endometrial cancer: endometrioid and papillary serous. The latter has a much more aggressive clinical course and the majority of these patients will die of this form of the disease.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide (Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Shire Pharmaceuticals), an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;">) is hypothesized to reduce the side effects, but preserve efficacy. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;">&#32;of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK (pharmacokinetic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial.  The Phase 2, open label, single arm trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20th Congress. We expect to present a more mature data set from the Phase 2 trial later this year. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401, with the reference drug Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(anagrelide; Shire Pharmaceuticals).</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Myeloproliferative neoplasms</font><font style="font-family:inherit;font-size:10pt;">: MPNs are a closely related group of hematological malignancies in which the bone marrow cells that produce the body's blood cells develop and function abnormally. The main myeloproliferative neoplasms are Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), and Chronic Myelogenous Leukemia (CML), all of which are associated with high platelet counts.  The MPNs are progressive blood cancers that can strike anyone at any age, and for which there is no known cure.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commercial Capabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Though we primarily develop innovative, targeted oncology therapeutics that address major unmet medical needs across the full spectrum of cancer care, we have established a commercial operation to market and sale acquired commercial products. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Abstral</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(fentanyl) Sublingual Tablets</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first commercial product, Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(fentanyl) Sublingual Tablets, is an important treatment option for inadequately controlled breakthrough cancer pain (BTcP), which affects more than 50% of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a convenient sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain in minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. Abstral is manufactured for us by contract manufacturers and we distribute and sell Abstral in the U.S. through our commercial organization. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><a name="sA08C0BF6F2C6422A2DABD437B656A38B"></a><br><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Zuplenz</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(ondansetron) Oral Soluble Film</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014 we licensed our second commercial product, Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ondansetron) Oral Soluble Film, from MonoSol Rx, LLC, which we launched on July 29, 2015. Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. It is estimated that up to 90% of chemotherapy and up to 80% of radiotherapy patients will experience CINV and RINV, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">3</sub></font><font style="font-family:inherit;font-size:10pt;">&#32;receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Ondansetron is the most widely prescribed drug in this class of anti-emetics, and used broadly across the oncology spectrum. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tables (ODT) with a safety profile equivalent to ondansetron.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology, an oral soluble film that dissolves on the tongue in less than 30 seconds. Zuplenz eliminates the burden of swallowing pills during periods of emesis, may be advantageous for patients with oral irritation, and may increase patient adherence and the patient's ability to keep the medication down without vomiting. MonoSol will exclusively manufacture Zuplenz for us for sale in the U.S. through our commercial organization.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sBF0D81FDC4B15945C6FDD437B6873E07"></a><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Operational Developments (in reverse chronological order)</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Launched Zuplenz - We officially launched Zuplenz</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">&#32;(ondansetron) oral soluble film.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29/30, 2015, we announced the official launch of Zuplenz (ondansetron) Oral Soluble Film, in the United States.  Zuplenz is now available nationwide and is supplied in both 4 mg and 8 mg ondansetron doses. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron.  The novel, PharmFilm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rapidly dissolves in the mouth in about 10 seconds. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eliminates the burden of swallowing pills during emesis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Does not require water to administer, making it ideal in cases of oral irritation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pleasant peppermint flavor with no gritty aftertaste.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonsedating.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz is approved in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV).  Zuplenz is also approved for moderately emetogenic CINV in pediatric patients four years and older.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active pharmaceutical ingredient in Zuplenz, ondansetron, is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. The National Comprehensive Cancer Network (NCCN) 2014 guidelines recommend the use of ondansetron in patients with highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.  Ondansetron belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. The product was licensed from MonoSol Rx, LLC, the developer of the oral soluble film technology, PharmFilm&#174;, and manufacturer of the product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">GALE 401 Phase 2 clinical trial data presented</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We presented data from our Phase 2 clinical trial of GALE-401 at the European Hematology Association 20</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Congress in Vienna, Austria.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 15, 2015, we announced our poster presentation entitled "Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,"&#160;which was presented on June 13, 2015.&#160;The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled.&#160;The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18).&#160;The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 versus anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is expected to be presented later this year.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Published Abstracts related to GALE-301 and Leica Biosystem&#8217;s Companion Diagnostic</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We presented two abstract publications at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 27, 2015, we announced two abstract publications at the ASCO 2015 Annual Meeting related to our cancer immunotherapy programs, one related to GALE-301 and one related to the companion diagnostic in our NeuVax Phase 3 PRESENT trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We presented data related to GALE-301 in abstract #e14031, entitled, "Preliminary Results of the Phase I/IIa Dose Finding Trial of a Folate Binding Protein Vaccine (E39+GM-CSF) in Ovarian and Endometrial Cancer Patients to Prevent Recurrence." This data showed that GALE-301 is well tolerated and elicits a strong and dose-dependent&#160;in vivo&#160;immune response. The trial is designed as a safety and dose optimization trial and is not powered for a disease free survival efficacy endpoint. However, early efficacy results from the trial are promising in the 1000 mcg dose cohort. Of the 51 patients enrolled in the trial, 29 were in the vaccinated group (15 patients at 1000 mcg vs. 14 patients at &lt; 1000 mcg) and 22 were in the control group. With 9.8 months median follow-up, the 1000 mcg vaccine dose group had only one clinical recurrence vs 11 in the control group (6.7% VG vs. 50% CG, p = 0.01). Combining all dose groups, the complete response (CR) rate was 38% in the </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">vaccine group vs. 50% in the control group (p = 0.41). Currently, the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We presented data related to our NeuVax Phase 3 PRESENT trial companion diagnostic in abstract #e11609, entitled, "Analytical Validation of BOND Oracle HER2 IHC System for Identifying Low to Intermediate HER2 Expressing Breast Cancer in NeuVax PRESENT Phase 3 Clinical Trial." This data demonstrated a direct correlation between cell line receptor load, quantitative measure of HER2 protein, and IHC score. The ability to discriminate HER2 protein expression at the low and intermediate levels in breast cancer tumors will identify patients for new treatments in development such as NeuVax. Specifically, the validation of the Bond Oracle HER2 IHC System to distinguish lower levels of HER2+ expressions supports its use as a companion diagnostic.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">NeuVax Phase 3 PRESENT Over-Enrollment Completed</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced the completion of enrollment in our NeuVax Phase 3 PRESENT clinical trial.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 14, 2015 we announced the completion of enrollment in the NeuVax&#8482; (nelipepimut-S) Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">arly-</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:inherit;font-size:10pt;">reatment) clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. As anticipated, we over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat (ITT) population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment (SPA), called for 700 patients; and, the Company expects this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th&#160;month of treatment, or a total of 141 events (recurrence or death) occur, whichever comes later.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Expanded Patient Population in NeuVax Combination Trial</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- We announced the expansion of the patient population in the NeuVax and trastuzumab combination trial in HER2 1+/2+ patients to include HLA A24+ and HLA-A26+ patients.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2015, we announce that human leukocyte antigen (HLA) - A24+ or HLA-A26+ women are now eligible for enrollment into the ongoing Phase 2b clinical trial with NeuVax&#8482; (nelipepimut-S) in combination with trastuzumab (Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; Genentech/Roche). The trial evaluates node positive and triple negative, node negative breast cancer patients with immunohistochemistry (IHC) HER2 1+/2+ expressing tumors who are disease-free after standard of care therapy.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Enrolled 700</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:underline;">Patient in NeuVax Phase 3 PRESENT Clinical Trial</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;- We announced enrollment of the 700</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;patient in our Phase 3 PRESENT clinical trial.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 9, 2015, we announced the enrollment of the 700</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;patient in the NeuVax&#8482; (nelipepimut-S) Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">arly-</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">reatment) clinical trial.  Seven hundred is the patient enrollment target as defined by the PRESENT Phase 3 clinical trial protocol.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><a name="sB6346B2A437695DA5237D437AAADEB23"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Three and Six Months Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and 2014 </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our net loss was approximately </font><font style="font-family:inherit;font-size:10pt;">$15.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:inherit;font-size:10pt;">$19.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The net loss decreased by </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, or approximately </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">, primarily attributable to a $4.6 million dollar reduction in our operating loss, discussed in more detail below, partially offset by a $0.9 million increase in our non-cash loss on our warrant liability.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our net loss was approximately </font><font style="font-family:inherit;font-size:10pt;">$26.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared with a net loss of </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The net loss increased by </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">, or approximately </font><font style="font-family:inherit;font-size:10pt;">17%</font><font style="font-family:inherit;font-size:10pt;">, primarily attributable to a $6.4 million non-cash gain on our warrant liability for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to a $3.1 million non-cash loss on our warrant liability for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, partially offset by a $5.3 million reduction in our operating loss, discussed in more detail below.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abstral is our first commercial product and revenue was recorded for the first time during the year ended December&#160;31, 2013. We acquired our second commercial product, Zuplenz, in the third quarter of 2014 and launched the product in July 2015. There was no gross or net revenue from the sale of Zuplenz in any of the periods presented. For these reasons, we expect our future results of operations may differ materially from our historical results. We expect to continue to incur significant costs and expenses in connection with our commercial operations in the U.S. We must achieve higher net sales before realizing a profit from the sale and distribution of our commercial products. Further analysis of the changes and trends in our operating results are discussed below.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company recognizes revenue from the sale of Abstral to wholesale pharmaceutical distributors and retail pharmacies, net of product-related discounts, allowances, an estimate of product returns, rebates, chargebacks, and patient assistance benefits, as applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross revenue for the three and six months ended June 30, 2015 and 2014 was comprised of gross to net deductions and net revenue as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="gale-201506_chartx46249.jpg" style="height:332px;width:332px;"><img src="gale-201506_chartx47273.jpg" style="height:332px;width:332px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:446px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="22px"></td><td width="200px"></td><td width="22px"></td><td width="200px"></td></tr><tr><td style="vertical-align:bottom;background-color:#0094ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenue</font></div></td><td style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross to net deductions</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><a name="sB6346B2A437695DA5237D437AAADEB23"></a><br><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenue for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;increased </font><font style="font-family:inherit;font-size:10pt;">45%</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The increase was a result of a </font><font style="font-family:inherit;font-size:10pt;">38%</font><font style="font-family:inherit;font-size:10pt;">&#32;improvement in the gross to net deductions and a </font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in gross revenue. In March of 2014 we launched the Galena Patient Services (GPS) program, a full service support program designed to navigate patient access to Abstral that is coordinated through a third party vendor.  Along with the launch of GPS, we also made changes to our patient assistance program (PAP) to reduce the use of free product vouchers and rely more heavily upon an expedited prior authorization process. The success of the GPS program has resulted in a significant improvement in our gross to net deductions as a percent of gross revenue. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Overall prescription demand increased </font><font style="font-family:inherit;font-size:10pt;">23%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. More importantly, non-voucher prescriptions increased </font><font style="font-family:inherit;font-size:10pt;">77%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, as a direct result of the successful implementation of our GPS program and the changes to our PAP program resulting in a reduction in the percentage of our prescriptions being filled with vouchers. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenue for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;increased </font><font style="font-family:inherit;font-size:10pt;">36%</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The increase was a result of a </font><font style="font-family:inherit;font-size:10pt;">38%</font><font style="font-family:inherit;font-size:10pt;">&#32;improvement in the gross to net deductions and gross revenues increased nominally. In March of 2014 we launched the Galena Patient Services (GPS) program, a full service support program designed to navigate patient access to Abstral that is coordinated through a third party vendor.  Along with the launch of GPS, we also made changes to our patient assistance program to reduce the use of free product vouchers and rely more heavily upon an expedited prior authorization process. The success of the GPS program has resulted in a significant improvement in our gross to net deductions as a percent of gross revenue. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Overall prescription demand increased </font><font style="font-family:inherit;font-size:10pt;">16%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. More importantly, non-voucher prescriptions increased </font><font style="font-family:inherit;font-size:10pt;">92%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, as a direct result of the successful implementation of our GPS program and the changes to our PAP program resulting in a reduction in the percentage of our prescriptions being filled with vouchers. Our current expectations for</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2015 net revenue from the sale of our commercial products is approximately $15 million, but there is no assurance we will achieve our expectations. We acquired our second commercial product, Zuplenz, in the third quarter of 2014 and launched the product in July 2015. No revenue has been recorded from the sale of Zuplenz in the periods presented. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Revenue and Amortization of Certain Acquired Intangible Assets</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue and amortization of certain acquired intangible assets for the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, were as follows (dollars in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="55%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% of net revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% of net revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue (excluding amortization of certain acquired intangible assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abstral royalties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct product costs and related overhead</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cost of revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue, which excludes the amortization of certain acquired intangible assets, was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, respectively. Variable cost of revenue includes the royalty due to Orexo and product costs. Product related overhead and other cost of revenue are fixed in nature, and will decrease or increase as a percentage of net revenue as net revenue increases or decreases, respectively. Cost of revenue improved slightly as a percent of net revenue which is attributable to the </font><font style="font-family:inherit;font-size:10pt;">45%</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in net revenue for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of certain acquired intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, respectively. Amortization of certain acquired intangible assets is a non-cash variable cost based on net revenue during the period. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><a name="sB6346B2A437695DA5237D437AAADEB23"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue and amortization of certain acquired intangible assets for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, were as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="55%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% of net revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% of net revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue (excluding amortization of certain acquired intangible assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Abstral royalties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct product costs and related overhead</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other cost of revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cost of revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">678</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of certain acquired intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue, which excludes the amortization of certain acquired intangible assets, was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, respectively. Variable cost of revenue includes the royalty due to Orexo and product costs. Product related overhead and other cost of revenue are fixed in nature, and will decrease or increase as a percentage of net revenue as net revenue increases or decreases, respectively. Cost of revenue improved slightly as a percent of net revenue, which is attributable to the </font><font style="font-family:inherit;font-size:10pt;">36%</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in net revenue for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of certain acquired intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, respectively. Amortization of certain acquired intangible assets is a non-cash variable cost based on net revenue during the period. </font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense consists primarily of clinical trial expenses, compensation-related costs for our employees dedicated to research and development activities, compensation paid to our Scientific Advisory Board (&#8220;SAB&#8221;) members, and licensing fees and patent prosecution costs. Research and development expense for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decreases of 10% and 11% for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the three and months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expense was primarily related to the completion of our enrollment efforts for the Phase 3 PRESENT clinical trial. We expect research and development expense related to our PRESENT trial to decrease throughout 2015 as we transition to the monitoring and follow-up phase. The expected decrease in costs could be partially offset by the increase in research and development expense related to enrollment efforts in our NeuVax combination clinical trials, ongoing trial costs related to our GALE-301 Phase 2 clinical trial, and completion of our Phase 2 clinical trial of the GALE-401 program. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><a name="sB6346B2A437695DA5237D437AAADEB23"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative Expense</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense includes compensation-related costs for our employees dedicated to sales and marketing, general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. Selling, general and administrative expense for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Selling, general and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">16%</font><font style="font-family:inherit;font-size:10pt;">&#32;decreases in selling, general, and administrative expense for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, was driven by the $3 million incurred in legal expenses during the three months ended related to the ongoing litigation and proceedings described in Part II, Item 1 of this report. During the third quarter of 2014 we exceeded the retention (deductible) under our insurance policy and have been realizing significant insurance recoveries against the fees associated with the litigation and proceedings referenced above. This decrease was partially offset by the ramp up of our commercial operations leading into the launch of Zuplenz, the expansion of our management team and infrastructure needed to support the expanded commercial operations and development pipeline. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Operating Income </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-operating income for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, was as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(314</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(449</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total non-operating income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(174</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in our non-operating income (increase in our net non-operating expense) during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to a increase in the change in fair value of warrants accounted for as liabilities. This increase in the estimated fair value of our warrant liabilities was primarily due to the increase in our common stock price, which is one of the most impactful inputs into the pricing model we use to estimate the fair value of our warrant liabilities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2014, there was no income tax benefit or expense recognized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><a name="sFD960609C3C238A58D98D437B6D9182B"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had cash and cash equivalents of approximately </font><font style="font-family:inherit;font-size:10pt;">$45.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, compared with </font><font style="font-family:inherit;font-size:10pt;">$23.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December&#160;31, 2014. </font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase of approximately </font><font style="font-family:inherit;font-size:10pt;">$21.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in our cash and cash equivalents from December&#160;31, 2014 to </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was attributable primarily to $47.4 million in net proceeds from issuance of common stock and warrants to purchase common stock, partially offset by $23.4 million used in operating activities, $1.9 million in payments on long-term debt, and $0.5 million for a milestone related to our acquisition of U.S. rights to Zuplenz.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 18, 2015, we announced the closing of our underwritten public offering of 24,358,974 shares of common stock and 12,179,487 warrants to purchase our common stock at an exercise price of $2.08. The underwriters also exercised their over-allotment option to purchase warrant to purchase an aggregate of 1,826,923 shares of our common stock. On April 10, 2015 the underwriters exercised their option to purchase an additional 3,653,846 shares of common stock for additional net proceeds of $5.4 million. The total net proceeds to us were approximately $40.8 million. </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to incur operating losses as we continue to commercialize Abstral, launch commercialization of Zuplenz in the U.S. and advance our product candidates through the drug development and regulatory process. We will need to generate significant revenue to achieve profitability and may never do so. In the absence of revenue from the commercialization of Abstral, Zuplenz or our product candidates, our potential sources of operational funding are proceeds from the sale of equity and funded research and development payments and payments received under partnership and collaborative agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our existing cash and cash equivalents, along with revenue from our commercial operations, should be sufficient to fund our operations for at least one year. This projection is based on our current planned operations and revenue expectations and is subject to changes in our plans and uncertainties inherent in our business, and we may need to seek to replenish our existing cash and cash equivalents sooner than we project. There is no guarantee that we will generate sufficient revenue from the sale of Abstral and Zuplenz to become profitable or that any debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to generate adequate revenue or obtain additional funding when needed, we would be forced to scale back, or terminate our operations or to seek to merge with or to be acquired by another company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows from operating, investing, and financing activities for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;($ in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.57504873294347%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="66%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash provided by (used in):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,415</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finance activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,613</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Flow from Operating Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was approximately </font><font style="font-family:inherit;font-size:10pt;">$23.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, compared with </font><font style="font-family:inherit;font-size:10pt;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. Despite a $5 million reduction in the operating loss for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared with the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">, net cash used in operating activities increased due to the paying down of accrued expenses and other current liabilities during the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><a name="sFD960609C3C238A58D98D437B6D9182B"></a><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Flow from Investing Activities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, compared with </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The decrease was due to the $2.1 million initial payment for GALE-401 rights during the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the $0.5 million milestone payment for U.S. rights to Zuplenz during the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Cash Flow from Financing Activities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$45.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, compared with </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. The increase was primarily attributable to $42.2 million in net proceeds from the issuance of common stock and warrants to purchase common stock during the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to net proceeds of common stock warrant exercises of&#160;$10.6 million&#160;and net proceeds of common stock option exercises of&#160;$4.1 million&#160;during the six months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sBECA697BAB6C6D9167CCD437B6FB4995"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not entered into any off-balance sheet financing arrangements other than operating leases.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Annual Report on Form 10-K for the year ended December&#160;31, 2014, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December&#160;31, 2014 that are not included in Note 1 of the accompanying condensed consolidated financial statements for the three and six months ended June 30, 2015. Readers are encouraged to read our Annual Report on Form 10-K in conjunction with this report.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s11F3570F85823B11DA36D437B72E44DC"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective of our investment activities is to preserve capital. We do not utilize hedging contracts or similar instruments.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to certain market risks relating primarily to interest rate risk on our cash and cash equivalents and risks relating to the financial viability of the institutions which hold our capital and through which we have invested our funds. We manage the latter risks by investing primarily in money market mutual funds.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are exposed to foreign currency exchange rate fluctuations relating to payments we make to certain vendors and suppliers and license partners using foreign currencies. We do not hedge against foreign currency risks. Consequently, changes in exchange rates could adversely affect our operating results and stock price. Such losses have not been significant to date.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s8B880DF4FAB61F6B1AA2D437B74FDDFC"></a><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the end of the period covered by this quarterly report on Form 10-Q, our principal executive officer and our principal accounting officer (the &#8220;Certifying Officers&#8221;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), such as this quarterly report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q:</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no change in our internal control over financial reporting that occurred during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><a name="s5D178B64068D10861B22D437B782D15F"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><a name="s19593798C0173A3E3DB5D437B7A222A8"></a><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Stockholder Derivative Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 23, 2015, U.S. District Court for the District of Oregon heard argument on the defendants&#8217; motion to stay and motion to dismiss.  On February 4, 2015, the District Court granted in part the motion to stay by staying any discovery until the ruling on the motion to dismiss.  On August 5, 2015, the District Court issued its decision by denying in part and granting in part defendants&#8217; motion to dismiss and granting plaintiffs leave to file an amended complaint. The court had stayed the derivative proceeding pending the outcome of the motion to dismiss in the securities class action case. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 4, 2105, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of June 30, 2015, we have not recorded any</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurer for substantially all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By letter dated December 23, 2014, Orexo and we received a Paragraph IV certification notice (Notice Letter) regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by Actavis Laboratories FL, Inc. (Actavis) requesting approval </font><font style="font-family:inherit;font-size:10pt;color:#404040;">to engage in the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">an</font><font style="font-family:inherit;font-size:10pt;color:#282828;">ufacture</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">use </font><font style="font-family:inherit;font-size:10pt;color:#565656;">or sale </font><font style="font-family:inherit;font-size:10pt;color:#404040;">of generic versions of the Abstral sublingual </font><font style="font-family:inherit;font-size:10pt;color:#282828;">t</font><font style="font-family:inherit;font-size:10pt;color:#565656;">a</font><font style="font-family:inherit;font-size:10pt;color:#282828;">blets</font><font style="font-family:inherit;font-size:10pt;color:#565656;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.1 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.2 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">g </font><font style="font-family:inherit;font-size:10pt;color:#404040;">base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">E</font><font style="font-family:inherit;font-size:10pt;color:#282828;">q </font><font style="font-family:inherit;font-size:10pt;color:#404040;">0.3 mg base, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">Eq 0.4 </font><font style="font-family:inherit;font-size:10pt;color:#404040;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.6 mg base and Eq 0.8 mg base. In the Notice Letter, Actavis </font><font style="font-family:inherit;font-size:10pt;">contends that the patents held by Orexo for Abstral that are listed in the Orange Book (U.S. Patents 6,759,059, 6,761,910 and 7,910,132, which cover compositions, formulations and methods of using Abstral and which expire in September 2019) and which are licensed to us under the Orexo License Agreement, are invalid, unenforceable and/or will not be infringed by the manufacture, use, or sale of the product set forth in the ANDA. On February 4, 2015, Orexo filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories Fl, Inc., Andrx Corporation, Actavis, Inc., and Actavis Pharma, Inc.  All of the defendants except Actavis Laboratories FL, Inc. were subsequently dismissed. Actavis has filed an answer and counterclaim. The lawsuit claims infringement of the three patents.  Orexo filed the lawsuit within 45 days from the receipt of the Notice Letter and under the Hatch-Waxman Act, the final FDA approval of Actavis&#8217; ANDA will be stayed up to 30 months from the date of receipt of the Notice Letter.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A scheduling conference was held on July 9, 2015, in the District Court and on July 10, 2015, the District Court issued a pre-trial scheduling order. The parties are now engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated under Orexo License Agreement to pay for 88% of the legal costs of the patent infringement lawsuit.  We intend to work with Orexo to continue to vigorously enforce intellectual property rights related to the Abstral product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><a name="s290DE3E2C8E86872E7CFD437B7D4A399"></a><div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A. RISK FACTORS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In addition the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2014 and most recent Quarterly Report on Form 10-Q for the three months ended March 31, 2015 filed with the SEC, you should consider the following new or updated risk factors:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to competition and may not be able to compete successfully.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the U.S. and worldwide are numerous and include pharmaceutical and biotechnology companies, educational institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize products that compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. In addition, our technology may be subject to competition from other technology or methods developed using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our technology. Our collaborators or we will face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent position, including potentially dominant patent positions of others. An inability to successfully complete our product development could lead to us having limited prospects for establishing market share or generating revenue from our technology.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For patients with early stage breast cancer, adjuvant therapy is often given to prevent recurrence and increase the chance of long-term disease free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted drug trastuzumab (Herceptin ) may be given to patients with tumors with high expression of HER2 (IHC 3+), in the adjuvant setting which may be useful in treating breast cancer.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon), and AE-37 (Antigen Express). While these development candidates are aimed at a number of different targets, and AE-37 has published data in the HER2 breast cancer patient population, there is no guarantee that any of the these compounds will not in the future be indicated for treatment of low to intermediate HER2 breast cancer patients and become directly competitive with NeuVax.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to achieve profitability with our commercial operations in a timely manner, and may have to make changes to our commercial strategy to maximize the value of our commercial assets to our shareholders.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We launched Abstral in the fourth quarter of 2013, and launched Zuplenz on July 29, 2015.  As of June 30, 2015, Abstral has not achieved profitability as a product line, and there is no assurance that it will achieve profitability within the period of time outlined by management in setting our commercial strategy.  Also, there is no assurance that we will be successful launching Zuplenz, or that Zuplenz will reach profitability as a product line in timely manner, if ever.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management may determine that a change to our commercial strategy is necessary to address the lack of profitability of the commercial products.  Such potential strategic changes include, but are not limited to, increased investment in our commercial operations, significant expansion or reduction to our sale force, acquisition of additional commercial products, or partial or full divesture of our commercial products and operations.  Any such significant change to our commercial strategy could materially affect the amounts of revenue we generate in future periods, the extent and timing of future costs incurred, and could result in changes to our financial results that are materially different than those realized historically.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain and enforce patent rights or other intellectual property rights that cover our commercial product or product candidates and that are of sufficient breadth to prevent third parties from competing against us.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><a name="s290DE3E2C8E86872E7CFD437B7D4A399"></a><div></div><br><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success with respect to our commercial product and product candidates will depend in part on our ability to obtain and maintain patent protection in the U.S. and abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. Our patents and patent applications, however, may not be sufficient to provide protection for Abstral, NeuVax, or our other products and product candidates against commercial competition.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active peptide found in NeuVax, the E75 peptide, has been known and studied for many years. We have one issued U.S. patent, US 6,514,942, covering the composition of matter of the E75 peptide, which expired in March 2015, prior to any potential commercialization of NeuVax. We do not have and will not be able to obtain any composition of matter patent protection for E75, the active peptide in NeuVax outside the U.S. We also have a license from The Henry M. Jackson Foundation to issued U.S. European, Japanese and Australian method of use patents, which expire in 2028, that are directed to a method of inducing immunity against breast cancer recurrence by administering a composition comprising the E75 peptide to patients who have both an immunohistochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression as well as a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression. The license further includes an issued U.S. method of use patent, which expires in 2028, that is directed to a method of inducing immunity against recurrence of any HER2/neu expressing tumors by administering the E75 peptide to patients with tumors having a FISH rating of less than about 2.0 for HER2/neu gene expression. Also included in the license is a method of use patent, which expires in 2026, that is directed to the use of NeuVax in combination with Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;to treat any HER2/neu expressing cancer. Thus, our method of use patents may not prevent competitors from seeking to develop and market NeuVax for use in cancer patients who do not meet these criteria. If any such alternative uses were approved, this could lead to off-label use and price erosion for our NeuVax product. We may seek FDA approval for use of NeuVax to treat cancer patients who fall outside the claimed IHC and FISH ranges and for other cancers as well. Although we are pursuing additional patent protection for NeuVax through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anagrelide hydrochloride, the sole active pharmaceutical ingredient, or &#8220;API,&#8221; in GALE-401, has been approved for many years and, thus, it is not possible to obtain composition of matter patents that cover anagrelide hydrochloride. As a result, competitors who obtain the requisite regulatory approval can offer products with the same API as GALE-401, so long as the competitors do not infringe any formulation patents that we may have or may obtain or license, if any. The only patent protection that we have or are likely to obtain covering GALE-401 are patents relating to specific formulations, methods using these formulations, and methods of manufacturing and packaging. We have an issued U.S. Patent, which expires in 2020, covering methods of using anagrelide to reduce platelet count in patients subject to veno-occlusive events. We have two granted patents in the United Kingdom, an issued U.S. patent and allowed Japanese application, which expire in 2029, covering controlled release formulations of anagrelide and methods of use. We also are prosecuting pending patent applications in other territories including, but not limited to, the U.S. Europe, India and Japan which may not issue prior to any potential commercialization of GALE-401. We may seek FDA approval for use of GALE-401 to treat patients with myeloproliferative neoplasms that include several hermatological disorders. Although we are pursuing additional patent protection for GALE-401 through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orexo AB filed an action in the U.S. District Court for the District of New Jersey on June&#160;30, 2011 asserting infringement by Mylan Pharmaceuticals Inc., of one of our licensed U.S. patents, US 6,761,910, covering Abstral. This patent is directed to pharmaceutical compositions for the treatment of acute disorders by sublingual administration. The claims of the patent cover formulations for other products in addition to Abstral, including Ambien (and generic forms of Ambien, which is the subject of the infringement action). Validity of the patent was challenged as part of the court proceeding, and certain claims in the patent were the subject of a Markman order. Though that action was settled,  that Markman order may be used to challenge any infringement claims Orexo would make in the action entitled, Orexo AB vs. Actavis Laboratories FL, Inc. pending in the U.S. District Court for the District of New Jersey. The outcome in the Orexo AB vs. Actavis Laboratories FL, Inc. action could affect our license of the Abstral patents and our ability to market, sell, distribute or manufacture Abstral in the U.S.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The active peptides found in GALE-301 are derived from Folate Binding Protein. One of the active peptides, E39, has been known and studied for many years. The other active peptide(s) in GALE-301 are derivatives of E39. We have a license from The Henry M. Jackson Foundation to issued and granted patents in the U.S., Europe, Canada, and Japan, covering composition of matter for the E39 derivative peptides alone and in combination with E39, as well as the use of these compositions for the treatment of cancer. These patents are expected to expire in 2022, prior to any potential commercialization of GALE-301. We do not have and will not be able to obtain any composition of matter patent protection for the E39 peptide in any territory. The license we have from The Henry M. Jackson Foundation grants us the right to develop and market GALE-301 </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><a name="s290DE3E2C8E86872E7CFD437B7D4A399"></a><div></div><br><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for any use, including methods of treating cancer. Our patents may not prevent competitors from seeking to develop and market the E39 peptide alone. If any such alternative uses of compositions containing the E39 peptide were approved, this could lead to off-label use and price erosion for GALE-301. We may seek FDA approval for use of GALE-301 to treat cancer patients with ovarian and endometrial cancers and for other cancers as well. Although we are pursuing additional patent protection for GALE-301 through pending patent applications, we may not be able to obtain additional patent protection that would provide us with a significant commercial advantage.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any patents we have or may obtain or license may not provide us with sufficient protection for our commercial product and product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Nor can we guarantee that the claims of these patents will be held valid or enforceable by the courts or the patent office or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in either the patent laws or in the interpretations of patent laws in the U.S. or abroad may diminish the value of our intellectual property. In addition, on September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The U.S. Patent Office is currently developing regulations and procedures to govern administration of the Leahy-Smith Act, and many substantive changes to patent law associated with the Leahy-Smith Act have not yet become effective. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in particular the post grant review processes and first-to-file provision and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we intend to take actions reasonably necessary to enforce our patent rights, we may not be able to detect infringement of our own or in-licensed patents, which may be especially difficult for methods of manufacturing or formulation products, and we depend, in part, on our licensors and collaborators to protect a substantial portion of our proprietary rights. In addition, third parties may challenge our in-licensed patents and any of our own patents that we may obtain, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or defend intellectual property rights is very complex, expensive, and may divert our management&#8217;s attention from our core business and may result in unfavorable results that could adversely affect our ability to prevent third parties from competing with us.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If another party has reason to assert a substantial new question of patentability against any of our claims in our own and in-licensed patents, the third party can request that the patent claims be reexamined, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits and, interference and reexamination proceedings, we may become a party to patent opposition proceedings where either the patentability of the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the medical device, biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product and/or product candidates infringe its patent rights. If a third-party&#8217;s patents were found to cover our commercial product and product candidates, proprietary technologies or its uses, we or our collaborators could be enjoined by a court and required to pay damages and could be unable to continue to commercialize our products or use our proprietary technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief which could prohibit us from making, using or selling our commercial product and product candidates pending a trial on the merits, which could be years away.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how, by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><a name="s290DE3E2C8E86872E7CFD437B7D4A399"></a><div></div><br><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">secrets used by our licensors, collaborators and suppliers. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent its use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of its other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of its former employers or its former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending against any such claims, any such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Capital Structure</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our outstanding warrants may result in dilution to our stockholders.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our outstanding March 2011 and April 2011 warrants to purchase a total of 791,398 shares of common stock as of December&#160;31, 2014 at a current exercise price of $0.65 per share contain so-called full-ratchet anti-dilution provisions. Our outstanding March 2010 and December 2012 warrants to purchase 25,000 and 3,031,311 shares of common stock as of December&#160;31, 2014 at current exercise prices of $2.15 per share and $1.90 per share, respectively, contain so-called weighted-average anti-dilution provisions. These anti-dilution provisions may be triggered by the issuance of the shares being offered hereby or upon any future issuance by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some exceptions.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of the warrants on either a full-ratchet or weighted-average basis, which would have a dilutive effect on our stockholders.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><a name="s7BFD57B5B5E849522C17D437B7F5DD66"></a><div></div><br><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="8%"></td><td width="1%"></td><td width="44%"></td><td width="47%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriting Agreement dated as of March&#160;13, 2015 by and between Galena Biopharma, Inc. and Raymond James &amp; Associates, Inc. (1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant Agreement, dated as of March 18, 2015, by and among Galena Biopharma, Inc., Computershare, Inc. and Computershare Trust Company, N.A. **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option under the Galena Biopharma, Inc., Amended and Restated 2007 Incentive Plan. * **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Nonstatutory Stock Option under the Galena Biopharma, Inc., Amended and Restated 2007 Incentive Plan.* **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan. (2)*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation and Consulting Agreement, dated as of June 24, 2015, by and between Galena Biopharma, Inc. and Margaret Kivinski and General Release, dated as of June 24, 2015, by Margaret Kivinski.**</font></div><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Offer Letter effective June 25, 2015, between Galena Biopharma, Inc. and Thomas J. Knapp. * **</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Mark W. Schwartz, Ph.D.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sarbanes-Oxley Act Section 302 Certification of Ryan M. Dunlap.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sarbanes-Oxley Act Section 906 Certification of Mark W. Schwartz, Ph.D., and Ryan M. Dunlap.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation.**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicates a management contract or compensatory plan or arrangement.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously filed as an Exhibit to the Registrant's Form 8-K filed on March 16, 2015 and incorporated herein by reference.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously filed as Annex B to the Registrant's Proxy Statement on Schedule 14A filed on April 30, 2015 and incorporated by reference herein by reference.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><a name="sB4DB23F5BA9DD3E9A7F7D437B8280F44"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIGNATURES</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="47%"></td><td width="5%"></td><td width="1%"></td><td width="47%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Date: August&#160;6, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Date: August&#160;6, 2015</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>gale-20150630xex31.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX3.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sFA97B8088B196C6F6802E046FC9CAC5C"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CERTIFICATE OF AMENDMENT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;Galena Biopharma, Inc., a Delaware corporation (the &#8220;Corporation&#8221;), hereby certifies that: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;">The following resolution has been unanimously adopted by the Corporation&#8217;s Board of Directors and has been approved by the holders of a majority of the Corporation&#8217;s outstanding common stock in accordance with the Delaware General Corporation Law for the purpose of amending the Corporation&#8217;s Amended and Restated Certificate of Incorporation: </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RESOLVED, that ARTICLE III, Section A of the Amended and Restated Certificate of Incorporation of the Corporation shall be amended to read in its entirety as follows: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">A.&#160;&#160;&#160;&#160;Classes of Stock.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;This Corporation is authorized to issue 280,000,000 shares, of which 275,000,000 shares shall be Common Stock with a par value of $0.0001 per share (&#8220;Common Stock&#8221;) and 5,000,000 shares shall be Preferred Stock with a par value of $0.0001 per share (&#8220;Preferred Stock&#8221;).&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The above amendment was duly adopted by the Corporation in accordance with the provisions of Section&#160;242 of the Delaware General Corporation Law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, Galena Biopharma, Inc. has caused this Certificate of Amendment to be signed by a duly authorized officer this 19</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of June 2015.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Galena Biopharma, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:   </font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Mark W. Schwartz</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>gale-20150630xex41.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX4.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s15EA529E10C255262F7CFAA9954BB54F"></a><div></div><br><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WARRANT AGREEMENT </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS WARRANT AGREEMENT made as of March 18, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Issuance Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), between Galena Biopharma, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;), Computershare Inc., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Computershare</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (and together with Computershare, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company has sold, or may sell, up to 24,358,974 shares of common stock, par value $0.0001 per share (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221; and includes any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock), of the Company and warrants to purchase 14,006,410 shares of Common Stock (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Share</font><font style="font-family:inherit;font-size:10pt;">&#8221; and, collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;), subject to adjustment as described herein (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant</font><font style="font-family:inherit;font-size:10pt;">&#8221; and, collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrants</font><font style="font-family:inherit;font-size:10pt;">&#8221;), pursuant to an Underwriting Agreement between the Company and Raymond James&#160;&amp; Associates, Inc., as Representative of the Underwriters, dated March 13, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Underwriting Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;); and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, both the Common Stock and the Warrants were issued by the Company in a public offering pursuant to an effective shelf registration statement on Form S-3, Registration No.&#160;333-188849 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Statement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) filed with the Securities and Exchange Commission (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Commission</font><font style="font-family:inherit;font-size:10pt;">&#8221;) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and a related base prospectus and prospectus supplement; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange and exercise of the Warrants; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Warrant Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Appointment of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Warrant Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrants</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Form of Warrant</font><font style="font-family:inherit;font-size:10pt;">. Each Warrant shall be issued in registered form only, shall be in substantially the form of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">&#32;hereto, the provisions of which are incorporated herein, and shall be signed by, or bear the facsimile signature of, the Chief Executive Officer, Chief Financial Officer, President or Secretary of the Company. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Effect of Countersignature</font><font style="font-family:inherit;font-size:10pt;">. Unless and until countersigned by the manual or facsimile signature of the Warrant Agent pursuant to this Warrant Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Register</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall maintain books (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Register</font><font style="font-family:inherit;font-size:10pt;">&#8221;) for the registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. The Warrants may be represented by definitive Warrant Certificates in physical form or by one or more book-entry warrant certificates (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Book-Entry Warrant Certificates</font><font style="font-family:inherit;font-size:10pt;">&#8221;) deposited with the Depository Trust Company (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Depository</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and registered in the name of Cede&#160;&amp; Co., a nominee of the Depository. Definitive Warrant Certificates shall be in substantially the form annexed hereto as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">. Ownership of beneficial interests in the Book-Entry Warrant Certificates shall be shown on, and the transfer of such ownership shall be effected through, records maintained (i)&#160;by the Depository or its nominee for each Book-Entry Warrant Certificate; (ii)&#160;by institutions that have accounts with the Depository (such institution, with respect to a Warrant in its account, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Participant</font><font style="font-family:inherit;font-size:10pt;">&#8221;); or (iii)&#160;directly on the book-entry records of the Warrant Agent with respect only to owners of beneficial interests that request such direct registration. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Depository subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement within ten (10)&#160;days after the Depository ceases to make its book-entry settlement available. In the event that the Company does not make alternative arrangements for book-entry settlement within ten (10)&#160;days or the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depository definitive Warrant Certificates in physical form evidencing such Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Beneficial Owner; Registered Holder</font><font style="font-family:inherit;font-size:10pt;">. The term &#8220;beneficial owner&#8221; shall mean any person in whose name ownership of a beneficial interest in the Warrants evidenced by (a)&#160;a Book-Entry Warrant Certificate is recorded in the records maintained by the Depository or its nominee or (b)&#160;a definitive Warrant Certificate is recorded in the book-entry records of the Warrant Agent. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant shall be registered in the Warrant Register (&#8220;registered holder&#8221;), as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on the Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Detachability of Warrants</font><font style="font-family:inherit;font-size:10pt;">. The Common Stock and the Warrants will be issued separately and will be separately transferable immediately upon issuance. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Terms and Exercise of Warrants</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">. The exercise price per whole share of the Common Stock under each Warrant shall be $2.08, subject to adjustment hereunder (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Price</font><font style="font-family:inherit;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Duration of Warrants</font><font style="font-family:inherit;font-size:10pt;">. A Warrant may be exercised only during the period (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Period</font><font style="font-family:inherit;font-size:10pt;">&#8221;) commencing on the Issuance Date and terminating at 5:00 P.M., Eastern time on March 18, 2020 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise of Warrants</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise and Payment</font><font style="font-family:inherit;font-size:10pt;">. A registered holder may exercise a Warrant by delivering, not later than 5:00 P.M., Eastern time, on any Business Day during the Exercise Period (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exercise Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to the Warrant Agent at its corporate trust department (i) the Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants to be exercised (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Book-Entry Warrants</font><font style="font-family:inherit;font-size:10pt;">&#8221;) free on the records of the Depository to an account of the Warrant Agent at the Depository designated for such purpose in writing by the Warrant Agent to the Depository from time to time, (ii) an election to purchase the Shares underlying the Warrants to be exercised (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Election to Purchase</font><font style="font-family:inherit;font-size:10pt;">&#8221;), properly completed and executed by the registered holder on the reverse of the Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depository&#8217;s procedures, and (iii), except as provided in Section 3.3.8, the Warrant Price for each Warrant to be exercised in lawful money of the United States of America by wire, certified or official bank check, or wire transfer, in immediately available funds. The term &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Price</font><font style="font-family:inherit;font-size:10pt;">&#8221; as used in this Warrant Agreement refers to price per share of Common Stock at which shares may be purchased at the time the Warrant is exercised. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of (A) the Warrant Certificate or the Book-Entry Warrants, (B) the Election to Purchase, or (C) the Warrant Price therefor, is received by the Warrant Agent after 5:00 P.M., Eastern time, on the specified Exercise Date, the Warrants will be deemed to be received and exercised on the Business Day next succeeding the Exercise Date. If the date specified as the Exercise Date is not a Business Day, the Warrants will be deemed to be received and exercised on the next succeeding day that is a Business Day. If the Warrants are received or deemed to be received after the Expiration Date, the exercise thereof will be null and void and any funds delivered to the Warrant Agent will be returned to the registered holder or Participant, as the case may be, as soon as practicable. In no event will interest accrue on funds deposited with the Warrant Agent in respect of an exercise or attempted exercise of Warrants. The validity of any exercise of Warrants will be determined by the Company in its sole discretion and such determination will be final and binding upon the registered holder and the Warrant Agent. Neither the Company nor the Warrant Agent shall have any obligation to inform a registered holder of the invalidity of any exercise of Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Warrant Agent shall forward funds received for warrant exercises in a given month by the 5th Business Day of the following month by wire transfer to an account designated by the Company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All funds received by Computershare under this Warrant Agreement that are to be distributed or applied by Computershare in the performance of services (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Funds</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shall be held by Computershare as agent for the Company and deposited in one or more bank accounts to be maintained by Computershare in its name as agent for the Company. Until paid pursuant to the terms of this Warrant Agreement, Computershare will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1 billion or with an average rating above investment grade by Standard and Poor&#8217;s Corporation (LT Local Issuer Credit Rating), Moody&#8217;s Investors Service, Inc. (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by Computershare in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. Computershare may from time to time receive interest, dividends or other earnings in connection with such deposits. Computershare shall not be obligated to pay such interest, dividends or earnings to the Company, any holder or any other party. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Issuance of Certificates</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall, within a reasonable time, advise the Company and the transfer agent and registrar in respect of (a)&#160;the Shares issuable upon such exercise as to the number of Warrants exercised in accordance with the terms and conditions of this Warrant Agreement, (b)&#160;the instructions of each registered holder or Participant, as the case may be, with respect to delivery of the Warrant Shares issuable upon such exercise, and the delivery of definitive Warrant certificates, as appropriate, evidencing the balance, if any, of the Warrants remaining after such exercise, (c)&#160;in case of a Book-Entry Warrant Certificate, the notation that shall be made to the records maintained by the Depository, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance, if any, of the Warrants remaining after such exercise and (d)&#160;such other information as the Company or such transfer agent and registrar shall reasonably require. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company shall cause the Warrant Agent to, by 5:00 P.M., Eastern time, on the third Business Day next succeeding the Exercise Date of any Warrant and the clearance of the funds in payment of the Warrant Price (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Shares Delivery Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), execute, issue and deliver, on the Company&#8217;s behalf, the Warrant Shares to which such registered holder or Participant, as the case may be, is entitled, in fully registered form, registered in such name or names as may be directed by such registered holder or the Participant, as the case may be. If the Warrant Agent fails for any reason to deliver to such registered holder or Participant, as the case may be, the Warrant Shares subject to an exercise notice by the Warrant Shares Delivery Date, the Company shall pay to the registered holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable exercise notice), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Shares Delivery Date until such Warrant Shares are delivered or the registered holder rescinds such exercise </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In lieu of delivering physical certificates representing the Warrant Shares issuable upon exercise, provided the Company&#8217;s transfer agent is participating in the Depository&#8217;s Fast Automated Securities Transfer program, the Company shall use its reasonable best efforts to cause its transfer agent to electronically transmit the Warrant Shares issuable upon exercise to the Depository&#8217;s Fast Automated Securities Transfer program. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Warrant Agent fails to comply with the preceding paragraphs in this Section&#160;3.3.2 by the Warrant Shares Delivery Date, then the registered holder or Participant will have the right to rescind its exercise. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Valid Issuance</font><font style="font-family:inherit;font-size:10pt;">. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Warrant Agreement shall be validly issued, fully paid and nonassessable. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Dividends</font><font style="font-family:inherit;font-size:10pt;">. The accrual of dividends, if any, on the Warrant Shares issued upon the valid exercise of any Warrant will be governed by the terms generally applicable to the Common Stock. From and after the issuance of such Warrant Shares, the former holder of the Warrants exercised will be entitled to the benefits generally available to other holders of Common Stock and such former holder&#8217;s right to receive payments of dividends and any other amounts payable in respect of the Warrant Shares shall be governed by, and shall be subject to, the terms and provisions generally applicable to the Common Stock. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.5 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">No Fractional Exercise</font><font style="font-family:inherit;font-size:10pt;">. A registered holder may exercise a Warrant from time to time only for whole shares of Common Stock. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of a Warrant. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. If fewer than all of the Warrants evidenced by a Warrant Certificate are exercised, a new Warrant Certificate for the number of unexercised Warrants remaining shall be executed by the Company and countersigned by the Warrant Agent as provided in Section&#160;2 of this Warrant Agreement, and delivered to the holder of the Warrant Certificate at the address specified on the books of the Warrant Agent or as otherwise specified by such registered holder. If fewer than all the Warrants evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the records maintained by the Depository, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. The Company shall provide an initial funding of one thousand dollars ($1,000) for the purpose of issuing cash in lieu of fractional shares. From time to time thereafter, the Warrant Agent may request additional funding to cover payments for fractional Warrant Shares. The Warrant Agent shall have no obligation to make such payments for fractional Warrant Shares unless the Company shall have provided the necessary funds to pay in full all amounts due and payable with respect thereto. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.6 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">No Transfer Taxes</font><font style="font-family:inherit;font-size:10pt;">. Issuance of Warrant Shares shall be made without charge to a registered holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the registered holder or in such name or names as may be directed by the registered holder; provided, however, that in the event Warrant Shares are to be issued in a name other than the name of the registered holder, a Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the registered holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any exercise notice. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.7 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Date of Issuance</font><font style="font-family:inherit;font-size:10pt;">. Each person in whose name any such certificate for shares of Common Stock is issued shall for all purposes be deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.8 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Optional Cashless Exercise</font><font style="font-family:inherit;font-size:10pt;">. If at any time during the term of this Warrant Agreement there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the Warrant Shares by the registered holder, then the Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A) = the VWAP on the Trading Day immediately preceding the date on which holder elects to exercise this Warrant by means of a &#8220;cashless exercise,&#8221; as set forth in the applicable exercise notice; </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">VWAP</font><font style="font-family:inherit;font-size:10pt;">&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&#160;if the Common Stock is then listed or quoted on a Trading Market (as defined below), the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160;if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c)&#160;if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Company and reasonably acceptable to the holders of a majority in interest of the total number of Warrants issued under the Underwriting Agreement then outstanding, the fees and expenses of which shall be paid by the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trading Day</font><font style="font-family:inherit;font-size:10pt;">&#8221; means a day on which the principal Trading Market is open for trading. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trading Market</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock Exchange, the OTC Bulletin Board or the OTC Markets, Inc. (or any successors to any of the foregoing). </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the first sentence of this Section&#160;3.3.8 or any other provision hereof, on the Termination Date, this Warrant, to the extent not exercised prior thereto, shall be automatically exercised via cashless exercise pursuant to this Section&#160;3.3.8. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon receipt of an Election to Purchase for a cashless exercise, the Company shall calculate and transmit to the Warrant Agent, and the Warrant Agent shall have no obligation under this Warrant Agreement to calculate, the Cashless Exercise Ratio. The number of shares of Common Stock to be issued on such exercise will be determined by the Company (with written notice thereof to the Warrant Agent) using the formula set forth in this Section&#160;3.3.8, the Warrant Agent shall have no duty or obligation to investigate or confirm whether the Company&#8217;s determination of the number of shares of Common Stock to be issued on such exercise, pursuant to this Section&#160;3.3.8 is accurate or correct. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.9 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disputes</font><font style="font-family:inherit;font-size:10pt;">. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the registered holder the number of Warrant Shares that are not disputed. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3.10 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitations on Exercise</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall not effect any exercise of this Warrant, and a registered holder shall not have the right to exercise any portion of the Warrant to the extent that after giving effect to such issuance after exercise as set forth on the applicable exercise notice, the registered holder (together with the registered holder&#8217;s affiliates, and any other persons acting as a group together with the registered holder or any of the registered holder&#8217;s affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the registered holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&#160;exercise of the remaining, nonexercised portion of the Warrant beneficially owned by the registered holder or any of its affiliates and (ii)&#160;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the registered holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this Section&#160;3.3.10, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exchange Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and the rules and regulations promulgated thereunder, it being acknowledged by the registered holder that the Company is not representing to the registered holder that such calculation is in compliance with Section&#160;13(d) of the Exchange Act and the registered holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&#160;3.3.10 applies, the determination of whether the Warrant is exercisable (in relation to other securities owned by the registered holder together with any affiliates) and of which portion of the Warrant is exercisable shall be in the sole discretion of the registered holder, and the submission of an exercise notice shall be deemed to be the registered holder&#8217;s determination of whether the Warrant is exercisable (in relation to other securities owned by the registered holder together with any affiliates) and of which portion of the Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&#160;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section&#160;3.3.10, in determining the number of outstanding shares of Common Stock, a registered holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&#160;the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&#160;a more recent public announcement by the Company or (C)&#160;a more recent written notice by the Company or the transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a registered holder, the Company shall within two Trading Days confirm orally and in writing to the registered holder the number of shares of Common Stock then outstanding as established by (A), (B)&#160;or (C)&#160;above, as applicable. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrant, by the registered holder or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Beneficial Ownership Limitation</font><font style="font-family:inherit;font-size:10pt;">&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of the Warrant. The registered holder, upon not less than 61 days&#8217; prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&#160;3.3.10, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of the Warrant held by the registered holder and the provisions of this Section&#160;3.3.10 shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered to the Company and shall only be effective with respect to such registered holder. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&#160;3.3.10 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of the Warrant. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Buy-in Procedures and Compensation</font><font style="font-family:inherit;font-size:10pt;">. In addition to any other rights available to a registered holder, if the Company fails to cause its transfer agent to transmit to the registered holder the Warrant Shares pursuant to an exercise on or before the Warrant Shares Delivery Date, and if after such date, the registered holder is required by its broker to purchase (in an open market transaction or otherwise) or the registered holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the registered holder of the Warrant Shares that the registered holder anticipated receiving from the Company upon such exercise (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Buy-In</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then the Company shall (A)&#160;pay in cash to the registered holder the amount, if any, by which (x)&#160;the registered holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&#160;the amount obtained by multiplying (1)&#160;the number of Warrant Shares that the Company was required to deliver to the registered holder in connection with the exercise at issue times (2)&#160;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&#160;at the option of the registered holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the registered holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the registered holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&#160;of the immediately preceding sentence the Company shall be required to pay the registered holder $1,000. The registered holder shall provide the Company written notice indicating the amounts payable to the registered holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a registered holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, the Company shall not be required to make the payments set forth herein in the case of uncertificated Warrant Shares if the registered holder fails to timely file a request with the Depository Trust Company to receive such uncertificated Warrant Shares. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5 Cost Basis Information. (a)&#160;In the event of a cash exercise, the Company hereby instructs the Warrant Agent to record cost basis for newly issued shares in a manner to be subsequently communicated by the Company to the Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) In the event of a cashless exercise: the Company shall provide cost basis for shares issued pursuant to a cashless exercise at the time the Company confirms the number of Warrant Shares issuable in connection with the cashless exercise to the Warrant Agent pursuant to Section&#160;3.3.3 hereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Adjustments</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock Dividends and Splits</font><font style="font-family:inherit;font-size:10pt;">. If the Company, at any time while a Warrant is outstanding: (i)&#160;pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of a Warrant), (ii)&#160;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&#160;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&#160;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of a Warrant shall be proportionately adjusted such that the aggregate Exercise Price of a Warrant shall remain unchanged. Any adjustment made pursuant to this Section&#160;2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsequent Rights Offerings</font><font style="font-family:inherit;font-size:10pt;">. If the Company, at any time while a Warrant is outstanding, shall issue rights, options or warrants to all holders of Common Stock (and not to the registered holders of the Warrants) entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the VWAP on the record date mentioned below, then, the Exercise Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of additional shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of shares which the aggregate offering price of the total number of shares so offered (assuming receipt by the Company in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP. Such adjustment shall be made whenever such rights, options or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pro Rata Distributions</font><font style="font-family:inherit;font-size:10pt;">. If the Company, at any time while a Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the registered holders of the Warrants) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security, then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors of the Company in good faith. In either case the adjustments shall be described in a statement provided to the registered holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fundamental Transaction</font><font style="font-family:inherit;font-size:10pt;">. If, at any time while a Warrant is outstanding, (i)&#160;the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a merger with a wholly-owned subsidiary of the Company for purposes of offering a corporate name change), (ii)&#160;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&#160;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&#160;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&#160;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fundamental Transaction</font><font style="font-family:inherit;font-size:10pt;">&#8221;), then, upon any subsequent exercise of a Warrant, the registered holders each shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of each registered holder (without regard to any limitation in Section&#160;3.3.10 on the exercise of a Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Alternate Consideration</font><font style="font-family:inherit;font-size:10pt;">&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which a Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&#160;3.3.10 on the exercise of a Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then each registered holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of a Warrant following such Fundamental Transaction. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing, in the event of a Fundamental Transaction, at the request of the registered holder delivered before the 90th day after such Fundamental Transaction, the Company (or the Successor Entity (as defined below) shall purchase a Warrant from the registered holder by paying to the registered holder, within five business days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of a Warrant on the date of such Fundamental Transaction. &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Black Scholes Value</font><font style="font-family:inherit;font-size:10pt;">&#8221; means the value of a Warrant based on the Black and Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Bloomberg</font><font style="font-family:inherit;font-size:10pt;">&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (i)&#160;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of a Warrant as of the date of the public announcement of the applicable Fundamental Transaction; (ii)&#160;an expected volatility equal to the lesser of 100% and the 60-day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction; (iii)&#160;the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction; and (iv)&#160;a remaining option time equal to the remaining term of a Warrant as of the date of the public announcement of the applicable Fundamental Transaction. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Successor Entity</font><font style="font-family:inherit;font-size:10pt;">&#8221;) to assume in writing all of the obligations of the Company under this Warrant Agreement and the other documents governing the transaction in accordance with the provisions of this Section&#160;4.4 pursuant to written agreements in form and substance reasonably satisfactory to the registered holder and approved by the registered holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the registered holder, deliver to the registered holder in exchange for a Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this registered holder which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of a Warrant (without regard to any limitations on the exercise of a Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of a Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the registered holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of a Warrant and the other documents governing the transaction referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under a Warrant and the other documents governing the transaction with the same effect as if such Successor Entity had been named as the Company herein. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Adjustment to Exercise Price</font><font style="font-family:inherit;font-size:10pt;">. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&#160;4, the Company shall give reasonable written notice thereof to the Warrant Agent, which notice shall set forth the Exercise Price after such adjustment and set forth a brief statement of the facts requiring such adjustment. The Company agrees that it will provide the Warrant Agent with any new or amended exercise terms. The Warrant Agent shall have no obligation under any Section of this Warrant Agreement to determine whether an adjustment made hereunder has occurred or are scheduled or contemplated to occur or to calculate any of the adjustments set forth in this Warrant Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices of Certain Events to Allow Exercise</font><font style="font-family:inherit;font-size:10pt;">. If (A)&#160;the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&#160;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&#160;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&#160;the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&#160;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to each registered holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&#160;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&#160;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The registered holder shall remain entitled to exercise a Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Form of Warrant</font><font style="font-family:inherit;font-size:10pt;">. The form of Warrant need not be changed because of any adjustment pursuant to this Section&#160;4, and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants initially issued pursuant to this Warrant Agreement. However, the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Calculations</font><font style="font-family:inherit;font-size:10pt;">. All calculations under this Section&#160;4 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&#160;4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Transfer and Exchange of Warrants</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration of Transfer</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Procedure for Surrender of Warrants</font><font style="font-family:inherit;font-size:10pt;">. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the registered holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that except as otherwise provided herein or in any Book-Entry Warrant Certificate, each Book-Entry Warrant Certificate may be transferred only in whole and only to the Depository, to another nominee of the Depository, to a successor depository, or to a nominee of a successor depository; provided further, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants or Warrant Shares must also bear a restrictive legend. Upon any such registration of transfer, the Company shall execute, and the Warrant Agent shall countersign and deliver, in the name of the designated transferee a new Warrant Certificate or Warrant Certificates of any authorized denomination evidencing in the aggregate a like number of unexercised Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A party requesting transfer of Warrants must provide any evidence of authority that may be required by the Warrant Agent, including but not limited to, a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fractional Warrants</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the issuance of a warrant certificate for a fraction of a warrant. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Service Charges</font><font style="font-family:inherit;font-size:10pt;">. No service charge shall be made for any exchange or registration of transfer of Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Execution and Countersignature</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Warrant Agreement, the Warrants required to be issued pursuant to the provisions of this Section&#160;5, and the Company, whenever required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Provisions Relating to Rights of Registered Holders of Warrants</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">No Rights as Stockholder</font><font style="font-family:inherit;font-size:10pt;">. Except as otherwise specifically provided herein, a registered holder, solely in its capacity as a holder of a Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant Agreement be construed to confer upon a registered holder, solely in its capacity as the registered holder of a Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the registered holder of the Warrant Shares which it is then entitled to receive upon the due exercise of a Warrant. In addition, nothing contained in this Warrant Agreement shall be construed as imposing any liabilities on a registered holder to purchase any securities (upon exercise of a Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. A Warrant does not entitle the registered holder thereof to any of the rights of a stockholder. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lost, Stolen or Destroyed Warrants</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall issue replacement Warrants in a form mutually agreed to by Warrant Agent and the Company for those certificates alleged to have been lost, stolen or destroyed, upon receipt by Warrant Agent of an open penalty surety bond satisfactory to it and holding it and Company harmless, absent notice to Warrant Agent that such certificates have been acquired by a bona fide purchaser. Warrant Agent may, at its option, issue replacement Warrants for mutilated certificates upon presentation thereof without such indemnity. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorized Shares</font><font style="font-family:inherit;font-size:10pt;">. The Company covenants that, during the period the Warrants are outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under a Warrant. The Company further covenants that its issuance of the Warrants shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under the Warrants. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by a Warrant will, upon exercise of the purchase rights represented by a Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except and to the extent as waived or consented to by a registered holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of a Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of a registered holder as set forth in this Warrant Agreement against impairment. Without limiting the generality of the foregoing, the Company will (i)&#160;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&#160;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of a Warrant and (iii)&#160;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant Agreement. Before taking any action which would result in an adjustment in the number of Warrant Shares for which a Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Concerning the Warrant Agent and Other Matters</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Payment of Taxes</font><font style="font-family:inherit;font-size:10pt;">. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of Warrants, but the Company or the Warrant Agent shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares. The Warrant Agent shall not register any transfer or issue or deliver any Warrant Certificate(s) unless or until the persons requesting the registration or issuance shall have paid to the Warrant Agent for the account of the Company the amount of such transfer tax, if any, or shall have established to the reasonable satisfaction of the Company and the Warrant Agent that such transfer tax, if any, has been paid. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Resignation, Consolidation, or Merger of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Appointment of Successor Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving thirty (30)&#160;days&#8217; notice in writing to the Company pursuant to the notice provisions in Section&#160;8.2 hereof. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of the Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&#8217;s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be authorized under applicable laws to exercise the powers of a transfer agent and subject to supervision or examination by federal or state authorities. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notice of Successor Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Merger or Consolidation of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. Any corporation into which the Warrant Agent may be merged or converted or with which it may be consolidated or any corporation resulting from any merger, conversion, or consolidation to which the Warrant Agent shall be a party, or any corporation succeeding to the business of the Warrant Agent, shall be the successor Warrant Agent under this Warrant Agreement without any further act. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fees and Expenses of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Remuneration</font><font style="font-family:inherit;font-size:10pt;">. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:10pt;">. The Company shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may be reasonably required by the Warrant Agent for the carrying out or performing by the Warrant Agent of the provisions of this Warrant Agreement. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Liability of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Reliance on Company Statement</font><font style="font-family:inherit;font-size:10pt;">. Whenever in the performance of its duties under this Warrant Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, President or Chairman of the Board of Directors of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon, and be held harmless for such reliance, such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Warrant Agreement, and shall not be held liable in connection with any delay in receiving such statement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:10pt;">. The Company covenants and agrees to indemnify and to hold the Warrant Agent harmless against any costs, expenses (including reasonable fees of its legal counsel), losses or damages, which may be paid, incurred or suffered by or to which it may become subject, arising from or out of, directly or indirectly, any claims or liability resulting from its actions as Warrant Agent pursuant hereto; provided, that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect to, such costs, expenses, losses and damages incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence, bad faith, or willful misconduct. This Section&#160;7.4.2 shall survive termination of this Warrant Agreement or any removal of the Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Instructions</font><font style="font-family:inherit;font-size:10pt;">. From time to time, Company may provide Warrant Agent with instructions concerning the services performed by the Warrant Agent hereunder. In addition, at any time Warrant Agent may apply to any officer of Company for instruction, and may consult with legal counsel for Warrant Agent or Company with respect to any matter arising in connection with the services to be performed by the Warrant Agent under this Warrant Agreement. Warrant Agent and its agents and subcontractors shall not be liable and shall be indemnified by Company for any action taken or omitted by Warrant Agent in reliance upon any Company instructions or upon the advice or opinion of such counsel. Warrant Agent shall not be held to have notice of any change of authority of any person, until receipt of written notice thereof from Company. This Section&#160;7.4.3 shall survive termination of this Warrant Agreement or any removal of the Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exclusions</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent shall have no responsibility with respect to the validity of this Warrant Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Warrant Agreement or in any Warrant; nor shall it be responsible to make calculations under Section&#160;3.3.8 or any adjustments required under the provisions of Section&#160;4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Warrant Agreement or any Warrant or as to whether any shares of Common Stock will when issued be valid and fully paid and nonassessable. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4.5. Rights and Duties of Warrant Agent. (a)&#160;The Warrant Agent may consult with legal counsel (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in accordance with such opinion. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) The Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Warrant Agreement or in the Warrant Certificates (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by the Company only. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) The Warrant Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any holder of Warrants with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) The Warrant Agent and any stockholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Warrant Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e) The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final judgment of a court of competent jurisdiction) in the selection and continued employment thereof. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f) The Warrant Agent may rely on and shall be held harmless and protected and shall incur no liability for or in respect of any action taken, suffered or omitted to be taken by it in reliance upon any certificate, statement, instrument, opinion, notice, letter, facsimile transmission, telegram or other document, or any security delivered to it, and believed by it to be genuine and to have been made or signed by the proper party or parties, or upon any written or oral instructions or statements from the Company with respect to any matter relating to its acting as Warrant Agent hereunder. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g) The Warrant Agent shall not be obligated to expend or risk its own funds or to take any action that it believes would expose or subject it to expense or liability or to a risk of incurring expense or liability, unless it has been furnished with assurances of repayment or indemnity satisfactory to it. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(h) The Warrant Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to any registration statement filed with the Commission or this Warrant Agreement, including without limitation obligations under applicable regulation or law. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) The Warrant Agent shall not be accountable or under any duty or responsibility for the use by the Company of any Warrants authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Warrant Agreement or for the application by the Company of the proceeds of the issue and sale, or exercise, of the Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(j) The Warrant Agent shall act hereunder solely as agent for the Company, and its duties shall be determined solely by the express provisions hereof (and no duties or obligations shall be inferred or implied). The Warrant Agent shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(k) The Warrant Agent may rely on and be fully authorized and protected in acting or failing to act upon (a)&#160;any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (b)&#160;any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(l) In the event the Warrant Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Warrant Agent hereunder, the Warrant Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Company, the holder of any Warrant Certificate or Book-Entry Warrant Certificate or any other person or entity for refraining from taking such action, unless the Warrant Agent receives written instructions signed by the Company which eliminates such ambiguity or uncertainty to the satisfaction of Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Acceptance of Agency</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent hereby accepts the agency established by this Warrant Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of Common Stock through the exercise of Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitation on Liability of Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding anything contained herein to the contrary, the Warrant Agent&#8217;s aggregate liability during any term of this Warrant Agreement with respect to, arising from, or arising in connection with this Warrant Agreement, or from all services provided or omitted to be provided under this Warrant Agreement, whether in contract, or in tort, or otherwise, is limited to, and shall not exceed, the amounts paid hereunder by the Company to Warrant Agent as fees and charges, but not including reimbursable expenses, during the twelve (12)&#160;months immediately preceding the event for which recovery from Warrant Agent is being sought. This Section&#160;7.6 shall survive termination of this Warrant Agreement or any removal of the Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Opinion of Counsel</font><font style="font-family:inherit;font-size:10pt;">. The Company shall provide an opinion of counsel prior to the Issuance Date to set up a reserve of Warrants and related Common Stock. The opinion shall state that all Warrants or Common Stock, as applicable, are: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) registered under the Act, or are exempt from such registration, and all appropriate state securities law filings have been made with respect to the warrants or shares; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) validly issued, fully paid and non-assessable. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Miscellaneous Provisions</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Successors</font><font style="font-family:inherit;font-size:10pt;">. Subject to applicable securities laws, this Warrant Agreement and the Warrants and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of each registered holder. The provisions of this Warrant Agreement are intended to be for the benefit of any holder from time to time of this Warrant Agreement and shall be enforceable by the holder or holder of Warrant Shares. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">. Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall delivered by hand or sent by registered or certified mail or overnight courier service addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows: </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Galena Biopharma, Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4640 SW Macadam Avenue, Suite 270 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portland, Oregon, 97239 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn: Ryan Dunlap </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered by hand or sent by registered or certified mail or overnight courier service addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows: </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computershare Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computershare Trust Company, N.A. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250 Royall Street </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canton, MA 02021 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn: Scott Travis </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">with a copy in each case to: </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kelley Drye&#160;&amp; Warren LLP </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101 Park Avenue </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10178 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn: Merrill Stone, Esq. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raymond James&#160;&amp; Associates, Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880 Carillon Parkway </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">St. Petersburg, Florida 33716 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention: Equity Capital Markets </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Jurisdiction</font><font style="font-family:inherit;font-size:10pt;">. The validity, interpretation, and performance of this Warrant Agreement and of the Warrants shall be governed in all respects by the laws of the State of Delaware, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Warrant Agreement shall be brought and enforced in the courts of the State of Delaware or the United States District Court for the District of Delaware, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenience forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section&#160;8.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Persons Having Rights under this Warrant Agreement</font><font style="font-family:inherit;font-size:10pt;">. Nothing in this Warrant Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Warrant Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.5. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Examination of the Warrant Agreement</font><font style="font-family:inherit;font-size:10pt;">. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant Agent, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:10pt;">. This Warrant Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. A signature to this Warrant Agreement transmitted electronically shall have the same authority, effect, and enforceability as an original signature. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Effect of Headings</font><font style="font-family:inherit;font-size:10pt;">. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall not affect the interpretation thereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Amendments</font><font style="font-family:inherit;font-size:10pt;">. This Warrant Agreement may be amended by the parties hereto without the consent of any registered holder: (i)&#160;for the purpose of curing any ambiguity or (ii)&#160;of curing, correcting or supplementing any defective provision contained herein or (iii)&#160;adding or for the purpose of changing any other provisions with respect to matters or questions arising under this Warrant Agreement as the parties may deem necessary or desirable and that the parties deem shall not materially adversely affect the interest of the registered holders. Any modifications or amendments to Section&#160;3.3.10 shall require the written consent of all the registered holders. All other modifications or amendments, including any amendment to increase the Warrant Price or shorten the Exercise Period, shall require the written consent of the registered holders of Warrants equal to at least 67% of the Warrant Shares issuable upon exercise of all then outstanding Warrants. As a condition precedent to the Warrant Agent&#8217;s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed amendment is in compliance with the terms of this Section&#160;8.8. No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of this Warrant Agreement unless the same consideration is also offered to all holders of the Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:10pt;">. Wherever possible, each provision of this Warrant Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.10 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Restrictions</font><font style="font-family:inherit;font-size:10pt;">. Each registered holder acknowledges that the Warrant Shares acquired upon the exercise of a Warrant, if not registered, and the registered holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Nonwaiver and Expenses</font><font style="font-family:inherit;font-size:10pt;">. No course of dealing or any delay or failure to exercise any right hereunder on the part of a registered holder shall operate as a waiver of such right or otherwise prejudice such a registered holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant Agreement or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant Agreement or the Warrants, which results in any material damages to a registered holder, the Company shall pay such registered holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the registered holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.12. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Limitation of Liability</font><font style="font-family:inherit;font-size:10pt;">. No provision hereof, in the absence of any affirmative action by the registered holder to exercise a Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of a registered holder, shall give rise to any liability of each registered holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.13. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:10pt;">. The registered holders, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant Agreement. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant Agreement and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:10pt;">. The Warrant Agent and the Company agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public warrant holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Warrant Agreement including the fees for services set forth in the attached schedule shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by law, including, without limitation, pursuant to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions). </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.15. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consequential Damages</font><font style="font-family:inherit;font-size:10pt;">. Neither party to this Warrant Agreement shall be liable to the other party for any consequential, indirect, special or incidental damages under any provisions of this Warrant Agreement or for any consequential, indirect, penal, special or incidental damages arising out of any act or failure to act hereunder even if that party has been advised of or has foreseen the possibility of such damages. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.16 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:10pt;">. Notwithstanding anything to the contrary contained herein, the Warrant Agent will not be liable for any delays or failures in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9. </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Certain Definitions</font><font style="font-family:inherit;font-size:10pt;">. For purposes of this Warrant Agreement, the following terms shall have the following meanings: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1 &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Business Day</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law or executive order to remain closed. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.2 &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221; means (i)&#160;the Company&#8217;s shares of Common Stock and (ii)&#160;any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3 &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Control</font><font style="font-family:inherit;font-size:10pt;">&#8221; (including the terms &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">controlling</font><font style="font-family:inherit;font-size:10pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">controlled by</font><font style="font-family:inherit;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">under common control with</font><font style="font-family:inherit;font-size:10pt;">&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4 &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:10pt;">&#8221; means the date that is the five-year anniversary of the Issuance Date (or March 18, 2020) or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Holiday</font><font style="font-family:inherit;font-size:10pt;">&#8221;), the next date that is not a Holiday, as the same may be extended pursuant to Section&#160;3.3.7. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.5 &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:10pt;">&#8221; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.6 &#8220;Principal Market&#8221; means the principal securities exchange or securities market on which the Common Shares are then traded. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Remainder of page intentionally left blank. Signature page follows.</font><font style="font-family:inherit;font-size:10pt;">] </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, this Warrant Agreement has been duly executed by the parties hereto as of the day and year first above written. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;" align="right"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.81196581196581%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="14%"></td><td width="2%"></td><td width="84%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;/s/ Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and CEO</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPUTERSHARE INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;/s/ Neda Sheridan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neda Sheridan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPUTERSHARE TRUST COMPANY, N.A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Neda Sheridan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neda Sheridan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT A </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WARRANT NUMBER: &#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GALENA BIOPHARMA, INC. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WARRANT CERTIFICATE </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="33%"></td><td width="1%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS CERTIFIES THAT, for value received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">is the registered holder of a Warrant or Warrants (the &#8220; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8221;) expiring on March 18, 2020, subject to extension in certain events (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to purchase [&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;] fully paid and non-assessable shares (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of Common Stock, par value $0.0001 per share (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221;), of Galena Biopharma, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;). The Warrant entitles the holder thereof to purchase from the Company such number of shares of Common Stock at the price of $2.08 per share (subject to adjustment), upon surrender of this Warrant Certificate and payment of the Warrant Price to Computershare Inc. and Computershare Trust Company, N.A. (collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Agent</font><font style="font-family:inherit;font-size:10pt;">&#8221;), at its corporate trust department, but only subject to the conditions set forth herein and in the Warrant Agreement between the Company and the Warrant Agent (as may be amended from time to time, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;). The Warrant Agreement provides that upon the occurrence of certain events, the Warrant Price and the number of Shares purchasable hereunder, set forth on the face hereof, may, subject to certain conditions, be adjusted. The term &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrant Price</font><font style="font-family:inherit;font-size:10pt;">&#8221; as used in this Warrant Certificate refers to the price per share of Common Stock at which Shares may be purchased at the time the Warrant is exercised. Capitalized terms used and not defined herein shall have the meanings set forth in the Warrant Agreement. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No fraction of a Share will be issued upon any exercise of a Warrant. If the holder of a Warrant would be entitled to receive a fraction of a Share upon any exercise of a Warrant, the Company shall, at its election, either pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the Exercise Price or round up such fraction to the next whole share. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon any exercise of the Warrant for less than the total number of full Shares provided for herein, there shall be issued to the registered holder hereof or the registered holder&#8217;s assignee a new Warrant Certificate covering the number of Shares for which the Warrant has not been exercised, provided that such holder has previously surrendered this Warrant to the Warrant Agent. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon surrender of the Warrant Certificate for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer, the Warrant Agent shall register the transfer. A new Warrant Certificate or Warrant Certificates evidencing in the aggregate a like number of Warrants shall be issued and the old Warrant Certificate shall be canceled. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant Certificates, when surrendered to the Warrant Agent, may be transferred or exchanged in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates evidencing in the aggregate a like number of Warrants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and the Warrant Agent may deem and treat the registered holder as the absolute owner of this Warrant Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Warrant Certificate does not entitle the registered holder to any of the rights of a stockholder of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Remainder of page intentionally left blank. Signature page follows.</font><font style="font-family:inherit;font-size:10pt;">] </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;" align="right"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.81196581196581%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="14%"></td><td width="2%"></td><td width="84%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">COUNTERSIGNED:</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPUTERSHARE INC.</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as Warrant Agent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized Officer</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPUTERSHARE TRUST COMPANY, N.A.</font></div><div style="padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as Warrant Agent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Signature page to Warrant Certificate</font><font style="font-family:inherit;font-size:10pt;">] </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ELECTION TO PURCHASE FORM </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(to be executed by the registered holder in order to exercise Warrants) </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undersigned registered holder irrevocably elects to exercise Warrants to purchase &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Common Stock represented by this Warrant Certificate and to purchase such shares of Common Stock issuable upon the exercise of such Warrants, and requests that such shares shall be issued in the name of </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(PLEASE TYPE OR PRINT NAME AND ADDRESS)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER) </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and be delivered to: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(PLEASE PRINT OR TYPE NAME AND ADDRESS)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and, at the sole election of the registered holder, if such number of Warrants shall not be all the Warrants evidenced by this Warrant Certificate, that a new Warrant Certificate for the balance of such Warrants be registered in the name of, and delivered to, the registered holder at the address stated below: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.81196581196581%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="14%"></td><td width="2%"></td><td width="84%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(SIGNATURE)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ADDRESS)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(TAX IDENTIFICATION NUMBER)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSIGNMENT </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(to be executed by the registered holder in order to assign Warrants) </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Value Received, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; hereby sells, assigns, and transfers unto </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(PLEASE TYPE OR PRINT NAME AND ADDRESS)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER) </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and be delivered to </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(PLEASE PRINT OR TYPE NAME AND ADDRESS)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Common Stock represented by this Warrant Certificate, and hereby irrevocably constitutes and appoints &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Attorney to transfer this Warrant Certificate on the books of the Company, with full power of substitution in the premises. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="7%"></td><td width="1%"></td><td width="23%"></td><td width="1%"></td><td width="24%"></td><td width="1%"></td><td width="21%"></td><td width="1%"></td><td width="21%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(SIGNATURE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The signature to the assignment of the Subscription Form must correspond to the name written upon the face of this Warrant Certificate in every particular, without alteration or enlargement or any change whatsoever, and must be guaranteed by a commercial bank or trust company or a member firm of the American Stock Exchange, New York Stock Exchange, Pacific Stock Exchange or Chicago Stock Exchange. </font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40259621v.2</font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">-  .</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>gale-20150630xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX10.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6A620969F64716C21CD9FA3DA75E6387"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Form of Incentive Stock Option</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Granted Under Galena Biopharma 2007 Incentive Plan</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Grant of Option.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This certificate evidences an incentive stock option (this &#8220;Stock Option&#8221;) granted by Galena Biopharma, Inc.,</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;">a Delaware corporation (the &#8220;Company&#8221;), on </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DATE OF GRANT</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Date of Grant&#8221;) to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NAME</font><font style="font-family:inherit;font-size:12pt;">, an employee of the Company (the &#8220;Participant&#8221;) pursuant to the Company&#8217;s 2007 Incentive Plan (as from time to time in effect, the &#8220;Plan&#8221;).  Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NUMBER OF SHARES</font><font style="font-family:inherit;font-size:12pt;">&#32;shares of common stock of the Company (the &#8220;Shares&#8221;) at </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">STRIKE PRICE</font><font style="font-family:inherit;font-size:12pt;">&#32;per Share, which is not less than the fair market value of the Shares on the Date of Grant.  The latest date on which this Stock Option, or any part thereof, may be exercised is </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10 YEARS FROM DATE OF GRANT</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Final Exercise Date&#8221;).  The Stock Option evidenced by this certificate is intended to be an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the &#8220;Code&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option shall vest and become exercisable in equal quarterly installments over four years beginning three months after the Grant Date.</font></div></td></tr></table><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, upon termination of the Participant&#8217;s Employment, any portion of this Stock Option that is not then exercisable will immediately expire and the remainder of this Stock Option will remain exercisable for three months (unless termination of the Participant&#8217;s Employment resulted from reasons that in the determination of the Administrator cast such discredit on the Participant as to justify immediate forfeiture of this Stock Option, in which case this entire Option shall immediately expire and no portion thereof shall remain exercisable); </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, that</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">  </sup></font><font style="font-family:inherit;font-size:12pt;">any portion of this Stock Option held by the Participant immediately prior to the Participant&#8217;s death, to the extent then exercisable, will remain exercisable for one year following the Participant&#8217;s death; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">and further provided</font><font style="font-family:inherit;font-size:12pt;">, that in no event shall any portion of this Stock Option be exercisable after the Final Exercise Date.</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup>&#160;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Exercise of Stock Option.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant&#8217;s executor, administrator, or legally appointed representative (in the event of the Participant&#8217;s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the &#8220;Option Holder&#8221;), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan.  Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows:  (i) by delivery of cash or check acceptable to the Administrator; (ii) upon and following an initial public offering of the Company and to the extent permitted by applicable law (as determined by the Administrator), through a broker-assisted exercise program acceptable to the Administrator; or (iii) through any combination of the foregoing.  In the event that this Stock Option is exercised by an Option Holder other than </font></div><br><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><a name="s6A620969F64716C21CD9FA3DA75E6387"></a><div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Notice of Disposition.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The person exercising this Stock Option shall notify the Company when making any disposition of the Shares acquired upon exercise of this Stock Option, whether by sale, gift or otherwise.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Restrictions on Transfer of Shares.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If at the time this Stock Option is exercised the Company or any of its stockholders is a party to any agreement restricting the transfer of any outstanding shares of the Company&#8217;s common stock, the Administrator may provide that this Stock Option may be exercised only if the Shares so acquired are made subject to the transfer restrictions set forth in that agreement (or if more than one such agreement is then in effect, the agreement or agreements specified by the Administrator).</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If requested by the Corporation and the managing underwriter of an offering by the Corporation of Common Stock pursuant to a registration statement under the Securities Act of 1933, as amended, each stockholder who acquires shares by exercise of this Option shall agree, by executing and delivering such form of agreement as the Company and such underwriter shall reasonably request, not to sell publicly or otherwise transfer or dispose of any shares held by such stockholder or other securities of the Corporation held by such stockholder for a specified period of time (not to exceed 180 days) immediately following the effective date of such registration statement; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">provided</font><font style="font-family:inherit;font-size:12pt;">, that such agreement shall apply only to the initial public offering of the Corporation&#8217;s securities.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Withholding Agreement to Provide Security.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If at the time this Stock Option is exercised the Company determines that under applicable law and regulations it could be liable for the withholding of any federal or state tax upon exercise or with respect to a disposition of any Shares acquired upon exercise of this Stock Option, this Stock Option may not be exercised unless the person exercising this Stock Option remits to the Company any amounts determined by the Company to be required to be withheld upon exercise (or makes other arrangements satisfactory to the Company for the payment of such taxes) and gives such security as the Company deems adequate to meet its potential liability for the withholding of tax upon a disposition of the Shares and agrees to augment such security from time to time in any amount reasonably determined by the Company to be necessary to preserve the adequacy of such security.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><a name="s6A620969F64716C21CD9FA3DA75E6387"></a><div></div><br><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Nontransferability of Stock Option.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution and is exercisable during the Participant&#8217;s lifetime only by the Participant (or in the event of the Participant&#8217;s incapacity, the person or persons legally appointed to act on the Participant&#8217;s behalf).</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Provisions of the Plan.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference.  A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant.  By exercising all or any part of this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><a name="s32E7B8522FC4FB6E9AFCFA3DA79AC0A2"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Galena Biopharma</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By   </font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mark W. Schwartz, President &amp; CEO</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated:&#160;&#160;[_________________]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acknowledged and agreed:</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">_________________________________</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NAME</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated:&#160;&#160;[_________________]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><a name="s32E7B8522FC4FB6E9AFCFA3DA79AC0A2"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>gale-20150630xex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX10.2</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sB0D0AA61AA3029318C3DFA3E695E8354"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Form of Nonstatutory Stock Option</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Granted Under Galena Biopharma, Inc. 2007 Incentive Plan</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Grant of Option; Vesting.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This certificate evidences a nonstatutory stock option (this &#8220;Stock Option&#8221;) granted by Galena Biopharma, Inc., a Delaware corporation (the &#8220;Company&#8221;), on </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DATE OF GRANT</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Date of Grant&#8221;) to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NAME</font><font style="font-family:inherit;font-size:12pt;">, (the "Participant") pursuant to the Company's 2007 Incentive Plan (as from time to time in effect, the "Plan").  Under this Stock Option, the Participant may purchase, in whole or in part, on the terms herein provided, a total of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NUMBER OF SHARES</font><font style="font-family:inherit;font-size:12pt;">&#32;shares of common stock of the Company (the "Shares") at </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">STRIKE PRICE</font><font style="font-family:inherit;font-size:12pt;">&#32;per share, which is not less than the fair market value of the Shares on the Date of Grant.  The latest date on which this Stock Option, or any part thereof, may be exercised is the earlier of (i) the date two years following the termination of the Participant&#8217;s service on the Board or (ii) </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10 YEARS FROM DATE OF GRANT</font><font style="font-family:inherit;font-size:12pt;">&#32;(the "Final Exercise Date").  The Stock Option evidenced by this certificate is intended to be, and is hereby designated, a nonstatutory option, that is, an option that does </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">not</font><font style="font-family:inherit;font-size:12pt;">&#32;qualify as an incentive stock option as defined in section 422 of the Internal Revenue Code of 1986, as amended from time to time (the "Code").</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option is exercisable as to </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">X</font><font style="font-family:inherit;font-size:12pt;">&#32;shares upon each of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY VESTING DATES</font><font style="font-family:inherit;font-size:12pt;">&#32;such that this stock option will be fully exercisable as of </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FINAL VESTING DATE</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding any other provision of this Stock Option, if the Participant's service as a member of the Board of Directors is terminated for cause, this entire Stock Option shall immediately expire and no portion thereof shall remain exercisable. In addition, in no event shall any portion of this Stock Option be exercisable after the Final Exercise Date. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Exercise of Stock Option.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each election to exercise this Stock Option shall be in writing, signed by the Participant or the Participant's executor, administrator, or legally appointed representative (in the event of the Participant&#8217;s incapacity) or the person or persons to whom this Stock Option is transferred by will or the applicable laws of descent and distribution (collectively, the "Option Holder"), and received by the Company at its principal office, accompanied by this certificate and payment in full as provided in the Plan.  Subject to the further terms and conditions provided in the Plan, the purchase price may be paid as follows: (i) by delivery of cash or check acceptable to the Administrator; (ii) upon and following the registration of the common stock of the Company under the Securities and Exchange Act of 1934 and to the extent permitted be applicable law (as determined by the Administrator), through a broker-assisted exercise program acceptable to the Administrator; or (iii) through the delivery of shares of common stock of the Company that have been outstanding for at least six months and that have a fair market value equal to the exercise price; or (iv) through any combination of the foregoing.  In the event that this Stock Option is exercised by an Option Holder other than the Participant, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise this Stock Option.</font></div><br><div></div><hr style="page-break-after:always"><a name="sB0D0AA61AA3029318C3DFA3E695E8354"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Restrictions on Transfer of Shares.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If at the time this Stock Option is exercised the Company or any of its shareholders is a party to any agreement restricting the transfer of any outstanding shares of the Company&#8217;s common stock, the Administrator may provide that this Stock Option may be exercised only if the Shares so acquired are made subject to the transfer restrictions set forth in that agreement (or if more than one such agreement is then in effect, the agreement or agreements specified by the Administrator).</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Withholding Agreement to Provide Security.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If at the time this Stock Option is exercised the Company determines that under applicable law and regulations it could be liable for the withholding of any federal or state tax upon exercise or with respect to a disposition of any Shares acquired upon exercise of this Stock Option, this Stock Option may not be exercised unless the person exercising this Stock Option remits to the Company any amounts determined by the Company to be required to be withheld upon exercise (or makes other arrangements satisfactory to the Company for the payment of such taxes) and gives such security as the Company deems adequate to meet its potential liability for the withholding of tax upon a disposition of the Shares and agrees to augment such security from time to time in any amount reasonably determined by the Company to be necessary to preserve the adequacy of such security.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Nontransferability of Stock Option.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option is not transferable by the Participant otherwise than by will or the laws of descent and distribution, and is exercisable during the Participant's lifetime only by the Participant (or in the event of the Participant's incapacity, the person or persons legally appointed to act on the Participant's behalf).</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Provisions of the Plan.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Stock Option is subject to the provisions of the Plan, which are incorporated herein by reference.  A copy of the Plan as in effect on the date of the grant of this Stock Option has been furnished to the Participant.  By exercising all or any part of this Stock Option, the Participant agrees to be bound by the terms of the Plan and this certificate.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified herein.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sF31F99BB74FD5150694BFA3E698E5E39"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Galena Biopharma, Inc. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">:&#160;&#160;&#160;&#160;&#160;                                                    </font><font style="font-family:inherit;font-size:12pt;color:#ffffff;text-decoration:underline;">1</font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Mark W. Schwartz,  President and CEO</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated:&#160;_________________</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;Acknowledged</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NAME</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated:&#160;&#160;_________________</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>gale-20150630xex104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX10.4</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">THIS SEPARATION AND CONSULTING AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is entered into on June 24, 2015 by and between the Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">R E C I T A L S</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, the Parties desire to provide for the termination of Kivinski&#8217;s employment with the Company on the terms and subject to the conditions set forth herein; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, in connection with such termination, the Parties desire that Kivinski be retained to provide consulting services to the Company as provided herein; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, the Parties desire to fully and finally resolve, without litigation, any and all claims and disputes between them concerning Kivinski&#8217;s employment by the Company, the termination of her employment and all related matters on the terms set forth herein;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">AGREEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing and the mutual promises contained in this Agreement, the Parties agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.  Unless otherwise defined herein, capitalized terms used herein shall have the meanings indicated in paragraph 7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination of Employment; Resignation</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski&#8217;s employment with the Company terminated on the Separation Date, and the Employment Agreement, together with any of Kivinski&#8217;s previous employment arrangements with the Company, is terminated as of the Separation Date, except that the terms of the Employment Agreement that continue beyond the termination of such employment, including, but not limited to Exhibit 1 thereof (</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">i.e.</font><font style="font-family:inherit;font-size:12pt;">, Employee Confidentiality, Non-Competition, and Proprietary Information Agreement) shall not be affected by this Agreement (provided, however, that the governing law and arbitration provisions of the Employment Agreement, paragraph 12 thereof, are superseded by this Agreement and have no force or effect after the Separation Date).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski hereby resigns as of the Separation Date from all offices and positions at the Company and any of its subsidiaries or affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Separation Arrangements</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To the extent it shall not have done so previously, upon the execution and delivery of this Agreement, the Company shall pay Kivinski any accrued and unpaid base salary, any and all accrued and unpaid vacation pay, any other paid time off as of the Separation Date.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To the extent it shall not have done so previously, upon presentation by Kivinski on or after the Separation Date, the Company shall reimburse Kivinski for any previously unreimbursed business expenses incurred by her prior to the Separation Date in accordance with the Company&#8217;s usual expense reimbursement policies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski acknowledges and agrees that the foregoing compensation is all of the compensation and benefits payable or otherwise to be provided to Kivinski by the Company on and after the Separation Date in connection with or as a result of Kivinski&#8217;s employment, or termination of employment, with the Company, and that Kivinski is not entitled to any other compensation, benefits or perquisites from the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In consideration of this Agreement, including the Release, the Company shall pay Kivinski the following compensation:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon the Effective Date, the Company shall pay Kivinski $100,000, which equals four months of Kivinski&#8217;s annual salary under the Employment Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall pay or reimburse Kivinski for up to $2,000 of reasonable, documented, out-of-pocket expenses incurred by her in relocating her residence from Oregon to her home in California following the Separation Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski agrees that all compensation payable under this Subparagraph 3(d) is in addition to any compensation she is otherwise entitled to under her Employment Agreement or otherwise as a result of any obligation arising from her employment with the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski agrees that all compensation payable under this Paragraph 3 shall be paid after withholding for taxes that, in the Company&#8217;s reasonable good faith judgment, are required to be withheld by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company Property</font><font style="font-family:inherit;font-size:12pt;">.  Kivinski hereby acknowledges and agrees that, to the extent she has not previously done so, on the date of this Agreement Kivinski shall return to the Company all Company property, including, but not limited to, all keys, credit cards, documents, equipment (including computer and telephone equipment) files, data, and records of any kind whatsoever that she has, or has had, in her possession or control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consulting Agreement</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company hereby agrees that, commencing on the Separation Date, the Company shall engage Kivinski as a consultant, and Kivinski hereby accepts such engagement with the Company, upon the terms hereinafter set forth.</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Term, Kivinski shall make herself reasonably available during the Company&#8217;s normal business hours to consult with the officers, directors, employees and other agents and representatives of the Company and its affiliates on all legal aspects of the business, operations and activities of the Company and its affiliates.  Kivinski shall make herself so available by telephone, via the Internet or other remote access, as the Company deems reasonably necessary in the performance of her consulting services hereunder.  During the Term, Kivinski shall devote such of her business time and attention as is reasonably necessary hereunder.  Kivinski shall do so to the best of her abilities and in a professional and diligent manner.  During the Term and subject to the performance of her duties under this paragraph 5(b), Kivinski may engage on a full-time or part-time basis in any other business activities, provided that nothing in this paragraph shall be construed as permitting Kivinski to engage in any activities expressly prohibited by the other terms and provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as directed and authorized, in advance, in writing by the Chief Executive Officer of the Company, Kivinski shall have no authority, and shall not purport, to execute or agree to any contract, agreement or instrument on behalf of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski shall only provide those services that are requested of her by the Chief Executive Officer of the Company, or his designee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As full consideration for all consulting services rendered hereunder by Kivinski, during the Term the Company shall (i)&#160;pay to Kivinski a consulting fee of $25,000 per month (prorated for any partial month), payable in accordance with the Company&#8217;s usual payroll practices, and (ii)&#160;pay or reimburse Kivinski for the premiums for continuation through COBRA or otherwise of Kivinski&#8217;s healthcare benefits as in effect prior to the Separation Date for herself and her family under the Company&#8217;s employee healthcare plans in effect from time to time; thereafter, Kivinski will be permitted to continue those benefits at her own expense through COBRA coverage, with additional materials on COBRA coverage to be provided to Kivinski by the Company at the appropriate time.  Kivinski&#8217;s coverage under the Company&#8217;s plans shall be subject to the terms of the applicable plan documents and generally applicable Company policies.  Nothing in this Agreement shall restrict or otherwise affect the Company&#8217;s right to alter, modify, add to or discontinue its employee healthcare benefits at any time as it may determine in its sole judgment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski shall be fully responsible to pay any and all ordinary expenses and disbursements that she incurs in the performance of her consulting services, except to the extent Kivinski is requested to travel or incur extraordinary expense at the request of the Company in performance of her consulting services.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is understood and agreed that, because Kivinski will not be an employee of the Company:</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall not withhold any taxes from amounts paid to Kivinski pursuant to paragraph 5(e);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski shall not be eligible to participate in any benefits or programs sponsored or financed by the Company for its employees; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski shall be solely liable and responsible for paying any and all taxes relating to all amounts paid to Kivinski under paragraph 5(e) or paragraph 6(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All systems, inventions, discoveries, apparatus, techniques, methods, know-how, formulae or improvements made, developed or conceived by the consultant during consultant&#8217;s engagement by the Company whenever or wherever made, developed or conceived, and whether or not during business hours, which constitute an improvement, on those heretofore, now or at any during consultant&#8217;s engagement, developed, manufactured or used by the Company in connection with the manufacture, process or marketing of any product heretofore or now or hereafter developed or distributed by the Company, or any services to be performed by the Company or of any product which shall or could reasonably be manufactured or developed or marketed in the reasonable expansion of the Company&#8217;s business, shall be and continue to remain the Company&#8217;s exclusive property, without any added compensation or any reimbursement for expenses to consultant, and upon the conception of any and every such invention, process, discovery or improvement and without waiting to perfect or complete it, consultant promises and agrees that consultant will immediately disclose it to the Company and to no one else and thenceforth will treat it as the property and secret of the Company.  Consultant will also execute any instruments requested from time to time by the Company to vest in it complete title and ownership to such invention, discovery or improvement and will, at the request of the Company, do such acts and execute such instrument as the Company may require, but at the Company&#8217;s expense to obtain Letters of Patent, trademarks or copyrights in the United States and foreign countries, for such invention, discovery or improvement and for the purpose of vesting title thereto in the Company, all without any reimbursement for expenses (except as provided above) and without any additional compensation of any kind to consultant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall have the right to terminate this Agreement only for Cause upon notice to Kivinski.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski shall have the right to terminate this Agreement upon not less than 10 days' notice to the Company at any time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Upon termination of this Agreement by the Company or Kivinski, the Company shall pay any accrued and unpaid consulting fees and payments or reimbursements under paragraph 5(e) through the date of termination.  The terms of paragraphs 7 and 8(b) and, to </font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the extent necessary to construe or enforce such paragraphs, paragraph 10 hereof shall survive the expiration or termination of the Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidentiality; Non-Disparagement</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski agrees that, other than as required by law, she will never disclose any information whatsoever concerning the Company, her employment by the Company (except the fact and nature of her employment), or the business, clinical trials, technologies or other aspect of the Company or its business.  Further, Kivinski agrees that, other than as required by law, she will never disclose any information concerning the termination of such employment, this Agreement or any of its terms or provisions, directly or by implication, except to members of her immediate family and to her legal and financial advisors, and then only on condition that they agree never to further disclose any such information to others.  Kivinski further agrees that she will never disparage or criticize the Company, its business, management, affiliates or product candidates, products or technology, and that she will not otherwise do or say anything that could disrupt the good morale of Company employees or harm their interests or reputation, in each case, except in connection with any legal proceeding by Kivinski to enforce her rights under this Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company agrees that, other than as required by law, including, without limitation, the requirement of Form&#160;8&#8209;K under the Securities Exchange Act of 1934, as amended, it will never, and will never permit its officers to, disclose any information concerning Kivinski's employment by the Company, the circumstances surrounding the termination of that employment, this Agreement or any of its terms or provisions, directly or by implication, except to their respective legal and financial advisors, and then only on condition that they agree not to further disclose any such information to others.  The Company further agrees that it will never make any disparaging statements concerning Kivinski in authorized corporate communications to third parties, except that the Company may provide to prospective employers of Kivinski upon their request the Company&#8217;s standard reference check and except in connection with any legal proceeding by the Company to enforce its rights under this Agreement.  In any authorized corporate communications in this regard, the Company will say only that Kivinski was employed as the Company&#8217;s Vice President and General Counsel until the termination of her employment as described in the Form&#160;8&#8209;K referred to above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge and agree that nothing in this Agreement constitutes an acknowledgement of wrongdoing by either of the Parties.  The Parties agree not to represent or imply to any third party that the Agreement in any way reflects an admission by any of the other Parties of wrongdoing or illegal conduct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Release; Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In further consideration of the Company entering into this Agreement, and its promise to make payments and to provide benefits hereunder to which Kivinski is otherwise </font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">not entitled, Kivinski shall, concurrently with her execution and delivery of this Agreement, execute and deliver to the Company the Release.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties hereby agree to make, execute and deliver such other instruments or documents, and to do or cause to be done such further or additional acts, as may be reasonably necessary to effectuate the purposes or to implement the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As used in this Agreement, the following capitalized terms shall have the meanings indicated:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, this Separation and Consulting Agreement, as it may be amended as provided herein, and the Release.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the consultant&#8217;s conviction of, or plea of guilty or nolo contendere to, any felony or other crime of moral turpitude, or the consultant&#8217;s act of fraud or material dishonesty injurious to the Company or its reputation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Galena Biopharma, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Release.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Employment Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the employment agreement between the Company and Kivinski entered into on or about July 28, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Kivinski</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Margaret Kivinski.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Kivinski and the Company, collectively.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Release</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the General Release in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit&#160;1</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Separation Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means June 18, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the period commencing on the Separation Date and ending on the six-month anniversary of the Separation Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be amended only by a subsequent writing executed by the Parties.</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement and the other agreements referred to in this Agreement set forth the entire understanding of the Parties regarding this subject matter and supersede all prior contracts, agreements, arrangements, communications, discussions, representations and warranties, whether oral or written, between the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each section and subsection of this Agreement constitutes a separate and distinct provision of this Agreement. It is the intent of the Parties that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applicable in each jurisdiction in which enforcement is sought. Accordingly, if any provision of this Agreement is adjudicated to be invalid, ineffective or unenforceable, the remaining provisions will not be affected by such adjudication. The invalid, ineffective or unenforceable provision will, without further action by the Parties, be automatically amended to effect the original purpose and intent of the invalid, ineffective or unenforceable provision; provided, however, that such amendment will apply only with respect to the operation of such provision in the particular jurisdiction with respect to which such adjudication is made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">None of the terms of this Agreement will be deemed to be waived or amended by either Party unless such a waiver or amendment specifically references this Agreement and is in writing signed by an authorized representative of the Party to be bound.  Any such signed waiver will be effective only in the specific instance and for the specific purpose for which it was made or given.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The headings in this Agreement are solely for convenience of reference and are not to be given any effect in the construction or interpretation of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement may be executed in counterparts, including counterparts transmitted by electronic mail or facsimile transmission, each of which will be deemed to be an original and all of which together will constitute one and the same instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Kivinski acknowledges that her failure to comply with any of the provisions of paragraph 7 of this Agreement will irreparably harm the business and that the Company will not have an adequate remedy at law in the event of such non-compliance.  Therefore, Kivinski acknowledges that the Company will be entitled to injunctive relief and specific performance without the posting of bond or other security, in addition to whatever other remedies it may have, at law or in equity, in any court of competent jurisdiction against any acts of non-compliance by Kivinski under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The prevailing Party in any litigation relating to an alleged breach of this Agreement shall be entitled to an award of its reasonable attorneys&#8217; fees and costs to the extent permitted by law.</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Oregon without regard to any conflict or choice of law rules that would result in the application of any other state&#8217;s law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Parties to this Agreement acknowledge that they have entered into this Agreement voluntarily, without coercion and based upon their judgment and not in reliance upon any representation or promises made by the other Party other than those contained or referred to herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement shall be binding upon and inure to the benefit of the Parties and their respective heirs, legal representatives, successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[Signature Page Follows]</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Parties have caused this Separation and Consulting Agreement to be executed as of the date first set forth above.</font></div><br><hr style="page-break-after:always"><a name="s6CF2BEC385CE189C96DBE04948C4B406"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="48%"></td><td width="52%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Margaret Kivinski         </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MARGARET KIVINSKI</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">GALENA BIOPHARMA, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:   </font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Mark W. Schwartz</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;Mark W. Schwartz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:48px;text-indent:-48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[Signature Page of Separation and Consulting Agreement]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><hr style="page-break-after:always"><a name="s2DC52E8DE20DFDE44FF7E04948F58670"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">EXHIBIT 1</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">GENERAL RELEASE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;For and in consideration of the payments and other benefits provided in the Separation and Consulting Agreement, dated June 24, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Separation Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), by and between Galena Biopharma, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and myself, and other good and valuable consideration, I, for and on behalf of myself and my heirs, administrators, executors, and assigns, effective the date hereof, do hereby fully and forever Release, remise and discharge the Company, its successors and assigns, and the direct and indirect parents, subsidiaries and affiliates of the Company, together with their respective officers, directors, partners, shareholders, members, managers, employees and agents (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Group</font><font style="font-family:inherit;font-size:12pt;">&#8221;), from any and all Claims (as defined below) which I had, may have had, or now have against the Company or any other member of the Group, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to my employment or the termination of my employment with the Company, including but not limited to Claims of retaliation, specifically including, but not limited to Claims arising from any complaints or disagreements with Company management, breach of contract, breach of the Employment Agreement, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, handicap, religion, disability or sexual preference.  This Release includes, but is not limited to, all Claims arising under Title VII of the Civil Rights Act, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family Medical Leave Act, the Equal Pay Act, the ERISA, the Family and Medical Leave Act of 1993, the ADA, the Fair Labor Standards Act, and all other federal and Oregon and California state and local labor and anti-discrimination laws, the common law and any other purported restriction on an employer&#8217;s right to terminate the employment of employees.  As used in this Release, the term &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, attorneys&#8217; fees, accounts, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;I specifically release all Claims under the Age Discrimination in Employment Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ADEA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Older Worker Benefit Protection Act relating to my employment and its termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;I understand and agree that this Release fully and finally releases and forever resolves the matters released and discharged in paragraph&#160;1 and 2, including those which may be unknown, unanticipated and/or unsuspected, and hereby expressly waive all benefits under California Civil Code Section&#160;1542, as well as under any other applicable state statutes or common law principles of similar effect, for the purpose of implementing a full and complete release.  I expressly acknowledge that this Release is intended to include all Claims, including Claims, if any, which I do not know or suspect to exist in my favor and that this Release extinguishes those Claims to the extent that such benefits may contravene the release set forth in </font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2DC52E8DE20DFDE44FF7E04948F58670"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">this paragraph&#160;3.  I acknowledge that I have read and understand California Civil Code Section&#160;1542, which provides as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.&#160;&#160;&#160;&#160;This Release does not release any rights which as a matter of law cannot be waived, including but not limited to the rights or claims Kivinski may have arising under any workers&#8217; compensation statute or to vested accrued benefits earned under an employee benefit plan maintained by the Company and governed by the Employee Retirement Income Security Act of 1974.  Nor is this Release intended to limit Kivinski from filing a charge with, or participating in an investigation conducted by, the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) or similar state or federal agency; provided, however, that Kivinski expressly waives and relinquishes any rights Kivinski might have to recover monetary damages or other relief, whether equitable or legal, in any such proceeding concerning events or actions that arose on or before the date Kivinski signed this Agreement and Release and Kivinski agrees to notify any such agency that this Release constitutes a full and final settlement by Kivinski of all claims released hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.&#160;&#160;&#160;&#160;I represent that I have not transferred or assigned, or purported to transfer or assign, any Claims or filed or permitted to be filed against the Group, individually or collectively, any lawsuits, claims, arbitrations, or proceedings and I covenant and agree that I will not do so at any time hereafter with respect to the subject matter of this Release and Claims released pursuant to this Release (including, without limitation, any Claims relating to the termination of my employment), except as may be necessary to enforce this Release, to obtain benefits described in or granted under this Release, or to seek a determination of the validity of the waiver of my rights under the ADEA.  Except as otherwise provided in the preceding sentence, I will not voluntarily participate in any judicial or other proceeding of any nature or description against any member of the Group that in any way involves the allegations and facts that I could have raised against any member of the Group as of the date hereof, except as provided by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.&#160;&#160;&#160;&#160;I am specifically agreeing to the terms of this Release because the Company has agreed to pay to me money and other benefits to which I am not otherwise entitled and has provided such other good and valuable consideration as specified in the Separation Agreement.  The Company has agreed to provide this money and other benefits because of my agreement to accept it in full settlement of all possible Claims I might have or ever had, and because of my execution of this Release.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2DC52E8DE20DFDE44FF7E04948F58670"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Release, I will retain any rights that I have pursuant to the Separation Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.&#160;&#160;&#160;&#160;I acknowledge that I have read this Release in its entirety, fully understand its meaning and am executing this Release voluntarily and of my own free will with full knowledge of its significance.  I acknowledge and warrant that I have had the opportunity to consider for twenty-one (21) days the terms and provisions of this Release, although I may execute the Agreement and Release before the expiration of that period, and that I have been advised by the Company to consult with an attorney prior to executing this Release.  I shall have the right to revoke this Release for a period of seven (7) days following my execution of this Release, by giving written notice of such revocation to the Company.  I understand that if I revoke this Release, the Separation Agreement shall be null and void </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ab initio</font><font style="font-family:inherit;font-size:12pt;">&#32;and of no further force or effect and in such event I shall immediately pay and return to the Company the amount I received pursuant to paragraph 3(a)(i) of the Separation Agreement.  This Release shall not become effective until the eighth day following my execution of it (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.&#160;&#160;&#160;&#160;The Company shall be entitled to have the provisions of this Release specifically enforced through injunctive relief, without having to prove the inadequacy of the available remedies at law, and without being required to post bond or security, it being acknowledged and agreed that such breach will cause irreparable injury to the Company and that money damages will not provide an adequate remedy to the Company.  Moreover, I understand and agree that if I breach any provisions of this Release, in addition to any other legal or equitable remedy the Company may have, I shall reimburse the Company for all its reasonable attorneys&#8217; fees and costs incurred by it arising out of any such breach to the extent permitted by and as consistent with the law.  The remedies set forth in this paragraph 9 shall not apply to any challenge to the validity of the waiver and Release of my rights under the ADEA.  In the event I challenge the validity of the waiver and Release of my rights under the ADEA, then the Company&#8217;s right to attorneys&#8217; fees and costs shall be governed by the provisions of the ADEA, so that the Company may recover such fees and costs if the lawsuit is brought by me in bad faith.  Any such action permitted to the Company by this paragraph, however, shall not affect or impair any of my obligations under this Release, including without limitation, the Release of claims in paragraphs 1 through 3 hereof.  I further agree that nothing herein shall preclude the Company from recovering attorneys&#8217; fees, costs or any other remedies specifically authorized under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.&#160;&#160;&#160;&#160;In the event that any one or more of the provisions of this Release is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.  Moreover, if any one or more of the provisions contained in this Release is held to be excessively broad as to duration, scope, activity or subject, such provisions will be construed by limiting and reducing them so as to be enforceable to the maximum extent compatible with applicable law.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2DC52E8DE20DFDE44FF7E04948F58670"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.&#160;&#160;&#160;&#160;Nothing herein shall be deemed to constitute an admission of wrongdoing by the Company or any member of the Group.  Neither this Release nor any of its terms shall be used as an admission or introduced as evidence as to any issue of law or fact in any proceeding, suit or action, other than an action to enforce this Release.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.&#160;&#160;&#160;&#160;The terms of this Release and all rights and obligations of the parties thereto, including its enforcement, shall be interpreted and governed by the laws of the State of Oregon, without regard to the choice of law provisions of Oregon law, to the extent such provisions require the application of the laws of any other jurisdiction.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:66px;"><div style="text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated: June 24, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MARGARET KIVINSKI</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se8612896d6484f7cbeced5690755962e"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">GENERAL RELEASE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.&#160;&#160;&#160;&#160;For and in consideration of the payments and other benefits provided in the Separation and Consulting Agreement, dated June 24, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Separation Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), by and between Galena Biopharma, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and myself, and other good and valuable consideration, I, for and on behalf of myself and my heirs, administrators, executors, and assigns, effective the date hereof, do hereby fully and forever Release, remise and discharge the Company, its successors and assigns, and the direct and indirect parents, subsidiaries and affiliates of the Company, together with their respective officers, directors, partners, shareholders, members, managers, employees and agents (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Group</font><font style="font-family:inherit;font-size:12pt;">&#8221;), from any and all Claims (as defined below) which I had, may have had, or now have against the Company or any other member of the Group, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to my employment or the termination of my employment with the Company, including but not limited to Claims of retaliation, specifically including, but not limited to Claims arising from any complaints or disagreements with Company management, breach of contract, breach of the Employment Agreement, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, handicap, religion, disability or sexual preference.  This Release includes, but is not limited to, all Claims arising under Title VII of the Civil Rights Act, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family Medical Leave Act, the Equal Pay Act, the ERISA, the Family and Medical Leave Act of 1993, the ADA, the Fair Labor Standards Act, and all other federal and Oregon and California state and local labor and anti-discrimination laws, the common law and any other purported restriction on an employer&#8217;s right to terminate the employment of employees.  As used in this Release, the term &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Claims</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, attorneys&#8217; fees, accounts, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.&#160;&#160;&#160;&#160;I specifically release all Claims under the Age Discrimination in Employment Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ADEA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Older Worker Benefit Protection Act relating to my employment and its termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.&#160;&#160;&#160;&#160;I understand and agree that this Release fully and finally releases and forever resolves the matters released and discharged in paragraph&#160;1 and 2, including those which may be unknown, unanticipated and/or unsuspected, and hereby expressly waive all benefits under California Civil Code Section&#160;1542, as well as under any other applicable state statutes or common law principles of similar effect, for the purpose of implementing a full and complete release.  I expressly acknowledge that this Release is intended to include all Claims, including Claims, if any, which I do not know or suspect to exist in my favor and that this Release extinguishes those Claims to the extent that such benefits may contravene the release set forth in this paragraph&#160;3.  I acknowledge that I have read and understand California Civil Code Section&#160;1542, which provides as follows:</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se8612896d6484f7cbeced5690755962e"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.&#160;&#160;&#160;&#160;This Release does not release any rights which as a matter of law cannot be waived, including but not limited to the rights or claims Kivinski may have arising under any workers&#8217; compensation statute or to vested accrued benefits earned under an employee benefit plan maintained by the Company and governed by the Employee Retirement Income Security Act of 1974.  Nor is this Release intended to limit Kivinski from filing a charge with, or participating in an investigation conducted by, the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) or similar state or federal agency; provided, however, that Kivinski expressly waives and relinquishes any rights Kivinski might have to recover monetary damages or other relief, whether equitable or legal, in any such proceeding concerning events or actions that arose on or before the date Kivinski signed this Agreement and Release and Kivinski agrees to notify any such agency that this Release constitutes a full and final settlement by Kivinski of all claims released hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.&#160;&#160;&#160;&#160;I represent that I have not transferred or assigned, or purported to transfer or assign, any Claims or filed or permitted to be filed against the Group, individually or collectively, any lawsuits, claims, arbitrations, or proceedings and I covenant and agree that I will not do so at any time hereafter with respect to the subject matter of this Release and Claims released pursuant to this Release (including, without limitation, any Claims relating to the termination of my employment), except as may be necessary to enforce this Release, to obtain benefits described in or granted under this Release, or to seek a determination of the validity of the waiver of my rights under the ADEA.  Except as otherwise provided in the preceding sentence, I will not voluntarily participate in any judicial or other proceeding of any nature or description against any member of the Group that in any way involves the allegations and facts that I could have raised against any member of the Group as of the date hereof, except as provided by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.&#160;&#160;&#160;&#160;I am specifically agreeing to the terms of this Release because the Company has agreed to pay to me money and other benefits to which I am not otherwise entitled and has provided such other good and valuable consideration as specified in the Separation Agreement.  The Company has agreed to provide this money and other benefits because of my agreement to accept it in full settlement of all possible Claims I might have or ever had, and because of my execution of this Release.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Release, I will retain any rights that I have pursuant to the Separation Agreement.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se8612896d6484f7cbeced5690755962e"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.&#160;&#160;&#160;&#160;I acknowledge that I have read this Release in its entirety, fully understand its meaning and am executing this Release voluntarily and of my own free will with full knowledge of its significance.  I acknowledge and warrant that I have had the opportunity to consider for twenty-one (21) days the terms and provisions of this Release, although I may execute the Agreement and Release before the expiration of that period, and that I have been advised by the Company to consult with an attorney prior to executing this Release.  I shall have the right to revoke this Release for a period of seven (7) days following my execution of this Release, by giving written notice of such revocation to the Company.  I understand that if I revoke this Release, the Separation Agreement shall be null and void </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ab initio</font><font style="font-family:inherit;font-size:12pt;">&#32;and of no further force or effect and in such event I shall immediately pay and return to the Company the amount I received pursuant to paragraph 3(a)(i) of the Separation Agreement.  This Release shall not become effective until the eighth day following my execution of it (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.&#160;&#160;&#160;&#160;The Company shall be entitled to have the provisions of this Release specifically enforced through injunctive relief, without having to prove the inadequacy of the available remedies at law, and without being required to post bond or security, it being acknowledged and agreed that such breach will cause irreparable injury to the Company and that money damages will not provide an adequate remedy to the Company.  Moreover, I understand and agree that if I breach any provisions of this Release, in addition to any other legal or equitable remedy the Company may have, I shall reimburse the Company for all its reasonable attorneys&#8217; fees and costs incurred by it arising out of any such breach to the extent permitted by and as consistent with the law.  The remedies set forth in this paragraph 9 shall not apply to any challenge to the validity of the waiver and Release of my rights under the ADEA.  In the event I challenge the validity of the waiver and Release of my rights under the ADEA, then the Company&#8217;s right to attorneys&#8217; fees and costs shall be governed by the provisions of the ADEA, so that the Company may recover such fees and costs if the lawsuit is brought by me in bad faith.  Any such action permitted to the Company by this paragraph, however, shall not affect or impair any of my obligations under this Release, including without limitation, the Release of claims in paragraphs 1 through 3 hereof.  I further agree that nothing herein shall preclude the Company from recovering attorneys&#8217; fees, costs or any other remedies specifically authorized under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.&#160;&#160;&#160;&#160;In the event that any one or more of the provisions of this Release is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.  Moreover, if any one or more of the provisions contained in this Release is held to be excessively broad as to duration, scope, activity or subject, such provisions will be construed by limiting and reducing them so as to be enforceable to the maximum extent compatible with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.&#160;&#160;&#160;&#160;Nothing herein shall be deemed to constitute an admission of wrongdoing by the Company or any member of the Group.  Neither this Release nor any of its terms shall be used as an admission or introduced as evidence as to any issue of law or fact in any proceeding, suit or action, other than an action to enforce this Release.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se8612896d6484f7cbeced5690755962e"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.&#160;&#160;&#160;&#160;The terms of this Release and all rights and obligations of the parties thereto, including its enforcement, shall be interpreted and governed by the laws of the State of Oregon, without regard to the choice of law provisions of Oregon law, to the extent such provisions require the application of the laws of any other jurisdiction.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:66px;"><div style="text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated: June 24, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Margaret Kivinski            </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MARGARET KIVINSKI</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>gale-20150630xex105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX10.5</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s99D3F3C9C079083B2863FA50D0419720"></a><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:341px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">June 23, 2015</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Via Electronic Mail</font></div><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Thomas J. Knapp </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dear Tom:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We are pleased to extend our offer of employment as interim General Counsel of Galena Biopharma, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;) on the terms set forth or referred to in this offer letter.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We understand that you have agreed to serve as a consultant to Sucampo Pharmaceuticals, Inc. through August of this year, but that such services will not interfere materially with your duties to the Company.  Except for the performance of your consulting services to Sucampo, during your employment by the Company you will devote all of your business and professional time, energy, business judgment, knowledge, skill and best efforts to the performance of your employment duties with the Company.  You will report directly to the Company&#8217;s President and Chief Executive Officer.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During your employment, you will commute as necessary to work at the Company&#8217;s offices in Portland, Oregon, or in the San Francisco Bay area to which the offices may be relocated, except for travel elsewhere from time to time as reasonably required in connection with your employment duties.  Our present expectation is that you initially would work from the Company&#8217;s offices at least three days a week.  On the days you are not working at the Company&#8217;s offices, you will make yourself available to work by remote access from your home in Maryland.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you accept our offer, your employment will commence on Thursday, June 25, 2015 and end on December 31, 2015, unless your employment is sooner terminated as provided below in this officer letter or is extended by mutual agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">COMPENSATION AND CERTAIN BENEFITS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Your compensation and employee benefits will be as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:82px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;">During the term of your employment by the Company, you will be entitled to a salary of $27,083.33 per month (prorated for any period of less than a full month), payable in accordance with our standard payroll practices and subject to deductions for applicable federal, state and local withholding.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s86CDAAE2EA09E742F384FA50D073221B"></a><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:82px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Thomas J. Knapp June 23, 2015</font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page 2 of 4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:82px;padding-top:4px;text-align:left;text-indent:48px;"><font style="padding-top:4px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;">You will be entitled to reimbursement of your reasonable business expenses, including your reasonable travel and lodging expenses only incurred in connection with your commute to the Company&#8217;s offices and the reasonable telephone expenses and similar out-of- pocket expense incurred in working remotely, in accordance with our standard expense reimbursement practices.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:82px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;">The Company will provide you the use of a Company computer, which you will be required to return to the Company upon termination of your employment.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:82px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;">As a one-time signing bonus, upon the date your employment commences, the Company will grant to you under its 2007 Amended and Restated Incentive Plan, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">2007 Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;), a non-qualified stock option to purchase up to 40,000 shares of common stock of the Company.  The option will have an exercise price equal to the closing price of our common stock on the date of grant, will be subject to vesting in six approximately equal monthly installments as of the end of each month during the period ending December 31, 2015, subject to your remaining in our continuous service through each monthly vesting date, and be on such other terms and provisions as are contained in the Company&#8217;s standard-form nonqualified stock option agreement under the 2007 Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE BENEFIT PLANS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">During your employment with the Company, you will be entitled to paid time off in accordance with our standard policies and to participate in all group benefit plans made available generally to employees of the Company.  The Company reserves the right to amend, modify or terminate its policies and benefit plans at any time.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMPLOYEE HANDBOOK AND OTHER POLICIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You will be bound by the employment terms contained in the Company&#8217;s Employee Handbook and other written policies of the Company in effect from time to time and be required to sign the Company&#8217;s standard-form Employee Confidentiality, Non-competition and Proprietary Information Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RIGHT TO WORK STATUS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the Immigration Reform and Control Act, the Company is required to verify identity and work authorization of all newly hired employees. Therefore, you will be required to complete the I-9 form upon hire. Within three business days of beginning your employment, you also will need to supply acceptable documentation (as noted on the I-9 Form) of your identity</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sA2B87CF43272A0640708FA50D0950E78"></a><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:1px;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:82px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Thomas J. Knapp June 23, 2015</font></div><div style="line-height:100%;padding-top:2px;text-align:left;padding-left:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page 3 of 4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and work authorization.  For your convenience, we have enclosed a copy of the I-9 form and List of acceptable documentation for your review.</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BACKGROUND CHECK</font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><a name="sA12DAF09B75DF263BEE5FA50D0C8918B"></a><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:26px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This offer is subject to our completion of a customary background check satisfactory to us.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div></div><br><a name="sEE68C2164AFDBBB42BBFFA50D0E92074"></a><div style="line-height:120%;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NATURE OF &#8220;AT WILL&#8221; EMPLOYMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you accept this offer, your employment will be &#8220;at will,&#8221; which means that either you or the Company may terminate your employment relationship at any time, with or without cause, upon not less than 30 days&#8217; advance written notice. This means, among other things, that upon termination of your employment relationship, the Company&#8217;s sole obligation to you will be to pay you any accrued and unpaid salary, plus any unreimbursed business expenses and accrued but unused paid time off as provided herein, through the termination date and any benefits in accordance with the Company&#8217;s employee benefit plans in which you are then participating as provided herein.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">* * * * * *</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you require further clarification or information, please contact me.</font></div><div style="line-height:120%;text-align:justify;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the terms of employment set forth in this offer letter are acceptable to you, please sign and date a copy of this offer letter where indicated below and return it to me. You can fax this page to me or sign, scan, and email it to me.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon execution by you, this offer letter will replace any prior or contemporaneous oral or written understanding or agreement concerning terms of employment between you and the Company.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This offer letter and any dispute concerning the validity, enforceability or interpretation of this offer letter or the terms of your employment will be governed by the internal laws of the State of Oregon without regard to conflict-of-law principles.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We look forward to you joining our team and to a mutually rewarding relationship.</font></div><div style="line-height:120%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:398px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;padding-left:240px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sincerely,</font></div><div style="line-height:100%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:center;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Mark W. Schwartz, Ph. D.</font></div><br><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s5C0339ACE3CD9B8AB54EFA50D11BDE3F"></a><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:8.5pt;"><font style="font-family:inherit;font-size:8.5pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Thomas J. Knapp June 23, 2015</font></div><div style="line-height:120%;text-align:left;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page 4 of 4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:401px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:82px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">I hereby accept the foregoing offer on the terms set forth above and acknowledge this agreement with the Company; and that no other terms, conditions or representations other than those contained herein form part of this agreement.  I understand that my employment relationship is on an &#8220;at-will&#8221; basis and can be terminated by either the Company or myself at any time, with or without cause, or upon not less than 30 days&#8217; advance written notice.  I hereby represent and warrant to the Company that (a) I have the legal right to enter into this agreement and to perform my employment obligations hereunder and (b) am not a party to any agreement or understanding, and am not subject to any restriction, which, in either case, could prevent me from entering into this agreement or performing my employment duties hereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.83177570093457%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:66px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dated: June 24, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Thomas J. Knapp</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><br><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>gale-20150630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX31.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s8DB840B0DF2C9A5CC58CD437D09171EE"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mark W. Schwartz, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: August 6, 2015</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark W. Schwartz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>gale-20150630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX31.2</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s3A5AE00CA726BC40BC94D437D1378C0C"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ryan M. Dunlap, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Galena Biopharma, Inc.;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: August 6, 2015</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="61%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Chief Financial Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>gale-20150630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>GALE-2015.06.30-EX32.1</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s1330BDF531A591A7CF7AD437D1DF266F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the accompanying Quarterly Report of Galena Biopharma, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officers of the Company certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="46%"></td><td width="8%"></td><td width="46%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark W. Schwartz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ryan M. Dunlap</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 6, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 6, 2015</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>gale-20150630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:6a2e4fb305b241ac9e602ebb73059c94,x:5b203ec6c2d74934bfb584f4a963585e-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:gale="http://www.galenabiopharma.com/20150630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="gale-20150630.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">gale:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jul18ToMar31_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-18</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:ZuplenzMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:ZuplenzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2MAY8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-07</xbrli:startDate>
			<xbrli:endDate>2013-05-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gale:FirstTrancheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Apr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-10</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:LincolnParkCapitalLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-18</xbrli:startDate>
			<xbrli:endDate>2014-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Mar18ToApr10">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-04-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MLVCo.LLCandMaximGroupLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:SeptemberTwoThousandThirteenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:DecemberTwoThousandTwelveWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:AprilTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandElevenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandFifteenWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:MarchTwoThousandTenWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">gale:ConsultantWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gale:TwoZeroZeroSevenIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3Jul17_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-17</xbrli:startDate>
			<xbrli:endDate>2014-07-17</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">gale:MDAndersonCancerCenterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4SharesOutstanding_us-gaap_BusinessAcquisitionAxis_gale_OrexoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:OrexoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3Jul17_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-07-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3Jul17">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-07-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3Jul17_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-07-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4OCT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q3Jul17_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-07-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_OrexoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gale:OrexoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">gale:CustomerOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="products">
		<xbrli:measure>gale:products</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="dosing_strength">
		<xbrli:measure>gale:dosing_strength</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="pharmacy">
		<xbrli:measure>gale:pharmacy</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2015Q2YTD" id="Fact-A56447C1C30FE187BE8ED437A5BDB936">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q2YTD" id="Fact-9A256C1FF6A56ECC3B76D437A5BCE851">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q2YTD" id="Fact-5C75F9CDC430530FE08DD437A5BC5707">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q2YTD" id="Fact-3D86482B90CA16CEAA3DD437A5BD8F93">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q2YTD" id="Fact-CBBF15A63BAD29CD7FB6D437A5BD4A47">2015-06-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q2YTD" id="Fact-F0DBDAF947DB873F048BD437A5BC6801">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q2YTD" id="Fact-360A7776B0B2D3869900D437A5BC48F5">0001390478</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2015Q3" decimals="INF" id="Fact-1C9B64FC4793AE38AF4CD437A5BCA42D" unitRef="shares">161862321</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2015Q2YTD" id="Fact-ED959FE33B1A8A20E30CD437A5BD03D4">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2015Q2YTD" id="Fact-BA7A98AF3246AAFF3843D437A5BC4B79">Galena Biopharma, Inc.</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2015Q2YTD" id="Fact-F89A6EC110C87F8548DDD437A5BCC2EF">GALE</dei:TradingSymbol>
	<gale:AccruedInventoryPurchasesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-4420ABE89487CBC41637FE56F52121E2" unitRef="usd">0</gale:AccruedInventoryPurchasesCurrent>
	<gale:AccruedInventoryPurchasesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-C06979CFAEC8523DA72EFE56F51E516C" unitRef="usd">420000</gale:AccruedInventoryPurchasesCurrent>
	<gale:AnnualMaintenanceFee contextRef="FI2015Q2_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="INF" id="Fact-042D24F394F189DD12D2D437A750A2B9" unitRef="usd">200000</gale:AnnualMaintenanceFee>
	<gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds contextRef="FD2014Q4YTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-6" id="Fact-D3E142D9583836900B40E0938D81993B" unitRef="usd">20000000</gale:AtMarketIssuanceSalesAgreementsMaximumGrossProceeds>
	<gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds contextRef="FI2014Q4_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="2" id="Fact-F71B916601570C2ECD85E0934E23CA9E" unitRef="number">0.03</gale:AtMarketIssuanceSalesAgreementsPercentofGrossProceeds>
	<gale:BusinessAcquisitionCashHeldByAcquiredEntity contextRef="I2013Q4SharesOutstanding_us-gaap_BusinessAcquisitionAxis_gale_OrexoMember" decimals="-6" id="Fact-655CACB669FBBB1774C8D437A7509D14" unitRef="usd">5000000</gale:BusinessAcquisitionCashHeldByAcquiredEntity>
	<gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights contextRef="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-571F576B6D91026D3EB4D437A652518E" unitRef="usd">8101000</gale:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2014Q2YTD" decimals="-3" id="Fact-D5F4CE8A24108821ABF3D437A6311F5A" unitRef="usd">6439000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings contextRef="FD2015Q2YTD" decimals="-3" id="Fact-F9D2AB710FD910CAB58DD437A625F86D" unitRef="usd">-3115000</gale:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2014Q2YTD" decimals="-3" id="Fact-5A68BCAC5D660B141F94D437A627C93B" unitRef="usd">-656000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchaseConsideration contextRef="FD2015Q2YTD" decimals="-3" id="Fact-727A60CA385FD4FE2C1DD437A62CF122" unitRef="usd">-238000</gale:ChangeInFairValueOfContingentPurchaseConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2014Q2QTD" decimals="-3" id="Fact-5A4395930A98D812C511D437A73D3E34" unitRef="usd">490000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2014Q2YTD" decimals="-3" id="Fact-EAEE42C1F25641121453D437A748C8BB" unitRef="usd">656000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q2QTD" decimals="-3" id="Fact-5AD47783DC782616EB7ED437A73E4BDE" unitRef="usd">-83000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q2YTD" decimals="-3" id="Fact-C022955DC7D363E634B7D437A7489DE9" unitRef="usd">238000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfContingentPurchasePriceConsideration contextRef="FD2015Q2YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-2BBB1A37510FE76FAFFDD437A66654DF" unitRef="usd">238000</gale:ChangeInFairValueOfContingentPurchasePriceConsideration>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1905342EF763B7F27121D437A70B8E88" unitRef="usd">3115000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-E906D4A377F8804323F8D437A70DEB11" unitRef="usd">82000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-C8A634684A0C30E4611BD437A70C4702" unitRef="usd">107000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-6C17224FFB72F225F0A7D437A70C7C76" unitRef="usd">23000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-B52DECB38F49292D3630D437A70C2B18" unitRef="usd">2663000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-C5CDC51B862AC7440D22D437A70CC79C" unitRef="usd">-2000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ChangeInFairValueOfWarrantLiabilities contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-DD6520791A046E1EABEFD437A70C656B" unitRef="usd">242000</gale:ChangeInFairValueOfWarrantLiabilities>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-43081693C98DE39F0141D437A7103C1F">2020-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2014Q3QTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-BC1413F5BF62E39B733DD437A7101D73">2014-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-65BCA1046DE8CA55F64ED437A6C70141">2017-04-30</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-B1967758AEE7973F95CDD437A6C00A50">2017-12-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-F45311158164945F55D7D437A6C1FF11">2016-03-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-99D68DCFD52BA7B9BDA8D437A6C8B1D0">2020-03-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-6BD808FE6B0E3C280429D437A6C01291">2016-03-31</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassOfWarrantsOrRightsExpirationDate contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-8B83FBE40913E3A35702D437A6C80DD7">2018-09-18</gale:ClassOfWarrantsOrRightsExpirationDate>
	<gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice contextRef="D2013Q2MAY8" id="Fact-BF6C6B45FB1BCD226912D437A68F86AF">P20D</gale:ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q2YTD" decimals="-3" id="Fact-6C9977AC5E462D375AA1D437A6AC5BDD" unitRef="shares">238000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightExpired contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-A9DD0170397F3BA48E92D437A6AC01E6" unitRef="shares">238000</gale:ClassofWarrantorRightExpired>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A48A2949B59445F8898FD437A6C89607" unitRef="shares">14006000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-4B0D1C1F7B1AA4DEF88ED437A6C823FD" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-442EA05D9F18CEF05F68D437A6C1536E" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-5746383D55F0C46F0E4BD437A6C19760" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-D7519BF9B5B1B8688CC5D437A6C7A710" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-2AF13AA310F1286A1EE2D437A6C7CADF" unitRef="shares">14006000</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-3A10FC682D75FEC878A9D437A6C861B1" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-0C61E7468A818E6D447AD437A6C0B25B" unitRef="shares">0</gale:ClassofWarrantorRightGranted>
	<gale:ClassofWarrantorRightTerm contextRef="D2013Q2MAY8" id="Fact-30490C5DE11F50A9CB28D437A68F2D79">P7Y</gale:ClassofWarrantorRightTerm>
	<gale:ClosingPriceOfCommonStock contextRef="FI2015Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="2" id="Fact-716B71C3B24DEA02089ED437A72A281F" unitRef="usdPerShare">1.70</gale:ClosingPriceOfCommonStock>
	<gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan contextRef="FI2015Q2" decimals="-3" id="Fact-858180FE0EBDB9D85245D437A6AAF893" unitRef="shares">674000</gale:CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2014Q4" decimals="-3" id="Fact-63811E14DA3573642748D437A5C9AC01" unitRef="usd">6651000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion contextRef="FI2015Q2" decimals="-3" id="Fact-622C5E9D45E453B10186D437A5CAED38" unitRef="usd">6889000</gale:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
	<gale:ContractResearchPayable contextRef="FI2014Q4" decimals="-3" id="Fact-B0D3D206674268CD4910D437A6832FD4" unitRef="usd">6967000</gale:ContractResearchPayable>
	<gale:ContractResearchPayable contextRef="FI2015Q2" decimals="-3" id="Fact-45C44B989D1531E39AE4D437A683B5D8" unitRef="usd">5779000</gale:ContractResearchPayable>
	<gale:ContractualObligationNetSalesThreshold contextRef="I2014Q3Jul17_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-5AFA302B14FA9CC78C9FFE4226D2A347" unitRef="usd">100000000</gale:ContractualObligationNetSalesThreshold>
	<gale:ContractualObligationNetSalesThreshold contextRef="I2014Q3Jul17_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-7FF83B87794B50E26DA0FE4226DE3922" unitRef="usd">20000000</gale:ContractualObligationNetSalesThreshold>
	<gale:ContractualObligationPotentialPaymentsfromNetSales contextRef="I2014Q3Jul17" decimals="-5" id="Fact-87647FFFFA80FCBA02EBFE40D65282C3" unitRef="usd">16500000</gale:ContractualObligationPotentialPaymentsfromNetSales>
	<gale:CreditMemosAcquisitionChannelInventoryCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-39655994382958CD1AECD437A68381E1" unitRef="usd">1995000</gale:CreditMemosAcquisitionChannelInventoryCurrent>
	<gale:CreditMemosAcquisitionChannelInventoryCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-E89007C0EEDBFBC3DBD1D437A683D921" unitRef="usd">1995000</gale:CreditMemosAcquisitionChannelInventoryCurrent>
	<gale:DebtInstrumentCashFacilityFee contextRef="I2013Q2May8" decimals="INF" id="Fact-92463396B882C3865E5AD437A68F4712" unitRef="number">0.01</gale:DebtInstrumentCashFacilityFee>
	<gale:DebtInstrumentCashFinalPayment contextRef="I2013Q2May8" decimals="INF" id="Fact-1F4D88E9F67C9EE190F2D437A68E5D17" unitRef="number">0.055</gale:DebtInstrumentCashFinalPayment>
	<gale:DebtInstrumentTermInterestOnly contextRef="D2013Q2MAY8" id="Fact-4F7E30643228FC841298D437A68EEFE0">P12M</gale:DebtInstrumentTermInterestOnly>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2014Q4" decimals="-3" id="Fact-6866FFB309ED8814D128D437A5CA095E" unitRef="usd">-215481000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:DeficitAccumulatedDuringDevelopmentalStage contextRef="FI2015Q2" decimals="-3" id="Fact-93E5F53A833809C6B9F3D437A5CCE710" unitRef="usd">-241678000</gale:DeficitAccumulatedDuringDevelopmentalStage>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts contextRef="FD2015Q2YTD" decimals="-3" id="Fact-C7DFC44DE02AAAFD0ADED437A729740D" unitRef="usd">5582000</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts>
	<gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition contextRef="FD2015Q2YTD" id="Fact-7373573C9250FD76B191D437A729A032">P2Y6M15D</gale:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees contextRef="FD2015Q2YTD" decimals="2" id="Fact-29990C9992193B672BBAD437A7298267" unitRef="number">0.15</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees>
	<gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement contextRef="FD2015Q2YTD" decimals="2" id="Fact-007440E683DB379BDD87D437A72ADD4D" unitRef="number">0.08</gale:EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement>
	<gale:EstimatedYearOfPatentExpiration contextRef="FD2015Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_OrexoMember" id="Fact-9985E826E17603D2724ED437A750A13F">2019</gale:EstimatedYearOfPatentExpiration>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-D57C974918EBBD187060D437A6ECB102">P2Y3M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-5F8001C3488C5F017221D437A6EAD075">P2Y11M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-D5D61311A332A815A3C3D437A6EC6896">P1Y2M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-60093D170CA06BF20D62D437A6EC12C9">P1Y2M27D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2014Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-22F507F3C1E27308D36DD437A6EAD2FB">P3Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" id="Fact-37CAF594F3C960C460EAD437A6DCEE74">P1Y9M22D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" id="Fact-435BE0882525D219EB81D437A6DCFC1E">P2Y5M23D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" id="Fact-5422D6583808ED7E88F8D437A6DCFE64">P8M5D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" id="Fact-4F4779FE53B229497CA2D437A6DB8C5C">P4Y8M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" id="Fact-D050B3D3B19ECEFC888ED437A6DCBCEE">P8M27D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" id="Fact-5604A1EFA1206188D461D437A6DB78FB">P3Y2M19D</gale:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
	<gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity contextRef="FD2015Q2YTD" decimals="-3" id="Fact-110A4E531F2B46C24992D437A626E7A6" unitRef="usd">10296000</gale:FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-305AFC9D465F3113D529D437A70D6B82" unitRef="usd">5383000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-A8E071110FF828B26CEDD437A70DD807" unitRef="usd">625000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-E2435EB40814661ADD63D437A70D0FDF" unitRef="usd">2027000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-36B0726B8B62F534A485D437A70D502F" unitRef="usd">163000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-2FD7F1837FF6F62FF90BD437A70BA7A5" unitRef="usd">0</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-F4132BA4E874F9129638D437A70BBD50" unitRef="usd">8000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-137CE40515EDC816840FD437A70D73AF" unitRef="usd">2560000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2" decimals="-3" id="Fact-344B2950DA9377028934D437A70D28B5" unitRef="usd">18794000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-DCF5A02ED9F8A4FBD9C4D437A70AA9C2" unitRef="usd">707000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-6FF076D096CAC9FA0291D437A70E3517" unitRef="usd">2134000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-AC8E2578AB8E2C6AAC7BD437A70BEE3E" unitRef="usd">186000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-C3E4C7EB90C773692B1AD437A70B8C3B" unitRef="usd">12959000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-2B07AFED2DAECC710D4FD437A70B6FCC" unitRef="usd">6000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsLiabilities contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-E52393067684A8622223D437A70C0287" unitRef="usd">2802000</gale:FairValueOfWarrantsLiabilities>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4" decimals="-3" id="Fact-DA366DD57641BF4A7BDDD437A5CDE913" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-95E870E8C3F538BCDF6AD437A66339C9" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BFF092E28282C58F1123D437A664C5B1" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F9F672F981021F84758D437A66382A7" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-238B02AA5B6160EE63B1D437A662ACC9" unitRef="usd">5383000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q2" decimals="-3" id="Fact-4697F978F1D71C6598C2D437A5C79B4F" unitRef="usd">18794000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-08566CEA6B5C62BACCE4D437A67CC3F4" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4277992B9EADAA31A010D437A67DB8B8" unitRef="usd">18794000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-115642DDBFF25E8918A9D437A67E7675" unitRef="usd">0</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueOfWarrantsPotentiallySettleableInCash contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-EA458CE47C4CC72F477DD437A67C097C" unitRef="usd">18794000</gale:FairValueOfWarrantsPotentiallySettleableInCash>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D9E0FF365EEE2DCBC4FFD437A70B5253" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-EC4202CFBCDA773328C0D437A70BB5F6" unitRef="usd">10296000</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGranted contextRef="FD2015Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-AFD1BBDDAB85C8F6E7F9D437A70CFD73" unitRef="usd">0</gale:FairValueofWarrantsGranted>
	<gale:FairValueofWarrantsGrantedperShare contextRef="I2013Q2May8" decimals="2" id="Fact-F1CF5292C22F59BCFA6CD437A6F8F3A0" unitRef="usdPerShare">1.93</gale:FairValueofWarrantsGrantedperShare>
	<gale:FinitelivedIntangibleAssetsAcquiredContingentConsideration contextRef="I2014Q3Jul17_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-343AE018B93C3E1CB6F6FE38CA9074B6" unitRef="usd">250000</gale:FinitelivedIntangibleAssetsAcquiredContingentConsideration>
	<gale:FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod contextRef="D2014Q3Jul17_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" id="Fact-682E590DFFDCC5DDCC58FE38E4635CAF">P30D</gale:FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod>
	<gale:FutureMilestonePayment contextRef="FI2014Q4" decimals="-3" id="Fact-C4D4EA1988362A5E47FDD437A6843C15" unitRef="usd">740000</gale:FutureMilestonePayment>
	<gale:FutureMilestonePayment contextRef="FI2015Q2" decimals="-3" id="Fact-E574B317DC6DECF25584D437A684FF91" unitRef="usd">240000</gale:FutureMilestonePayment>
	<gale:FutureMilestonePayment contextRef="FI2015Q2_dei_LegalEntityAxis_gale_MDAndersonCancerCenterMember" decimals="INF" id="Fact-2C8CC49EA9E3CF52432BD437A751EE57" unitRef="usd">200000</gale:FutureMilestonePayment>
	<gale:GALE401rights contextRef="FI2014Q4" decimals="-3" id="Fact-C08AFECB1DFFDA529845D437A5CB9DF5" unitRef="usd">9255000</gale:GALE401rights>
	<gale:GALE401rights contextRef="FI2015Q2" decimals="-3" id="Fact-D279564123547C7874D6D437A5CACBF8" unitRef="usd">9255000</gale:GALE401rights>
	<gale:InProcessResearchDevelopment contextRef="FI2014Q4" decimals="-3" id="Fact-B18ABBD8007099796A12D437A5CD06DF" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:InProcessResearchDevelopment contextRef="FI2015Q2" decimals="-3" id="Fact-C67C1291D9D127AB00FDD437A5CCA91D" unitRef="usd">12864000</gale:InProcessResearchDevelopment>
	<gale:LossContingencyPercentageofLegalFeesPaid contextRef="FI2015Q2" decimals="2" id="Fact-F722CEFED75D57396854FE1ACD7604FE" unitRef="number">0.88</gale:LossContingencyPercentageofLegalFeesPaid>
	<gale:LossOnWarrantExchange contextRef="FD2014Q2QTD" decimals="-3" id="Fact-416D8A60D7D6CA2D945DD437A5EA6FA3" unitRef="usd">3353000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2014Q2YTD" decimals="-3" id="Fact-AE7CA7D8E4A4FD01CAE5D437A5D81758" unitRef="usd">-6439000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q2QTD" decimals="-3" id="Fact-9C3DEA48E6CA837A0882D437A5EA25CF" unitRef="usd">4267000</gale:LossOnWarrantExchange>
	<gale:LossOnWarrantExchange contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2EF88D205432DDA70B43D437A5DAE86D" unitRef="usd">3115000</gale:LossOnWarrantExchange>
	<gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents contextRef="FD2014Q3QTD" id="Fact-1742439AFD22118FC48FD437A647B442">P90D</gale:MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents>
	<gale:MiscellaneousOtherIncomeExpense contextRef="FD2014Q2QTD" decimals="-3" id="Fact-8A85842A5D05A089CB1FD437A73D8338" unitRef="usd">-1000</gale:MiscellaneousOtherIncomeExpense>
	<gale:MiscellaneousOtherIncomeExpense contextRef="FD2014Q2YTD" decimals="-3" id="Fact-A3E5C7983D242C09EF24D437A7471BAD" unitRef="usd">0</gale:MiscellaneousOtherIncomeExpense>
	<gale:MiscellaneousOtherIncomeExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-F5ACF705A8D7E76055D9D437A73D8ACC" unitRef="usd">0</gale:MiscellaneousOtherIncomeExpense>
	<gale:MiscellaneousOtherIncomeExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2EC74376D995F9FCE540D437A7481289" unitRef="usd">0</gale:MiscellaneousOtherIncomeExpense>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2014Q2YTD" decimals="-3" id="Fact-36C9271188194DE78A2FD437A6335D0A" unitRef="usd">10585000</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NetProceedsFromExerciseOfCommonStockWarrants contextRef="FD2015Q2YTD" decimals="-3" id="Fact-3E82172499EEF5C4F1ABD437A62665E2" unitRef="usd">0</gale:NetProceedsFromExerciseOfCommonStockWarrants>
	<gale:NumberofCommericalProducts contextRef="FI2015Q2" decimals="INF" id="Fact-3645BB1CB74B62E6EE9CD437A75F4717" unitRef="products">1</gale:NumberofCommericalProducts>
	<gale:NumberofDaysAveragedforExercisePrice contextRef="D2013Q2MAY8" id="Fact-09467144110A0E422A37D437A6F263D3">P20D</gale:NumberofDaysAveragedforExercisePrice>
	<gale:NumberofDosingStrengths contextRef="FI2015Q2" decimals="INF" id="Fact-D1792E26524E8D0601A4D437A75F015C" unitRef="dosing_strength">6</gale:NumberofDosingStrengths>
	<gale:NumberofSharesPerUnit contextRef="I2015Q1Mar18" decimals="INF" id="Fact-B2D52CC6DB7E2B249E85D437A6A25179" unitRef="shares">0.50</gale:NumberofSharesPerUnit>
	<gale:NumberofTopPerformingPharmacies contextRef="FD2014Q2QTD" decimals="INF" id="Fact-AF22142E764933BB1CE5FE4A3DBB0B55" unitRef="pharmacy">3</gale:NumberofTopPerformingPharmacies>
	<gale:NumberofTopPerformingPharmacies contextRef="FD2014Q2YTD" decimals="INF" id="Fact-0266AB64E018954551F8FE4A3E5A8FE0" unitRef="pharmacy">3</gale:NumberofTopPerformingPharmacies>
	<gale:NumberofTopPerformingPharmacies contextRef="FD2015Q2QTD" decimals="INF" id="Fact-CE13619EF6B895E71C99FE48BF0026DC" unitRef="pharmacy">3</gale:NumberofTopPerformingPharmacies>
	<gale:NumberofTopPerformingPharmacies contextRef="FD2015Q2YTD" decimals="INF" id="Fact-1DD7F18CC030917C4ED9FE47EE407871" unitRef="pharmacy">3</gale:NumberofTopPerformingPharmacies>
	<gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan contextRef="FI2015Q2" decimals="-3" id="Fact-D24B7330B897BA445AFBD437A6AB31C5" unitRef="shares">10066000</gale:OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan>
	<gale:PatientAssistanceProgramCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-AF5F170231F49B854684D437A68AE77C" unitRef="usd">2444000</gale:PatientAssistanceProgramCurrent>
	<gale:PatientAssistanceProgramCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-709E9E16730BDBAB9326D437A6842067" unitRef="usd">953000</gale:PatientAssistanceProgramCurrent>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Apr10" decimals="-5" id="Fact-0A81BCE2D865D1E8A2A2D437A6A8A471" unitRef="usd">5400000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses contextRef="D2015Q2Mar18ToApr10" decimals="-5" id="Fact-5D7F7E33633D182998CBD437A6A3C367" unitRef="usd">40800000</gale:ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses>
	<gale:PurchaseAgreementTerm contextRef="D2014Q4Nov18" id="Fact-C649D550BC93E00B78CAE08A4D5D0B76">P36M</gale:PurchaseAgreementTerm>
	<gale:ReclassificationOfWarrantLiabilityUponExercise contextRef="FD2014Q2YTD" decimals="-3" id="Fact-C7F9654224BCD3088192D437A62E4960" unitRef="usd">27020000</gale:ReclassificationOfWarrantLiabilityUponExercise>
	<gale:SalesAndDistributionsRights contextRef="FI2014Q4" decimals="-3" id="Fact-2E08CA1DA323BDED0760D437A5CD7815" unitRef="usd">14533000</gale:SalesAndDistributionsRights>
	<gale:SalesAndDistributionsRights contextRef="FI2015Q2" decimals="-3" id="Fact-9E6ADEF83AD161432289D437A5CDD21E" unitRef="usd">13946000</gale:SalesAndDistributionsRights>
	<gale:SalesAndDistributionsRightsZuplenz contextRef="FI2014Q4" decimals="-3" id="Fact-7B76A8BC67F95F4F6DE5D437A5CCD529" unitRef="usd">8101000</gale:SalesAndDistributionsRightsZuplenz>
	<gale:SalesAndDistributionsRightsZuplenz contextRef="FI2015Q2" decimals="-3" id="Fact-5CC3E7468FE441C8DB9AD437A5CB09EC" unitRef="usd">8101000</gale:SalesAndDistributionsRightsZuplenz>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod contextRef="FD2015Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-D78ED80A16E30FAB8CE1D437A72A7EB6">P10Y</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1365A72D12068CDBA0EDD437A739A897" unitRef="usd">16000</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue>
	<gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A6E81914F1DEF63EFF56D437A7394D8E" unitRef="usd">89000</gale:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q1Mar18" decimals="0" id="Fact-619E9E46323349BE29B8D437A6A2EA1A" unitRef="shares">1826923</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:StockIssuedDuringPeriodSharesOverallotmentOption contextRef="D2015Q2Apr10" decimals="INF" id="Fact-518834DA3E79DED42827D437A6A00B64" unitRef="shares">3653846</gale:StockIssuedDuringPeriodSharesOverallotmentOption>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-8E758A7A34814200CE78D437A6EAF9D3" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-1BAEB5BD3AE3C322FEA2D437A6EB49B6" unitRef="usdPerShare">1.90</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-03540B67A0DF615F0124D437A6EBA51A" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-6EA3BD260F2E511667BAD437A6ED8425" unitRef="usdPerShare">2.15</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-44C0BBABA87B383889AFD437A6EA68E6" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="2" id="Fact-B09B4FA637B521626DC3D437A6DA7EB7" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="2" id="Fact-A661057785B43BAD1229D437A6DB10D6" unitRef="usdPerShare">1.83</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="2" id="Fact-9D8F6FAAA4A761BE6DA8D437A6DA3632" unitRef="usdPerShare">0.65</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="2" id="Fact-E3BAD8B3E434CF036C43D437A6DB7F9A" unitRef="usdPerShare">2.08</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="2" id="Fact-97A267F793CE0C737ADCD437A6DBA2BA" unitRef="usdPerShare">2.02</gale:WarrantStrikePrice>
	<gale:WarrantStrikePrice contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="2" id="Fact-E915414F9CDF3904D598D437A6DA735C" unitRef="usdPerShare">2.50</gale:WarrantStrikePrice>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-2050737F0EA9950B4D00D437A6EB1E91" unitRef="number">0.7824</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-C8F8DC1559C30BE53E76D437A6EABEC5" unitRef="number">0.7685</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-5DF8B1BBEC92C7947393D437A6ED28D6" unitRef="number">0.7738</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-FA112C4619E40950B700D437A6EABF89" unitRef="number">0.7712</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-67DEA53AC404C47E9391D437A6ECC8E2" unitRef="number">0.7560</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-4E35CCEE53D64A117FA4D437A6DA3D0F" unitRef="number">0.7703</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-B56197991E9957D968CBD437A6DBD05E" unitRef="number">0.7200</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-9363F5510FD527340D8BD437A6DC74C6" unitRef="number">0.6312</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-8F1F6EBE8CB86BFB2BA5D437A6DA78C5" unitRef="number">0.7298</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-D720E40141DD14EBF9C6D437A6DB2A53" unitRef="number">0.6481</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsExpectedVolatility contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-22A924A5BD8048C07EFFD437A6DBF7E5" unitRef="number">0.7559</gale:WarrantsFairValueAssumptionsExpectedVolatility>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-56A735B1ADBB91105E36D437A6EBA141" unitRef="number">0.0080</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-FB0B6514C69109A45DBAD437A6EDD047" unitRef="number">0.0109</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-4067297678B2A7608877D437A6EC56FB" unitRef="number">0.0032</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-AF41AD352EC57AA171ABD437A6EB7926" unitRef="number">0.0035</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-06A75D441A7C2E50EB24D437A6EC7B41" unitRef="number">0.0130</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="4" id="Fact-DF4B488687CEF71DB383D437A6DB2E8E" unitRef="number">0.0057</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="4" id="Fact-3BE457E4166931B79C24D437A6DA473A" unitRef="number">0.0082</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="4" id="Fact-0AE9F13C9F046D8C76A8D437A6DC747C" unitRef="number">0.0017</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="4" id="Fact-5742833DD764446681D6D437A6DC0146" unitRef="number">0.0154</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="4" id="Fact-E37B43F6FAD71780DC4CD437A6DA630F" unitRef="number">0.0019</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsFairValueAssumptionsRiskFreeInterestRate contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="4" id="Fact-8D84C8BB13744F5618A3D437A6DB20A3" unitRef="number">0.0108</gale:WarrantsFairValueAssumptionsRiskFreeInterestRate>
	<gale:WarrantsGrantedNumberofShares contextRef="I2013Q2May8" decimals="0" id="Fact-586E26A02C49C65F71F2D437A6F8CF53" unitRef="shares">182186</gale:WarrantsGrantedNumberofShares>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-3BD81E40159C1B3A52CBD437A5CB1B6C" unitRef="usd">2271000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-26417A89A33679B4EFE3D437A5C9D67A" unitRef="usd">2318000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-179670D8DB08BFF9E939D437A5C80E59" unitRef="usd">1839000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-34C2D63FBEBCD692443FD437A5C74E31" unitRef="usd">1818000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-325082B61BF9FF8BA7C5D437A5C91578" unitRef="usd">15669000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-0AB7BADFBFBD9DFCA995D437A5CB69F4" unitRef="usd">12923000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-7BE1F764AEFD271C38E9D437A6843A16" unitRef="usd">860000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-BC8AC5B3E49A722B044CD437A684E481" unitRef="usd">1087000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-A08435CAEA18A2025EFAD437A685C646" unitRef="usd">408000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-4C8A9F9624CAE31E5C65D437A6842B63" unitRef="usd">431000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2014Q4" decimals="-3" id="Fact-9A41CA74D5748AA92C04D437A5CA80B4" unitRef="usd">256377000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q2" decimals="-3" id="Fact-A470E7C69926B83AB859D437A5CA6CC3" unitRef="usd">294877000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q2YTD" decimals="-3" id="Fact-BA9B91378D5E4F8B5E5DD437A604CB7D" unitRef="usd">1272000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BCDDD1D0EDDF8824DE0BD437A603EC4F" unitRef="usd">1272000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2QTD" decimals="-3" id="Fact-2D0AD06737891F480C11D437A711E207" unitRef="usd">1452000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-C4ECA73901BBD711C07AD437A711F607" unitRef="usd">187000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-6C5075FE1E6224B8556CD437A7114D62" unitRef="usd">1265000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2YTD" decimals="-3" id="Fact-ED6A4AA2268D6FC2C9E0D437A71C04F6" unitRef="usd">3136000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DE421E14195AE86C7224D437A71C3B5B" unitRef="usd">347000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-6E7E27B181636F45FB80D437A71B123B" unitRef="usd">2789000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-CEDDF5F16B9E1CAB1C7BD437A711D838" unitRef="usd">643000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-071F833801BEE0222AC9D437A71115AD" unitRef="usd">93000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-66109D3992864A1C2A87D437A71141BA" unitRef="usd">550000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1120A0134C6E9241C8F3D437A71C29A2" unitRef="usd">1272000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-C2DC6B8EAD30A39AF086D437A71C12AF" unitRef="usd">170000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-98DB15C0E2C8C9D67C9DD437A71CD5D8" unitRef="usd">1102000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2014Q4" decimals="0" id="Fact-1E1B484FE9F56A40D7AFD437A649F624" unitRef="usd">160000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2015Q2" decimals="0" id="Fact-D1375E204507830292E2D437A645BE28" unitRef="usd">160000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q2QTD" decimals="-3" id="Fact-A5FEAB1D7DCD75390E7DD437A5EAB452" unitRef="usd">98000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q2YTD" decimals="-3" id="Fact-3EB915B15E523294BF16D437A5D785A2" unitRef="usd">189000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q2QTD" decimals="-3" id="Fact-7E42AE4BC4E0D5D11DFBD437A5E9FF39" unitRef="usd">442000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q2YTD" decimals="-3" id="Fact-6210A92B1E1814E808A2D437A5D7D796" unitRef="usd">588000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q2YTD" decimals="-3" id="Fact-8537891CFB86366434D0D437A74B88A3" unitRef="shares">19408000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-480A6CC188AF215F4405D437A74A6950" unitRef="shares">9848000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-C45FF62EEF4131E77505D437A74B1795" unitRef="shares">9560000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2E3DBBBE427E472EC77AD437A74BBEF1" unitRef="shares">33719000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F77F11549FC75EA932C6D437A74AD220" unitRef="shares">11411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-753C8E59F8C9E4402A20D437A74AA359" unitRef="shares">22308000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-E502AB6BB326F486B3FDD437A5CDC727" unitRef="usd">80488000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q2" decimals="-3" id="Fact-092F9EE2998D6ACFE94DD437A5CC2767" unitRef="usd">101967000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-4EBE83EDDA367CE18FC4D437A5CABAEF" unitRef="usd">29024000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-441F153E38ED60DF4731D437A5CDE5FB" unitRef="usd">51122000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3F59DD53FF4593064D88D437A6633B25" unitRef="usd">19477000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9C178523D0853599F268D437A664DF75" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F5C2D9B01311E07A8221D437A66414A9" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A4DEEE064E67AFBEFCA9D437A662D59D" unitRef="usd">19477000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5D2DB6F501802E2265EAD437A67CC409" unitRef="usd">42913000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1B7DA208D33015E21840D437A67D2876" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-80492624DF4908DCBE84D437A67E850B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-049B5B55810BDC178574D437A67C60A0" unitRef="usd">42913000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D40D9ACBA6BAB29123DCD437A652B96D" unitRef="usd">2482000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q1Jul18ToMar31_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-468C6F356DEF5AF71C64D437A65171D2" unitRef="usd">8273000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="D2015Q1Jul18ToMar31_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-6101B092CA074B63035AD437A65284A1" unitRef="usd">240000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
	<us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="D2015Q1Jul18ToMar31_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-DCFA0D82CB29A27057FED437A6513DC5" unitRef="usd">1995000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-3D1B106D53B912D7A49DD437A6523A3E" unitRef="usd">3556000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-6874306AE3FF47700A25D437A6267D24" unitRef="usd">47787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q2" decimals="-3" id="Fact-9FC75A2D72E2E2B40D3BD437A627D859" unitRef="usd">39162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-BCA7FED75B779DC7515CD437A5CBE5BB" unitRef="usd">23650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q2" decimals="-3" id="Fact-188920D48330F3BF17B4D437A5C96A54" unitRef="usd">45279000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6515D5BDC5BA1702F87AD437A662FED1" unitRef="usd">19477000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9EE3D61E505A03F6D741D437A663D111" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-822AE8327CA80466D150D437A662C091" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-048C685E138E475C6CADD437A663ACC7" unitRef="usd">19477000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-304D42F53C1C0E6AE220D437A67CD788" unitRef="usd">42913000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CB9D5677265B447EE096D437A67DEFF8" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4077B11022B80F083B47D437A67DB2D5" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8B4C7CE0FB9700830889D437A67CAD45" unitRef="usd">42913000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q2YTD" decimals="-3" id="Fact-5F462A36AD67CABC38F0D437A6324D1D" unitRef="usd">-8625000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A4E0FA21632F6501A6EFD437A6314CBB" unitRef="usd">21629000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q2May8" decimals="INF" id="Fact-FFA70F966148CE22A083D437A68EE481" unitRef="usdPerShare">2.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q1Mar18" decimals="INF" id="Fact-1764AB176E5EECD42727D437A6A282FF" unitRef="usdPerShare">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q2May8_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-FEDF3308CD14E8CB4F69D437A68FE170" unitRef="shares">182186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q1Mar18" decimals="INF" id="Fact-0AFAB26656173F99699FD437A6A1568A" unitRef="shares">1826923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-32C0F6AB8E3AE211506CD437A6C87315" unitRef="shares">8540000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-045808EBBA406CA2F907D437A6C1CCE0" unitRef="shares">615000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-840FCDD1AAE4004B213ED437A6C906FF" unitRef="shares">720000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-67B09498F2A3B6045D4AD437A6C0820E" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-ECD60DA6529083021AE3D437A6C67EF1" unitRef="shares">176000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-A39A43FFBEB7AA54EA94D437A6C7B846" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-6555FFD74074B1CF1AA1D437A6C848E2" unitRef="shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-2E0B1C8DD6837CA40C91D437A6C037B9" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2" decimals="-3" id="Fact-55D91823255CBDBF5A1CD437A6ABF84C" unitRef="shares">22308000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_AprilTwoThousandElevenWarrantMember" decimals="-3" id="Fact-893121531A37619BAD75D437A6C8CBF1" unitRef="shares">615000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_ConsultantWarrantsMember" decimals="-3" id="Fact-C0CD625BB5FB92DDFE3DD437A6C76168" unitRef="shares">482000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_DecemberTwoThousandTwelveWarrantMember" decimals="-3" id="Fact-EEF2804CFECC65778ED4D437A6C8A0DA" unitRef="shares">3031000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandElevenWarrantMember" decimals="-3" id="Fact-646526DC0B53B1DFC5F2D437A6C042AE" unitRef="shares">176000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandFifteenWarrantsMember" decimals="-3" id="Fact-1C170B1DE81369405B59D437A6C843FB" unitRef="shares">14006000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_MarchTwoThousandTenWarrantMember" decimals="-3" id="Fact-2B7BFB63F5B81580688AD437A6C74B16" unitRef="shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q2_us-gaap_ClassOfWarrantOrRightAxis_gale_SeptemberTwoThousandThirteenWarrantMember" decimals="-3" id="Fact-1B88F01D7D874258739FD437A6C14BF3" unitRef="shares">3973000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-0CD7AD4AE499D66DC7C5D437A5CDB584" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q2" id="Fact-234F49176410654E55E9D437A5C9E514" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2015Q2" decimals="-3" id="Fact-87BE231F50DF0662BEB3D437A6AB41AB" unitRef="shares">44459000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-547CDC8A62D606D0422FD437A5D484AA" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q2" decimals="INF" id="Fact-46C6D5D6995996A7965ED437A5D465B3" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-1F14E91BFD99619D22ACD437A5D39481" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q2" decimals="INF" id="Fact-407FFCDC09D8EBD05F14D437A5D3C261" unitRef="shares">275000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2015Q1Mar18" decimals="INF" id="Fact-B64D7CD4C589A75FD316D437A6A9F211" unitRef="shares">3653846</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4" decimals="INF" id="Fact-A747507297BA294AC1C0D437A5D34874" unitRef="shares">110100701</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q2" decimals="INF" id="Fact-BE538FE7AE591C4AF760D437A5D3266D" unitRef="shares">121457118</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-837AD251F64BD8CFE411D437A5D48140" unitRef="shares">109425701</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q2" decimals="INF" id="Fact-7DB3B2ED9B9FC3D26E76D437A5D2C750" unitRef="shares">121457118</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-4DE973C92F51E65F394ED437A5CCAEDE" unitRef="usd">12000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2015Q2" decimals="-3" id="Fact-937D386B90E1C91556BCD437A5C8B463" unitRef="usd">15000</us-gaap:CommonStockValue>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" decimals="2" id="Fact-DDD29156D0D9285C08FCD437A75F0931" unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-AD33E0BFE0EC026463AEE0AE14BCC5F3" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-D360B54757D659ABE27BE0AE0F1875FD" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-9400B0B0EC4A1DF20C1CE0AE018B8B7D" unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-A2AD64651C3FFFCACB7CE0AE0AC04425" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-83036505C641500EBC9EE0AE064EA4B9" unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" decimals="2" id="Fact-04253552703489F97951FE466897DC68" unitRef="number">0.59</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-EF476943AE1C688C0994D437A769407E" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-9CB2C2E26467689F90EBD437A7690300" unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-71B5454AFE4A31CBB161D437A7684F11" unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-C473D03C74DE945F95E7D437A769DE4F" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-1B677C37E5B5E2C36280D437A768AC76" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-D61F2A1C69E7C1376774D437A75B8E97" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-FF9030E7405553B18FA4D437A75C65F2" unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-ADEA5362E4AFED480B25D437A75BE079" unitRef="number">0.63</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-CA84E4C939BB36630E01D437A75B6F2B" unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2014Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-6FD6BE458F4D7264AF14D437A75B8FB3" unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" decimals="2" id="Fact-D787BF06DED2547CED09D437A75FDD60" unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-AF9DDCAC98EA9B6D7FCAE0AE10ED7CE5" unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-30C3330A6485BFDD362FE0AE0C4BADE5" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-A8B0F02028AAEBD71644E0ADFE98CAC0" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-25C80EC000C7084EE775E0AE07DE256C" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-6F543DFD0F983611BA1BE0AE033FE695" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" decimals="2" id="Fact-325C67B95763E885CA3BFE4669E3025E" unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-86AE9485A1756BCB3F19D437A75BD06C" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-99C8AA2ED5FC6C4F9E60D437A75CD9CB" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-0DD2428E69BE0F0E277FD437A75C5959" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-0EBFF1DCA7E934409068D437A75B439F" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-EEBBC521FEAC8C58B107D437A75B9565" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFiveMember" decimals="2" id="Fact-9DE7A0378CE483815523D437A76954E0" unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerFourMember" decimals="2" id="Fact-774255644AF62829D6CAD437A769B98D" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerOneMember" decimals="2" id="Fact-D6EF39139DF3964C65E2D437A7685364" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerThreeMember" decimals="2" id="Fact-2906D922649C7775B1B4D437A768A35B" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_MajorCustomersAxis_gale_CustomerTwoMember" decimals="2" id="Fact-2037DF20E64AA983BCAED437A769301B" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E0DB68F5F662BAD56765D437A66313EB" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B037FCFCF63906696EE7D437A664ED5B" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-745B61AC94B78D91EB8AD437A6665DAE" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A9ABF230599FA19F35ABD437A66497D8" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6A81EA9E5D7C12FB5F2BD437A662F4D1" unitRef="usd">6651000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-53C05AF84295B01E2751D437A67D3597" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-497A16C29AF76D538B62D437A67DCB85" unitRef="usd">0</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-025E2D7D2DF746A9BD51D437A666E4EF" unitRef="usd">6889000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-98D5E1669756A74126F3D437A67EEC22" unitRef="usd">6889000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D1476CF0A7ADB1E11D9CD437A67C2F9A" unitRef="usd">6889000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
	<us-gaap:CostOfRevenue contextRef="FD2014Q2QTD" decimals="-3" id="Fact-415C0CE7AEC55F3BED17D437A5E8F75A" unitRef="usd">347000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2014Q2YTD" decimals="-3" id="Fact-FD4D10D8EA4EF8E1AA4DD437A5D80F31" unitRef="usd">678000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2015Q2QTD" decimals="-3" id="Fact-5B6AD5659226ACC05898D437A5E8DE57" unitRef="usd">468000</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue contextRef="FD2015Q2YTD" decimals="-3" id="Fact-25A9C5D4515BDB3A7015D437A5D8BF98" unitRef="usd">861000</us-gaap:CostOfRevenue>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q2QTD" decimals="-3" id="Fact-D58503C967B26B186041D437A5E98931" unitRef="usd">18114000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q2YTD" decimals="-3" id="Fact-E6BEEB127086A9875363D437A5D9391A" unitRef="usd">32136000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q2QTD" decimals="-3" id="Fact-5B460504790A9764BA43D437A5E8EDDC" unitRef="usd">14651000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q2YTD" decimals="-3" id="Fact-91B5BAE23E0ECA93EEC2D437A5D799D3" unitRef="usd">28527000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="I2013Q2May8_us-gaap_LongtermDebtTypeAxis_gale_FirstTrancheMember" decimals="-6" id="Fact-1681A9FCCBAE4F444C15D437A68EC8F1" unitRef="usd">10000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q2May8" decimals="INF" id="Fact-86586A8DF736C17BD8B4D437A68F9C0F" unitRef="number">0.0845</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentTerm contextRef="D2013Q2MAY8" id="Fact-C55840F51E661A31E23FD437A68FECB1">P30M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-A373C9E7875B7E9F73B7D437A5CC9918" unitRef="usd">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2015Q2" decimals="-3" id="Fact-506E3F6DA6D748C78186D437A5CA540C" unitRef="usd">-5053000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-16A88D5927BE4725C18AD437A5C89634" unitRef="usd">87000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepositsAssetsNoncurrent contextRef="FI2015Q2" decimals="-3" id="Fact-167997F98490BB35D857D437A5C866BB" unitRef="usd">78000</us-gaap:DepositsAssetsNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q2YTD" decimals="-3" id="Fact-F54E65556890E94FE331D437A62E410F" unitRef="usd">461000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q2YTD" decimals="-3" id="Fact-7961400A3CC414F5EC1CD437A627BEE1" unitRef="usd">816000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q2QTD" decimals="2" id="Fact-30AF2FE8958E92A38350D437A5E89214" unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q2YTD" decimals="2" id="Fact-44066092982EF7D0282ED437A5D5C3F4" unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-0A46035D87B6E54112B9D437A5E9B9EC" unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q2YTD" decimals="2" id="Fact-CA71103081ABB02BE86DD437A5D5339C" unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-7BCFED6BEAFE9140A124D437A68A96D0" unitRef="usd">2198000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-6FB46FCDD53EB42F82F0D437A68361EA" unitRef="usd">1974000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-01C0E825FEBE78ADF795D437A66322B4" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-056315E71225737F631CD437A6626A02" unitRef="usd">5383000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-77D8CDC6CDDD057F8A6ED437A664D012" unitRef="usd">6651000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BE3C9FDDDC0390EF4836D437A663BA76" unitRef="usd">12034000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1434D24D379F37D38FCED437A67DE4BF" unitRef="usd">0</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-231FBB90C29B80510272D437A67D8A72" unitRef="usd">18794000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-023EF96408B6ED204BABD437A67C0289" unitRef="usd">6889000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2015Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F17730507CEC998AEEDCD437A67DAD15" unitRef="usd">25683000</us-gaap:EquityFairValueDisclosure>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-8BAC5B6B29894A93FEFBD437A6F8AF3B" unitRef="number">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2013Q2MAY8" id="Fact-F6C0A46299D9CE544FA7D437A6F834A9">P7Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-A0DBE4561FF4ED4C6F9BD437A6F967B9" unitRef="number">0.7534</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2013Q2MAY8" decimals="4" id="Fact-BD722E15468D7CBFF235D437A6F7FB58" unitRef="number">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueOfAssetsAcquired contextRef="D2015Q1Jul18ToMar31_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-3D0BB94C5C98A51AFD09D437A65159D3" unitRef="usd">8273000</us-gaap:FairValueOfAssetsAcquired>
	<us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-6" id="Fact-D0294DE44B61C4FCD679FE36AC9AD3BA" unitRef="usd">5000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
	<us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="FD2015Q2YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-6" id="Fact-4E3579431B90338166A1FE378A1D725E" unitRef="usd">1000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-3" id="Fact-5B1291D2D170FFC9BA86D437A5C793EB" unitRef="usd">6069000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q2" decimals="-3" id="Fact-F1F2558EE816812D6F79D437A5C9D94F" unitRef="usd">6069000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q2_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-B2B8954E865AD7B74F1AD437A652E7AD" unitRef="usd">172000</us-gaap:Goodwill>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2014Q2YTD" decimals="-3" id="Fact-35C4D026141B9D2A7772D437A6277904" unitRef="usd">-624000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q2YTD" decimals="-3" id="Fact-E749BEDA2538861B4B29D437A62DCBF8" unitRef="usd">47000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q2YTD" decimals="-3" id="Fact-52216F7B6D57F8297FCFD437A62F446E" unitRef="usd">-1531000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q2YTD" decimals="-3" id="Fact-3F9D637EE629C7EFFDCBD437A6328CCB" unitRef="usd">-21000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q2YTD" decimals="-3" id="Fact-DECBA7B68CB35E48BF4AD437A62FAE47" unitRef="usd">3122000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-90AFAED12534D0BD66C4D437A6275D7F" unitRef="usd">-2246000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q2YTD" decimals="-3" id="Fact-2112B372A6F728FEA4D9D437A62D0B6B" unitRef="usd">47000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q2YTD" decimals="-3" id="Fact-6D3D1C7723756312AA58D437A625AE90" unitRef="usd">771000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q2YTD" decimals="-3" id="Fact-47FC62A22B1EEF7D7059D437A630FB72" unitRef="usd">339000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q2YTD" decimals="-3" id="Fact-A83E9373A6B3CB668B94D437A626CCC6" unitRef="usd">-290000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2014Q2QTD" decimals="-3" id="Fact-75B51C38D504D33FB7D6D437A5EA16CA" unitRef="usd">-314000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2014Q2YTD" decimals="-3" id="Fact-EA8FE14A3CEA1663EA88D437A5DA9C09" unitRef="usd">-628000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-6B7FF9D98A4D7D62EEC7D437A5E84D70" unitRef="usd">-207000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2015Q2YTD" decimals="-3" id="Fact-44CA39CA5E5BE17254BCD437A5D963BF" unitRef="usd">-449000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestPaid contextRef="FD2014Q2YTD" decimals="-3" id="Fact-564B1FA6607F485BEC28D437A6317C82" unitRef="usd">423000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2015Q2YTD" decimals="-3" id="Fact-AFB34B94921714827B82D437A62E1B7C" unitRef="usd">312000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-A8EEB9952B0341A85061D437A684AA62" unitRef="usd">57000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-9AAF1833F39C61BF6762D437A68577E0" unitRef="usd">44000</us-gaap:InterestPayableCurrent>
	<us-gaap:InventoryFinishedGoods contextRef="FI2014Q4" decimals="-3" id="Fact-E2893CD3DE2C9D7FFFDCD437A646AB0D" unitRef="usd">200000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="FI2015Q2" decimals="-3" id="Fact-D589765A43E8280B194AD437A6479F6B" unitRef="usd">162000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryNet contextRef="FI2014Q4" decimals="-3" id="Fact-ABEFB6DB495E27F9F4FFD437A5C9FC9A" unitRef="usd">655000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2015Q2" decimals="-3" id="Fact-B34E8AEF7F24B17E22F8D437A5CE74F8" unitRef="usd">1426000</us-gaap:InventoryNet>
	<us-gaap:InventoryWorkInProcess contextRef="FI2014Q4" decimals="-3" id="Fact-E5D85CC04F1BD8AA99B1D437A6476293" unitRef="usd">455000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="FI2015Q2" decimals="-3" id="Fact-A94C76B20B9C1A5CFECDD437A64550F2" unitRef="usd">1264000</us-gaap:InventoryWorkInProcess>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-9979A056D08B41DEB619D437A5C7CCBF" unitRef="usd">43429000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q2" decimals="-3" id="Fact-D1277662EDA1C427D9A3D437A5CED520" unitRef="usd">52602000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-62879486BAE6D779E5AFD437A5C9BAA8" unitRef="usd">80488000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q2" decimals="-3" id="Fact-B391C9F5CC1E2C39DB71D437A5C917B9" unitRef="usd">101967000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-8F2A0FB89F4C5CEB2207D437A5CC08DE" unitRef="usd">27233000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-BF64BD62914E41E8D0C7D437A5CBF0E6" unitRef="usd">38114000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-D041650E3E28D3F87194D437A5C91502" unitRef="usd">3910000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-0DEC40A16656C07A4870D437A5CB05AF" unitRef="usd">4079000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-ED3460B6CD116299BE2ED437A5CE54A1" unitRef="usd">4492000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q2" decimals="-3" id="Fact-C1842C30A2F6CAEF2930D437A5CB91A5" unitRef="usd">2546000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q2YTD" decimals="-3" id="Fact-C8397EACA64422031136D437A6305190" unitRef="usd">14739000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-DA03CEF7AE758F7D4B80D437A6309B0B" unitRef="usd">45613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q2YTD" decimals="-3" id="Fact-9F8BBA6F50144F24FD29D437A62EE386" unitRef="usd">-2344000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-69CFD8572C28ADB8B81BD437A633F652" unitRef="usd">-569000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q2YTD" decimals="-3" id="Fact-4509E9BCF1FA1625A5CDD437A6264036" unitRef="usd">-21020000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-6B74FC0D10A66BDFCB32D437A626B61A" unitRef="usd">-23415000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-E8A1C0B09D63C58A585ED437A5E9E0D8" unitRef="usd">-19941000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2YTD" decimals="-3" id="Fact-11FB88B11560A52EBBF4D437A5D5ABC7" unitRef="usd">-22477000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-1BDA515A42ED6A3E344CD437A5E8ECE5" unitRef="usd">-15660000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2YTD" decimals="-3" id="Fact-D3F6511181B4C7530E32D437A5DB7146" unitRef="usd">-26197000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DF24443026E85F1395F5D437A6049312" unitRef="usd">-26197000</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-44A378643A474C1D25CFD437A5EA12F6" unitRef="usd">-15783000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q2YTD" decimals="-3" id="Fact-D4BCEEA3B018DC7B607CD437A5DA5A4B" unitRef="usd">-27632000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-8A81D03E73765984D463D437A5E97E80" unitRef="usd">-11269000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2YTD" decimals="-3" id="Fact-0AAB63473A420A693770D437A5DAE465" unitRef="usd">-22395000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q2QTD" decimals="-3" id="Fact-3C1A3B09D7116D155AE0D437A5E9037A" unitRef="usd">-491000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q2YTD" decimals="-3" id="Fact-FC253384745272827DF2D437A5D53DAA" unitRef="usd">-656000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-6B67DF9B83CA71D8E14DD437A5E83D28" unitRef="usd">83000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-FBEDA9AD5D4F9292C184D437A5D634E8" unitRef="usd">-238000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2014Q2QTD" decimals="-3" id="Fact-790F0383B5E57CC01D20D437A5EA451A" unitRef="usd">-4158000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2014Q2YTD" decimals="-3" id="Fact-4FDF0EBA544997750EFFD437A5D98E77" unitRef="usd">5155000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-6FA16E6ED11D69338255D437A5EA711C" unitRef="usd">-4391000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:OtherOperatingIncomeExpenseNet contextRef="FD2015Q2YTD" decimals="-3" id="Fact-C37A837C0EBD5BE0B27DD437A5D876BF" unitRef="usd">-3802000</us-gaap:OtherOperatingIncomeExpenseNet>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2014Q2YTD" decimals="-3" id="Fact-9C8CF679048A7458D643D437A626CACA" unitRef="usd">2315000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q2YTD" decimals="-3" id="Fact-367B7D52E7277FFD2248D437A6323266" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="D2013Q4OCT" decimals="-6" id="Fact-97ADB0E6AEF2AEA70C87D437A750D0C2" unitRef="usd">10000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2014Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-97598E7AFF55A48E68F8D437A6315D3F" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q2YTD_us-gaap_BusinessAcquisitionAxis_gale_ZuplenzMember" decimals="-3" id="Fact-C65E9AA5789B54D7AFF5D437A62F4754" unitRef="usd">500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q2YTD" decimals="-3" id="Fact-D2F0258027D4C2F7D5EED437A630D2A2" unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q2YTD" decimals="-3" id="Fact-69574AFEB2B36448C417D437A62FC2B1" unitRef="usd">69000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="INF" id="Fact-41D20DCA7B79AF737535D437A5D43BF7" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q2" decimals="INF" id="Fact-E5740251E63C8F5627FBD437A5D38E5D" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2014Q4" decimals="INF" id="Fact-2AF1AB2381156CD2EA94D437A5D2623B" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q2" decimals="INF" id="Fact-7172551BA1AF63DDA49FD437A5D419AB" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F1CB2625EA290A0D96B4D437A5CAC488" unitRef="usd">2680000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q2" decimals="-3" id="Fact-11E32AF96B20D9F1330CD437A5CC2E57" unitRef="usd">2399000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2014Q2YTD" decimals="-3" id="Fact-48B15DFFAF06A4DAADDFD437A62D51EF" unitRef="usd">10000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromInterestReceived contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1041BCA7BCDF2BDD08DDD437A6262379" unitRef="usd">2000</us-gaap:ProceedsFromInterestReceived>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q2YTD" decimals="-3" id="Fact-B20FFC9E7ADA9C7F3B8ED437A63304B8" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q2YTD" decimals="-3" id="Fact-E48D00ABBB292B13F7FCD437A6300287" unitRef="usd">47416000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-C04DA914F48A0926FE7EE08CCA9176DE" unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-73A25BE3DC5EE069E167E089F9E9EA98" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q1Mar18" decimals="-6" id="Fact-51E119DD17742AA5E73CD437A6A03AC1" unitRef="usd">38000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2014Q2YTD" decimals="-3" id="Fact-FD360A3F3A2303E1FB81D437A627D62A" unitRef="usd">91000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-AFC48D688C82E68F0C7AE08D0B8B0D0D" unitRef="usd">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-BA59C7EBEC31E575FDEED437A6A8333F" unitRef="usd">2300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2015Q2YTD" decimals="-3" id="Fact-7AA4E5B0EE9F7860E56AD437A63216E4" unitRef="usd">110000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q2YTD" decimals="-3" id="Fact-3698F61580313E980C47D437A62E3C41" unitRef="usd">4070000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-B72C5D9DC9F3B2B555E9D437A62FFE8D" unitRef="usd">1000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-5C558E0D0423FFE53C95D437A5CCEA82" unitRef="usd">555000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q2" decimals="-3" id="Fact-E32E918D422CFC509E4FD437A5CD3721" unitRef="usd">532000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-4E46D2DE5A895C345CFFD437A6466A17">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q2YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_gale_EquipmentFurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-CD8EB6DECEAC0A68A604D437A6466D7E">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2014Q2YTD" decimals="-3" id="Fact-288386E047B23466CA00D437A6345667" unitRef="usd">7000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2015Q2YTD" decimals="-3" id="Fact-89821B32E01314458DBCD437A625A494" unitRef="usd">1914000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q2QTD" decimals="-3" id="Fact-CB8473F931ACFC8F0D7ED437A5E9D860" unitRef="usd">8069000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q2YTD" decimals="-3" id="Fact-2EE5750E1ECA1AA69846D437A5D71B94" unitRef="usd">14839000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-26DB0047A9864A4913D2D437A5EA08BF" unitRef="usd">7290000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-3A492E703EA8315470B9D437A5D59A70" unitRef="usd">13200000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-2F6AFBA70444F84AA1DED437A5C8FB32" unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q2" decimals="-3" id="Fact-DABA111A971C24179E12D437A5CBAD09" unitRef="usd">200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:SalesDiscountsServices contextRef="FD2014Q3YTD" decimals="-6" id="Fact-F5E89AE680C15CC327C5D437A645536F" unitRef="usd">0</us-gaap:SalesDiscountsServices>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q2QTD" decimals="-3" id="Fact-7F7C52475BBEF1CF159DD437A5EA3DE1" unitRef="usd">2331000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2014Q2YTD" decimals="-3" id="Fact-E911B7AE2C12348364CBD437A5D56642" unitRef="usd">4504000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q2QTD" decimals="-3" id="Fact-D8638E49B9F776C574E3D437A5EB96F2" unitRef="usd">3382000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2015Q2YTD" decimals="-3" id="Fact-4FD121999D43BBC45EA2D437A5D9B37D" unitRef="usd">6132000</us-gaap:SalesRevenueNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q2QTD" decimals="-3" id="Fact-B77C685CCDE3FC71FE57D437A5E87CC3" unitRef="usd">9600000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q2YTD" decimals="-3" id="Fact-49F7F47375058B8B12A9D437A5D6C2AD" unitRef="usd">16430000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q2QTD" decimals="-3" id="Fact-63B894C2ABDA3356A583D437A5E832D5" unitRef="usd">6451000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q2YTD" decimals="-3" id="Fact-549507418C67CC826646D437A5D7537F" unitRef="usd">13878000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q2YTD" decimals="-3" id="Fact-BC2BA83B13D6F0BA9BB6D437A633621D" unitRef="usd">3136000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q2YTD" decimals="-3" id="Fact-ECC69882E774EE41CD5BD437A6332DB8" unitRef="usd">1272000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2015Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" id="Fact-58DD28A9C4F1D7618A90D437A72A4FA8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q2QTD" decimals="INF" id="Fact-921A2E7A1F84629A3C70D437A72BE6F9" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q2YTD" decimals="INF" id="Fact-20D24E00D9FD077F8ADCD437A72F1B40" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-9B967D7DB08BD8459A78D437A72BAF59" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-458DA58700A5B6AEFD00D437A72F88AA" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q2QTD" decimals="INF" id="Fact-57C876674ECC6CD4ED25D437A72BEA75" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q2YTD" decimals="INF" id="Fact-91F6B6DB26465E7D011ED437A72FB048" unitRef="number">0.7853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-E652C0ED46AC094E3C97D437A72BC53C" unitRef="number">0.7332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-D2E72FC9326F645AA37CD437A72F541D" unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q2QTD" decimals="INF" id="Fact-85DC1BAE42AE37AE907CD437A72BAF8D" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q2YTD" decimals="INF" id="Fact-E18E7233EB69577605E1D437A72FBD64" unitRef="number">0.0206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q2QTD" decimals="INF" id="Fact-776C8793633593D2B8E6D437A72BE0C0" unitRef="number">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q2YTD" decimals="INF" id="Fact-BF490925C9465C407E40D437A72F140B" unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2015Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-F99AA8AFC5C62B444E60D437A72963FB" unitRef="shares">26500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2015Q2_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-95E9C4D71BDD936DFFF7D437A72A1F9F" unitRef="shares">10066000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q2" decimals="-3" id="Fact-88E0A8B62B46DDC2E7B4D437A739B6DA" unitRef="shares">6169000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2015Q2" decimals="2" id="Fact-6F68238463815CF90F77D437A73B54BE" unitRef="usdPerShare">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q2YTD" decimals="-3" id="Fact-1FC54035FA36ED17B710D437A739C841" unitRef="usd">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q2YTD" decimals="-3" id="Fact-18268343277D21AB9359D437A73A5F77" unitRef="shares">860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q2YTD" decimals="-3" id="Fact-0E6A8F1478FD20F7E1F7D437A73AACC6" unitRef="shares">3682000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q2YTD_us-gaap_TitleOfIndividualAxis_gale_TwoZeroZeroSevenIncentivePlanMember" decimals="INF" id="Fact-BA44067A766655953F73D437A72AB1FB" unitRef="shares">11411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q2QTD" decimals="2" id="Fact-DA4D25096C399D73224BFB22B81577BF" unitRef="usdPerShare">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q2YTD" decimals="2" id="Fact-7C130C87B0AF142D1916D437A72A8A79" unitRef="usdPerShare">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4" decimals="-3" id="Fact-439F56C9916C1E1C7492D437A73AF8EF" unitRef="usd">820000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q2" decimals="-3" id="Fact-EE35CC4651E078F63BB3D437A73A079D" unitRef="usd">892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4" decimals="-3" id="Fact-7F1E985AAA9E8E8D86BBD437A739203F" unitRef="shares">8590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q2" decimals="-3" id="Fact-04F6824215EA7392D951D437A6ABBAD7" unitRef="shares">11411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4" decimals="2" id="Fact-E48814E403419F76EA62D437A73AF3A5" unitRef="usdPerShare">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q2" decimals="2" id="Fact-08B16C490F781232C2C0D437A73A1712" unitRef="usdPerShare">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2015Q2" decimals="-3" id="Fact-EEDF85727A5B7E6E2D82D437A7393BAB" unitRef="usd">749000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q2YTD" decimals="2" id="Fact-F46AA41AF367A46A5F03D437A73962F1" unitRef="usdPerShare">0.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q2YTD" decimals="2" id="Fact-C3677A303D0FF4CC63B5D437A7396B95" unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q2YTD" decimals="2" id="Fact-9F67E5DBA163A4C7D7E8D437A73A3F5A" unitRef="usdPerShare">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="INF" id="Fact-28A332DEC927109FE311E08C1B66CB10" unitRef="usdPerShare">2.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q1Mar18" decimals="2" id="Fact-D0EFC65FFAFBA0980493D437A6A2277D" unitRef="usdPerShare">1.56</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q2QTD" id="Fact-05586323E8EF5F4CB3D0D437A72B45AC">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q2YTD" id="Fact-39C4DAF613A420612356D437A72FFE61">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q2QTD" id="Fact-1F7EFCD47B3D65D6A46AD437A72B8B86">P5Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q2YTD" id="Fact-A894562D1942EC31DFFFD437A72F8D85">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-665C9B1487BEC57B605ED437A728BA7B">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q2YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-F53CD578CE1F8FA8E3E8D437A72A43A7">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q2YTD" id="Fact-216C38C0FB79264A530FD437A729121B">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BC37BDAADF58F6154111D437A601F3E9" unitRef="shares">130146341</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1984FEB832772FD47DD0D437A6022D74" unitRef="shares">162391381</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C6B282F225FD8076BA36D437A60486A6" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B2270AC503CEC525DE68D437A604F615" unitRef="shares">85372</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D06E18C135B5BF2A8164E08C5F3B27CA" unitRef="shares">631221</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q1Mar18" decimals="0" id="Fact-68AA340CE9B95087041BD437A6A1DAA1" unitRef="shares">24358974</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q2QTD_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-6FCE8C754580AE948B00E08D54EA5564" unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q2QTD_dei_LegalEntityAxis_gale_MLVCo.LLCandMaximGroupLLCMember" decimals="-5" id="Fact-FAFD1ED88F9802795BF3D437A6A248B3" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-57EF1ED007895524DC5AD437A60371E9" unitRef="shares">32158685</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2014Q4Nov18_dei_LegalEntityAxis_gale_LincolnParkCapitalLLCMember" decimals="-5" id="Fact-1891825D8E5814A2F343E08B36B5F70A" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-2F446F79A049CB421198D437A73A9EBD" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7F3CDE0B230EE0A32163D437A5ECFD7C" unitRef="shares">983</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q2YTD" decimals="-3" id="Fact-E07CEA7DE9B10A9AA349D437A60251E5" unitRef="usd">-10296000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-28F0B8D852A64047532BD437A604D866" unitRef="usd">-10296000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-0A492F4D0B13E894D3C7D437A60201F2" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q2YTD" decimals="-3" id="Fact-BA8DB4F3B1A12B875181D437A60149E9" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5AD4BA0A3B1AC3BDEA74D437A6035CF9" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q2YTD" decimals="-3" id="Fact-01275700DA56A3D9B7F7D437A6032B9F" unitRef="usd">47416000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3E2BFDA25111FDE6AD28D437A60329B9" unitRef="usd">47413000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-BCBF735478DB870B767AD437A6036AFA" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q2YTD" decimals="-3" id="Fact-DE93603DD721DA9491CED437A5EC71FA" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E7E8BACFEF1A610DD6B3D437A5EC0BC6" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-2D25F65A277599A4F7AFD437A5CA0522" unitRef="usd">37059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q2" decimals="-3" id="Fact-BE60679400E7133139DCD437A5CC9E9D" unitRef="usd">49365000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-3" id="Fact-1123D65909CE066B2332D437A6026853" unitRef="usd">37059000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-90F97C76E5D337A58538D437A603B089" unitRef="usd">256377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-81D107DAD6FDEAA5041CD437A603F9B7" unitRef="usd">12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AAEF72EFF44F508F6626D437A601A39F" unitRef="usd">-215481000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-8E168C4B550A7334A85AD437A604BE3F" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q2" decimals="-3" id="Fact-9F27BFC5C5B2F07E1557D437A602320A" unitRef="usd">49365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7FB55EC9EA8A8A47BCFCD437A602F08D" unitRef="usd">294877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-65760D344E9898ADC5BAD437A60262D7" unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E6380B867AE1E1AADB35D437A603378C" unitRef="usd">-241678000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-D104E4B5814C14EE0316D437A604607E" unitRef="usd">-3849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TreasuryStockShares contextRef="FI2014Q4" decimals="INF" id="Fact-E323DB2970F42310304BD437A5D31836" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q2" decimals="INF" id="Fact-81E81078AB16D0F430ABD437A5D29386" unitRef="shares">675000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-4815F6B624A1AB9D7482D437A5C74485" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q2" decimals="-3" id="Fact-80AB586F72E51AD85387D437A5C870B8" unitRef="usd">3849000</us-gaap:TreasuryStockValue>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q2QTD" decimals="0" id="Fact-24D000AFD0CE1CABD534D437A5E9E9BA" unitRef="shares">118083988</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2014Q2YTD" decimals="0" id="Fact-8CAEC0863F529AA9300DD437A5D88954" unitRef="shares">117154099</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q2QTD" decimals="0" id="Fact-42B958ABD3F42F90721BD437A5E99107" unitRef="shares">161383398</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q2YTD" decimals="0" id="Fact-51EC3260B602BE55A42CD437A5D749F7" unitRef="shares">148647581</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock contextRef="FD2015Q2YTD" id="Fact-BC31E9D4A8E6DB7D1942D437A6F83863">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Warrant liability, June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;12,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
	<gale:CommonStockAreReservedForFutureIssuanceTableTextBlock contextRef="FD2015Q2YTD" id="Fact-AB41D3C1046498AD4B01D437A6A2725F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - On March 18, 2015 the company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="84%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:CommonStockAreReservedForFutureIssuanceTableTextBlock>
	<gale:ContingentConsiderationPolicyPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-6EFDC1C31764E0AF4B7BD437A646370A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:ContingentConsiderationPolicyPolicyTextBlock>
	<gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-1B9B6C2ADB0E598CA87FD437A645B85F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</gale:PatentsAndPatentApplicationCostsPolicyPolicyTextBlock>
	<gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock contextRef="FD2015Q2YTD" id="Fact-555F5FF07886607BCED4D437A74C9CC3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;Three and Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,848&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock>
	<gale:ScheduleOfWarrantActivityTableTableTextBlock contextRef="FD2015Q2YTD" id="Fact-286D2016349373A04F5CD437A6F7CF10">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of warrant activity for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Consultant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and Oxford Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Varies 2014-2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantActivityTableTableTextBlock>
	<gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock contextRef="FD2015Q2YTD" id="Fact-4AE39A33B3BA1A1B7568D437A6F86AF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;72.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;75.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;72.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;63.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;64.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;75.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;78.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</gale:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2015Q2YTD" id="Fact-B5D85359BB15BF65227DD437A67FB644">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="70%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit memos for expiring Zuplenz channel inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patient assistance programs and rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory purchases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Zuplenz milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-957B24EFE5209AF309E8D437A65492E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 17, 2014 the Company entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film (Zuplenz), an FDA approved product. The transaction was accounted for as a business combination under the acquisition method of accounting based on Accounting Standards Codification 805, "&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Combinations.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;" Accordingly, the assets acquired and liabilities assumed were recorded at fair value. As of the issuance date of the condensed consolidated financial statements for the quarter ended June 30, 2015, the Company finalized the valuation of the acquired assets and liabilities for the transaction. Specifically, more complete information for credit memos for expiring channel inventory and the anticipated gross-to-net deductions on the replacement inventory was provided in order to finalize the business combination accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the purchase price consideration and allocation of purchase price:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.39024390243902%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="75%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total Acquisition Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Purchase price consideration:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit memos for expiring channel inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Asset acquired:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The above contingent consideration represents a risk adjusted net present value relating to cash payments on achievement of certain milestones.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2015Q2YTD" id="Fact-0FFFF8C356CBB4E5D918D437A644D8E1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-A0757B907FB8A8A70EA7D437A647BFD8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="FD2015Q2YTD" id="Fact-49953234724ED4FD9983D437A648E3FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the company&amp;#8217;s financial institutions as collateral for its corporate credit cards&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-96420B4161A0AB0D8F57D437A6901A1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Legal Proceedings, Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Legal Proceedings &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In re Galena Biopharma, Inc. Stockholder Derivative Litigation and In Re Galena Biopharma, Inc. Derivative Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 23, 2015, U.S. District Court for the District of Oregon heard argument on the defendants&amp;#8217; motion to stay and motion to dismiss.  On February 4, 2015, the District Court granted in part the motion to stay by staying any discovery until the ruling on the motion to dismiss.  On August 5, 2015, the District Court issued its decision by denying in part and granting in part defendants&amp;#8217; motion to dismiss and granting plaintiffs leave to file an amended complaint. The court had stayed the derivative proceeding pending the outcome of the motion to dismiss in the securities class action case. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 4, 2105, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We intend to vigorously defend against and seek resolution to the foregoing claims.  As of June 30, 2015, we have not recorded any&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurer for substantially all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;SEC Investigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ANDA Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;By letter dated December 23, 2014, Orexo and we received a Paragraph IV certification notice (Notice Letter) regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by Actavis Laboratories FL, Inc. (Actavis) requesting approval &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;to engage in the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;m&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;an&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;ufacture&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#6c6c6c;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;use &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;or sale &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;of generic versions of the Abstral sublingual &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;t&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;a&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;blets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;Eq 0.1 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;mg base&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#6c6c6c;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;Eq 0.2 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;m&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;g &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;base&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#6c6c6c;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;E&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#282828;"&gt;q &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;0.3 mg base, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#565656;"&gt;Eq 0.4 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;mg base&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#6c6c6c;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#404040;"&gt;Eq 0.6 mg base and Eq 0.8 mg base. In the Notice Letter, Actavis &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;contends that the patents held by Orexo for Abstral that are listed in the Orange Book (U.S. Patents 6,759,059, 6,761,910 and 7,910,132, which cover compositions, formulations and methods of using Abstral and which expire in September 2019) and which are licensed to us under the Orexo License Agreement, are invalid, unenforceable and/or will not be infringed by the manufacture, use, or sale of the product set forth in the ANDA. On February 4, 2015, Orexo filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories Fl, Inc., Andrx Corporation, Actavis, Inc., and Actavis Pharma, Inc.  All of the defendants except Actavis Laboratories FL, Inc. were subsequently dismissed. Actavis has filed an answer and counterclaim. The lawsuit claims infringement of the three patents.  Orexo filed the lawsuit within 45 days from the receipt of the Notice Letter and under the Hatch-Waxman Act, the final FDA approval of Actavis&amp;#8217; ANDA will be stayed up to 30 months from the date of receipt of the Notice Letter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A scheduling conference was held on July 9, 2015, in the District Court and on July 10, 2015, the District Court issued a pre-trial scheduling order. The parties are now engaged in written discovery.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We are obligated under Orexo License Agreement to pay for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the legal costs of the patent infringement lawsuit.  We intend to work with Orexo to continue to vigorously enforce intellectual property rights related to the Abstral product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:40px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company applies the disclosure provisions FASB ASC Topic 460 (&amp;#8220;ASC 460&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Guarantor&amp;#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&amp;#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&amp;#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&amp;#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-9020B397785D9B1512F0D437A64667FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2015Q2YTD" id="Fact-8411BB9A7B6C335D0BD4D437A645ABB8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-8FFA28063F71234ACF82D437A75F377F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Customers and Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company is engaged in the business of developing and commercializing pharmaceutical products. As of June 30, 2015, the Company had sales from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; active commercial product, Abstral, available in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dosing strengths, and all sales reported are in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales to the following customers represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or more of net revenue during at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the periods are presented as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="40%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="70%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to concentrations in our customer base, concentrations also exist with respect to the dispensing pharmacies to which our customers sell Abstral. For example &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our prescriptions, at wholesaler acquisition cost, were dispensed by our top &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pharmacies for the three month periods ending June 30, 2015 and 2014, respectively. Additionally, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our prescriptions, at wholesaler acquisition cost, were dispensed by our top &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pharmacies for the six months periods ending June 30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-AD3C52B747135753D0B9D437A647CB09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-2918573667C3EFEF87D6D437A68F419C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the "Loan"). The Loan payment terms include &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;12&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months of interest-only payments at the fixed coupon rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;8.45%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, followed by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cash facility fee and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cash final payment and granted to the lenders &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;182,186&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.47&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which equaled a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2015Q2YTD" id="Fact-9F2013969540EF09BF69D437A72AD2CD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Options to Purchase Shares of Common Stock&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions ASC&amp;#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2014, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average fair value of options granted during the three and six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.14&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company&amp;#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&amp;#160;718-10, which averages the contractual term of the company&amp;#8217;s options of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with the average vesting term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;four years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for an average of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;six years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for options granted to its employees, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5,582,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&amp;#8217;s operating expenses over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.54&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;26,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock were reserved for issuance under the company&amp;#8217;s 2007 Incentive Plan, including &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;11,411,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares subject to outstanding common stock options granted under the plan and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;10,066,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;four years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The options will expire, unless previously exercised, no later than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the grant date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic values of outstanding and exercisable options at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were calculated based on the closing price of the company&amp;#8217;s common stock as reported on The NASDAQ Capital Market on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&amp;#8217;s common stock and the exercise price of the underlying options.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-AFA72CFE303CE73EBBBFD437A74C766B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2015Q2YTD" id="Fact-ED6FA87020097A056131D437A74DD904">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Earnings per Share.&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;&amp;#160;Three and Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,848&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33,719&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2015Q2YTD" id="Fact-8F223FE55447F7A6C104D437A66EBE13">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending Level 3 liabilities for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="86%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-FEBD7C4FF5E7399819C5D437A66E6428">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2015Q2YTD" id="Fact-D0CDB9AFF61932110FF9D437A647612C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-6B77EB1137D31CB5D9C7D437A66DEC7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company follows ASC&amp;#160;820, &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;) for the company&amp;#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1&amp;#160;&amp;#8212; quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2&amp;#160;&amp;#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:108px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3&amp;#160;&amp;#8212; significant unobservable inputs that reflect management&amp;#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:106px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company categorized its cash equivalents as Level&amp;#160;1. The valuations for Level&amp;#160;1 were determined based on a &amp;#8220;market approach&amp;#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&amp;#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&amp;#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company did not transfer any financial instruments into or out of Level 3 classification during the three and six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="86%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Using&amp;#160;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in the estimated fair value of the contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-92CECF65D46A4C2A4A7BD437A6457B30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-94F9FDEAFF798EC50F28D437A6468D79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and six months periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-035DF5CDF3182C61FF87D437A7509542">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with the acquisition of NeuVax&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;TM&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&amp;#8220;MDACC&amp;#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&amp;#8220;HJF&amp;#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective December&amp;#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&amp;#8220;ABIC&amp;#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&amp;#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March&amp;#160;18, 2013, we acquired Abstral&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets, a transmucosal immediate-release fentanyl (TIRF) product, for sale and distribution in the United States from Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, and exclusively licensed certain intellectual property from Orexo to use, distribute, market, sell, offer for sale Abstral solely in the United States and to non-exclusively manufacture Abstral for use, distribute, market, sell, offer for sale and import Abstral solely in the United States. Abstral has been approved by the U.S. Food and Drug Administration (FDA).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under our agreement with Orexo, we assumed responsibility for the U.S. commercialization of Abstral and for all regulatory and reporting matters in the U.S. We also agreed to establish and maintain through 2015 (marketing period) a specified minimum commercial field force to market, sell and distribute Abstral and to use commercially reasonable efforts to reach the specified sales milestones. Orexo is entitled to reacquire the U.S. rights to Abstral from us for no consideration if we breach our obligations to establish and maintain the requisite sales force throughout the marketing period. We expect to maintain our sales efforts beyond this date. We officially launched U.S. commercial sales of Abstral in October 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In exchange for the U.S. rights to Abstral, (1)&amp;#160;we paid Orexo &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront, and a&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment in cash in October 2013 upon the approval by the FDA of a specified U.S. manufacturer of Abstral; and (2)&amp;#160;we agreed to pay to Orexo: (a)&amp;#160;three one-time future cash milestone payments based on our net sales of Abstral; and (b)&amp;#160;a low double-digit royalty on future net sales. No further milestone or royalty payments will be due after the date on which all claims of the last remaining licensed patents expire (currently &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) or become invalidated by a patent office, court, or other governmental agency of competent jurisdiction in a final and non-appealable judgment. In exchange of license, Galena agreed to pay eight-eight percent of the expenses and costs incurred to prosecute any ANDA action..&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 17, 2014, we entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film, an FDA-approved product for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). In exchange for the U.S. rights to Zuplenz, and in connection with the effectiveness of the license and transfer to us of the New Drug Application (NDA) for Zuplenz, we paid MonoSol a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash and shares of our common stock in 2014 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash in 2015. In addition to these payments, we will pay MonoSol &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.25 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days after MonoSol&amp;#8217;s payment of applicable fees relating to the notice of allowance by the United States Patent and Trademark Office of a U.S. patent with composition claims covering Zuplenz that extend beyond 2028, (ii) future cash milestone payments of up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on our achievement of specified &amp;#8220;net sales&amp;#8221; of Zuplenz in amounts ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and (iii) a low double-digit royalty on future &amp;#8220;net sales.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the license agreement, we assumed responsibility for the commercialization of Zuplenz and for all regulatory and reporting matters in the U.S. We also agreed in the license and supply agreement to use our best commercial efforts to begin commercializing Zuplenz in the U.S. in accordance with a joint commercialization plan to be established by the company and MonoSol. We also agreed that, until net sales of Zuplenz exceed a specified minimum amount or a competing product has been approved by the FDA and is placed into the market for sale, we will maintain a specified minimum number of field sales force personnel on specified terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the license and supply agreement, MonoSol has the exclusive right to supply all of our requirements for Zuplenz, subject to certain conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-CC3D6C8E66CF528BA414D437A6445B73">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Inventories are stated at the lower of cost or market value and are determined using the first-in, first-out ("FIFO") method. Inventories consist of work-in-process and finished goods of our commercial products. The company has entered into manufacturing and supply agreements for the manufacture and final packaging of Abstral and Zuplenz finished goods. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company had inventories of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,426,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,264,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of work-in-process and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$162,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of finished goods. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock contextRef="FD2015Q2YTD" id="Fact-0AF1B4E9E84F8F84BBFAD437A6F81264">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of warrant activity for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Consultant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and Oxford Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;8,540&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Outstanding, June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,973&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;September 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;December 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;April 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;March 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Varies 2014-2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrants classified as liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&amp;#160;April 2011,&amp;#160;March 2011,&amp;#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;72.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;75.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;72.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;63.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;64.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Strike price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Volatility %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;75.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;76.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;78.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;77.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Risk-free rate %&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The changes in fair value of the warrant liability for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 2015 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;April&amp;#160;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2011&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2010&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Warrant liability, January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Fair value of warrants issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;242&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Warrant liability, June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;12,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;707&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrants classified as equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;182,186&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.47&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which equaled to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;75.34%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, expected term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, risk-free rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;1.20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and a dividend rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;0.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of the warrants granted was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.93&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="FD2015Q2YTD" id="Fact-C44A75CBBD980346B338D437A646B1D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Galena Biopharma, Inc. (&amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our,&amp;#8221; &amp;#8220;Galena&amp;#8221; or the &amp;#8220;company&amp;#8221;) is a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena&amp;#8217;s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax&amp;#8482; (nelipepimut-S) currently in an international, Phase 3 clinical trial. The company&amp;#8217;s commercial drugs include Abstral&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets and Zuplenz&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film. Collectively, our clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to&amp;#160;improve cancer care,&amp;#160;from direct treatment of the disease to the reduction of its debilitating side-effects.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Novel Cancer Immunotherapies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our targeted cancer immunotherapy approach is based upon preventing recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow.  Once a patient&amp;#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care.  Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have undetected minimal residual disease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our therapies utilize immunologically active peptides combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&amp;#8217;s own immune system to target, seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system through an intradermal mode of delivery.  We are currently engaged in multiple clinical trials with NeuVax&amp;#8482;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(nelipepimut-S) and GALE-301, or Folate Binding Protein (FBP), targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;NeuVax&amp;#8482; (nelipepimut-S)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NeuVax&amp;#8482; (nelipepimut-S), our lead product candidate, is a targeted cancer immunotherapy and is being developed for the prevention of cancer recurrence in human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nona-peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may be a predictive factor of Disease Free Survival (DFS) and Overall Survival (OS) - suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to the HLA A2, A3, A24 or A26 proteins on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including undetected occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We have multiple trials currently ongoing for NeuVax. For our global pivotal, fully enrolled, Phase 3 PRESENT (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;P&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;revention of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;R&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ecurrence in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;arly-&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;S&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;tage, Node-Positive Breast Cancer with Low to Intermediate HER2 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;xpression with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NeuVax&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;T&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;reatment) trial, NeuVax is targeting the 30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &amp;#8220;disease recurrence,&amp;#8221; after achieving &amp;#8220;no evidence of disease&amp;#8221; (NED) status, (or becoming a &amp;#8220;survivor&amp;#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of population). NeuVax has also been shown to bind to A24 and A26 which represents an additional 10-15% of the population in the U.S., but importantly, represents up to 70% of the population in Japan. Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor.  These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographic footprint of NeuVax:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Phase 3 Ongoing: Our Phase 3 PRESENT (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;P&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;revention of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;R&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ecurrence in&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; E&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;arly- &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;S&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;tage, Node-Positive Breast Cancer with Low to Intermediate HER2 &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;E&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;xpression with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NeuVax T&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;reatment) study has completed enrollment of 758 patients with HER2 1+ and 2+ under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is fully enrolled with trial sites in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;www.neuvax.com&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative HLA A2/A3/A24/A26 breast cancer patients to study NeuVax in combination with trastuzumab (Herceptin&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; Genentech/Roche) in the adjuvant setting. This trial is partially funded by Genentech/Roche.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:65px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with Herceptin. The study will enroll 100 patients who are neoadjuvantly treated node positive and negative HER2 IHC 3+ patients, not achieving a pathological complete response (pCR) or adjuvantly treated node positive HER2 IHC 3+ patients. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program (CDMRP) which is funded through specific requests from individual members of Congress that are part of the Defense Appropriations Act. Funds are "set aside" (obligated) in entirety at the time of assistance agreement award. The grant was awarded under a Breast Cancer Research Program (BCRP) Breakthrough Award given to the lead investigator for the trial.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:66px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Phase 2 Planned: In January 2014, we partnered with Dr.&amp;#160;Reddy&amp;#8217;s Laboratories, Ltd. in India for the commercialization of NeuVax in that region. Dr.&amp;#160;Reddy&amp;#8217;s is responsible for managing a Phase 2 gastric cancer trial of NeuVax in India in patients that express any level of HER2 (1+, 2+, and 3+). The trial  is expected to initiate in 2016. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;GALE-301 (folate binding protein or FBP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our second immunotherapy product candidate, GALE-301, targets folate binding protein receptor-alpha, a well-validated therapeutic target, which&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. GALE-301 is an immunogenic peptide and can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of an FBP peptide combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. Current treatments for these diseases are principally with chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in May 2015 at the American Society of Clinical Oncology conference and demonstrated the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence, and that the agent was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;in vivo&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; immune response. We expect to present a more mature data set from the Phase 2a trial this Fall at the European Society for Medical Oncology European Cancer Congress 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Hematology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;GALE-401 (anagrelide controlled release (CR))&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide (Agrylin&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Shire Pharmaceuticals), an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (C&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:7pt"&gt;max&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) is hypothesized to reduce the side effects, but preserve efficacy. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:7pt"&gt;max&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK (pharmacokinetic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial.  The Phase 2, open label, single arm trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20th Congress. We expect to present a more mature data set from the Phase 2 trial later this year. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401, with the reference drug Agrylin&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(anagrelide; Shire Pharmaceuticals).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Commercial Capabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Abstral&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; (fentanyl) Sublingual Tablets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Our first commercial product, Abstral&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (fentanyl) Sublingual Tablets, is an important treatment option for inadequately controlled breakthrough cancer pain (BTcP), which affects more than 50% of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a convenient sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain in minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. Abstral is manufactured for us by contract manufacturers and we distribute and sell Abstral in the U.S. through our commercial organization. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Zuplenz&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; (ondansetron) Oral Soluble Film&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2014 we licensed our second commercial product, Zuplenz&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ondansetron) Oral Soluble Film, from MonoSol Rx, LLC, which we launched on July 29, 2015. Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. It is estimated that up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of chemotherapy and up to 80% of radiotherapy patients will experience CINV and RINV, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:7pt"&gt;3&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Ondansetron is the most widely prescribed drug in this class of anti-emetics, and used broadly across the oncology spectrum. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tables (ODT) with a safety profile equivalent to ondansetron.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Zuplenz utilizes MonoSol&amp;#8217;s proprietary PharmFilm&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; technology, an oral soluble film that dissolves on the tongue in less than 30 seconds. Zuplenz eliminates the burden of swallowing pills during periods of emesis, may be advantageous for patients with oral irritation, and may increase patient adherence and the patient's ability to keep the medication down without vomiting. MonoSol will exclusively manufacture Zuplenz for us for sale in the U.S. through our commercial organization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &amp;#8220;company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; or &amp;#8220;our&amp;#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &amp;#8220;Apthera,&amp;#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212;&amp;#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company considers all highly liquid debt instruments with an original maturity of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days&amp;#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Cash&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Restricted cash consists of certificates of deposit on hand with the company&amp;#8217;s financial institutions as collateral for its corporate credit cards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The company maintains credit limits for all customers based upon several factors, including but not limited to financial condition and stability, payment history, published credit reports and use of credit references. Management performs analysis to evaluate accounts receivables to ensure recorded amounts reflect estimated net realizable value. An allowance for doubtful accounts is established based on the Company's best estimate of the amount of probable credit losses in the Company's accounts receivable. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2014 the allowance for doubtful accounts was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventories&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Inventories are stated at the lower of cost or market value and are determined using the first-in, first-out ("FIFO") method. Inventories consist of work-in-process and finished goods of our commercial products. The company has entered into manufacturing and supply agreements for the manufacture and final packaging of Abstral and Zuplenz finished goods. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company had inventories of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,426,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,264,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of work-in-process and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$162,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of finished goods. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company had inventories of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$655,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$455,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of work-in-process and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of finished goods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant changes in the manner of its use of acquired assets or the strategy for its overall business;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant negative industry or economic trends;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"&gt;&lt;font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant decline in stock price for a sustained period; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:67px;text-align:left;"&gt;&lt;font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;"&gt;&amp;#8226;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant decline in market capitalization relative to net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&amp;#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - The company recognizes revenue from the sale of Abstral. No revenue has been recorded from the sale of Zuplenz as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We sell Abstral product in the United States to wholesale pharmaceutical distributors and retail pharmacies, or our "customers," subject to rights of return. We recognize Abstral product sales at the time title transfers to our customer, and provide allowances for estimated future product returns, prompt pay discounts, wholesaler discounts, rebates, chargebacks, patient assistance program benefits and other deductions as needed. The company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the company will be required to make adjustments to these allowances in the future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Returns - The company estimates future returns based on historical return information, as well as information regarding prescription information and sell-through trends, in relation to the estimated amount of product in the sales channels and product expiration dates. The allowance for returns is recorded as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prompt Pay Discounts - As an incentive for prompt payment, the company offers a cash discount to customers, which is generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of gross sales. The company expects that all customers will comply with the contractual terms to earn the discount. The company records prompt pay discounts as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Wholesaler Discounts - The company offers discounts on sales to wholesalers and distributors based on contractually determined rates. The company accrues the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rebates - The company participates in certain rebate programs, which provide discounted prescriptions to members of certain managed care organizations, group purchasing organizations and specialty pharmacies. Under these rebate programs, the company pays the rebates generally two to three months after the end of the quarter in which prescriptions subject to the rebate are filled. The company estimates and accrues these rebates based on current contract prices, historical and estimated future percentages of product sold to qualifying member pharmacies and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction to revenue in the period that the related revenue is recognized, with a corresponding liability in accrued expenses and other current liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Chargebacks - The company provides discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid or Medicare contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the company the difference between the current retail price and the price the entity paid for the product. The company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historic chargeback activity. Chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patient Assistance Programs - The company offers discount card programs to eligible patients for Abstral in which those patients receive discounts on their Abstral prescriptions that are reimbursed by the company. The company estimates the total amount that will be recognized based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognizes the discount as a reduction of revenue and as an other current liability (see Note 4) in the same period the related revenue is recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Acquisitions and In-Licensing &amp;#8212;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we determined there were no variable interest entities required to be consolidated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Contingent Purchase Price Consideration&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Patents and Patent Application Costs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&amp;#160;740-10, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&amp;#8221; (&amp;#8220;ASC 740-10&amp;#8221;).&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ASC 740-10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&amp;#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&amp;#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&amp;#8217;s assumptions or changes in the company&amp;#8217;s assumptions in future periods are recorded in the period they become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There was no income tax expense or benefit for the three and six months periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the company&amp;#8217;s cash equivalents were invested in money market mutual funds. The company&amp;#8217;s investment policy does not allow investment in any debt securities rated less than &amp;#8220;investment grade&amp;#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Comprehensive Loss&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-0E8E3F46D37BE9E32551D437A73CD0A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Income (Expense)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other income (expense) is summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="43%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of the contingent purchase price liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2015Q2YTD" id="Fact-278461A5D7E34A3340D6D437A6477815">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Reclassifications&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-8A039C98E2087DDA169FD437A646133B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equipment and Furnishings&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years) of the related assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2015Q2YTD" id="Fact-79D0070600DFF773BD13D437A6472A63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2015Q2YTD" id="Fact-F0A655AD7AAA6E967995D437A646A4DA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - The company recognizes revenue from the sale of Abstral. No revenue has been recorded from the sale of Zuplenz as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We sell Abstral product in the United States to wholesale pharmaceutical distributors and retail pharmacies, or our "customers," subject to rights of return. We recognize Abstral product sales at the time title transfers to our customer, and provide allowances for estimated future product returns, prompt pay discounts, wholesaler discounts, rebates, chargebacks, patient assistance program benefits and other deductions as needed. The company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the company will be required to make adjustments to these allowances in the future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Returns - The company estimates future returns based on historical return information, as well as information regarding prescription information and sell-through trends, in relation to the estimated amount of product in the sales channels and product expiration dates. The allowance for returns is recorded as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prompt Pay Discounts - As an incentive for prompt payment, the company offers a cash discount to customers, which is generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of gross sales. The company expects that all customers will comply with the contractual terms to earn the discount. The company records prompt pay discounts as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Wholesaler Discounts - The company offers discounts on sales to wholesalers and distributors based on contractually determined rates. The company accrues the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rebates - The company participates in certain rebate programs, which provide discounted prescriptions to members of certain managed care organizations, group purchasing organizations and specialty pharmacies. Under these rebate programs, the company pays the rebates generally two to three months after the end of the quarter in which prescriptions subject to the rebate are filled. The company estimates and accrues these rebates based on current contract prices, historical and estimated future percentages of product sold to qualifying member pharmacies and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction to revenue in the period that the related revenue is recognized, with a corresponding liability in accrued expenses and other current liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Chargebacks - The company provides discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid or Medicare contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the company the difference between the current retail price and the price the entity paid for the product. The company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historic chargeback activity. Chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized, with a corresponding allowance against accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patient Assistance Programs - The company offers discount card programs to eligible patients for Abstral in which those patients receive discounts on their Abstral prescriptions that are reimbursed by the company. The company estimates the total amount that will be recognized based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognizes the discount as a reduction of revenue and as an other current liability (see Note 4) in the same period the related revenue is recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2015Q2YTD" id="Fact-790CE03923BF33B663EBD437A67F7751">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="70%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Clinical trial costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit memos for expiring Zuplenz channel inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patient assistance programs and rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Royalties&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;408&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory purchases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Zuplenz milestone payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,669&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2015Q2YTD" id="Fact-4A0D689A9286D48EB9D3D437A729F1D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2014, respectively (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Selling, general, and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2015Q2YTD" id="Fact-CFF00C1A05A431D62F25D437A66EFCFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,889&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Description&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;In&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants potentially settleable in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent purchase price consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities measured and recorded at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,034&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2015Q2YTD" id="Fact-2F02079416221B85FACDD437A73CACF7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other Income (Expense)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other income (expense) is summarized as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="43%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of the contingent purchase price liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(490&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2015Q2YTD" id="Fact-45BB635CF0418279C5E5D437A65321ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the purchase price consideration and allocation of purchase price:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.39024390243902%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="75%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total Acquisition Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Purchase price consideration:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit memos for expiring channel inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Asset acquired:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Zuplenz rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of assets acquired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2015Q2YTD" id="Fact-60FF3F26D081E23896B5D437A72989EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes option activity of the company:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(In Thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;892&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercisable at June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2015Q2YTD" id="Fact-9B080F6B25BD7A3799CED437A729749B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected lives (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2015Q2YTD" id="Fact-AE082DE2C54645F69E8ED437A75FDFF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales to the following customers represented &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or more of net revenue during at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the periods are presented as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="40%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="70%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer E&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to concentrations in our customer base, concentrations also exist with respect to the dispensing pharmacies to which our customers sell Abstral. For example &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our prescriptions, at wholesaler acquisition cost, were dispensed by our top &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pharmacies for the three month periods ending June 30, 2015 and 2014, respectively. Additionally, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of our prescriptions, at wholesaler acquisition cost, were dispensed by our top &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pharmacies for the six months periods ending June 30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2015Q2YTD" id="Fact-A919586F364BD00BE61BD437A646EDF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company follows the provisions of the FASB ASC Topic 718, &amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASC 718&amp;#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&amp;#160;718 is recognized as an expense over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&amp;#8220;ASC 505-50&amp;#8221;), &amp;#8220; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity Based Payments to Non- Employees&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&amp;#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q2YTD" id="Fact-66FF2C9220580F5B5FEED437A6A31CF0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company has authorized up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of preferred stock, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&amp;#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The company has authorized up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;275,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of common stock, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;par value per share, for issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;November 2014 Purchase Agreement with Lincoln Park Capital, LLC - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in shares of the company's common stock, subject to certain limitations and conditions over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the company's common stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;631,221&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting commissions and other offering expenses. In addition to LPC&amp;#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from LPC&amp;#8217;s subsequent purchases of a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock, excluding the commitment fee shares. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;At Market Issuance Sales Agreements &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp;amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds from the sale of shares, up to a total limit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net proceeds from the sale of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended June 30, 2015 or during the three and six months ended June 30, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;March 2015 Underwritten Public Offering&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - On March 18, 2015 the company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,358,974&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; units at a price to the public of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.56&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$38 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of a share of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,826,923&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,653,846&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for additional net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after deducting underwriting discounts and commissions and offering expenses payable by the company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares of common stock for future issuance are reserved for as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="84%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&amp;#160;30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options reserved for future issuance under the Company&amp;#8217;s 2007 Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,066&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares reserved for future issuance under the Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total reserved for future issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2015Q2YTD" id="Fact-86ADA16340809B5D80ADD437A76B5385">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The company evaluated all events or transactions that occurred after &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2015Q2YTD" id="Fact-8B9EA16AD0F51BFB4BF6D437A6455D68">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The company maintains credit limits for all customers based upon several factors, including but not limited to financial condition and stability, payment history, published credit reports and use of credit references. Management performs analysis to evaluate accounts receivables to ensure recorded amounts reflect estimated net realizable value. An allowance for doubtful accounts is established based on the Company's best estimate of the amount of probable credit losses in the Company's accounts receivable. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2014 the allowance for doubtful accounts was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2015Q2YTD" id="Fact-EB4D3E36BFB5C2B8D1FCD437A645AD12">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Uses of Estimates in Preparation of Financial Statements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>gale-20150630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.galenabiopharma.com/20150630" xmlns:gale="http://www.galenabiopharma.com/20150630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gale-20150630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentation" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAndBasisOfPresentationPolicies" roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - Business and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.galenabiopharma.com/role/BusinessCombinations">
        <link:definition>2102100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails">
        <link:definition>2402402 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables">
        <link:definition>2302301 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail">
        <link:definition>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesDetailsDetails" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails">
        <link:definition>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsCommitmentsAndContingenciesNotes" roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes">
        <link:definition>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.galenabiopharma.com/role/LicenseAgreements">
        <link:definition>2114100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail">
        <link:definition>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.galenabiopharma.com/role/LongTermDebt">
        <link:definition>2107100 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails">
        <link:definition>2407401 - Disclosure - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.galenabiopharma.com/role/NetLossPerShare">
        <link:definition>2113100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareCommonSharesExcludedFromNetLossDetail" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail">
        <link:definition>2413402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables">
        <link:definition>2313301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNotes" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes">
        <link:definition>2112100 - Disclosure - Other Income (Expense) (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTableDetails" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails">
        <link:definition>2412402 - Disclosure - Other Income (Expense) Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseTables" roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables">
        <link:definition>2312301 - Disclosure - Other Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails">
        <link:definition>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskNotes" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes">
        <link:definition>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables">
        <link:definition>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation">
        <link:definition>2111100 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockBasedCompensationDetails" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails">
        <link:definition>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail">
        <link:definition>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables">
        <link:definition>2311301 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.galenabiopharma.com/role/StockholdersEquity">
        <link:definition>2109100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail">
        <link:definition>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables">
        <link:definition>2309301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.galenabiopharma.com/role/SubsequentEvents">
        <link:definition>2116100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.galenabiopharma.com/role/Warrants">
        <link:definition>2110100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsChangesInFairValueOfWarrantLiabilityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail">
        <link:definition>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail">
        <link:definition>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsScheduleOfWarrantActivityDetail" roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail">
        <link:definition>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.galenabiopharma.com/role/WarrantsTables">
        <link:definition>2310301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWarrantsClassifiedAsEquityDetails" roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails">
        <link:definition>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gale_AccruedInventoryPurchasesCurrent" name="AccruedInventoryPurchasesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_AprilTwoThousandElevenWarrantMember" name="AprilTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" name="AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" name="AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessAcquisitionCashHeldByAcquiredEntity" name="BusinessAcquisitionCashHeldByAcquiredEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchaseConsideration" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfContingentPurchasePriceConsideration" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassOfWarrantsOrRightsExpirationDate" name="ClassOfWarrantsOrRightsExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" name="ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightExpired" name="ClassofWarrantorRightExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightFairValueRollForward" name="ClassofWarrantorRightFairValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightGranted" name="ClassofWarrantorRightGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ClassofWarrantorRightOutstandingRollForward" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" name="CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ConsultantWarrantsMember" name="ConsultantWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentConsiderationPolicyPolicyTextBlock" name="ContingentConsiderationPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractResearchPayable" name="ContractResearchPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationNetSalesThreshold" name="ContractualObligationNetSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ContractualObligationPotentialPaymentsfromNetSales" name="ContractualObligationPotentialPaymentsfromNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_CreditMemosAcquisitionChannelInventoryCurrent" name="CreditMemosAcquisitionChannelInventoryCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_CustomerFiveMember" name="CustomerFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerFourMember" name="CustomerFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerThreeMember" name="CustomerThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DebtInstrumentCashFacilityFee" name="DebtInstrumentCashFacilityFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentCashFinalPayment" name="DebtInstrumentCashFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_DebtInstrumentTermInterestOnly" name="DebtInstrumentTermInterestOnly" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_DecemberTwoThousandTwelveWarrantMember" name="DecemberTwoThousandTwelveWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_DeficitAccumulatedDuringDevelopmentalStage" name="DeficitAccumulatedDuringDevelopmentalStage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" name="EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_EstimatedYearOfPatentExpiration" name="EstimatedYearOfPatentExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" name="FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueOfWarrantsLiabilities" name="FairValueOfWarrantsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueOfWarrantsPotentiallySettleableInCash" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FairValueofWarrantsGranted" name="FairValueofWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_FairValueofWarrantsGrantedperShare" name="FairValueofWarrantsGrantedperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" name="FinitelivedIntangibleAssetsAcquiredContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" name="FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_FirstTrancheMember" name="FirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_FutureMilestonePayment" name="FutureMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_GALE401rights" name="GALE401rights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_InProcessResearchDevelopment" name="InProcessResearchDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_LincolnParkCapitalLLCMember" name="LincolnParkCapitalLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_LossContingencyPercentageofLegalFeesPaid" name="LossContingencyPercentageofLegalFeesPaid" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_LossOnWarrantExchange" name="LossOnWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MLVCo.LLCandMaximGroupLLCMember" name="MLVCo.LLCandMaximGroupLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandElevenWarrantMember" name="MarchTwoThousandElevenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandFifteenWarrantsMember" name="MarchTwoThousandFifteenWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_MarchTwoThousandTenWarrantMember" name="MarchTwoThousandTenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" name="MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_MiscellaneousOtherIncomeExpense" name="MiscellaneousOtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_NetProceedsFromExerciseOfCommonStockWarrants" name="NetProceedsFromExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofCommericalProducts" name="NumberofCommericalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofDaysAveragedforExercisePrice" name="NumberofDaysAveragedforExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_NumberofDosingStrengths" name="NumberofDosingStrengths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofSharesPerUnit" name="NumberofSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_NumberofTopPerformingPharmacies" name="NumberofTopPerformingPharmacies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" name="OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_OrexoMember" name="OrexoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" name="PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_PatientAssistanceProgramCurrent" name="PatientAssistanceProgramCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" name="ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_PurchaseAgreementTerm" name="PurchaseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ReclassificationOfWarrantLiabilityUponExercise" name="ReclassificationOfWarrantLiabilityUponExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="gale_SalesAndDistributionsRights" name="SalesAndDistributionsRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_SalesAndDistributionsRightsZuplenz" name="SalesAndDistributionsRightsZuplenz" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" name="ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantActivityTableTableTextBlock" name="ScheduleOfWarrantActivityTableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_SeptemberTwoThousandThirteenWarrantMember" name="SeptemberTwoThousandThirteenWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="gale_StockIssuedDuringPeriodSharesOverallotmentOption" name="StockIssuedDuringPeriodSharesOverallotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="gale_TwoZeroZeroSevenIncentivePlanMember" name="TwoZeroZeroSevenIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="gale_WarrantStrikePrice" name="WarrantStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsExpectedVolatility" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="gale_WarrantsGrantedNumberofShares" name="WarrantsGrantedNumberofShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="gale_ZuplenzMember" name="ZuplenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>gale-20150630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_c30e2344-3447-c5b8-6835-36aef383625e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_ContractResearchPayable_c30e2344-3447-c5b8-6835-36aef383625e" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_382f14b8-2774-f5dd-d258-36aef3aa6efe" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_FutureMilestonePayment_382f14b8-2774-f5dd-d258-36aef3aa6efe" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_c607fef0-6470-11e4-a349-22000a1e8102" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_c607fef0-6470-11e4-a349-22000a1e8102" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_6bfb7f90-9a12-d9d8-2b93-36aef3d2168e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_PatientAssistanceProgramCurrent_6bfb7f90-9a12-d9d8-2b93-36aef3d2168e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d69c5cc5-fc70-31a7-c2b1-924eb363b75b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_839b6add-8ba5-8eb9-6911-0eee956b66c8" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_839b6add-8ba5-8eb9-6911-0eee956b66c8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_bb772f62-f5a6-bab7-e2c1-84f314d9b18f" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_us-gaap_InterestPayableCurrent_bb772f62-f5a6-bab7-e2c1-84f314d9b18f" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_1157FDED3C533A684802FE56EC7359BD" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:to="loc_gale_AccruedInventoryPurchasesCurrent_1157FDED3C533A684802FE56EC7359BD" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd7b63fa-09ae-1100-16fe-5ac027208548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1d834322-984c-3ee2-a4a0-2dc90b007763" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_LongTermDebtCurrent_0601d697-1537-c3cb-caaf-11141ac92b39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_17dd34ae-bdb5-d249-f1b5-084376fff348" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_17dd34ae-bdb5-d249-f1b5-084376fff348" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_f1e0e921-cfc7-a57a-5c75-36aef3d5be11" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_f1e0e921-cfc7-a57a-5c75-36aef3d5be11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b83a57-ffbc-fc48-170d-f8b25d163e54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_PreferredStockValue_9fd7dfd7-596e-4c7f-4077-abbf8130d157" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c55800a-0ae8-71c7-e1d1-5e4859c50246" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_85633807-18f7-72ee-eb13-36aef39d8fa0" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_85633807-18f7-72ee-eb13-36aef39d8fa0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_TreasuryStockValue_719740e5-b138-f870-281f-ac4786e101c2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a7bb915d-e645-20d7-7b2e-623731454f45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_59dbb0ce-8e17-487b-ae40-e3a584ab7a36" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_59dbb0ce-8e17-487b-ae40-e3a584ab7a36" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a00a52e0-8d97-7156-7079-2c628ca1666f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_InventoryNet_a00a52e0-8d97-7156-7079-2c628ca1666f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_1b17581d-51a2-b3bc-44d6-36aef38b22b9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_InProcessResearchDevelopment_1b17581d-51a2-b3bc-44d6-36aef38b22b9" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_0f09d8a4-c43c-d798-bdef-36aef3c509ef" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_SalesAndDistributionsRights_0f09d8a4-c43c-d798-bdef-36aef3c509ef" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_57cf43da-6457-11e4-a349-22000a1e8102" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_57cf43da-6457-11e4-a349-22000a1e8102" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_3ef739be-0bee-34dc-69c0-36aef3c444cf" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_gale_GALE401rights_3ef739be-0bee-34dc-69c0-36aef3c444cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_d38e3ea0-c47e-8d3f-d1c1-10b307bfbf64" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_d38e3ea0-c47e-8d3f-d1c1-10b307bfbf64" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_59d54f92-5751-9336-8cc7-36aef3ce858c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_59d54f92-5751-9336-8cc7-36aef3ce858c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_46f27a16-fc41-aca3-91c1-4e39fa4c2ce6" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_46f27a16-fc41-aca3-91c1-4e39fa4c2ce6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_555855ee-67fc-e384-4c0f-c30d34ed47e5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76f611bf-6cac-2837-6d7c-3028d488fc3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_ShareBasedCompensation_aa7a0bc5-86c6-13a8-3676-9960bad8007f" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_dae75ce7-425a-7119-0dd6-36aef384b473" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_dae75ce7-425a-7119-0dd6-36aef384b473" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_30c404fa-c20d-e897-c0b6-36aef387c11b" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_30c404fa-c20d-e897-c0b6-36aef387c11b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fc73bf45-b7cf-c894-bf3a-f56c9d39cbe4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d2a8fa0f-43df-513c-7a7b-93e04034bb1e" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d2a8fa0f-43df-513c-7a7b-93e04034bb1e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_07d730ea-b32b-956c-677e-cf5b73c388b0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9fb8522-752c-3209-8cca-60e64f420ad5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5cb9a7e8-dd26-27c7-9313-c478703eadea" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_SalesRevenueNet_0863786b-6bf9-966f-db7b-d5636f830397" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_ba3cee0f-0b78-d604-d45b-dd6d9f2c2132" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_CostOfRevenue_ba3cee0f-0b78-d604-d45b-dd6d9f2c2132" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_581512af-7ae6-1b38-5ef5-f123bd81ccb9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_581512af-7ae6-1b38-5ef5-f123bd81ccb9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f5487d97-18cc-be7a-d1d1-ec68e0b0a9f3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c1b76359-2bf3-ac34-0e0e-8614c806c9a0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_a362a907-2b45-0c69-51a9-36aef3a302f1" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_gale_LossOnWarrantExchange_a362a907-2b45-0c69-51a9-36aef3a302f1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_a12c4ccc-a50c-b165-5045-f74bbea2c47f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_a12c4ccc-a50c-b165-5045-f74bbea2c47f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_99cc4179-c5f2-7860-2937-70c2f8f826bc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_27b74f5e-bc16-8d0b-2d8b-f8fb77af5bf6" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_aa7fcc1c-b1c3-0bc9-16a4-36aef3d4e0cc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_397f7477-1aa4-42ae-c7e8-4b8ec1fcc54c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityFairValueDisclosure_302a6e98-c762-716f-8178-ceed50d9741b" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_397f7477-1aa4-42ae-c7e8-4b8ec1fcc54c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e04c7e47-0e17-b87c-b6be-bac174a68406" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e04c7e47-0e17-b87c-b6be-bac174a68406" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b392c6a6-07f0-050a-e07d-ef62a880a291" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b392c6a6-07f0-050a-e07d-ef62a880a291" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_e869d365-5f39-2489-9730-36aef3a6a861" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_e869d365-5f39-2489-9730-36aef3a6a861" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_cca78d49-9821-d11e-1e65-36aef3ba77c1" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a51b337f-fe8a-e677-aa85-f24cc1bc3ff0" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_cca78d49-9821-d11e-1e65-36aef3ba77c1" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>gale-20150630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:to="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:to="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8A1A5DED521B7CA8E19ED437A847893B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:to="loc_us-gaap_MinimumMember_8A1A5DED521B7CA8E19ED437A847893B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_588134C4FB16A401AA9ED437A8475385" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:to="loc_us-gaap_MaximumMember_588134C4FB16A401AA9ED437A8475385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:to="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:to="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:to="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_77260F78EA2D17B496A3D437A833EC3B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:to="loc_us-gaap_CommonStockMember_77260F78EA2D17B496A3D437A833EC3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:to="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0712BE7473026EB40782F4C7DD23C9EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_CommonStockMember_0712BE7473026EB40782F4C7DD23C9EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_A96C497CD1C54D72E6D8E00155E02045" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:to="loc_gale_ZuplenzMember_A96C497CD1C54D72E6D8E00155E02045" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7BDDBFFE16BB516AEF2DE00156337385" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_NetIncomeLoss_7BDDBFFE16BB516AEF2DE00156337385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:to="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:to="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:to="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FC2912C01585E1764263FE181A16F06E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:to="loc_us-gaap_CommonStockMember_FC2912C01585E1764263FE181A16F06E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_BBCD6E47E06B2E24DC80FE181A16D4E3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_BBCD6E47E06B2E24DC80FE181A16D4E3" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_1713758DB541EF1D223BFE181A1671D7" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_gale_ClosingPriceOfCommonStock_1713758DB541EF1D223BFE181A1671D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_486070BBC0A56D7D2A86FE181A179EE7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_486070BBC0A56D7D2A86FE181A179EE7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:to="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:to="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:to="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_852C248756B87D1132C8FE4277D66465" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:to="loc_us-gaap_MinimumMember_852C248756B87D1132C8FE4277D66465" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CC579042E92813ACADC2FE42922A0B16" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:to="loc_us-gaap_MaximumMember_CC579042E92813ACADC2FE42922A0B16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:to="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:to="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:to="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:to="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_30D90A8BE620C9BCF481FE4041A7EA18" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_30D90A8BE620C9BCF481FE4041A7EA18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:to="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:to="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:to="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:to="loc_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_40847A9D3222F6405685D437A88C04A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:to="loc_us-gaap_WarrantMember_40847A9D3222F6405685D437A88C04A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:to="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:to="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:to="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_6E81FA4CE416CB63E8C8D437A8DBB035" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:to="loc_us-gaap_MinimumMember_6E81FA4CE416CB63E8C8D437A8DBB035" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_973F54FEE52BC966EAD7D437A8DC577A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:to="loc_us-gaap_MaximumMember_973F54FEE52BC966EAD7D437A8DC577A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9E6CCF2C7E19FE7ABC6BD437A788F51A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9E6CCF2C7E19FE7ABC6BD437A788F51A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:to="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:to="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:to="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:to="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:to="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:to="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:to="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_3221C6B59A58CBE9813AD437A7C88B72" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_3221C6B59A58CBE9813AD437A7C88B72" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_062A76813DA827ACBB1ED437A7C8B77B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_062A76813DA827ACBB1ED437A7C8B77B" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_526FE72AF0242D391A63D437A7C80543" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_526FE72AF0242D391A63D437A7C80543" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_096664FE5EECDA554163D437A7C8D127" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_096664FE5EECDA554163D437A7C8D127" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_822E6CC465AEB353328CD437A7C870ED" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_822E6CC465AEB353328CD437A7C870ED" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_0924F77705CEC5918622D437A7C92137" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_0924F77705CEC5918622D437A7C92137" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:to="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_9786E18752B13F54A0D7D437A828C394" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_9786E18752B13F54A0D7D437A828C394" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_0385CC57B561DABCCE78D437A82924BF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_0385CC57B561DABCCE78D437A82924BF" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_7D3A2632BE5D7800CA2AD437A8294DBB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_7D3A2632BE5D7800CA2AD437A8294DBB" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_84AF1EF841FAACC1F85FD437A8294905" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_84AF1EF841FAACC1F85FD437A8294905" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_C909256C55AD8FDDEBD3D437A829EFB7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_C909256C55AD8FDDEBD3D437A829EFB7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_4579514E25A76C64B197D437A82932D2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_4579514E25A76C64B197D437A82932D2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:to="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:to="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:to="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:to="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26B751AE7E485C6BFD15D437A7E91226" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26B751AE7E485C6BFD15D437A7E91226" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="arc" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>gale-20150630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2015 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_label_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Fifteen Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:to="lab_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="arc" />
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_terseLabel_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2013 Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_label_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:label id="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7_documentation_en-US" xlink:label="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September Two Thousand Thirteen Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:to="lab_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="arc" />
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_terseLabel_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2012 Warrants [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_label_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:label id="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9_documentation_en-US" xlink:label="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December Two Thousand Twelve Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:to="lab_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="arc" />
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_terseLabel_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_label_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992_documentation_en-US" xlink:label="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:to="lab_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2011 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_label_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Eleven Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:to="lab_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="arc" />
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_terseLabel_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2010 Warrants [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_label_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:label id="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A_documentation_en-US" xlink:label="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March Two Thousand Ten Warrant [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:to="lab_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="arc" />
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_terseLabel_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_label_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:label id="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B_documentation_en-US" xlink:label="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consultant Warrants [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:to="lab_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB_label_en-US" xlink:label="lab_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:to="lab_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB_label_en-US" xlink:label="lab_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:to="lab_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458_label_en-US" xlink:label="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:to="lab_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6_label_en-US" xlink:label="lab_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:to="lab_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="lab_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Beginning balance</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Granted</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:to="lab_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:to="lab_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding , Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:type="arc" />
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_terseLabel_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_label_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:label id="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9_documentation_en-US" xlink:label="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Expiration Date</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:to="lab_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:to="lab_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="arc" />
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_terseLabel_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_label_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:label id="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D_documentation_en-US" xlink:label="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Zero Zero Seven Incentive Plan [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:to="lab_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Employees</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to employees.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_terseLabel_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_label_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annualized Forfeiture Rate For Options Granted To Senior Management</link:label>
    <link:label id="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25_documentation_en-US" xlink:label="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annualized forfeiture rate for options granted to senior management.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:to="lab_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="arc" />
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_terseLabel_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_label_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E_documentation_en-US" xlink:label="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:to="lab_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding common stock options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting periods of options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expire from date of grant</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="arc" />
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_terseLabel_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing price of the Company's common stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_label_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088_documentation_en-US" xlink:label="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:to="lab_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:to="lab_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F_label_en-US" xlink:label="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:to="lab_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8_label_en-US" xlink:label="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:to="lab_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="arc" />
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_terseLabel_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_label_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:label id="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD_documentation_en-US" xlink:label="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lincoln Park Capital, LLC [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:to="lab_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="arc" />
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_terseLabel_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_label_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:label id="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268_documentation_en-US" xlink:label="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MLV &amp; Co. LLC and Maxim Group LLC [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:to="lab_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:to="lab_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:to="lab_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:to="lab_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5_label_en-US" xlink:label="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:to="lab_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="lab_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="arc" />
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_terseLabel_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_label_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:label id="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65_documentation_en-US" xlink:label="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement Term</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:to="lab_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423_label_en-US" xlink:label="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:to="lab_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Percent of Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="arc" />
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_terseLabel_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_label_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:label id="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99_documentation_en-US" xlink:label="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At Market Issuance Sales Agreements, Maximum Gross Proceeds</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:to="lab_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="arc" />
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_terseLabel_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_label_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:label id="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2_documentation_en-US" xlink:label="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Per Unit</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:to="lab_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares availabe from warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="arc" />
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_terseLabel_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_label_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:label id="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6_documentation_en-US" xlink:label="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Overallotment Option</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:to="lab_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="arc" />
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_terseLabel_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_label_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:label id="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F_documentation_en-US" xlink:label="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:to="lab_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:type="arc" />
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B_label_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B_documentation_en-US" xlink:label="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="lab_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF_label_en-US" xlink:label="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:to="lab_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A_label_en-US" xlink:label="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:to="lab_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:to="lab_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:to="lab_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4_label_en-US" xlink:label="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:to="lab_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC_terseLabel_en-US" xlink:label="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC_label_en-US" xlink:label="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:to="lab_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:to="lab_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:to="lab_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:to="lab_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4_label_en-US" xlink:label="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:to="lab_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C_label_en-US" xlink:label="lab_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:to="lab_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="lab_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:to="lab_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:to="lab_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:to="lab_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:to="lab_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants issued in connection with March 2015 common stock offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation for directors and employees</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:to="lab_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:to="lab_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_terseLabel_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_label_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:label id="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87_documentation_en-US" xlink:label="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted, Number of Shares</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:to="lab_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_terseLabel_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Days Averaged for Exercise Price</link:label>
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_label_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Days Averaged for Exercise Price</link:label>
    <link:label id="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894_documentation_en-US" xlink:label="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price is based on the average closing price over this many trading days up to the date of the grant.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:to="lab_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted, per Share</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:to="lab_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Total Number of Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Number of Shares, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Weighted Average Exercise Price, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Granted</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:type="arc" />
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_terseLabel_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Cancelled</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_label_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:label id="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659_documentation_en-US" xlink:label="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:to="lab_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options activity, Aggregate Intrinsic Value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table [Table Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Activity Table</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:to="lab_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_label_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6_documentation_en-US" xlink:label="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:to="lab_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:type="arc" />
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_terseLabel_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_label_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:label id="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997_documentation_en-US" xlink:label="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrant Liability Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:to="lab_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:type="arc" />
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_terseLabel_en-US" xlink:label="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strike price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_label_en-US" xlink:label="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272_documentation_en-US" xlink:label="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:to="lab_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_label_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:to="lab_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:to="lab_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="arc" />
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_terseLabel_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_label_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5_documentation_en-US" xlink:label="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:to="lab_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable Inputs (Level 3) [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27_verboseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604_totalLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:to="lab_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:to="lab_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Excluded from Net Loss</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_label_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:label id="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24_documentation_en-US" xlink:label="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:to="lab_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:type="arc" />
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_terseLabel_en-US" xlink:label="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_label_en-US" xlink:label="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2_documentation_en-US" xlink:label="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:to="lab_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:type="arc" />
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_terseLabel_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring Zuplenz channel inventory</link:label>
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_label_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Memos Acquisition Channel Inventory, Current</link:label>
    <link:label id="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A_documentation_en-US" xlink:label="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Memos Acquisition Channel Inventory, Current</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:to="lab_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:type="arc" />
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_terseLabel_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient assistance programs and rebates</link:label>
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_label_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Assistance Program, Current</link:label>
    <link:label id="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF_documentation_en-US" xlink:label="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Assistance Program, Current</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:to="lab_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:type="arc" />
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_terseLabel_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory purchases</link:label>
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_label_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Inventory Purchases, Current</link:label>
    <link:label id="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07_documentation_en-US" xlink:label="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Inventory Purchases, Current</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:to="lab_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8_verboseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz milestone payments</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8_label_en-US" xlink:label="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:label id="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8_documentation_en-US" xlink:label="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payment</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:to="lab_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:to="lab_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="arc" />
    <link:label id="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D_terseLabel_en-US" xlink:label="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D_label_en-US" xlink:label="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:label id="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D_documentation_en-US" xlink:label="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zuplenz [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:to="lab_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit memos for expiring channel inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="arc" />
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D_terseLabel_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D_label_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:label id="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D_documentation_en-US" xlink:label="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:to="lab_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50_label_en-US" xlink:label="lab_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:to="lab_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:type="arc" />
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_terseLabel_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_label_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:label id="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974_documentation_en-US" xlink:label="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Warrants Granted</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:to="lab_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="lab_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_periodStartLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Beginning balance</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_terseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:to="lab_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499_periodEndLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, Ending balance</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:to="lab_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:to="lab_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="lab_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:type="arc" />
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_terseLabel_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of legal fees obligated to pay</link:label>
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_label_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Percentage of Legal Fees Paid</link:label>
    <link:label id="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C_documentation_en-US" xlink:label="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Percentage of Legal Fees Paid</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:to="lab_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for milestone payment, other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="lab_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="arc" />
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_terseLabel_en-US" xlink:label="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_label_en-US" xlink:label="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:label id="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D_documentation_en-US" xlink:label="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Tranche [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:to="lab_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan, amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for interest only payments</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_label_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:label id="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78_documentation_en-US" xlink:label="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:to="lab_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments at the fixed coupon rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for principal and interest payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:to="lab_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash facility fee percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Facility Fee</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:to="lab_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="arc" />
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_terseLabel_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash final payment percentage</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_label_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:label id="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A_documentation_en-US" xlink:label="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cash Final Payment</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:to="lab_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:to="lab_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="arc" />
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_terseLabel_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duration of average market price used for warrant exercise price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_label_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:label id="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F_documentation_en-US" xlink:label="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Average Market Price Used For Exercise Price</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:to="lab_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:to="lab_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:to="lab_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:to="lab_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the contingent purchase price liability</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:type="arc" />
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_terseLabel_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense)</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_label_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Income Expense</link:label>
    <link:label id="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208_documentation_en-US" xlink:label="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other income (expense).</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:to="lab_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Proceedings, Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:type="arc" />
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_terseLabel_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_label_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Reserved For Future Issuance Under Companies Incentive Plan</link:label>
    <link:label id="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36_documentation_en-US" xlink:label="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options reserved for future issuance under the Company's 2007 Incentive Plan.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:to="lab_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_terseLabel_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_label_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1_documentation_en-US" xlink:label="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:to="lab_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B_negatedLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of the contingent purchase price consideration</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:type="arc" />
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_terseLabel_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock are Reserved for Future Issuance</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_label_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Are Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label id="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185_documentation_en-US" xlink:label="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:to="lab_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="lab_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:to="lab_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:to="lab_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:to="lab_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="arc" />
    <link:label id="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028_terseLabel_en-US" xlink:label="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028_label_en-US" xlink:label="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028_documentation_en-US" xlink:label="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:to="lab_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="arc" />
    <link:label id="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED_terseLabel_en-US" xlink:label="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED_label_en-US" xlink:label="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED_documentation_en-US" xlink:label="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:to="lab_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="arc" />
    <link:label id="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0_terseLabel_en-US" xlink:label="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0_label_en-US" xlink:label="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0_documentation_en-US" xlink:label="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:to="lab_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8_terseLabel_en-US" xlink:label="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8_label_en-US" xlink:label="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:label id="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8_documentation_en-US" xlink:label="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Four [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:to="lab_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="arc" />
    <link:label id="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC_terseLabel_en-US" xlink:label="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC_label_en-US" xlink:label="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:label id="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC_documentation_en-US" xlink:label="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Five [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:to="lab_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:type="arc" />
    <link:label id="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6_terseLabel_en-US" xlink:label="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6_label_en-US" xlink:label="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:label id="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6_documentation_en-US" xlink:label="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Commerical Products</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:to="lab_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="arc" />
    <link:label id="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A_terseLabel_en-US" xlink:label="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A_label_en-US" xlink:label="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:label id="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A_documentation_en-US" xlink:label="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Dosing Strengths</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:to="lab_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="arc" />
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071_terseLabel_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071_label_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:label id="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071_documentation_en-US" xlink:label="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Top Performing Pharmacies</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:to="lab_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="arc" />
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B_terseLabel_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B_label_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B_documentation_en-US" xlink:label="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:to="lab_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="arc" />
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF_terseLabel_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF_label_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF_documentation_en-US" xlink:label="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="lab_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="arc" />
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610_terseLabel_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Highly-liquid debt instruments maturity days</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610_label_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:label id="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610_documentation_en-US" xlink:label="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:to="lab_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B_label_en-US" xlink:label="lab_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:to="lab_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:to="lab_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:to="lab_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10_terseLabel_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prompyt pay discount, percent of gross sales</link:label>
    <link:label id="lab_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:to="lab_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of certain acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uses of Estimates in Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:to="lab_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and In-Licensing</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:type="arc" />
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC_terseLabel_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC_label_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC_documentation_en-US" xlink:label="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:to="lab_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:type="arc" />
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237_terseLabel_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237_label_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents And Patent Application Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237_documentation_en-US" xlink:label="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patents and Patent Application Costs [Policy Text Block]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:to="lab_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:to="lab_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="lab_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:to="lab_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue (excluding amortization of certain acquired intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:to="lab_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:to="lab_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:to="lab_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:type="arc" />
    <link:label id="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C_negatedTerseLabel_en-US" xlink:label="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants potentially settleable in cash</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C_label_en-US" xlink:label="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Warrant Exchange</link:label>
    <link:label id="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C_documentation_en-US" xlink:label="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on warrant exchange.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:to="lab_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:to="lab_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding: basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="lab_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:to="lab_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment and furnishings, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:type="arc" />
    <link:label id="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0_terseLabel_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0_label_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0_documentation_en-US" xlink:label="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:to="lab_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abstral rights, net</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:to="lab_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:type="arc" />
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC_terseLabel_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zuplenz rights</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC_label_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:label id="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC_documentation_en-US" xlink:label="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Distributions Rights, Zuplenz</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:to="lab_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:type="arc" />
    <link:label id="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19_terseLabel_en-US" xlink:label="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19_label_en-US" xlink:label="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:label id="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19_documentation_en-US" xlink:label="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GALE-401 rights</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:to="lab_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D_label_en-US" xlink:label="lab_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:to="lab_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:to="lab_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants potentially settleable in cash</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:to="lab_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:to="lab_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:to="lab_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:type="arc" />
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF_terseLabel_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF_label_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF_documentation_en-US" xlink:label="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:to="lab_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A_label_en-US" xlink:label="lab_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:to="lab_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:to="lab_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:to="lab_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 275,000,000 shares authorized, 161,716,381 shares issued and 162,391,381 shares outstanding at June 30, 2015; 200,000,000 shares authorized, 130,146,341 shares issued and 129,471,341 shares outstanding at December 31, 2014</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:to="lab_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:type="arc" />
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89_negatedLabel_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89_label_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit Accumulated During Developmental Stage</link:label>
    <link:label id="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89_documentation_en-US" xlink:label="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deficit accumulated during the developmental stage.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:to="lab_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less treasury shares at cost, 675,000 shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:to="lab_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:to="lab_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:to="lab_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:to="lab_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="arc" />
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E_negatedTerseLabel_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E_label_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E_documentation_en-US" xlink:label="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:to="lab_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Zuplenz rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of GALE-401 rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for purchase of equipment and furnishings</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="arc" />
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF_terseLabel_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF_label_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Exercise Of Common Stock Warrants</link:label>
    <link:label id="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF_documentation_en-US" xlink:label="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from exercise of common stock warrants.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:to="lab_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued in connection with ESPP</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principle payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received during the periods for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:to="lab_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the periods for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC_label_en-US" xlink:label="lab_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:to="lab_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="arc" />
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F_terseLabel_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as cost of equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F_label_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity</link:label>
    <link:label id="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F_documentation_en-US" xlink:label="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued in connection with common stock recorded as a cost of equity.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:to="lab_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="arc" />
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E_negatedTerseLabel_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liabilities upon exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E_label_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Warrant Liability Upon Exercise</link:label>
    <link:label id="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E_documentation_en-US" xlink:label="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon exercise.</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:to="lab_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Description [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Customer and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="lab_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:to="lab_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="arc" />
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_terseLabel_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_label_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049_documentation_en-US" xlink:label="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:to="lab_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="arc" />
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_terseLabel_en-US" xlink:label="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_label_en-US" xlink:label="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:label id="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C_documentation_en-US" xlink:label="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orexo [Member]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:to="lab_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="arc" />
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_terseLabel_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_label_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53_documentation_en-US" xlink:label="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="lab_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:type="arc" />
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_terseLabel_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_label_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:label id="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE_documentation_en-US" xlink:label="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Maintenance Fee</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:to="lab_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="arc" />
    <link:label id="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A_terseLabel_en-US" xlink:label="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for Phase 3</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:to="lab_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of Abstral rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="arc" />
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_terseLabel_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining cash held of Abstral rights</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_label_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:label id="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F_documentation_en-US" xlink:label="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Cash Held By Acquired Entity</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:to="lab_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="arc" />
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_terseLabel_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated year of licensed patents expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_label_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:label id="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE_documentation_en-US" xlink:label="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Year Of Patent Expiration</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:to="lab_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="arc" />
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_terseLabel_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_label_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:label id="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8_documentation_en-US" xlink:label="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:to="lab_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_label_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:label id="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA_documentation_en-US" xlink:label="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Potential Payments from Net Sales</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:to="lab_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="arc" />
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_terseLabel_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_label_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:label id="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569_documentation_en-US" xlink:label="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Net Sales Threshold</link:label>
    <link:loc xlink:href="gale-20150630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:to="lab_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>gale-20150630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="gale-20150630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:href="gale-20150630.xsd#BusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:href="gale-20150630.xsd#BusinessCombinations" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:href="gale-20150630.xsd#BusinessCombinationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:href="gale-20150630.xsd#BusinessCombinationsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="gale-20150630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:href="gale-20150630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:href="gale-20150630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:href="gale-20150630.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:href="gale-20150630.xsd#FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:href="gale-20150630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:href="gale-20150630.xsd#LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:href="gale-20150630.xsd#LicenseAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:href="gale-20150630.xsd#LicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebt" xlink:href="gale-20150630.xsd#LongTermDebt" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:href="gale-20150630.xsd#LongTermDebtDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:href="gale-20150630.xsd#NetLossPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:href="gale-20150630.xsd#NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:href="gale-20150630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:href="gale-20150630.xsd#OtherIncomeExpenseNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTableDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:href="gale-20150630.xsd#OtherIncomeExpenseTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:href="gale-20150630.xsd#SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:href="gale-20150630.xsd#StockBasedCompensation" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:href="gale-20150630.xsd#StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:href="gale-20150630.xsd#StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:href="gale-20150630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:href="gale-20150630.xsd#StockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="gale-20150630.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:href="gale-20150630.xsd#StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:href="gale-20150630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:href="gale-20150630.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/Warrants" xlink:href="gale-20150630.xsd#Warrants" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:href="gale-20150630.xsd#WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:href="gale-20150630.xsd#WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:href="gale-20150630.xsd#WarrantsScheduleOfWarrantActivityDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsTables" xlink:href="gale-20150630.xsd#WarrantsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:href="gale-20150630.xsd#WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_621E0E258FFE156652C3D437A8800D1B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_621E0E258FFE156652C3D437A8800D1B" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_E4BB2197AFC60E9737C0D437A8809BBD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractResearchPayable" xlink:label="loc_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_gale_ContractResearchPayable_62877174DC00BFEE4684FE434294DED2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CreditMemosAcquisitionChannelInventoryCurrent" xlink:label="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_gale_CreditMemosAcquisitionChannelInventoryCurrent_FBBEFCCD4689C5D390AAFE434295DD2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C3639E272396BAB26AC6FE4342951107" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_10AFE3D57EBF9AEA7E0BFE434295E278" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_PatientAssistanceProgramCurrent" xlink:label="loc_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_gale_PatientAssistanceProgramCurrent_E5D5B0E7682A14492FA0FE4342958BBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_380DA7AD4E89A5A42128FE4342952E34" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AccruedInventoryPurchasesCurrent" xlink:label="loc_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_gale_AccruedInventoryPurchasesCurrent_7C6FD3F809FC0AF6A5EDFE56F7AC5B07" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_gale_FutureMilestonePayment_EEAB95E87828F9E90B76FE4342955DF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_us-gaap_InterestPayableCurrent_C1EC3A7337A75E6D57E5FE434295002C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2F3F25382D9B801B75FFE434294B543" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B50BF38B2DBAD70D429EFE4342957EC3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A8CC2F23CFB33C574E6DD437A81CC440" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40E1BC40660E7F36A115D437A81CFBFC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06F5A1A819E913F583F9D437A8AB9613" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3F6734EDF6D3993EAE67D437A8AB46E5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ED8284C8A12FF1774C7DD437A847B10E" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ED8284C8A12FF1774C7DD437A847B10E" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E5899F470D521FDD2430D437A847A41B" xlink:to="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8A1A5DED521B7CA8E19ED437A847893B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:to="loc_us-gaap_MinimumMember_8A1A5DED521B7CA8E19ED437A847893B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_588134C4FB16A401AA9ED437A8475385" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7C7CE8441C59EF0852DED437A8471F8D" xlink:to="loc_us-gaap_MaximumMember_588134C4FB16A401AA9ED437A8475385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1457A62BB17A34FB17DCD437A8477304" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EquipmentFurnitureAndFixturesMember" xlink:label="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_BC0A36AD926EB4F6A3BAD437A8470412" xlink:to="loc_gale_EquipmentFurnitureAndFixturesMember_17BB191A91AEFC8AFBF3D437A847EC5B" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_87895854A11AFB753C94D437A8478921" xlink:to="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_24672312C7EBE2D1FBD0D437A8480204" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents" xlink:label="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents_972A591E64DD090C4015D437A8483610" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryNet_EDDB462609D5B13BD599D437A848059B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryWorkInProcess_C4FB0C77C9DE6E1283D1D437A84841A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_InventoryFinishedGoods_9E2472FF83B8DCE13BA0D437A8486314" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA4CC5ACE58A55B3E774D437A848BAE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesDiscountsServices" xlink:label="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_SalesDiscountsServices_5DB129FF8F7598F68F4BD437A8488B10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems_A96A8AFC21A75C43B87ED437A847FCEF" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_742D7D29461C87815021D437A8484E71" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_UseOfEstimates_13EF1C5EA786758F8D80D437A7BDF2FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_EE2C878D7B26E10B46BCD437A7BD8751" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_E7F0B8CA5F02805AD150D437A7BD742D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_900AC08B149229C30775D437A7BDF474" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_A0DBB1A4F3D74ECEFA8DD437A7C23AA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3A08AFD4CA198D1F6ECBD437A7C3567D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1BB6ACDEB73E9E2A87C7D437A7C36237" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_02871BACA4717BD94F87D437A7C3254E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_784F7CD30C16A71140E1D437A7C3EF07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0A41C85C42A7A3F69990D437A7C31A2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_C4FD6C94F98B1E7F41EFD437A7C3D7FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_449D4FA74FED95550B03D437A7C31049" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_gale_ContingentConsiderationPolicyPolicyTextBlock_209B256504EC3AEB9CBED437A7C3E9DC" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock" xlink:label="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock_A7F76D789FC808EFFAB6D437A7C3D237" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_EFCF2F11C5036282EF0FD437A7C3CE32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_A64FF8EE7EABC2D79A13D437A7C3F559" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9A4BCCD2E23289F9A667D437A7C3A9E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9B1BD1EBA3FFC2591C78D437A7C345AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_F3928BA9AAB2FE02F3DDD437A7C3E94A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C9E0DCC907443AAF3522D437A7C31FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D7B3C23B816709E9F6E6D437A7BDDDF0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_46EA26DB0FC81F5549AAD437A7C4AC92" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinations" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F569D23DB5AC6B30F354D437A83D0018" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F569D23DB5AC6B30F354D437A83D0018" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_DBD9ACE8D939D6810178D437A83DAD50" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_EA6E2E1004B967CEA35ED437A83392AF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DFA6104B48DC8D56B848D437A8334655" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D5DAAA238789C798D363D437A8332721" xlink:to="loc_gale_ZuplenzMember_ADF447C540906617B907D437A8337B9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25A9606C4FCBCA014C29D437A8333613" xlink:to="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_77260F78EA2D17B496A3D437A833EC3B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_736B49CF25BD05823EFAD437A833EF1F" xlink:to="loc_us-gaap_CommonStockMember_77260F78EA2D17B496A3D437A833EC3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_E0723D6FB3AF2B9F20E7D437A8334FAA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4F54C372F215B1BB519BD437A833D20C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_E6C639084BF1C87F572DD437A834F0CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_25D5F1C1C0398CFD7086D437A83481CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0B72ED11BCBA8AE8DCD4D437A8344549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_855D6766D51DFDA57449D437A8348FF4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights" xlink:label="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights_47D5696723B48DC30124D437A834102D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_Goodwill_62FF7E8D5B277D1FD258D437A8349A50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_628570BD609A5D1E72BAD437A8331545" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_13C0BCFF464623693AE3D437A83415DC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/BusinessCombinationsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_645A3B896AA944118B2DD437A87C9C32" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_645A3B896AA944118B2DD437A87C9C32" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_D6D50833EBB52BD91D4DD437A87C393D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D1D667AE5F2CBCE9336E0015658B947" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D1D667AE5F2CBCE9336E0015658B947" xlink:to="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94B4B0177FAF6AABB623E0015659213A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_B52EE1365B2589860D18E0015659F323" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_B9F1B1924F79ECECC9BCE00156597ED2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_DB0B1920415A4DBA3E5EE001565AEC2E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_InventoryNet_DB0B1920415A4DBA3E5EE001565AEC2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04A80B8BE67E086FFA5CE001565A4407" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C10CBA9470C50148D905E0015659803F" xlink:to="loc_us-gaap_AssetsCurrent_D75F3F313453A13A55FEE001565AD4DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26D387C07CB178A3A02EE001565AF9F6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_InProcessResearchDevelopment" xlink:label="loc_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_gale_InProcessResearchDevelopment_A64F687F2DABCB4B37D3E001565A0AD0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRights" xlink:label="loc_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_gale_SalesAndDistributionsRights_CAFED28F7714B5DC7350E001565A76BE" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SalesAndDistributionsRightsZuplenz" xlink:label="loc_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_gale_SalesAndDistributionsRightsZuplenz_A857158570443E92644EE001565B5BAC" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_GALE401rights" xlink:label="loc_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_gale_GALE401rights_C9D7F4877C8E59F520AEE001565B3F19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_939BAF3A7ADF4954363AE001565B02DB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_us-gaap_Goodwill_939BAF3A7ADF4954363AE001565B02DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_0087C35B2C27F95A214DE001565B00AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8BFA44355647963B99EEE00156585B95" xlink:to="loc_us-gaap_Assets_278BAA2438F3B1A85253E001565BFF9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D1D667AE5F2CBCE9336E0015658B947" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="loc_us-gaap_AccountsPayableCurrent_1A0927314D80855E0BD2E001565C1C51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_12C26565E07533135FCFE001565C4A24" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_E282FD728B72A917C94AE001565C206C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="loc_us-gaap_LongTermDebtCurrent_796B64A4C563DC2E2BB2E001565D2C3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20FE421B055BD8E49F70E001565B3F21" xlink:to="loc_us-gaap_LiabilitiesCurrent_DDA0A9A7B2CC5E7E69A8E001565DE666" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_900E9E143E459569FB60E001565D48BA" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:label="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion_C719E875D9B3F9C5883FE001565D0FBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5B527B215B05716FE735E001565DB161" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_Liabilities_63F138B3B1DEB74B0BB1E001565E761A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_B18CFC8431A603D3E871E001565E3411" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_us-gaap_PreferredStockValue_2583F3C04CAC6591F57DE001565E64A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_us-gaap_CommonStockValue_E35BE241E61F2ED501B1E001565EAB90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_743FD001B2F001D12477E001565EFD99" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DeficitAccumulatedDuringDevelopmentalStage" xlink:label="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_gale_DeficitAccumulatedDuringDevelopmentalStage_181F397E427B9273A92BE001565ECE89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_us-gaap_TreasuryStockValue_42EB59B2479989EB5BB5E001565F9FC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0EBAB26FB36A877CF0AAE001565E65C2" xlink:to="loc_us-gaap_StockholdersEquity_400ED023D4C81CA8FFDDE001565F3CD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C1C36E494C88ABE277DCE001565BCF9F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_D697EC94FB44308C2C17E001565FA23B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1A0B29A59902D6485E80D437A80E9BC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1A0B29A59902D6485E80D437A80E9BC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_032349A7351A2F848D5ED437A80E6783" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_032349A7351A2F848D5ED437A80E6783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_PreferredStockSharesIssued_B08F220960165EED5E0CD437A80E3D24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_783BCA75A335436C5B1BD437A80F37CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0A3020CCF620D09A2ED3D437A80F8430" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0A3020CCF620D09A2ED3D437A80F8430" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BC0FA22FD8806D25E17CD437A80FFCEB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_BC0FA22FD8806D25E17CD437A80FFCEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_CommonStockSharesIssued_580032C848AD83EA93B7D437A80F2380" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_279343300353C4A61A71D437A80F09A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A8CF279FDCE3F10ACFCDD437A80EBF16" xlink:to="loc_us-gaap_TreasuryStockShares_6335DDA8410976B89C7AD437A80F0980" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3BBD9A1752532EEADD11F4C7DD21B903" xlink:to="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B08724EAD7C5BC93EFA8F4C7DD223A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0712BE7473026EB40782F4C7DD23C9EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_CommonStockMember_0712BE7473026EB40782F4C7DD23C9EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4DDC85CEE30ECDDD60D7F4C7DD23A126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_RetainedEarningsMember_A4663AE632B686D22AB6F4C7DD230214" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D2419D4A4ADE8AE7CEDAF4C7DD222A4D" xlink:to="loc_us-gaap_TreasuryStockMember_07763747FFC2EC7CFDBAF4C7DD232A48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1CC67194A778DE3FE269F4C7DD22ED7C" xlink:to="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3B9186D191B68856A1BEF4C7DD23BDEF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_SharesOutstanding_A1046F45C0540B35AB49F4C7DD23800A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7BA66963451080F54E19F4C7DD23A26A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31924CAC393D0065F4B4F4C7DD2359E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1CFBE7751DCCCD375D59F4C7DD23DCDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_07D0BD308DAC4496A63CF4C7DD249F64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_E0BEA1A19015FE2E7970F4C7DD241F0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9004479B47C6447F9E9FF4C7DD244392" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3545F072C8962C1E16F1F4C7DD2480AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F416EF764F0C878C539F4C7DD24BAAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_673E64906356BB784F7BF4C7DD2A8575" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_553E63F6AFCA0A7A0F64F4C7DD2A1567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_NetIncomeLoss_229E2BFA0BBA0AA6DC68F4C7DD2A8C04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_SharesOutstanding_83C6B0B411EBF7AAAB15F4C7DD2A3771" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7971EE13A7179A82F680F4C7DD239878" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5DF53F9D54740D4228AEF4C7DD2A8DD8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_EA0DBDCAB2A1D63BB446E00155DF556F" xlink:to="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_411ED278BCC0E302695FE00155E08198" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ZuplenzMember" xlink:label="loc_gale_ZuplenzMember_A96C497CD1C54D72E6D8E00155E02045" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F247CA2B34F13F687208E00155E08E7A" xlink:to="loc_gale_ZuplenzMember_A96C497CD1C54D72E6D8E00155E02045" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D549680C6EFB4747A5EEE00155DF81A4" xlink:to="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7BDDBFFE16BB516AEF2DE00156337385" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_NetIncomeLoss_7BDDBFFE16BB516AEF2DE00156337385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2447E7784069D1D6B3EDE00156339695" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_us-gaap_ShareBasedCompensation_5330A5C283101DD1C8C0E0015633C130" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:label="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_73BE2CDC08A031879EC3E0015633B4B1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchaseConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A420CF0BB1528FB08341E00156331E55" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchaseConsideration_95B86207C9F3B4D3F73AE0015634973E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8B33C2611552C891AB3EE00156346A84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2F8C0480388659F22CE1E00156343F11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0D165571B36163621DC4E0015635F9BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_EE4400485F9A3053FAE7E0015635D82C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7790FBC78F2B85F32BC3E001563412DD" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B0578B08A790708E4BE5E00156358BE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E2249F071E1A99AE39EEE00156333FBA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_103808FA5138D51EF19AE0015635E3CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7BB6F7C1C62564F5632FE0015636E725" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_DD3AD9DFFF8E2715C99BE0015636233D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8F06DFA25330A782A0A7E00156379633" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2E3A18EAEEAC4376438EE001563648FD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80FEC2B92B1FC78BD3B2E0015637E31B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AAD93EFCF41DE9FF6AD4E0015637EEAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1F9B4859601F62D40AFAE001563825A2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NetProceedsFromExerciseOfCommonStockWarrants" xlink:label="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_gale_NetProceedsFromExerciseOfCommonStockWarrants_46F5769E02D9D5506197E001563883BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_F7091E3DF4FAF8115450E0015638D507" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8992C40AA5275D693D8BE0015638292F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_133D0241DC70A6A99F83E0015637595D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200B04C730736FD9F0E8E0015638DB94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9B89C06CAFEAB41AC51FE001563903B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_007E3962F923B689C29CE0015639CA8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F363830A4F90E30A933BE0015639D1A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_F8F4AE2C9B288414C4B7E00156395460" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2B7F18B87E157EE21A6DE0015639EE42" xlink:to="loc_us-gaap_InterestPaid_6B6E1711BAD3B96FDD8EE0015639A1FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5C049B04A4953743B1A2E00155E01D55" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity" xlink:label="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:to="loc_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity_F925574847168A108221E001563ABA5F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7702C76BD26170A7C1ACE00156391CBB" xlink:to="loc_gale_ReclassificationOfWarrantLiabilityUponExercise_95CC32C685394DBE7941E001563A988E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_SalesRevenueNet_4809771C2837A29C424ED437A802D681" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_CostOfRevenue_729766E245E6DBB36AC7D437A80207D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_F3DD09C0E894106433BBD437A803974E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_B2098FCC814FDD514203D437A80325AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_E247F68B3A22D397D5FAD437A8035EE0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_E247F68B3A22D397D5FAD437A8035EE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_CostsAndExpenses_8B208A41B18848154B8CD437A80317F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D8F3D317F77F2D5A8BF8D437A80287ED" xlink:to="loc_us-gaap_OperatingIncomeLoss_1E663B048E2405F01BDBD437A803D364" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LossOnWarrantExchange" xlink:label="loc_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:to="loc_gale_LossOnWarrantExchange_BC84E973CEFA60787269D437A8035C2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_5FDA42F3DBB65FB7E7C1D437A8037181" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6EDC35E8D3970852C1CBD437A8038B84" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6EDC35E8D3970852C1CBD437A8038B84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2AA359EC5F52BF15CE9CD437A8039BE5" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_74A7C8C3D85B1AC36D41D437A8037E09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_NetIncomeLoss_6810F9FBEEEEBAA97B20D437A80422ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_424D09C7F6DEEEC8FB14D437A80413FF" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_92B97423BAD7C78479F5D437A8049B19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62AE4A6B7AC361C8D5C8D437A8027007" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FC60C5F0E24B486D5A6BD437A804A7EC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="gale-20150630.xsd#gale_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_EntityRegistrantName_4CA8E64EE750940F2A67D437A8A74CEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_TradingSymbol_54C35470A8E06442AAEDD437A8A7766A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_EntityCentralIndexKey_DBD5FEB02F10CAD2F579D437A8A71BE1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_CurrentFiscalYearEndDate_E656564C8CD0B2FC44D0D437A8A7C9EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_EntityFilerCategory_2BE0217543B78868C0EDD437A8A77BF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_DocumentType_557B6A2194C36C4ED775D437A8A7A0CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_DocumentPeriodEndDate_17AA5E2297C8E9D574AFD437A8A79E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_DocumentFiscalYearFocus_E47DFC2985FBAE329324D437A8A7E12D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_DocumentFiscalPeriodFocus_B3020BE0F39B1A8098E0D437A8A8362F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_AmendmentFlag_1F6856A920B1B65D3F81D437A8A82BC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_DocumentDocumentAndEntityInformationAbstract_1A7CB92A6197C44B7482D437A8A7A07B" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_F310A2BE8F73DDBC578DD437A8A82598" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F0A27E92AEF1F7D24E97D437A856C2FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F0A27E92AEF1F7D24E97D437A856C2FF" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E36AF168428E573E3ACD437A8565EA1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2B8344AE75E63BAAE842D437A8192DC3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2B8344AE75E63BAAE842D437A8192DC3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4037FEF96F251ABE7A22D437A8194253" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DBC59B826A2C6F5A9681D437A819FEE4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BF28BD05D737C9F139D4D437A8192AFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CCFBA377365C3592F131D437A8192C27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_AF81E71BDA555018048CD437A8198B14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F57C29FF4CDF0B2DD85ED437A81AE8B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98B11B5B2B609DD6546BD437A8196BF1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_57B5A032C455ED3D5705D437A81A37C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_73DF5CABC5C48A959B87D437A81911FA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F3512865654CF76F3279D437A81ABAF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1EAB2149962C81CDE630D437A81A23FE" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_525DB7E9046BBEC871E2D437A81AE82A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05BCB887C9BA085D49B6D437A81AA831" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsPotentiallySettleableInCash" xlink:label="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_gale_FairValueOfWarrantsPotentiallySettleableInCash_0E8D8C826A1E2A6C0D1CD437A81A3E27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_7E14C71CD3205E23A071D437A81A82B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BFB3EBE7ACA0DC3100ECD437A81A7A6F" xlink:to="loc_us-gaap_EquityFairValueDisclosure_1572A44CB261510351F7D437A81A0604" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CB1D5874696A61C15B50D437A87251FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CB1D5874696A61C15B50D437A87251FF" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50F199DD81B6E1D30235D437A872E164" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_223C2B3003966E47DEA0D437A872452A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_99DE9C09C6C48635C392D437A87270E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_C3771F3B7C92A0A34571D437A872D417" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4FE1C73B3B7D50EF19EDD437A872FA40" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_4B6A38AFB00B6807218BD437A873FFC7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_52A656B53F048EF2759DD437A873559B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8732F40A98F7FAE472E9D437A873940D" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_C2A70710A33627C03919D437A8731411" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2E720D1EBFAA606C5441D437A7A41D0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A1C8EC8653E0A4D3481D437A7A4E39C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A77CB4B9645BA7DDE892D437A7A4313D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FFC93B6ADF25C4054AC8FE181A141901" xlink:to="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B1C6D2CE00E4236FCC2FE181A16B492" xlink:to="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FC2912C01585E1764263FE181A16F06E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:to="loc_us-gaap_CommonStockMember_FC2912C01585E1764263FE181A16F06E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_BBCD6E47E06B2E24DC80FE181A16D4E3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96E1BB622E8D709E3796FE181A16ECCD" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_BBCD6E47E06B2E24DC80FE181A16D4E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_C6F07DECA4C67BB1B216FE181A15FE33" xlink:to="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LossContingencyPercentageofLegalFeesPaid" xlink:label="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_gale_LossContingencyPercentageofLegalFeesPaid_F00BF5D58304DFD240FBFE1ACD23940C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_285868716D67328EE265FE181A16C5A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_E94B3EFD1B990E792272FE181A164182" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_1713758DB541EF1D223BFE181A1671D7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_gale_ClosingPriceOfCommonStock_1713758DB541EF1D223BFE181A1671D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_486070BBC0A56D7D2A86FE181A179EE7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_DF915E0B58705FA19550FE181A16EEA3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_486070BBC0A56D7D2A86FE181A179EE7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BFA03AEB2D266D67125FD437A80B4D42" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BFA03AEB2D266D67125FD437A80B4D42" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C71E375B0673379F8A72D437A80BF0E3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D530DC217A50DD0ED7FD437A88D7750" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8BDD75E7B7B2217DB2DAD437A88DFEA1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2B418C97A11A9091AF0BFE4041A5C036" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsTable" xlink:label="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2B418C97A11A9091AF0BFE4041A5C036" xlink:to="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_271D4BDFD0BE6014AA68FE42BE19B60F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_A24017C57FEC4E7B92BBFE42BF99C0A9" xlink:to="loc_us-gaap_DistributionRightsMember_09B64E25799A64DA97A0FE42BE410425" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_DA75E890EA4FE67FCB31FE4254A229F0" xlink:to="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_852C248756B87D1132C8FE4277D66465" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:to="loc_us-gaap_MinimumMember_852C248756B87D1132C8FE4277D66465" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CC579042E92813ACADC2FE42922A0B16" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6C45E2F1EB469A380F3FFE4255882AA1" xlink:to="loc_us-gaap_MaximumMember_CC579042E92813ACADC2FE42922A0B16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_E5552CA950AD3CE81C09FE4041A57117" xlink:to="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MDAndersonCancerCenterMember" xlink:label="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2439CD40296C074937EBFE4041A56A82" xlink:to="loc_gale_MDAndersonCancerCenterMember_098161B1A1370BF63639FE4041A6B049" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_D40D99958D6AD92F53B1FE4041A6E552" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_OrexoMember" xlink:label="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FBB62248FBD98728EA76FE4041A6DB73" xlink:to="loc_gale_OrexoMember_AE2DC51ADFCE36B13F30FE4041A6712C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsTable_F781F9580A1B4A067993FE4041A56BFE" xlink:to="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AnnualMaintenanceFee" xlink:label="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_AnnualMaintenanceFee_96449DF6B945C53F0001FE4041A6F0DE" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FutureMilestonePayment" xlink:label="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FutureMilestonePayment_DF1E4ADA5FD324854E5EFE4041A6D78A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_36545A68A5275BF94ABDFE4041A66725" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_BusinessAcquisitionCashHeldByAcquiredEntity" xlink:label="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_BusinessAcquisitionCashHeldByAcquiredEntity_426AAE939EE328565A46FE4041A63E7F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedYearOfPatentExpiration" xlink:label="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_EstimatedYearOfPatentExpiration_85AEE263DCA0135F0DB0FE4041A609EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_30D90A8BE620C9BCF481FE4041A7EA18" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_30D90A8BE620C9BCF481FE4041A7EA18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_A9EFC5BA77392814E61BFE42BDCED0D8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration_B890EC9BA3C943F9C7FEFE42BDE28EC1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod" xlink:label="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod_B75B4CEF66068DE21429FE42BDF50DA8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractualObligationPotentialPaymentsfromNetSales" xlink:label="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_ContractualObligationPotentialPaymentsfromNetSales_C1D3ADB1D732AA85120AFE40D63865DA" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ContractualObligationNetSalesThreshold" xlink:label="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_LicenseAndCollaborationAgreementsLineItems_ACFE1C5668A46140E176FE4041A6DC53" xlink:to="loc_gale_ContractualObligationNetSalesThreshold_6249554A14ECB0FED920FE422689E569" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebt" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4A12A959034597E05B8ED437A7D02A7F" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_B9F72BF7B750AB5928ACD437A7D0C657" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/LongTermDebtDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_828A95BE343F5304798BD437A7F67DC9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_828A95BE343F5304798BD437A7F67DC9" xlink:to="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E62A004E50F3A73BB61D437A7F61F7D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FirstTrancheMember" xlink:label="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7DDD0E60B7A10868F1F4D437A7F6BAE4" xlink:to="loc_gale_FirstTrancheMember_344BEF29263512FC37ECD437A7F62E6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1F37E46B6D06172F51DAD437A7F650FB" xlink:to="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_5E688BADBFCC29A91442D437A7F79168" xlink:to="loc_us-gaap_MaximumMember_7F935F5FBFEF23849EE2D437A7F7B8D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3C7D5ECD4F6692ACEE28D437A7F6E74C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0156303EA843A34CBF28D437A7F7CAB6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentTermInterestOnly" xlink:label="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentTermInterestOnly_D087E374FFFC07E653B6D437A7F79E78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_93413ADA0246CDAEF4C0D437A7F770EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_DebtInstrumentTerm_DD611BF32F2D570191D6D437A7F780B2" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFacilityFee" xlink:label="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentCashFacilityFee_74EADE7D491B0173A25FD437A7F7E396" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DebtInstrumentCashFinalPayment" xlink:label="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_DebtInstrumentCashFinalPayment_9C57256B864F37E7FEE3D437A7F7F26A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightTerm" xlink:label="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_ClassofWarrantorRightTerm_A6C9B310D0355EB4AF10D437A7F7FF0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_B76919DDC8B091500A93D437A7F7C4F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8267AECCFC44464305F0D437A7F7FFB7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice" xlink:label="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0D600B759081C0FB34D2D437A7F703C4" xlink:to="loc_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice_80802391D1721CCE9B9DD437A7F7460F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C0710CDC6629A30F2620D437A7DE6990" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C0710CDC6629A30F2620D437A7DE6990" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_66A4135E89F0B058EED1D437A7DE1BE1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3247EB52614F1D87BB01D437A88BA70C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3247EB52614F1D87BB01D437A88BA70C" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CCC94C44A8B29856D498D437A88C6BEF" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_40847A9D3222F6405685D437A88C04A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:to="loc_us-gaap_WarrantMember_40847A9D3222F6405685D437A88C04A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_77A7B9B397606869E672D437A88CB82C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88F4589C60050099EBA8D437A88C957B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B3D17458A6C41B65D40AD437A88C7E03" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06DA4490C0DB35B9C367D437A88C1488" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F0B349432B509407FBDED437A88C7745" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock" xlink:label="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_04443C39FBEF377BD209D437A8888DBE" xlink:to="loc_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock_38607CC23D1657E20E20D437A8882E24" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ABCD40994C199CE0D589D437A87D6A2D" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_40A3F8C4BF1C5E9D54AFD437A87D2D0D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_72F08F936C933EDE2134E0E460E6DE72" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:label="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_72F08F936C933EDE2134E0E460E6DE72" xlink:to="loc_gale_ChangeInFairValueOfContingentPurchasePriceConsideration_327343672781E47286E0E0E460E7EC54" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MiscellaneousOtherIncomeExpense" xlink:label="loc_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_72F08F936C933EDE2134E0E460E6DE72" xlink:to="loc_gale_MiscellaneousOtherIncomeExpense_75B2257EFEAF1FACB457E0E460E73208" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_72F08F936C933EDE2134E0E460E6DE72" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_37CC78385D5C023D4353E0E460E892F7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/OtherIncomeExpenseTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_C6C2112EB0AB6AA42962D437A81D8F4A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_C6C2112EB0AB6AA42962D437A81D8F4A" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_81C34FA38AB4D8939E78D437A81D4DB9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_C2B6CD17BD3B883A5E92FE43422662BA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_C2B6CD17BD3B883A5E92FE43422662BA" xlink:to="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_68B8870E6DDCD660B2CCFE4342266ED6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_BA68B4284E5B26DA7FC2FE4342262E08" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_EF6E0EA127D359CAD4F8FE434227BE32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_836AB7150B9E1216B925FE4342270A35" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_F6659474F27E867CD387FE434228773A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5B3B90344090BE424A7FFE4342283065" xlink:to="loc_us-gaap_AccountsReceivableMember_4976B7E912C184336C51FE434228945B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_FBFF291D3B4A03E70244FE434228F9C7" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerOneMember" xlink:label="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerOneMember_453165C0F9DEB223904BFE4342291028" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerTwoMember" xlink:label="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerTwoMember_31DF6AD12D05AD0C8B3EFE434229CAED" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerThreeMember" xlink:label="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerThreeMember_0DB23152D7C4041ED25BFE434229EAF0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerFourMember" xlink:label="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerFourMember_7E6B40E3C969DC29AF43FE43422949D8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CustomerFiveMember" xlink:label="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_450BC0037F66DF16D93BFE4342282C4A" xlink:to="loc_gale_CustomerFiveMember_D44374CBB8CB92C3517EFE43422A95FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2384BC8BADA9B29C2EF2FE4342264F94" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofCommericalProducts" xlink:label="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofCommericalProducts_4A2628807F487E46609CFE43422A79D6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofDosingStrengths" xlink:label="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofDosingStrengths_AEDE6C8060A9937EB512FE43422AD63A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_FD7DEC81A18D67AEEBE3FE43422A080A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofTopPerformingPharmacies" xlink:label="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9BB0211D0A55182AD106FE43422AB58D" xlink:to="loc_gale_NumberofTopPerformingPharmacies_65BDA0133EF367B8FEE8FE47EDCA5071" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_4ADD7603A93EE6BE9E43D437A8245D23" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_4ADD7603A93EE6BE9E43D437A8245D23" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_386468F16B6F953F000DD437A824FD06" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_49660DDC52AE79431B09D437A89C8F2F" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_430D582A647C83D24175D437A89C63EA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9462F4930AA1211986C7D437A7ABD09C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9462F4930AA1211986C7D437A7ABD09C" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6B727E90505BA66A3072D437A7AB98D6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7E85F6F1B6117E8A8DE5D437A8D63791" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_37D04CB02900ECF2D83ED437A8DB9889" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_TwoZeroZeroSevenIncentivePlanMember" xlink:label="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6F050AFBAC92696EC99ED437A8DB21B0" xlink:to="loc_gale_TwoZeroZeroSevenIncentivePlanMember_3569BBBCD6F77F0A850FD437A8DB403D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3FD46B0BE40229EA0525D437A8DB18FC" xlink:to="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_6E81FA4CE416CB63E8C8D437A8DBB035" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:to="loc_us-gaap_MinimumMember_6E81FA4CE416CB63E8C8D437A8DBB035" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_973F54FEE52BC966EAD7D437A8DC577A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2A123C802E857727D52BD437A8DBDF54" xlink:to="loc_us-gaap_MaximumMember_973F54FEE52BC966EAD7D437A8DC577A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F5773B746C19551646A9D437A8D6B994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BE4413B284B13F58F217D437A8DC87F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_BE28FE045B3C540A4BE9D437A8DC3E77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_D525A51C046B26DD5DBBD437A8DC5227" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees_C0F7985F4677193B9DD5D437A8DC3F38" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement" xlink:label="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement_F0BBDB53FCEE3DEB2C4ED437A8DC2E25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_FA6294AE2173535FEFEED437A8DC4F4C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts_28C93D262968539CB4E4D437A8DC65F4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:label="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_B994D0ACC9831D52EAC8D437A8DCA77E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D83DA58C9D71F19CC97CD437A8DC1A22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4BC086F6995BE30F4760D437A8DC338E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5CFC4C385EC772873318D437A8DDE591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_585608EB1707B23625B1D437A8DDBF4F" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod_3F36D59DE615DB878371D437A8DDBDB0" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClosingPriceOfCommonStock" xlink:label="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8132D3BBDE0A1C182A9D437A8DCBCDA" xlink:to="loc_gale_ClosingPriceOfCommonStock_456D30DB02DB7D85B7ABD437A8DD3088" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD650B66223218054CA9D437A787646A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD650B66223218054CA9D437A787646A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B5B2BDB167FCF14E51E0D437A78732EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1C29891BBCC8C57BDD4FD437A787EF26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83C78FE6F28837EEBBE7D437A7877901" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_FAC5EC139D855DDD9DECD437A788172A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76B74DDC58F7C0AA3580D437A787BF5C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9E6CCF2C7E19FE7ABC6BD437A788F51A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1B7BA064EF2B36D8B184D437A788D4FC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9E6CCF2C7E19FE7ABC6BD437A788F51A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EAB23AD698A01E84AD1CD437A83B464D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EAB23AD698A01E84AD1CD437A83B464D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44390EFB9260CACE1B14D437A83C46C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EAB23AD698A01E84AD1CD437A83B464D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EE4FF02E3E334E121F2FD437A83C43BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EAB23AD698A01E84AD1CD437A83B464D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5B2D63BCB3FF18ABFCAAD437A83CCC56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EAB23AD698A01E84AD1CD437A83B464D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817A40DEB6ADAB0A6E8CD437A83C035D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_058898DC007A22153BE1D437A7B1CE37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85E6513E9BE5DC7F4354D437A7B13D52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4895442FE72824E10575D437A7B15C3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50F0496096AAEE40B281D437A7B10CC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6603FC8348047067E67CD437A7B1656C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDAE06F734811FEF8262D437A7B11B66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E081E39EBDE6B994009FD437A7B1DADD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47F12BC0C42303C1FB4AD437A7B116F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66B6C8785F219B89A23ED437A7B74C38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5357EEBD59B1B2D9D380D437A7B789C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60CDCF098857AFBD4E21D437A7B7F052" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47A4C21DA76054F33C7ED437A7B1E289" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_540306261DFD310EAA7BD437A7B7DF9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7E6E5EAABE0264A5C7B5D437A7B72138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2EAFD0796FB8A72A3D7AD437A7B7B010" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue_D2685925FAEA9E3D6993D437A7B7DDF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1A66E3888A03A0357819D437A7B7AE07" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue" xlink:label="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue_29B83A35DEBDCCB59A34D437A7B7D659" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CEE84ADD94F0CA22BA6BD437A7B7318B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B495BDF3128D48F2715ED437A7B1CDDE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_A183061B65EE564792CCD437A7B7A0FE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414671BD9CD68568BD9BD437A87522A1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414671BD9CD68568BD9BD437A87522A1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DCAFD8BA33BF4698CF17D437A875D574" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414671BD9CD68568BD9BD437A87522A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_C61B4286DC8D89C48C20D437A87AB5C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414671BD9CD68568BD9BD437A87522A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_425E118923AF26BD393AD437A87B4687" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_FA16D521C7FF951ADCE7D437A8A91616" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_FA16D521C7FF951ADCE7D437A8A91616" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6DFCB6F6DC371FE37789D437A8A932FD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D0B7AC41B516A5A38654FE43427D614E" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_D9D6108FCBA2B4E1E997FE43427E346F" xlink:to="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_LincolnParkCapitalLLCMember" xlink:label="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:to="loc_gale_LincolnParkCapitalLLCMember_1728A5C3981DBA376340FE43427E51CD" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MLVCo.LLCandMaximGroupLLCMember" xlink:label="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_565CD3F6E001F7376BEBFE43427E28C8" xlink:to="loc_gale_MLVCo.LLCandMaximGroupLLCMember_40A9216BF4C93C416B1CFE43427E4268" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F9E7C0C8518DD44E2E77FE43427E2179" xlink:to="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:to="loc_us-gaap_CommonStockMember_D3EFBAB58A62B30D7352FE43427E01A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_736E82FEDC64B671B42CFE43427EFB83" xlink:to="loc_us-gaap_WarrantMember_D037335C9BCA1FD4C110FE43427E22D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EFDF607BC7BBEA58F366FE43427E9A0A" xlink:to="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_584662C57827E421254DFE43427E7F42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8E7138333CA594AA85D3FE43427FD092" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B07011C96386E25EAF54FE43427F4E56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_D7F6014F65214D748614FE43427FB9AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0BA25A562550FF6405BEFE43427FB0A5" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_PurchaseAgreementTerm" xlink:label="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_PurchaseAgreementTerm_6C6A97330F9737F296A3FE43427F2F65" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_30EBAE1575F34EA5209BFE43427F99D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_SharePrice_5B2F29C921DE81A57454FE43427F3423" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_B123B2FAEF5218EAD460FE43427FB4D1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds_D8E9FDD675F9AFF6C0AEFE43427F44F4" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds" xlink:label="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds_F3F585B8BB48E41A204BFE43427F5D99" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofSharesPerUnit" xlink:label="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_NumberofSharesPerUnit_3A2879CA1992AC099432FE43427FB3E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71C756F5DDA65BE21C9AFE43427F572F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4CEC8845FFFCC36D141CFE43427FBDBC" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_StockIssuedDuringPeriodSharesOverallotmentOption" xlink:label="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_StockIssuedDuringPeriodSharesOverallotmentOption_C532A919FFA015EA5B66FE43427FDBD6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses" xlink:label="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_87EF746C8B346D0FBB7DFE43427ECEB5" xlink:to="loc_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses_DCA08018F366F445267AFE434280861F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_91D76E92C226E4558117D437A7EC4321" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3DD50C95F5A0442CAE00D437A7EC7FDE" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan" xlink:label="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:to="loc_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan_F68C8B82F9383138DEFBD437A7ECDF36" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan" xlink:label="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:to="loc_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan_44EB5312A3238A28789DD437A7EC19F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81A39EDCE44E73B80A95D437A7EB734C" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F91D996E7D16E9BA7706D437A7EC5593" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_957E58129371472D7638D437A7F9467F" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:label="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_957E58129371472D7638D437A7F9467F" xlink:to="loc_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock_E26D2C25CAFDC8FA57EDD437A7F96185" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0BA28247B42A24F9FB65D437A849EBB3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_83CA0294D0A1B790B4CDD437A849421E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/Warrants" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_975849BA693F549CBA1DD437A84B7541" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_975849BA693F549CBA1DD437A84B7541" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_DD01C7B7151EA391BB08D437A84BC6B7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D1F127EE1172F5E6A097D437A7C83124" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D1F127EE1172F5E6A097D437A7C83124" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_B807CD3358D2AD85650ED437A7C819E1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_3221C6B59A58CBE9813AD437A7C88B72" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_3221C6B59A58CBE9813AD437A7C88B72" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_062A76813DA827ACBB1ED437A7C8B77B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_062A76813DA827ACBB1ED437A7C8B77B" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_526FE72AF0242D391A63D437A7C80543" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_526FE72AF0242D391A63D437A7C80543" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_096664FE5EECDA554163D437A7C8D127" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_096664FE5EECDA554163D437A7C8D127" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_822E6CC465AEB353328CD437A7C870ED" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_822E6CC465AEB353328CD437A7C870ED" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_0924F77705CEC5918622D437A7C92137" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_A86DEEBC0A72C201241FD437A7C8451E" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_0924F77705CEC5918622D437A7C92137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6C57209735BEA17D8572D437A7C8BA0A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGranted" xlink:label="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:to="loc_gale_FairValueofWarrantsGranted_530C1847E8E6FDC36EFCD437A7C9A974" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightFairValueRollForward" xlink:label="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_696BBFF555FCCA40780CD437A7C9DF62" xlink:to="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_D1935D80FC4CB2D6D301D437A7C98F2C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="loc_gale_ChangeInFairValueOfWarrantLiabilities_4B88DAEBF47F831DFC7ED437A7C9A1C1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantsLiabilities" xlink:label="loc_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightFairValueRollForward_5C2205A92295D257BC36D437A7C908D3" xlink:to="loc_gale_FairValueOfWarrantsLiabilities_1932CB80608B4590B137D437A7C98499" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_93198981ABB182479486D437A8289296" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_93198981ABB182479486D437A8289296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_24B60D1D0C9D34C20ECBD437A828296F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_9786E18752B13F54A0D7D437A828C394" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_9786E18752B13F54A0D7D437A828C394" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_0385CC57B561DABCCE78D437A82924BF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_0385CC57B561DABCCE78D437A82924BF" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_7D3A2632BE5D7800CA2AD437A8294DBB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_7D3A2632BE5D7800CA2AD437A8294DBB" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_84AF1EF841FAACC1F85FD437A8294905" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_84AF1EF841FAACC1F85FD437A8294905" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_C909256C55AD8FDDEBD3D437A829EFB7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_C909256C55AD8FDDEBD3D437A829EFB7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_4579514E25A76C64B197D437A82932D2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B907C51D213C374CBEBCD437A828CEA7" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_4579514E25A76C64B197D437A82932D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_419BC3A4ABC5A6F499CBD437A828D775" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantStrikePrice" xlink:label="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantStrikePrice_FBFA498BFCC6E0C8E8D4D437A829C272" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:label="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_AFFD74EB3F8CB8F5C8ABD437A8291577" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsExpectedVolatility" xlink:label="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantsFairValueAssumptionsExpectedVolatility_DCBFC30ABDD75F226672D437A8298759" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_CBA6285CA856BDAEB741D437A8295E83" xlink:to="loc_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate_D1E53385B2E589E8563FD437A82EB7A5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_A5863121C67F09D360EFE0E750CF1660" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2041866F3E51CF45815AE0E750CF7A7E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandFifteenWarrantsMember" xlink:label="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandFifteenWarrantsMember_ED5049CB8BD0B0B399DEE0E750CF75F8" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_SeptemberTwoThousandThirteenWarrantMember" xlink:label="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_SeptemberTwoThousandThirteenWarrantMember_DFFE9BE094F9505C3315E0E750CF6BE7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_DecemberTwoThousandTwelveWarrantMember" xlink:label="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_DecemberTwoThousandTwelveWarrantMember_45A1F646FB1246FD60BEE0E750CFC2C9" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_AprilTwoThousandElevenWarrantMember" xlink:label="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_AprilTwoThousandElevenWarrantMember_720BCFDC80F34394AF5DE0E750CFE992" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandElevenWarrantMember" xlink:label="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandElevenWarrantMember_FA35227ED3EF2AECF34FE0E750CFA90C" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_MarchTwoThousandTenWarrantMember" xlink:label="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_MarchTwoThousandTenWarrantMember_B58706C50A7FDFC2EB6DE0E750CFF97A" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ConsultantWarrantsMember" xlink:label="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_C19E9C9355FD8FEACD49E0E750CF1744" xlink:to="loc_gale_ConsultantWarrantsMember_76D9DD15EA8EA2778126E0E750CFD95B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_84D0D2421BB43EA0F96AE0E750D085EB" xlink:to="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:to="loc_us-gaap_MinimumMember_D4A40A4D953FC7D8893CE0E750D0C458" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0AE072BEC049F6F211B7E0E750D062CB" xlink:to="loc_us-gaap_MaximumMember_8BE457887C55AB0BA843E0E750D0FCC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_45FEC658F8CCAD46500BE0E750CF7963" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightOutstandingRollForward" xlink:label="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16A6FF46AFA034A48119E0E750D0871D" xlink:to="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ECD543A45F35CAB69103E0E750D01D13" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightGranted" xlink:label="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassofWarrantorRightGranted_9A314EBCE8131E0F095AE0E750D0B2C7" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassofWarrantorRightExpired" xlink:label="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassofWarrantorRightExpired_C138AB45DF312823F8B3E0ED92D252E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6672AC4EC982E71C1D1FE0E750D020FD" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ClassOfWarrantsOrRightsExpirationDate" xlink:label="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gale_ClassofWarrantorRightOutstandingRollForward_81F9DAFE56A4C6C4D19BE0E750D0976B" xlink:to="loc_gale_ClassOfWarrantsOrRightsExpirationDate_1DED05DF4FFD197BC55BE0E750D083E9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_29EED7A7A8D8542194B5D437A87F525B" xlink:type="locator" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfWarrantActivityTableTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_29EED7A7A8D8542194B5D437A87F525B" xlink:to="loc_gale_ScheduleOfWarrantActivityTableTableTextBlock_3042C6FDEEF6926E125DD437A87F3644" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:label="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_29EED7A7A8D8542194B5D437A87F525B" xlink:to="loc_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock_503F7D8A16AE9B9708D1D437A87F06D6" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_29EED7A7A8D8542194B5D437A87F525B" xlink:to="loc_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock_D2B3A8B610D957DA7415D437A87FC997" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_F5780A715E0B58D78E0ED437A7E8C0E9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_F5780A715E0B58D78E0ED437A7E8C0E9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_979E567E02EADCF1CB6ED437A7E8B3C3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8FA8D14C175D21A6DBB7D437A7E99FBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1BD95505C7F3178A09DCD437A7E871F2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_WarrantsGrantedNumberofShares" xlink:label="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_WarrantsGrantedNumberofShares_F6DB130979048F1148DED437A7E9DB87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26B751AE7E485C6BFD15D437A7E91226" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26B751AE7E485C6BFD15D437A7E91226" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_NumberofDaysAveragedforExercisePrice" xlink:label="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_NumberofDaysAveragedforExercisePrice_725047590530D94B4061D437A7E9C894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_134F67F090598FCEF02DD437A7E94204" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_42B8DA61EF1157678E57D437A7E902DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_1631E9287B0D99238808D437A7E9A891" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5BA27794F9C31EF2FDB6D437A7E930E1" xlink:type="arc" />
    <loc xlink:href="gale-20150630.xsd#gale_FairValueofWarrantsGrantedperShare" xlink:label="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8F59AE39C0974ACE3001D437A7E97688" xlink:to="loc_gale_FairValueofWarrantsGrantedperShare_B4516424B2F6E7114559D437A7E96687" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gale-201506_chartx46249.jpg
<TEXT>
begin 644 gale-201506_chartx46249.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %, 4P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** $.0"0,D X&<9/89[9]:_(K]K'_@I3\7/V4?C/\ LO\
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M2^+'P&U#XB+9Q_#GP%J7BWXD>&?%WA?3/%NO6_AKPM=+"-.MO$.G7WC*_P!
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MM#-]DT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=3U/3M%TZ_U?
M5[ZTTS2M+LKO4=2U*_N(K2QT_3[&WDN[V]O;J=DAMK2TMH9;BYN)G2*&&-Y9
M&5%8CRWX(_'[X-?M(>"C\1O@7\1_"WQ1\#?VO?Z"/%/A#4/[3T9M8TN.UDU#
M3X[P11+)<6:7MKYXC#*C3*A;>&5<O]I-?A7/\%O&^F?&O7O$'ACX9:[9V/A_
MQ3KOA?7O'/A36M/M=:U:PL+:6U\4_#F6V\6^'$?4);2&ZUG3KRQBLK669M0O
M;?3FNGKYE_9M\3^+_!OPU\1?#SXB_';6_$EMXS^*WC#P+^QE\2_C=:IH/Q;^
M(?@6?X;:)XG\/V_B=;_3?#]YXUU[PCXP_P"%AZ/X8\6:AHFE>)/B)\//"?A?
MQ3K$.LZYJESXC\0@'V9HGQ9^&?B34/$NE:#X\\*:M?\ @]+N7Q-;V.N:?,VC
M0:=/-::E=7KB<1)9Z9?VMYINJ7J2/9Z9JEE?:7?SVVH6=U;19UA\;OA%J?A+
M5O'>G_$;P?=^$="N8+/5M>@UNS>PL;V\>T33+.=P_FB[ULZAIC>'[98FG\01
MZKI,NAQZA'JFGO<_A+XZ^#_QK^)7[+/[-_PF^%>F>)K3XD_ 7_@GI\9_A-^T
M/X=3PU?66H77C;4/!7[/_AC7/@]<RW:6EIJ?BKXJ>)_ 7C75]$BL+^_M_$=G
MID?BI[YM,UW1-2U7W_XJZ9X@\>?MG> _VGO!_P#:^I?LL^ -;_99M?B==1>$
M]3M].U?7?"NA_MVV<GBMK6_M;'6+FP^#.N_&_P"!EYXPU)=+GM?"LBRS7TMK
M=_#36DT, _9/PYXET#Q?HMAXC\,:QIVO:'J<3RV&JZ5=17EE<K%-+;3JDT+,
MHEMKJ">TNX'V3VEY;W%I<Q0W,$T2;=?%O[%_ASQ5IEA^T;XKUB&_M/"'Q5_:
MJ^+'Q,^$FGZA:2Z=+!\-]:TWP5HT6K6^FSK'<6NG>-_&WAWQQ\1-+FN(+>?5
MM.\7VVOO"/[7$DGVBP)4@$J2" P )4D<$ @@D=0""/4$4 +17XK_ /!5GXP_
MM1_L$_L/_%+]J?X8_M%ZIXN\8_#[QE\ ](TSPS\0_A3\'[_P=J=E\3OVA?A=
M\*]>@U>'POX2\)^("(?#WC35+BPET[7[">'4H+.5Y)8EEB?]B1I>J')_X2.^
M^\P_X\-&XPQ&/^0>>F,9[]30!OT5@_V5JG_0QWW_ ( :+_\ *^C^RM4_Z&.^
M_P# #1?_ )7T ;U%8/\ 96J?]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\ Y7T
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MBQU#3?#G@>_L;VW7<&GL[RTT.:VNH%*L&FMY9(U*.&8%6Q\&_&WPN?&_PO\
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M^'?#4>HD)'J%]I7@CP#X63Q!>6<,>FW'B:;6FTHW&FBTN[GZ;90RE6 *L"K
M\@@C!!'H1P:6B@#^<?\ X.$?V;_@-X"_X)1_M!>+?!OPE\"^&_$VG_$7]D@6
M&NZ1H=O9ZE9_VA^V+\!K"]-O<1$,ANK&ZNK.8$,'M[F9",L"O]#0\,^'SDG1
M[#)9R3Y"\G>V2<]R>3[U^*/_  <?_P#*(']H[_LHW['G_K:'[/\ 7[E+T/\
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MN?\ LGOBC_TY^&J_;B@#"_X1CP]_T![#_P !T_PH_P"$8\/?] >P_P# =/\
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M,_>O+E_YY2_]^I/_ (FCRY?^>4O_ 'ZD_P#B:_%C_A)_$?\ T,&N?^#C4O\
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MC3QQXC^&UQ<_#NYUCX@ZSJ=YXY6Q\!/%X.T*P\0V6@>&[+3M)TNUT^U^*?\
M@I5X4D\9^-_@A80>$/ -U?:1X?\ B3JUIXL^)'B[]J32=,BT=+KPC>^/=,\-
M>&OV;?%_@V+7]?\ #W@C1=3^(FIR>,M3DU1?#OANZT;P'IU]/K/BB?3/I?\
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M+QN(Q4Z+HU)?6L1B:SK2590I_KC_ ,$5[RVL/VQ-1GNI1%%_PI?QW'O*2/\
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MJ '5_&Y_P5]_Y/Q^)_\ V+'PN_\ 4#TBO[(Z_C<_X*^_\GX_$_\ [%CX7?\
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M[+^\?^F?'T/(Z'D&@#H:_C<_X*^_\GX_$_\ [%CX7?\ J!Z17]@?]HZW_P!
M'_RK67_QNOX]/^"N<D\O[=7Q-DN;?[+,?#/PQ#0>?'<;0/ NDA3YL05&W#G
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M +.-D7_JBXH/S*HHHK_8X_Q5"BBB@ HHHH _7O\ X(E_\GE:C_V13QY_Z?O
MU?UNU_)%_P $2_\ D\K4?^R*>//_ $_>!J_K=K_%[Z>'_)]/^[.X?_\ 3N9'
M^X'T _\ DP5/_LLN(_\ TUE@4445_&!_; 5_/E_P7O\ ^14_9F_[&?XG_P#I
MD\(5_0;7\^7_  7O_P"14_9F_P"QG^)__ID\(5_2GT0?^4B_#C_L(XB_]9#B
M _F;Z8O_ "C;XF_]@G#O_K8\/'\VE*&88(9@5QM*L5*X& 5((((' ((XXZ4E
M%?[N'^  2$S*5F+3*=N5F9I5.UUD7*R%@0LB)(%(*[T5L94$*68X+,S$# +,
M6( [ DD@>PXI**B-.G&<IQIPC.:C&<XQBIRC"_)&4DKR4.:7*FVH\SM:[*<Y
MN$*3G)TZ;FZ=-R;A!U.7G<(WY8N?)#F:2YN6-[V0I))R68M_>+$M_P!]$EL^
M^<T$DG+%F/<L2Q/U)))_$TE%62>S?LX_\G#? 7_LM7PI_P#4^\/U_?B.GXM_
M,U_ =^SC_P G#? 7_LM7PI_]3[P_7]^(Z?BW\S7^5?[1/_DI?#+_ +$?$7_J
M?EI_K7^S;_Y);Q0_['_#_P#ZKL<+1117^<9_I:%%%% !1110 4444 %%%% "
M8 )/<^YQ^ Z#/? &>^:4# QSQZDD_F<D_B:** "BHIYX+6":YN9HK>WMXI)Y
MYYY$AA@AB0R2RS2R,L<44:*SR2.RHB@LS  FJ6CZSH_B+2=-U_0-5TW6]#UF
MQM=4TC6=(OK74]*U33;V%+BSU#3M1L9I[.^L;N!TGMKNUGEMYX766*1T8,0#
M2HKG=*\7^%-=U#7-)T3Q-X>UC5?#%PMGXDTS2]:TS4-0\/W<AF$=IKEE:74U
MSI-S)]GGV0:A%;RMY,N%S&X7.L_B-\/M0\-W_C*P\=>#K[PCI3W$>J>*;/Q/
MH=SX<TV2S\K[8E_KD-^^EV;VAFB%RMS=QM 9(_,"^8FX [.BJ&EZKIFN:=9:
MOHNHV&KZ3J5M%>:=JFEWEOJ&G7]G.H>"[LKVTDFM;JVF0AXIX)9(I%(9'(J_
M0!^&?_!Q_P#\H@?VCO\ LHW['G_K:'[/]?N4O0_[S_\ H;5^&O\ P<?_ /*(
M']H[_LHW['G_ *VA^S_7[E+T/^\__H;4 .K^-S_@K[_R?C\3_P#L6/A=_P"H
M'I%?V1U_&Y_P5]_Y/Q^)_P#V+'PN_P#4#TBO[B^@!_R>K._^S<YY_P"M!PH?
MPC^T-_Y,;DW_ &<;(O\ U1<4'YE4445_L<?XJA1110 4444 ?KW_ ,$2_P#D
M\K4?^R*>//\ T_>!J_K=K^2+_@B7_P GE:C_ -D4\>?^G[P-7];M?XO?3P_Y
M/I_W9W#_ /Z=S(_W ^@'_P F"I_]EEQ'_P"FLL"BBBOXP/[8"OY\O^"]_P#R
M*G[,W_8S_$__ -,GA"OZ#:_GR_X+W_\ (J?LS?\ 8S_$_P#],GA"OZ4^B#_R
MD7X<?]A'$7_K(<0'\S?3%_Y1M\3?^P3AW_UL>'C^;2BBBO\ =P_P "BBB@ H
MHHH ]F_9Q_Y.&^ O_9:OA3_ZGWA^O[\1T_%OYFOX#OV<?^3AO@+_ -EJ^%/_
M *GWA^O[\1T_%OYFO\J_VB?_ "4OAE_V(^(O_4_+3_6O]FW_ ,DMXH?]C_A_
M_P!5V.%HHHK_ #C/]+0HHHH **** "BBB@ HHHH **** .>\7#3SX6\2#518
M'2SH.LKJ*ZH+0Z8UB=-NA=KJ(O\ -B;$P&078O ;4P&07 ,1>OSM_P""<'BC
M1M,_X)@?\$^- TOQ9X0T'Q9XL_8R^!GAGX;V6IZOI%H-8\7Z1\!](O4T?1=,
M>ZAEU:\T)-*N;[5-&TN&>]T[3]*U![FVMXK*Y,/Z7RQ13Q20S1I+#*C1RQ2H
MLD<D;J5=)(W#(Z.I*LK JP)!!!Q7+ZSX&\)^()/#CZQH6FWR^$M>@\4>'X9K
M2#R-,\0V@G^QZO;Q*BJE[:/<SSV\JXV7+BY*M/'%(@!_//XV\-?%OQ5^RO\
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M/\!([(0^(Y/BOXB_L\6EVT%Y,RZ)>->16SZ?BU6\>[M_Z&A:^(#G&LV(&Y\
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M_!&W_P N*_ '_@O%#J,7A7]FG[??078/B;XG",0V'V+81HOA'<6)O+KS,C
MPF/4]*_H<K^?+_@O?_R*G[,W_8S_ !/_ /3)X0K^E/H@_P#*1?AOY8CB+_UD
M.(%^I_,WTQ?^4;?$W_L$X=_];'AX_FTHHHK_ '</\  HHHH **** /9/V=0Y
M_:#^! C<1R'XS_"L1NR>8J.?'F@!':/<GF*K88IO3> 5WKG</[UA:>(><:U8
MXR?^8&?4^FK\_7C/6OX*_P!G'_DX;X"_]EJ^%/\ ZGWA^O[\1T_%OYFO\J_V
MB?\ R4OAE_V(^(O_ %/RT_UK_9M_\DMXH?\ 8_X?_P#5=CC"^R>(?^@U8_\
M@C;_ .7%:=E'>Q1,M]=17<ID)62&T-FJQE5 0Q&YNMS!@Q+^8,A@-@VY-NBO
M\XS_ $M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#/_@X_P#^
M40/[1W_91OV//_6T/V?Z_<I>A_WG_P#0VK\-?^#C_P#Y1 _M'?\ 91OV//\
MUM#]G^OW*7H?]Y__ $-J '5_&Y_P5]_Y/Q^)_P#V+'PN_P#4#TBO[(Z_C<_X
M*^_\GX_$_P#[%CX7?^H'I%?W%] #_D]6=_\ 9N<\_P#6@X4/X1_:&_\ )C<F
M_P"SC9%_ZHN*#\RJ***_V./\50HHHH **** /U[_ .")?_)Y6H_]D4\>?^G[
MP-7];M?R1?\ !$O_ )/*U'_LBGCS_P!/W@:OZW:_Q>^GA_R?3_NSN'__ $[F
M1_N!] /_ ),%3_[++B/_ --98%%%%?Q@?VP%?SY?\%[_ /D5/V9O^QG^)_\
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M #2T?\. _P#@CC_TCZ_9^_\ !-XB_P#FEK^Q?^*C57_HSU/_ ,3^7_T%>O\
M3T_BS_BFG3_Z/1+_ ,5TO+_JNO7^MOY*BZ $EXP!R29H< >I_>4;T/1X_P#O
M]#_\<K^G#]HO_@@O_P $G=%_9_\ CEK'@+_@GW\$QXXTOX/?$_4?!S:#X=\5
M7NN+XJL/ VO7?AUM&L[3Q!/<W6JC68;+^SK:W@GGGO##%##)*Z(>H^%?_!!#
M_@D7J/PR^'=_XD_X)\_ H>(;WP+X0N]=&HZ#XHM]0_MFZ\.:9<:I]N@N?$:3
MPW@OY+@744R)+'.'25%D5A1_Q4:J?]&>A_XG\O\ Z"_7^GH?\4TZ?_1Z)?\
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M[7ZW^\Y_X4.7WOUZ_M&P_P"?VT_\"K?_ ..T?VC8?\_MI_X%6_\ \=K\A?\
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M(Y7_ ()\_L_$A6(']C>(^2 2!QXF!Y/ISZ5\P?LN?\$(O^"6VOZ9\;7^(_\
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M@_RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN/$6J6MI%!?ZY/I.C0V^DZ9-JMRDM[+8:9!#I]H\Q@LXHX(T4;U%% !1110
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M)NM9\7"SLM/BL-6GN+G[-HNLS:=B_"G]DSQ5\,OV@]7^.47C3X>R6VI_LO>
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MY[_48H[67[):%W8 N>&_VR_AKX7\,?#V/XL_%/P=XW\8?%/P]\8?B+\+[WX
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gale-201506_chartx47273.jpg
<TEXT>
begin 644 gale-201506_chartx47273.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %, 4P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_A([[E0?^0?HHZC/3^SSCZ9/UIW]E:I_P!#'??^ &B__*^@#>HK!_LK5/\
MH8[[_P  -%_^5]']E:I_T,=]_P" &B__ "OH WJ*P?[*U3_H8[[_ , -%_\
ME?6%>C6[;7-$TQ/$-R8-2@UB6=FT[2#*C:?%9R0B)A9*H#&X?S-R.6 4*4P2
M0#NZ*P?[*U3_ *&.^_\  #1?_E?1_96J?]#'??\ @!HO_P KZ -ZBL'^RM4_
MZ&.^_P# #1?_ )7T?V5JG_0QWW_@!HO_ ,KZ -ZBL'^RM4_Z&.^_\ -%_P#E
M?1_96J?]#'??^ &B_P#ROH WJ*P?[*U3_H8[[_P T7_Y7T?V5JG_ $,=]_X
M:+_\KZ -ZBL'^RM4_P"ACOO_   T7_Y7T?V5JG_0QWW_ ( :+_\ *^@#>HK!
M_LK5/^ACOO\ P T7_P"5]8UM'K4VO:MI;>(;H06&FZ)>1.-.T<2M+J4^M13K
M(QLBK(JZ= 8@L:,K/+N9P4V ';T5@_V5JG_0QWW_ ( :+_\ *^C^RM4_Z&.^
M_P# #1?_ )7T ;U%8/\ 96J?]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\ Y7T
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M .@BGT %%%% !7(:M_R-OA3_ *]/$W_I-I==?7(:M_R-OA3_ *]/$W_I-I=
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MB[PVWP\^VV\MCI%E-901M:V]QXGTFP6XNKM))I0#^E;_ (;Z_9[/_,0\7_\
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M/_#$DLKPJSR.VFPEF8GJS'))[DDU_/:O4?4?SK^BK]FW_D@?P?\ ^R>>%O\
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MZ[:MI>F>&;/X'?!^'X?%?%%]=Z&O@B(:_<>+%\0>)AJGT;\'?A3X3^!WPO\
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M-C60Q,VR5,.H5BN)8XV. P.0I'/!SG%O ]_S/^-+C'_ZR?YT %%%% !1110
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M=-57XT_'F-OBCX$_9-_887P1XGL[;XU^/K/3;[PM=ZI\5? GB/5])^P00?\
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M_)O>!//C&O\ ^J7&,_T:_9P?\G!\0?\ LC<+_P"KO!GV917/_P!HZW_T ?\
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M%X?U/?XA@^()M7OY18W5Q>R:S)X7B-U+IS/G3=%*S36L<IO9ZZKXC2^(]/\
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MCDK_ $1[+_CSM/\ KV@_]%)7^=Q:?\?=I_U]6W_HY*_T1[+_ (\[3_KV@_\
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M_G7]TO["'_)FG[,7_9$_A_\ ^F"UK^%I>H^H_G7]TO["'_)FG[,7_9$_A_\
M^F"UK_/K]H9_R;W@3_LL:_\ ZI<8?Z-?LX/^3@^(/_9&X7_U=X,^LJ***_R4
M/]?@KYT_:_\ ^34/VE_^R#?%K_U!-=KZ+KYT_:__ .34/VE_^R#?%K_U!-=K
MZ?@G_DL^$?\ LI\@_P#5KA#Y7CK_ )(GC#_LE\__ /55BS^#%>@^@_E2TB]!
M]!_*EK_I)/\ F2EN_5_F%%%% @HHHH L6G_'W:?]?5M_Z.2O]$>R_P"/.T_Z
M]H/_ $4E?YW%I_Q]VG_7U;?^CDK_ $1[+_CSM/\ KV@_]%)7^8_[1K_FS_\
MW?W_ +YA_J;^S4V\9/7@#\N,BS1117^8Y_J6%%%% !1110 4444 %%%% !11
M10 5\G?M9_%;]E'X/>%?#/BG]JCQ-\"O#FGRZ[>:3\.3\>?$?@CPYX>O_&E_
MHUY'+;:5>^/9/['L[\Z&-0BU/6(K:>[TKP[<ZN%W0WTUG??6-5+JPL;[R_ME
MG:W?E;Q']IMH;CRQ)LWA/.C?9OV)NVXW;%W9VC !^.6IZ/\ #33O^"6GBOX#
M?L4_%KP1\3YS\!OB#KG@2U^%WB?3==/BKX?_ /"QM1;XLQ_!_0M U&34)_ -
MB^J>-?AK\.[3PHMSHOAZ)/#G@?1+MIK*RM6Y3XS-=^*OVFK'XD_"_4-!O_V1
M=#\6?\$]5^,6J>&;16\!W>H>#?&?[5UY=7UQJ.F2P>'YK+X>#Q/^RUJ?Q NI
M(9[/PUX;L/",GB2XL],\)3Q:3^S,O@GPK/XGT?QE-HFGR>)/#VCZEH.@ZJ;>
M);K1]*UF6TFU:TT]T13;QZ@VGV(N I(V6J)$(UDN//Z1;>!8WA6&)8I&E9X@
MBB-VG=Y)RT8 0F:221YB1^]>1VDW,[$@'XB?#"XDT']MCQO\6?B%J&@V'['O
MB3Q-^UY'\%=:\069B\ IXXU_PK^P_9>)=7L-3OY)O#1B^(&J^"_VJ)/"&I0P
MP1^)P?BA+H5UJ,/B^4ZS^@/[ FA?$;PU^QQ^SSHGQ6CU"W\9Z?\ #?28KJPU
M>"YM=8TG17N+V?P;HFL6M[)+>VFKZ'X)F\-Z-JEK>O\ ;+6_L;BWNTBN(I8T
M^NOLUOY4<'DQ>3$83%#Y:>5&;=TDMRD>W8A@>*-X-JCR6C1HMA12)J ,?Q!;
M:U>:)JMKX<U6ST/7KBQN(=(UB_TDZ]9:;J#QE;:\NM&74M'.IP02$2260U73
MS<*#&+N'.\?@%^WMX=^,.D_\%%/^"(3>/_BAX4\90S_M<_'V/2H-"^$[^"7T
MZZ3]DCXF/<7%S<R?$?Q8=2CEMB(([80V)BD;[0;B41) _P#0K7XA?\%,/^4A
M_P#P0P_[/#_:$_\ 60/B50!^SJ6GB'8F-:L<;5_Y@9'8=AK! ^@X%.-IXAXS
MK5CC(_Y@9]1ZZOQ]><=:VX_]7'_N+_Z"*<>GXK_,4UJTN[0'^>/XLR/%7B@$
MY(\2^( 3C&3_ &S?9(&3@$\@9..F3UK KH/%O_(U^*?^QF\0_P#IZOJY^O\
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M_34#_ETS+_D88[_L+Q'_ *=F%%%%=)Q!1110 J]1]1_.O[I?V$/^3-/V8O\
MLB?P_P#_ $P6M?PM+U'U'\Z_NE_80_Y,T_9B_P"R)_#_ /\ 3!:U_GU^T,_Y
M-[P)_P!EC7_]4N,/]&OV<'_)P?$'_LC<+_ZN\&?65%%%?Y*'^OP5\Z?M?_\
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M_@UY[*QN1>7NOIH:7MQ;M>2-J"6B3RPR&+7_ (J-5/\ HST/_$_EV_[(KO\
MAKY&/_%-.G_T>B7_ (KI>7_5=KS_ *V_G-WK_?C_ ._L/_QRC>O]^/\ [^P_
M_'*_K5_X<!_\$<?^D?7[/W_@F\1?_-+1_P . _\ @CC_ -(^OV?O_!-XB_\
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M+Q#:V5S)+8V</AR2\MK<WUO->'_%1JI_T9Z'_B?R\O\ JBO7[EWT/^*:=/\
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M-/A-\ ?"FD&:W/EW&K^%OA!\%HKOQ#J-J#HL_B+XHZ[I>A3ZE9:)_:]_S/P
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M?B)^S<W[//B_PI=ZA\2Y?@?9_M=?#[1?AOXC^(&IZKJGA3X'?M,_%7PA\3?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pipeline4302015a01.jpg
<TEXT>
begin 644 pipeline4302015a01.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +8!+(# 2(  A$! Q$!_\0
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M2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\
M7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5
M?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\
MJ2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK
M_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"
M_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^
M9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?H
MH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#P
MR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[
MQ/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@
M)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$
M2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\
M7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5
M?_F"_P#PR'_$2?\ J2_^9'_[Q/\ 7@HK_(?HH_X@)_U5?_F"_P#PR'_$2?\
MJ2_^9'_[Q/\ 7@HK_+;_ .;"?^[O/_>,U\AUSX?P+^L>W_XRGD]AB:F'_P"1
M)S<WLU%\_P#R-X\M^;X=;6^)W-:OB)[/V?\ PC\WM*4*O_(PM;GO[O\ N+O:
MV^E^R/\ 7@HK_(?HKH_X@)_U5?\ Y@O_ ,,F7_$2?^I+_P"9'_[Q/]>"BO\
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M_P A^BC_ (@)_P!57_Y@O_PR'_$2?^I+_P"9'_[Q/]>"BO\ (?HH_P"("?\
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M$_UX**_R'Z*/^("?]57_ .8+_P##(?\ $2?^I+_YD?\ [Q/]>"BO\A^BC_B
MG_55_P#F"_\ PR'_ !$G_J2_^9'_ .\3_7@HK_(?HH_X@)_U5?\ Y@O_ ,,A
M_P 1)_ZDO_F1_P#O$_UX**_R'Z*/^("?]57_ .8+_P##(?\ $2?^I+_YD?\
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M7[>.B?M9^+OA5\._BQ^SM\/_ !?X;\)>"O%WQF_X133? 7C6^\$?V_X7^/\
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M!\W/>$7S\O+SWBGS<OV>;?EZ7MT"BBB@L**** "BBB@ HHHH **** "BBB@
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MW1K'Q.G[1'[&/PV\)^,/BEXK^$_P2\3_ !7^-VJ^$],_:3UKP=XB;PGJFM?
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MQH[ZUL-9NM0T/Q%9:/\ T=Q/\)_CYKG_  <#MIOQ[^&VA?"WXG:7^R[::/\
M';1?$MGX[^&-@=1\"^(=,TF^U;Q%\/I_$<7_  C+^)8K?0/%]Y9?;)O#MA+J
MUSJ5F/[.NK<?(7A/]H_]G#_@FI\#/V$_V<]8^/WP:_:G\:>%?VV(/VH/C%XA
M_9W\1R?%3X;?"OX>R:;XB\!M#H'BZSL8(];\2I8:FGBF'P_%8Z;K\=]9ZFEW
MI%I8WGAS6/$&7^N'$U3$YK+ 4*>98C#8G$TZ.0TLJQ=J=!>&V7\4X:N\TA4Y
M7*?$6+HY7'#5'*O4I8NEAT_K.)P=6"ADF4+^RZ6.K2R^E7P7"->OF53&X=SJ
MXC-L_AEF<8=X"</:4HX7*5C,V6+2CA\-+!3]M&5&G6IR_,#X\_\ !(7]I;X"
M?"CQ_P#%&]\??LW?%*[^#,?AJ?X__"GX+_&"#QU\7_V?[7Q/:23VUW\6/")T
M'2;728+"\0:9J)T+6?$4GF&?6=.CU#PIIVK>(;#R#XA?\$\?C3\-?&W[&W@/
M7?$_PNN]7_;@\)?#+QE\*+G2=:\63Z;X>TSXK:GI&E>'8/B'->>";"ZTF_LK
MC6K5]:B\-V?BVWMX8[AK&ZU%TCCE_H=_; _:W^&/@GX3_MJ?$;X>?&G_ ()!
MMX6_:1\&^(O"'P]TO]G7X+^)/&?[:'QKTCXN:=J\UWIO[0+Z+\7?!#_#7Q#H
M]OJ#:MKWC/QGHOC'2H_$$%S-K7A#2_$TVF>$-4\MN7_9@_:?B_X(_P#[2Z_M
MS_LJ?"+1_P!D;X<_ KP)\:OAG\4O'_\ 87QBL/$?PR\3>#(DM?#?@%K4:IJM
MEJ?B.PO-/U;Q!K0\,^%?#OAJ-/'\.OZ]X76]N;&:?&'$=++GB<33=2-3#\34
M<#BJ>58N7UO,<)D^28[):%2G"A[.5:MBZ^<T:<L-_LN+CAHX)/\ M'!8R+TI
M9'E=?,*%%?NHK'<-3S+#SQE*+P&7XROG^'SJ2E.JZE.EAUA,EJ26);QF$EC5
M4J)X3&8*I/YT_92_X(M>%]0O_P#@H!X._:6^,G[/Z?$G]FCX?^(_"_A.RA^-
M'B#PKX/\%^/]6^'%GXLT/XW_ !0%WX+T#Q19_!CPU_PD6E/9^)KM+32YM?\
M#GBVPUSPQKVE::L5W\9_%?\ 8P_L#]A7]G?QIX+^$/PP\7_$KXB?M6?$3X$:
M9\<OA5\=/BA\0O$OQLU#0_$_CWPSH>@:'\'M0\!Z3\,-*\)ZA>Z)9-X0\:^%
MO%VI>(/%%C;Z/=7^B:>^MW\5G^NNC_&[]G;XB_MT_P#!:KP+%^TM^SWX/TK]
MJG]G.#P)\'/BSXY^*WAC1/@IX@UR;X=Z7X7F0?$NVNM3T.X2RU'7H7N+?1VU
M;5);;3M:>PTZ\FTJZ@3YZ\-_M%_!3]EW]B/_ ()MZ%K?Q8^%GQ+\6_LM?\%(
M/'/BWXE^$OA+\1?"_C+Q!)X'\,^//BA!/XZ\/Z1:7T>L7OA#7["2WUCP;K][
MIFFZ9XEL-1T>6VN8$U2"09_VOQ/0Q6(JP>-S/%QSVEBL-ELJ6,H4'1K>#V8Y
MQ0P\(T*E.G5P6(XBIQP/U:M[;#T\QPSQ*IT\SK4:M)8?!91BL+EJQ#H9=A\3
MPUDL<7BHU,.ZBQ,O%;*\KS+$.=:$YX;%X;):]3&5*T?9UIY=BH86K*KE>&J4
M:GP[\6?^"+G[5GPF^&/Q(\?3>.OV:OB%XK^"7A30/&OQU^ ?PM^,*>+_ (]?
M!7P[KF@MXCDOOB'X-'AVPT>P71]+CFN;S^R/%&M+JMM!/J7A)_$NCQ/J0_).
MTM+F_NK:QLH);J\O+B&TM+:!&DGN+FXD6&""&-06DEFE=(XT4%F=@H!)%?T7
M_M@_ /\ 9(\0ZW^WW^UH_P#P4R^%-S\.OVBM+MOB5\$_@W\!_B2/$?Q;\>^.
M?$NN:/\ $/2_ /[07P!:STO5+7PWI/B"&:PT^+5-6L+WP7K8T?QKXO7PY?\
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MN[****]PXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /KSXR?\
M)J/[&?\ W<3_ .K(TNOD.OKSXR?\FH_L9_\ =Q/_ *LC2Z^0Z\[*_P#=JO\
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M>+M5TO1]._M+6KW4M8O_ +'8VT$'VO4]0O;^XV>;=74\S/(WJ7_!,GQ?X3\
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M]G_!73_@GM^R/\%O@-X>^+G[%&E/#!\!OC3JG[,/[54A\4>./$MW=?$H>%M
MU?3/$-Y;^+-?UZRT86FH+=Z7JZ>'!I.C?VQXIT[3K?3]UDZ6OS'_ ,$5M8^
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MO'-T-+%EX:^(<ZZ!H@TV_NIM6M[1FT7^W[73KQK6VUBXTV36_#8UKN_VG_\
M@C]\>_V2],OA\3?C9^RAJ7CZ:]\&V?@+X'^"OBKXCUWX[?&!?'&M:9X;TB^^
M%WPMNOA[I/B/7-.BU^^O=(O;O5H=!07?A_7#9"^MX;"?4/KB0? G]@G_ ()M
M_M'_  )N/VM/V<_VF_BS^V-\3OA-+X-\,_L\>-;CQ_H/@/P)\.M>\/>);OQK
MX]OKG3=)N/ _B.[@DN+&;PYX@TW3K^.\ATR'2[G7%L?$K>&ZW_!2;]K'X1:%
M_P %H/A5^T]X.\8^$OC=\*_A9J7[-OBB]U7X:>*_#OCW1KW3_!;Z=J7B33-
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MQ<_[-#\>_P#JYO@%7]UE?PI_\&Q/_)^WQ<_[-#\>_P#JYO@%7]UE?R)XR_\
M);5_^Q=E_P#Z;F?MW G_ "3]/_L*Q/\ Z5$****_*C[(**** "BBB@ KR']H
M/_D@GQO_ .R0_$K_ -0S6J]>KS_XLVMK??"OXEV5] MU97GP_P#&5K>6KO/$
MES:W'AS4H;B!Y+:6"YC6:)WC9[>>&= Q:*6.0*XZL"G+&X-+=XK#I>KJP2.7
M'5H8?!8S$5.9TZ&%Q%::BDY.%*C.<N5-I.5HNR;2;ZK<_P KW]H/_DO?QO\
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M/@CR1_S4W]LO_P"BIJ3_ (45^QE_T9#\$O\ PYW[9?\ ]%32_L_.?^A+C/\
MPIRC_P">9LOI)>%$K6SG,-?^I)F?_P SG\W%%?TDK\"?V,2<']B'X)=/^BG?
MME^W_5U%6/\ A0?[%_\ T9%\%/\ PYW[97_T4]2\#G"=GDV,_P#"G*/_ )YF
MB^D;X5/;.,?_ .&7,_\ YG/YKJ*_I47X _L7D9/[$7P5Z_\ 13OVRO;_ *NG
MIW_"@/V+O^C(O@K_ .'/_;)_^BGJ7A,W6CR;&_\ A3E'_P \S6/TA_"V5K9Q
MCM;;Y-F?6W_4/YG\U-%?TN#]GS]BTD#_ (8C^"W)'_-3_P!LG_Z*:I/^&>?V
M*_\ HR/X+_\ AS_VR/\ Z*6I>&S5;Y-C=?\ J(RCR_ZF?F:+Z07A@]LXQO\
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M#:/BMP/+;-*VU]<MS'R_ZAO,_E8HK^JY?V1?V%VSG]BOX3<8_P":J?M@>_\
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M*O+_ *FOG^'I>UF66-V684?_  1CO_F3^K>A_%Q17]IB_P#!-O\ X)W$@?\
M#'7@;_P[_P"U?Z?]G#587_@FM_P3L(!_X8[\$?\ AW_VKO7_ +.%J7QM@UH\
MJSC_ ,!RK_YZFBQN7.UL?0UM;]SCNMO^H3S_  ?E?^*NBO[6%_X)I_\ !.LC
M)_8[\$]?^BO_ +5OM_U<)4__  [/_P""=/\ T9YX*_\ #P?M6_\ T0=2^.,"
MM\JSC7^[E7E_U-?,T6(P+VQ]#_P5CO\ YD/XH**_ME3_ ()E?\$YVQG]CWP7
MTSQ\8/VK/;_JX*I5_P""8_\ P3F) _X8]\&?^'A_:K]/^S@JE\=X!:O*LY_\
M!RK_ .>O]6]"XU<'*UL?A]7;^%CM_P#PC/XE:*_MQ7_@F%_P3D(R?V/O!W7_
M *+#^U7[?]7 U*O_  3 _P""<;9S^Q]X.XQ_S6']JKW_ .K@*G_7W+_^A7G/
M_@&5_P#SU-$\*_\ F.PVO_3O&^7_ %!_U9^5_P"(FBO[>U_X)>?\$XFSG]C_
M ,'\8_YK%^U5[_\ 5P%6$_X);?\ !-]L9_8_\(],\?&+]JGV_P"J_5#\0,M2
MN\KSK_P#*_+_ *FOG^'I>U##O18[#?\ @O&__,9_#Y17]Q"_\$L_^";Q('_#
M('A+_P /'^U1Z?\ 9?JE'_!+#_@FZ2!_PR!X3Y(_YK'^U1_\_P!J?^(AY9_T
M*\Z_\%Y7_P#/4I4:+T6.PO\ X!C?+_J#\S^'*BO[E%_X)5_\$VVSG]D'PIQC
M_FL?[4_O_P!5\J?_ (=3?\$V?^C0O"W_ (>3]J;_ .?W4_\ $1LJ_P"A7G?_
M (+RO_Y[?U9^5]5A*;T^O837^[C?_F/^K'\,E%?W/C_@E'_P38(!_P"&0O"_
M('_-9/VIO_G]U*O_  2A_P"":Y /_#(?AC_P\G[4OK_V7JH_XB3E/_0KSO\
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MX/[)>D]/^BU?M.>W_5;JG_B+G#RNGEN?:?\ 4/EGE_U-O,I<+XQJZQF _P#
ML9_\Q?U;T/X Z*_T %_X(Q_\$OR0/^&3-*_\/5^TWZ?]ENJ4?\$8/^"7Q('_
M  R9I?)'_-:_VF__ )]M+_B+O#W_ $+<_P#_  GRS_Y[?U9^5Z7"N-:NL7E^
MZ7QXSK;_ *@O,_S^J*_T"?\ AR[_ ,$O/^C3-,_\/7^TU_\ /MIZ_P#!%O\
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M]"WB#_PFRS_Y[?U9^5[7!N8N_P#M>7:*_P#$QG_S$?Y[U%?Z$R_\$2?^"6I
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M'_J%F_\ T%99_P"#L7_\Q'^=A17^BDO_  0L_P""5)&3^RI'U_Z+A^TE[?\
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MAF/ M?C[ACA_*\KXIS#BO'^).58;%1PM'ABKE%.=7)<3PY@L-#,<?B:V>8'
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MW!<Z1$8+C45,#&T:X#65I<W%Q=7R-=-P.E>*/@IXA_9Y^.GQ2F_9=^"5K?\
M[//Q/T[3_AQIUIH%_;P:Q:7^IVNBZ''\3KR+55U?QY%8-J4U_K6GZCJ:Z)X@
M>&TMI-)LU@$[9T_%*G7G@X8;AS,\0\5#(X5.7%Y;3>&QV?YQG&08+!R]MB*:
MJ?\ "ID]:G/$4VZ,<//ZS-PY53J>C5^CU7P%/,*F8\=9#@U@/];\31YLLSRM
M]>R?@K(^'.)<VS.DL-@ZLJ4GD?$F%KT<#7C#$5,=!8&#FISQ-'\=TZGZ?U%7
M:_;"W_9Y^#7QG^-G[)_B>]\ >$O!.B?$OX W7Q1\;^!/!EI_PB_A/6=;T2QT
M2YM[*ULK!XTL+&6Z\01O?K:HMU=:7I;)>7-S<2S7;<!^T)X/^"VO_!_4M?OM
M1_8PT7XK^%?'VAR^#]'_ &8/%>F,OB7P1K&L:7I>IZ#XI\-F/3IM:UC3UG?4
MWU6'3[E8[>QD%M#H]I-J<5ZL+XIY9C<=E>"I95F7M,?3POUMQ5*HLNQ&,QF/
MRZA1FJ<I/$4XXS+JJQ.*AR4:&'JT,1>=Z].AMC?HZ9_EN6YYF=?B/(?8Y=B\
MPIY;&3Q-%YU@<KPN3YABL92=>%/ZI7J8'.\//!Y=553$XG$8;&8;]TUA*F+_
M "33H?K_ $%/K]C?VBM/^&5]^U+X>_9/\,_!/X0>"_"GC/7OAK_PE7C7P_X%
MTVR^(2-J#:?J5_:>$M9M7M[#PIIM[I-M9:9<V^G:1YLUS)JNHRS22ZG<I)Y-
M\<_B!\)HG_:0^#,?[)WA.QL?A7<V_A_X>>./AOX9?2/$_AB70M5_X14^+/BG
MX^"W=]J.F:G<3V=W90WM@T.M7UU!HVKWU[J-[;>);;7+N/ZN:1R65'AO'J6<
M9;EF<^S^O9;S87*,XQ>%P67XN;J5Z4*M2MB,16G+"TY>UI8;"RJ3:KUJ.%ES
M9OX.X?(5Q*\1QQE$J?#F><0\+QK/*,]4,QXEX4RW%YKGF6TU1P>(GAJ.'PE#
M#4J.8UX+#8C'8U4H\N"PV(S"'PMXR^%?CWX>Z1X&\0>,-!_LC2/B/H,7BCP7
M=_VIHVH?VSH4L=K+'?>1I>HWMUIVZ.]MF^S:K#8W@\W#6X9) G"5^M<GP7\*
MZ_KW[!-IH'PA\$>))->^"K>,/&VDW%_8_#K2/$]QI>A:'>OK_C[Q+I7AK7=0
MU.TLKR9+S4$FT?6+W5U:33I$>&^N<W/VB_!WPB\6?LE>(OB1HFD? 27QYX#^
M)-CX9O/$'[/'@74O _@ZTNKFXTRTU3P\-3OI"?B+8I;7L%]:>*H+>VTFX,T!
MT6VMU2^FU#S<%XD4JV(R#!8G UJ];.,5'"5,9@X4Z=#!UL9FV;99E\,1A/K>
M-K8:,WE=ZE7%8FE&LJGM,$L1*-?#8;Z'./ O$X7!\89M@,WPV%PW#.$K8ZAE
M>9U*U7&YEA,NR?AS-,UK83,7EV4X;'.G_;W+2I9=@<2\-/#RP^:3P2GA<7C/
MS-^(_P *_'GP?\0Q^%/B+H7_  CNOSZ58:W%8?VIHVK;M,U+SOL5S]JT+4=3
MLE\[R)?W+7(N(]O[V*/<N>(3[H_'^9K[[_X*3_\ )PNF?]DL\#_^Y:O@1/NC
M\?YFOJN%LVQ.>\,9!G6,A0IXK-,KP..Q%/#1J0P\*V)P\:M2-&%6I6J1IJ4F
MH*=6I)*RE.3U/@_$+AS \(<><9<*Y;5Q5?+^'>)LYR7!5L=.C5QM7"Y=CJV%
MH5,54P]##4)XB=.E&56='#T*<IMN%*$6HJ=.A^O]!4R=3]/ZBH4Z'Z_T%3)U
M/T_J*]L^9I=/\*_0L)U/T_J*EJ).I^G]14M8S^)_+\D=\=UZK\R9/NC\?YFI
MTZ'Z_P!!4"?='X_S-3IT/U_H*PGNO3]6=D-GZ_HB>/O^']:G3J?I_45!'W_#
M^M3IU/T_J*YI_$_E^2/0AL_7]$7%Z#Z#^5/3[P_'^1IB]!]!_*GI]X?C_(U$
MMGZ/\CMI=/\ "OT+:=#]?Z"GTQ.A^O\ 04^N:?POY?FCOI[Q]/T+R?='X_S-
M2)]X?C_(U&GW1^/\S4B?>'X_R-<T]EZ_HST:73_"OT+4??\ #^M25''W_#^M
M25D=]'9>C_,MIU/T_J*L)U/T_J*KIU/T_J*L)U/T_J*YSMI=/\2_0MI]T?C_
M #-3IT/U_H*@3[H_'^9J=.A^O]!6$MWZO\SOAL_7]$3Q]_P_K5RJ<??\/ZU<
MKF.R.Z]5^99AZ#Z'^=64^\/Q_D:K0]!]#_.K*?>'X_R-<\]G_A7_ *2COA]G
M_MW]"=>H^H_G5N/O^']:J+U'U'\ZMQ]_P_K7+/X7\OS1VPV?K^B)TZGZ?U%6
M8^_X?UJLG4_3^HJS'W_#^M9S^)_+\D=E/>/I^A:3[H_'^9JQ%V_WA_2JZ?='
MX_S-6(NW^\/Z5S2W?J_S/1I=/\*_0M5:3[P_'^1JK5I/O#\?Y&L)_$_E^2.V
MGM'U_4L)]X?C_(U.O4?4?SJ!/O#\?Y&IUZCZC^=83W7I^K.R&[]/U1<3H?K_
M $%6ZJ)T/U_H*MUS3^)_+\D=U/>/I^A8JTGWA^/\C56K2?>'X_R-<\_B?R_)
M'73Z_+]2=>H^H_G5U/NC\?YFJ2]1]1_.KJ?='X_S-8U.GS_0[:>\?3]"U5F/
MJOT_I5:K,?5?I_2N6?Q/Y?DCIA\2^?Y,LI]X?C_(U<3[H_'^9JFGWA^/\C5Q
M/NC\?YFL)[KT_5G=#[/_ &[^A.G0_7^@JW51.A^O]!5NL*G3Y_H=E/K\OU+4
M7;_=']*L)]X?C_(U7B[?[H_I5A/O#\?Y&L)[+U_1G52Z?XE^A;3H?K_05/'W
M_#^M0)T/U_H*GC[_ (?UK(ZX[KU7YEB/O^']:O1=O]T?TJC'W_#^M7HNW^Z/
MZ5RS^%_+\T=4-WZ?JBPGWA^/\C4Z]1]1_.H$^\/Q_D:G7J/J/YUB=$-WZ?JB
MW'W_  _K5RJ<??\ #^M7*YSNCNO5?F3KT'T'\JG3[H_'^9J!>@^@_E4Z?='X
M_P S7.=$=UZK\RQ%V_WA_2K558NW^\/Z5:K&?Q/Y?DCIA\2^?Y,L5.O0?0?R
MJ"IUZ#Z#^58U.GS_ $-X[KU7YEB/HOU_K5Y.A^O]!5&/HOU_K5Y.A^O]!69N
M3Q]_P_K4E1Q]_P /ZU)7.=,=UZK\RS'U7Z?TJPO4?4?SJO'U7Z?TJPO4?4?S
MK*>Z]/U9U0W?I^J+B=#]?Z"GTQ.A^O\ 04^LE\4O^W?R-X?$OG^3)UZ#Z#^5
M68OX?Q_K59>@^@_E5F+^'\?ZUSR^S_B7ZF\=UZK\RQ4J=#]?Z"HJE3H?K_05
M-3I\_P!#<MT].I^G]13*>G4_3^HKFEO+T7YQ-H?"OG^;)T^\/Q_D:G7J/J/Y
MU GWA^/\C4Z]1]1_.H-H_#_V\OSB3U)'W_#^M1U)'W_#^M3/X7\OS1H3IU/T
M_J*EJ).I^G]14M8F\=EZ+\B5.A^O]!4\??\ #^M0)T/U_H*GC[_A_6IG\+^7
MYHN'Q+Y_DR2IUZ#Z#^505.O0?0?RK$Z(_:_PO]"=/NC\?YFGKU'U'\Z8GW1^
M/\S3UZCZC^=!K'9>B_(GIZ=3]/ZBF4].I^G]17.,EI5ZCZC^=)2KU'U'\Z#6
M&S]?T1/1117.66*G7H/H/Y5!4Z]!]!_*@N&[]/U0Y>H^H_G4]0+U'U'\ZGH-
M0IZ=3]/ZBF4].I^G]17.!+11107#=^GZHE3H?K_04^F)T/U_H*?06OBE_P!N
M_D%%%%!1*G0_7^@I],3H?K_04^H7QR]/\@)(^_X?UJ2HX^_X?UJ2HG\3^7Y(
MVA\*^?YL<GWA^/\ (U-4*?>'X_R-35)04444 %%%%1/9>OZ,"5.A^O\ 04^F
M)T/U_H*?60!1116\MGZ/\AQW7JOS"E7J/J/YTE*O4?4?SK W)Z***#G"BBB@
MWCLO1?D%%%% PHHHH **** "BBB@ KAOB?\ \DT^(?\ V(WBW_TP:A7<US?C
M'1[GQ#X0\5:!92017FN>&]<T>TENFD2VCN=3TRZLH)+AXHIY4@26=&F:*&:1
M8PQ2*1@$/5@9QIXW"5)R484\5AYSD]HQC5A*4GY))MGGYO2J5\JS.A1@ZE6M
ME^-I4H1^*=2IAJL(0CYRDTEYL_C*^)O_ "4OXB_]CWXN_P#3_?UB>&?$>N^$
M/$&C>*/#&J7FB>(= U"VU71]6L)3#>6&H6<@FM[F!P"-R2*-R.KQ2H6BE1XG
M=&_5SQA_P28_:,\0>+_%>OV7C3X*16>N^)==UFTBNO$?CI+F.UU/4[J]MX[E
M(OAQ-$DZ13(LRQ331K(&"2R* YYY?^"07[2H(/\ PF_P-_\ "E\?>G_9,Z_T
M6H>*GAI/+Z&&Q/%>2SA+!4</B*%9SG"<7AXTZM*K3G1<9PDN:$X23C)-IIIG
M^%&)^CC]("CGF+S' >&_%E"M3S>OC<#C<+&E1K4:D,9*OAL5AZ]/%PJ4JM.2
MA5HU:<HU*<U&<7&44URVK?\ !57]J?5/!TOA:-OAWI.IS:9:Z=)X\TGPM?P^
M,?-A\@76JQ)=>(+SPA;:GJ212I=/:^$H;2V^USRZ/9Z7/'92VGS9\%_VHOB)
M\&=-\7>&[72_!'Q&\#>.+B+4?$_P]^+7AL>-/!NIZ]!/:SV_B273GO=/NQK4
M)LX4>9=0%K>^7;3:C9WEUIND7&G_ &!_PZ%_:4_Z'?X'?^%+X]_^=I3U_P""
M0W[2:YSXW^!W./\ F9?'OO\ ]4TKYO#9_P" V!P6*R[ XSA/#8/'8BAB\51H
M4ITW5Q.%G&IA*WM8TE5A/"5$ZF$]G4@L+4E4J8=4Y5*DI?H68\%_3)SC-LMS
MW-<J\2<?FN4X#%99@,3B\12K+#X#,(>SS'"O#3Q#PM:EF5/EIYDJ]"J\PITL
M/3QCK0PU"-/YYB_;<^,D?QJ\*_&YK3P5)J?@30;WPOX'\")HFHV'PT\(^'K[
M1[C19-*T+PYI6MZ?>VL"6UPTB2OK4MVTD-E!/<3:?865C;^<Z1^T%XSTGX5_
M%/X1VVF>&'\-_%[Q'IOB?Q+>SV6JMK=C?Z5J=MJEO#H=S'K45A;6;W%K&DT=
M_INIS-"SJEQ&Y61?M/\ X=%_M(_]#M\$/_"D\>?_ #M:D7_@D=^T@ !_PFWP
M1_\ "D\>>O\ V36M8<7^#%%TO89OPY26'64J@J7M:<::R/$XC'93RQC32O@L
M9B\3B:<FG*5:O5G4<Y3;.2KX7_2LQ?UCZ[PQQUBGC/\ 618F6)>'K3K1XOP>
M!P'$L:E2I7E-QS?!9=@<+B8\R2H82C3I*E&"1\\Z!^VQ\5/#WB+X&>)++0/A
M]+?? #P/J'P_\&Q76E>(WM-3T;4M$BT">Y\31Q>*X)KS4TLXEEBFTJ?1K5;D
ML[V4D1$(\XTO]H'QEI'PM^*GPCMM,\,/X;^+OB/3/$_B2]GLM5;6[&_TK4K7
M5+>'0[F/6HK"VLWN+2-)H[_3=3F:%G5+B-RLB_9X_P""1_[2 (/_  FWP1X(
M_P"9D\>?_.VJ3_ATE^T=_P!#K\$O_"D\=_\ SMJFCQ=X,T'"5'..'J<H5<!6
M@XRKIQJY7F&+S7+YKW-\+F./QF+I=%6Q%1M--)=]?PS^E-C5*.,X7XUKQJ8;
M.<'452&#:EAN(LKR[)<[HNU5>YF65Y1EF"Q*T;HX.BHN+3D_EN7]KKXNB_\
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M%[MOX-#?3_I^?FRG4_3^HJ6OTF7_ ()8_M! Y/C'X-]/^A@\;>W_ %3VG_\
M#K/]H'_H</@Y_P"%!XV_^=[64O$W@%MM<4Y7K_T\J>2_Y]'8O ?Q@NO^, S_
M '7_ "YH>7_3_P#K7LS\W$^Z/Q_F:G3H?K_05^D"_P#!+;]H  #_ (3#X._^
M%!XU]?\ LGM2+_P2Y^/X&#XO^#W7_H8/&OM_U3ZL9^)G 3>G%&6;?\_*GG_T
MZ.J'@5XO):\ Y]O_ ,^J'E_T_/SBC[_A_6ITZGZ?U%?HVO\ P2\^/RYSXO\
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M583J?I_45]^+_P $W?CB#D^*OA1T_P"@YXO]O^I%J5?^"<'QP!R?%7PIZ?\
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M+_I[_7R/A6'H/H?YU93[P_'^1K[GC_X)Y_&A.OB?X7]#TUKQ7ZY_Z$H5*O\
MP3W^,X(/_"3?##_P=>*_3_L2JPEQWP@T[9_@/A2^.?\ *O[AVQ\*O$1<M^$L
MUTM?]W2Z6_Z>_P!?(^&EZCZC^=6X^_X?UK[?'_!/KXS @_\ "3?#'@C_ )C/
MBK_YBZG7_@G_ /&1<Y\2_#+G'_,9\4^__4F5SRXYX2<7;/L#_P"!S[K^Y_7R
M9U0\+?$%*SX4S5:_\^Z7E_T]/B!.I^G]15F/O^']:^VE_8"^,8.3XE^&?3_H
M,^*?;_J3:F7]@7XPKG/B3X:<X_YC'BCW_P"I-J)<<<)-MK/<#T^W/LO[AU0\
M,./TXWX6S165OX=+M;_GZ?%*?='X_P S5B+M_O#^E?:B_L%?&  #_A)/AM_X
M./%'K_V)U2I^P;\7EQGQ'\-^N>-8\3^W_4GUSOC;A2[_ .%S [O[<^_^#S_J
MS.VGX:\>*U^&,S7NI?PZ>^G_ $\/C"K2?>'X_P C7V7_ ,,(_%W_ *&/X<?^
M#?Q-_P#,A4R_L*_%L$'_ (2+X<_^#?Q-Z?\ 8H5E+C3A9MM9W@NGVI]E_<.N
M'AQQRN6_#.9+7^2GW_Z^'QLGWA^/\C4Z]1]1_.OL=?V&?BT"#_PD7PZ_\&WB
M7T_[%&I1^PY\600?^$A^'?!'_,6\2_\ S)5C/C+A=M6SK!;?S3[_ .#S_JS.
MJ'AUQNG=\-YBM/Y*?E_T\/C].A^O]!5NOKQ?V(?BN!@^(/A[U_Z"WB3V_P"I
M3J?_ (8E^*O_ $,'P^_\&OB/_P"92L)<8<,MMK.<'_X%/M_@.N'A]QHN6_#N
M8JRU]RGV_P"OA\B5:3[P_'^1KZV_X8I^*G_0?^'_ /X-?$?_ ,RE3+^Q;\4@
M0?[?\ ?^#3Q%Z?\ 8JUA+B[AIMM9Q@]?[T_)?R'3#@'C)7OP]F"V^Q3_ /EG
MF?)2]1]1_.KJ?='X_P S7U:/V,/BB"#_ &]X!X(_YBGB+_YEJL+^QK\3P /[
M=\!_^#3Q#Z_]BO64^+>&W:V;X3_P*?6W]PZX<"<7KEOD&/6G\D.W_7P^5*LQ
M]5^G]*^J/^&.?B;_ -!WP)_X,_$'_P S%3)^Q[\3%QG7/ O [:GK_IC_ *%B
MN>7%7#KD[9MA/_ I=E_<_KY,WCP-Q:FF\AQW_@$.W^/S_JS/EI/O#\?Y&KB?
M='X_S-?3R_L@_$H$'^W/ W_@SU_T_P"Q9JPO[(WQ(  _MOP1_P"#+7O7_L6J
MQGQ1P^WIFN%V_FEY_P!TZX\%<5KEOD>.TM?W(>7]_P#K7LSY@3H?K_05;KZ8
M7]DGXC@8.M^">O\ T$M=]O\ J6ZG_P"&3?B+_P!!KP5_X,==_P#F<K*?$^0.
MULTPKW^U+R_NG5#@WBA7ODF-6WV8?_)^9\U1=O\ =']*L)]X?C_(U])I^RE\
M1%QG6?!?3'&HZY[?]2Y4J_LJ_$($'^V?!G_@QUST_P"Q=K&?$N1-*V9X;?\
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M+7H/H/Y5.GW1^/\ ,U[B/V>?&@ ']J>%^ /^7W5O_E)4J_L]^,P /[3\,?\
M@;JOK_V!:P_MS*?^@^A]\O\ Y$W7#F>77_"9B=U]F/?_ !'B,7;_ 'A_2K5>
MTI^S_P",EQG4_#/7/%[JOM_U!:F_X4'XP_Z"7AK_ ,#-4_\ E-64LZRIR=L=
M0^^79?W?Z^3-X\/9TFF\NQ'_ (#'M_B\_P"K,\8J=>@^@_E7LO\ PH;Q?_T$
MO#?_ (&:I_\ *>I!\"?%P ']H^'. /\ E[U/_P"5%93SG*W:V-HO?J_+^Z;+
M(,YNO^$[$;KI'O\ XCQZ/HOU_K5Y.A^O]!7K"? WQ:N,ZCX=X/:[U/US_P!
MBK*_!/Q4!@ZAX?Z_\_>I>W_4)J/[8RS_ *#:/WO_ "-?[!SC_H7XC[H__)>?
MY]F>2Q]_P_K4E>MK\%?%*YS?^'^<?\O6H^__ %"JH:G\+=9T:W2ZU+5] MH)
M)E@1_-U>;,K))(J;8-&E<92*0[BH4;<%@2H.4<TP$Y*,,53G*3M&,>:4FWT2
M46V_)+OV9K/*,RHQ=6MA*E*E"TIU*KA3IPC=:RG*:C%>;:1YY'U7Z?TJPO4?
M4?SKI$\+1KC/B/0>!VC\1>F/^A?J5?#,>1_Q4>A=?^>?B'MS_P! "KGB*3>G
MM-O^?-;S_P"G9C",4_X^$U7_ $&83R_Z?&$G0_7^@I]=3!X5\X2B/7]$?R8G
MN)/DUY=L4>W>WS:&N<9'RKECG@'FH_\ A'8O^AAT3_OUX@_^459K$4^:7\3[
M/_+FMV_Z]G1&*3C)UL,HN]F\7ADG;1V?MK.ST=MNI@KT'T'\JLQ?P_C_ %K9
M&@0  ?\ "0Z+P!_RRU__ .453QZ' ,?\5!HQQGI%KW?/KH8]:QE5CI[M7XE_
MRYK?_(>9HG3NO]HPFZ_YC,+Y?]/OZU[,QZE3H?K_ $%;/]B6_P#T']'_ ._6
MN_\ RDIZZ-;@8.O:1U_YY:[[?]06IG5B[6C5_P#!%;K;_IV;<]+_ *",)_X6
M87_Y<9U/3J?I_45J_P!EVO\ T'M)_P"_.N?_ "FIRZ9: Y.NZ3T_YXZY[?\
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M7^T8;9?\Q%#R_P"GGG_5F)3TZGZ?U%2!+0]-3L_^_6I?_(%/5+0')U*SZ?\
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M>THXS$XC+*%7&4,%A)U\95HPO3H2E*,7^[]%?PP_\$]?^"ZG_!0#X-_L$?\
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M[-P_BZE"6E2GA>)>'L'GV5U[NT:E.LYYIE[E2Y^3%9+BG4Y(5L-[3U.BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>=?$W_ ) -I_V%[?\ ](K^O1:\[^)@
M+:'9*H+,^LVR(J@LS.UI?JJJH!+,Q( 4 DDX KMR[3'89O;VJ_4\;B%-Y+F*
M2;;H-))7;;G!))+5MO9'A=.3[P_'^1K3_L'7?^@'K/\ X*K_ /\ D>G+H6N[
MA_Q)-9[_ /,*O_0_].]?;^VH_P#/VE_X,C_GYK[S\96#Q=U_LN(W7_+BKW7]
MWS7WD^D_\Q+_ +!-Y_[3K)KI],T?6(_[0\S2-53?IEW&F_3;U=\C>7M1=T W
M.V#M498X.!69_8>N?] 76/\ P5W_ /\ (]9QK4?:5/WM/7DM[\==/7S7WH[J
MF%Q7L,.OJV(NO:W7L:EU>:M?W=#+IZ=3]/ZBM'^P]<_Z NL?^"N__P#D>GIH
M>M@G.BZP./\ H%WWJ/\ IWK3VU'_ )^TO_!D?\_-?>8?5,7_ - V(_\ !-3_
M .1*%%:?]B:U_P! ;5__  67W_QBC^Q-:_Z VK_^"R^_^,4>VH_\_:7_ (,C
M_GYK[P^J8O\ Z!L1_P"":G_R)F45I_V)K7_0&U?_ ,%E]_\ &*/[$UK_ * V
MK_\ @LOO_C%3*M1Y7^]I=/\ EY'NO,N&$Q5_]VQ&W_/FIW7]TSTZGZ?U%2U>
M31=:!.=&U<<?] R^]1_TPJ3^QM9_Z ^K?^"R]_\ C%$JU'E?[VGT_P"7D>Z\
M_-&GU7%?] V(_P#!-3_Y'S7WF;3TZGZ?U%7_ .QM9_Z ^K?^"R]_^,4]-&UD
M$YT?5AQ_T#;WU'_3"L?;4O\ G[3_ / X_P"8XX7%77^S8C=?\N:GE_=*52IT
M/U_H*N?V/K'_ $"-5_\ !;>__&*D32-7 .=)U0<_] Z]]O\ IA1[:E_S]I_^
M!Q_S.A87$W7^SU]U_P NJG?_  D=E_Q^6G_7S!_Z-2EN_P#C]NO^OJ;_ -'-
M5ZTTK55NK9FTO4U5;B%F9M/O JJ)%)))AP !R2> .32W6E:JUW<,NEZFRM<S
M,K#3[PJ5,K$,"(<$$<@@X(YKE]K3]HG[2%N1_;CU<;=>O0[5A\1[%?N*W\=/
M^%/;D6OP[%-.A^O]!3ZMII>J '.EZD.?^@?>>W_3&G_V7JG_ $#-2_\  "[_
M /C-7[6E_P _*?\ X''_ #\U]X_J^(_Y\5O_  5/_P"1*-3)]T?C_,U8_LO5
M/^@9J7_@!=__ !FI5TS4]H_XEFH]_P#EPN_4_P#3&HG5IV7[R&_\\>WKYK[S
M=8>O9?N*VR_Y=S\O[OFOO((^_P"']:DJRFFZD,YTW41TZV-W[_\ 3&G_ -G:
MC_T#M0_\ ;K_ .-5E[2G_P _(?\ @4?\S:-"ORK]S5_\%S[^A$O0?0?RI:M#
M3]0P/^)??]!_RY77_P :I?[/U#_H'W__ (!77_QJLE4AR/WX;_S+R\S:%"MK
M^YJ]/^7<_/R(D^Z/Q_F:L)]T?C_,TY;"_P!H_P! ON__ "YW/J?^F53K97VT
M?Z#>]_\ ESN?4_\ 3*I]I#^>'_@2_P _-?>;0HUK_P *IM_)+R\B)/O#\?Y&
MIJ>ME>[A_H5[W_Y=+CT/_3*I?L=Y_P ^=Y_X"7'_ ,;K&4X<S]^/_@2[>ITQ
MI5;K]W4^!+X);WVVW$7H/H/Y5>3_ (\S_P!?/_M(5 +6[P/]$N^@_P"76X_^
M-U<2WN1:E3;7(;[1NV_9I]VWRP,X\O.,\9Z9XK.4X>[[T?B7VE_F=-*G45[T
MY_#+[,NO+;IU*M.3[P_'^1J3[-<_\^MU_P" T_\ \;IRV]SN'^BW7?\ Y=I_
M0_\ 3.LY2CS/WH].J[+S\T:1IU/>]R?PO[,O+R%7J/J/YU/31!<9'^C7/4?\
MN\WK_P!<ZF\F?_GWN/\ P'F_^(J)2CROWH].J[HZ(0G?X);?ROR\A$ZGZ?U%
M2TB0S G,%P./^>$WJ/\ 8J3RIO\ GC/_ -^)?_B*QNNZ^]&O)/\ EE_X"_\
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M30:CJ*;N'HW_ 'P__P 31N'HW_?#_P#Q- #J*874 LQ*JH+,S*RJ !DDD@
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MA0SV]OK]S\/[_6/BK8)H.M1Z!-KNMW]O;WCW'UW\7O@+_P %HD_X*A_L=_\
M!4/X:?L'>"_B#XD\!?\ !,KPS\)/VD/@SXR_:<^!OP]&L?&:]\0?$RZ^(?PC
M\!^.=+\3^-+73_$B:MXD\/>+_"OC:Y\-ZC\,+G18;G1-4\2V.JS2V]M_2/\
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M#D&4J/[Q2PV5Y?\ 4,+G-:I/DA3QL\FQ^<Y6EA:,Z6)PN=8K$QQ%"$H82/\
M&[JW[/?[0W_!-+_@V?\ ^"FWPN_:K^&:?#KXI?&3]H+XFV?P]\%+XP\"^.;W
MQ/HW[0WC7X0> _"%]I5S\-?%7BW3Y]3O(FUS4;?P^;T:_ NCRRZCI-O;?.W]
M;G[!7PBUCX ?L0?L@?!#Q' EMXE^$O[,_P #_A[XF@072I%XE\*?#?PYHWB!
M52]_TN,#6;2](BG"219\LQQA1&K_ (Q? _\ 9*_;DMO#_A7XI6/@_P".EA^S
M'^T1X1^(2^%](^(FKRZ?\//VB/A?IL'B#PQ8_$?0/ GBO3[34=:\.Z1XRT_7
M;CX9_$ZSU70[JPU_1M5UGPI=P7.E7%?5]&-_VC'4*\?<5'&\:YGC82^/^W>,
M^(L/F6<X:G!7]C@<M639?1P<:LYXSV^(Q]#%?[I1KXHP?^SX*K0E[\JN'X4R
M_"3C\']A<*<//+\FJSEI[7'8VIF>:8C&5*<8X65".7U,,H^UK4J11110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A[^T=_P %
M-_V[_"G[9'QO_9+_ &+/^"5/_#;L7[/W@OX+>+OB+\1/^&Y?@Y^S7_9,GQPT
M7Q'K/A;2_P#A$OBQX!N6OOE\)Z_!]MT/Q)K0_P! \W4;;23=645S]#_L6_\
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M (+=_P##XW_AG?\ X7A_PE7A/_A57_#37_"&?\)-_P ,<?\ #-NB_P#"JO\
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MWQ!+#I\.GII5IXE\0>&_+?V0O^"H'Q<^)?[2=E^QI^W?^PQXU_X)Y_M.^./
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M^"F_[8FF>'O^"?7P\^%O_!0OPW^S[\6/C)^P7\.?VA=?^&O[//[$6H?M[_\
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M&M6G@Z].?U3&?R2_&7_@H]^US^W'_P $'O\ @M%\+?VP];\3^-?'7[)GQ_\
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M3"5%4SN%*I@Z5.A!87"U\L>%X@P>799_J[A?WSHHHK0@**** "BBB@ HHHH
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MQ%XD\7^"I?A[\ ?A1X+D\'^+?&7ARS\'^+_%'A9_#?A/36\/^(O%?A+3M/\
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MCAXSA0C)O64:$*E2-%.ZIQJ3C#E4I)\?)\/? $WCZU^*LO@?P?+\4;'PE>^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %6+2TN[^[MK"PMKB]OKVXAM
M+.SM(9+F[N[NYD6&WMK:WA5YI[B>9TBAAB1Y)9'5$5F8 EI:7=_=VUA86UQ>
MWU[<0VEG9VD,ES=W=W<R+#;VUM;PJ\T]Q/,Z10PQ(\DLCJB*S, ?Z%?V OV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/$<FD^&O >CZ]J-Y%I-]X]OH[C5KWQ9XIU'6HM2\4ZK<)]C^*/B%_P %0/\
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MXW\%?"_]F[X8^.O!&K^"8;LP>*;W0OB&&\(>+[.R@U&U\3:3'?Z1J7V5\/\
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M'J\OPN\#7_CCP=X(T75?%"?$G3[67P<L?CO7_$.M0:R?#6M)?6.EQ^)KV?\
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M:F1]Z4H1UE"E4K27:G2J86E4E=Z-QJ8W"QY4W)JJI*+C&;C[5117YN?MH_\
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M;W5UWG[+7[2WPO\ VP/V=/A!^U!\'KZ^N?AG\:? FC^//#:ZVFG6NO:-;ZE
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M236>_P#S"K_T/_3O7^>117'_ *^5O^A;2_\ "F7_ ,I]?Z6O]XK]F-A$T_\
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MZ6?E3?\ /&?_ +\2_P#Q%3!),#]U-T'_ "QE_P#B*_S1J*/]9'_T!K_P>_\
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M[X?_ .)HW#T;_OA__B:_S*:*/[=_ZA?_ "O_ /<1Q_9_V=_^(M=+?\D'Z?\
M59G^FMN'HW_?#_\ Q-&X>C?]\/\ _$U_F4T4?V[_ -0O_E?_ .XE?\2 _P#5
MV?\ S0__ ,<S_36W#T;_ +X?_P")HW#T;_OA_P#XFO\ ,IHH_MW_ *A?_*__
M -Q#_B0'_J[/_FA__CF?Z:ID11ECM&5&6!499@JC+ #+,0JCJ6( R33Z_P T
M#P]XAUWPEKNC^*/"^L:CX?\ $?A_4;/5]#US2+R>PU32=4L)TN;*_L+VV>.>
MVNK:>-)89HG5T=00:_LF_P""8/\ P5 T/]JW0[+X2_%N]T[0/VAM T[KB&PT
MSXIZ9809G\1>'H%\N"V\16T$;7'B?PS;JJHBS:[H4/\ 8_\ :%AX>Z\)FM+$
MU/93A[&;_AWGSQF_Y;\L+2_E33YMD[V3_'?&7Z)7$_A;P_'BC)\[_P!=\FPO
M.\]GA\EGE&-R:C>*I8V6#69YO];R]7DL7BJ=:G+!>Y4JT'AG5Q%']F:*0$$
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M9W^#OPS^+?QP^.O@GP?_ &)\5/VD+CX?77QH\4_\)!XIU+_A,I_A9X7D\&>
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MD?[,G[7?B?X2275XD>E?LX?M\:Y\"_'/BKQ[\*;<WTR+IWPX_:ZLM.USXC^
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MX>T_Q9I=TTD0DUO1?L>I1SZ?=7UK/^GGP$_X((_\$B/V9?C;I'[1/P9_8G\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM/X5UR\_:+E^ KZC++%I,EM<?!J/QT1+I)3P])\+C^V2WA6U\%L?AI#XRF\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XI\8?
M]?\ #;_LJO@/_P!/$=>UUX'^T+9ZQ-X1T^\T"X-IK.F>(=-U/2KI8XIC:ZCI
M\5W=V5P(KB.6"4P7,,<HCFBEBD*A)$9"5/5@HN>*HP5KRDXJ^UY1DE?RNSS<
MWG&EEV*JRORTXPG*UK\L*M.3M=I7LM+M+S/\Z.BOZK+_ /9PUL74PM/@Y^S1
M';^8WE*?V2?V86VIGY1N?X1,QP.[$GW/6J?_  SCXD_Z(_\ LS_^(D?LO_\
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M_AD+4#T^"?[,Y_[M1_9I_P#G2T?\,A:A_P!$3_9G_P#$4/V:?_G2TO[ K_\
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M5">(5=OP=^#ND> =(M_]'1KYD5YIG4-(TC#+,S'+%BQ)9B2222222:][
M& . !0    , < "EKV3^) HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]!3ZOV5+_GW3_P# (_Y>2^X?UC$?\_ZW_@V?_P D6?MM[_S_ %[_ .!=S_\
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MX?\ GFOZ_P"-*+>#(_=KU';WJ6E7J/J/YTI)<KT73\T%WW?]?\,ON#[-;_\
M/)/RH^S6_P#SR3\JGHK$+ON_Z_X9?<0?9K?_ )Y)^5'V:W_YY)^53T4%PW^7
M^1!]FM_^>2?E1]FM_P#GDGY5/10:D'V:W_YY)^5'V:W_ .>2?E4]% $(MX%.
M1$@/KBIJ** "BBB@ HHHH **** "BBB@ JGJ.H6>DZ??:IJ,ZVNGZ;9W6H7U
MRX=DM[.S@>XN9W6-7<K#!&\C!$9R%(56. ;E<-\3_P#DFGQ#_P"Q&\6_^F#4
M*WPM*-?%8:A)M1K5Z-*3C;F4:E2,&XW35TFVKIJ^Z9QYCB9X/+\=BZ<8RJ87
M!XK$PC.[A*="A.K&,U%QDXN44I6DG:]FGJ<;=?M*_LYV5S<V5[\?O@I:7EG/
M-:W=I=?%3P+;W-K=6\C17%M<P2Z\DL$\$J/%-#*BR12*R.JLI @_X:>_9J_Z
M.&^!O_AV? /_ ,OZ_D8^)O\ R4OXB_\ 8]^+O_3_ ']<4GWA^/\ (U_86'^C
M'D5;#X>L^*,V3K4*-5I8/!V3J4XS:5W>R<K*Y_EMC/VA/&6&QV,PD?#SAF4<
M+C,1AHS>:9JI2C1K2I*32C9.2C=I:)NQ_8[_ ,-._LU_]'"_ [_P[/@+_P"7
M]+_PTY^S8>G[0GP./_=6/ 7_ ,OZ_CGJ2/O^']:TE]&#(8V_XRC-]?\ J#P?
MEYDK]H3QDTG_ ,0\X9U2_P"9IFO_ ,B?V*_\--?LW?\ 1P?P0_\ #K^ _P#Y
M?TO_  TS^S?_ -'!?!'_ ,.OX#_^7U?QZU,GW1^/\S6+^C+D2;7^L^;:?]0>
M#[>ITP_:!\82M?P^X:6MO^1IFGE_=/[!/^&F/V;_ /HX'X(_^'6\!_\ R^I?
M^&E_V<?^C@/@E_X=;P)_\OJ_C]7J/J/YU/2_XEFR+_HI\V_\(\'_ )G5'Z??
M%\K7X X;U5_^1GFG:_\ *?U]_P##2_[.)Z?M ?!(_P#=5? G_P OJ=_PTI^S
MG_T7[X*?^'4\"_\ R^K^05.I^G]15VHE]&C(T[?ZS9MI_P!0F#\O,WC]/;BZ
M5_\ C >'-+?\S/,__D3^N[_AI3]G0]/C[\%3_P!U4\"__+VC_AI/]G3_ *+[
M\%?_  Z?@;_Y>U_(LG0_7^@I]9R^C7D:=O\ 67-=O^@3"?YG3#Z=W%LTF^ ^
M'5=K_F99GUM_=\S^N?\ X:2_9V_Z+W\%O_#I>!O_ )>TO_#2'[.__1>O@O\
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M+7>'TPN))?\ -'9&M+_[_C_+^Z?U)?\ #0'P&/3XV_",_P#=2?!O_P NJ/\
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M7M7_ "/T4'C7P:>GBWPR?IKVE'_V[I?^$S\'_P#0V>&O_![I?_R57YY1=O\
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MA_'^M2_;*WOTM6E_"EU_[C#67X%M+EQ>K2_WBCY?]0GK_2U[+^RKC_GYT?\
M\*#0O_EC2_V5<'I<Z0?^X_H7_P L:Y2I4Z'Z_P!!4R=:-O?I:_\ 3J?E_P!/
MC3^S,#VQ?_A11_\ F0Z?^R+K_GOI/_@^T/\ ^6-']CW9Z3Z2?^X]H?\ \L:P
MZ>G4_3^HK*52M[R<J6EG_"GY?]/GW-(97@;7MB]?^HBCW_[!/+^NNZFCW8/^
MNTKI_P!!W1#Z>FH5)_8]W_SUTO\ \'FB_P#RPK%3[P_'^1J=>H^H_G4NK7:L
MY4O_  5/R_Z?>O\ 2UV658%J_P#M>Z7\>CY?]0OF:G]C7G_/33/_  =Z+_\
M)]/31KS)_>:9T_Z#6C'T]+^L^I(^_P"']:S<ZR3?-2T_Z=S\O^GWK_6]+*<"
MFG_M>G_3^C_\RFA_8]X>DFFG_N,Z/_\ )]2KH]X!S)IW7_H,:1[?]/U44ZGZ
M?U%2U'MJ_>E_X+G_ /+C=93@='?%='_'H^7_ %"^O]+72M=*NH[FWD:33PD<
M\3NW]KZ2<*LBLQP+TDX )P 2>PIUQI5W)=3R(^GLCW$KJW]K:4,JTC,IP;T$
M9!S@@'U&:H)T/U_H*GC[_A_6LI2JI\_-3NE:WLY6LVK_ /+W<WCEV$Y53_VF
MW/SW]M2O=1M_T#VM\K^>FMM=*NP.7L.O_06TKV_Z?:?_ &5=_P!ZQ_\ !KI?
M_P F55J=>@^@_E4^VK=Z7_@N7_RWU_I:ZK*\&[ZXG1-_Q:73_N7)/[(O/6R_
M\&FF?_)E2KI5V !FRS_V$],]?^ONFI]T?C_,T]>H^H_G4NK6:M>G_P""Y?\
MRWU_#MKLLLPEEKB=E_R]I>7_ %#^O]+61-*NQG)L^W_,2TWW_P"GNG_V7=GH
M;,_]Q+3O_DJBGIU/T_J*Q]M5[T__  "7_P L+6785)*^(T_Z>T__ )1Z_AVU
M>--N@!S:=!_S$=/_ /DJE_LVZ];3_P &&G__ "52TJ]1]1_.I]I4LU>%G_<E
MY?\ 3SR-89=A;-WK[V_B4^B_Z\^9(NFW0 !-K_X'V'K_ -?-3+87  !:U_\
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MO+_X:3\#WOC+^T?^$+W_ /"%_9/"H\3?V;]D_P"$L7_A(_,S]B^V?:M"V?\
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MPKKEQX=U;QA+HMKHNF-X9TXZKH_A>*YNI]4NM+G35IK>*=-.BN(+O3_[8/\
MHMS<^&_%?XE?#"[_ &2/A'\&/"OC1?$_BKP#\4OB%J%^B>'O$>CI<>&[W7?%
MK:%KZR:KIL-C&NLV%]IU\NF1ZC<ZC8"\%M?0Q3V]PL?D0P?&F-SO#1S#%\2X
M#%XGB7AG'8J>%P-*OE>58>KX=YC'-'EV*K95B,KEAL-G\ZN6NGB:F-H4J]/!
MU\30J8W$O%XSZB>:>%N5\(XV>499P'G&78/P[XTRC+Z&/SC$83/^(L?A?'K(
M99$L[R_#<0X/B"CF>,X*I4.(8UL%0RS%U\)B<WP>"QD<ERV.6Y3L7G[#'BC3
M_C?XC^&-WX[T*U\#>$O!,'Q1UWXMW.FW,>E6?PYF1V76QH,=[---JK2P7MO#
MHD6KM%.]C<RKJPM8S<"CJ_[(FF2ZU\$[WX??%[3?B'\*?C5XVMOA]8?$:S\'
M:MH%_P"'?$YU(V5[9:OX*UG4H[Q?+MQ)>Z:)=7LYM2CM;SS(+"V6QO-0^P8_
MVW/A+H?Q\GU71?&FJ6_@OQE^SWX.^'%W\0M&\):A=WO@'QWH.HZ]<66LR^'/
M$VD6\^M:;HR:Q-->16FDZM#>2/:I;VU^B7$2\+X\_:I\*7OCG]G;3]5_:/\
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M_#5^!?\ Y0U$OI+Y&W?_ %9S;7_J+P?EY&\?H$\71O\ \9]PYK;_ )EF9_\
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MA?+R]?ZVZ8_0WXF2M_KED6]_]PS#R_O'\MR]!]!_*GI]X?C_ "-?U(?\,^?
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M[=YEAHC>3I]S/'_Q3V@KMECV;'^73ESC)^5LJ>X/%9_]IR_\^>B?^$YX?_\
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MNXW_ .@BUOG?RUTCJ=>@^@_E0NJW9'*6'7_H$Z5[?].5/_M6[_NV/_@JTO\
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M /$4]&)SD)V_Y9Q^_P#LU+;;;MOY^GEZ_P!;:QE%)+7[EW]?7^GI&GWA^/\
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M_O/^SS^S/\.OVE_^"HW[&-I^V?X4^&W[5WB+X=_\$$/V??&KZC\1/ NL^)/
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M3(\QJU75MA(X?/.$N).+H8&E6<&Y8["4N&JV55ZDHJ$L3C\/BUAX1H2P=?\
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M_P %6S^U+_PHO]@B/_@N+<?L06WPON?^"LWP,L?%,O[%EW^T=8?#G_A0E_\
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MSL?^'['_  52_P"CH8/_  Q'[-?_ ,YVE_X?L_\ !5/_ *.BA_\ #$_LV?\
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MW3-"\/Z)J'B6U_X3&:T^@/A=_P $#OCK\"_@_P#\%*?AG\)?^"F7BJS\7?\
M!2;Q'X.U_P >?';QW^SA8^*/B[X.98O&'_"Y3;:CX6^./P[\.:SJOQ9E\:ZU
M:6&L:7X<\&-\.]#N[FQTNSUG5/[.U[2_8?V3?^"#_@;]@+]KOX(_M(?L3?'B
M[^"_P^\-_LY>&/V>OVH/@-JOPQ/C+2/VLY/"UK/'9_%[7_$]I\1_"-I\/?BQ
M>:DNF:_J&NZ7X+\1V$FKZ?=26^F6UIXD\56>M>9C(5/[.QN'PGMW4CG>>XO"
M2<XTL75X=K\0\/8O"91]8G7Q'L\TK8>EBZ^!Q,JT895E>!SGA]9C3AQ'A*F
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MVUOQ1\(-2T#XMQ>)TTN*V\;>-_\ A*['Q!8:'=?9/!&ARV<OQ/Y7]HGXD_\
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M['U.:6_T_P"SW4CRGUI?AK\.E^(DGQ>7P#X*7XL2^#H_AY+\3U\*Z$/B))X
MBUE_$47@:3QJ+ >)7\'1>())-=C\,MJ9T5-9D?4ULA>LTY^#O^"/_P"T-\6_
MVK_^":_[)G[1/QW\1VOBSXN?%;P!JGB/QQX@L=#T3PW9:AJB^-O%6F0_8]#\
M.:=I6CZ?:VNGZ?965O%:6,+/%;)-=O<7LMQ<S>S_ +)_[5W_  T_KW[6^B?\
M(%_P@_\ PRS^UMX^_9:^U?\ "4_\)+_PG7_"#^"?AOXQ_P"$Z\G_ (1SP_\
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M*C^QQ^R(WQM'[2[?LK?LX-^T<NH#5A^T ?@=\,3\;1JHT7_A&AJ8^*I\+_\
M"=C4!X<_XD O1KWVD:+_ ,2H2?8?W%?1]%$O?A6IS]ZGB95)XB$O>AB)U9SJ
M59UHN\:LJDZE2=24U)SG4G*3;G)LC[DZ52'NU*$(4Z$X^[.C3IJG&G"E)6E3
MA"-*E&$8-1BJ5-124(V\/\/?L^_#SPS^T%\3OVF-.M)1\3OBQ\./AA\+/$UV
M;'PW:VB^%?A-J_C_ %OPXD-SIF@:?XAU*_N;WXBZN-2N_%&O^(A%9Z=H=AH4
M.B6=G<07ON%%%$O>JU:TO>JUO8>UJ/6=3ZMA,/@,/SRWE['!83"X6G?X*%"E
M35HPBD+2$*:TA3]I[."TC#VU>KB:O)':/M<17K5ZEDN>M5J597G.4F4444 %
M%%% !1110 5XI\8?]?\ #;_LJO@/_P!/$=>UUXI\8?\ 7_#;_LJO@/\ ]/$=
M=&%_WBG_ -O_ /I$C@S/_<:WK1_]/TS_ "BJ***_T(/YN"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_='_@GG_P $\?V,/B[^QM\8OVT/V[?B
M]\9/@O\ "WP!\5],^&VAZ]\,9](GMKDW%EX8BN9[_0%^$OQ7\5:O//K_ (PT
MC2[231-.@@M4AU"XO(VMK6YN[3\+J_L#^'GC+]B/]D;_ ((O?L>^ /V^?A1\
M3/B[X%_:8\4>+?BI;>"?A1>W&F:K=:J-?O\ Q5X?US6;^U^*/P@U'^S=/\*Z
MCX1C:*VUR]@DO[FR66PN8H(;U?@>.\QQV&7#F79;/-_K.:YW*.)I9 L*\XJ9
M3@,JS+'YA+!?76L-&4)4,+&=2KS1I1J>T=.KR^SE]1P[AL-+#YYC\9'+E1P6
M"P5'#U<V==8"&8YAG&7X?#PJ_54Z_-5PJQ\:+BE%UU3A.45-,_/C]I__ ()J
M?L&Z]^QMXW_:[_X)M_M,_%3XUZ3\'/'GASP5\3O#/Q5TC[)>:C<>,M7\*:)H
M\'AF*\^%'P;UK2=0TZY\4V%[*]_HGB#1_$EE<75OINIZ9J6A7-IJ/T_\;?\
M@F-_P1(_9%UKPC\,?VM_VQ_VI_AO\:-3^'GA?QIKWAK1;.#Q7I<?]LI=V-U=
M6%YX+_91\<6%E8RZYI&LQ6&FZAK]QJ\%C!;SW1FAN;:\NLKPC^VI^S)^TO\
M$']D?_@FG_P3R_9JUWX"_LU^,_VEOAI\3_C%J/Q"O5F\=^.7\$>+!\0/$.AW
MUO:^+OB3>ZMIEKI7A33]4/B;Q5X_U[5[U-'T3PM8Z7X6\/\ AFUFU+]/-3_;
MM_8/^/O_  5%\:?L7_'C]B/X#^(O'&D:]>_"KP/^TK\1_"_PT^)>H^*_'WA:
MP@O-.\$ZQIWB?X9Q:UX4TY]1.O\ A_P]/;>-O$K-XCMM+TV'2K4^('N-,_.\
M?FW%F"BJ.85N*8X7)<JSCB#&_4,=DN'SNADV99M##Y!4S^K4PN)PU:KA,-E&
M<XG$QP%"M4H4\;&%65.EEU5+Z;"8#)L3)/ T\JE6S?.*.786.-PF/KX:O6R?
M(\!/-Z>14Z>(PLZ2Q6:9QA:6'HXVJYXR6'I_5G.IC*;?XU>/O^",7P>M_P!O
M/]BOX._"/XL?$/Q_^RC^V3X$U#XI^'_&-S+X?TWXIZ%X'\+>#?\ A+?$=RVJ
M77@^P\/SC5]-N-$U3PUJ%[X TVYM1KPT#4_#D]]I#:EJW7>-OV.O^#='X=>,
MO%GP_P#&'[>W[7&E>+? WB77?"'BC3(O#>L:M%IWB'PWJ=UHVLV,>J:-^Q=J
M.CZDEIJ-G<VZW^E7]]IUVL8N+*[N;:2.9_N_]B#XL_M7_'O_ (*K?M9?%W]J
M_P .:)<>*?V$?V?_ !]\-M"^&'P@T+Q+)X=LM7U+Q!;'3XOAWHMS-XJ\4:]J
M/Q'T?P]XFU:WU&>YU37-?.J:18Z7IB:=%I.BZ7X=\1OVP+F?0?'GBOQ)_P &
MQD6@WDVD>*/$.O?$?Q;\!EN(=%N9+.^U+5/&WB;4]6_8ALEGBTZ4SZ[K5_J>
MKVBRI#<W%[J4 :2Z3K6-XIQ6<2RG&9IFE7$93EO#64XRIP]GW#N6X6IG&(P4
MLRQV+JQSBA/$8^<\-F>6455P%"4:SPLZZ4I8JG3CPRAE&'RC#9AA,%@G2S!\
M09U0IYME^:8O%/+WFF(P.482GBL'.CA,/1IT<JQ,JD,9)5:=;$.56=.E&R_-
M_P"%G[ O[%]U\(/VF?VY?BS\4?VB]1_89^&GQXUCX*?!'1?@QH/@_4/V@/B5
M;2Z_H]GX<\=^)-9\>Z#X=\%^$]'72-:TZYO-/UWP?X<O=5N;JY@63PYJEEI6
M@^*?!/VK_P!F/]B6W^"WPN_:%_85_:0U_P 8:;XR\3K\/?%W[,?[0&M_#BW_
M &J?!OB>2?5C9>*!X>\!G3['5O!&J0VMG9O<6.BSZ=I-W=:7-!XN\02ZW?:3
MX3^J_P!CS]KC]M__ (),?!/P9XB^)?[/'AGXI_L0_M@'5?&7AWPMXH\0^%Y]
M.\4W%_X1M=,U5]"\5>%+OQLW@._\1Z.WAZ/Q#X0^*7@K5DUW1?#VH66D^&M+
MU"'Q#JUM]L?M&_L;_LC_ !7_ &EO^"2OQT_9C^$]]^SW-^V=\3=)\:>,_@+J
M>FVOANT3X?\ @:^\-^.;[QG8> M,O=4T?P=;WOAF&^MX+;PF;'P9XBTJYT+6
M;#3M+OIM:OM0]JIQ#F&4YIC<9CL?BL7@:M'B[.LBQN"Q>7X[AO-\DR'*\9BI
M9=6I48+&99CLK6%A.MC8SJ?6LPHXG#K$5J,ZE"&5/)L'CJ.78/#T8TVLQX2R
M+-(5:5?"\095F^9XO"X*O.HJJGALQH9I66.J*"IN6!PV)PM66'POU6,ES/QM
M_P""8W_!$C]D76O"/PQ_:W_;'_:G^&_QHU/X>>%_&FO>&M%LX/%>EQ_VREW8
MW5U87G@O]E'QQ865C+KFD:S%8:;J&OW&KP6,%O/=&:&YMKRZ\)_9V_X)K_\
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M&F^6G4G5P53"9EAJ=**A&& SNM5JYIG6#G[6./S+$8MRG#+\3/+ESX:4J-;
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M4\.L305"K4I5:M%8BLJ52K0YU0J5*?LE"=2BJU3V,Y1<J?M:G(USRO\ SU?
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MM5U"9M$:XEL_$&K>'[[Q9X>BO&\.:.;ZT\-Z]I%G??97^V6\XO+W[3E_!/\
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MJ49+RDFCYZ?0/"CL6;P?X?)))S_Q.\\_]QKFD7PYX2) _P"$/\/_ )ZWZ?\
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M5N??_GY4_P#D_)&T<14LM*6R_P"7%#LO^G?E_5V8R^$_"C9SX9T?C';4??\
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M2T\#?M1>-/V<O%'[:FF>/?V4_"WBO2OA=\+_ !YXA^'?PT^#VB_!&'1_ WQ
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M$?%__@JUXB_X:3_:Q^,O]E_M_?$_X*?V%\>OC'_PL3PYJ/\ PBG@+X.^+_\
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MZ'P-J>MZG<Z?J=Q=3"Z'Y1_"+1_VY? ?_!'[X+?\%O+[_@JE^V5XY^-_P?\
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MEX\LOC@G_"-I\#XM*LM*\-:O=ZS/I6G7>M:^GBWQCK?I_P"PY^T3^S__ ,%
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M%8JG7_<CXE?M6_\ "O/VS_V6_P!D3_A O[8_X:5^&'[2/Q(_X6%_PE/]G_\
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M7P'_ .GB.NC"_P"\4_\ M_\ ](D<&9_[C6]:/_I^F?Y15%%%?Z$'\W!1110
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M?SI*5>H^H_G2G\+^7YH">BBBL0"BBB@N&[]/U04444&H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '$:)\,_AQX9\6>.O'GAOX?^"/#_CGXH-H#_$SQGHGA
M30=*\6?$1_"FE-H7A9_'7B*PL+?6/%S>&M$=]'T!M?O-0.C:4[:?IQMK1C"?
M/-5_95_9?U[X,P_LXZY^S?\  76?V>K:6.>W^ ^J_!_X>ZC\&8)H==D\40S0
M_"^\\.S>"(I8O$TTOB*.1-#5TUV635U(U!VN#[U15*4HRYXRE&=^;F3:ES.G
M[)RYD[W=)NE>]_9OD^'0EQC*/+*,7%*DE%I.*5%WHJSTM2>M+_GV]869\+_'
M/]E+Q+X>_8W\>?L]?\$Y9O@7^Q;XO%E<:A\+M/T?X#_#6X^ <>JW&O1>(/%'
M@WQM\)K7P?=>&8O!7Q<@.L>%/'FN:%X:N/$^DVGB:_\ %FD6^IZY80V-]^8O
M_!.K_@E'^T=\*/VL?#7[6O[6O@3_ ()C? *Y^"WP[^(_@3X'_ 3_ ()5_ OQ
M5\(?A5JOB3XS?\(Q:?$7XR_&'6_&VB>&_$WB'QL/"O@_1O N@^'Q::OX=M](
M6/6+6?1M5M;N/6OZ(J*SK0A7PU#"2C&%&ABGBXJC%4I3K.O2Q3<IP2E%RQ%&
M%2K4I.E6Q5-U,'BZN(P%6IA9Z492H8FIBXRE*O4HSH*=5NHZ5.I@ZN75(TN>
M[4)8&O6PT:,W/#T/:3Q.&HT<9*6)?R+/_P $_?V#+K7/B3XGNOV)/V1;GQ+\
M98M6@^+_ (AG_9M^#4VN?%6'7_$VG^--=A^).K2>#&O_ !S%K7C'2=*\6:M'
MXGN-434O$VF:?KUX)M5LK:ZC[[QE^RG^R[\1?&L7Q*^(/[-WP#\=?$:#X?:K
M\)8?'_C+X/?#SQ/XUA^%6O:?K>DZY\,HO%6M^';[78_A]K.E>)?$>F:KX,2_
M'AS4=/\ $&MV=YILUMJM_'/[Y16G//GG4YI>TJ5)5JE3F?/.K*>&J2JSE?FE
M4E4P6#J2G)N3GA,-)MRH4G#/ECR0I\L?9TZ;HTZ=ER0HN%>DZ4(6Y8TW2Q6)
MING%*/)B*\+<M:HI>6>(?@9\$O%W@/PS\*_%?P=^%GB?X8>"Y_!]UX.^''B'
MX?>$M:\!^$[KX>S6=QX!N?#/A#4M(N?#V@S^!Y].T^;P?-I>G6LGAJ:PLY-%
M:R>U@9+GQ7^#GPB^//@G4OAI\<OA7\./C/\ #C69]/NM7^'_ ,5_ _AGXB^"
M=5NM)O8-2TJYU+PIXOTO6-"OI],U&VMM0T^:ZL)9+*]MX+JV:*>*.1?1Z*FG
M^Z]G[+]U[*C'#TO9^Y[/#P=64*%/EMR48NO6<:4;0BZU5J*=2=ZG^\Y_:?O.
M>L\1/G][GQ#]E>O/FOS5G[&C>J[S?LJ7O?NXV^5?%7[%?[->M_LL_$3]C3PE
M\)_A_P#!K]GSXE>#_&/@O5_A]\&OAQ\,_!7A?2=.\>+=MXEO_#O@P>"]1^']
MAK=]=WUUJO\ :-SX0OV76I!K)C;4XXKI/IS2]-L=%TS3M'TRW2TTW2;&TTW3
M[6//EVUC8V\=K:6\>XD[(8(HXUR2=JC))YJ]14\L;45RQMAY8R5!))*E+,98
M6>/E325HRQD\#@YXEK6M+#493<G"+5<TFZC<I-U8X>-1MMNI'"1K0PL9O>4<
M-#$5XT%*ZHQK58T^55)I\?X#^'O@#X6>&;3P5\,? _@_X<^#=/O-:U&P\)>
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M&,<8VYSSN[5G*3]WW)?$NL/_ )(Z:48Z_O(/W9=*G]WO3Z=?PN4Z<GWA^/\
M(U-NM/\ GC<?^!,?_P B4Y6M=P_<W'?_ )>8_0_].E9R;YG[LNG6/9?WOZMZ
M&D8Q][]Y#X7TJ>7]P1>H^H_G4] :VR/W4_4?\O$?K_UZU-NM_P#GE-_W_3_Y
M'J)-\K]V73^7NO[QT0BK_'';M/R_N#$ZGZ?U%2TJ-!DXCFZ?\]T/<?\ 3N*D
MS!_SSE_[_)_\8K&[[/\ #_,UY5_/'[I__(D53KT'T'\J;F#_ )YR_P#?Y/\
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M"+K5;Z\NO#_B5/#ES;7/V2/^"W7C_P ?_L2_\%*I--_;W_96_:&\;_L0Z/\
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MQ..P[C.=>I@WAJ52C#,YU<!2_=>BOYDOVZ_VI?\ @H#^Q[^SO^R#\$OVD?\
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MC*,DI1DFFDTT%>=?$W_D VG_ &%[?_TBOZ]%KS[XC1M<:5I-I&5\^]\06%I
MKL$5IKF"]AB4L?N@NZ@G!P.<<5Z&7M+&X9MV2J)MO9))MMGB<01E/)LPA!.4
MIT.6,5NY2G!)+S;/"*<GWA^/\C7YD?\ #Y7_ ()B?]'9Z-_X9C]IW_YQM*O_
M  66_P""8@(/_#6>C?\ AF/VG?3_ +(;7ZC_ &%GW_0@S[_PRYG_ /,OG^?9
MGXJJ+NOWV#W7_,=@O+_J(_K7LS]4M)_YB7_8)O/_ &G637YJV7_!:+_@E_;?
M:_,_:QTH_:+&XMDV?!?]ILXDEV;2V[X(+A!M.XC<PXPIJC_P^9_X)A_]'9:/
M_P"&7_:=_P#G'5G'(<_YYO\ L#/K/DL_[%S/6RU_YA?/\^S.RI&#HT(K$8)R
MC[7F7U[!75YIJ_[_ *H_3BGIU/T_J*_,3_A\S_P3#_Z.RT?_ ,,O^T[_ /..
MIR_\%FO^"80.3^UEH_3_ *(O^T[[?]4.K3^PL^_Z$&??^&7,_P#YE\_S[,Q]
MFO\ G_@__"[!?_+S]/J*_,3_ (?.?\$PO^CLM(_\,O\ M.?_ #CJ/^'SG_!,
M+_H[+2/_  R_[3G_ ,XZC^PL^_Z$&??^&7,__F7S_/LP]FO^?^#_ /"[!?\
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MFO;_ *HC3O\ A];_ ,$N_P#H[#3?_#*_M-?_ #DJO_5[B'_HGL__ /#+F?\
M\R^?Y]F/VE#_ *"\#_X7X/\ ^7GZE5,GW1^/\S7Y7_\ #ZW_ ()=_P#1V&F_
M^&5_::_^<E4B_P#!:_\ X)=  ?\ #5^G?^&5_:9]?^R)5$^'>(FE;A[/]_\
MH2YGV_[!?/\ JS-E6PUE_MF V7_,?@_+_I__ %KV9^J4??\ #^M25^5J_P#!
M;+_@ERN<_M7Z=SC_ )HK^TS[_P#5$Z=_P^T_X)<?]'7Z?_X97]IG_P"<G6?^
MKG$?_1.Y_P#^&7,__F4UCB,*HJ^-P'_A?@^__7\_5=>@^@_E2U^58_X+;_\
M!+< #_AJZPX _P":*_M,?_.4I?\ A]O_ ,$M_P#HZZP_\,I^TQ_\Y2LUPUQ)
MR-?ZNY_=O_H2YGY?]0IK#$X17OCL MO^8_!__+_,_5E/NC\?YFK"?='X_P S
M7(^#/&7A7X@>%]!\9^"=?TGQ1X4\3Z59:YX>\0:'?6^I:3K.D:E EU8:CIU]
M:O);W5K=6\B2Q2Q.RLK>H(KKD^Z/Q_F:\.491E*,HN,HMQE&2:E&2=G&2=FF
MFFFFKIZ,[8?$_3_(D3[P_'^1J:H4^\/Q_D:FK"?Q/Y?DCJCNO\"_,G7H/H/Y
M5>3_ (\S_P!?/_M(517H/H/Y5>3_ (\S_P!?/_M(5G+[/^)?J=-+K_AG_P"V
M$5.3[P_'^1IM.3[P_'^1K.?Q/Y?DC2/VO\+_ $)UZCZC^=3U O4?4?SJ>LY_
M"_E^:.F&[]/U0].I^G]14M1)U/T_J*EK$U"IUZ#Z#^505.O0?0?RH-X[+T7Y
M$R=#]?Z"GTQ.A^O]!3ZQG\3^7Y(TAN_3]4%21]_P_K4=21]_P_K4FI)3TZGZ
M?U%,IZ=3]/ZB@<=UZK\R=OX?]T?UIM.;^'_=']:;2CLO1?D;A2KU'U'\Z2E7
MJ/J/YTI_"_E^: GHHHK$ HHHH+AN_3]4%%%%!J%%%% !1110 4444 %%%% !
M1110 4444 %%%% !7Y:?\%K?VC?C-^R1_P $NOVNOVB_V>_&7_"O_C)\+_!?
MA35O WC'_A'O"OBO^P]0U+XG^!O#M[<?\(]XWT/Q+X5U/S]'UC4K/RM8T/4(
M(_M/VB&..ZA@GB_4NOQ]_P""^OPR^)'QC_X)!_MM?#3X0_#[QO\ %3XC^*_
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MJ_B+Q-X@O-/T71-,M@RFXO\ 4KVVM8009)5R*_&7X.?\%\?V%OBC^VE^T_\
MLN:Q\>OV3? GPV^!^A_!?4/A3^TOJ7[8_P '[OP/^TIK7Q1T*34_$7ACX?65
MT-%T&35/AOJ@B\/ZU#X<^('CJ[GOYXTOK'0+AELW_6WX[? WX6_M+_![XB?
M/XV^%_\ A-?A+\5_#%_X.\?^$_[;\1>&_P"W_#>IJJWVG?V[X2U?0?$NE>>$
M4?;-%UG3K^+&8;J,DY_F;^"'_!JA^PAX+_;=_:5^)_Q(^ 'PZU_]D#5-+^"-
MW^Q[\+-"_:"_:N7XA_"GQKX5T8O\6]8\<7C>+="GU6S\3^*X[74_#UOJGQ)^
M(]M%:1-"FF^'(6:P>\7R+)\7/".3S6-7"JE&:BH*G+-<GA'ZNKS57VE&>8T\
MV]M33P>4^VQN7NMF-*A22P6N<X6&,TREX?%.M*GK/VD<'C)2=1OD<*M.4<+/
M*H4ZGL\9F#^K8]T<&Y5)?T8_M@^/?%7PM_9(_:C^)_@+5AH?C?X=?LY_&WQ[
MX+UP6.FZH-'\5>$?AGXF\0^'=6&FZQ9ZCH^HC3]7T^SO!8ZK87VFW?D^1?6=
MU:R2PO\ SR?LK_\ !<;X>^*/^"'DWQJ^-7_!17]E6V_X*.C]ES]H;Q-'HWB+
MXI_LQ>$/BU_PN?P_)\31\*[8? *WDT72V\0SKIO@[^Q/"7_"N#!XE$E@9M%U
M7^U9#>?T!_MP>'==\5_L4_M?>$_">AZOXE\3>)/V6_C_ .'?#7AKP_IM[K6O
M>(-=UCX3>+=-T;0]$TC3H;G4=6U?5=0N;:PTW3;&WN+V_O9X;6UAEGE1&_C]
M_97_ .#=7]C/Q1_P0\F^-7QJ_8"^*MM_P4='[+G[0WB:/1O$7B3]K#PA\6O^
M%S^'Y/B:/A7;#X!6_C_1=+;Q#.NF^#O[$\)?\*X,'B426!FT75?[5D-YZ>"C
M3>(X#4H8>6-K<1YW3Q-&LH_V5B:<*'"+HTLZJ-.J\OA5JXM8;VE"M%1JX^4(
M*4JD9^;C)5E@>+Y.56&'I93D<J57#.3S.A6G3XR=>64P?)#VTX4L/+$N-:E)
MUZ&5J;:4)4_UK_9K_P""V'AKX,?\$JO^"=_[0_[:&I?%[]I/]K/]L7P_>Z7X
M&^$'[./P@\-^+?V@OV@_&NG>--4TK6YOA_\ "3P9'\/O!L=MX7T:;1)M:DAD
M\,Z?B6RL--BU/Q-J^G:7J7T,O_!>_P#8M_X83_: _;PN?!G[2>D:%^RI\0]%
M^%'[1O[-OB?X8:#X._:O^#OQ#\0?$'1OAYI7ACQG\-O%WCW0_"=I>W%YKVGZ
MXTUK\1;RQATF/5M,FND\:>']?\):9_+]\3?^";7[9.D?L=_\$(?VG6^$7_!1
MK1--_93^"_Q1^$?[4/PW_8;34OA;_P %$?@E:^/?B!X@E\-^+OA)X'\3:3_P
MF$VM:N/$=WI_C;2(?#<<P\'64,>M7NA>'M7N?$VB[_C3_@GG\<=:_P""/O\
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M ((X_M3VW[9?P _;A_:__P""I_Q#_;"^+'P-\._&7X;6VBR_LW^!OV>/ ?\
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MXTU/0?!=I?ZYXN\'>![GP-=1:CJ?_"$^%_"UAH-[%XMUZ'3_ !IIG'^'?^"
M_CBU^#G_  4 ^'/Q!_X* ^-?C/XZ_P""A7B;]ESXE?$[XS?$CX':1/XJT/XI
M_ /QAIWC3QAJNF:+X;^*'AWPX_P^\=7MDVB?#[X::99^';?X*>$XM'\-V?B+
MQSI^B6JR?LS^V7^V'\(?V%_@3KOQ]^,T7C35M!T_6?#GA#POX(^&?A6Z\<_%
M'XH_$;QKJD.A>!/AA\,_!]I-:-XB\<^-==N(-)T'3[G4-+TT3R-=:KJVEZ9;
MW=_;^;_L'?\ !0GX2?M_^$_B5K'@/X=_'SX'>/?@QXYB^'OQ@^ ?[4?PR?X0
M?'CX8Z_J&B67B;PX_C#P+_;7B*"QT[Q;X;U"UUWPW>V^M7@O+%IDN8[.^M;J
MSAQJTXX:&#=7FI_7,?/&49SG-ULQS3V^/S"6:8ZHY.OF685*M'-(QS;,98C$
MUJ5+,<OCBIT(8K#+?#U9U9XEX?EF\!1HQG&$(.AEN#H8K+*]++\%2Y?89=E]
M#%SR;$O)L!"A@J-2KEN*G@X>UPU26A\=/V,+3XW_ +7'[&?[4.H>.X=+L/V2
M]#_:3T&]^&MSX-76[?XGVG[1/P]T/P#<I/XE?Q-IR>%H?#,.CO?RV[^&O%"^
M(4O&L&?1A$;N;\L?#/\ P0;^)ND7/A3]GKQ!_P %+OC9XP_X)5^!/BGHGQ-\
M*?\ !/35O@W\,DU9;#PIXM@^)'A7X1>)OVKQ?S_$KQ-\$M&^(,$4Z?#V;PO8
MVO\ PA-II?A*RO=.U72;'QC%_1=13G",\*\%)-4'0IX:/+*4*U*A3HXK#>SH
M8J#CBL.JN'QN)H8ET*U.6+HU/98J5:%.G&&='_9Z]'$4O=JT+\E_?IM_7O[3
MISJT9\U&O4PV/;Q>"J5Z=2I@:TISP<J#G/F_!GQ__P $BOVN]&^)OQ?7]C+_
M (*W?&K]C3]E7]H/XC^+?BM\5OV:] _9Y^$7Q5\0:)XR^+&K7.I?&V__ &>?
MV@/&&IV'C?\ 9YB\<RWE[K_AZ'PMHNK-\/\ XB:IK7C[2Y-2O=073K;[F^'G
M["-M\.?VUO#G[7-G\7_%GBBT\,?L)^$/V)+;P;X]@U7QGXYUN#PA\33\0XOB
MSXR^-6N^+;O6O%OBK6DVZ=X@@U;PO)J6KZM)=^)KWQ1-<7<FGC] ***T(5UB
M8SA&-/&.$L11HQ6'P\ZD,YR[B!UHX;#JE0I8BOG.4Y?C\7B:5.%?&U<.HXNI
M7I5*U.HZ4I4?JW)*3EA%*&'JU6Z]:%-Y5CLCC1=>LZE:IAZ.4YEC<%A</4J3
MH82G7<L+3HU*=*</#?VG?@Q_PT=^S?\ 'W]GS_A)/^$-_P"%X_!KXF?"/_A+
MO['_ .$A_P"$7_X6)X-UGPE_PD']@?VKH?\ ;?\ 8_\ :W]H?V3_ &UI']H?
M9_LG]I6/F_:8_COXA_\ !.;_ (3SX&_\$WO@O_PN/^RO^'?/QE_9:^+G_"2?
M\*]^W?\ "W/^&:O .I^!_P#A'_['_P"$XL_^$!_X33^T?[4_M;^U?&G_  CG
MD_8O[-U[S/M:?IM7SU^T9^TQ\._V8-#^%^N_$:V\2WD'Q>^/WP7_ &;_  ?:
M>%M,L]3O9/B#\<_&MAX(\*3ZB-0U/2+2Q\.:9=WLNL>)-2-W)=VFBZ?>G2M-
MUG5WL-(OJK_OL-6A7][#87)^*Z->_NQHY/GF4X>EQ2ZDX\LHTJV4Y11=6NY>
MUP=/"SK8.IAJDZM2:HKV6)HRH^[B<5FO#-2AU=7-<HS2M4X;48RO'GHYIFE5
M4Z5E2Q4\1&EBX5Z4*<(?D[X]_P""1'[7.B?$OXO1?L7_ /!6WXT_L9?LI_M
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M#<ZAJNKZKJ%S9Z1HFCZ?;W&H:OK%_8Z;8P2W5U#&V>&I/$UYY=A85*N*KXC
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M1:;X<T.SL]'TJQMHOA']B?\ X*^? S]M+XMW7P$G^ ?[9O[(7QJNOA_)\6/
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MMZTO_3],_P HJBBBO]"#^;@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#]H_\ @E%_P5=\4_L2>*+/X5?%6\U7Q/\
MLO\ B?52][8H+C4M6^$6KZE<;[OQ=X1M$\VXNO#UU<2-=^,/!]HC/<NT_B/P
MY!_PD/\ :>F>+/[NO!/C3PO\0O"N@>-/!>O:5XG\+>)]*LM<\/\ B#0[ZWU+
M2-9TC4H$NK'4=.OK626WNK2ZMY$EAFB=D=&!!ZX_RHJ_<S_@C9_P4J^*O[-'
MQ5\)_LX:UI?BGXI? [XI>*;;2-+\(:%:7>O>*?AQXIUZ[P_B7P/IL(EN+OP_
M=W$LE]XU\*0 1F,7GBS1%BUJ+5['Q3^0>(? -/,J>(S[*(0I9A2A.MC\,G&%
M/'4X1YIUX-M0ABX03E.]HXF*;;5=7K?4Y%G+I2IX+%-RI2:IX>KJY4I2:4:4
M]W*DW90>KI-VUI_P_P"[Y/O#\?Y&IJS["[BO88[B%U='&0RD,IX/(()!'N#@
M]N*T*_G"7Q/Y?DC[Q*TDGNH)/[R=>@^@_E5Y/^/,_P#7S_[2%45Z#Z#^57D_
MX\S_ -?/_M(5G+[/^)?J=-+K_AG_ .V$5.3[P_'^1IM.3[P_'^1K.?Q/Y?DC
M2/VO\+_0G7J/J/YU/4"]1]1_.IZSG\+^7YHZ8;OT_5#TZGZ?U%2U$G4_3^HJ
M6L34*G7H/H/Y5!4Z]!]!_*@WCLO1?D3)T/U_H*?3$Z'Z_P!!3ZQG\3^7Y(TA
MN_3]4%21]_P_K4=21]_P_K4FI)3TZGZ?U%,IZ=3]/ZB@<=UZK\R=OX?]T?UI
MM.;^'_=']:;2CLO1?D;A2KU'U'\Z2E7J/J/YTI_"_E^: GHHHK$ HHHH+AN_
M3]4%%%%!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5\(?L7_\$]/@O^POXM_:
MT\9?"3Q/\4/$6I_MD_M$>+/VF/B=!\1=:\*:O8:%X[\8WM_?:GI/@.+PSX*\
M(W&E^$H)M1G6PL/$-UXHUF*-(A<:]=,KN_W?11/]Y3A2G[U.GBZ6.A![1Q='
M"X[!4JZ_Z>0PN98ZA%[<F)JJUVFB/N5)U8>[4J8:I@YS6\L+6Q.#Q=6@_P"Y
M/$Y?@JS6_/AZ;3LFF4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '\@]S_P $]?V&?^"B7_!5'_@MQX1_;@\4^(=?\,_!7Q'^
MS-X]\(?#&#XV>(_A/X8^&LWBC]CGX=Z9XE_:;N[+POK_ (<76?$/A73_  O9
M>']+U_QU)X@\ >%-/_M:'5/#MR/$-PTGA'P7O;K_ (*0?#[_ ((E_L;_ +>?
MQF^)/B_]E?XW> /V];_Q!IU[\0?''@:3]O76_P!E;XKZ9X-_9ATGXG^//"VO
M^'?$7B=V^&]@OQIM[>'7(-3\5^)/"EGXN^T7-YJ&F7,/ZC7W_!$;]GO]KW]N
MO_@HU\8_^"@_[)GASXF?#GQ]\:_V;O'?[*GC.^^(.I:%K&K:3X0_9D\&?#SX
MCH9/A#\1=!\;V/AR/QCH T[4_!?Q(AL]#\076EV6MVV@:I:P66IC]5_VF_\
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M[/P5+!JLN-9\DR>'((I8+JSCTZVTO^L'XR_L[_!W]H&;X37'Q=\'_P#"72_
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M67Q)\/WT5SJ7[6'QWM/CEXELK:RU>SMM%U&S^%'PY^&(L"^K^*/$[:E?7C>
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MJR?#[QI_PSEH6JW'PUU/_A64.H:'!_PCEUJJ:9XS_P"$>\W6Y;=]6O GU/\
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MIY\1?VE_^"?'Q_\ BWX'U+X6^)?A1^S#\ OV9=$\??MD?"G7[+XA_";]G?\
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M_K7PM_T4N0?^'G+O_FD?]E9GI_PFX_7;_8\1KZ?N]=T?G317Z+?\.I?VV_\
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M@_\ !*#]N!25;P)\(0P)!!_:[_8\!!!P00?CUD$'@@\@TO\ 6SA;_HI>'_\
MP\Y=_P#-(_[)S7_H69A_X1XG_P"5^:^\_.6BOT:_X=0?MP'IX%^$)_[N[_8\
M_P#G]4?\.G_VX?\ H1/A#_XEW^QY_P#/ZI_ZV<+?]%+P_P#^'G+O_FGS7WA_
M9.:_]"S,/_"+$_\ RL_.6BOT:_X=/_MP_P#0B?"'_P 2[_8\_P#G]4O_  Z>
M_;B_Z$/X1?\ B77['O\ \_JE_K9PK_T4O#__ (><N_\ FD/[)S7_ *%F8?\
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MC:[U)R>FB'_/3TJL/V,/ 1.!K.C_ /@-KW_RCKZWIR?>'X_R-?:^P7_/R?\
MX#1\O^G/E^+[GY!',9W2]A16J^WB^Z_ZBO)?U<^6-._8N\"_Z=C5-)D_XEUU
MG;!K0\L?)F1M^CIE5[A-[G/RHW.,[_AB[P'_ -!C1_\ P'UW_P"4E?:FD_\
M,2_[!-Y_[3K)K.-!>TJ?O)_8^S1[?]>O+\6=M3'35'#OV-'7VOVL3I::M_S$
M7Z+=L^0?^&+O ?\ T&-'_P# ?7?_ )24]/V+O >?^0OH_3M;Z[GMZZ+BOKNG
MIU/T_J*MX=/3VD__  &AY?\ 3GROZW,%F$U_RXH_^!XKI;_J)\K?>?(O_#%W
M@3_H+Z1_X#ZY_P#*6C_AB[P)_P!!?2/_  'US_Y2U]?T4OJL?^?E3_P&C_\
M*?+\^[#^T)_\^*'3[6*Z6_ZB?[J_$^0/^&+O G_07TC_ ,!]<_\ E+2_\,7^
M!/\ H+:.?^W?7?Z:**^OJ*F6&BDVJD]+?9H]U_TZ_KYLN&/DW_ H[?SXK^ZO
M^@GR/D-?V+_ A/&K:1T[0:[_ /*<5(/V+_ HSG5=(/U@US_Y45]=IU/T_J*E
MIRPZ2;]I/3^[1MNO^G/DC18^:5O84?\ P/%>7_43Y(^0?^&,/ ?_ $%-)_\
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M3H?K_04^J]@O^?D_NI?_ "L:Q<E_RZI:?WL1Y?\ 3_R_/NSXY_X8P\"_\_\
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M7_"E &1R.H]?7Z4VE7J/J/YTI?"]7T[=UY!\E^/^?]7?E:>BBBL0^2_'_/\
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M/$GB_P 165SXC\*:QX0T4VU_XDU>6?QK/JMK9R11^3I]L?LE_P#!9[0/!/\
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MX@^)5MX'EM/%<>I:A9:=\.?!S+;7L7Y]? ;_ (+T_M;?%S4O^"?7P[U+X8?
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MBPRR;$9?C<+3Q.*K1CB<7C*N)A6Q=&E4H;7QG_;0_P""JWQZ_:C_ &B?@/\
M\$K?A+^PT?A_^QI>>%/ ?QN^+/[;OB/XU/#\1_C/XP\#Z%\16^&OP9\/?!*Z
ML+W1)? 'AG6])@\4ZYX\DFT;6-7\1V,&G7^EQZ+?_P!H?KY\)?B9X\UC]G[P
MC\5_VA_A9/\ LZ_$(?#\>*_B[\*=0\8^%/B&OPQUK2]/GN_%6DQ>-_ NHZMX
M8\5Z58&SNKS2M;TJZ#7^D26DU[8:7J37>EV?X_\ QP_8B_X*I_!/]I[]I'XS
M_P#!+3XV_L6:%\._VU[CPSXN^.GP_P#VQ/"GQ;N=1^$/QE\+^!=$^&<WQ=^
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MOB%K_A_0D^&_B7P/;^,_%7B+X56WBO6]6\4^)?"?PN\4Z]XU\':;I_B:+1/
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M]D#_ ()_?'/X&?M4_ #X^?$'7?A/-X>^&'_!);X*?L'^*-%\'>)O&&N:S/\
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MCX7?MJ?"+]G;_@IM\'?V,?!GP^_:L^#7QS^+/P)UK]D[Q/\ %_Q#XL^%FJ?
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MU3*OX0OV5_VJ)?A!*_PZ^(J:GXA^"/B'4VO[RSL%CN_$/PW\0W<<%K+X_P#
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MC-[?]4TIW_#?_P"QS_T7+3?_  WWQF_^=I7\P-%/_B"G#'_0TXC_ /"G*O\
MYS?U=^5C_6"O_P! >!^[&?\ S8?T_?\ #?\ ^QS_ -%RTW_PWWQF_P#G:5(O
M_!0']C@ #_A>6G?^&^^,OK_V36OY?:*3\$^&'H\TXC_\*<J_^<W]7]"EQ%B5
M_P P> T\L9Y?]1O]7?E;^H9?^"@G[&ZYS\<M.YQ_S3[XR^__ %36G?\ #P7]
MC;_HN.G_ /AOOC+_ /.VK^7>BI_X@CPO_P!#3B/_ ,*LJ_\ G,4N)<4E98/
M:?W<9_\ -I_48/\ @H1^QJ !_P +QL. /^:>_&3_ .=M6CI/[>G[(6N:II^C
M:;\;M&?4-5O;;3[)+[PE\3=$LVNKN9((1=:QK_@;2M%TV#>X\V]U34;.R@3+
MSW$: L/Y8J*A^!_#'))0S3B)2:?*YXC*Y14K:.48Y13E**:3E&,X-JZ4HWNK
MCQ/BD_\ <\#9VO98M.U];-XN23M>S<9);N+V/[7(G5T!4Y'(^G)JTGW1^/\
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M_A0?R>7L_P"$L_X2S_A*/FW?\([_ &/Q_:5><_#S_AO7_AM+_@J9_P /$?\
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MXI_^WOMO]E?\2_R*]C_;G_X>&?\ #Y/X ?\ #OK_ (8R_P"%Z_\ #L'XI_\
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M2?+3RV..]G5J*K#FAA55Q:H5X4Z*Q="G6A7AA*WLL*\73A3=6&#G4G&CZ?\
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MK]FJ'_AGKPCH6A?&"P\&>-O^$O?PL=&^+/\ PGFBZMXFU[_A&_"$%EJ?A?\
MX1+^R]5EFN]>T]X_[!*PE4BL;C,$E-O"0RZI[25*I3C4CF&683'V]^"C"I1J
MUZU#V3G*K4PU/"YER0P>9X*53;V<E2IUFX<M2=:FHJI3E44J+CS.5)3=6$)*
M<'"I.$:=2:JTJ<YU,/75,HHHK0@**** "BBB@ HHHH **** "BBB@ KQ3XP_
MZ_X;?]E5\!_^GB.O:Z\4^,/^O^&W_95? ?\ Z>(ZZ,+_ +Q3_P"W_P#TB1P9
MG_N-;UH_^GZ9_E%4445_H0?S<%%%% !1110 4444 %%%% !1110 5]H?LJ_M
M33_".<_#CXA1:KXC^"?B/53>W5AIR)>^(_ASXCO4M[1_'WP^AN9[>&2]DAM[
M.W\7>#YKNRT?X@:/96MG=W.D^(])\)^+/#/Q@JL[*B*SNS!55069F8X5549)
M8D@  $DG YK]//@G\&9O@%=6&O:[81W?[2$XAN=)TBZA6>V_9V@E59(=4U6"
M16BF^/DL;++I^FS*T?P11DO+Y&^,9@M_A)Y^85J=.%.DHSJXNK.^"I4I<E95
MH6_?QJ)2]A3H<R=:NXRC&,E2Y*TZT*%7LP5.K.JY0DH4H+]_4FN:FJ<MX2C=
M>TE4LU"FFFVG+FA&$JD/O_Q-X?O?"FOZGX<U&6":]TN6*.62W6ZB5TN+:&\M
MVFLM0MK'5M)O#;7$/V_0]=T[2O$6@WWVC1O$6D:3K=AJ&FVN'6!X>L[JTL8U
MO)I9[ELR32RNTDDDK_-(\CN2SR.Q+.[,S,Q)8DG-;]?58?VOU>A[>2G7]E3]
MM.,>2,ZO(O:2C"\N12E=J'-+E3Y;NUSGJ\GM)NFK0<I.$6VW&+;Y4VTN:T;>
M]97WLM@HHHK8S"BBB@ HHHH **** "BBB@ K]HO^"=O[:?B"75O#_P"SQ\1A
MJOB&"ZC>Q^'7B>&WNM3U#2H;&TEN3X;\1"!)KB3P_:65M+)IFO2@CPW;0&SU
M:5?#D<%WX?\ Q]\+>%M?\:Z_IWAGPSITNJZUJLK16EI$T42*D44EQ=7=W=7$
MD-II^FZ?:0SWVIZG?3V^GZ9I]O<W]_<V]G;S3)^TO[(WP 7P=+#%X9V7U]="
M$>+_ !V+::*7Q T<L<_]B>'A=10W>F>"+&YBCEMXI8K;4O%%]!#K_B"&V6#0
MO#_AG\G\6\VX<PO#\\OS:C'&9GBHRJ93AJ4XPQ6&KJ\%F#JVE+#X>D[QE>+6
M,M+#*$H>VG1^DX:PV-J8Q5Z$O986FU'$SDFX58Z/ZO&-USU)73337L4U4;NX
M0J?M#!(DRI(ARK#(/U&?ZU:K)TBV>TL[>!V+-'&JDGD\+WK6K^29;_)?DC]!
M7Q+_  +\R=>@^@_E5Y/^/,_]?/\ [2%45Z#Z#^57D_X\S_U\_P#M(5G+[/\
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MXVU+PSX$_;H\/>#?#>K>+/$^JR:WXH\1:GHGAGX&:5I][K7BC5II]1\1:K+
M=0UF]GGNK^YGN)6E/]&-%=%6I.M&4:CYE4GAZM6Z2=6MA,&\NPE>LTDZU?"Y
M=;+L-7JN=:A@(PP5*<,-"%*..'2PM2%7#_NYTO:*G):^SA5QLLRJTH*5XQHU
M<PJ5,?5H)*C4QE2IB9PE6J3G+E_&/A+3O&_@KQ5X$U>XOX=)\7^%]<\):G=V
M,T$>J1:=K^DW6CWMQ9SW5M=VR7Z6UW+);S7%G<P+<!'EMIHPT3?#WPS_ .":
M_P "_A5H_P#P3ST3P]XK^+%Y:?\ !-3P]XJ\-? J36==\'W%QXLL/%_P>U+X
M)ZG+\67L? FG1Z[=P>%=4N-0L9/!\7@.&+Q D-W<07.FJ^DR?H316/LX>PHX
M9J]##X3,\#1IMMJGA,YPV#PF:4$VW)PQV&P&#HU[MRE##T[---NHMP=>4?=>
M)E@YUVO^7DLOEC)8)R\\/+,,8Z=K6>(J7O=6^</CY^R_X!_:+\3_ +-OBSQM
MJ_C#2]1_9<^/ND_M%_#^'PMJ&BV-EK'C;1_ ?C[X>6NE^,8]6\/ZY/J'A631
M?B+K=U/8Z+<^'M7;5+72IX]<BM(+NROOA;]K?_@C)^SS^U+\>KW]J/P?\=OV
MSOV(?VAO%'AJS\'?%;XM?L$_M!77[/7BGXX^&M&CTR+PKIGQ>_XICQ=I7B=_
M",.EV]MHFJ6FFZ1K4]DEEI^O:EK>G^'_  M:Z%^O%%;^UFY2DY<SG@J.734D
MIPG@L-CL5F>&P\H23A*&'S'&XG'4'*+G1Q=18BG*-6G2E#-4X1MRQY7'%5\;
M&46XR6)Q6#PF7XFJIQ:DGB,#@<)A:\4^2K0H0ISC*/,G\:?L1_L'_ #]@+X7
MZO\ #;X&V'BS5=2\:^*=0^(?Q@^+_P 4O%-[\0?C=\>/BEK:)_PD7Q0^,/Q"
MU*."[\4>,?$%PLE]?/:6>D:!:7=W?/HF@Z3%>7,4GV%>VD=_9W=C,SK%>6T]
MI*T942+'<1/"[1EE=0X5R4+(ZAL$JPR#9HK&C".'M[%<C]K4KN5W*<Z]:K+$
M5L15J3<IU:]?$3J5Z]>K*=6O7J5*U6<ZDYR=8E+&4ZE+$I5:52@L+*DTHTUA
M8T5AH8:$(<L:>'I8>,</1HTU"G1HPA2I1A3A&*^:?V//V6/A]^Q+^S1\(_V5
MOA5K'C+Q!\/?@QX=N/#/A?6?B#J&B:KXSO["YUK5-=>;7]0\.>'O"FB75V+O
M5KF-)-.\.Z5"+9($-NTJR32]K\*?@'\)_@A>_%[4OA9X6;PI?_'?XL^(/CG\
M5+I=<\1ZVWB?XJ^*-#\-^'-<\5K%XEU?6;;1&O-&\(^';0:'X>ATKPU;'3OM
M%KHT-S=WTUU[#1348JG3HV3I4:U+$4J4ES4Z>(HT,3A:->,)7BJU+#8S%X>%
M5+VD:&*Q-)25.O5C/2K4J5J]?$U)REB,5"M3Q%=-QJU:>)Q%#%5Z<ZD>63IU
M<5A<-B)T[\DJ^&P]5Q]I0I2C^9GQ0_X)8_!7XH_\$]M5_P"";D_Q9_:%\$_!
MGQ,=0/C3Q]\/?%7P]\/?&GQL/$/Q*U'XL^.$\2>))_A=J?@Z:+XB^,=7U2X\
M=PZ;X TR'7M-U'4-)=(+'4+Z*X\I_9&_X(\:;^R%\7_A[\5M&_X*5?\ !6WX
MYZ/\.--U;2-)^!?[27[8]O\ $W]GS5M-U'PEJ?A"QLO$/PRM/ACX9M;^U\+6
MNHQ:MX3MK;4;&WT37M'T2_AB>/3UMI/V)HHQ"6*H1P^(_>48?6N6#]VTL=4A
M5QE3FCRS=;%U*5*6)K.3JUO8T%4G*-"DH31?U>K7K4;4ZF)<77E%*U3DH3PT
M$XM.*C3HU*D*48Q4:2J5)4U&52<I>/W'P$^$UU\>]*_:>G\*>9\<M%^$FM?
MO3/'']N^)5^S?"OQ%XOT3Q[K'A;_ (1I-87PA-]L\6>'-&U7^V[C0)?$=O\
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M5_\ 0QU>ON1OTUUP_G^%_3\6O^&6/VG?^C<OCQ_X:'X@_P#S/4?\,L?M._\
M1N7QX_\ #0_$'_YGJ_:ZU_8.M1<VY-SI^!/%G;J^CLV/,7.U5O2S'T5023P
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MR^/'_AH?B#_\SU?MI_PP=9_\_&G_ /@VTC_Y,%2K^P?9@ ?:-/(]1JND^O\
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M9_Z^?_:0J(6DN!\]MT'_ "^V?_Q^KB6T@M2NZ#/VC/\ Q]6I7'E@?>$VW/\
MLYW8YQCFLY3A[OO1^)?:7^9TTJ=17O3G\,OLRZ\MNG4ITY/O#\?Y&IOLTG]Z
MW_\  NT_^/4Y;:3</FM^_P#R]VOH?^FU9RE'F?O1Z=5V7GYHTC3J>][D_A?V
M9>7D(O4?4?SJ>@6\F1\T'4?\O5MZ_P#76IO(?^]#_P"!%O\ _':B4H\K]Z/3
MJNZ.B$)W^"6W\K\O(8G4_3^HJ6E2!P3\T/3_ )^(#W'I)4GDOZQ?]_X/_CE8
MW7=?>C7DG_++_P !?^1%4Z]!]!_*F^2_K%_W_@_^.5,(FP.8^@_Y;1?_ !=%
MUW7WHW4967NRV71^7EYK[QR=#]?Z"GT)&P!Y3K_SUC/IZ/3_ "V]4_[^1_\
MQ58R:YGJNG7R7^:+A&5_A>W9^0RI(^_X?UI/+;U3_OY'_P#%5(B$9Y3M_P M
M$/KZ-2NNZ_K_ (=?>:V?9_<Q:>G4_3^HI-I]5_[[3_XJGHI!/*]/[RGN/0T7
M7=?U_P .OO'%.ZT>ZZ/N2M_#_NC^M-I[#[O3[H[CW]Z;@^WYC_&E%JRU6R_0
MVL^S_K_AU]XE*O4?4?SHP?;\Q_C2@'(Z=1W'K]:4FN5ZKI^:"S[/^O\ AU]Y
M-1116(6?9_U_PZ^\****"X;_ "_R"BBB@U"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^G]13*>G4_3^HK$<=UZK\R6I4Z'Z_P!!452IT/U_H*#HCNO5?F7++_C\M/\
MKY@_]&I2W?\ Q^W7_7U-_P"CFI++_C\M/^OF#_T:E+=_\?MU_P!?4W_HYJY/
M^7B_P/\ ]*B=T?X"_P"OZ_\ 2!Z=#]?Z"GTQ.A^O]!3ZL85,GW1^/\S4-3)]
MT?C_ #-1/9>OZ,WCLO1?D31]_P /ZU)4<??\/ZU)61O#X5\_S9.O0?0?RI:1
M>@^@_E2UDO@EZ_Y&U/K\OU)D^Z/Q_F:L)]T?C_,U73[H_'^9JPGW1^/\S4&\
M-WZ?JB1/O#\?Y&IJA3[P_'^1J:L9_$_E^2.J.Z_P+\R=>@^@_E5Y/^/,_P#7
MS_[2%45Z#Z#^57D_X\S_ -?/_M(5G+[/^)?J=-+K_AG_ .V$5.3[P_'^1IM.
M3[P_'^1K.?Q/Y?DC2/VO\+_0G7J/J/YU/4"]1]1_.IZSG\+^7YHZ8;OT_5#T
MZGZ?U%2U$G4_3^HJ6L34*G7H/H/Y5!4Z]!]!_*@WCLO1?D3)T/U_H*?3$Z'Z
M_P!!3ZQG\3^7Y(TAN_3]4%21]_P_K4=21]_P_K4FI)3TZGZ?U%,IZ=3]/ZB@
M<=UZK\R=OX?]T?UIM.;^'_=']:;2CLO1?D;A2KU'U'\Z2E7J/J/YTI_"_E^:
M GHHHK$ HHHH+AN_3]4%%%%!J%%%% !1110 4444 %%%% !1110 4444 %9^
MKZC%H^E:GJT\<DL.EZ?>ZC-%%M\V2*QMI;F2./>53S'2(JFYE7<1N(&36A4<
ML44\4D$\<<T,T;Q30RHLD4L4BE)(Y(W!22.1"5=&!5E)5@02*J#BIP<XN4%*
M+G%/E<HIKFBGT;5TGTO<SJJI*E4C2FH573FJ<Y1YHPJ.+4)RC]I1E9N/5*Q\
MW?\ #3OA'_H >(_^^=,_^3Z/^&G?"/\ T /$?_?.F?\ R?7N?_"(>$_^A7\.
M_P#@DTW_ .1J/^$0\)_]"OX=_P#!)IO_ ,C5])]=X6_Z$N._\.,O_D#X'^R?
M$?\ Z*W)O_##'R_Z>>O];>&?\-.^$?\ H >(_P#OG3/_ )/H_P"&G?"/_0 \
M1_\ ?.F?_)]>Y_\ "(>$_P#H5_#O_@DTW_Y&H_X1#PG_ -"OX=_\$FF__(U'
MUWA;_H2X[_PXR_\ D _LGQ'_ .BMR;_PPQ\O^GGK_6WAG_#3OA'_ * 'B/\
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M  C^@_\ 0$TC_P %ME_\9H_X1_0?^@)I'_@MLO\ XS3^O\,?]"#%?^'6M_\
M(_U=^5C^Q?$/_HMLN_\ $;PO_P N_J[\K?.O_#4&@_\ 0K:O_P"!EE_A1_PU
M!H/_ $*VK_\ @99?X5]%?\(_H/\ T!-(_P#!;9?_ !FC_A']!_Z FD?^"VR_
M^,T?7^&/^A!BO_#K6_\ D?ZN_*Q_8OB'_P!%MEW_ (C>%_\ EW]7?E;YU_X:
M@T'_ *%;5_\ P,LO\*/^&H-!_P"A6U?_ ,#++_"OHK_A']!_Z FD?^"VR_\
MC-'_  C^@_\ 0$TC_P %ME_\9H^O\,?]"#%?^'6M_P#(_P!7?E8_L7Q#_P"B
MVR[_ ,1O"_\ R[^KORM\Z_\ #4&@_P#0K:O_ .!EE_A1_P -0:#_ -"MJ_\
MX&67^%?17_"/Z#_T!-(_\%ME_P#&:/\ A']!_P"@)I'_ (+;+_XS1]?X8_Z$
M&*_\.M;_ .1_J[\K']B^(?\ T6V7?^(WA?\ Y=_5WY6^=?\ AJ#0?^A6U?\
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M_0G7G_@Y@_\ E=7U#]@L?^?*T_\  :'_ .(H^P6/_/E:?^ T/_Q%']I<-?\
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M7^'_ /$5RW_Y<?+C_M2605C'X,NF?'RJ^N11J3Z,ZZ7(5'N$;Z55_P"&I_\
MJ1/_ "Y__P 'J^KTLK.-@\=I;(ZG*ND$2LI]0P0$'W!JS1_:?#:VX8E+SEG6
M-B]MO=IVMU[_ "T1_J]Q]+5^(D*?E#A'*9I^;<Z]T_):'R/_ ,-3_P#4B?\
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MQ];G^K'&W_1QL1_XC.4__+3Y(_X:3U[_ *)^?_!C>_\ RJH_X:3U[_HGY_\
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MW7F:?V)F/_11YE_X!0_^1/%_^$S^(G_0J?\ E"US_P"2J<OC3XB@\>$\\?\
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M:ZQX:S!I/_6O/%_V_1_^0\OS[N_@@\8?%_ QX6&.W_$EOO\ Y+H_X3#XO_\
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M5_\ D!JA6NOW-7=?\NY]_0^G*E3H?K_05\Q?\-K?L6_]'D_LB_\ B4'P(_\
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M1DME,8_7W_@Z0_8)_9S\,_L0?'7]O35? MOXC_:X\=>+?V1OAMJ'Q.\07/\
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M%Y\9/$WA32[GQ;H>A2^'[3P?+H1#W_CG3]0CNM/M_N?P/_R)?A#_ +%?P_\
M^FFTK^/7_@G7//X\^#W_  =:_''Q/-*WQ%\8_M ?MG_#K6[*\D>34-)\(_"3
MX/?%:T\":9*;@K>):Z=9^)]4T:RAEM[>W@BT@P6<421/;P<_"T5FV X3K8OW
ML1Q#G_!.23</W5.E'.*.,SO-L1IS-N>4Y#F66X:E&*]GBLSP^+=11P3I5L,\
MJ2P%;B%8>T:>2\/<49U",_?E6J9;B,NR? 4')_#&EC<\PN95IVG[:GETL$XP
M6->(H=U!_P 'J/\ P2TN)H8$^ G[?H>:6.%"WPM_9V"AI'"*6(_:I8A06&2
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M*[."Q\0:3H%AKGAK4]:_2S]FWXW_ /#1_P $_ ?QJ_X5#\<?@-_PG=AJ%_\
M\*E_:2\ ?\*N^-O@W^S]:U/1?L?CSP'_ &MKG_"/7][_ &;_ &MI]O\ VK>?
M:=%O]-O]Z?:O*C_A,_X)Y?%7Q6G[17_!=GP9^TS\;_@'^W?^V)\;_P#@E]\0
MOBSXB_;D_9 ^*7@KQ[^SK/\ #_X;?!Q/ L?PMM-(\ _"OX6>&M-\5@ZYX/\
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MVTFZ^P>,O&G@+1_[*MY+*4ZC/_;WVN)&C-M8W;%E3^16S\!G_@DE_P %&_\
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M_:A\.K\.OAWX=^(:_M'>*OA,-(_95\?+XBC\/R#P3\-?B^/$%R/%/Q!T0>(
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M7J8'!8BU/%Q^L+-J]!K$X6C*MQOFW">"GA*L?9TL10P^(RW'0Q%6I/"2KX+
MX#&8&EC,SSIY)E_^F%X7_:<_X2?]JSXE_LK_ /#/?[3_ (>_X5K\/] \?_\
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M7EM$SSI^#/A;_@X>\,>.?#/AWQKX)_X(]?\ !>#QCX-\7:'I7B;PGXM\+?\
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M-GASX5V_AOXR:!_P3ITWX@:5J:?$'Q]K,FD^)OVL?V?_ -I'Q3^T3?Q:3?\
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MQ]^+6G>'O^"CG[>?_!13XK?\+&LK[X/:YJ_@!?@%^Q-^RI^RXG@?P[\'=?\
M 'QDTO2)/V;;#]I&_P!=37QXO\/SWR>*+GQM#!X'YLO?]JT<GQ&&_=+/,CX:
MQ>6T*VKK9AQ)FO'='!X>O[+VV)A4E@>%(2K+ X;,(T+U*LZ4,'AL9F#TQO\
MPG5\UP]>]7^R,YSS"8VM2]WV>#R/+.!YXJI057V6'FO[2XIG1PL<7B<'4Q45
M2A3E+%XG#9;3_NUB_:R^'4W[9=W^PZNB^-1\6++]FVT_:BE\0MIVA#X=MX O
M?B5<_"V+1X]6'B,^)3XQ7Q!:R7DFGMX2311HS)<+X@>]+:>ONOCGQQX/^&7@
MOQ9\1OB%XFT7P9X#\!^'-:\7^,_%WB/4+?2M \,>%_#FG7&K:[KVM:G=O';6
M&EZ3IEI<WU]=SNL4%O!)(Y 6OYZ_V(O&FN?$C_@JU^SA\0O$]_?:IXE\=?\
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MUO6E_P"GZ9_E%4445_H0?S<%%%% !1110 4444 %%%% !1110 4444 %%%%
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M8>'O"_A?P]I%LEGIFBZ%HFEP6NG:9IMC;1I#;6EI;Q0Q(H"H.2?R_P#VL?\
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M7H4,+6J5:33A4J5L-A<+AJLYQ<JE##4*,VZ=&G&/S'^R;^QO^S=^PY\%[/\
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M+/PI_8J_9F^"/COP)\2_AA\-/^$8\;?#/]F?P=^QYX(UK_A,OB!K7]B?LY^
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MW0?P7G_R)5Q(8_LI'VJ C[1G=MNMN?+ V\VP;/?[NW'?/%1*2]W27Q+[$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X/^T'HE
M[K/@RWBTZZN+&_BUJTN+*]M)I+>[M+N"UO9;:YM;B%DF@N()D26":)TDBE57
M1@R@CWBO.OB;_P @&T_["]O_ .D=_7;ER3QN&3U3JI-=TTSQ^().&39A):.-
M!M-:--3C9_)ZGY,7_P ./VDYKN:2#X[?&*&)Y&9(X_B9XV5%!/"JJZV%4 =
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M]1]1_.E/X7\OS0$]%%%8@%%%%!<-WZ?J@HHHH-0HHHH **** "BBB@ HHHH
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M/BG_ .6/\1__ )D*7_ANS]E7_HJ?_ED?$;_YD*_G43H?K_04^LI> _""3?\
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MJU_S 9Q_\_C]Z%_;-_9K;I\2,_\ <G^/1_/PM3Q^V5^S:3@?$?\ \M#QY_\
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MM3KT'T'\JB7"N7QM:MC=;[U*'E_U#FJXUS5M+ZOE^K7_ "ZQ/_S6?:H^+'@
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MF&J86IQ#=)>W?$:QZ]O_ &4C[$_:4^!-I\=OVP+BQ\0^(Y/"'@'P'\ /#7Q
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MQ&'96_Y-]_\ CN?Q#U,GW1^/\S7]N5%9/Z4%VW_J/O\ ]5-_^+YT1_9Y<O\
MS=^^M_\ D@+=O^JV\C^)!>H^H_G4]?VT44O^)H/^J'_\V7_\7SIC^SZY;?\
M&W+V5O\ D@O*W_1:'\32=3]/ZBKM?VL45#^D[=M_ZD;_ /52_P#X -H_L_\
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M'_X+-H_1NY;?\9G>RM_R3OE;_H>G\VJ?='X_S-6(NW^\/Z5_2%16;\8KMO\
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M (,;O_X]6,J=;5\M+5)?Q)>7_3KR\C2&:X71<N(TZ^SI]_\ K]YF8GWA^/\
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M,O"'P\\+:_XY\?\ BKPWX&\$^%-+N]<\4>,/&&N:7X9\+>&]$T^)I[_6-?\
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M]IS?NL=;WI)JW^R:Z']0E/3J?I_45_+Q_P 1+VA_]&.ZQ_XE/8?_ $,U*/\
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M)367_P!#12C_ (.9M&!R/V'-6_\ $IK+_P"AHK/_ (A_QE_T(JG_ (<<F_\
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M?^)2V?\ ]#52_P#$3EI?_1C6I?\ B4MI_P#0U57_ !#SC3_H15/_  XY-_\
M/+^K/RN_[0RW_H84?_!&._\ F0_JBJ9/NC\?YFOY5_\ B)RTO_HQK4O_ !*6
MT_\ H:J</^#G73 ,?\,-:C_XE):?_0UU$O#OC1JRR*>__0QR;M_V,O,U6996
MDE_:%'1+_EQCO+_J$_JWI?\ JLC[_A_6I*_E2'_!SOIJYQ^PUJ//K^U):?\
MT-=+_P 1/.G?]&,ZA_XE):__ $-E1_Q#KC7_ *$4_P#PY9-_\\C6.:Y4DD\P
MI?\ @C'?_,A_5FO0?0?RI:_E.'_!SYIX '_##-_Q_P!726O_ -#91_Q$^Z?_
M -&,7_\ XE);?_0VU"\..-N5K^PIW;_Z&63>7_4R-(9OE*O?,*6MO^8?'?\
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MQ5=6&JW6IZ1X/T_Q!KMKI]XVG+;R_@%_P18\>^'_ (+?\%N?VG?'/Q6_;8^
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M^-8_VC=<\*FVO/B=I\%MXUNO#<UO;Q:P/"[ZTVBQ>+57Q7;6<6NHEXOZL?\
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M9-1Q6495Q2E3HJ&-IUL9EN1X?/<;"<*+QV,S3/)TG/&8N."7S?\ LT_MV_\
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M?T6Z\2V.MW]E/IWBN^U?4[>TT_2-/M1X=?4].T+7-$\E_:#_ ."('BK]H?\
MX)V_"?\ 8?\ 'W[??QU^)'Q"\%_M&>!?VE_'W[4?[0.FZ[\=O%WC[Q=X8BUT
M:OX6\/>#]:^*?A^/X9?#VYEUI;?P7X2TCQ?K.G>!M*L5@G7Q5K.H:MX@OGC%
M3C5K4\#*<</4R#-\)3?M*U63ECO#?-LGQ&7XIU989\^/XQQE+&4:^(IYU.C1
MC3E#-\JRYU,LHZY;.2GA:V/4'6I<1Y-CZO[NG3C"&"\0\MS>GCL+&C"NE2P7
M"F'K86KA<//*J4ZBY(Y3F..ITLPK?$OQ$_;E\7?LP?\ !9;_ (+,>.)O!/PM
M\2^&OV6O^"5_A/X[^'+'3_@M\&/#?Q.\4>)-!\'?"+6;30?&/Q_T/P)I7QT\
M6>$;G4;D6X\->*_B-KOAW0[$6[Z%HEM-H^CQVOXN_P#!4C7?^"LWQR_X(G?
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M2O#XHET3Q/X2\:^!=4U#Q/?>#]!T=M36YB\6W4\7[JV__!$'XR_#/X%_L/\
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MF42RZ<JDO84J^6Y?B,+F$JU?*Z$\3C9X&ME>)PE7'YQC/S^_X**_\%4_CO\
MLA?''X)_\$[OBC_P5Q\"?L9>(_AG^S-X)^+OQU_;\U?_ ()[WW[0/Q*_:*^*
M'BS6?%.C:)\/O!7[-W@3P_XV^$/PR\&+X<L(_%GC+6+F?3M6AUF#P[IOA75)
MK+_A)].O>O\ @Q_P65_:O_:__8Z^ 7P@_9B^.OP:U[]K7XV?\% _%/\ P3]T
M[]N?_A27B71/A_JWPU^'WPCO?C9JO[7WA[]G?X@Z=I$.F_%'6OAG%I+S_"3Q
M5IEAX&3XDMXBMM/TG3O!\NAV]G^DOQ&_X)6?MH:W<?!KXW_"#_@JQXO^!G[>
M'A7X,:?^SY^T%^T]HG[)/PA\9?#G]J7X8^'O$_B/Q9X,F\;?LL>+?%=UX#\,
M_$7P;J>O2Q:!X]T?Q1>S6&GZAXNT^ST>UM?%/E:3V/C?_@DAXQ^)?[(GA3X1
M?$/]OG]I7QE^V'X!^.Z?M9_#[]O'7!I5YXK^'?[2T>G7.FIJ'P^^"TE^W@/P
M1^SL+"^U'0#^S!X9U33/!9\):KJVB_VV+_4KS79?%PU&K1PF48?#.E@JV&X<
MH82A4KPCBL-@,RH^'&)RGDS&C"FZ6)A_KY/"YS*K4P7$]:>'PRG3QV%PE:KD
MJN+C'ZW]<OC82SGVV*CA/]BJ8_!?Z\X7'SJ96[PGA(3X+AB\KI8:GB>&Z%*K
MB5"I@*V*H4<UC\=?L2^ _P!L'X6_\%T/&GP\_;.^/?@K]J?Q[X<_X)2:6?"/
M[1/A3X6Z1\#]9^)/@;5?VM)]5@7XA_"+PQ>:CX+\&^,?"?B.Z\1>%+=O!.H7
M.@^(/!6E>#]?O%M_%=_XFMX_3/\ @X-^%W[1OQ$\$_\ !/U_@1^U-_PSI#'_
M ,%%_P!EKPE<0?\ "D/ OQ=^T_$[QS\3O#FG_!SXM^;XQU"Q:'_A1>N66K^(
M?^$"0'P_\3?[;_LGQ3<VEGIMJ[_1'[%G_!+SXT_L[?MA>)?VX/VCOV\?&O[:
M'QT\?_LS1_L[^/M7\5_!GPI\(]&E&E_%*+QQX:U;X>>$_ ?BRZ\&?##P=HOA
MNPT[0KGX=:)X:O&USQK>>,/BAJ?B^34O%]SH5C]+_P#!1W]BSQ/^W3\ -!^%
M_P /OCWJO[,GQ4^'OQL^#O[0'PE^-FE_#_0_BHO@GXC_  9\7VWBGP]?ZC\.
M_$.L>'M*\5V+;+J--.N]=TZUCU(Z??7Z:OIEI?>']7ZZ/O8WBZ=/_9J><9+B
M<MR^KF?^W4GBZWA?E?#$*F)IO^TI_4(YYAZU)T*E*LHX"GR+"RPKA1E%3W,/
MPLJG^T5,JSS#X_,(9?\ ['+ZM'Q%S'/J\L/)?4(?6'DV)CBJ52FZ$X8N4*E)
MX?'4XJC^#NC_  8_X*6_%#_@IM_P5X\$?L=?MM> /V4-7\&:7^P;K_Q3^/6M
M?LY^!OC;XW^,'Q!TK]DO^RO#O@C1_AKXUN/^%=?#;P)XDN7\2>+_ !SXLMX=
M=\2Z)JD'@K0O!^EW6BGQ4)]&W_X* ?\ !2K]LGX:_P#!$?PU^SI\??A]^RW\
M6_\ @H!\+_VN+']HGXBO\&/!7Q;\,^%/%/[.^C^'5U/XA^%/ /C>U5[W6[34
M?#OBW_A&_"%IXHTSPC/JOC"%?$$VN:#HEG*G[D?LN_L3^*/@)\?/VN_VA_&_
MQLM/BQXS_:]T/]F6V\6Q6/PPB^'=EH7B;X ?!D?"O7?$=I%!XY\607EM\1=4
MDNO%T&A0VVDP^#(IU\.Q7WB)(5U=OE_]F'_@D+_PSA<_\$RKC_AH7_A,O^'<
M^B_M>Z1L_P"%3?\ "._\+B_X:KDO7^T;O^%EZY_PKW_A _MF/*V^./\ A*/+
MSYOAW?A<^>7*\70I3H8FC@:N$P.'Q+I8ETU5X=RZG0KX^-6IB\-FF9X'.LO3
MIXS,ZN8\TL7CJ%6IBLGGAZ%"XPBI_5Z]2%:@_P"R:E:M052A"=;!Y7GE#%TL
M)[.GA:^"R^O7KY70EA,)2P5)4\+@\3AZ6'Q=/%XN?R>UU_P6*_;!^.O[0_[/
M_P"S;_P44\"_LL>$O^">EK\)_@3XN^->N?L?_!OXO?$']MG]I+Q)\$_ OQ.^
M(7C#QWX2UZ^3P7\!_ &FR^(-#_X1JP^%FAFXME\7>(([RT\2?V3I$&C^+VO_
M  44_P""E_[9&J_\$M_A=\!?B#\*OV/_ (O_ +6O@7_@HO\ #G]IW6+GX:^'
M?C7X ^&_Q1_9 \9^!_ &L?%OX6^%_%$\FN^);G1M4TGQM<?#/P+K'Q!L?"D]
MWXUT]OB3<>.M+\*Q+J/W[^TW_P $H_VD?$W[2WQ@_:9_8#_X*4?$#_@GQXA_
M:?T/PKIO[4WA"P_9X^&'[1OA#XGZ[X!\/Q^$/!GCSP;:>/M<\,7?PA\>6OA-
M[K1]?\4>&KG4-4UUXM#U"WN-&N](F;4_2_@C_P $B_A9^S;\2/\ @G?XD^#7
MQ'\2Z?X#_8 ^&/[4_@"T\+>-M%M?%_C?XTZU^U,/"=]XJ^(GC3XD6.J^%K+2
M_%,7B;0-6\3:V+/P%J%CXBO?$4EI80^%K'3;>&6\7^XJT8Y?^\E1J<F$Q4OW
MN'PV2O#8:E1P6,PV/]J\SX@PN(='%2S/'4,=3Q$\NS26*QN-PV<T\LA.$_>_
MV?+'>Y34,;/-:"_=U<1F\LGSN-3&4:N#Y%A\CQV:U<+]1RS"U,.\OI8C+_88
M+*GE%7%5OQCE^/7_  72\8_LZ_M^Z_HG_!0#X$>"==_X)#_$7XY^#/%/Q(MO
MV1?A_KGB?_@H%>?"_P *1?&2\C^)/AW59Y_!'[-6BZ3\.]1\+^&M'C^#_AO6
M]7US7]5\1?VKJ]G%HNEZ]JG9:K!^W7^VQ_P5*\%_$#]CG]HKP-^Q)XF^,?\
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MA\--5O\ PF?#$GB+Q7X)UWPWXVTEO[?CM];\31:MJ&JQ'3--\(?3=U_P0[\
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MD^']A!Y9)>(5'&YXZGU#)W_9>(ITJDG1<LGH\7^S%\"?^"[$&K_"OXT?&?\
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MAN_3]4%%%%!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#+_H[#XP?^(?^$__ *+^C_AR+\,O^CL/C!_XA_X3_P#HOZ/^(K\ ?]#_ /\
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M_H4_X<B_#+_H[#XP?^(?^$__ *+^C_AR+\,O^CL/C!_XA_X3_P#HOZ/^(K\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCI,"6]E D,: !510H '3@ 5IT44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2/BGX*T/2K#4OAW:^$[[2)+7PI8V?B#0[BPUX_V@NJM?W?Z1?M2? +Q=H/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %& >HS110 W8G]U?^^1_A1L3^ZO_?(_PHHH -J_W5_(?X4ZBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766794128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">22,308<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">11,411<span></span>
</td>
<td class="nump">8,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan', window );">Options reserved for future issuance under the Company's 2007 Incentive Plan</a></td>
<td class="nump">10,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan', window );">Shares reserved for future issuance under the Employee Stock Purchase Plan</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved for future issuance</a></td>
<td class="nump">44,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options reserved for future issuance under the Company's 2007 Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770087136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) Table (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of the contingent purchase price liability</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">$ (490)<span></span>
</td>
<td class="num">$ (238)<span></span>
</td>
<td class="num">$ (656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MiscellaneousOtherIncomeExpense', window );">Miscellaneous other income (expense)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">$ (491)<span></span>
</td>
<td class="num">$ (238)<span></span>
</td>
<td class="num">$ (656)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MiscellaneousOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous other income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MiscellaneousOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`)F.!D?UR6KY[`$``*0?```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,W9W4[;,!0'\%>I<HL:UQ\%-E%N@-L-:7L!+SEMK,:Q99M2WGYV"A.K
M"J(;E?XW3=-CGW.2D_QN>O7SR5.<;&T_Q$75I>2_,A:;CJR.M?,TY,C2!:M3
M/@TKYG6SUBMB8C8[9XT;$@UIFDJ.ZOKJ^X9","U-;G:!DGM1:>][T^ADW,`V
M0[N7=>J62]-0ZYH'F[?4*9>FLQRO)O<ZI&_:YA1LV[,QL/OD=8FSSRD8?2#=
MQHXHV;Z.Z:FG>*C^+O)2^9:6^J%/1Q5^OG=UH'Y<$SOCGTO=;7.6F'];5#D:
M/U1A?^-[G1E;AN:'U5\[ROD_7LO>3=S8_C;H1[-78'.R,95C;;49#HWJT87U
M+^?6G_F84+FJEMJI#WEA2.;`4Y(7W^=H9#GU?]5^>5(:%^A#!<O"$[X4G0[4
M_D@AS_?PN_%ZP>GZ*',=O[\U]#$8V7@X(1)']2%`^I`@?2B0/N8@?9R#]'$!
MTL<E2!]?0/K@,Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*
MK`)%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DE
MBJP215:%(JM"D56AR*I09%4HLBH4616*K`I%5H4BJT*1=8XBZ_R/K&S\<_[Z
M-U!+`P04````"`"9C@9'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++
M;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\
M#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&10IXV+!XUE])"1#M@2[`L
MRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)
M4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^
M.R6:E((C-Z."N[_8_`)02P,$%`````@`F8X&1^N^@:7C`0``1A\``!H```!X
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MH-MRT"TEZ*X<=$<)NB\'W5."I`8RUIPDA#5':P%<"\=K`6`+1VP!9`O';`%H
M"T=M`6P+QVT!<`M';@%T"\=N`7@+1V\%>BM';P5Z*^E;&WUL<_16H+=R]%:@
MMW+T5J"W<O16H+=R]%:@MW+T5J"W<O16H+=R]#:@MW'T-J"W<?0VH+>1]DK0
M9@E';P-Z&T=O`WH;1V\#>AM';P-Z&T=O`WH;1V\#>AM';P=Z.T=O!WH[1V\'
M>CM';P=Z.VFO&VUV<_1VH+=S]':@MW/T=J"W<_1VH+=S]':@MW/T;H#>#4?O
M!NC=</1N+O1.73O%[4N>#OT^7;OFO^&PZ`+OE-^.\?HIYZFPX4+K/*\4P_EX
M]5=TGOHW)'SZ9?[X#E!+`P04````"`"9C@9'//P+D$4#```I#0``$````&1O
M8U!R;W!S+V%P<"YX;6R]5U%/XD`0_BL;7DZ3TR*HEQ!L4H'+F2"2*Z?/RW:`
MC=M=W-D2O5]_TQ:P:"G4A_/%W>E\LS/??#LM78W-SMB:)5@G`=EKK#1VR'C3
M6#BW['@>B@7$',_)1=/3F;$Q=[2U<\_,9E)`WX@D!NV\5K-Y[<&K`QU!=+;<
M!FWXW?248+E44G`GC?;OI;`&S<RQP:L`U?4^.F0(BAR"2*QT;WXS]RF:,I]0
M<`4].LN?<860>[T;,Y^>B9=<OWGY;BCU,_Y93DR?.RBB=A_DT1?<0D2'[D3?
M&C.?7V]4ITJQO077<XB*OI\?;KAX!(MII1>M\R;];2G8V//8P".IYV,N+?K=
ME>NL0#ACUVU:N:]V*3(B;3H^3B@_;+`I1TB7-XT5MY)KUV`H_]*VU<B/S:W9
M6BW16?_)V&=<`#CL>EMCMBSZ%M?RTK^ZR#QHM>OI;2OSU[3MU)U:)M(IP(?9
MF%OWGZC(:MH0<771*%2_"<&XCMA`.Y(CN]/Y4=2\(B7;5>]AU!^,PD&?T2I\
M&-[U@PEM;H-A,.H-V!<P[3J8<$+_[@>C+V"NOH"Y+L7<)B@U(&:\W7*4R,R,
MC2T@D<E=-8:N\53JC&`L]?Q)<F&/7"7`[H%C8B'M4;EO((1-@)KW2C)!R#-Z
M<`NPK)=86XH9&CT_<V!CUH=I>;)#F'-%!1D!D"H8OZ=IQ])EF90W.71&/"^,
MBNCF?V.#EX345.KXQ*WE^PK*HJ2<4E'IP*.J]FLQ+_1."Q,#.UES<,I.1L8!
MGI9"1N#8T%`;QH3,1F`Y`73!*!8+YA8JZ`_E7$NZC%0.\8V.\K!Y#WI&B_+0
M83)%>$G2:S=8[8U<*;'6Q?$28R<3/E7[Z-BCM0VHON9:ET>+HSJSC4JJO?;)
M98VJI9JJ<S[+YD!>5<)H-^NWO%VKY7UP7*JZ/:?4G"R_:7LQOT&0TNOKI%T^
MC7=GTX%"*J=4^T<-(091)%/J>`U,>A0)+2R?H._R#>E%'B4*TF:NK2PX@"G0
M_8XZ@,F_S)!)S=[A!S#;54]Q1!(LM:N"@]*+%BAER@50@4%,XKJ8M$<U,=F3
M.D,@N],DNZ.'P$8%M#OR15)0F]KS)JT:'E<[@^#3)^>'#TQO]X>1_P]02P,$
M%`````@`F8X&1]7RPWH_`0``:0,``!$```!D;V-0<F]P<R]C;W)E+GAM;,V3
M34_#,`R&_PKJO4N[L8&JK@=`G)B$Q!"(6TB\+:SY4.*IZ[\G\TK+@,MNW.K:
M[^/7<5(*5PCKX=%;!QX5A(N]KDTHA)LG&T17,!;$!C0/HUAA8G)EO>880[]F
MCHLM7P,;9]F,:4`N.7)V`*:N)R95*44A/'"TOL-+T>/=SM<$DX)!#1H,!I:/
M<I94SV9K;&-*-NBK,CJN><"%E6JE0-ZT0]GO5.R,X'4XRD'V[>GOGQXHPY*N
M<A]47]4TS:B94%T<.&>OBX<G.IM4F8#<"(BJH`IL'<R3K\XOD]N[Y7U2C;-\
MFF;7:39;YE?%=%Q<SMX.DYWX&PSK;HA_Z_C+(&T7%=9PYFY)(VFY]$D@"4%X
MY5!9<Q:.,-_$!`N[]P\0>#ZH$])EVT+;6"]#1?=KB`XO)ZYL;7U[3/V(3EY5
M]0E02P,$%`````@`F8X&1YE<G",0!@``G"<``!,```!X;"]T:&5M92]T:&5M
M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'ED
MD81_OT<V$,N6#>V23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R>&#9+]O6N[<O
MWN!7,B0103`9IZ_PP`JE3%ZU6FD`PSA]R1,2P]R"BPA+>!3+UES@6QHO(];J
MM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y
M;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4
M!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`<!.!1NY["
MG?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K=]W3CHG&K=!X
M#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5`TR``6'!VULS2`Y9>
M*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@
MPI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4?VFK`:?MNYO/
MD_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1I24RS^_Y"NM.
M/&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG`LR+7E$8D19_(+;KD$3BU20TR
M$S\(G8:8:E`<`J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]5Z%82=J$^!!&
M&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&
M08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH,QK!1J\;=8=H
MTCQZ_@7YG#4*')$;'0)G&[-&(81IN_`>KR2.FJW"$2M"/F(9-AIRM1:!MG&I
MA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKM
MHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9J
MGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT
M/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_`[/UH/I[Q
M[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*$IY"&V[I4_5*
ME=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X2O2QS'!.'LL,
M.V<\DAVV=Z`=-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y"M-2D&_#^>G%
M>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&
M4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>7
M7%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^
M6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V
M#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5YYN<KGHB=OJ7=\%@\OUPR4</
MY3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#NDI`&$P'-E,E$
M\`*"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP#`4A%W+C[^^3:G>,
MU_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_
MVU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->YA,L0Z1^P7V*
MBH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;
M]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV
M#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"`"9C@9'UAJ/
M>DT"``!\"@``#0```'AL+W-T>6QE<RYX;6S-5EMKVS`4_BM"&:.%$=LI36EK
M&T8A,-C*H'GH6Y%MV1;HXLERYO373Q=?DD"6-DU+_:*C3T??^71T[..P5FN*
M'TJ,%6@9Y74$2Z6J&\^KTQ(S5$]%A;E>R85D2.FI++RZDAAEM=G$J#?S_;G'
M$.$P#GG#%DS5(!4-5Q&\&"#@]M^)#$?PZ>SKGT:HVR_`C9-ODXG_='Z[BY_9
MA7,(',>/+(+!_!)Z+R>=^OK9RVQ7=^CGKZ3_'_D.]96A]KH4Q6$N^)BI&71`
M'-;/8(6H]@^,>RJHD$#IJ]`:+,(1P\[C#E&22&+`'#%"UPZ>&<#>7N?'"!?2
MQG81=N-,_3&2+)((^MWS\G#)R&X'<SQ"Z?;Q-!"'%5(*2[[0$]#9RW6E#\<%
MQTZD]3O@74BT#F:7&QOLH.,F0F98#I$#V$-Q2'&N]`9)BM*,2E1&NE!*,&UD
M!!6"(VHH^QV=H6E33.F#>5<>\RWN-@?.Q]RQ#X%1T9LZ$9TYEH%-JK?)YK@W
M:8_C!6T^!-"[4571]7=*"LZP$^N@A>AFA^B#/?1QB'I64`I)GK6_*814`UA"
ML,)2D703^2M1M<2MZBK8:_-]"H\]\GMJ.GW61C6Z!#\Z/4<'M]!]PQ(L%_;#
M^'I)%U>'K\R^G7!'YL=6S1$23I`<T]H^K;3YYY7V/C5UBFJ_?J,RKVL,&]UG
MJ_<,*$@:0A7AO01D_A;NC6RZU1;&OJ,YLW9L.795H43_"FY%T609SE%#U6^R
M$LHN1G"T?QKYP7SP6@X4$1SM7S@C#;NV"L;_S?@?4$L#!!0````(`)F.!D<U
MEEXKAP0``,80```/````>&PO=V]R:V)O;VLN>&ULE9==;QHY%(;_BC4WFTK=
MPGQ`VJA4(D!W(Q$2E2B]-C,&K'C&U/8DV?[Z/1Z@O`2#PA7S@9^QCY]S;'^U
M5R_:/,VT?F*OI:KLE>E%2^=65ZV6S9>BY/:37HF*WLVU*;FC6[-HZ?E<YF*H
M\[H4E6LE[7:W983B3NK*+N7*1AN:?0_-KHS@A5T*X4JUAI5<5M&WK_9J+I5X
M%,82F/'5:L)+T8M>5<04MVY42">*7I31K7X1>P],O;JNI?(WG78G:GG8=JCW
MAN6Z$&O8PU+:GYL7$2O$G-?*/5!GM]_M17&2)4EWS?!_>Y3BQ2+0/V`\=_)9
M//!9+VI'C-=.?Y?*"3/D3OQC=+V2U8)8$9M+8]W4#[?Y9RDK6<K?OM]T9Y?Z
MY5]MY&]=.:ZFN=%*-:W\BZ81?<'^>4)]=#+?^Z/CLQ]^)GI1MTW`9VGE3"KI
M_NM%S;42?B2M-T-IPK^[8E43G.T4,UX5;%0YHK";:CUY%!K?!_KS3=%\V%Q)
MNC`W1;P.%8(&=Y/A:#(=#1E=3>_&-\/^`]U<]\?]R6#$`)0`*#D7E`(H!5#Z
M;M#T@7YN1Q,`90#*S@5U`-0!4.=<4!=`70!U#T'7M965L+:9M6MNI65ZSNZ-
ML#25W`'H$D"7)T`#7<YDM<YO:/X9FG\^;/Z=2\,>N:H%NQ7<UD9XEQ#P!0!?
M#@']/#>U(/->J6I8L1[0G5L*PP:U,:A?&_UK'Z+&NEK\3=E8LJ&880CB/7,#
MZH[%@BN*GLZ%*"B'[4<?CE*Z9C"H;HSNQ@%YIT[G3TNM"JHL?['1KYKR"=NC
MLG'`V9_<&+X?P1CMC`-Z-M_T%E`<J=\^D`>YBV+&`3/7(;^I<ET*=K&9C0_L
M8J*=L!^0A&;&`34G=#769-0]`:=+;@2V1AWC@(]C6G7HRZR_,.+`I1AMC`,Z
M3N6BDK1P401)'^MH,&:MU$!7^5Y'T,LX(.:TGEGQJ_:5<?3\IA\)JI@$5#R9
MGDF,*'0S";@93%!V04N$VI^89*^L!M0\DJM;%J+0TB1@Z<FL33)$H;S),7G?
M)$QP>&AP$C!XFSG!QBAM$I#V6`IM8(A"@Y.`P<<R*=`KU#D)Z'R82D$,JIR$
M5#Z5%6D;%U04.SU7[!3%3E'L]/UB#X7C4NT-,$6STW/,IO$YB74PW=LR!,P^
MBOHA<BHAB$*STX#9)Y,DQ5U#BFZG`;?WE[9PD%#Q-*#XR44NO404*IX&%`_G
M;+^@O3E-(D<4*IZ&*G80Y3M&R3?%53Q%S=.`YKL",*632%$KX=W</&5]W.ZA
MYEE`\QT*?-C!$(6:9P'-=ZC!DE<+TD!6;$=%%&J>!33?H?Y<#>B09"FW23,,
M>X::9P'-C]>[OE(:-<_V]L9G[#X(96U=(@HUSP*:GT!YMQ"%MF=G%?3F#:+0
M]NS]!;TIQ)2*B$+;LW<6]*WK=(<HM#T+V'ZX48(,5+AG[:#MG8#M)]>'#A;U
M#MK>B3>GS-W!DL[65-,+?^RVS6?HW)K[LSC]K+?/6<?OO/S]+9W/>Y$_1--Y
MN59J0,_NJK'FS5%S3=Z>OK_]#U!+`P04````"`"9C@9'%W)58$X"``#U!P``
M&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;(V5WXZC(!3&7\7X`(/@O[:Q
M)M-N)K,7FTSF8O>:MK2:47&!UMFW7T"+#IBI-Q7H]YW?03F<K*/L@Q>$".^S
MKAJ^]0LAV@T`_%B0&O,GVI)&_G.FK,9"3MD%\)81?-*FN@(H"!)0X[+Q\TRO
MO;$\HU=1E0UY8QZ_UC5F_W:DHMW6A_Y]X;V\%$(M@#P#QG<J:]+PDC8>(^>M
M_PPW>Q@IB5;\+DG')V-/)7^@]$--?IZV?J!R(!4Y"A4"R\>-[$E5J4B2_'<(
M.C*5<3J^1W_1VY7I'S`G>UK]*4^BD-D&OG<B9WRMQ#OM7LFPAU@%/-**ZU_O
M>.6"UG>+[]7XLW^6C7YV_3\Q&FSS!C08D#&@\%M#.!A"8^A?'>@ST_OZ@07.
M,T8[C[=8?6VXD7*F@LC(:J!?E`XJ=\;EZBT/,G!380;%KE>@B0(:!9"Q9P'H
M#M@AQXZ^`O:N(GP,",T.0FT/)_;HL3TR]DC;HXD]MEZ`JT@>`V(#B!U[:@%<
MQ>HQ(#&`Q+&O+4"OB+6BZ3]AN`ZB=`$F-9C4P4#[J,Q(%IR5E4&L7+]U6'8S
MD@6G96T0:]<?68@92?P8`8.QI@(W0F)7U8PF74"95"YT(ZQL"G2^/`H6[0:-
M'.1R[`,V:))IE0<+*&,5P]"A(&A39C1H`64L=NC6,@JMZVC0?*F6!*X2%"+[
M,(/)+5L3=M'=AWM'>FU$?\F:5=/AGG4?`*,\SUI\(;\PNY0-]PY4R+M>W\AG
M2@61&05/,I="]F`SJ<A9J&$JQZSO2OU$T/;>9$VGS_\#4$L#!!0````(`)F.
M!D<?*6VB$@0``/D3```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC9A=
M<YLX%(;_"N/[+=*1!"+C>&;M3F?WHC.=7G2O22S'3/GP`HG;?U^^@N@YHN@F
M!O(>Z1&(!\'^7M7?FZLQ;?"CR,OF<7=MV]M#&#;/5U.DS8?J9LKN/Y>J+M*V
MVZU?PN96F_0\%!5Y"(Q%89%FY>ZP'XY]J0_[ZK7-L])\J8/FM2C2^N?1Y-7]
M<<=W[P>^9B_7MC\0'O;A7'?."E,V654&M;D\[O[F#R<A^\B0^):9>[/8#GKX
MIZKZWN_\>W[<L9[!Y.:Y[9M(NY\W<S)YWK?4]?S_U*CMLR]<;K^W_FD8;H?_
ME#;F5.7_9>?VVM&R77`VE_0U;[]6]W_,-`;5-_A<Y<WP-WA^;=JJ>"_9!47Z
M8_S-RN'W/OY'LZG,70!3`<P%7/ZQ0$P%`A6$(]DPKH]IFQ[V=74/FEO:7VW^
MT,7KOI&NY7YC.%%#H]W(FN[HVP'D/GSKVYDBQS$"R\COB9,CH>9(V/7OA(`9
M`H9ZL:R/MNO%7"^&>KFLC]$@QD@\1,HA(A7$"1H(38&(%-MFD3.+I"P:L8P1
MM>R%,43RY\PJAYHY%.5`HSTJT@?7',&>7"&1;)-$,TE$2`0:[3&BG<C%%!A)
M:"A2'M,LGD%B"L(12$Q/NTCP+'&$(NUQ<?1,HBD)NJ>.FG2B.`=\Y]$4)&QQ
M!Z^R)#-+0ED$8DDH"^8].3(^5X<SJR)&28B+&)TIH".)A;056^=9J)%3'H5Y
M..U()!)/75=,JL5Y7N>QEN1`>2+,`Z0CS1G'.!NI=1KK7$ZE*[!TI\RRGP24
MPC0;J74::UU.M2NP=CEU:L0B?'-OI=9IK'LYE:_`\N54K#%VKR.C8P\2ZUY.
MY2NQ?+G#OHPG48QI:$XSJ;4'D'4PC\FS7OI,/.M.3N4IL3RYPXN"/-I<*8A]
M:*P].=6GQ/KDU(T<$A`8QQ%3D<_4`RM1H!*56*+@L*..$RQ11TP)[>$LL`X%
MZE")'0I4CI*1I9DC)1+N\=2%Q3J3&A2K^@C4C4)S3DX.C4$,/D8'ZU"@#I78
MH4#MJ)C"<V<KM4YC'0K4H93&84>MR;5RI"+E<6.!=2A0ATIL=*!^!$4>OHZ4
ME`EXT%B/@L.CV.A39OGVH"!B>*'DB$DAP><VMQH%NI;U>4T!JU'01,1>5\BJ
M#ZCZ%!;QE(E_<QH^(8Z,Q]415GJ"2@_?(4=!;0:)U#%^RKER*A*QQW-76.\)
MZCV%-2RHT4#RB*P"7#FNI/:X6L*Z3U#WX97845"I_24TGNBGS=@ZS^*=G;I/
M81<+:C69="_DF(?&1,R4#X^UGZ#V4^0C@J0SU;52<N1<*Z5P\9'FEKZ8SVG]
MDI5-\%2U;54,7V4N5=6:KDGVH1O=U:3G>2<WE[;?C+OM>OPR->ZTU>W]0]O\
MM>_P"U!+`P04````"`"9C@9']J4SH1X"```:!P``&````'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;(V5WY*;(!3&7\7Q`190T9@QSC3I=-J+SNSL17M-$A*=
M1;%`XO;M"VBH1=/$"_GC]YWS.S!"T7/Q+BM*5?#1L%9NPDJI;@V`/%2T(?*%
M=[357TY<-$3IH3@#V0E*CM;4,!!!F(*&U&U8%G;N590%ORA6M_15!/+2-$3\
MWE+&^TV(PMO$6WVNE)D`90&<[U@WM)4U;P-!3YOP$UKO<J.P@A\U[>6D'QCV
M/>?O9O#MN`FA0:",'I2)0'1SI3O*F`FD$_\:8_Y-:8S3_BWZ%UNMIM\327><
M_:R/JM*P,`R.]$0N3+WQ_BL=2\`FX($S:=_!X2(5;VZ6,&C(Q]#6K6W[X4N:
MC;9E0S0:(F=`R7\-\6B(/0,8R&Q=GXDB92%X'\B.F,U&:RT7)HB.;#IVH6Q0
M79G4L]<2KPIP-7%&R7:01!-)]*]BMZ#`3@)T_D6(R$%$UA]/(?+'_MCY8^M/
M)OX4>D4,DI65M%8"7R"$R*ODH>PN3>)HDCF-EV8[2/`D#8;V\7`>Z^[R8,>#
MYSS>!F[Q<ZOS4':7)G4TZ9PF]FC26=51MKP^"TH(GUVAS#%E<Z;$8\IFF5"$
M$IPAY/TNNP4E@@C"[)EU6CFFU9P)>TRKIYD6E#!/(OP44^Z8\CE3ZC'ELTRI
MW3L/Z*%LH`&38ZPC9_J=B'/=RF#/E3X1[;EUXEQ1'1*^Z&B5OJC<@-&3,MU,
M]\5P=@\#Q;O;3>2NP_(/4$L#!!0````(`)F.!D?P:I=\X@,``%41```8````
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULC9C+DILZ$(9?A?)^!MT1+H^K8NQ4
MLCA5J2Q.UHPMVU2X.(#'R=M'7`Q,MR9F8T#^NM5_2Z@E5K>B_%F=C:F]WUF:
M5R^+<UU?EKY?[<\FBZOGXF)R^\^Q*+.XMH_ER:\NI8D/K5&6^HP0Y6=QDB_6
MJ[;M6[E>%=<Z37+SK?2J:Y;%Y9^-28O;RX(N[@W?D].Y;AK\]<H?[`Y)9O(J
M*7*O-,>7Q2>ZW#'2("WQ?V)NU>3>:X)_+8J?S</7P\N"-#&8U.SKQD5L+V\F
M,FG:>+(]_^J=CGTVAM/[N_?/K5P;_FM<F:A(?R2'^FRC)0OO8([Q-:V_%[<O
MIM<@&X?[(JW:7V]_K>HBNYLLO"S^W5V3O+W>NG\TZ<W<!JPW8(/!T(_;@/<&
M?#00_S00O8&8VX/L#23HP>^TMYG;QG6\7I7%S:LN<3.?Z-+B9>/$>FYNVJ%H
MG=K<5;;U;:V"E?_6^.F138>P*:+?(UN,T('P;?_.(-@]B`U#YNQ]!Q$F5`AB
M>.AD]T\G'X;)AUSQUIY/[`/RV%X,]J*U%U-["G+=(4&+Y"W"N8;)P!#C''C:
M8DA1#C."(2&)>*Q)#IHDS@E[;*\&>X5SPD%..D1.@X03,,(,%V`>;S&C%<C:
M#C,JT(_U!(.>`.L10$^`^@A82(`@#&F"ICR&[!`3X&KGH(3F,V:^'E1IK$H"
M51IG3DB0W@A#H8+Q;C%$N0[`B.\<E!)\QOL8#JI"K$H!52&>>P*^CI@)X?J(
M$:FA(,Q0/6.0*!G7<H(%H<6<.&:#0@/EPC2E8"IO'1C3DH%.=PZ,,\K5#'63
M2D6Q.@W54=31$Z4,OCB1DY.!YE"?@V.,AQ(*='&!XC.60LI&A0POIG-FP%BA
M*$<YT@3FB.-8!8-5/W)AG$N4(1=&*4H0QNS;.D?<6#XIKI\:UL^>>3\0!&ES
M4!Q/;@<E1`B5.2C%9M0,.A91*K$R!I5)7!$XU(69)Q'"G8&+8APN1RY*R3FO
M[%C<*:[N,.8-Q27WR<X,M""Y,"K11M2!<4W@OL>!22KE#'%CI:>XU&M8ZGLF
M>+_.*`6KO9,+0X&&SL$Q14.TX+HX)B;5X&.%8]6G&JU'>DZ.Q@I+<8G5L,3V
M3#B-E3RC\7=3<(_W`88FMQN;L1ZQL=PR7&XU++?,44?M/EQS#O<(D0NEFMB=
M&MPJ;%VHT$H$$BZ(.Z?7@$I!0JC6GYP9,U.>VM-ZY>V+:UYWQZ"A=?@B\(DU
M9T[0OJ'+B#K:MW2YZ\[[H_OUZA*?S']Q>4KRRGLM:GO2;<^CQZ*HC55`GFWL
M9Q,?AH?4'.OF-FA&I#OU=P]U<;E_Q!B^I*S_`E!+`P04````"`"9C@9'5Z!!
M>`\#``!4#```&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(U777.B,!3]
M*PSO+;GY(G34F:VML_NP,YU]V'VF&I4I$!>P=O_]A@\!DRB^5,!S[CGW)AS3
MV4D5'^5>RLK[RM*\G/O[JCH\!4&YWLLL+A_50>;ZFZTJLKC2M\4N*`^%C#<-
M*4L#C!`/LCC)_<6L>?96+&;J6*5)+M\*KSQF65S\>Y:I.LU]\,\/?B6[?54_
M"!:SH.=MDDSF9:)RKY#;N?\-GE;`:TB#^)W(4SFZ]FKS[TI]U#<_-G,?U1YD
M*M=572+6'Y]R*=.TKJ25_W9%!\V:.+X^5U\U[6K[[W$IERK]DVRJO7:+?&\C
MM_$QK7ZITW?9]<#J@FN5ELU?;WTL*Y6=*;Z7Q5_M9Y(WGZ?V&X$ZFIN`.P+N
M"7";0#H"Z0D8WR30CD![`N$W":PCL$$ANDG@'8$/!-H,OQU6,^J7N(H7LT*=
MO/(0UQL0GC2\J(OHRO5%LW9-43WL4C_]7`@Q"S[K.AWDN87@,22ZA"QM2(0N
M(2\."%Q"7AT0?`E9.2"DAP2Z4V>[N&\7-WPZYE.CEQ;"&DC>0(`@H)Q0F%8B
MO1*QE9@QV!82CI1(B)@Y6QL%QE1>;`AFG(2A,5\;]H"!46&LP\J!(X)&T]W3
MOGO:E"#C[ODTG_5\9D_/Z&;)K'4BNAO!!9L6XKT0MX7,_<\M(1I2X(8=;B^F
ML4KN.G=LW[!W&]INS>T26BIH6D'T"L)2`&2\RL_"DG@`A"-S(L*:B)D)DX6N
M&HYZPY'#L+&AEY&E(Q@)\;0,H"$HD4,(FU&)[/``*PEO@ZZ;&:4V.,P0TPPX
MDB,TLZ-#L6NHZW:&5`4[5@%1TXXC6)&YMY8.5"3N>$=@2%ZPHQ>0F;W@B%5S
M,L0V?(>1(02!6D:$-15JOP.8@YEVK].XZXZ&6`4[5P&9[RW8R0H<DPB(N*?_
M(5O!#E=`H3D`.SAI1#@S3=DP8.:"V1@<46']#CIP#U@G>F@D_\H%=/P2!J/#
MUB'>R9]QL4ORTGM7E3ZW-:>KK5*5U"71HQ[K7A_Q^YM4;JOZ,M3717OH;6\J
M=3B?X?M_)!;_`5!+`P04````"`"9C@9'X.M36U($```"%0``&````'AL+W=O
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M_0\SY1`.`?=UT8Y_O?VM[>KRH\C**_.?C]]+-?[>'_])@JF87`"F`C`7F.N1
M"^!4`&T!/6;Z<#;F]5O>Y=M-4]^]]IH/O:U>>GDS!.DC#P]C0XU!^\S:_NO[
M5@7)QG\?`DV:W4,#2\VL\/OH8A7P4<4.6'%XKB#CBBC]O`:<D\"Q/#XEX1!`
MSP'T&$`O`B2:-,)#$H^2:I2L(5)I3%*19*#C^',WX>PFY.FHX/,`T1P@8NDH
MI4@^#TVX,)JHB"3#-3IRZ/IX-A(+1DCG[V)6B8*8CA`N0H71YU:2V4HB6$%B
M)1%J42&QPD7K2*/#<$MG+ZG@A8ZWE%4#2"9FQC51Z-`H*K#3/Q#&6N@08D$0
M)603480HG@X9D9F@42$ZC#<%U@PP,QA0+\![,(Z9&T&E'::QLEA2*+1,3-T@
M;YDTH&:X:(TN8TY9QBD..4WGXJ1YFO&4<()F'8%V\&()IT+NA4[&21,2E%)&
M"3)4``YV+"^5!$RV"G(:K@$UXX.H4P$X$%Q9<JI8F)@N'6Z)IP3D`9L,'&=L
M\`G$`W2BA$6>$IA'";!3'&CKQ4Y@LB.(P*%EP%(/`L$,G0N3Z*F>D+F15/VH
M<)@.8!$*BG<VH$,("S[@X%-`UQ3@3-.Q9LN^(',8O&#!!P+X(*1F.-,H@P6)
M#F(7+Q9[P+&G@"Y/P)E&9X$@44&8.,P"L-P#SKU^LT/-<*(M]W^3'2Y*77;E
M%GH@0`\H]$"`F4KI9B639`YK)5C>@;!5A)2ZX=M`'49T&Y<),J5CE^42+#U!
MH"?;2@!'(ZB(^LX$V3J)P&7L6(*"0%"D!`5IVQB%;/1P67]&21RZ#"U%4:`H
M4HHBYZ,.(:8M),@P[5O2P9#%*`H810>,HL4H"AA%BE'D?*3G%4'B<H3#Q9E6
M8"A2AB(')-(#5B:(M,OJ@A:BJ(66=3AIH$4?"NA#BCX4T!=`ZE*3!1L*8&-'
M)Y1V:;'3+@TMM5"@E@MGT'(&DU_;Z*$E`PIDT!15D^CI9B(,*!@$%6T1?W&U
M5)KF-%ZYM=Z^OE7=X]IG_CI?ZWV%X6J*?-^IE^QQ.6?#;#?7_&3^RIO3I6J]
MM[KKZG*\GCK6=6=ZA\&7OLO.)C_,+X4Y=L-CW#\WCRNZQTM77S]N'.=KS^W_
M4$L#!!0````(`)F.!D?+73?^GP$``+$#```8````>&PO=V]R:W-H965T<R]S
M:&5E=#<N>&ULC5/;;MP@$/T5Q`<$W])6*Z^E;**J?:@4Y:%]9NVQC0*,"WB=
M_GT!K\DF7;5],3/C<\Z<X5(O:)[M".#(BY+:[NGHW+1CS+8C*&YO<`+M__1H
M%'<^-0.SDP'>19*2K,BR#TQQH6E3Q]JC:6J<G10:'@VQLU+<_#J`Q&5/<[H5
MGL0PNE!@3<T2KQ,*M!6HB8%^3^_RW:$*B`CX+F"Q%S$)WH^(SR'YVNUI%BR`
MA-8%!>Z7$]R#E$'(-_YYUGQM&8B7\:;^.4[KW1^YA7N4/T3G1F\VHZ2#GL_2
M/>'R!<XCW`;!%J6-7]+.UJ':*)0H_K*N0L=U6?^4&^TZH3@3BD3XE$7C:Z-H
M\X$[WM0&%V(G'LXNWWFX"2)>.01Q[BCJC5I?/35YE=?L%(3.F,.**2XQ"<&\
M^M46Q=;B4/Q!+_Y-+Y/#,M++-P[_0Z!*`E44J/XZXC5,^:X)N]A3!6:(5\>2
M%F?MUBU-U70[[XIX)J_PII[X`-^X&82VY(C.GVS<_Q[1@;>2W=Q2,OKWDQ()
MO0OA1Q^;]4JMB<-I>R#IE3:_`5!+`P04````"`"9C@9'#72'+J`!``"Q`P``
M&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(53VVZ<,!#]%<L?$+/`IM6*
M1<JFJMJ'2E$>VF<O#&#%]E#;+.G?US;@;-M5\X)GAG/.G/&EFM&\V`'`D5<E
MM3W2P;GQP)AM!E#<WN$(VO_IT"CN?&IZ9D<#O(TD)5F>9?=,<:%I7<7:DZDK
MG)P4&IX,L9-2W/PZ@<3Y2'=T*SR+?G"AP.J*)5XK%&@K4!,#W9$^[`ZG,B`B
MX+N`V5[%)'@_([Z$Y&M[I%FP`!(:%Q2X7R[P"%(&(=_XYZKYUC(0K^--_7.<
MUKL_<PN/*'^(U@W>;$9)"QV?I'O&^0NL(^R#8(/2QB]I)NM0;11*%']=5J'C
M.B]_BF*EW2;D*R%/A(]9-+XTBC8_<<?KRN!,[,C#V>T.'FZ"B%<.09P[BGJC
MUE<O]:XL*W8)0BOFM&#R:TQ",*]^LT6^M3CE_]#S]^E%<EA$>O&'P_W[`F42
M**-`^=\1;V'N_VK"KO94@>GCU;&DP4F[94M3-=W.ASR>R1N\KD;>PS=N>J$M
M.:/S)QOWOT-TX*UD=WM*!O]^4B*A<R'\X&.S7*DE<3AN#R2]TOHW4$L#!!0`
M```(`)F.!D?-AF+4H0$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#DN
M>&ULA5/;;IPP$/T5RQ\0LRRY=,4B95-%R4.E*`_MLQ<&L&)[J&V6].]K&W"V
M[:IYP3/#.6?.^%).:-YL#^#(NY+:[FGOW+!CS-8]*&ZO<`#M_[1H%'<^-1VS
M@P'>1)*2+,^R&Z:XT+0J8^W%5"6.3@H-+X;842EN?AU`XK2G&[H67D77NU!@
M5<D2KQ$*M!6HB8%V3^\WNT,1$!'P7<!DSV(2O!\1WT+RW.QI%BR`A-H%!>Z7
M$SR`E$'(-_ZY:'ZT#,3S>%5_C--Z]T=NX0'E#]&XWIO-*&F@Y:-TKS@]P3+"
M=1"L4=KX)?5H':J50HGB[_,J=%RG^<^V6&B7"?E"R!/A+HO&YT;1YE?N>%4:
MG(@=>#B[S<[#31#QRB&(<T=1;]3ZZJG:%+<E.P6A!7.8,?DY)B&85[_8(E];
M'/)_Z/GG]&URN(WT[1\.[SX7*))`$06*_XYX"?/EKR;L;$\5F"Y>'4MJ'+6;
MMS15T^V\S^.9?,"K<N`=?..F$]J2(SI_LG'_6T0'WDIV=4U)[]]/2B2T+H2W
M/C;SE9H3A\/Z0-(KK7X#4$L#!!0````(`)F.!D?Y-5C7H`$``+$#```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(U3RV[;,!#\%8(?$,JRG`2&+"!.
M432'`D$.[9F65A(1DJN2E)7^?4A*8MS6:'L1=U<SL[-\E!.:5]L#./*FI+8'
MVCLW[!FS=0^*VQL<0/L_+1K%G4]-Q^Q@@#>1I"3+L^R6*2XTK<I8>S95B:.3
M0L.S(794BIN?1Y`X'>B&KH47T?4N%%A5LL1KA`)M!6IBH#W0A\W^6`1$!'P3
M,-F+F`3O)\37D#PU!YH%"R"A=D&!^^4,CR!E$/*-?RR:'RT#\3)>U3_':;W[
M$[?PB/*[:%SOS6:4--#R4;H7G+[`,L(N"-8H;?R2>K0.U4JA1/&W>14ZKM/\
MI[A;:-<)^4+($^$^B\;G1M'F)^YX51J<B!UX.+O-WL--$/'*(8AS1U%OU/KJ
MN=KLLI*=@]"".<Z8_!*3$,RK7VV1KRV.^1_T_-_T;7*XC?3M+P[_HW^1!(HH
M4/QUQ&N8WUVRBSU58+IX=2RI<=1NWM)43;?S(8]G\@&ORH%W\)6;3FA+3NC\
MR<;];Q$=>"O9S8Z2WK^?E$AH70CO?&SF*S4G#H?U@:176KT#4$L#!!0````(
M`)F.!D<!S4MFH0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;(53RV[;,!#\%8(?$,JRG!2&+"!.$22'`D$.[9F65A(1DJN2E)7^?4E*8MS6
M:"[B[FIF=I:/<D+S9GL`1]Z5U/9`>^>&/6.V[D%Q>X,#:/^G1:.X\ZGIF!T,
M\":2E&1YEMTRQ86F51EK+Z8J<712:'@QQ(Y*<?/K"!*G`]W0M?`JNMZ%`JM*
MEGB-4*"M0$T,M`=ZO]D?BX"(@.\")GL1D^#]A/@6DN?F0+-@`234+BAPOYSA
M`:0,0K[QST7SHV4@7L:K^F.<UKL_<0L/*'^(QO7>;$9)`RT?I7O%Z0F6$79!
ML$9IXY?4HW6H5@HEBK_/J]!QG>8_^=U"NT[(%T*>"%^R:'QN%&U^Y8Y7I<&)
MV(&'L]OL/=P$$:\<@CAW%/5&K:^>J\UN6[)S$%HPQQF37V(2@GGUJRWRM<4Q
M_X>>?T[?)H?;2-_^X;#X7*!(`D44*/X[XC7,[J\F[&)/%9@N7AU+:ARUF[<T
M5=/MO,_CF7S`JW+@'7SCIA/:DA,Z?[)Q_UM$!]Y*=K.CI/?O)R426A?".Q^;
M^4K-B<-A?2#IE5:_`5!+`P04````"`"9C@9'ZYE7Y:0!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6R%4\MNVS`0_!6"'Q#*LAVGABP@3A&T
MAP)!#NV9EE82$9*KD)25_GU)2F*<U$`NXNYJ9G:6CV)$\V([`$?>E-3V0#OG
M^CUCMNI`<7N#/6C_IT&CN/.I:9GM#?`ZDI1D>9;=,L6%IF41:T^F+'!P4FAX
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M0N=/-NY_@^C`6\ENMI1T_OVD1$+C0KCSL9FNU)0X[)<'DEYI^0]02P,$%```
M``@`F8X&1Y;:.36?`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N
M>&ULC5/+;MLP$/P5@A\02K23%H8L($X0)(<`00[MF996$A&2JY"4E?Y]2>H1
MMS7:7L3=U<SL+!_%B/;-=0">?&AEW)YVWO<[QES5@1;N"GLPX4^#5@L?4MLR
MUUL0=2)IQ7B6W3`MI*%ED6HOMBQP\$H:>+'$#5H+^^,`"L<]S>E2>)5MYV.!
ME05;>;748)Q$0RPT>WJ;[P[;B$B`;Q)&=Q:3Z/V(^!:3IWI/LV@!%%0^*HBP
MG.`.E(I"H?'[K/G9,A+/XT7](4T;W!^%@SM4WV7MNV`VHZ2&1@S*O^+X"/,(
MUU&P0N72EU2#\Z@7"B5:?$RK-&D=IS\\GVF7"7PF\)7P-4O&IT;)YKWPHBPL
MCL3U(IY=O@MP&T6"<@S2W$DT&'6A>BKSFZQ@IR@T8PX3AI]C5@0+ZA=;\*7%
M@?]!Y_^F;U:'FT3?_.+P/_IO5X%M$MC^=<1+F-]=LK,]U6#;='4<J7`P?MK2
MM;K>SEN>SN037A:]:.%9V%8:1X[HP\FF_6\0/00KV=4U)5UX/VNBH/$Q_!)B
M.UVI*?'8+P]D?:7E3U!+`P04````"`"9C@9'P>/^+*$!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6R%4\MNVS`0_!6"'Q#*LIP4ABP@3A&T
MAP)!#NV9EE82$9*KD)25_GU)2F*<UF@NXNYJ9G:6CW)"\V)[`$?>E-3V0'OG
MACUCMNY!<7N#`VC_IT6CN/.IZ9@=#/`FDI1D>9;=,L6%IE49:T^F*G%T4FAX
M,L2.2G'S^P@2IP/=T+7P++K>A0*K2I9XC5"@K4!-#+0'>K_9'XN`B("?`B9[
M$9/@_83X$I+OS8%FP0)(J%U0X'XYPP-(&81\X]=%\[UE(%[&J_ICG-:[/W$+
M#RA_B<;UWFQ&20,M'Z5[QND;+"/L@F"-TL8OJ4?K4*T42A1_FU>AXSK-?XJ[
MA7:=D"^$/!&^9-'XW"C:_,H=KTJ#$[$##V>WV7NX"2)>.01Q[BCJC5I?/5>;
MVVW)SD%HP1QG3'Z)20CFU:^VR-<6Q_P?>OXY?9L<;B-]^\%A\;E`D02**%#\
M=\1KF-U?3=C%GBHP7;PZEM0X:C=O::JFVWF?QS-YAU?EP#OXP4TGM"4G=/YD
MX_ZWB`Z\E>QF1TGOWT]*)+0NA'<^-O.5FA.'P_I`TBNM_@!02P,$%`````@`
MF8X&1T-)`82A`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&UL
MA5/+;MLP$/P5@A\0RK)B!X8L($Y1M(<"00[MF996$A&2JY*4E?Y]24IBW-9H
M+N+N:F9VEH]R0O-J>P!'WI34]DA[YX8#8[;N07%[AP-H_Z=%H[CSJ>F8'0SP
M)I*49'F6[9CB0M.JC+5G4Y4X.BDT/!MB1Z6X^74"B=.1;NA:>!%=[T*!525+
MO$8HT%:@)@;:(WW<'$Y%0$3`=P&3O8I)\'Y&?`W)U^9(LV`!)-0N*'"_7.`)
MI`Q"OO'/1?.]92!>QZOZYSBM=W_F%IY0_A"-Z[W9C)(&6CY*]X+3%UA&N`^"
M-4H;OZ0>K4.U4BA1_&U>A8[K-/_9%POM-B%?"'DB/&31^-PHVOS$':]*@Q.Q
M`P]GMSEXN`DB7CD$<>XHZHU:7[U4F]VN9)<@M&!.,R:_QB0$\^HW6^1KBU/^
M#SW_F+Y-#K>1OOW#X?YC@2()%%&@^.^(MS`/?S5A5WNJP'3QZEA2XZC=O*6I
MFF[G8Q[/Y!U>E0/OX!LWG="6G-'YDXW[WR(Z\%:RNWM*>O]^4B*A=2'<^]C,
M5VI.'`[K`TFOM/H-4$L#!!0````(`)F.!D=P4F'EHP$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;(53VT[C,!#]%<L?@).TT-TJC41!B'U8
M"?&P^^PFD\3"]@3;:>#OL9T+6;82+_',Y)PS9WS)!S0OM@5PY$U);0^T=:[;
M,V;+%A2W5]B!]G]J-(H[GYJ&V<X`KR))298ER0U37&A:Y+'V9(H<>R>%AB=#
M;*\4-^]'D#@<:$KGPK-H6A<*K,C9PJN$`FT%:F*@/M#;='_<!D0$_!$PV%5,
M@O<3XDM(?E4'F@0+(*%T08'[Y0QW(&40\HU?)\W/EH&XCF?UASBM=W_B%NY0
M_A65:[W9A)(*:MY+]XS#(TPC7`?!$J6-7U+VUJ&:*90H_C:N0L=U&/]L=A/M
M,B&;"-E"^)%$XV.C:/.>.U[D!@=B.Q[.+MU[N`DB7CD$<>XHZHU:7ST7Z<W/
MG)V#T(0YCIALC5D0S*M?;)'-+8[9?_3L>_IF<;B)],VZ^R[Y7F"["&RCP/8?
M@?3+B)<P7UVRU9XJ,$V\.I:4V&LW;NE276[G;1;/Y!->Y!UOX#<WC="6G-#Y
MDXW[7R,Z\%:2JVM*6O]^ED1"[4*X\[$9K]28..SF![*\TN(#4$L#!!0````(
M`)F.!D=8NWD&H`$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;(53VVZ<,!#]%<L?$+/`-M6*1<JFJMJ'2E$>VF<O#&#%]E#;+.G?US;@;-M5
M\X)GAG/.G/&EFM&\V`'`D5<EM3W2P;GQP)AM!E#<WN$(VO_IT"CN?&IZ9D<#
MO(TD)5F>91^8XD+3NHJU)U-7.#DI-#P98B>EN/EU`HGSD>[H5G@6_>!"@=45
M2[Q6*-!6H"8&NB-]V!U.94!$P'<!L[V*2?!^1GP)R=?V2+-@`20T+BAPOUS@
M$:0,0K[QSU7SK64@7L>;^N<XK7=_YA8>4?X0K1N\V8R2%CH^2?>,\Q=81]@'
MP0:EC5_23-:AVBB4*/ZZK$+'=5[^%-E*NTW(5T*>"!\C@2V-HLU/W/&Z,C@3
M._)P=KN#AYL@XI5#$.>.HMZH]=5+O;LO*G8)0BOFM&#R:TQ",*]^LT6^M3CE
M_]#S]^E%<EA$>O&'P_)]@3()E%&@_.^(MS#[OYJPJSU58/IX=2QI<-)NV=)4
M3;?S(8]G\@:OJY'W\(V;7FA+SNC\R<;][Q`=>"O9W9Z2P;^?E$CH7`CO?6R6
M*[4D#L?M@:176O\&4$L#!!0````(`)F.!D<^SB?+H0$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;(53RV[;,!#\%8(?$,JR'0>&+"!.$22'
M`$$.[9F65A(1DJN2E)7^?4E*8MS6:"[B[FIF=I:/8D3S;CL`1SZ4U/9`.^?Z
M/6.VZD!Q>X,]:/^G0:.X\ZEIF>T-\#J2E&1YEMTRQ86F91%KKZ8L<'!2:'@U
MQ`Y*<?/K"!+'`UW1I?`FVLZ%`BL+EGBU4*"M0$T,-`=ZO]H?-P$1`=\%C/8B
M)L'["?$]),_U@6;!`DBH7%#@?CG#`T@9A'SCG[/F9\M`O(P7]<<XK7=_XA8>
M4/X0M>N\V8R2&AH^2/>&XQ/,(VR#8(72QB^I!NM0+11*%/^85J'C.DY_MNN9
M=IV0SX0\$>ZR:'QJ%&U^XXZ7A<&1V)Z'LUOM/=P$$:\<@CAW%/5&K:^>R]7N
MMF#G(#1CCA,FO\0D!//J5UOD2XMC_@\]_YJ^3@[7D;[^P^'N:X%-$MA$@<U_
M1[R&N?NK";O84P6FC5?'D@H'[:8M3=5T.^_S>":?\++H>0LOW+1"6W)"YT\V
M[G^#Z,!;R6ZVE'3^_:1$0N-"N/.QF:[4E#CLEP>27FGY&U!+`P04````"`"9
MC@9'*#9=A*,!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R%
M4\M.Y#`0_!7+'X"3S/#84282`T)P6`EQV#U[DDYB8;N#[4S8OU_;>1!@)"YQ
M=Z>JNMJ/?$#S:EL`1]Z5U'9/6^>Z'6.V;$%Q>X$=:/^G1J.X\ZEIF.T,\"J2
ME&19DEPQQ86F11YKSZ;(L7=2:'@VQ/9*<?/O`!*'/4WI7'@13>M"@14Y6WB5
M4*"M0$T,U'MZF^X.VX"(@#\"!KN*2?!^1'P-R5.UITFP`!)*%Q2X7TYP!U(&
M(=_X;=+\:!F(ZWA6?XC3>O=';N$.Y5]1N=:;32BIH.:]="\X/,(TPF40+%':
M^"5E;QVJF4*)XN_C*G1<A_'/U6:BG2=D$R%;"#=)-#XVBC;ON>-%;G`@MN/A
M[-*=AYL@XI5#$.>.HMZH]=53D5[_RMDI"$V8PXC)UI@%P;SZV1;9W.*0?:-G
M/],WB\--I&_6W6^2GP6VB\`V"FP_":1?1CR'^>J2K?94@6GBU;&DQ%Z[<4N7
MZG([;[-X)A_P(N]X`[^Y:82VY(C.GVS<_QK1@;>27%Q2TOKWLR02:A?":Q^;
M\4J-B<-N?B#+*RW^`U!+`P04````"`"9C@9'L]K=OJ$!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6R%4\MNVS`0_!6"'Q#*LMRFABP@3A&T
MAP)!#NV9EE82$9*KD)25_GU)2F*<UF@NXNYJ9G:6CW)"\VQ[`$=>E=3V0'OG
MACUCMNY!<7N#`VC_IT6CN/.IZ9@=#/`FDI1D>99]8HH+3:LRUAY-5>+HI-#P
M:(@=E>+F]Q$D3@>ZH6OA272]"P56E2SQ&J%`6X&:&&@/]&ZS/Q8!$0$_!4SV
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MQOUO$1UX*]G-CI+>OY^42&A="#_[V,Q7:DX<#NL#2:^T^@-02P,$%`````@`
MF8X&1PO)>N>T`@``P@L``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MC5;;CMHP$/V5*!^PB2?AM@J1EJVJ]J'2:A_:9P,&HDUB&AO8_GUM!VS6'@F_
M$-N<.6=,S@Q37?CP(0Z,R>2S:WNQ3`]2'I^S3&P.K*/BB1]9K[[9\:&C4FV'
M?2:.`Z-;$]2U&>3Y-.MHTZ=U9<[>AKKB)]DV/7L;$G'J.CK\6[&67Y8I26\'
M[\W^(/5!5E>9C=LV'>M%P_MD8+ME^D*>5U!JB$'\;MA%W*T3G?R:\P^]^;E=
MIKG.@;5L(S4%58\S>V5MJYF4\M\KJ=/4@??K&_MW<UV5_IH*]LK;/\U6'E2V
M>9ILV8Z>6OG.+S_8]0X33;CAK3"?R>8D).]N(6G2T<_QV?3F>1F_F<RN87@`
M7`/`!LQSD_@H9-+\1B6MJX%?$G&D^N619P4?-(EBU@MS;T.J$A7J]%R3^;3*
MSIKHBEF-&+C'6$2FV%$)N$FL(`B'Q^&%S;`PX<6]>AE!4%J"TA"47ZXX\ZZ(
M8>:/12969((0+#P1!+/('XM,K<@4(2">"(:)^+EF5F2&$!2>"(8I'XO,K<@<
M(9AX(AAF^EAD8446"('_XC%,Q(LGN:N@'*'P7ST"4HTQ0N>N4DE`4>2^3(B!
M/*)8"3@90"C`U\%`182.*VM2(!2EKX.!)A$ZKOI)6-J0!QT.`\TB=%P#(&%U
M0S[W=3#0(D+']0`2%CB0P`<8*,8'K@V0L,:!!#[`0#$^<)V`A&4.)/`!!HKQ
M@6L&)*QT(($/,%"$#\"U`T`JG?@^0$$1/@#7#@`I=?!]@()B_KQ=/P"DU,'W
M`0J*\`&X?@!(J8/O`Q04X0-P_0"04@??!RC(]T%V-V-U;-B;45(D&W[JY3AB
MV5,[KKZ`F=$<O*Z.=,]^T6'?]")9<ZDF/3./[3B73.62/ZF><5`#M=VT;"?U
M<J;6PSABCAO)C[>)V8[M]7]02P,$%`````@`F8X&1\]U8Y>E`0``L0,``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULA5/;;IPP$/T5RQ\0@Y=MTQ6+
ME$T5M0^5HCRTSUX8P(HOQ#9+^O>U#3@D72DO>&8XY\P97\I)FV?;`SCT*H6R
M1]P[-QP(L74/DMD;/8#R?UIM)',^-1VQ@P'61)(4A&;9%R(95[@J8^W15*4>
MG>`*'@VRHY3,_#V!T-,1YW@M//&N=Z%`JI(D7L,E*,NU0@;:([[+#Z<B("+@
M-X?);F(4O)^U?@[)S^:(LV`!!-0N*#"_7.`>A`A"OO'+HOG6,A"W\:K^$*?U
M[L_,PKT6?WCC>F\VPZB!EHW"/>GI!RPC[(-@K86-7U2/UFFY4C"2['5>N8KK
M-/\I\H5VG4`7`DV$VRP:GQM%F]^98U5I](3LP,+9Y0</-T'$*X<@SAU%O5'K
MJY>*TMN27(+0@CG-&+K!Y`E!O/K5%G1M<:+_T>GG]%URN(OTW;9[L?]<H$@"
M110HWHWX[<.(5S"[[$,3LME3"::+5\>B6H_*S5N:JNEVWM%X)F_PJAQ8![^8
MZ;BRZ*R=/]FX_ZW6#KR5[&:/4>_?3TH$M"Z$7WULYBLU)TX/ZP-)K[3Z!U!+
M`P04````"`"9C@9'KKS%Z:P!```6!```&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6R%5-UNFS`4?A6+!ZB)(5L5$:2FU;1=3*IZL5T[<`"K-H?:)G1O
M/]O\A&5(N8GMP_=W=.QD`^IWTP!8\JED:XY18VUWH-04#2AN'K"#UGVI4"MN
MW5'7U'0:>!E(2E(6QU^HXJ*-\BS47G6>86^E:.%5$],KQ?6?$T@<CM$NF@MO
MHFZL+]`\HPNO%`I:([`E&JIC]+0[G/8>$0"_!`QFM2<^^QGQW1]^E,<H]A%`
M0F&]`G?+!9Y!2B_DC#\FS:NE)Z[WL_JWT*U+?^8&GE'^%J5M7-@X(B54O)?V
M#8?O,+40$A8H3?@E16\LJID2$<4_QU6T81W&+X_Q1-LFL(G`;@AT-`HQ7[CE
M>:9Q(*;C?G:[@X-K+^*4_2;T'41=4..JEYPENXQ>O-"$.8T8ML)<$=2I;UJP
MV>+$_J.S^_1D29@$>K)V3Q_O"Z2+0!H$TG]:9#<M;F&2^R;[Q62_(9#>F&QA
M]C<F=#4X!;H.]].0`OO6CG-;JLL3>&)A\%=XGG6\AI]<UZ(UY(S679\PY`K1
M@HL2/[@LC7NDRT%"9?WVJ]OK\=Z.!XO=_`J7OX+\+U!+`P04````"`"9C@9'
M3FM3(*4!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R-4\MN
MVS`0_!6"'Q#*M)VDABP@3E&TAP)!#NV9EE82$9*KDI25_GU)ZA$E-=!>Q-W5
MS.PL'_F`]L6U`)Z\:F7<D;;>=P?&7-F"%NX&.S#A3XU6"Q]2VS#761!5(FG%
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MT[>+PVVB;]?=]__1?[<([)+`[MV(=Q]&O(:Y_]"$K?94@VW2U7&DQ-[X<4N7
MZG(['W@ZDS=XD7>B@>_"-M(X<D8?3C;M?XWH(5C);O:4M.']+(F"VL?P+L1V
MO%)CXK&;'\CR2HL_4$L#!!0````(`)F.!D<C2TX^H@$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;(U3W6Z;,!1^%<L/4!-"LRTB2$VG:;N8
M5/5BNW;@`%9M'V:;T+W];`,NZB)M-_CX\/WYKYS0O-@>P)%7);4]T=ZYX<B8
MK7M0W-[A`-K_:=$H[OS4=,P.!G@324JR/,L.3'&A:57&WI.I2AR=%!J>#+&C
M4MS\/H/$Z41W=&T\BZYWH<&JDB5>(Q1H*U`3`^V)/NR.YR(@(N"'@,EN:A*R
M7Q!?PN1;<Z)9B``2:A<4N!^N\`A2!B%O_&O1?+,,Q&V]JG^)J_7I+]S"(\J?
MHG&]#YM1TD#+1^F><?H*RQ+N@V"-TL8OJ4?K4*T42A1_G4>AXSC-?XK#0KM-
MR!="G@@?LQA\-HHQ/W/'J]+@1.S`P]GMCAYN@HA7#D5<=Q3U0:WO7JM\_ZED
MUR"T8,XS)M]@=@G!O/I-BWRU..=_T?-_T_<IX3[2]UOWPW_X%TF@B`+%UK_(
MWBWQ%N:]"=OLJ0+3Q:MC28VC=O.6IFZZG0]Y/),W>%4.O(/OW'1"6W)!YT\V
M[G^+Z,!'R>[N*>G]^TD3":T+Y0=?F_E*S1.'P_I`TBNM_@!02P,$%`````@`
MF8X&1_U!PCB^`0``>P0``!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
MC53-;J,P$'X5BP>HB4-(%1&DIJO5]E"IZF'W[,``5FW,VB9TWWYM`RY-D=(+
M'H^_GQDQ=C9(]:8;`(/>!6_U,6J,Z0X8ZZ(!0?6=[*"U)Y54@AJ[5376G0):
M>I+@F,1QB@5E;91G/O>B\DSVAK,67A32O1!4_3L!E\,QVD1SXI75C7$)G&<X
M\$HFH-5,MDA!=8P>-H=3ZA`>\)O!H!<Q<K6?I7QSFZ?R&,6N!.!0&*=`[7*!
M1^#<"5GCOY/FAZ4C+N-9_:?OUE9_IAH>)?_#2M/88N,(E5#1GIM7.?R"J86=
M$RPDU_Z+BEX;*69*A`1]'U?6^G483_;[B;9.(!.!!,)][`L?C7R9/ZBA>:;D
M@'1'W;_;'"Q<.1&K[`+?MQ>UA6J;O>0D(1F^.*$)<QHQ9('9!`2VZJL69+8X
MD2]T<IN^#15N/7V[=$^3VP))$$B\0/*IQ>U5BVN8;YCL@LEN16!W9;*&26^;
MI,$D71'87YFL8>ZO3/!B.@2HVE\"C0K9MV8<CI`-]^R!^.GZ@.=91VMXIJIF
MK49G:>R,^DFJI#1@2XGO;,.-?0G"AD-E7+BWL1HOQ[@QLINO>GAO\O]02P,$
M%`````@`F8X&1VDT?LR_`0``>P0``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&ULC51?;YLP$/\J%A^@)@Z0+2)(3:MI>YA4]6%[=N``JS:FM@G=MY]M
MP$494O:"S^??GSMQ=CY*]:9;`(,^!._T*6J-Z8\8Z[(%0?6#[*&S)[54@AJ[
M50W6O0):>9+@F,1QA@5E753D/O>BBEP.AK,.7A32@Q!4_3D#E^,IVD5+XI4U
MK7$)7.0X\"HFH--,=DA!?8H>=\=SYA`>\(O!J%<Q<K5?I'QSFQ_5*8I="<"A
M-$Z!VN4*3\"Y$[+&[[/FIZ4CKN-%_9OOUE9_H1J>)/_-*M/:8N,(55#3@9M7
M.7Z'N874"9:2:_]%Y:"-%`LE0H)^3"OK_#I.)X=DIFT3R$P@@?`E]H5/1K[,
M9VIHD2LY(MU3]^]V1PM73L0JN\#W[45MH=IFKP5)ON;XZH1FS'G"D!5F%Q#8
MJF]:D,7B3/ZAD_OT?:AP[^G[M7MVN"^0!('$"R1K_S2^:7$+\Q]-IL$DW1`@
M-R9;F/U]DRR89!L"R8W)%B:],<&KZ1"@&G\)-"KET)EI.$(VW+-'XJ?K$U[D
M/6W@)U4-ZS2Z2&-GU$]2+:4!6TK\8!MN[4L0-AQJX\*#C=5T.::-D?URU<-[
M4_P%4$L#!!0````(`)F.!D>>:(-2I0$``+$#```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;(53VVZ<,!#]%<L?$(-W-U0K%BF;*FH?*D5Y:)^],(`5
M7XAMEO3O:QMP:!(I+WAF..?,&5_*29MGVP,X]"J%LB?<.S<<";%U#Y+9&SV`
M\G]:;21S/C4=L8,!UD22%(1FV2V1C"M<E;'V:*I2CTYP!8\&V5%*9OZ>0>CI
MA'.\%IYXU[M0(%5)$J_A$I3E6B$#[0G?Y<?S/B`BX#>'R6YB%+Q?M'X.R<_F
MA+-@`034+B@POUSA'H0(0K[QRZ+YUC(0M_&J_A"G]>XOS,*]%G]XXWIO-L.H
M@9:-PCWIZ0<L(QR"8*V%C5]4C]9IN5(PDNQU7KF*ZS3_V14+[7,"70@T$;YE
MT?C<*-K\SARK2J,G9`<6SBX_>K@)(EXY!''N*.J-6E^]5O1P6Y)K$%HPYQE#
M-Y@\(8A7_[0%75N<Z0<Z_9J^2PYWD;[;=B^RKP7V26`?!?;_C5B\&_$C)B_>
MNR2;/95@NGAU+*KUJ-R\I:F:;N<=C6?R!J_*@77PBYF.*XLNVOF3C?O?:NW`
M6\EN#ACU_OVD1$#K0ECXV,Q7:DZ<'M8'DEYI]0]02P,$%`````@`F8X&1WDL
MVZBF`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULA5/+;MLP
M$/P5@A\0RK0<IX8L($X1M(<"00[MF996$A$^%)*RTK\O24F,DAK(1=Q=S<S.
M\E&,VKS8#L"A-RF4/>+.N?Y`B*TZD,S>Z!Z4_]-H(YGSJ6F)[0VP.I*D(#3+
M;HED7.&RB+4G4Q9Z<((K>#+(#E(R\_<$0H]'O,%+X9FWG0L%4A8D\6HN05FN
M%3+0'/']YG#*`R("?G,8[2I&P?M9ZY>0_*R/.`L60$#E@@+SRP4>0(@@Y!N_
MSIKO+0-Q'2_JCW%:[_[,+#QH\8?7KO-F,XQJ:-@@W+,>?\`\PBX(5EK8^$75
M8)V6"P4CR=ZFE:NXCM.?[7ZF72?0F4`3X2Z+QJ=&T>9WYEA9&#TBV[-P=IN#
MAYL@XI5#$.>.HMZH]=5+27=W!;D$H1ESFC!TA=DD!/'J5UO0I<6)_D>G7].W
MR>$VTK?K[OO\:X$\">11(/\PXK=/(U[!W&:?FI#5GDHP;;PZ%E5Z4&[:TE1-
MM_.>QC-YAY=%SUKXQ4S+E45G[?S)QOUOM';@K60W.XPZ_WY2(J!Q(=S[V$Q7
M:DJ<[I<'DEYI^0]02P,$%`````@`F8X&1T>OA8^A`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S`N>&ULA5/+;MLP$/P5@A\0RK23!H8L($Y1M(<"
M00[MF996$A&2JY*4E?Y]2>IAQ360B[B[FIF=Y2,?T+ZY%L"3=ZV,.]#6^V[/
MF"M;T,+=80<F_*G1:N%#:AOF.@NB2B2M&,^R!Z:%-+3(4^W%%CGV7DD#+Y:X
M7FMA_QY!X7"@&SH77F73^EA@1<X67B4U&"?1$`OU@3YM]L==1"3`+PF#6\4D
M>C\AOL7D1W6@6;0`"DH?%418SO`,2D6AT/C/I'EI&8GK>%;_EJ8-[D_"P3.J
MW[+R;3";45)!+7KE7W'X#M,(]U&P1.72EY2]\ZAG"B5:O(^K-&D=QC^/V42[
M3>`3@5\1V-@HV?PJO"ARBP-QG8AGM]D'N(TB03D&:>XD&HRZ4#T7_&&3LW,4
MFC#'$<-7F`N"!?6;+?C<XLC_H_//Z=O%X3;1M^ONC]GG`KM%8)<$=A]&Y%<C
MWL)LKYJPU9YJL$VZ.HZ4V!L_;NE276[G$T]G<H$7>2<:^"EL(XTC)_3A9-/^
MUX@>@I7L[IZ2-KR?)5%0^QA^";$=K]28>.SF![*\TN(?4$L#!!0````(`)F.
M!D=T<?<JW@(``!T,```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)U7
M77.B,!3]*PP_H!`^`CCH3-%:]F%G.GW8/J<:E2D0E\3:_?>;!`Q*LFNF?2@A
MGG/NN3=PO>9GTGW0`\;,^6KJEL[=`V/'F>?1S0$WB#Z0(V[Y)SO2-8CQVV[O
MT6.'T5:2FMH+?!]Z#:I:=Y'+O9=ND9,3JZL6OW0./34-ZOX4N";GN0O<R\9K
MM3\PL>$M<D_QME6#6UJ1UNGP;NX^@ED)H(!(Q*\*G^G5VA'FWPGY$#<_MG/7
M%QYPC3=,2"!^^<1+7-="B4?^/8B.,07Q>GU17\MTN?UW1/&2U&_5EAVX6]]U
MMGB'3C5[)><2#SG$0G!#:BK_.YL39:2Y4%RG05_]M6KE]=Q_DF0#S4P(!D*@
M""J.F1`.A'`D1/\E1`,ALB7$`R&VM00'`K2-D`R$Q#9".A#2202O/PYYF"O$
MT"+OR-FA1R0><3#C\$Z(<&6QD$^'%.7'2?GNYR*`4>Y]"J$!4_28X`H#TUO(
MDPX!MXAG'1'`6&$\;M+H-+@X+0)=X#;$TH"`\!:STC$PF^1R-]#ZOLBSA9?2
M@+&H2*C.+I3\\"9&<E\@4@*1%(AN!"8G6_281&+:_F2AS_\F1;.#E7=A_W0=
M*]>QP?6D_$L#)K$(`E40J`F$DUR*'A)?YQ(%4"^-):[4<3".K6J3*-N)(>_)
MFU@DNA_^SNN^+7&ECHLL?:?*=VKP/7GKBE3W`P/=MAVL3+4G48!L7&?*=69P
M'4X:0:;%L0@!_+%!^UJ0!$X;M*\%B2(]YY4!EZ5Z!0VP.-5Q:P,.I)E5#<'5
M-Q`P5#&RD`A&B>![G1",O12$!A?QM#`F$+2(,[9<8.BYB8W5L?^!^)O9CMT-
MZ.W-D*T)E$[B>%>#1H.[O9PZJ;,AIY;UWU5J5TVVCX$85";[!9BM@&'_"<S6
M_=PZRB_R(]KCGZC;5RUUW@GCXY$<8G:$,,R]^P^\1@<^JZN;&N^86"9\W?73
M:W_#R/$RC*M?!(N_4$L#!!0````(`)F.!D?C5@2(<P(``,0(```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;)U6S6ZC,!!^%<0#%&SS&Q&D)E'5/:Q4
M];![=A(GH`)F;2=TWWYM0PP!ND&]!-M\/S,3CX:DH>R#9X0(Z[,L*KZV,R'J
ME>/P0T9*S)]H32KYYD19B87<LK/#:T;P49/*PH&N&S@ESBL[3?39&TL3>A%%
M7I$W9O%+66+V=T,*VJQM8-\.WO-S)M2!DR:.X1WSDE0\IY7%R&EM/X/5#@0*
MHA&_<M+PP=I2P>\I_5";'\>U[:H82$$.0DE@^;B2+2D*I22=_W2BO:<B#M<W
M]1>=K@Q_CSG9TN)W?A29C-:UK2,YX4LAWFGS2KH<?"5XH`77O];AP@4M;Q3;
M*O%G^\PK_6S:-W[8T>8)L"-`0S`^\P34$5!/\/Y+\#J"-R(X;2JZ$#LL<)HP
MVEB\QNIZ@)6$,R4BE=5"5U:+RE)P>7I-81@GSE4)=9A-BX%#3.0:C"/U9TW@
MS60#9P3`O<EV!G./V,T@_,=1(),JTGQT%P5\+.`9`4\+>`,!%(VR:"&AAE0:
M$KC!J)Z[!Z`O(_%-)/XD$H`6"`1&(/A>+4(C$$XB@.&H%BW$'Z2)?#]X;!(9
MDVAJ$J'1Y8PFQ83>@LL9&Y-XQL0;F<235$`<+[A\P.T;S9WQ\<>=YDZ,(ABB
M!4:#C@;3:QJ,_IH.<^<#7+#`!_8^\'$[=)B[PH4+[AGHNQ:@F;H%X[JAR2U8
M6+>^N\&TO6$4+I#HVQ+XWVLKT#<F"&:BF)0UF+GT$R-G,`-*PLYZF'+K0"^5
M:$>`.34#^QGJ&=+#TZ3&9_(3LW-><6M/A9Q$>EZ<*!5$!N,^R:0S^4EA-@4Y
M";4,Y9JU0[;="%K?OAG,ATOZ#U!+`P04````"`"9C@9'8P2$(8@#``#7$@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R=6-MNHS`4_!7$!Q1L<ZV2
M2&U6J]V'E:H^[#[3Q$E0`6?!:;I_O]R"J<\!K+R$2^9,QL8S.69U%>5[=>)<
M6I]Y5E1K^R3E^=%QJMV)YTGU(,Z\J+\YB#)/9'U9'IWJ7/)DWQ;EF4-=-W#R
M)"WLS:J]]U)N5N(BL[3@+Z557?(\*?\]\TQ<US:Q;S=>T^-)-C><S<H9ZO9I
MSHLJ%855\L/:?B*/6Q8UD!;Q.^77:G1N->+?A'AO+G[NU[;;:.`9W\F&(JD/
M'WS+LZQAJG_Y;T^J?K,I')_?V+^WPZWEOR45WXKL3[J7IUJM:UM[?D@NF7P5
MUQ^\'X/?$.Y$5K6?UNY229'?2FPK3SZ[8UJTQVOW3>3V97@![0OH4$"\V0+6
M%S"MP.F4M>/ZELADLRK%U:K.2?.TR6,-+QN2FKDY:2>J):U'5M5W/S8TBE?.
M1T/48YX[#!UCOB*V",(?($XM`%5!!Q6TK6?C^MA=)F`#`6L)O"\$1!M&APE;
M3-%B2!3&GC84B/)9Q):U>(,6#]%"EPG\@<"_;S:"@2!`%#!M-CJ,/QIG$.E/
M?HN``I\L2PD'*2$BQ5LFB`:"")D,@[45#P0QHB#0)B,&X_3J]:--V1:B2.R%
MX;(8XBJ_N4".Y^I^<XWD(#!3/2/_D_L6&U'F)=3`?#W(7W`?`C.S'U%90+`P
MT)=_#UI8_QC*R`!$Q0&!>>"!A/7`[U`_B,`3AS!"76;@)Z+2A?C(])@L&I4O
M)+C/E$3E`L&"0;=E#UHT`H29&D'E#(D,C!F9Z8$P4STJMDA\GS&IRAH*LP8:
MD\(4T8:]G85,"U$A0XF!(WO0K)`YR+2049\!HPIXD<((`CKF(-,Z5$11+*(B
M`PH5*]2[SX-4)0'%DD#W8`^:G8XYR+00E2<4-BS`>Q3V(D#''&1:APHE&M[I
M.14C%,8(XCDD()`_0P1F]F=(58Q0K/T!UH.=#9C;.<AT@Z["B"&-CVX]AG0T
M6(L.86;SPE0D,2R28@,*%28,V[48.)"-MBU8#N@.9+`)T9_.+&1:B$H3AC0I
MN@,9[#Z`CCG(M`X52>S.O0]38<*PW0_8"RZGR2QD6HA*$X:U.+KU&.Q=D#X4
M0QGUH4PE$T,:'&#`".Q^,34("JIQ1J\@SLF1_TK*8UI4UIN04N3M.X>#$)+7
MC.Y#/;(33_;#1<8/LCD-Z_.R>^_274AQOKU&&MYE;?X#4$L#!!0````(`)F.
M!D>WH3740@(``$8'```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)U5
M39.B,!#]*Q3WG4#X$"RD:A2W=@];-36'G7/4*-0DA$VBS/[[30)&!6:T]B))
M\][KUQWL9"WC[Z+$6#H?E-1BX992-G,`Q+;$%(DGUN!:O=DS3I%46WX`HN$8
M[0R)$@`]+P845;6;9R;VPO.,'26I:OS"'7&D%/&_2TQ8NW!]]QQXK0ZEU`&0
M9\#R=A7%M:A8[7"\7[C/_GR=:H0!_*YP*Z[6CO:^8>Q=;W[N%JZG+6""MU(K
M(/4XX14F1`NIQ']ZS4M*3;Q>G]6_FVJ5^PT2>,7(6[63I3+KN<X.[]&1R%?6
M_L!]"9$6W#(BS*^S/0K)Z)GB.A1]=,^J-L^V>Y-X/6V:`'L"M`2;9YH0](3@
M0@B_)(0](7PT0]03HD$&T-5N.E<@B?*,L]81#=*?DS]7<*Y%E+)>F*,PHJIW
M0D5/>>!Y&3AIH1ZS[##P"A,GMY!B#/$M`B@#DR[@V<42CNCP-L%JC(C3@8>[
M(NLO13ZU&=AF!88?W#3K@3I#*Q`:@?!&8&!RV6%F!E,;3!(,FC&&?`O3P:D5
M$R`8#,YM/0&*H_A^29$M*1J5!%-X7R"V`O'_-75F!68331UTK.@PT56=<1P]
MD"6Q69+[1U<DHRPW+?\T2VJSI!-9PL$'DH[.+$Z2X9_A#JBS`JZF!,7\8.:S
M<+;L6,ONN[=1>P4\0SUE!O&E/U_Y$_%"71G=A+_(YUF##O@7XH>J%LZ&237;
MS`3:,R:Q\NX]J:Z4ZE*S&X+W4B]GNEW=G.\VDC7G6\M>G?D_4$L#!!0````(
M`)F.!D<AW4O290(``)0(```9````>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;(V6WY*;(!3&7\7Q`59`_+=CG&GL=-J+SNSL17M-$A*=5;%"XO;M"Y@8%]B:
MFPCXG>_\SC&"^<B&-UY1*KSWMNGXQJ^$Z)^#@.\KVA+^Q'K:R3M'-K1$R.EP
M"G@_4'+006T3(`#BH"5UYQ>Y7GL9BIR=15-W]&7P^+EMR?!W2QLV;GSHWQ9>
MZU,EU$)0Y,$<=ZA;VO&:==Y`CQO_"WPN(5(2K?A5TY$OQIZ"WS'VIB8_#AL?
M*`;:T+U0%D1>+K2D3:.<9.8_5]-[3A6X'-_<O^ER)?Z.<%JRYG=]$)6D!;YW
MH$=R;L0K&[_3:PV1,MRSANM?;W_F@K6W$-]KR?MTK3M]':<[*;B&N0/0-0#-
M`1#_-R"\!H1&0#"1Z;J^$D&*?&"CQWNBGC9\EO)!F4AG-="-TJ:R,BY7+T4(
MHCRX**.K9CMIT$*#/BI*A^)N$D@`)P6:*9".#Q?Q,(+K!N%L$&H#_*&,V"AC
MTB1:TVE-E"2948DMBK,X64?!,PIVH"0&RJ2)%EE@EAEM+U=$GZ)$,TKD0$D-
ME,B1)<$&BBU",$O74>(9)7:@&+W?QC8*2(W6E;8HC<$Z23*3)#8)!`9)8B7)
MHM``L34(8[Q.DLXDJ8,$&B2IE06'AJ9T:,`##R>;03('B/&*;S,["3+:5MJ:
M!YX,!/?-"#A`0G,W`H[&FR0.48(?@5GLC-`!@TT8:+?%?'D<FNB!'07>MT>(
M+!1LM059.Q=$&3+_M2Y9%,>9P1,LSH^>G.A/,ISJCGL[)N11I`^,(V."2DOP
M)"NKY"?"/&GH4:AA(L?#=&A.$\'ZVS?`_"%2_`-02P,$%`````@`F8X&1R(2
M+[I4`@``Q@@``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULG5;;CILP
M$/T5Q`<$;&Y)E"`UJ:KVH=)J']IG)W$"6L#4=L+V[VL;8H@UVZ!]`=N<.6>&
MX=AL.L;?1$&I]-[KJA%;OY"R70>!.!:T)F+!6MJH)V?&:R+5E%\"T7)*3B:H
MK@(<AFE0D[+Q\XU9>^'YAEUE53;TA7OB6M>$_]W1BG5;'_GWA=?R4DB]$.2;
MP,:=RIHVHF2-Q^EYZW]!ZSW*-,0@?I6T$Y.QIY,_,/:F)S].6S_4.="*'J6F
M(.IVHWM:59I)*?\92$=-'3@=W]F_F7)5^@<BZ)Y5O\N3+%2VH>^=Z)E<*_G*
MNN]TJ"'1A$=6"7/UCE<A67T/\;V:O/?WLC'WKG^2A4,8'("'`&P#4/S?@&@(
MB)R`H,_,U/652))O..L\T1+=;;16<*Y)%+,>F!=E2%5E0JW>\@@EF^"FB0;,
MKL?@!TSZB-E#F,QB`I4#F`BVB6!#$#T0+)\31)8@,@3Q`\'*J03`X/"Y2&Q%
M8H``.2(0!C\72:Q(`A!$C@B$B9^+I%8D!0C<QD.8]+E(9D4R@"!S1"#,C,8O
MK<@2('`;#V"B&8U?69$50.`T?M]C$H-I#`8M<;J:].Y#(12.C@P!*>Q:L@>M
M)EIX$6>N*2%4../EHLD&@8!TW*\1!,WX'-'H?X0!BF0&Q;@#H.AS>P@:_8T`
M\[I]W@T@I]%H.<,::'0Y`BP<S:$8/8S23Q8\.A0!]HM<BPZ@;%JPZYY@<N*T
MY$)_$GXI&^$=F%2'ESEBSHQ)JOC"A2J]4#\5=E+1L]3#3(UY?\SV$\G:^U^#
M_77)_P%02P,$%`````@`F8X&1\.'>;LW`@``2@<``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&ULG57=CJ,@%'X5XP.,`FIM8TVFW4QF+S:9S,7N-6UI
M-0/B`JVS;[^`%ATUJ9D;!?Q^SCG((6NX^)`%(<K[9+226[]0JMX$@3P6A&'Y
MQ&M2Z2]G+AA6>BHN@:P%P2=+8C2`89@$#)>5GV=V[4WD&;\J6E;D37CRRA@6
M_W:$\F;K`_^^\%Y>"F46@CP+'.]4,E+)DE>>(.>M_PPV>X`,Q")^EZ21@[%G
M@C]P_F$F/T];/S0Q$$J.RDA@_;J1/:'4*&GGOYUH[VF(P_%=_<6FJ\,_8$GV
MG/XI3ZK0T8:^=R)G?*7JG3>OI,LA-H)'3J5]>L>K5)S=*;['\&?[+BO[;MHO
M:=C1Y@FP(T!'<#[S!-014$^(;*9M9#:O'UCA/!.\\62-S6Z#C88+(Z*5S<`6
MRHKJS*1>O>4(I5EP,T(=9M=BX``#'"+0ZK,6\&ZQ@Q,Z_&JPGR*2]6,'Y))`
MEH^^)+%`('("D16(A@)1.*K"'&9!'6)G$L\(C"JQ:S$KBZDL9A3&?HJ`",2/
MXTA<',DDCO5XQY.)2;2*0/+89>5<5E.7\#$_=?ST>WNZ=@+KF7*C49XM)A[D
MB2"(TR1=4%`0]H<H?%S2#C.L*5I@,CBI8&JRX/\#L%>`WZLIZ$\:0`LR1;-_
MSSC;8-"B&!$7V[JE=^372K7MPZVZZ^$9FA8W6M^9:\.VOEXFSVI\(;^PN)25
M]`Y<Z09JV]R9<T5TE.&3WO5"7VQN0LE9F>%*CT7;ZMN)XO7]YG+79_X?4$L#
M!!0````(`)F.!D>,N/Y>Q@,```03```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;)U8VW*;,!#]%88/"&B%N&0<SS1VG#@SG<GTH7TFL1PS`>0"B=._
M+Q<9@:0TV^0A7'S.WK1[$"Q.HGJI#YPWSGN1E_65>VB:XZ7GU4\'7J3UA3CR
MLOUE+ZHB;=K+ZMFKCQ5/=SVIR#WP_=`KTJQTEXO^WD.U7(C7)L]*_E`Y]6M1
MI-6?:YZ+TY5+W/.-']GSH>EN>,N%-_)V6<'+.A.E4_']E?N-7-[3'M(C?F;\
M5$_.G2[X1R%>NHOM[LKUNQAXSI^:SD3:'M[XBN=Y9ZGU_%L:53X[XO3\;'W3
MI]N&_YC6?"7R7]FN.;31^JZSX_OT-6]^B-,=ESFPSN"3R.O^O_/T6C>B.%-<
MITC?AV-6]L?3\$OL2YJ=`)(`(X$$_R102:!80B`)`9;`)(%A":$DA%A")`D1
MEA!+0HPE))*08`G=F@\KYVL4;UCROF'6:9,N%Y4X.?4Q[<:(7';XJK/3&N].
M^A;L[;8]4[=WWY8T"!;>6V=)8JX'#,PP;(Y963`DFF/6-COA''.#\+4Q,3!'
MW'Z*N#,183*';"U&M$CN;5FKC+RV]/;ZPUA_Z"W06;X1P@(=+=#>0C#-A&@%
M&R"LAY0]A/G]GU8V)&[[.>[CP(,Q\,`,7'.T&2#QQ)%_T;K1\KO%P;:?PCZ.
MFHU1,S-JJLT",\I#0T9CO=<W)@XB^\*@D5L+TO?1BQ..:89FFMH(;4+<XN!@
MVT]A'T<=C5%'1M0TB+75&3#1='5B:]%-("$F[,Z$)017[7B,.[;$K<G1VH)A
M&"_)Z"6Q6-"6835@DFG2%PPC:<17SQ3?<)1HSX*5Q,P:-:`L3J(`XVSR`".6
MK$#W)A]S_JR]&,:3DFH"%D_Z[$O0M(!PX6L]>&]%H72?*.$GIO)3JJ\G,;6:
MQ!`F0#'.E%@34ZTI,S8*`4[Y5A;@?T2EQ)B8:DP9TZ-BQH2RP#+P-Q9@X,=8
M[21*/(FIGA0W1$K*2/3%G0%1LD)LNJ+UXEJ"9EDGEO)L;,``71TE0\2F0\9>
M,3'U@6&=@=(B,+7($+VU!$TS`XP;I4)@JI`N>1N)F3_%T2E-MHPV'8HQ-I1V
M`/UB=X&2!+!(@M%=$C0;/OQ^!-2H@SGJ>H778.Y^0DH`,)L(4.,+MO%-,#;4
M^,)7QQ?4^`)B?#=@3B50='W55((YE68'FT-)T`I`U5!2RU#J>_^M%8192:K&
MDEHV!_H^=BM!LPK:6]2;O%8?TV?^/:V>L[)V'D73OJ/WK]%[(1K>6FUW%ZYS
MX.ENO,CYONE.H_:\&C[2#!>-.)Z_.8T?OI9_`5!+`P04````"`"9C@9'1@$\
MZ>@!``!Q!0``&0```'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R-5-V2FR`4
M?A7'!UC\`<UFC#--.IWVHC,[>]%>DW@2G06Q0.+V[0MHJ*M.TQLYP/=W9*#H
MA7Q3-8`.WCEKU2ZLM>ZV"*E3#9RJ)]%!:W;.0G*JS51>D.HDT,J1.$-)%&6(
MTZ8-R\*MO<BR$%?-FA9>9*"NG%/Y>P],]+LP#N\+K\VEUG8!E07RO*KAT*I&
MM(&$\R[\%&\/N44XP(\&>C6I`YO]*,2;G7RK=F%D(P"#D[8*U`PW.`!C5L@8
M_QHU_UI:XK2^JW]QW9KT1ZK@(-C/IM*U"1N%005G>F7Z5?1?86R!6,&38,I]
M@]-5:<'OE##@]'T8F]:-_;"SB4;:.B$9"8DGQ/B?A'0DI#,"&I*YOCY33<M"
MBCY0';6''6\-7%H1HVP+]Z.<J.E,F=5;F69I@6Y6:,3L!TPRP20?$8<5!/$0
M9`*LIDA\BL3QTPD_SN+'`JD72)T`_M`&GK4Q8(C#M$/()(TVLU:6J`W!T>,L
MV&?!*UG(+`M>N,0QCN-9EB5J0Y[_(POQ6<A*EFR6A2RSF#N>/;;)O$VV8I//
M;+*%39;CQR:Y-\E73&:GM\\7)AAC\CRS09/;T=$+?*?RTK0J.`IM+IJ[#F<A
M-!C%Z,F(U>;]\Q,&9VW+W-1R>!*&B1;=_8'SKVSY!U!+`P04````"`"9C@9'
M44*\ANL#```X%@``&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R=F-V.
MFTH,QU\%Y0$*\\7'*ANIV:KJN3A2U8MSKMEDDJ`"D\)DT[Y]84(P9=S&Y68#
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MNLC]A?N@7-"NLK9[^K81<;8.W_I`@\WV9L,G-G'ZJ\F+;\)&B[!+`,V"W[/8
M<L^=Q_%,`K%Y+"'&0H5S%]-"D^AQ`#D&D"Z`_"4`F^5XLU'.IG8VJ9($%36J
M*$2%SU24I\)DA^5CF7B4B1$9,9.)/1DNTL<BR2B2(")R)I+X(EQ$!)ETE$D1
M&?4X0#8&R):U!HN`HHC0'(/1M%:*RH151FB.P6A!=S`.2ISPU0U&2Y0`2R80
MI3GZJ%%"T`%Z&88OH<T8H,G4PCX![!C&G=<G/G@BF]#Y>R%`CV'L>:WBPT<I
M!\AC&'I>FZ1+RP%"64;I$LPH(XPAX)@C'*>$SX0#I)PMZQ(.]'&,OGF7<)\^
M$0G*U`7X.,;5O$L&H[_L$@[H<0R]>9=P?W02RP%`.38\O34",4HI.D`Q1RA.
M"<L(!SYYLK!+`#Z.P>=UB0]?S`C#D0-[',/*:Y)L29,(($]@$W3>),*?H*1J
M!.`IL!DZ[Q',*"7\QQ+`L$`83B4AQ&1C7;BR"D!/4)96X:/'$L(4%T">H*RM
MPM];*=4`=P*;GEZ/^-.35@W`*;#AZ?4(8I12>A$(%@C!*255@%,LW%TED"<I
MNZOTR>.$8B6`)RG+J_275THQ@)VD+*[2'YVD8@!-2=E:,2-*A\C);TZ$WY2P
M^$I`4R[<6B5P)RE;J_2Y2SA%![B3E*55+EI:)5`GL;DY_^TK_;E)^O$K`4V)
MS4VO%?VY*2FKA`)^%;:S$E)5P*9:N+,J`$]AX,V(V&)&*6%#5T">0J#***D"
M5$HNK'9R2D/8-+>843;?-,/)05VEFZ,[P&R#G;G4]G9.-SX=#TG?<W?0!^:;
M]3D_ZG_SYEC4;?!JK#65.]0[&&-UETOTKLOEI//]>%/J@^TOD^ZZN1ULWFZL
M.=_/:<?#XLU/4$L#!!0````(`)F.!D?CK=`DI0,``$(3```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;)V8W6ZC,!"%7P7Q`,$>.P2J-%*;U6KW8J6J
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M1A:-_@PVIT;)\C(D#,KLO3_FE3Z>^V\2,@S#!\`P`,8!,/]R`!L&,#,@UC/M
M*]/S^I:I;+6LY3EHCEGW:].[%J^[(&WD[D0_*!VTG5G3WGU;L126T5L7:&`>
M>P:N&/J16+L$2]G(1&T%:!EP*>,1G`!6$6N$F$]G8.-$F1[/KTM<>`3@8P"N
M`[`/<^33`>9C@+E;03JW'G7/I)JI^EG.2#*=)1ZSQ$B6V,J",8OI)(LQR0()
MD%A),":=3I*,21(G`"?$2H(Q=#I).B9)$5EX/&]*3`>1VX1!KYJ0>DAC@#YJ
M8VXWXM?0Y\6`*08\%(1`G-@MBT(>MD!-UU*D;1VE(1`GW"X&@WR>C'$`RCT4
MB4*Q70P&>70@-6Y"$3M)B$<(8Q4TOE&YQ@@HUN6.<A>.*.DL8?8SP2@/PZ#&
M,:AK!XAT,<]([&(PR*<8XRP4L197NB[$*;&+P2`/EP-C4D`\I(M!U/D?QB"?
M_WIC=X#870(>(8Q)`=PF73#6`IBUV-(=H&M1DEELN^X4]7DYQES`M017NPC$
MJ>UT*.13C#$7P-Y5;.TB$*>VTZ&0A].!L2EP7U<0[2(0M;L:A3RZ&HSA`6)X
MB8_PC$M!<J-VC;<`YBV.=E,O[4Y0G[]:&W=AKB>XVD4@#K;5H9"'U3'C+@Q[
MF;*UBT`<;*M#(0^K8\:G&/8*9&L7@\#N:A3R^9FNED"(XR6Q1PCC4NS&51`S
MWL)\UD$,70@Y/Q!&^5@=,^["?!9,",3!MCH4\K`Z9MR%^2RL$(B#;74HY&%U
MS/@4\UF`81!SNAJ#[*Z.KK8L2E'O]59.$VSDJ5+]CL5X=]PN>@"]Y6'PU?*8
M[<6OK-[G51.\2*5DJ;<W=E(JT=9"9JUF#B+;CA>%V*GN=-&>U_T63W^AY/&R
M8S5NFZW^`U!+`P04````"`"9C@9'&_04W5D#``#P$```&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6R=F$V/FS`0AO\*RKT+GC$?6261-EM5[:'2:@_M
MF4V<!"W@%)S-]M^7KS`D1LJ42P!G_+YC>QX9LSCKXKT\*&6<SRS-R^7L8,SQ
MT77+S4%E<?F@CRJO_MGI(HM-]5CLW?)8J'C;=,I2%SPO<+,XR6>K1=/V4JP6
M^F32)%<OA5.>LBPN_JY5JL_+F9A=&EZ3_<'4#>YJX?;]MDFF\C+1N5.HW7+V
M)![7$NJ0)N)7HL[EX-ZIDW_3^KU^^+%=SKPZ!Y6JC:DEXNKRH9Y5FM9*E?.?
M3I0\ZX[#^XOZMV:X5?IO<:F>=?H[V9I#E:TW<[9J%Y]2\ZK/WU4W!K\6W.BT
M;'Z=S:DT.KMTF3E9_-E>D[RYGMM_PJCK-MX!N@[0=X`V\=:H2?-K;.+5HM!G
MISS&]>*)QRJ\J$4JY?JF&7<C6B5:5JT?*XFP<#]JH2YFW<;`($;T$6ZE/FH!
M%XLU6-TEXGT!['/$1@`'`CB7]P5D+R`;`7F5@;P99!L3-C%Y.T@/YL%]&[^W
M\:T\)?KW!8)>(!C),[C)LXWQ!WGZ&#&F,^Q=PA&7\,8EM%Q0",98HMXE&G&)
M;EPBRT5$(6=IY[W-W++!D)&G\(@`;UIYB0%$@E%@79#__Q4F@)Q@6HT)HDD@
MH\JZH&&R'L.%D!-CS-U661<T=($@8!2S(.B$SRBT+NAJ[F'NSQE.1*>P\<0P
M8D@0>B*<6&O$E1@#RZHUFRS.\A%68CZMSH"X`H]19UW0507X`2-7(/I@C+[;
M4@.;/I#`\"'V`!B5U@5=^40>QX@(!9M0C#AS0OB!G+A^!!:,@66MGPT6>!`R
MC(@K&-OVK/6S]SWA<7P(/AC;^*SULW<^$,A`%`A1L!'%B%,"Q!],Y`^)/^3P
MAS9_`7!\"#_DX(<V?IP90:(/.?2A35_(J1(<O&R.P<=8?R3X<")\2/`A!SX<
MV=4XNR<2>\AA#VWV@&-#Z"$'/;31$Q'C]0B)/!PCCR-!Y.%$\B21)SGD29L\
MQKN$).XDASMI<_>%P9TD[B2'NRYH>'JZG75W<"+-5+%O#MZEL]&GW+0'TKZU
M/]P_-6=[E\)7BV.\5S_C8I_DI?.F374N;DZO.ZV-JC+Q'JJA'E2\[1]2M3/U
M;5C=%^V!O'TP^GCYOM!_Y%C]`U!+`P04````"`"9C@9'RUG`80L"``!_!@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5=N2FR`8?A7'!P@@'F+&
M.-.DTVDO.K.S%^TU23`ZBV*!Q.W;%]"PKF&:W,C![_0#8C%P\29K2E7PWK).
M;L-:J7X#@#S6M"5RQ7O:Z3<5%RU1>BC.0/:"DI,EM0Q$$*:@)4T7EH6=>Q%E
MP2^*-1U]$8&\M"T1?W>4\6$;HO`V\=J<:V4F0%D`QSLU+>UDP[M`T&H;?D&;
M/8(&8A&_&CK(63\PX0^<OYG!C],VA"8#9?2HC`31S97N*6-&23O_F40_/`UQ
MWK^I?[/EZO@'(NF>L]_-2=4Z+0R#$ZW(A:E7/GRG4PV)$3QR)NTS.%ZDXNV-
M$@8M>1_;IK/M,+Y)XXGF)T03(7($]'\"G@AX00!C,EO75Z)(60@^!+(G9K?1
M1L.%$='*IF,7RHKJRJ2>O98QS@MP-4(39C=BHAD&H_0S9N_#9`X#=`9OD,@%
MB:P`G@OD\6,![`2P%8CGE<1P4<F(22RFLQBTCM`Z?>P3.Y_XS@<G>.$S8O*9
M3[2*L\62^4!P_3A*XJ(DGI+1(LH]!N,GUC5U)JG')%J8^##XL4GF3#*/0+PP
MN<=@#!^;K)W)VF.2+$Q\F">.1^Y,<H_`8N=W/LP3&X_@QV<+/1)WWRV\.V%H
ME2_W!<RNBIZ<Z4\BSDTG@P-7^M:Q=T/%N:):$:[T::KUW\`-&*V4Z6:Z+\;[
M<1PHWM^N>_?/*?\!4$L#!!0````(`)F.!D?X;@]?7`(``!T(```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;)U678^C(!3]*\8?,`I^MK$FTX_)[,,F
MDWG8?:8MK6947*!U]M\OH*46V6DS+P6NYQSN/96+64?H!RLPYLYG735LX1:<
MMW//8[L"UX@]D18WXLF!T!IQL:1'C[44H[TBU94'?3_V:E0V;IZIV!O-,W+B
M5=G@-^JP4UTC^G>)*](M7.!>`N_EL>`RX.69IWG[LL8-*TGC4'Q8N,]@O@&^
MA"C$KQ)W;#1W9/);0C[DXL=^X?HR!USA'9<22`QGO,)5)97$SG\&T>N>DCB>
M7]1?5+DB_2UB>$6JW^6>%R);WW7V^(!.%7\GW2L>:HBDX(Y43/TZNQ/CI+Y0
M7*=&G_U8-FKL^B>I/]#L!#@0H";H?>R$8"`$5T+X)2$<".&C.T0#(3)V\/K:
ME7-KQ%&>4=(YK$7R?0)S`:=21"C+B?HKE*CPCHGH.0\C/_/.4FC`+'L,'&'B
M]!:RGD*`1G@B`6L6\)+%$D[H\':#U101SXP<[HILOA3Y;YJ!-BM0_.#&K`?J
M#+5`J`3"&P$CR66/212FZ9,,`\.-*09,A-86$$Q,2Z:@``3Q_9HB75-DJ2FX
M+Q!K@?A[KB9:('G`U1X3C>J<F:9.(2!-#$\MF,0X+ILI)@B3^_6DNI[44D]X
M7V"F!6;?<Q3XU[;@/^#I`!J_/)'9/%86$(!Q9/8/"PKXYLMJ0<$D-8^P-^I]
M-:9'=>LP9T=.#>]/LX[JF^T9RMYIQ)=@O@*6^%K>A*K77N7SK$5'_!/18]DP
M9TNXZ-BJKQX(X5@D[S\)DPMQ5^M%A0]<3A/I?G][]0M.VLMEK+\(\G]02P,$
M%`````@`F8X&1[+W.W`\`@``N@<``!D```!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&ULC57+CML@%/T5RQ\P^.TV<BQ-'E6[J#2:1;LF#GYHP+A`XNG?%[!#
M$D*3;`Q<GW.XYV)SBY&R#]XB)+Q/@GN^]%LAA@4`O&H1@?R%#JB7;VK*"!1R
MR1K`!X;@7I,(!E$09(#`KO?+0L?>6%G0@\!=C]Z8QP^$0/9WA3`=EW[HGP+O
M7=,*%0!E`0QOWQ'4\X[V'D/UTG\-%]M<(33@5X=&?C'W5.X[2C_4XL=^Z0<J
M!811)90"E,,1K1'&2DAN_&?6/&^IB)?SD_HW[59FOX,<K2G^W>U%*Y,-?&^/
M:GC`XIV.W]%L(56"%<5</[WJP`4E)XKO$?@YC5VOQW%ZDR<SS4V(9D)D"-%]
M0CP38D,([Q.2F9"<=XCO$M*9D)YWT(<#)N^Z<ALH8%DP.GI\@.IS"A<2SI2(
M5%83?11:5-:.R^BQ3-*T`$<E-&-6$R:ZP&1?KB&;6TAH$$`FX,PB.F6QBF[H
MT?4&ZUM$]M7*X:'(]J[(?].,3;%BS8\O76;Y8X'$""1:(+FJ=F95VX7)K6HX
M,(E])"X="[-U89ZH2&H,I;<"66`9<F%"RY`#<V/(I6.?L`L3/S:4&4.90R"Q
M#+DPUC^S<6&LD]ZZ,$]\3KE)-G<(6%5;.3!V9==/8#9/8+;W,9,A<'$S$<0:
MW1.X5]%#+Z9_S41-VWF-U,UFQ5?A8ATZXAO9IJ:N<I8OBP$VZ"=D3==S;T>%
MO$_UK5=3*I!,/7B1M6UE(S4+C&JAIKDJ^M1;IH6@PZE3FG9=_@-02P,$%```
M``@`F8X&1W%M`R0I`P``O0T``!D```!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULG5?;;J,P$/T5Q`<4;.Y1$JE)NMI]6*GJP^XS39P$%7"*G:;[]VL;8A,S
M#:@O`9PS<\X,GF$\O]#FC1T)X<YG5=9LX1XY/\T\CVV/I,K9`SV16ORSITV5
M<_'8'#QV:DB^4T95Z6'?C[TJ+VIW.5=KS\UR3L^\+&KRW#CL7%5Y\V]%2GI9
MN,B]+KP4AR.7"]YR[FF[75&1FA6T=AJR7[B/:/:$(PE1B#\%N;#>O2/%OU+Z
M)A]^[1:N+S60DFRY=)&+RP=9D[*4G@3S>^?4<$K#_OW5^P\5KI#_FC.RIN7?
M8L>/0JWO.CNRS\\E?Z&7GZ2+02G<TI*I7V=[9IQ65Q/7J?+/]EK4ZGII_TG]
MS@PVP)T!U@::!S8(.H/`&(1W#<+.(-0&^#Y#U!E$%H/7QJXRM\EYOIPW].*P
M4R[W$YH)>".=",_R1KT*Y53DCHG5CV489W/O0SKJ,*L6@WN8.+V%;(80I!&>
M$`"JP%<5*SPPQ[<$ZR'"EKD9=?)TU\F7,@.=K$#9!_UD)?ZX@U`[")6#\,8!
MLK+=8C*%J=M4/OAVK!`(A>-2(BTE`J18^=I`F&"<)-8D,>`@M$@@3#1.DFB2
M!'`06R00)ADG235).G006>E:M9BD]U+B,+#V\1"#!HXV``C;+^=I"`I0$(_'
ME.F8,B`I=F%G`Y8H2O$X"_)-B_$!'GM#0Z!T0FVA7BM#@`MD\[2@J)^V.!7?
MS2E<V'!A@&M*6DPS0=_L)LBT$P3TDS2P(X9`$UH%,KT"#1M!$$RH460Z`8J_
M&:VI<P04\3!:"#1%JBEU!-1Z.J&PD*DLE'TO6FRJ!D,%D5@=IP/U=S..(]_O
M;^?NXS@!^;4L4V1X2I'A89$A%"(TC<Q4&8:J++5S@(=D8@R.@1Q,0'XMRU0N
M#@!9@VD$`DTH.VS*&P.5FPV"@F:*"1]I;,H;`]_YS!Y+.M#MR)'88NZ#6C%>
M;S:M2'-0IP+F;.FYYNVTI5?UR>,1R]G66E^AV1H!ZQMQ4FG/%<;]<G[*#^1W
MWAR*FCFOE(N)6LV]>THY$=K]!Z']*,Y2^J$D>RYO$YFP]G31/G!ZNAZ6](EM
M^1]02P,$%`````@`F8X&1XAJ-?:K`@``70H``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&ULC9;-CML@%(5?Q?*^,9<8_XR22)VIJG91:32+=DT2DEAC
MF]20R?3M"]C!#E@*FQCPN?>[8`YA=>7=NS@Q)J//IF[%.CY)>7Y*$K$[L8:*
M!3^S5KTY\*ZA4G6[8R+.':-[$]34"48H2QI:M?%F9<9>N\V*7V1=M>RUB\2E
M:6CW[YG5_+J.(;X-O%7'D]0#R6:5V+A]U;!65+R-.G98QU_AZ1D;B5'\KMA5
M3-J1+G[+^;ON_-RO8Z1K8#7;29V"JL<'>V%UK3,I\M\AZ<C4@=/V+?MW,UU5
M_I8*]L+K/]5>GE2U*([V[$`OM7SCUQ]LF`/1"7>\%N8WVEV$Y,TM)(X:^MD_
MJ]8\K_V;`@UA\P%X",`VH#1U]QQ3Y3<JZ6;5\6LDSE1_.WA2ZD[G4(EUPTS;
MY%1U"C7ZL4E+O$H^=*)!\]QK\$13E%:2J/2S#&P9V,0O[QC+QPF6-L'2)$CO
M$J1.D;V&&$W;%TE*])B26DHZ0R$.)?4HRZS`CRG$4L@,)7,HQ*-\@<>,S#*R
M&4;N,#*?460!ZY5;2CY#*1Q*[E$`4@B83&$QQ0RF=#"%A\D@"]BCI:64WAXE
M*&`U`(U.0EZA!(%KI5Y43C?0`I,`T,2R,`/R/#L8&TV7?I$'V`Y&XP*>(2U=
M$O9):%&$S&ET./@6)\BU^""Z(^%%6@201I>#;W."7)L/(H<48G08G0Z^U0ER
MK3Z([C=$&F`0&.T.OM\)<OT^B/+I`8E#=OAH>/`=3Y#K>/`M'_)O`:/AP7<\
M0:[CP;=\R**-AH?2IP!R*:5/R1YC\'@JX)E3`=Q381#=KUG`9L/CH8!G#@5P
M#X5!--T#>>I^G&1R=3C3(_M%NV/5BFC+I;J$F+O"@7/)5$*T4"6?U%W/=FIV
MD+J9JW;7WW[ZCN3GVV7.WB@W_P%02P,$%`````@`F8X&1[K5S]`S`@``"0<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#@N>&ULC57+CMHP%/V5*/L9YPV#
M0J0A4+6+2J-9M&L#SD-CQZEMR/3O:SO!!"<#W6#[YIQS7^8Z[2C[X!5"PODD
MN.%KMQ*B70'`#Q4BD#_3%C7R2T$9@4(>60EXRQ`\:A+!(/"\!!!8-VZ6:ML;
MRU)Z$KANT!MS^(D0R/YN$*;=VO7=B^&]+BNA#"!+@>$=:X(:7M/&8:A8NZ_^
M:I<HA`;\JE''1WM'Q;ZG]$,=?AS7KJ="0!@=A%*`<CFC'&&LA*3C/X/FU:4B
MCO<7]6\Z6QG]'G*44_R[/HI*!NNYSA$5\(3%.^V^HR&%6`D>*.;ZUSF<N*#D
M0G$=`C_[M6[TVO5?DFB@S1."@1`8@O$S3P@'0G@EW/<0#83H?SW$`R&V/(`^
M=UVY+10P2QGM'-Y"=9W\E80S)2*5U4:W0HO*VG%I/6>Q'Z;@K(0&S*;'!"-,
MLKR%;*<0WR"`#&`VBN`2Q2:8T(-;!_D4D;Q8,3P4V=T5^3+,T!0KU/QPG.7"
M>RP0&8%("T0WU8ZL:O>8A<8T&K.T&I)/(4_1BV>58P84A%;?=C.@)$X>IQ2;
ME.*9E&(KI1X3C[Q8P>93Q)-OY?-09'</\64FB<DDF62RM"[0)GG<FRE$]L;.
M908T[<T,:-H;,/JC$\1*/6*Y<Z"G1O17UUC-%'\-U*"P[!M_E?LS]JV<^OV0
MOLIG:0M+]!.RLFZXLZ="CB<]1`I*!9*Q>\^RN)5\E\P!HT*H[4)5O1_5_4'0
M]O+PF-<O^P=02P,$%`````@`F8X&1]#LJ=D:`@``9@8``!D```!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&ULG57;CILP$/T5Q`<LMKE'!&E#5;4/E5;[T#X[
MB0-H;4QM)VS_OK8A3@*1$NU+;`_GG#DSQ$,Q</$A&T*4]\EH)]=^HU2_"@*Y
M:PC#\H7WI--/#EPPK/11U('L!<%[2V(T0``D`<-MYY>%C;V)LN!'1=N.O`E/
M'AG#XM^&4#ZL?>B?`^]MW2@3",HB<+Q]RT@G6]YY@AS6_BM<51`8B$7\;LD@
MK_:>,;_E_,,<?N[7/C`>""4[922P7DZD(I0:)9WY[R1ZR6F(U_NS^G=;KK:_
MQ9)4G/YI]ZK1;H'O[<D!'ZEZY\,/,M40&\$=I]+^>KNC5)R=*;['\.>XMIU=
MA_%)!B;:?0*:",@17)[[A'`BA!="9"L=G=FZOF&%RT+PP9,]-F\;KC1<&!&M
M;#:V45945R9U]%3&,"F"DQ&:,)L1@ZXPT"$"K7XW!3JGV*`%'=TFJ):()'^<
M(71%A)8?WA21/A:(G$!D!:(;@6S6A1$36TQG,6&8PGQ6RA(%\PADC\W$SDQ\
MQ\P3[4B<0/*U=J1.('VB'>FB4(1",$-52U0>)^"QE\QYR99>T!,"N1/(O]8-
M""YW!#S1CPET\^9A!.&L(7=@>1;-_Q_!U?5E1-1VK$EOQX^=&J^6B[K1^8K,
M]9_%-V:DVK%PD2F+'M?D%Q9UVTEORY4>+G8$'#A71)L$+]I>HX>^.U!R4&:;
MZKT8Q^!X4+P_3W7W:2G_`U!+`P04````"`"9C@9'LD<ZYMD"``"8#```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6R=5]%RXB`4_95,/J`)$!+MJ#-;
M6V?W86<Z?=A]1D7--`EN0.W^_1(2P0#=,N;!0#SWW'N``\GLPMIW?J!41!]U
MU?!Y?!#B^)@D?'.@->$/[$@;^<^.M341LMON$WYL*=FJH+I*8)KF24W*)E[,
MU+/7=C%C)U&5#7UM(WZJ:]+^?:(5N\QC$%\?O)7[@^@>)(M9HN.V94T;7K(F
M:NEN'G\#CRN(.XA"_"KIA=^THZ[X-6/O7>?'=AZG70VTHAO141!Y.],EK:J.
M26;^,Y":G%W@;?O*OE)R9?EKPNF25;_+K3C(:M,XVM(=.57BC5V^TT&#JG##
M*JY^H\V)"U9?0^*H)A_]O6S4_=+_,TF','\`'`*@#@#9?P/0$(!"`[(A(`L-
MP$,`#@W(AX#<"DCZP5)#_4P$6<Q:=HGXD70+$#Q*>-N12.:NH>9.D<K!YO+I
M>8$AF"7GCFC`//48.,+`,6;IPZ`QYMG%6"PO+B*?CB$K#PG6D$1J]0J&6C!4
M\6A4:/8U`=($2!%D(P)L*>TQA<(T?9%9*B]+BPLKQK!/R\ET.9FGG-R:G,S)
M`]+^^CH3UIFPDPEEU@0^8R>3I?G%14`$<%`IN2XE]X@NK%6;NZ)S'"BZT)D*
M3Z;)UP0333"Y;[U--<'44X%EBN74T8I#YQ>D9B](W50HM4W<@_#M!*9@&I#H
M9M,!GD0@@,+8&-SI8V",##Q.1O:"!AXKAXZL,2GPN=3>-`80OB>5<2EP;9I-
M8`"%<1?([QQ;8QO@\0U"]KE2?"(X2+*Q&)BX.Q,*.!2`,1F8WB<9&O=`GWML
MR=!USW4K#M`,C86@ST(A!=^<A'=:"!H+09^%['4-70L!2W%_''J`P=L8-&:#
M'K.AW)X(]TR$.#"5,1MTS8:1?1!Y0?89DMR\L!W)GOXD[;YL>+1F0K[[J3>T
M'6."2L+T01(>Y&>"[E1T)[IF(=MM_^+<=P0[7K\#],?(XA]02P,$%`````@`
MF8X&1],#2[G1`P``;Q0``!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
MG5C;DJ(P$/T5B@\82$(2M=2J\5:[#ULU-0^[SXQ&I0:("W&<_?OE)L'0:HH7
MA7CZI'/L/H1,+S+[S(]"*.<[B=-\YAZ5.DT\+]\>11+F+_(DTN*7O<R24!6W
MV<'+3YD(=U50$GO8]YF7A%'JSJ?5V%LVG\JSBJ-4O&5.?DZ2,/NW$+&\S%SD
M7@?>H\-1E0/>?.JU<;LH$6D>R=3)Q'[FOJ+)AHQ+2(7X'8E+WKEVRN0_I/PL
M;W[N9JY?YB!BL54E15A\?8FEB..2J9CY;T.JYRP#N]=7]DVUW"+]CS`72QG_
MB7;J6&3KN\Y.[,-SK-[EY8=HUD!+PJV,\^K3V9YS)9-KB.LDX7?]':75]Z7^
MA?$F#`[`30!N`P+Z,(`T`:0-P/AA0-`$!+8ST":`VL[`F@#6!B!6B5^+54F]
M"E4XGV;RXN2GL"Q`-"G@64E2,)<7U7]7D19BY\7HUYR2\=3[*HD:S*+&X`Z&
MC6XAJSX$W2(V?009DQ;C%4F"F>)KI@O<(Z"!?SO)$L(8B:PL>-86/)L^!M/G
MZR&M\J2*)S=SX.<$04L05`3!#0$Q_KH:0RM,"OTOJT>(NTG0-@D*)!$82=#>
M%,Q(XA'B;A*L38(!25`C"=:;PM!J^12Q>HI8/T+<70AO%\*!A5@H,6H)1L.*
M:MP2C($,N"$EA#$,80EA#%]9`1AJ=B*$L2A0Y&N'\P$*"TU0QR31,%D1UA38
M0E@(1,TR!4&!Z<<0R&B)-0BR*#>D30P1@();4&@;0\%`<;4)(<B%>N("(&J6
M+0@RZQ8",;-P028;<;6M(<#7F$WQ:T-!?*"XVE+0R$9<`,2P*2X$,CT6!`6F
MN'U0P&W*3AL=`IR%63S`L786[`\3%VMGP<A"7`#476VS]0&8F/F<!4$&TQH$
M^1;+TFZ'`6?I[!GO4VAGP0/W1U@["X9V2-R4!`"91;D!06.+9+1'8<`/N(VJ
MV@\P&RB)]@,,[3!ZD@`@LP4W`(A@"W_#VEDPT.K<PM^P[F(\'B8)T5U,@/U!
M3Q((Q`U_VT"@SI/Y?C+:#PC0>]QB"TET[Q$\4)+.JPGP5.]+`H"X624`B-@\
MPHCN8@+T'K=YT]*]1^A`273O$>@=HR<)`.+,E`0"V52)[F("-*C-XX_HWB,#
MWQ2([CUB\ZX`@;BYZP)!YJX+`HW,71<(,NO-ZQR.)"([5.=8N;.5YU35;^CM
M:'M6]EJ=QACC"S19(F!\A2;K^B1,T\^GI_`@?H79(4ISYT,J)9/JX&4OI1)%
M[OY+4:5'$>[:FUCL57G)B^NL/@^K;Y0\78_WVC/&^7]02P,$%`````@`F8X&
M1]UFV=2H@@``IN8!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R]V7(CV94@
M^-SS%6YAD2/2Y$`2X!ZJDAF#P5!&52Q4,#)S>MKFP0DX0%<XW"%W!Q<]Z6$^
MH5_*K/NE/J`_HC]%7S)GO?=<7T!$2C.E:=-#!$G`_2[GGGOVY9_JNHD>5WE1
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M_^T__:>M)VTA\!8^[.!:^TF9M_?9WT\[`(!7Y_QZGBS;WRZ2O.ZL7,^P7*T`
MTVZ:<O8UCF[H'D2?-DW=P&4!K.@<Z:>/;ZX^WER]B>"WFT_OW[VY^`)_O+YX
M?_'Q\BJZ^>'JZLL-W*@?;]Y$>R_WHY=15D1?[LI-#>-U=YW.W#4Y&L*>I*[3
MIG[5^3JI[^A&S_"7](^;[![1O>E,\CF%*Y+-$#GPT1[D09)11U4Z2V&,VSR-
MHR)MVL^]*^YA]++*NH3BNDK723:/TD<@5W7W^R]E`T<Z"_;3.0_8P-I1J<6F
M*K+Z#@Z@'EC,:%V5L[3&9=>`53.&Q3R]3_.2QNGLDVA)'E79\J[I'_7_W*P!
M@G^21_HHP>CH8#+T=5G.'[*\0T#>I.NRS@"^N+ZRN8-[W`\!AE+_=XH+>9;<
M9GG6P"%T$,(=Y#IYPE/L^;[:I/Z4S()FW>';;[]-LBH"#-ND4;F('I(*J2[,
M53;P8I;D^5,$"V_R%*=&I._#-=W&NJR(P,-(>5DL1TU:K>#L;CLG$F+.EN6]
M21<I/#2/FN31/=<AE.^#R0@'<`VS<%G]B]@R.1*1K$&D8Z#.@&T"ZJ;%K.=A
M(C5W93Y/J_I7=&^;I^[E9K)4,UEZ>3`^.`#$6R=R!+^)IJ?',7R&_X1[1\FF
MN8/K^:=T'D>3DTE\.CF)#\\F^G56UWCZN+[)R30^/)_8;TM/\J*DB8"NIXZY
MPVP\T^!L\.3D"&8[ZIUM>AX?G4[LMZW9@`RFJUO`PR%2>#&?9W@R<`Q(:$:$
M7NL,CJ4'R3>K34ZL<)XNLEG6P:GW2#4:$*+J3?7DMM/`J=6`$B<,V`&1B%&A
M-D?XES__FQSBLVA#T*A[CO^7,9F]ZP2Q]BYM,N"8^\!T7D;?#ZS[I@&($'4%
M='^;%0F@)G)9I$S;)2V@[7*S!!D=$D9[FWH>K>'8:,[]9]_L8,YVK-]YHO"U
M;YPEP->='BV'I8,O#JOL&SL>[\T7^/'AZB,<[:>W\-6'Z\]7/\!S[WZZBMY_
MNME=JCC<66[O7#20C\M5&GET&4:,CT`[*V"WQ:;#:2[A)C&V*Z_I(7`UX:*,
M$.VEC[-\PP1AA63X3XERB%E:-:#@1,D,+@NB4U8`^)<9\AGFEAV,^+RC3'"3
MYCE,&4=`JT%^SF-Z(9FOLH+TBB:[[[+1;U[>`%/K`*G]W*<URO0(DKRLN]\2
MY\[XP/9DC/TNH.]@,<20%W\+#OZN`/8)`F5GXEZ!JG^-_?`HRF)4NAWO-#RB
M8!]H]'.B&3.YPW@5.]!YG=39C+$DRS?(-`K[+KWT'/GY.45Y,)V/DGM8/<#:
MSAB0BU?1;7N^;Z4-2!INOGRZ_-<?/KU_<_7YYE?1U>]_?/?E/T>_^,51=!*M
MF%ZD2"^B0+'?F>C0(0[03Q)YHO_R@9A\AY`8YGXMS/V2F?OP*X;+OV$N/_BL
MH\G;5_$Z769%@:AWF^3`'M/8B`9;];3.F\^^`506%P68!8_1;_L(VU`RO"+1
M(/HOG\L\!SVX@@L[[ZSZ';`MFA()40^SVO7Y79^+-FOX-7U,JUE6!W1DD-G9
MMQW1$?$0B4Q9%.F,B.E#UMQ%'XAN$^H%$Y<+$"9Z6.[@2GO&3E?KO'Q*4WEB
MO8&I\!C6<&S?"K%O';]7#1@!/4"UO%PAE6.6LB@K(`Z@C(.N+?Q!ANU*=;AB
M&>/2CG&!8%XR![]]BNQSU\D3F]P0G^+HTQI?@-.[DC.M<6-L?>E=<O2.C^[-
M!D]#GHRCGY"OQ'+'9%`W9F>D*Q;]>V[:5JMB^-JSC^\F9UW<_!"]??_IY]WE
M*[*\+/+RH8X65;F*/-<".2F[']#.YW_8U*0C1DV)MI821'#@LX[?P*?X.UES
M-C5?CIU&?I.N8;B,3Y[D%RNA"`/ML$C@MC15/8"'N\H1L[[[O?O+HBBC]E74
MV9RV.S1YW0()"5>TXYW,(MZ^]9S]ZEE3S<==#NHYM,F*>Q"DGCE<>HD6AW2!
M9$Q1V0!\SUBDPG<=-8(7TR%CV[,;[5OT<QM=L+ZY?:,X$YGTTKG"9T=>U7W3
M\B?A'DR1N@<_]-H0)H=OA`QAD*==W5Q?=P<"$3=;`P58,T4&2;%XQAKF3@.V
M>Y^AK`;$O0^Z?2]F3NB86Z%CMJL9>=#>C'08[DITZ^0@@-^ZEX-L'2/%2S?T
MYLUF#;!".(%8.,_J&=#,3<6XH>@&VW&^H_Z+Q"0`34/,O7#9/%]-=R03[6;X
M)GWCBUN672@%-E<*+^,NEV7`&#N,@0&B(O.I$'N2FK10I0A=0]3G=)8#!<Q`
MPG;ZKLP6&+8"J7#(JCXD>6\E<=M-\J\W=5:@.0\AA[I<C>]<HTL`(-['280;
MD.A2YAD::(=M'.B4?56ODUGZSR_6.&AUG[[X;?3\K-$G4`7OL_0AZG=!1GM_
M^?-_>TCCO_SYOT?PVZ;6W\I-I;_RF_@'0`7Q#3Y#!IT43_`AW%V8/[K5<6?I
MALR`D3P"L)P1S8;%B`%$,0QQ`4\JR;,_L:I=E/=DZHBC)JF6:4.OS<J\7#[A
MS%6RIM%!1KF#>YK,YQ7N?I7\`5:V2N<T;T%4,9E5),O`<A<;T%OJ-6!AM5GQ
M/05B#OHXB'KC2'?W;[6USY`%?@'G`A(2<WPBLRO0"E$^0H5O!,HTZMAY5M"\
MS*!C)&]J/XJJ\G:#)HK5:E.4O($GI)G+*EE%.9/-C^GFI^3Q+__WOT=[19IG
MZW2=K3;-Z&9?O0'Y$UZDI."[722LHL;1-3'10[^"I@)0CD%<3"-W/O]6&S!'
M\VJSK&6%::2.J/_Y/Z*]!6),\93O1S>;6S1%;>"++RBCB&2C^(\/E\4\`?&D
MJ<IB/_J$0]R4^0:--6^S?#4&%2#/\=(#.)_B"%#)0"DX]XAL6^E2L818#_`3
MN!>+)T639'XOA,B@`#!2/*)-P?<>SB1;(3-*[>G&?&JLQ)"EO5'3,R(&D$'B
M0_`R_EFE\\U,KSOZR8#S(5UA<0IEPE$*NM^LJ<?11Y@ICRYYJG?F>#/RVE8>
M?V4Y(0HD:UAK`NHEW!V6>(EPK<D(2=/!BNGT1>J@0>+HX2Z3EX!RKL0\A2P4
M?D4T62%,$G)MTI:*#7DS/,X#S;_/[E&?8XEWP[!;5N7#./I$N@Q00`!IT1#N
M-!L0X7DV>'*5-DF-\)C%-'RY:<@X!@M:,?EN4I2L&T3/5?+5,2C9%X/6;"T)
MC'ZS*O.DHRSDI$HT9N6Y+DNN+<)8+E(-OV2KI,I@"`:[/DMR.BX@`9WG'N&R
ME\`2JQ&`89E63_MD9\15/MR5T5URCTB0)XRXT5V:Y,W=$Q\=J-)/=9.NX(+?
M;AK8')K6,U@6O;4IYG#8Y-E&B^T*O;LI8,R&F2UB&2_9(PD@,9"]5!`#*!SN
M'&8E9HL\'03%>4JW]Q:(_)S9)VY&UJ-[BHF-XD.XP;O-"B@%@*78Y.7LJ4EA
MJ4`*@38OTQ%2TH(63C8KW/@B0?4^VJON?O=A='GS=I\MSP]E]16)$Y!T9##N
M(`UJE`]%"!JZ1P1_T*/3]"NB!U_@IDF`VR,S<%#16YKF.5RG'VD&V;.`!)2Q
M&N9'\@XO.CPQI`3I`M+@%M%=)(#@9#JNDT7:$,%=9!A,`+,`TL%&X-(S*<1S
MS'%QN+NF?$0#'M&3IS7-`?A'F"W+=<='5!8.*Z\%;P@Z;HT`B?2^_)JR&`V2
M"\$:UM&(+-3<5>5F><>G[20:<[H*4GV.J'^5@%Z*R+4JYT07YL`PX'H\C:.?
M`2%`G/,L(RV6`!J2P>"P&Q+P0TY1,TH-\Q\\.]+L#@\F,3+_MR4R/I`AV/QQ
MC?N!\??>OK[>5Y;][)V'%VZ19`&6+!,*"(&Q[^'Z)FPT`.D;:`JM4,".]'9P
MD8/?,./)TV2.@$?2CL/-LSEL(6:AY1DB#8LA4HM;$MD@9=FPNT$9(=PG7T98
MD1P;DEF`N-PYU`'6=/E^N/H\W4>EOY*[UMHW+L/A1CE'RH]W'03W9*27!J8@
MA8(X'CZ</J(H"?<+KGH5P4OH&Q(DPPD9';,"+GST`(^-0/:'6P/Z-P4O$!V5
MO3JF2Q*([MH=)$%*SA+),_#J$F,&21*1'=PG,_B86$5(T9CLB.[R![D>2$\9
MRO577"$K-@[]K5^L+,88$)80J:COD"JQ<%@X11,1`$5BX:59-5/JQ^R-B%"T
M=_GELMXGBG!+G*E"@9*(L1P8O/Q&1(:W59J"I(3,%-:S]^:M7)=/PJS\5Y]N
MT"%>;Y9+U:W@+&`7Q>R)Y(RZ9._!*@,R+0RV1I)&O#XF]A<!P4YC)E:(SVRW
M$T0;1Q?(TT`"YULITLP/[R^BBVD<71S"O^D1@O!B>J*'3H(6X%`&5%:@0XLC
M4#!S#VX3$/0_;@B"RCR`2*),C1I9!'RF).(9?8GRI]7ZCCD/0/1]O4]H`"`3
M4H<68OB8F-:R``Z(#K4-RJ'(#=E-"B=;/L6.^.&B8%Q0;V+&W,Y-T75[-F`X
M<CF#\VZ")VD>"W%$;A!!,\99LW6EQS`?B"0UB9=,]ME3"]ND[0#4V4[GF!>,
MZ)BX[H3NSX@I"^+S2(X`GH7I&J`O$4?5PA:(IA-O<?1;R+8G\L!=2N+B<+I\
MT<;HH2'*M\S+6PQ3`7&/Y#%4@Y`M5"B<S[WZ</WYZ@;=<GO1=120M,]10,RN
M@,'D3Z/H)D*>&X,(#`(QQVW`&E\S)1")F&[V^_(!P4*.6E3.$%9T?%>1G)\:
M!81&?(E40M_GK<:6_@7<Y9!"@$9''`DD5&W*GT:+%(A$JL1)SMV)A$E1;$C2
M@A4MBU+,B?C^C^.;,4F"R$F1A$1WH.PC5<_JKS))5K7&Y8M(OGN6SA\0619X
M:4L4PT%95CW#WUE2K4D4A6MQEZ7WN"]XLD"Y`?4?)E7R(CZ\]_'J#8BK@*F@
MHX,&5GD5(,$W5;`GC9R`2K[>I)J/RL4(9>9(^=J>2+]QA+'=RNY`C$SF;+MW
M5Q:W/Z+-.^@10J*.4,&5(<ZR*D'7H]_J;`G:*5J5V*_,N^8UO^*C?_?#933Y
M]??37Z,2.2N%&J'N7*+C0)E"LEP2@J!@122:.2<ZWU'R62O6[>DD0L*<O/\(
MHGE2/3$UHI=(2RCI5%3Z9U&7">7W%X?1'O/K/-U\90*F!))X*C_C`.$T!N)2
MR0IEO5F&IX:$H19DJ%)96<TZWR/H!@TJ%R?'WY&-L5P3+R*@"[(C(R,*<YNF
MA;*TDN@[_D1BCNM&:MZ=I$"KB'JQ)P>C"<_#XJG.91&>]1FG.:+";L;;K''*
MTX.!0?XE62?`?W^DIZ8\%;XZ:R1Z%VF$.ZW^"QDC&!&/BY)0$'6Z]1U2Q.Y-
M`$*7Y^4#Z>-\B&(A$/6.$/I[A\B1PVW$?W2J$$,@]IDG:Q@/L8V`@?S\*4VJ
MVDPA!"(320;53?J3E74KZM412N$`G++2N],F.PA20*_;W"N.<\?]8\NO&.-1
M&F%))N<E)[TV`3U*@>T>("$IG_KD/LM.`"9F3_@]@6;/<#Z![CZQ',]=Y*Y[
M(X*R&W3BY$!'47)NJ11PT8`*\(H!X'@ZN+S`_K-,W1DORK*!>\F:/N/_*R!G
M_^ZXTR>>\A5ISW_?+*MN-O,GNKUHO\A)L6!VJT:GT^,S0T!P&!I\\FL""Q!%
MEGN3Z`8E*PQ#`?I8@M8>7=0@$]8TSM[-]<4^:?@-&Q`=ZWI;EASH^@9TV^@B
M$))!27MSP82=Y0EO1Z0_9RGN&9D`JE\<33LOT:8W0G,@&ND5ZJR:`<Z'$H48
M*.A+@#`[23\"5;F++E:@G,R2&-"K1A,FY_\D_/O5I@*YAVGQN[I*TAPD6D_#
MC"LEXALM@$9![!8IPH9,#-'#P\,8),E[D($`_M'8H-'TUN/11;#%8._B_U@F
M(.R/2-PK*WSH$&0*M3ZY`4/$1W`P(/!^R*DBFPLI(.[1,U7ZKDB79'#R?.A[
MH/#?(W4?$&"0@Q$$5#@J1*5*O)L%3AV>^1,2'%`OTPHU37CN?_Z/Z#?1[U(T
MK:6SN^\_ET`P]SM&,C&*(;*@X*7[(YY/DM-B4XC/KS56`'0#\V(`MGYP)2V[
M;,[MA]&9G\>,!SD"X'L'(:-&\E^DI>X0#85X;S'*+I`G\'S\@:C`<OAKPZR`
MCAJ9C:RE=VJ^<Q??JPM[Z\O/1(.?G;MONG%TS4`GD*NDW_AC8;NLT_G?I'A(
M2FXP%8'6\*8$V5%U$'SN$L`MY(P.]`U9R&%)'\2)XN)6K\59L7?YYL/GZWUO
M@18<T%&=+EBAHH@!I1):,,_NV>*W(J<;>:AT>M'4JY1P2T4,7?8%"DS`'!*.
MX;F8-4#B8-::WG@!6`IR(X@(+T"6!!JU1)@2,B,_J-#P)_Y@U)YQ<'0@HE2,
MAF>8GZ.2$@P_8D0BFAH]H/B%'Z)57NAQR"JZP'E]B;#!I[XJ0"BL*5K"R1:J
MDI/N;B^"LR6)Y\9>GFMFL*^`&8&8!2H+R!<8PA>C@H'@`NU3B>X;D#H^I_,Y
M^WO>)[=EE7""5!R];V!W`)1W<!*)F]"ZWISYT5\Y.I<J7;)U)1@]JQ6Y*;`8
M!P2A.5GR;=#5>VL0VTT)68,I>#WPBZ=K.*FH]F0LSM'FAF_1U=B;_#H&'LF,
MXO#7PLL\]372789>(>3=,#S`[&3LS)C1WH)MF&HM40T$K9NOX0Q1S*@Q)FK>
M]=JU;8C>-LK**<F.?8.KI6^4Y.N[Q!G<[@'Z<Z($UL:F)G1WTY!AH*X/(N9(
MP`.O[$T/1F<'.",CO9A0X\!^BJ`*N$AM0)&1NM!CKY#`B,+;>IR-PUEMK*4&
M(3<:L,F8^2BP"BD#7L4"7W(3]ID$8S7`AFY01;&DS8'[[;*A0384OIZU.FN6
MF/,<UCI+[;R'3(W6'$1#Q)3C'+QJS<>:+%U6EEM%O<%84K$SV*6B7>DW^&S,
M[@?WAM5;$(AHY`4ZEK/NX544$*%RX$M(B)!AK<L'HA:X^G2!010S4(K@Z57&
MGA<8-T.K<D4N&A"*#%,9`KC&?>'9XO"JA+-!Y4/RQ,&S0H1%!BRB&U"3D3@C
M']`!/ZF3'W`$(,*^04*P%2!-4^DEB9!TH@8MP:FB%*+R5JO%%>=[*$69`_0Y
M.QZ??@?4`RU#JQEH=66-I+[<K/>C>P#4Y'P\_<X0Q@)0.N<'@'M'_QP=C`_.
M]V.."8E.S[XSCF*ZV^PP=$8B8^6)6/T1"!`&$'NAV]^4FBE-A^E]F+]#.W<T
M89W`.J4(3S%4!%]*T'=>D@<X0LM/VU!)NAP31;RX:B!)`*$J=`J2G6:.AG-D
MI-W#YC,F4>,M6K1E$RRMFV-$L*C4X([1/24<TS%\Q(@Q"'`P/S_I(@?WD(D@
M&L[=(:!2`9]PK!B(4?N]O!#8)*@`,T&05M0.?O105OG\`<?EV!U2II^=+##G
M%0EH@VZMWC*-=M;6C!\RM"]?![$PR(;?7X[]9G'.!*WPO&3"GPQ!-,\X%M*M
M;N]B63WE++IC6C@(-NW!R8X5@7HW(A/3?>H<7K$1,$SL0T@%5T_HV`((9(N4
M$XU05`;]OE[5T=Z'ZX_U/H6\(`F)DML"M3'2^X`]$_JND4/D&#V,_%J,)9YH
M)_=)EG,FSTIU:@?H=R`<`U^K!7CV6!**!TGF^#5@\KV7$9#@WL)3Z3VS>]`"
MZ5(3;<5U)PC@&15%H&.9IVO,*"D:6EN5`E32F*^Q&I17R2/PNE7KQ;U+_"*B
M&*>[IS42]!H51V:%\+J8_W#!$AO"]C0-TG+4=AQ]4"L^7[$)Z2T9J\GG9R[:
MH-[<HA=,+*UL_?/AM30GHPTO+02:MUV55<=/%J,)DJ@BPPRI4.2ID%QPA&3M
MWDQ)`4X*A?,L6=-1$IT3\/6>OVY2@YU<H"C-`5!$=G3]KT!A&9G+K\#_`9_W
MU5M/!J2")B/7)XMTYEJKQJ@B)[Q7+LC8C4>X;FPXE#P38WAT$0$VICE%`RPQ
M-:Y:";%SEHS)62>"Y,>"J"[E(];]UPJ)PNH6+<<EN:J0UW;NB(2`=V01O&=C
MMY>F7(]R=)=*!`-1?L$D)MK(1@)^2XG2EN$Z&FRH[878V1&,TP.85@GS7\<M
M!'ZX1]%.D?N.,221`__0=KE$2;($RKU*V8_C`EJ`=,4:GRCW&KWSQP?'>[?[
M>]-]^S*@!H4]L:E[A@=-.()J^$/"[,C&\1%-<'$93""-[$+4W"V$_#8D?,S)
M@N9)K^%.OQF@PF,JX2%Q;9=X3S0H=><X.U0^%EF%TKH?RM'R78>)G62OT6`&
M3=<NM0>DO3GHZNR.,$SPUFJQSO:$81ZOO\RN'5],F-PQ@@!9+N"\R/Z/PD++
M9#5V:\_$#W+O39=T^B+J)TC^=#M[/@J@`33=I,"':(?N^I'BZ;+)@X73BCNW
M3./HX(*S?(CK73+GH'2WV/O_<O3#/DFD-OGW*#!*OF:Z23DT2%6R,E,M[DF7
MEU48F8TJ#V4_P5V@*VU`RL1)88-V3O6M2&"/"`A%DB]3S-=<,Q,F]['&-MQF
MI;!8JC1!(4OHV2Z(42FBL.X$QPQ\E&0,`VB!*O'6+#3A@XA=E[E$N-FSP/%8
M3Q:=AND[<O8L70P>!W"539.V$`*ME46]VLS*&C_I2`EN#WM?WGU^N^]4<9&;
M12_'^'!2DFN4\A2[\(WH,XKF5QBF[G.3/F1DA,DH*U2"4/<^7WW`0(X9U7,1
MUA6L%3!N@]$@&]6F-C7.1-<'/K;?2\[<`VF*0"!!+&!$JY'ONC&-Z]E*E88`
ME-4R*<1,,_Z&.%R2EC<YB\JXCAPMW421O9&CC]#L/H4$V'XHBQ(^CCX_DJ!K
M1.<\`='\CID`K^4\%B5`9^DG"82O<XS;<#>X7\$7ZP@%=)24MH7T#(A"(T8-
MZ^0>904*4/.H0.DRH;?N00DF?K1W^>[C3_OL!]_MA<_\`O.8NM&L<92@^QZ_
M_@2/AQM'-Z_;/9(K0GVTG'FSF%B+65COW2(N?!Q][)F32!5HPR(S<2RCI&"8
M@&9B_566DAIU^\2[40^KB9R86TN$T,4`P"CT./?K.'I'!$65=M&%V:=\SMPB
M>!DGX&_/^%M[%):4HZG?K9BV3^_B><2D`6OT.5-8C:D-$Q2,P@60EU,!8NXQ
M/D9Q!,@=JXQ*8A:2:L!F:8S:Q<HB*;KJ"ACH>/3#E^C01_=1C&I99%ID`4-K
MB6C<YN7,A4@G+O+<C81V0HJG0(?:YE8LUP1"C`0C!:D/T3"0VVU!0P?IY%$)
M1E,10&@&!`G3CU#.(1J$AC;='\8]C!"_LEG-Z$T9'+=5F<PI1-GE5KCL#,VO
M"-!;#4;P#G`IGV5%T5)FC:BL4$!.C0%22TE@)+8$*NBG-U\DI"5I1?1&@T/Z
M94B<=:U$BHS8[%A(&S0DD!Q']!+H';JR*!K[B91JTJ)J(7@+?(;`KURQ5H^D
MYXFYN#6*Z/!`&:1?C%C9&E'A;C<5:*5TZ`^):FYK,B!(>I>F=F%BU"HEM4(#
M%#7ZN=PP:6S9-HFY5%76J.Z'!#)Y\MEWZM%,YG?&XF:BO'\%^"HR!0#W:YJN
M&9,<\H.N^,`N.8ST]NBG[$#NZ2S?U!Q1;[BC`XDP4?Q1)USNX]L88G_>$^[E
M!L08RAC#+/.>="LF#9(J0Y0,W9)JDU^XXD2U%J%QJ3/S"&&&$;ZHI%.<SAI3
M=ROQBK(NL]Y4F#C:N`2332Y6/%%HB(`(:;Y!LZ&W\UT]SCA5F4IZ<>#!WLW5
M)?"/'PM!,K9=I8\-AQX^8,8H>AYFB&"QUV94B45R43:<\=$$>5R:ZF4SP23A
MBW/!\`\7U<;;X_AJD(?QZ@(B(!$$*I4!\<?8LHLUT6U.,XME)/V0PM^*^?81
MABUI.-H+^GK\(OJ1TH86T95P&:X;0*?A[`6^T-2-/\N__/F_2EQ/\"P#:A=4
M(.2IYD26F3YY)%MK5FVM)7V(<")/,`&'@5$!YA8C.3E1,RQ$8#0<`/PJ^>I-
MX(PG0+$W*ZERP,8QXNBBSJ("F%(>/ED=V`?:DZNN`7LVF=5GQ`^](P8C%-4%
MB7L!I62E;SE:=<E6'[*IK?R.IX1C=`-O.+V&O!0`\!R73HX4!$LE(0ILHD"S
MH`/8.+KVI\)N:#EC/'I%AYV)@/#MF=N,7'M2SSCPH`>Q*7GD`@BC+I:#@C5;
MTHWG*8MC&II0ZQ>-CMDP,9;1^E)*07'((ZJZ#NA^W,J]RKH>^E[*BM)XM`XA
MO;DV=%6CVZK.M!C.AN&KC'X`SV[]HG'DTJ[IERN3=NVASW#0*@PUV1-$R,\S
M>&-.&>D`BAKE#<_QB%UGRPR#ALA@)<KP^0&@Z%.--(/IIA@RP[QO69O-!!=_
MI?',X/U9J0$/W?B27U,6*3*WZBN&).@!BO^*?W#E33PN5P*5YL-MM\JB!GY2
MK.G%0&:4E9$0OG<D3*KIRB9\>J1%(&7-AD^(`M-R,M*)NS2C75;KDN+89R@-
M4WX=BBR4V?V39G9[`OK.P-T=6E)53U(Q32I<R%77Z$0IE$+%HFGJ-OQC#SA;
M_C5IE1*-Q3?-59ER<<#ZR%JQN_CB'DA--,,S0SR$=7%=`Q.J+$=7*90UB7X<
MN9H=G]VBHE&`J)A6P[X<@1_>5M%6R12VJ9MRA8AL$CWK])X/@1)+@L0%]!Z@
MRY:&X8OISQ/%R<S)-YBO0_)9K*4;X*+4:":%#S::RB/+XB.I59HGY-)O5$X`
MT<WS&[BV2`YJ,C]A\@5GM9$1)>T[+7Z@(`;B,_L=1BPP)=CH@@65[:,`%(0J
MG=880\5($B9T(6-NN;EM%IO<S\@:I4M5NE4C,P<VT:G\"M.V:C^;\B=>#?G`
MJO*6YM53*^O:"4IFF)Y]PB()2X+2I!QWV2X?RI,^LQ\TY;^<G'#N`NC,OKPQ
M73#[-ZKSQ(B<NX;=<L2O,0&W4ESFF@PD(:#E/D64IPB+C4OF)$OS"/5,_@V%
M^+T7;]^]_?1B'U-][Y#=VMF5(&+M!5!BX557^U@*1O")+$M165IRNQB8U$,H
M%P@#9BD`DRL6ED9+T`SP&HM7//F@K=I:@)U&H44K,%5X]I4CDE"F$DN;36(/
ME]I_H+&EJQRM;6`!C[^<Q$?3$SJU6&$C<\)7TY,CS4WI`]9++'TKW_>OIHM,
MSZ_HY)AKQK96<R0?#ZU%JNKVK26LAOW6%^@AW!RLE=W"5$).X81<(BK`1#P@
M--JRSXM1+[S7GFP`[<+;@^;Q.MKSLC6'\!.UO)=0_GV]]A2C065&4)`=1UHA
MFV..?97,"Q9T<6?!(QC_C(!ITE&>L:6N55F3(TPQ-)1+7B%=VK"GNF$YP:4=
M$>.%(\PJ!ES3$G2QI`&[4DEK(O_*@J(J.09JH;YPXH28S+ABTU#ME#\[/NK\
M)/-A&AP6P476SB7=FEYYR[B-[NCH4,`&`66Y)-<#,\=LA:([UA5I;4=DX]AM
M/^1EC,+.3<VQ_E9/G_D"6W*_"Z9OR%.%;[D"IP)[H06FE@2+-EHYX%;*I/RF
M,YN+]44S+[Q/]DLTVI0KC,0#KCCO>6N>S@A1,ZUC`Q*B4'=T8-4H#J1ST5@H
MC&O;$$*P1:;1<$P75B35V&[+\JORR``W)>NP@Y`D&7K$E0M#>3#"P^?MLV/7
MXRT0VNB/@*MD.KKG`27W`#U"RDJ8_61?03VYP\0#/",W%C`./#)V)SG>PQXF
M@RSB/J11GMAL!O@2TCG:*7Q0:&TM-5^@71NNUMJ.V)#4]D6YFWQ?LWJS6DL:
M7*OX6\_]DRE:@FW_P[37OJ?31Z[0%<Z(9EUQOM#J5E@AYE8OA:AB23[CP$L+
MTD]JY8F1"NRT#[N$UO(8RDO%)0`27E6E`RZRAA?`-9K4BT!U3%E*1#49I02Z
M<$(2RA8X@@6Z"?662AA&:^&J1#]/>D-L<=A6!TJ`$!`WN><]JK9)19;X&V8V
MHTB58!UE;+F*/-R";F?XA,1F!&#W9C[<45V5&1.[D.A+:KF/,^R%>^W6@0P!
MUW++4CK22!)JC4S&-G(TDS[)Y=&:/&*]1.'>KH^E9T++(D6Y@@QX%"#9H4NX
ME><YF(^:E%6S4]?BHYB5,#&B)E%:%6BN^&>\3H3(FJ\M7L:R#GBWM]OW7)66
MQ"J:43JW2-\Z,8\:`Z04G[\%XNUQ<C=)(XXD@!1_]J.67-S64(S9*&VW*3*2
ME92^(;M04084M0S1)^D1E=&NP7:\SQP?+MV<+-!<Y'CMC'XNC(@,_UY4Q_)*
M[B&W+*=2=EY3J7[[TC)3<V#.:+B7[5.(QB:A5&.;<(K11:9V;?J(%ID8WH!7
MM.H*K4W%*L;'K,EYR6L$UYQ>R/;%;9UQJN@B>T3!MG+G0'HHOKZ7W>^3C882
M:-GU0LM.ZK*@U%$T]Y(,]W,:QA%H&$2O91G.$(V1*0&LY05UP0E:Y+=*07[)
M]3'*(9&*`B^<+2-^H7&*%`G)8;5DS@5-K*#5^4R!]A)Q%760F\-@HRB01<KQ
MB:0ZRG1Q$&'BU&G6`OTU7VQ(#=1I>"TUA[FO,8Z`/(RL=,<>()7]M$IOV7D"
M<FBUA#]F7W$$=97Y!"*-:[P%JK((F^K,-3R<+@N6HTOG(0&A,Q495LWZM9$.
M_["9+[WM/+6.#<492H$N5Y:\.[B00)*$=G*QD'-25N.I8]TC;!%G:"TO<56#
M:T,2_%$(WO$9X*4CX+=H@-^)G)6<D=?UV'Z5<0XS?F?S/P/29_-"*Q#C*\FX
M(=?V6J+S_2,:>#-R:7`DW,<^A+]T>5H>I0)[D;U?C,.HK!1I[B*@Z(GT<9UI
MW#%[';YTC$"Z;Z%)6@,S,:D%C2>!,B?K$_@7A]>PN-=#W&+UEL/(G`[`E;'<
M$I(E&BR;?N/6-5^7ZP33`N5BP#E>U%)2!P6!>]Z&OUF(&"$F49ETW!*Q9+UB
M[%Q0*N)SG+P>/Z7`CR5%&!"4PZO#,:KJZPKLJX2[E('Y9.WB')E%<6XIFC/1
M2)E4#%)=UKC#JJIYW4LX_FZ.Z6=/O^PQ?>D>@5\[6IZ3O,40*N?]\WS`W4<#
MOOS)"@Z51VWCNJHV$MG@SKL%+LZ/<0;CN94"[(K82GXGQB57H%$#>PP[>YY_
M.9E5Q(]GUQ<<)Y7VD#.UMJ3>(T7"1PRD=1)<+B5;*Q775BW,;EPA0[T0RNJ,
M8&L)&YV?2:?5T=A9/*<*B4&0!`S,^4Q2>IL3!,SW3!ZYZ`"&USC88;2!!'Z2
MUZ^UW";8XU,M$&(0&-L<:.ITAFBBDQ8?7/V&R"V76Q99N6JXJ(5"PF[;R!Q^
M(A+?%QE&88T'N`V9P3UVUGZ-'M'%X^DB.4E<P^(DGB-99NS%#4Q&YS*$ED_4
M94[,DZ1_KF7*)]9&3#\@IT^P_XG-ND^*A`[)$4>%ZWA<2RHC;NW.2)R*M16E
M!ZB4ZVPG<1#?T-!O'%UZX:I]41CS+=$RQ3U+TTP+C8&5,TF\3>?D4+MA3\$-
MQIQN@#KLO;VY<6;@WS%"1C=8$AF%EE:)#,GV+B)XR2-"D2[+)O.*8SO+_B<D
MB@DFJ"_0XL";Q\Q2#,P*;QE/P-ER&:D`_'OE^50G/D@][LAV*>S"-_,0=TH/
M!6U114SD"&A)YI,3!]\BDQN+P=$ME<@L@_O.>+G0C(G;M'E`-8T>D4-74DR:
MCXLNH[_XXE/G4U=QF[^E3>URDXV([N^QOTY&P/?WB>]8/'3=I4`'WW@S@99`
M?PIQ=_O%Z_*27=G(7RG`B;9RX;65:ZV4NU5`(->_KZJ+@E*>L>TA",(VL>LJ
MXI1UV@X-3D/!@_WO7A<,V)EF]55IMKK=5+6_:[+4(7P@%9+;E;*H3D-Y+<:=
MS:U/1?(4FYT)HB?-4XZC0B->+B$QVPFQD3:$)O]"48,#N2B"I9=H8LTVX)P?
M2^!V1_N_4#*Y\'FJM3B^1N\I(X"+S_U7JAR((G56C%RJ@",R='TU.I:L`@^I
M6L+(6F*B!+R/X.$NI1W!L]A/"@!`.??<UTT:N)';1!.0J,:)B5]Q3=YZ7V4*
M@@'/$F8BH:!H/:"'UG@^?LN8&HC1J"02/:0]"R63H\GH7208A.BS7]:;2FW<
M0\NQ88!DTUN`-!`[`QT-PU92":TU$6?M^8=<TP]I:,5#`Q[EX!?ET+JR-+0Z
MW(:A;EQ"&/,1GCU4<3X,A07Z]H.<H^>!*<(0WX07ZI8;OZ#+C:Z*VC%TP^60
M77`5U%Z/1Y'Z"$6=&NL,E$7^U"("B?$`$$;I$FR-(28UE\XORA5]:K*:V!0B
M@4Q1NKQ'-!X_I)@M)3*N8\PV1C(XW4L?97FM.[ZF'5_:-D0<U#?0HPBWTK>1
MEGFA:=DV#"2]:\>>%KMVOO0"?:A?$D\Y$@\1S9HF7*(PB./4D+VGP+`4MF5R
ML=98W80B24Q@9FW[R.(A5>D=DK+[E)P1Q`6=!8U_QX)"N8:N<V=0!*LKE&&%
M&Y>&RBY+"D#SXQ$YR$FH]PD#[&67LOK._<(ZDK<CB=;@S(:2OMXNWJRS8;'!
M0O0[W5,D#3LK'ES3V47XGK-Q3'W]@YW9V@&7['ZL50B[SVH;G?[VXN9U='%S
M&7TIUR`9G4[.8HSG[@[)?=?LQU2]%&._X6UX#PN4QJYPI80YM[V*AHVZ`MMV
M)MFK"[*SO<,T%(YJ.*&[:\ZYY-J[+J:&-ZY#GNMP%RN'0(,I-Q+T47E!\R9.
MXY%>-V/9<N_Z@A@6+B]%I,!@N;^0/0'EW<,0*+:\&2P\Z*R.6!)\L18?)A6A
MRN.BJ)'5#^_)51=,ZM;UIC0-59_0@II*RH.%:<LP8.2A7B`-[%N00SI2+=HH
M>'QP/#H^<)C%?S)R(6)*T\K7MM4@W3;L-Q==Z4JC,:+G1XL0DB)MX,'@$%HP
M+\G==I]R7Q=.505.0Q8K/N(D"(#L/QKMM.3"VAMK"R&:Z<6@#O5TI6QE&`9X
MR]_;=[)D0G?1!38&ZS6V01B!XEQ2=#R].T+F2Z:+<H[A2"WB;D()>QA$V(#&
M]7Q2-=!UG0IPPN!TI\$5)4P2MTCG@C'4]@1NH/9UX(4$(9`H#6Y#<8ROL;B+
MLQ@[T\PU#/3NC39-]]_T([C(&YPT8$#E8<G8B3)CSJ)]>#6K5&IM<LSYV%>@
MXZA37^[@2BTP$EC>VWS:,Y`!IO'.<-[J^4$>N`='CRO,=R.DIV.,81`Y,>:H
M3OHM?:3&1KDG+30$W)4[+)FGBHVX!0=7-'=V&27F8<$J-4^-?>&I\`MW2-(Q
M2+;8*D[M;`9N(:&59^_R\R<JRN.=5:(:CW0G,G`CA5)1926&B-N30KI<Y$:R
MTE`%PX-YLVU=^#).3:]ZXZM$SK/N2^Y6#GGG[).:E2;R\9)/7(W)IG(MYU8#
M*R[I1JXRH!!-68CED8MAXNH$^>QY)?[I%LO:XBT)7M'AI8ZQRRRW<6@DH@U%
MD[GOU2K@%_R%(G?N2R9RW$@QQ`P^'U0G\F3IPO99O&>-B8Q10G&)U?+A.,Z/
MIV+#T#=KF(>+K(XV:WF:F`==_%F5IMJZD.@*A;$Y![2(TSB1-^#IMR%V!2OX
M6I0/>3IGDX<^;XZ8B[0'XQ,90`_SE^0Q[2;H&*YNM;]2.Y4ZB]X<TPM(YTP>
M29J03A(L6Z88;8IIN-Z46`>V1'S+Z?4^X+.=O,;FI4Z*F=+M'1/XG(QQ>G0P
MFARP*&%21W%/%BJ!;$NOH`2B)MO^S1$:LEN>EI<\\O5T@0,4#>+7+YR%ZY70
M%67IJ)M,9Y3R-H0J%^S%-PE+_)+#Q*_<2N-D,3;*KC,\WJ9![@4MQ^0HFNB[
MG6XERNYD_B'Y1FJ`>8RAS3#`7,0:]0EI>WHDHE7]3YQ4XLJA($]"*X$;5Z+U
M$+6,$:-GOQ+!X2+:J!H[5M,LV;9!,=V,GF-M1$VI]*D;K"T+H_6(C0FHMH$$
MU(C+ASNID<OU#Z#S^7+'S$K[:Q2[D"60(JI2:@0/`F$+`-H&GO[C-X$K6*2[
M'1+2^XY*/YQU3F@NO[?E1+,JI_1$U.F"!`L^<ZL6$F,R:B-6G5$AQ#"A]CPT
M0:FF4(?V?1$XQ,6=!LX4CIK<44`8GX^XI3E2^P$8Q0/JF.E#QP*)@OVCI&7P
M4Z3G;G+*F$"#=_)(1D-V<K&O[$T/76S%]B@?L'NT><$8,AJ&U0\]Z<F-%AX(
M=)F.&^-)6@,2?RFDNAXE-&$0H3].I_ZXP_0EU,@I3/[G[%$-9SI[2C6FNXE6
MF`[#S0JDBR''*7$F'K:`PY:??<BHCA/DB0%)\%>!C'*^!B!G"G.2&-41(DMY
MD&&IZ9!$TFQ#0Z='6+=9&2#:K#.79N7A7"8%U967+1?#K9+'0ZF)^)PD8=9<
MNHDE&9^$1FKW0PE/%5]=(`(:#;.5,!`4"IV-=L$.5RK*R]H@YSWND$O%.F$[
MVY:LUX-9M:L-83P6':^[H<K\FO1MI:CE>9ER6"P=O7V`K-)/G$-<^YH+E;C@
M-0H8F+IY:8DE69'9HZ5#&B=$K-G43FGIIK7A`FQE'2IJS8F&92$4F3.#?]&I
M!GBTM2GV0SF4%.Q<;SN>[F5@:GV/45ILFVY;8(,T9KUN^(4X-PMMF!4:;Y4/
M8JM-[Q06<N`*'HX'^R]?&OOW3@\--UT>>/Z35+*:G)H<3W47!(F,),E0X<I[
M5WRK-Y]12D!*V13=-95`,>F3OGKM-]0`VY-G79'8J%TD5NNHPRA2A(@JX,\T
M6H!LK/6`L\1XQJSK0%+XR+WJA&>GD!B!^D::5"&,Y[Z[]]G!<1R]B'H/8`Q?
M7'CK3QSXHEQF6-LIA4P.!=8TL,TUQARCE`N'P_[EQ"^LXP;U<#:6/%\B0L]0
M`YIZ&%D<(`XEKG)IV4".LGX9D_+6WI\O2.J.<<Q=9!9<@"EF*=PUJ+"QL92/
MSUQGE:Y*B:O&,%8N[\6N;>\+5WD#RT1Q4-N<`S9'33EBKNHBH$NGKN3)+!4*
MK`-Q$5,I#$M%^.=<84:AP5[=/KSS>"4N*E?YENN!PG%CU)`ZX5ONQ-"H3>[W
MW'5&0@TY>/Q5](5"#(P''5M.IK9&PO66"5[YNA<=ZOPR.HR/CT^HS(^SD4[C
MH[-I]+Z+OZ^&G8#3HP,54W8ZQ$E\?GXL&PM'>AF=Q=/30\Z&=9CWRE$=H4/X
MV.1@XK,1)Z=3AH@SO+9OI8Z,!Y;<EO=;_(BVIQG+0L[TBQBF!6K5D*K]/$N&
M\%H-_H0I9.YQOD(-EG16K`XS,<?ZP=AGMSSVQI7.V<9/!L;M=<.A7GXV90O$
MT'MD_/4SQ]8:`>]2*T#3\*.G/L@`-3'Q.,:52SXYM3HT@?]XP,L;NP($NP^4
M2T=9R99F'T-B'X+CK-#L^A1IQ=+;JOR:2CDRXKRL5&@]ZO?41R0KUALQ6!-;
M9J.WP/N5/#0A:>:/F]+%R8F=B'@X"Z-\M3@C;N:!&)I<=-8I#<B2CI77REL4
M&R5,@Q:F)]5OP7$%>4O0\ZF_B[,/B(A,U9G%R]_-T.35'-)J[#HV17<ETOV%
M"W9XZP[A3J>LQ@/7(Z0EN#!G$N@I<1Q3MJF@M`;]#1BHAM9M[P8F!BXE^I-*
MUW1$W5J/D5]T;)2AJT=,0H`)GS&Q87![6@FA>*D8"7\)5HSIWK9JBPD(G(XB
M%@C,"PY2Q%$\Q+?4&+$=&LZS%6B@9.>3PQ4EH7:HR>?-P[K7\8+8^(W0FU:X
M/H0BTF6UN^3LKJ#G)7&(WB32((+0**7P"?%S/7'/<I%)W'+G/2NBZ=7EF!1\
M/-0<BEFN\5+*,\:L(:J(D[2I;8,)!O%^=06QXTI;!0<L<6E.P4'VT!&;@KR6
M%IPV^2H(PAD$;>#V'`0GFUJ'8/D-.Q)(A^4W7'.E;"7."<\_X_`1KJSC[([U
MAJLIDSB"2_?>'2TZ1W[4*HS'I]A7*4PE];XDF(T^PN361RYR-$,M%0Y;M]J2
M!)W6&*:#W6*U&\*#?A9HC^RY0W)&M5[](*A]54=[]'2YJ6'&>O]5],8DK(5&
MD]\SO;EF>O,.]2:B-Q^$WNP)/=L/*DM0D8#HDR?J[Q@5Y>GI?O2C)?GAMX?[
M4@/E5;<<VLOH:!J?3P[M+\A-^'\6)#59.V3U?=K6,\,9V?=5]/..E.UE-#F+
M3\^/W$C!GY<[7H&3^.SLG-[`?_P7[ZX?/[9M<7H<GYP==M?#H]JC[U;[^;L[
M_LEY?'1Z:G_YJXY_VW"_\/B/XT,#;?O7[H=_<CPQAX]__=+#GTSC@\.CSG)D
M4,/)Y]F<76*2`!VI0:!K8B;IEM*Q29E1=A,68[2A,[WF]3ZS.@S*5O4+VE&!
M<1J!">(V769%H4'-*;N:=`%]MHAG)LQJ(W]WR.*0SO,C,7>+\=OQ^353W]CU
MC9K(]'H0ET&`3S]G[L2\;L6AZ>&93HLX$>Y:[_ZS8;7/L6G+H-J18YUX,1:)
M6L()>4H,MQX]I*C94^??L*(&EH;#HAHL84G7U2$E(O0G^4JI+;G`]U`-I8+8
M!TP_V)8T%3T6A(>(>NGK*#CS36`=D"*+7,.<>UJPR"&N+B>Y$!61K7:M`A>2
MY'9ED]R8W&J?0$.VVF]?<Q0.OT5#8>S-L*W@VV:++KXI`\_YE33(Q(E,[6L8
M(F^72;4"J3CR!&G=Z>DYX?KYR>D6LY2:E(;,4_Q_$&3,))=]N\[9"\^='D73
M>')^AKE."VUM&RTPHF\2'YR=1F<G!RXUJEO(0?/N.*/R_/@0C7!'1]'G\BG)
M"69'AY/HZ.#,541\<E<4OIL>$)77_7@9UUFBT#YW"O_>N:0,\8G"),>GWWJ`
MQ%W.I\A/)B!CG)RW\>=]62RYSND;D)[;W^)GQG2T!0_#<=#Y@8T=S^CX#^F&
MAAZ/O$RTV,*,2_"VO!R?'A=8/(@]J"FW"PDKTU*?Q#@XZ)PBC34/Q\6`W:(Q
MY$%LYAPIA3QT=I=R$<8#/(@<L68/GWCQ'A;W0AK'XN\N5IPK`RBUFDR5;YE:
ML"/*)W''*527:[D`.<$`KDI,(F?CH^/OHMA7]+I]PFX`?DPI$FCHE;AWI0:0
M8`@K=JZ6,;53O^<+R%UMWU&T2)&:8)%&MB9M@KDKD<`/CF?RG91(XCC,)[P@
M0D6/Q\?ZI131?'+1?R98U@]7DQ>YB$94)=IIZVCM4=[%S3PF9W`SSTZX"'10
M&-1'!3<<)8VN+I_T`V<X'1^=1NJ.QG95V&PC@?U'HWF"S04!99:NBI=[KS.!
MBYAVW$7KD>&J.\3^?;H$$%QSP3GT\L9<B+_QEE<G4E(J]QXFY]7[[7&VO[3;
M#?S&I?S56^F\@'@&2Y3RYJ^SDE/8N;0_IS_<4?<LH!$5*`RDIKSW_94XV3#Z
M/#A$_VN?3+//0_69D5/T3<85LV'AF\J'DKB/X6@_5>D2Z\FDF-*:5,L-V_\+
M%Y*(;M.F_LN?_PWNI>;)`TO03D+Z$0@+V'Z!4@S?IK<5+>?(>O!:B]&K0KW'
M*C%KAC,`.<"?+$I+;1&J)^4#P#DH2-?;OYR+S1)+!QYO60S;12328,8!5;<8
M_,#]+G2-[HK;#X>`)$L(7UKG%!ZU6-1HP+^70JQ4U@JH'8O_9)O"Q]0DA2O$
M*K8(C%0[0SI,6#L$C-:I#VP#^6SFZQ[UK$NS8WUL!_>U$><V4+C4@@_/<H+N
M9K,%&>*^S.%$N/:`C)YBN'V.J47!6F5LR@##;<^I<R)]5J?I5W%-$4"8A=4I
M$GL[A(..SAX>)44[(6<HB`K?9\NR`C&-BK+@.?F4<.*]Z5>,#H/UV[I&&'#(
M/3,!(MFJ/U:'&`=MA$W3JMQBZ(H10-J1;Z2]T*B]Z7I]3G+:DB3:L<]!!F"C
M,,>J,KAP/%MQ`DAFXAHLF_5R+P/._I5GJ)9?9DI%Z-XY^+OF3FTT@*3:,\.F
MBKL<JY?,N>@ZZ>)A22EZD`*`&#TQ!IG=HR9E6/K-V'PRNN,NG@/O(^\8>1F_
MJ14D)*!)VNA0_,--4`8EJV0)3IS@@;DYLC/+AZGU#D18$PSC@;F_E!A7,"PW
M)RY`\K-UK^*+A'%UV@;HSW(.@42H[E;:5)/053!UO)TYWJ7AM0,W<\\08-U.
M]*.9:"#.,\!N2#,*>^52>:G=`"?VU<;)9D9E<.LZ785]A//5)4G[M7OV9X8H
MWW]7/V77UCU1IJ%J-![>0U>YIVG2*H0TCJR%^N4QH'W4:I@'*:N15BZC,`JG
M]5`LZ<:J$&PH%X,3>2?UL*BT(N^[2;2G(FT*-@\HL5A$81>F#9Q\[EP^L]*G
M^+A7,PLS(#(?WUQ8OOX:RW#@?B.F#4ZK%"X/%!FX]V.IEUO*22!-O4[@AE3)
M^BYZ]Y/IC8&CXNT'!$`Y#'^^IQFH=:R4A@-.='%[BP'8-.O']"%Z0UU>C2-H
M#]>ZC[<!Y".#A!@W!3"]F#7)/1SB^X0\L%QW_>U[D6+VY.O]@'9HQUGJC;!,
MO*F)$NQ=\?J8S[IR12TI@0?.3+IC._*E%31L_TX,SJ(&LE=_C`[&DVC%P58P
M*'T`ZDSD/XGPHT-]1AXY:K]SXCX@E,:/SO0C4CQP+0&L8P<>ZDI5S&M_0S2=
M^2[-B?SP^=I:(B[D(,\T`!1?_$0E.*/76/UZCV0_S>L^B4^/S^,#^(>_GDSB
M<U#W<*VG^%L\.9RJUD"$E7!?8[YCVVNUEC!RC%@C*+.QS+8-$.T#K19T?#?8
MQ4GUL/-]\PSO0&IGP)%O+"/@7;^70,`+I8*QQ%\"EF1SP(,B128S2[4LZ/>8
MFF5R((`'H?$D=3523!,$0J/8XI&8WK@H%3=?H<+@C$R`[@.BK1R1"#-\@&YJ
M+OJ;/-2;S)<<W5$RQXOW+]C3_<G)+/WW*M?>81?%O'J$$=D?2#D5\H8^P48U
M'N3::A;8:$F`X.59"G1=#TVKUYFB!)`ONM+[3@8<NU<QRE=@A`)!K>UYV7I:
M$6MD44.AY80D`TE9(=OJY:Z,@Q-HS`A(9P'F1\?<U\C5#"`ZN7:C!9?3ERV@
M[WY(FMG=Z.?D<9607TG*\I/>[V-$N4^V;!65`*+DFD8G4CNK^-Z\T:EYL6U9
MZ&VHN5:79#IJ.2D,#21J44JX[;DB9J]XS+Q.(W,/GE>)T/*=CB3)SZ^`(A#Y
MP"B8)=7.#@]"O3E5L4+N4'C-;:R200E$><F9U03L@2M/1A+I5GYV]IW"AD46
MEE3TZ@Y?O)9*@)T]Q,1&DW)A&9<=830&H2_T+M4:WG!U7N#D(%V+6-H2PUI%
M?,>!#<$ZLR38S]6F!C;(U5;:7=E)3!2/UF!*KZG!K#D*=QD6J9+#(;;!&3D:
M11/&%U1DOS6&NR"N@8R_INH,)YRIP&,74E.%OS$V)6Q;=J4AIR9&Q6+B3C`2
M(^;43GN?+$%>N(8]%$WP1,$%KM<]&D)G3VSF$PG0B\YA7EE?1>&!K?."6E6P
M2&-VU5:1ZUO`RPY-Q[IY=I_--QQ8S#9+EE<+2?.C`N]\.B9=F+:[R1OLP.<K
M2ZFJQ]RL/;=$;"?41;I;^4K"OY=+%/0P^Y8+UJ&T)?9U;F!BE^_+B5+Z%%4(
M$,]:3=!6A2_N6Q!CVY)Z<Y@3()*78?ZNJMR;(A.3-N8]BH<J#;`J1(?8Y$"[
M;`^J>S]G84F3DV,?$XV^8!+Q6?-QF3L<?<?9+\$R0:R^QV;UJ\3U'K9>1\&5
M5F573M1W>Q2;I:E,TBK.<73B*W/`[[XLQ^]`R$C0>T+!A!=AH2QC#OULBW_@
MUN5%*B[RSJG1[PK)U/=?(TSAX_06B%<A5YO\9IBH\M]CJNJ&9D^O@TJ;&\X=
M6^I`G&\^3U>%US&`=V_J=J*/*UF)U>1;;]12)XRL;<`KUNJ*_Q.AJ-YJU><"
ME4TH')V[/">Y0_6&4@(E)5[*SXLLZ!:0,I%\$N4N<!*H;:%Y6DL:-A+5$3^O
M1IABSM7NOVU+Y0(>]#6%5:E72<]3;S]1E=4N_9XM=U($@B($M18N"=-*G3IK
MHNM8H>N`W#1JY^_%58GV`[R$X4J24]J=M3@NT\%6ZRT0>:;$;5]DA1F^TR-<
M4*?W7-,PGOKP8*UZZ9V$EO9:M,1JVPZ7<1Y9;Q)*R,)[P-9Q>QA;?OTKJ:'3
M?D8JZPP[+.P@*#7*"]>5YEIRP:1V00'<J2WO2G(E]2VCWF3>>;1V`Y%K)XY>
M'HSAB0FBE;C\7<M19L::SC/6?K_V?19HR1A2;S!X0JQG:]\7$?\`A@?BF:LF
MS3(E*Y/>K'=?$C'3(8A+HGBF'\!%%'W>?60*3[8FX6ZGB7QE%@.`@LVQ%&[#
MF(.*F41@7Y?H_@"8O7$WD=@_];?Q0-EZ"41>)DKG`$>',=:LE6\XT.EIWY%:
M5]TWG:=UB![Y))R+T.?\'K,*\P+-1U^C2VZTQ8VD1ZC\ND$F9VJ`LI!H>;B=
M<S/9=9*]]]>7^W'0#KS+Z!%:SBI,KB*L'0,_X66!W<MC[]#&'%X'/C/.K^H6
M,&TM(V4CF,L95L44FZ>O3W5XP@H="2Z=HHQNZV.$>=#DO/M,3%N@/$@N2"-/
MS*/I^-AM:)?=H)OXY120PR-$._E=\?7D<!)/IY,!'%.X$DF?.4T&K<5.@$K:
MO1FXP^9".[61]R1D"&3?I6TZ%.V40DNEK0\_QKE,)3?I0G_WT?C<@226(NF2
M3D<*LEJ4@RI+*`Y0))4K<&2$6-FK)$KSM.Z0^ESE0;'3SEF:V$*.N-`41QC*
M^8_</GOV=^3V1QQ?E^8M+2:NALJ!<'U?''Y\VH,N[?7'["N9>^G6'J\C71>-
M1-)&[S39\X9Z(UQXR7"D\2[3(PEXP0%[<WUW&6[OXLN'?<GU??]3]+^#AO@;
M&&U,1`*/\T/RF*VBWU&I?B(<I'FC8%[OCZ.W)"!1OYR2?]HX3W--81HZ!53;
MZ#J(4Y#ZZ%6NUB4/'&\%I=XN?C:2WD28CP6@I'`,LOXX"P;W[7`GWFG5Q'/%
M0M#T;(D@<;A'0.'"T9A[P^8H=/0^`>T*+:2MLN0V&\(I78XYRC["I#A3NF4G
MI`82=&B7&2!Y9\L3@_%;(F""D_GRP=72D**^W+=C^W5%T'1"?[>'_'Y[I/`1
M-HE&4PT-0=TAU!QVS5ZF3TJ.Y/K@P\)9CX.C0MF<+:<;.XPXJQQ5PS,XB@^/
MSRC(#[L#2DE[22I3OB-O12\GX^,3XA#421`%AA9:XD.'9ZW@,+,KW0'&BEUA
MV"D-%!0T*(22=*47CJ;2TI$V&NI@?'S`)*WWU6U!4`=GGN7Q/>A9K@:P$4B1
MDX]0_Y=&!6N7ZLV&&@&XM-ORE+ZP[N[#^.3X,#X[.AGBH^J>V!+\%9]-3RA4
ML7^(<1=)XNX2%2A:Z*M_=W;VWB7A[IRI"._F+HN[@(/(6T;EOW)QS\*5BB[X
M<^BPT6-#5*2``U'2]H--/Z:T0Q$<SLDKS^\`G_)%18E*O3PB'^&@\.)@AG^8
MADHD@;;DFK9$XZH8MML"W`S#3\*[72T'SD-&ZT+JJEH,I1_T%;%Q>2CHAL>Z
M%;C`Z30^A,MY$Q3LM`],)O'19!)]6FNU*;.`]@H]*;\T2MSTX.`4;5XI-]ZZ
MS@&+`1L/3DYT]SL.JE5O9;6^X#B.>`*TE3-=MHYV=!0?'7>BC14T0Y_3H7YF
MQP)U,=@I\M&]_>7.QJ@C]Y?Z#I1)H*16>W3LFH#2/G-S3]S,@:?WT'_N8Q8.
M)E/_,9,*^&SB/W/#]GUVX#^[=)6G.=:?XZ0]#.AL/GG,ZJ:TH`)^"$SR$/X_
M.)Q$)_#9Y/0DFAY'IR!8G<7'&'_.^M$$N].?N$RG]C_Y.ICNBOS?\\%W]C#Q
M95]_A"L-`"^##RP52U_(K;KRK?048K"/X$S.@J,X]2=PZH%\8G_]*2$W+THR
M(QK.0=@D1>R82QT'7G]-H]%DK#0HNXP>+S*$]7T_-JOPWR9A:<WWVV;H7;TE
MV`%YU+C0KFF8UZCV1`S^S0IS,^+6C8C#FQ";&Q`;S(]%O5&L5SMND.+]7-YZ
M,>]D[E/6G.MV^YBZ&L$A$T?Z,93996FU7TZ[^E%@<@TZZ&I&=I#F*\4++JC0
MF*]\Z*H@[I!MIE3-ASW6KLKU"BT1J([`]]UY@[8/VW.3G^FB0(TA&NXO3T&W
M>\*/]X?Z0C@(9C;+_?FL?1\\9N@\I:GU\^+_8%I]TU395Y707T8DG^,/D.]?
M@L)'>9X'XY-C_P,>F5(R%Z?1H[:^1R5=]Z.C\>DT.AQ/@>R-C\[P]0F^=0;_
M`4_^J<0P)4*`[X",C\_/\.?Q^/B<_SXXP)^GXX-#^'ER.(8MPL\C'.0[*E@X
M6J!>1[DIW\'@QT?TXP"'`7EM2C^.3^G'1'[@T`SU;L;7?R24!;SG!SW@!4SH
M!^\A@I?@!FK[!%Z?((RG;<@>CT\(DB?CLV/\>8:/$&0/S_@G0;8'HH<'#-%S
MAN@!_3ADP![B6$1^=&WW?E:;*4F!NC8TP5M`LQ7WHS)O$N'VQ;!\Y&7[42Y8
M"J0#Q/*D\@43&BQH.'>-@<;A&O-L8?,XJ<2.75N58A%"B=AIM5=M$0(IVAI"
MK3W>G]*JM$E4Q'12T`%F3=`GFCR/4DZ%!W8>EJ<LY6HSODII0%]@2IP%J]3/
MDDU8?%9\':90!#$BT7B2)VUARU.I^]=75-V%>.\HDQ*#VZ*7_`?3/19"?V[O
MKB^[FI/>I_'QR0']/)ABBO_)%+^;G""!/'-)\6'5,,-#6%0]B*?G_:*J?.5S
MN!?](TWC$YAR>C2%-TXC%#`/04X%*?4PGGA0!AMJ96UCNN7Q.>WD#"@Y_IQ0
M<O_I`=4P.#O!W?D:#P/RG(A75X.28*\<-RRN2;L:\L6KV]Q5U!.7^86S(Z!S
MN0PS.,FS0?D^8ENDO$@G_I'A4U.:@M1-=".@C?J;\O[^BIP_,?/]K1/_PDI#
M=/UV+C6$P)M3#8];/AU2;<^1QL#E[8A(EMPK.>"&,=YN9XD\K!.XTN$1II*F
M`6M#BDZIE\3BXC9Y):/S]`#?DP1YYX>6K]'!^EWTK!"G!X^^L)?`=P];1LBV
M!&^E3L'TL"@&.Y^=:XQ*F9=-2\#V5>/P.^._]*W"*)O*=@JS[J-V]8.!,`?I
M#623RSMITMY*`:`)TM`_2VS%)?<UL6VV7+>A9T(D1MT%.#,1[,^99[R):ZN[
M?:"!EQ2V^MNWW#([_N4MM[P9TGT;]+[Y7[J[%M/SOX_N6NW&6N-_-,6Z^T=3
MK+_GIEAVW=T.6:')N+<F,&4$%7H!;`O!H8NTBR6E'C"E;.UWL*W/0:QIMC`4
M;+"M$7RA\3[P.%?A.#<P0_\W-`/I\_ZWP79A+Z-S*C1R1I+N*<KSAR"AW:34
MKC?67E/"MTU/==C[,>CLDWAZ@K5<)B`X3^-35T]M$.0@21_1C/'1\91^3D^G
M5"IY<G@2,#T,Q]WQIKI+YM%""QZ-5)JT(EK0$:5[GZE1,N4W6*R4"_0W/18L
M?DS"75@"<3(^08L#B@%DUT&[PW1\<`(_C&7C])!-$?S8Z1'(A6S=.$9[T977
M^+'9J9I,CL>G)]%!=((VC9/QU%A66OKV`9N?>G^08-T&<,OV&D+M%]4M8]<C
MF5_"H##X#*!G(@?M->KVD/!5H%K:PRSMM]EX*X;KWN5M-E2)^*^PVW")+!P?
MB;90E*0B,F:R>+=9;:34DG+PI=%P6LNN:7I20Z5POU,A<0AV((IH1%VQQ.O!
M9ZK$-#0$];$\YQ[%OE^%=K12&"B*J!"@HRQ0I>-G2?8LW)-DV'J4[W8!1LC3
M^D`QM`U>>J_-*<2(9XQ,V':%R_*$-B7"6+$_Y<X@%1BB0,:JR[8Y+20)9/YR
MA599[J)F#MC6V^P4)L+P*;(:W($0Q06>@K%ZNIEX6=JUOB*9!"9<I!EQ>J=^
M'G]'ZVA?<$F^,*+LV>"#`(J,TJ-<=S&$$9D*VV?I-8IPU=)J#84B&TWA.+KV
M5N#>,FX;+$]@Z2;IZFUW/@]'U;9J3QR9GG%ULZW#BXD3Y[@#\MB99$L+'6FN
M]/(X/CZ;4@PUYBL71D`,^.B,_42F>Z;W=2G$M8:ZMS"4W:[IB1>6^B^VU@!P
M\1HDTR==!B!2*T5S'A_QW1W:<#M:9WH2'V\-'==D,1._T!,&,=L>6V&54@[>
ML#,:*=A",UA%&YE-0&TNU=$X?L,.[`,:3=C%TMC0C6!55BXB&P<,NNZETK&)
M6O-A'!B3)D[A(R>>6-QPKG'T4Z!RU7U<N>'T`%\4!M.G4^8.CC3S&O55NB*<
M+X\)[=16"8E.)@FH&C"%AH&(DN3X#GBVX,(HO5[_K%"O2JK&@828JET\/F[(
M*`Y?BF%E[UT!(ZM$'?TL*!M=",I>J8622O%&%PXEWP&OR$#$GTFATM9`)@*"
MZH"V3.1G\3$YL@['9!,_`\'L=P+QP_CD;`HRW>EA!,+RE0LOVYM$^^AB`F$Z
MND2LSM$RNH>5#??%>7C2F38,O>!H)'28G:%$?78^=38G@Q?=%T_BR<DYK?8(
M7S\]XA*F_GYF#A@DWM5MWSH%0)@9G![7GHGNL-'&0Z\8Z%*$KFKOW:Y6U[[1
M1%G0@C]>W+RY^+WF9VC,=MFNO<UAI*<'[:C+P?VRG5JL;]JJT;?]#%J:ZB9Z
M]?*=[`1=H[D+2LR?#'7O6#ZY@JBT,-V3XJ+[0]7K@J>YM(V0]V'39O\,.Z[C
M4V^P`5L?Y)K/M[G'_G9:UY!+287$_BJ]WM\'5PLUV+VC<[R;+S4J"GXY.3Z!
M7SYD-5[?I$@Q$;,_R(*CJO#.J[^+*=C`TW[*2=^4[2/X"%A'_=NN83`BA9U,
MOZ0J*`3(/;'EW+O#M<H"2+@GR_!SS<U,:]<8CNZ:HON=]*0;[-#+QLKIR0'E
M%;NEKG7V,3;N>)W@!=TR`1M--Y(A0.(X7A_W1M+`+;_=-)II8&^CI#AJ2&I'
MU"D<H[%S!M&A6#`EWVA3H[^C-9)4R#GDODR4)>==0R3I0?J9$[LZ(ZO_P$5[
MP8ZP3-U]N@U,U^[I\"'C+95/:&:$A-/I;'#SL`UQ0+J0QB[J+3`A:@/+YN0C
M%(Y4@E%>)EZ5X9,V6F-6L11*J:(/6L$`"[2-W+S]Q`_WM`NI^[G/;QLP&PG"
M/"<7OG%,]3\MDL5Y?`9B"-.IP\/X=').]?T/SCIE2=LU43K!PZZQ&-</!5Q8
M4F]L;E&P8_'4SBRH:ZB_&W51K:30D_,IQ4FXGE-?X;K_5VN1N#)2VJ&YIRJ)
MQLY+A\C_N"(E/E/,%:X()_Q%54GPJKC$)[,D;^O!Q-4-A\#+/$[9:M?MD,:O
M0JW:)4W4Y:QMRLMHD6]0<T=_(MYD;7I<.N_4E^X<-7!D5K_6J)%U.O]^<TD0
M!6N5(MRI<(=SJG2*=OPFNBL?T,+4J0WCZK)0%C#>73MEYJ5.;"&N+7O8H2+M
M\VI7?`36S2IC29HP&HZU$G78MYR-'[YE8HFUOS8_)8_1EP]A1V#?(5"*#]%I
M2,M.6V%A(V6L73-5EX*=`"7"6GX(JX3>1Q3YL<@HWYZ5P2^`[W7T`9@NAN8B
M7X15D1Y519=TXZEHR8<W%Y>7U#Q/A_DA+0#3X<5_269?\:6W""?OL\6M7'`%
M2CW##R@&HKKW(9VC$R+5(H$PP0__\I:&9S.J&&:EP"?0]8>RRH'PS6V%T(3+
MJTDU*+(X*:LMTCQ;I^MLM6E&-X!W0*CGFO')39[I5?P`"\!FR\*5XR.C(P]I
MVF'5?OQ.53SF]S)%35WB9[B[,6<"LOW!QP%FM1Z5JT9J"<*:RBV++9$;&Z=<
M%GZ12BB0V'MB+*C;IFK!$T1`B!92X!*MY)J3K:+KSU<W5Q^_2),"CX>FQKXB
M=[=R/WF''S!Y%M7)01+NZ)2,[0KS$$:N4^#9,U_S2*Z?%1-\V<!T=E>4>;DD
M$_\5A4$B7OA8W%B"[7O*[S_;9?CB];M+47L13.\Q]1;Y04(A-"!:2E;-E_0^
MD5IZ,UH\:K=4TP<&X((^K6K\:B^B&3PZ>R2FLL2>DSA^`Y3Y75TE*;<^1IN2
MP%")X`S%0`[MH"AZBEZ%A>&K?Y!P.-\!-TT:Q8[;BKI)SOB.F]!R1'Z=7F1C
MK'LG8UQML!@:8*9>WIH2AQV;T]9V,2=5BSK#4GBJB_>[<I(QU1?QVP9TN<6"
M#&3R):B"OJ\4$$WVZAY/I"H$>D,H/;E*%R#VM2&'8K7F:P'`]#;C5WQ(LC+A
M?=H(VM[=;?@3\\FR2$;$62HFUYD)<C6B`?PJCN"`^KM%QZZXCRE?`Y.64CD2
M._+FEE/%+8%'.P0KGF0:GKR4S.Q42_&R#$,5KSI7F,MTNHLL$&S=9SXA/A:"
MB"OAL_7*67&9;CJ6Y<UYFWD6$`R3TFS32S2D@[E`S2V=V;B-%4R[Z;.'3&J5
MHVKA/NP5OD#1JGC*][&$M%:/_9)0[5BD`-2`:K69E81;&L>#589)9M#7H[TO
M[SZ_W?=ERQ9:;S2X"7(&#?-AI`PW#7D^"!!<I/#B=;3WZ?/_,;[YP@W*`6K5
MDJX*;I3/*:!!3F3@\\)BK`_I/"TDPTJI3O[DZ:FOLM57[M`LAA`AC<U=CH.+
M'G->JM^NJ\5;YCAC[V:%8)"[RJS.U&QUPY"S]9L60*7W5G1A=EC+V#V$[CQ2
MZ5TS>"&")"J\+4OV='%]9!/0@<GR0"?WE610`\56?Q<$):.@"'`]1,)-9>^R
M[\5I2N\J7;,:1S$WP5]:.MM6H<5BG.ZB$OB!IP.:9Y)&1I)&0F^P3L7YH)XU
ML8B_'UPXA,)JL[+ZUH(<P%Q,\QFF8/?$>&8&RI]LX?)T@0:'.FQZY=?!A,FT
MKQ;L11\>IG-(L#2^RDJH`XOGQ`[CA"2Q0[45C0AJ`?;8X37@25M)?!M,@]!(
M6JV`B*&-O>OPH3:XZ=Q\V30W($[-PRAD;M.GDO0B3,4CS]#/*"XN,@%FGFP*
MJA?9PC%/U!4`,/RG65-J\@0I,@'3&`9>'.U-]EV7'3X#VW)HLP;H*L]*HI>^
MU%%7D-4<Q]9RO`VK5UA9!/A)JS1DI3+[_`V7\YO2>OVM0/D;?M#:7T5[R;Z$
MW<#21I1PH[HFKJVGIY7CF7A$@;(>SGN[3YVA'J)Y"7PG'<VS)>C&RH@]SW5#
M8/0I?%B1`.TG1O&BS;VU'/$<(^P7C<@Q'.A?:*0*/"+5!M6XDI`4I6E,CE>H
M9B2UOO>D]Q;@%%;ZCO9Q">)&E8+=6EW&U<CF"HA8ZPW6'WL]8(E*58&+EAY7
MLR<79$TO_F%39?6<J\J1M4(*,G.4?#$"'$@3=A'[CM`67V$TIVU)IYWPK,GZ
M.Z+_U=*B``GZCFF)0BE_B&]7)394:5*RH5`=:.YY,A[;/CVHE'#,HA5!>A7:
M`I>6XX<4<U.2*U,EC;W+S_NV1GOLM0PXC@2YRN\NWE^-C@XF<63[$[3L#:"%
MYW5;BY&B;"_HRQ>LY?.#:(!%3Q?,5B(=*1]0!/-ZT=C-&DF]T%I#/%#3`4S"
M3G=LF-/MD5@#UW7D6*U*JV0O=)P8>V34J4GRS2G([_S\H.[7;=*Z%I,X`F!U
M6\Z>X)E5ED1[5U_VQ[(E=`!(L+4J9"JP4H`CR=8]8K4YG\O/X5'8.G9]IA@2
M`UYGY4])C7;O2BP?O0:"M/M^K"M/ZA;Z=L=$H\!\U)0C)"YHH,C1Z=HB+DA5
M*DR7V:3=ZDS^YJMJ;K3]7<D?XP#9R?1T/%TVDHMEVKS)3#0])R-)_(?0$KUV
M&GMO3"1\[ZC<^:FY="U[P#Q=4,VW^V?T%"Y*5A;E39D/26CF]FJ?0U0J2BRJ
M7Z=PA8M][->01S`&DOGH;9:OAM%?9UG3V>B-Q8BH7)MPD2A"Y:17:5,"R<0>
M)H#C)=M4GD:@YFYFZ#U#OPF;_>[+%5>8V;M\]_$GT"JJ9)[M]L)G?H&L8B5V
M_..P)HQZZ7O\^A,\OI/$(.!RI;+[FO:E:N<INCX`EAJU.S#KJ_)$?QL3ZF*"
MBW$SJYRB9VS*ZAG)Q-9:V%*K#!XC'Q*%V1Z,N^_S`\>=.H1LEO>6M0?)`\#;
MK2N#`:=^1&EV<'C`S0Z8P\NC9"\QMD"Q8=(=:O<M(DLIMQ[@X.WR@0R-JO<$
M.MNUV$31_(NF)I14L7:2OAT88R4/TW4744G#&5'ULA"]3Q^I7K](L-.#*2CM
M5&;Y&5J#%EBNF=<*BGLY.3$'$$AD@R3I+W_^;T[40C<Y?*F+1+ECQ9YZ]&NX
MPLRV,E]#@NZ!+?7$Q:*S'>4\.S_YZ7?G#<_KE;TJI6[O;Z52[FC[H9X^&Q09
MT0KI*:E1\:BM=K!HBS-V"3W1$$GTAS(KFIX]4V`@AW(Z/2UMUPAFT8<O4U=K
M!G2-)?TFD.UU;1P&V*LC:QI0)9&CHN8)Y1^T/E#KD8)RFF#],V5C7EETE@]/
M.IR:V+<.'][`JKK51M?D_\&NPTC7W*N$@+N;1)5J:?G>EMV;S-[R$K>B072H
MVM7M'9GNJ=9K.I)UTDA-#^[+#5",E59>ORPIIM7;7J4',R63#$1[X7?\]H^%
M3$Y^[2UIK#WS/SO]WV@3-KB(3!^N.PL>@^^/L%`A5X,0VU>M95]4.7"@.2(.
M?NF"XAU&(8DD-__,A83(57=&4F<V\)&^F+></0*U)-\:?`V[:.XT`3I7>X6+
M8928J![#'M>:;;3/H_HY9@Z>,`9G%Z08?/P=7LU563DON\K'$M8#C"HGSPEI
MW0L3YB.EFMQ8/ACOET;?.<3I#</3+R^P--AW$=5BF6+>TQ'^Z;Y^'4WQ&_QL
MBAE0DP/[[276>_@NPB^FT\ZW;S!J%CZDPC@XRIG]]HK^/,1J.D?Z_I=O!S)+
M6RX*CFO)<J@MESGN@7BWM%/M(;]#;W;=PMZ/(+_.$5_V+4!IPR>'(1@)`),0
M>%3$YC@$V12?.0P!-<'/Z(N6V#>S%]DW"-4WN0]=ZR%B1>DC!G?U]1J=9_5:
MHG+D`F=\`=A08,>OV2`K]X^SLR7R)3HZ_8XNV_'I=TJ<$<*S*EM+<7^,@Z.D
M0KAAH7T!K212^E)6D[K>F@THU8=V96'Z)Y=6UQLEW6UW2?]L5_,XGLKZS_\_
M6K_)QOLER^\0?U^VX>J^+PBL\\`V=M1YUC*)E$L'I4Q9TWM7"!KU*C9F:0S7
M3`Q?K&V$&T,IW)1J)D,CJS6]/3@(O%R_92SAS93I@*5#)`)V'J5YG3Y0=H]0
M]P(9M*]LW9MQW#==&%4SS[B\!O=*I9@LB7;2[!Z.Q*],"I'D5#A`,IPZY_9:
M^2N>,T;9$A&[9N(D2NBU]+WM"!H_2FGW*\EX(HH`[V*"H[)Z7V3FQNWN;S6.
M*YVQ#I_E8WP6R+V"N.]DM`8..L,.5[4F1E,4%78<]/))J&^BP7R%W3X37Y_#
MY+UIZ%SJ]NGBHVP25\(%L]C_HA*#Z'+(83B,,*'.(KZ:H8G%WFA-:A=9-O1.
M8XSLDNK?!RB-">Q;CDH<[+85X[.)*FZ7=Z">BQLN3TMMN[BO%Z=8.,S.G]3$
M!Q?+`ZR#O]?^D*BNBAYY3Q&8+8^:&BS/XPR'<K"I<.;`H';Z@KNT]QN>*1#H
M@I0=UX$-NTNV8^M]J':*)?4++7PRLXONP.)SJG6H)&+DV0=HWY>BGW#2(V9M
MN>/UZZA24^.*)0&T)=.O[%KA-]>&<FAD9=69%@7NHM3*<&+:=;'4G*;37ORE
MVK/H%RR\=8\@[U*3P0<[E7;43<JA'&*QY&X]$38>B[#55;4Q@<*8AP?Z(+ES
MX`RQ6S0Y?\[%K(7!+DA-66$G&U#J%S#F)9E/7-P[`'_%#>KQA@OXN9T8'SWP
MZO1)M6>'*%SA8<4_R'#5O2*?I<=1RA!YYFL"DOE,JICXBOF^6W,J6AG-BZ=X
MQUFU3=`0AXQ[_BHA2+-F([(A=Z+@2%J."2.8<(-8&(+UQ!E6(VJOFVK-_:3I
M/)X]O/-G]@M>\3B25-P:S5G1E/:I9AH(]=3=K76X<9^:8#Z44N@2#"6);.0W
MDZ"V1R)ZDD;@TY=J\I$VVC3>9'X7"9GEV,-`F%+I,6E2>`<]+G0YG]T:=W@D
M&@4W28TWM1X9=0+Q22)>A#=1XAK6BG[N5A&IVTU#$D_.48T4QNV.RQE2V)33
MN%I_:D*^R[`)'WZP47N9+(L/D>^-]F37;[0O%_;%<"P;Z!'2.7PCR9]0/,*`
M"9%`^\Z7'RB(!_LR20Z'%M1VQ>>AL\Y.YCZ$*ITO!C4;RS;"$.VPS6)C%$^N
MR^OM@=:%=>G*5Y"]4F=3%N]K^P".W7(I"CDU[DN8M8?IV6=_KC<%&W446)KT
MF?UP:;H3C@%N(VGTN,I?U>MDEO[SB[6DA;_X[;L"95KN]HS7UOZ-Q@WBVG,5
M<K@,`(E%-5DT@X1-31LP$7NF`!3&:HZR(I;?,/!E[\7;=V\_O=B7T.IQ,+NM
M_5A67^'5$35S$#D;77ET:LM24[7%,Q/:FOIJ-UBWH`\249M8VZ[I]3T;IR9K
MP(F2V==D*<U9;&B3VH;#I6ZI:&!6.2?&I;`@UT9\-#V1^&^!C<SY$FL*'6D%
MA#Y@`5*X"@GMU?2U-/0)-6\W%3Z.Z80[/TB(%'Z[,-^&:$68)+RWPC#'L.@8
M0I,"-7*L/"0568*+:BMKIW@=I'R/US?8S$#D#T0Q*>LC]U@+0K!PWR'LV].N
MOC%)"\$2/()UVLDEG8YRZ83FWE%M0RH_`KT!D0$S?I&LXZ<-BS6<+Y"SRR<#
M],DJAGK3TARH;4^.YM_8V>(6E>OGGBW4#$"<-*MFFQ6F',Z(EE$`=6K'Q[AI
M$FW50#".WC(/"C#9BX<<FIEH)V366$!"6B[)3L[,-5NA+I2E#^WMB,H0N^V'
MG"T.;;VO`-;_'EECNJE0+#>Y8$J&'%:XF(O1$=BKE0?-<.GRR<E6);'<W-G5
M?].9K4"/)$?!S(%K8Q)!%0$C*\I5-L/(E6+>\]8\G1&69V'!)>+_0)5J#H\7
M%9"CR;8,(:199")UA;$;^)ZN`_+-V[+\JAPSP$W-JVXC)(FF'G'EMN&)>)M2
MZ^PX3)_"PK`N`+5;O.<!ZUJ5^K"\&&5H97<E5T?Q8P&+6$@_,\-EN&R+09::
MT5OSO-#&!/@2TEC::8.%0:1'D)J8FH<2X)^N[8AXV20IEC;#W]>28;Q.JKZJ
M:#WW3ZU8H6#<_S#MM>]I]C76K1DI:P5Q;,ZK6VT0Z'HI1./42A(!2,D2]Y"A
MW5FRWY[=AUU":WD,Y:7B4L:=4Y4.I%I3AQ?`3A.9PU9@Y4C6=]R=54A"V0)'
ML$`WH=Y2B8!J+5QM"\^3WI;YT)>5L4J$$!`WN6=<JF6B#I+,[N)OF-F,(G4-
M=)2QY2KR<`NZG>$YSPP!V+V95!<')1HB=B'1KS=`F6NAUH-PK]TZD"'@6J1>
M$M)($G&-],4Q*F@)?9++@P6_0!/6H`,J(V76Q[(TH661HC235%RUNX<NX5:>
MYV!N-[IJ<DP'^"AVNDVA;;E4@U]0F0TO;S`BLYSAVBJ6=<"[V9)!Y7QZ%.)6
M\W36D]*Y1?K6B7G4&""E^/PM$&^/D[M)&D%F7S]J^>8R=BC&[+ND2Y$;LN*[
M``>LX68H:AFB3](C%/>88=A.^MG79M[AD9:>;8H$#T9".O_8Q](]Y#;B5-+.
M:RZRIF\SD2XM+*A,B+N7[5,,QB:A<(F4*N%)@%5ATZK9"UA+G-0\Q2.H6*WQ
MGAK$8,Q]H(_7".!Y+"%)'&2(8D6&%B7L$H2JI)P<^V`I?NE^/Y(&IUK%A98M
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MG)%7+=G^18C)W\'`2)TE[ML02_,YAM$EG*%H/<_!(YR,GN<CYSDE=0`M=R*=
MN_!06VO1VIOL_6(<1O6F2',MG<E/I+YCW-Q7L0R-2+KOK-W@NU+<X?PIH5R%
MB7[!OWSK]JJ/N,4:F0<C<X0BES]S2TB6:/!L^HUCUWQ=KN&ZO'$=,D?4:1Q!
MJG4**43<W2R.1+.81&F"5+:1JXSR2.QU42HB&\FLFW)*403<+5<2<0(4HN0L
M=3<&]EG"77PN?[*F_'9W(#1R)E6A(1RTK'&'56$3@3["\7=S3#][^F6/Z4OW
M"/S:78T`RQ`JYX#U?,#=1P.^_,F*&CT%6F&9U48*0+KS;H&+>(0W.,^M%&!7
MQ%;V.[%ER;WT81R&G3W/OYR4*^+'L^L+CK/&=!RMO&),5[U'BH2/&$CK)*@^
MSRQ;*Q77P$IF-\I,W(505F=$X2"DAJ@R6:J=7RLAVT-!`8@SZNQ<+9-"[`\P
M\)(ZNDLB.%DP[?=,'MOYSN3S_=$4L^DLMPGV^%0+A!@$QA3X4/(9FF[@/E%.
M>BN(=$T]S]WE";=M9`X_$5?>SS!Y:SS`;<A$[K&S]FOTB"ZN8$5X%M=@BX8C
M66;LQ0U7+JBV?*(N<V*>I"\LGKB2"?D66HCI!R0KH7B\V`CM<JB#A';A.A[7
MM*^%+9:[`X5R2ME6E!Z@4K[,((>B5-BO*,C@DZHF`E<3NS'&RH8J7+4O"F.^
M)5K>OXRI!QO0];@&XZ86],<MO$WGY)"[82_"#:;>;H`Z[+V]N7%6Y]\Q0D8W
MVM^DE5<NI7V*"%[RB%"DR[+)O*J)55#P/FM.PT](%!-L<[-`&P5O_AY63%45
M@UO&$U!%#TR$*?7WRO,II59+R76K-10AE3YYMMZCI(MU*6B+*C;4@,G0DDQ;
M'VUYBXQT+`9'>%0^%DQJ2=T-5Q>50U=23)J/3L=_\<5O,LJCS>8F%<N4U]I^
MDXV([N^QOTY&P/?WB>]8/'3=6:F6&V\F<`5]0]S=?O&ZO&17-O)7"G"BK5QX
M;>5:*/9V`8&B%1QU)T$IS]A:(1H0JUPF<UU%G+(VS_!BTE#P8(^_UP4#=D;"
M'`$S6]UNJKJ3)C*$#Z1"<EPSB^I<-=)I,>YL'(*T"[PY/6F>2@E]RN%BU6<[
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M^[:*RJVUA,VUM-EVI_>71-D]!::2L'BS:[*HZ0??T`B[&S]J*NA)MJA-P*6N
M@+_D'3J9BQS+NBZ#<#CL*<EU&-GS1W%@?CQ3^MN5CQ-G-<-VX[P8[49=(DH[
M6QJ3`!B.C.8.574VJB8I2L]8]\$%(Q+I`E:E6&@P5HETSA8C<9EW@O9-'\'+
M+;T8AY[;M0^BRJIA_6CJC(@%I#M#<M]!^S$FJE(!/.Z$PS7P_M9=%4U+K%_>
M59'3W*@S+/>W\Q%RVPH@_R_<:C&I6X3E/[#58@L%N=^BPRS^DY&+*IMS']77
M86M1P`/LSQA=N6Y&E$?]CYZ-_^C9^/?<L['=IK$GJ-RW('QC2A1KXXEO?D'C
MTOL[&SJ^U<^KL,B,DQFJYP=Y0$-4W.>6\AV29MPP>)',7+MC+0894W6("@,L
M'6FB(>"NW:7)/`I:.57#*YH[&XDR`U>[F;)'U%0$"G7_%^Z0F:GH%NNZE&A%
M;3[.^KM;2&AQV;O\_*G>#QQ'HJ:.="<R<!,A<:\Y65'S-VE)#-C;E$&'U5M(
M)WFS;5WX,DY-KWI#J,3-LQY*KD\.>.>4&C)C9.QO)?^T&G;3`HM3.6X.!"!#
M"P42$U?.AV:2<ANP.D$^>UZV?''(\K9X+H)7=/BH-"9:J^^I9#@4"^:^5PW=
M+_@+Q=W<ETPD2>9KH0R?#^I/>;)T(?BLS["*2(8AH=C$JOEP@HHD-J1<ZN-A
MBX719BU/^YZ$LRI-"XGV;5P0FG,&BR*`$WECFGX;8E>P@J]%^9"G<S8_Z//F
MB%$1V-3!^!TJ)6UKOB2/78)DO^N(ID:`L)HQRGZU=II@O1"S"D@?3QY)<*&8
MU9D4PD\QK!3+K7D+8!V8`/&M6TW*])&=[;0_M@IUDO.41>R8^NC$F=.C`^H.
MB5++A<^'Q#U9J`1B-+V"PHY:6OLW)RWW4*"EY26/FKDJ_GX*XO#K%R8F'2;O
M4JU*V4U#-`:+-H0J%]7%EPX>:LC/X5=N!7\R]!I#@"\Q%)9@H>68[,Z@>]L.
M%YCJB&!X+(E2K%,D'F-H,PPP%YK&C1I;9CP)756W$>>2N-ZCR+[0@N+&E;`\
M1"UCX.G9KP1>N-`U4]D@\L7>"3V!CJMLA'DI;K"VV(U186QH0<42A*U&/#52
MB#'J]!Y@KNL:<5$)10U0=I%&(+!46,C?IYSV`&$+`-K&K_[C-_$FF+W?CN3H
M?4<%K8JJ(1*:R^]MD=2LRNE77*229!#I%VHT4.)A1D.%;3IYQ?"K]CPT0:DF
M2X?V?8$SQ/"=C8`I''5%Z:_F4*0/P%,>4)V%W\@VN4;#;J.:(KU&;B]ZBE3J
M34YY%6BG3A[)/,^^*79QO>FABZV0'&49=H\VHQIC0\/X^:$G/;FQ%5*<VM3Q
M/K@^C,B*V*HH;3VIXZL[3J=IN</<WD/<E&-(AWJ)$Z<6@U`:%-E-2##O14;U
M=VB1UX`Y#2217(;%/+97`-KZ,#'1MT$>J.9<$CFT+9F<NF,]966`I+/.7)K(
MAW.9M%K,^:9!\1%-#>YFYEJ2:K(9\3G)]"0,48')YZV1=>`!V_(67UWL`5I5
MJ7V,5/KQMN\%^UBILC<KK9PJN4-J%:NN[0QB+DPQE"F\VG#36J".=3>>F5_C
M1$<.;9Z7*<?.$MK8!Z3M#N5%8RW+2CP.XG774&$0",Q+2ZRZAX("&F02+G<2
ML0)5.]VHF^7&S4GQ(N#=G]/$DIM8%D+-.=OY%YUJ@$=#+],9/I1#J<O.V[;;
MZ7:OBC5-8[^]YY\0:W_;IAUD9^O=QB_$`0K42!QBP:O*=$%0\_*JTAY7G:BS
M<)-#_<%SG]V>JGOMNRB%G4U9WAQZCZP"KKA%'5O9$]ZE+CRF;F!/WOF`,\LX
M38UWPE419%>%=8D,."YBET&Z^T`L3;DD.#9>)?8A4.LJU,>?(NWN?%N57X$)
MSJDO?>'"@=@C/X[>XT_X8KT12P;%NZ=A>2]^:$+H],=-Z8(91"L@V8K)!R,&
M)SK,/!!#`5MGG=*`C&KVAI6W>-'%84D+TY/JE]<UMA3=]N5M*79>0F4A:O.D
M2=1QU4V\X=4<TFKL.C9%=R4$5LW*]K(\X4XG=_H!'Y8EN%@T(L&4#[CA4LP^
M,F-`'1E:M[T;F.^QE!`=*HG0(4ZU'B._Z/@]0U>/F(M">4>R<>##[6GE^>"E
M8B3\)5@QIGO;JL$C('!<1?OI)<')S--EQ7VB?#WT;=!P)M-`9B"M3LOQ,5FO
M'6KR>?.P[G6\(-8E&9II"VX*#[H%520@-5PO.=NQZ'G31HA)@X3?C5)RYXD!
M]2E*Q!B+SF:WW'G/BFAZM64G4EP3CH*#!@/SMSQCA%CA!:G6LZ7RL<8YZ1TV
M"N*A%K@=_ZT]!0?90T=LN-RG!:>-D`_\RH.@#>SI@^!DQ7H(EM^P(X%TF))-
MH=%XJME*K%;>/!B'CW#Y!*=E2KL]3JC`I8==(UT(2Q4&32:FX(E4G9&P#OH(
M<Y8>N9+%#.4*+D$VV.+7]<W=*?KD'\U^_]'L]__?S7X'"]I=VHB7/6J.U:U@
MYT)<L>C=ED";]GL4_=)N,:R=S>N^`*>0^$A=V-)3Y?#Q5])YU\2716^0&A@!
M^7K+!*^BRT&]YF5T&!\?GR"`3(_@^.AL&KVW<@I7YWXU'%\T/3I0!7^5KDHA
M?)BX0TX>">;ST7^3^/S\6#86CO0R.HNGIX=<;,)%>;UR.8F2&X>/30XF/ME_
M<CIEB#C/:CM03$;>53\9PI,=X[%B'8W8UY7C?;;P5('IG<+YJ.#B#KCE%+(P
M&^L6"]$0A^]7;BPS?H[].N-8;XW*H-A5W>E8_<;DBX4&C-^S)'G-DN2[`HO_
M(=7X()+DGDBJ^T$I"*ZO^<F+Z^]8R)"GI_O1CU:8#[\]W)>B):^ZY=9>1D?3
M^'QR:']!/8'_9]34[.I0B?/A<@:2VX<SM^F5;]/]C,SZ$MO_G9X?N9&"/R]W
M%&Y.XK.S<WH#__%?O+M^_-BVQ>EQ?')VV%T/CVJ/OEOYZ>_N^+&'^>FI_>6O
M.OYMP_W"XS^.#PVT[5^['_[)\<0</O[U2P]_,HT/#H\ZRZ%!>\I+E@5&0SBF
MICJ"`44G@IKF#E]#0D3M%`JM:R6EB74\NX^>@L9]EO.L-C:0#@$;X@<_DH)E
M<7,[YKUF.AG[1EHRO8`,$Q],]$Z_=M0)I=UZVM/#,YT63R_<M=S2GH)^E&IT
M95.-^-9=2M2\%05VD9Z^;<BA!>V6^V0%R";@ENUS?;:T>A@<P7$&B.:GI^<$
MO/.3TRTRCLHG0[(._Q^$I/)M8_><\]?!<Z='((--SL\PRV0!\BN;RJG]S20^
M.#N-SD!ITJ24;@J]9CQQ+MOY\2%*=$='T6?JV8(P.SJ<1$<'9ZY.W9-#*_AN
M>D`77/?3T[<&A;U3^/?.Y1R(6PLF.3Z-OO$`B;"<3Y&43("]G'0P],;H0;_2
MV,EAZ8PD60Y[1>WK,^NWG!#UEIUZ[T2Y:;_,/7<)/RA+\Z'*&G1R7I/&C=V"
MN/O/J-.@]SCP3TD)\$0RX'085MPY24CL"=.C^/#XC(X<Z_K4MF.P>&S=6]'+
MR?_3WK7^QFT<\<_I7T$$=BL!%,/'D;Q#@0)7274=6)%@.<X'HRAD^^P(E4^"
M3DIL(']\9V;?G-DE[Z0T*.`/R244N3O[FIW';V8*D-51OZ0<0#@@%=:M,S^I
M!'O``TP1GSW\_EMO5&8$W^X7H''#4VHH<!JL5UIM]10_G$Q3\]+`3OTJR&71
ME@JR('Y*@UH[-4Z'>6"A]P)VH<OS2P8'@5R'\\=8#]!\#U!AT@&#-Q;[BZ.U
M$Z[37E@:+USY`CA,#7#@)I_/.J\DUA`)^AVBQLQ=[3>EBC95^;SN:./*3?`J
MSKK42$"BF12#W)%'Y_<NDC2L(#6)N"4L!`A<Y2,2-SJO9#UPZX`VD&#WML7,
M;E^U'U0TVO#%.WFG^+#XH>D`_W]\!'>>#5974G@R*XNY7QF+(JTU2HDR<NDY
M([N*2VRP5H5I+C<;:ZRP9]\R1X-@'(;GG<?GS]2#-R8:Y6KRV%Q"NI$\RU8@
M]>U#=9TW<#C/`WN+_T)5Y;.JRDYO#'S$(V!(X;VMO'3H>>3JLNP11J838)QA
M>2O8C677F=%/;-0@YC6U3BW'%CO@K4KD3;8VF^6SEMT]=FJFR#WZ9:78P"4U
MR>P:JO@HFFKK$=F1#;<UX;)31=SALGM'Q0[I'*L7?+)UB>US*QK!X]H]5MP"
MGE7NF6U6>E:Z9X<V<$7)@I\_8(8T^V>U/*=N<W&A&462!N[)!OY=@OC2P;.J
M[[""4`\2RSQO42`A@WA681+9SFH]PW_TGX/NCJDV\/OH-WLH6N^;GY#28.)U
MXQ%2T;"F#]:QRVIC9@S&$:S)/%B*WJU`[R:Y\__S-945(''V@)I+9SVW\P^[
MSAFHE)X31ERH0TZZ._[Q!%U.HJV*J2Z_>GWX*6[''%HNU,8['*1BR3SL#][@
MYZ`T_,=(-D\RDFOP!^0B$&L+4I3+HFO=#[Q2DX:D/$R8LGU/Y_2=%7V=-44-
M>Z68S?'S"K^:P[^`E[V^QD0&Y&AZ"GN_6&!UI[XMVH7Z_Q(+8?5]45)YK*:H
ML+I5-\-&GA+ZZN`#>EC)H?04&F^I1A82_!0ZF-?T`V(\_E3Z!YM6L\[UIC]R
MEO7T+DIA>F$GR-/;X/32O-4%',^JJ'".Z^',MD5',]D5<ZR3U<_Q%9I9*E@&
MOS2SPHPVI9K1A9K1DGX:-;%8=XOI+`Z4*!Y0JRT/;Q0Z<QZD,7K\O,#WB1<(
M"3X).>(//F_JQOAI.#K)V**L577>=B7]EC7:YKH:_U9U>##GUIH5.A`\WJ7N
ME3*O%_*]HO_D3#H?Y)9J4'!!'Y_5\`7H\346L=NKX4II\LI-93"@@1$'E>5V
M02.9`P?!WXJL<GU)QL=YAZ.SQEE1F=:1AX$Q8I)A1[FI5N^5H"5%[FJ;SPY.
M,I1\0?O4&'X_:#86F)EP4GCA#6+P=QIVFX+;AL7/V+G8K5ZB5"8Q&N#V)%N0
ML61.Z]WCKFYF/9R^JRL22'1TE%;8O8P\,/86.":FV4=[5`7;I\Y[ZPZ(3CGL
MIQGU"!)R3;]U7Y/OL&HZ9K[S$"@XR5IT>*;VOY+01#:F;2?W&[T?QF,^+>#;
M[2SF'P\J:@W3<X>'%)W:E'$Y4'ET*.:CKBS"DNG*".$=5='AE8'\A"YFO#C@
M/L="EM[5U#?J+E&O];.B+M7UU.*%;Z\\73Y`WWEM`0)HF75X*758B]N^1W`$
M!-1\H6JZI9(?I!^9E>CUC>@\8P??Q#,;]28,T#6N[Q\LR$'KA7O/U[`>YM1E
M/^E5SY9ZU8^-VJ\<LTMK&GF^!A%BC9@2=<D.&O($>S*@#RX3T#)(U&@*NCWF
M,///=*1NDW?`S:L"I'XX4,?6<+)7`7,O482HLD-4-#&M6K:'%MQ]+=YUK-M0
MHU!Z-HHT<SQU\T5ME6YMWE#Y;H<?=GG5+8C:&7[>SYAVJVSR.I!K3[/N_4E7
M@?SI\`L!4S1FN%4+?/Q9&_PH;M$T,VES:5"B25#@^=@B.)55T!=M/QV#KGU0
M<6C/V]6[B_N-*<M$IB<*UE'`&PS'A+X/;+_R98%<;`H#L<*/;ZX*C$-:M5R0
MK'/JN)[\MMY8BWP.NU`=M*;)>Q#VT8-9SA^IJ/.N!:U'-J&IW!>V@)_F:$NC
M-E0EC^P--96]6GV^@UL%ALZKC'XMM?RUU/+74LM?2RW_GY5:GE*RUXT8]I5%
MC,$M?T29]O:S@^S'\Z-L[PECM8N`Y3">N;HI#,%<S32BPBG(;-J<C?_IW05>
M.+FI*IR]>8&B^7.,0V(\>IFN&C=\_9]4PO,@5L+35NS$6IULX*7XV"OKE@_K
MDR7?#6N5\6*T(.U^"=-BYR:IXB!W-_-80\N?[C]E;TZ(>_TK^RV+US,S+S'`
MN%AZ;/A6HT+ON<_\\\,I:.6V(P!>M7$WWLX%\?;2$^2'[<R3&_GDXK8P;+^-
MDN##;U/;-`:19>]-1\LRL9?#9D5#?PP).WS90#V\)0Q@%+%5\U'#DU&UOR=\
M5F)J(UO#1^9%G7]IH!XK89Z$A<4G<Q+&*S[/>3#1N3<WL2XU-E(LFNQ!)1_2
M)6RE$/=YF<!]QNC<LL/MX*./U.ENBQX])9/PDSML=W]4/JS/'C9^J')A;%E(
M'V@AGL;\YB7(]B@F8HY#OL\?&_7(.+9%BQHH9`)L>*R$KPEO;HN3W/J2DO"'
MTR^-*/Q0BB5/(A`%\20$(0HY4*<@$1E$V,`18Z*3ATJ,W5@<G,@;"S&*C/]?
MKS^J@ME'*"+*R_:=C4U:4R$H.!.TEB<*$B3(1*!IE`KTQ>)-2-PPB+#A'XD(
M5X,\*6F\0JHI_-:,D=(@QV:BJK7F$9TB"_#4<<FJKA;(HQB(A19J)E<5LY:9
MA2U9-N&&BN<<]L+DRS)"']U'.K?>%]R!7L)Q-LBB++E_E1K018Z_F%K>D1;:
MHN4M&+\<;I3AWWI9=G4V:[UW+GZ!C77Q5M=G,1Y!QI!"D.3>_>:]`T@R#>WH
MWIF^C,?#1*73]_<;#7<RCN`0A#ELKY85GZ&,SVX5RN/V"CH`M2_ZUHOK"ZPX
M17FZV-]6'V%USA3`#U6%G$30RSN7\\$*2*0IZG.Z`Y\E>W386.J4G07)[:^(
M3H)B7[^]NOQH4BO!OF*'8R[M13_;ZU+)XYG1,5!5?'8KV+F?"\&8%@W(>&"N
MP-;38-2[6P>6-\C'2IF/_7#]BV5RS#AP>'6A4J1H]2(U^P;R28?&S<-M=JYK
M%:J!L.^,P+`TY<^S5\+9;;H(SU&^BC/IC#!G%/HV\%:(#M-P#Z#Z)3JJ\J%_
MRL=BF9<X2319&N*F<ZR=Z80CBI(\.U4EG36Z57D`HE/ZC_24YN1V^=''MAZY
MNGZ'`V"KA6K'LKJ^P"0S5^OL#-@3B(M4S1EDT!>'47XQ9<!VG1&=(!8S'^]W
MJKI[\N)U]N>+3S=_A=<+:@$'3KP1C^W]37(TRSNM\;@I5UX'NT-Q.,[H0XS`
M<$1^64J\95(7AI>GVY>9Q5;!%0$/T7>@$Z.B[%D"(\L[0P`E,P?G3N#DOXC0
M9)%%/`I$6;;OI!J.PY13>.0=5R3!QWS'=5KM$S'F>>:4->VM&7ZG_>M;\=8;
MR<@5(4`K@)'>)91;U(IJ`;TQB?]/WWR#J%S!D"[`YN)L$>WNIK6*>6DC8+M8
M:_`Z&3]5:[UPR3.,7I3#H4#0E+&F)&A?E-5JDZQJBF&,)$1@PJYFH.</>A=N
MB:&Q/3V77.P9:7U$R`Y:Y[O(L8#'!'D'+,,IPH)NF;*P1T]K4O;ST;["8>/(
MWN%+,YTL>&Y<;M5"5&]\W"_3[A`HS)X.0;]<#6UG[*%VH&3U"#G-1+()\\T)
M1MRR0%#)1X%(9?:PUKVWIO>Z$7LW[\%Q3K](D'1.)L*JV5/$GTNT\V%6U'VV
ML)W722J;D?<(+\^)1,RW0&3;2Y3S0=H5;,5.]1CJ]%L$X>>D(0Q=H**22&OX
M]Y:TNI]$6^0UBBN0B!-(QC@"B3B^#1POFPZ-]SA56O___GYM_=9M1+>-L-#M
MA1&OH4GRD8_\'I6-QM#F$_I(BS]N'5PD%X[U\L.EPBXIQ6`_L,+$;XGA/.8,
MV!G7M8^P&*Z&=RJ1.-2A$ROH(9)SAWOUF/Y+P;0);+3A1W^T5<G($/M(0=3P
M$K$66(F2JJ@Y9QDEY,C`>J4F2XDCI_=\'LTFEP@I&(\7V-_!@.=4*5TW*E9&
M+#<!"P8<Z`IT*#N"KL\VACI10]"(SVA$`I,18F5LXH*]!O";LKKXX3+$[Z=M
M)>(:3,#C.]XI"3H"5)WOT4ZXHB5+.N+9V4-W%MDQ;*3+BT#OTFW=\CM<!L0/
MW](`%"=/S.3KS@@]&H(F"Q/=0.B(DA1B[[=8T\E&VX3S*GJ^HE7YEL@2=(6+
MMU^"8Z?-VMD2+[?D@;)8?>.O"#T2N0FX8`=1O;ZQ%8HPE[GDCP&E4'3(..5'
MI5DF/@"3]V%U2;85DN3QA`PB/X+Z?*RS5F*E#^EJLUIC^327@)A);E*//ZZ]
MZD,!=T(_,C>+F<I5-@W!K\-E4?#$F#S=6=U$%EJU<<RK5>:;70(?QF`.F*X_
MHG2;D`]3LT[:$C-Y1W3R8RDM093ORED:`MM=S&AW'O@%KU:^H>^C*,"]#NKR
M;?SR<9'9<X$B:!137A13H)8^X;+LM4(%&\=$:!=]EX!\Q?F5&"D4L*M`*!]C
M7X+-\G?G:;F)I]C&Z"E'+^7!66!P%7E:;<93/7MY)#0JCRDIVS9C0Y@>VI"-
M>MIE=D)\SM06O+"H_]%&R$=CT-([)3:I(ZU.4!)W;GG+?33:WM8;:K3%Z,[:
MG<:D.KQSLZG]&&DS&K+X@"5/M+GE8B=:VGJ9$VUMO<`ING9:VD2#B46-Q%6J
M,+0=D($1.T\:)'D52QIQ<KG!6;U8KZ`_G9A/5X#96VT1R#DE8G-'E^,2!F6C
M)L]=A:&PDT/*JF[5>YM"WM&8="_(HELB_;@ISTFE95G,:$C,>YT6?N7GM=](
MYI/QL,Z8\#D:X1E%8L'^6/O@F,U#@$#?WU\56=7+6)_3=W<VN()!(2T=!.^"
M+6E+O'B4I=;P9(A](AGZ3*6B8\<(88`W%Y<Z1YH7SX'@$17>IM.+LT\]G?-4
MX;[(ON2RVEM<E]W^YU*\SNGMZO-U=%U>KK`P%6E(2.O/&)`_2IM3-LEBCR`U
M-:U8;?Z.:%K%7=/9$<[^ZG8#TT#L]C8[Q`#)V[C"I8H]4@FMU5H%9*VX;3HR
M8W9F*-QU@Q"3X:=':.[">@BX-`H+E4`>@DJP.D#;SGMDT<`HJ6ZHP@(9A!WK
M8N)GN9]G.5D$X,$-YE;*/!,5[T9&9NX:7&WNH*1SY.;V&E,<;MZ32OAO6)75
M^N/=SSJLD=TK_K>SV$LA641,ZH`[V1YO&YB9=PHF2G1EOV6&Q(3C0.FSYYKX
MQ)NOKF]P\I'W$=3,16_^EL6&H[;R2Q7^G1O*,AJ1CR]S8<,)[,%@8BP<3$`I
MUZ+=J1%M0_5">CH36]AV/'^/CJ<6:1$[K3OI:25Z*;8E,`[(JT4,G4A*+;JP
MMR7E*$I*)4_`3'PJSNNVM!Q':6E$"+U(RM*$X[]TX?C;;?I.QC%.;#>^^::V
M$-\=C;A3I[8;7^I:G-ZI[<:7K1+;-?M`XKJN^53O;"/TXK&6GXK'IAVPH^\V
MF[N__1=02P$"%`,4````"`"9C@9']<EJ^>P!``"D'P``$P``````````````
M@`$`````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(4`Q0````(`)F.!D=(=07N
MQ0```"L"```+``````````````"``1T"``!?<F5L<R\N<F5L<U!+`0(4`Q0`
M```(`)F.!D?KOH&EXP$``$8?```:``````````````"``0L#``!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(4`Q0````(`)F.!D<\_`N010,``"D-
M```0``````````````"``28%``!D;V-0<F]P<R]A<'`N>&UL4$L!`A0#%```
M``@`F8X&1]7RPWH_`0``:0,``!$``````````````(`!F0@``&1O8U!R;W!S
M+V-O<F4N>&UL4$L!`A0#%`````@`F8X&1YE<G",0!@``G"<``!,`````````
M`````(`!!PH``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"%`,4````"`"9C@9'
MUAJ/>DT"``!\"@``#0``````````````@`%($```>&PO<W1Y;&5S+GAM;%!+
M`0(4`Q0````(`)F.!D<UEEXKAP0``,80```/``````````````"``<`2``!X
M;"]W;W)K8F]O:RYX;6Q02P$"%`,4````"`"9C@9'%W)58$X"``#U!P``&```
M````````````@`%T%P``>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`A0#
M%`````@`F8X&1Q\I;:(2!```^1,``!@``````````````(`!^!D``'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+`0(4`Q0````(`)F.!D?VI3.A'@(``!H'
M```8``````````````"``4`>``!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"%`,4````"`"9C@9'\&J7?.(#``!5$0``&```````````````@`&4(```
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`A0#%`````@`F8X&1U>@07@/
M`P``5`P``!@``````````````(`!K"0``'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+`0(4`Q0````(`)F.!D?@ZU-;4@0```(5```8``````````````"`
M`?$G``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"%`,4````"`"9C@9'
MRUTW_I\!``"Q`P``&```````````````@`%Y+```>&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L!`A0#%`````@`F8X&1PUTARZ@`0``L0,``!@`````````
M`````(`!3BX``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(4`Q0````(
M`)F.!D?-AF+4H0$``+$#```8``````````````"``20P``!X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"%`,4````"`"9C@9'^358UZ`!``"Q`P``&0``
M````````````@`'[,0``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(4
M`Q0````(`)F.!D<!S4MFH0$``+$#```9``````````````"``=(S``!X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L!`A0#%`````@`F8X&1^N95^6D`0``
ML0,``!D``````````````(`!JC4``'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"%`,4````"`"9C@9'EMHY-9\!``"Q`P``&0``````````````@`&%
M-P``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(4`Q0````(`)F.!D?!
MX_XLH0$``+$#```9``````````````"``5LY``!X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L!`A0#%`````@`F8X&1T-)`82A`0``L0,``!D`````````
M`````(`!,SL``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"%`,4````
M"`"9C@9'<%)AY:,!``"Q`P``&0``````````````@`$+/0``>&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+`0(4`Q0````(`)F.!D=8NWD&H`$``+$#```9
M``````````````"``>4^``!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M`A0#%`````@`F8X&1S[.)\NA`0``L0,``!D``````````````(`!O$```'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"%`,4````"`"9C@9'*#9=A*,!
M``"Q`P``&0``````````````@`&40@``>&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+`0(4`Q0````(`)F.!D>SVMV^H0$``+$#```9``````````````"`
M`6Y$``!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`A0#%`````@`F8X&
M1PO)>N>T`@``P@L``!D``````````````(`!1D8``'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"%`,4````"`"9C@9'SW5CEZ4!``"Q`P``&0``````
M````````@`$Q20``>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(4`Q0`
M```(`)F.!D>NO,7IK`$``!8$```9``````````````"``0U+``!X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L!`A0#%`````@`F8X&1TYK4R"E`0``L0,`
M`!D``````````````(`!\$P``'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"%`,4````"`"9C@9'(TM./J(!``"Q`P``&0``````````````@`',3@``
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+`0(4`Q0````(`)F.!D?]0<(X
MO@$``'L$```9``````````````"``:50``!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L!`A0#%`````@`F8X&1VDT?LR_`0``>P0``!D`````````````
M`(`!FE(``'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"%`,4````"`"9
MC@9'GFB#4J4!``"Q`P``&0``````````````@`&05```>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(4`Q0````(`)F.!D=Y+-NHI@$``+$#```9````
M``````````"``6Q6``!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!`A0#
M%`````@`F8X&1T>OA8^A`0``L0,``!D``````````````(`!25@``'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"%`,4````"`"9C@9'=''W*MX"```=
M#```&0``````````````@`$A6@``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+`0(4`Q0````(`)F.!D?C5@2(<P(``,0(```9``````````````"``39=
M``!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!`A0#%`````@`F8X&1V,$
MA"&(`P``UQ(``!D``````````````(`!X%\``'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"%`,4````"`"9C@9'MZ$UU$("``!&!P``&0``````````
M````@`&?8P``>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(4`Q0````(
M`)F.!D<AW4O290(``)0(```9``````````````"``1AF``!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L!`A0#%`````@`F8X&1R(2+[I4`@``Q@@``!D`
M`````````````(`!M&@``'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M%`,4````"`"9C@9'PX=YNS<"``!*!P``&0``````````````@`$_:P``>&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(4`Q0````(`)F.!D>,N/Y>Q@,`
M``03```9``````````````"``:UM``!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L!`A0#%`````@`F8X&1T8!/.GH`0``<04``!D``````````````(`!
MJG$``'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"%`,4````"`"9C@9'
M44*\ANL#```X%@``&0``````````````@`')<P``>&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+`0(4`Q0````(`)F.!D?CK=`DI0,``$(3```9````````
M``````"``>MW``!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!`A0#%```
M``@`F8X&1QOT%-U9`P``\!```!D``````````````(`!QWL``'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"%`,4````"`"9C@9'RUG`80L"``!_!@``
M&0``````````````@`%7?P``>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M`0(4`Q0````(`)F.!D?X;@]?7`(``!T(```9``````````````"``9F!``!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!`A0#%`````@`F8X&1[+W.W`\
M`@``N@<``!D``````````````(`!+(0``'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"%`,4````"`"9C@9'<6T#)"D#``"]#0``&0``````````````
M@`&?A@``>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+`0(4`Q0````(`)F.
M!D>(:C7VJP(``%T*```9``````````````"``?^)``!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L!`A0#%`````@`F8X&1[K5S]`S`@``"0<``!D`````
M`````````(`!X8P``'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"%`,4
M````"`"9C@9'T.RIV1H"``!F!@``&0``````````````@`%+CP``>&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+`0(4`Q0````(`)F.!D>R1SKFV0(``)@,
M```9``````````````"``9R1``!X;"]W;W)K<VAE971S+W-H965T-3`N>&UL
M4$L!`A0#%`````@`F8X&1],#2[G1`P``;Q0``!D``````````````(`!K)0`
M`'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"%`,4````"`"9C@9'W6;9
MU*B"``"FY@$`%```````````````@`&TF```>&PO<VAA<F5D4W1R:6YG<RYX
8;6Q02P4&`````#P`/`!6$```CAL!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770101136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Additional Information) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees', window );">Estimated annualized forfeiture rate for options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement', window );">Estimated annualized forfeiture rate for options granted to senior management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 3,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember', window );">2007 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares subject to outstanding common stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">10,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting periods of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod', window );">Options expire from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annualized forfeiture rate for options granted to senior management.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gale_TwoZeroZeroSevenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766847600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">$ 18,794<span></span>
</td>
<td class="nump">$ 5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,889<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">42,913<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">42,913<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">18,794<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,889<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">25,683<span></span>
</td>
<td class="nump">12,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">42,913<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">42,913<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">18,794<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">18,794<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrants potentially settleable in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent purchase price consideration</a></td>
<td class="nump">6,889<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 6,889<span></span>
</td>
<td class="nump">$ 6,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015922704032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Common Stock are Reserved for Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:inherit;font-size:10pt;"> - On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">24,358,974</font><font style="font-family:inherit;font-size:10pt;"> units at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$1.56</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$38 million</font><font style="font-family:inherit;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.08</font><font style="font-family:inherit;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:inherit;font-size:10pt;">$40.8 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015769523056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 17, 2014</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FutureMilestonePayment', window );">Milestone payment for Phase 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition of Abstral rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationPotentialPaymentsfromNetSales', window );">Contractual Obligation, Potential Payments from Net Sales</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_OrexoMember', window );">Orexo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessAcquisitionCashHeldByAcquiredEntity', window );">Remaining cash held of Abstral rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_EstimatedYearOfPatentExpiration', window );">Estimated year of licensed patents expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember', window );">M D Anderson Cancer Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FutureMilestonePayment', window );">Milestone payment for Phase 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationNetSalesThreshold', window );">Contractual Obligation, Net Sales Threshold</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractualObligationNetSalesThreshold', window );">Contractual Obligation, Net Sales Threshold</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration', window );">Finite-lived Intangible Assets Acquired, Contingent Consideration</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod', window );">Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessAcquisitionCashHeldByAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Cash Held By Acquired Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessAcquisitionCashHeldByAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractualObligationNetSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Net Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractualObligationNetSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractualObligationPotentialPaymentsfromNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Potential Payments from Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractualObligationPotentialPaymentsfromNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_EstimatedYearOfPatentExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Year Of Patent Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_EstimatedYearOfPatentExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible Assets Acquired, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FinitelivedIntangibleAssetsAcquiredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived Intangible Assets Acquired, Contingent Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FinitelivedIntangibleAssetsAcquiredContingentConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_OrexoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_OrexoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015769719072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Changes in Fair Value of Warrant Liability) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">$ 10,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">3,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">18,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">2,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">12,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGranted', window );">Fair Value of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">2,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">2,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">2,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Beginning balance</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsLiabilities', window );">Warrant liability, Ending balance</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777459584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossContingencyPercentageofLegalFeesPaid', window );">Percentage of legal fees obligated to pay</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 47,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock for milestone payment, other</a></td>
<td class="nump">32,158,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">$ 47,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossContingencyPercentageofLegalFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Percentage of Legal Fees Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossContingencyPercentageofLegalFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770077248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Based Compensation (Stock Option Activity) (Detail) - Jun. 30, 2015 - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Beginning Balance</a></td>
<td class="nump">8,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options activity, Total Number of Shares, Granted</a></td>
<td class="nump">3,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options activity, Total Number of Shares, Exercised</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options activity, Total Number of Shares, Cancelled</a></td>
<td class="num">(860)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total Number of Shares, outstanding Ending Balance</a></td>
<td class="nump">11,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Total Number of Shares, exercisable</a></td>
<td class="nump">6,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Granted</a></td>
<td class="nump">1.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">2.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options activity, Weighted Average Exercise Price, exercisable</a></td>
<td class="nump">$ 3.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Granted</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Cancelled</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Stock options activity, Aggregate Intrinsic Value, exercisable</a></td>
<td class="nump">$ 749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>31
<FILENAME>0001390478-15-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-15-000037-xbrl.zip
M4$L#!!0````(`$>'!D=I1#]@RSH!`$?Q$0`1`!P`9V%L92TR,#$U,#8S,"YX
M;6Q55`D``V;*PU5FRL-5=7@+``$$)0X```0Y`0``[%U9<^,VMGZ>6W7_@Z^?
M1VV``+>NI*>X=CQCI]UM)YG,2XH689NW*5+AXB6_?@XI4A(E2A9M+22%J<J4
M6P2!LWSXSCD`2/[PC^>1?_+(HM@+@Q]/\0=T>L*"8>AZP?V/I[]<#[1KX_S\
M]!^?_O=_?OB_P>#?^K>+$S,<IB,6)"=&Q)R$N2=/7O)P\IO+XN\G=U$X.ODM
MC+Y[C\Y@4-PU_B@Y`J-WMP2)MP+%SE!E$A+8[:T,OZA#E?[]^2-<080-I:'@
MRE0E]/;N5E3H'754B8B*R":]/=]&OO<Q^_\3$#R(/P[#-$BBEQ]/'Y)D_/'L
M++OT(6;##_?AXUEQ\4Q`F`P0'A!\6MZ61A'HN>J^XFIV(ZW>Z#*O_AZX4-.<
M/0\?ZMMG5VINN'=\-KWAZ>GI0_9#X-QZX?C!B4;.AV$XRFX3D410>9,7/+(X
MJ1]G<JW&!%X<4@'+E<'R.\/H'IHC<E:T*&_PO>#[FM;9Y5LG9F7SP/&&<;U,
M^:5,)%P5*0B#(!W5C^$FT5GR,F9GT&@`K5CD#:?WO7Y3]8:(W:W41#J#JV7#
MV!O6JP`7:A2(DW&THCU<J;DAC0?WCC.>WG/GQ+>Y(,6%&H3`E2CT65Q[3WZE
M_J;,#O4WY5?J;DHB=K_23NH97"^;9A?<A9DQM>?D8J5I4MM4G#1-YIMZZP`:
MQ(D3#*>0>UZ"Z!/)6V-55<_RJ].FL5O7$+K%9_^^O+@>/K"1,VOLO=YX,)4&
MB.IO/V2#?8SS*]_8W4D^^,>'''C9E!Z4<_@#2'):7,X<\>-I[(W&/NATEO<S
M8;QA&"3L.3GQ0&K;S.[]*OQ^8^9#E6V`DKWD)?^E_,ESLQ_O/!:=Y*)4J:7$
MIG'^K]-/")0A*J*R\L/9XLV34<Z6ABE&&</4"MW*P&")*#$A.GS*9,U@A7#9
MP>S:_!TL<.?:2P."9@.ZT];E;[,ARU\*"ZVPV7EN,M):>TVPDQ3:RS`)I[T6
M5]ZCO9VI3[_2+JA/!UC8A?HP8;J@_@+VMZ)^P1=?.\07],!\D=N,=HAC:4..
MI;NS66=P1AOB;%<VF\3R/XJ4[X_K!'K-"BSKSQ0T,L+1.`S@G['V[,735O#S
M*`RNDW#X_9*-;EFT3YM/S<GN,T$GOTU^=&'PY['O#;UD(M>)ZT&;27U9"/]Q
MK8JGG\IF2SK^<%8[1"'3V;)0G4Y:RKC5$!F:ZWH)F-OQKQS//0\,9^PECM];
ME*S5=[>(V4_@;DX.'`)[@T!/2(.'DZZ10U'3-?3S3<2<.(U>^NWI&BWWYNL=
M%K`-??V-)8X7,-=RHL`+[N/>NKM>T2.<W=SCW9[CS3W.XW87_=R<RWG<[B*+
MO[F`XT1^;"5;<^KG1?XAUGEV%1)(-[;GR,XRGTYLS]']!`D]C8$4XU@;PHR(
M<]3G4S\[.?#'?]*QSX*_NC?/5VAU^BE3ZV-%K2,+`+/=1@Z!`T"@/9NGI,\;
MSNH>-D^OHA"Z25ZN?.!E+7"SE&*<041_N7D9L]D4FEZP4\@\DS1BT-KVGK._
MBBQTEHT[P3VKY%Z77N"-TE'W)N`&]BDFXP8&6CM%&P@UM>\LV:L8^`BCP8%@
M[3QS6.\4UO,&/D)80X3KTO$@^<`1;L($^)^ICY6;\-*)".8)XF$21'F`E2;3
MA\Q5R3O9U^?^[_+*\-N]N;Q*:/A.''^YRQ?-^[,YM"TDO&4A<M&B;=B+VL<N
ML^UXT:^.GS+]Y3+?B<FM84?LSS1['JX"KFG;N9;Q-Y8].^<%]]W#VP:ZSV"P
MB?*=7Y)>@8SIGS^!Z9UH^/!RP1Z97P^.\V"<)G'>@"SP%P?;:^:LP=NR/;=%
M?AS_.\:_P/&_5?P+'/^=PC_F^-\J_C''__Y.:7'\<_RW%?_[6)_@8.7(V!DS
M\LJ05X;'C']>&?+*L%/XW\W*X+'!=!.:/L(ZB:.AL]Q0<W*)`Z+5@&C;*2$S
M?Q1"N-1^5[IQ2H@,4/;&MHUM-FFO;--FYX7-G)?VVJSR"$G%`ML@GCD+3)GD
M(@SN$Q:-3':;5,](VEX4)S>1$X`%ND<M=7H5AR*6%=M;--F34WMT9/6PIT-W
MZ[HB#]#&$4:MI:3E=PYBU"3TS;??5NB#PNKG\!&WE\<7CD5BW.18Y$+[[;W8
M%5\Z48N-5LVZR9P)MI9U`W"RK-MEWA\7#(*!E<LUBWF7%[\:X8>+"\,)W)QF
M/D=A.H9_=X<X0;>/"[H5<>\5Y?:803=_*JI2DF_QS'B[9\0B]Y+&IZNW3R,E
M]ZZ>1!=>,`S]X,J)OA</G_=D`JU1;)^K4W@7S#AY\S%WZOZ<VK:7.9M\<A\>
M!RW(%3>B`YXH<5K8D!;Z_B3.]BFEP?)(^Y[%:1N=%6R6)_HW8;?66IKF^]M>
M:YGN8O,XL/<XL.>3ZP5__.9$$?3])?KFW3\D,S^;;)@K=_,4WCR$:0P6N7EB
M_B,K;NB.NZ>TN$KAPOF;:7Q,&+AFXV3))`]>E#`6]!8&&RO=:23,K8UR,+0>
M#&U;2VU*))?9^8YY$_88,J_I>F2TP?.(0^0172<,J-H\?\Z`EL\>>\P9&ZC;
M:=IX9[CHN?<W4+?3WF\>-'B^<+2!HCE8>*S8+UOT`#(\P'#(+#Z0P9<_NK'\
MT8*',9KFLT88Q*F?)5)%BPY^M^8UJ*S2L?.9:S.:X,G(`2-+6ZAA_L%/'E9:
M&U;V_$*$ACFI[=W-V:.'$6,CA8\)`7RI_,!;[GMZ])O#H(4P:%TBT1PX?-7T
M:,'2,-+P*N5@&RSMB#%\`?3(R]3FD.&+6$<#CG=NU_/*M?,+G^]<N^#AY,CS
M"4X!1QHV&I`&3R@Z2@_O#`Y\6:*C?I]]J/2]4[R/7Y#>"14T&+]%'XMNP1=B
M]P36KKYDKXU@W=]+_EH)UN(%'"6TSH-A.&+3I_TOPJ$S_?CI]/T*S/>]X/XS
M"UCD^%K@:NX(IGR<1-#VD5G/8[`[ZV!:M4;Y&6`::;_?5/S0K_"HJ^`V`=0W
M%K,L@P%CFMFKEL/\B_"%)7L*HPUT/K(Z[HW@X6S44C9J!:!H\_#&V>C0;$0;
MAC*Z._!P-NH#&S5_]J,U;,0!U5)`M8*AWE"]\?!VZ/#6EDKM#>&-@^?0X&E#
M*%O<B;GQ$I]]N3L/7._1<U/'GZUNWCR%_V%1_M]UMEL-%L]T?F17OA-T#S"U
MFA:+EQNHVOE]F(7ZG#N^%8YO9>6]`)4>;;FU:,NK.\[NZI95B[:,6NIL#11Q
M/3_-&.\Z^[*NEW@LMIZ'?NHRUX["D1&.QFF2IU9?[BPG"J"DBZ]8=/W@1$Q_
MJ>^@`A]K-/;#%\;RMTM_&6<]=0]*.S34#)PK+<6!N@^@=O:(T5[`>>R//E#.
MG.T%9QN8LPW5_8&`RIFSC<S9'D!67K1F0[V5L`LPF'L>))"B>[<^T^*8);'^
M<NG\?QCE1\TJ`#.S;0/O-LW<D!\\Z^"F20.]9]A9I7BK8;27EZ]Q&'4+1BW(
MXXH#OO],?2QS''441_GA6RPWB6KS[;>ZB;+ZDT>F%K@LBL/`<((ABPS0DT7=
M`<F:[QVMT:S+6R292\E7FJ=U\9<TR7IT(=>;SGD]C;V`P808_IEZL3?=7LW]
M_25BSV%WW%M.YQ4Z%:Z>4VIOGB4#C+;\9/(Y9_U.LG[E>?4*AV\;%:W]UM_^
M3,"W?[H%7W,2KKX8-ZT%;R5KRWF]0?:_$`>V]V'ZU^'.M[;;!_>Z!0">D!U-
MX5YW7M8(\Z,ZD3/)2N+O^HO.@N'#R(FJ'XR^!M/%W[+#/2G['(9N_#-+%A[3
MG20^:9R$(RAMYI[O+7ZZ>>H@EEXST-Q)[9466@NS!K(L&[A\:GC1POL%=EO.
M\AX,V`\1Z^#9WVY!>V;C_2Z3M>(IAT."F[-V#UF[1<#^_4#`_A)PSMXML*<6
M;O4^:^\8FP.[I\!N"V,?"MBV]\B1O5MDSTQ\G-`^5#)BAVF'-K:[">VIB8\S
M'3D4M'D!V=,"LA7`7GQ=-N?L/B'[()S=HJV:@W$V7]'NZ8HV!S=?'^GE^DB+
M@,WW(?L+[8.Q=BLVV0\(;K[XU\_%O[9`^Y#KVKR0[&4AV99U[0.R-L^U>YIK
MMX6S#[;XQ].17J8C;5G7/N2&#2\C>UI&M@7<AUS9YKN1/=R-Y(M_O(CL:1'9
MEES[D!OM/-?N9:[=%M9^:ZZM#8=A&B3@NB'S'IU;GRT`NZ:GFY=Q]4GIJRAT
MTV&RU+3/@%]EN&W!?8W=9T*L-SS/RODTX-/@&*/!6W-X/@WX-.A1OO_6_5`^
M#?@TZ-'>Z<)KE[<W#8Y\H7+7:&_E,F5+7P*]1U#W?6OI\+#FI\HY6_<0UD>\
MJ72X%(2S=2_9NBUIR,&`W?-3B0>'=3=>_-,S4/=]E_3@J.[(><2>E8P<UGV$
M]='GUGT_KG5X6'?C=3]]8VL.ZQ["NBUL?3!8\X*Q?P7C@4"=!MX$T>/)5FM<
M@=2(.7$:L8EURA9E9^7%N?ZSWNHZ=\,X^^Q:G$0LN$\>5H^QT/`-0\7YQ]YJ
M1R@LFS=X0\]I[);?"*YT[WJ/,%4J?LKN^3D%)#E)6,'G;$`O#JF`Y8^_7)LU
MLORM(LU"5W.#F"P(1UZP>IA7=*Z.L]A;>6VFX6LV"M(E6JI*,H8_WV#[,2@P
M<H8O:]!9M'B;8VO[7>^BI5ZS[RMJP`1NQ@:V[]R?%-/M&[NK1(S320AQALE`
M$R5*90,;!-D65F3=4BR3$ED3=5-7B73ZZ<[Q8[#84N?3(8TTBK+?O'CH^+\S
M)[(F5+#!Z*HFB)*!;5L".2S#(+HL%:,;EB+BTT^#,B-<-])4%#,<IJ-IBZN<
M?FSX+=Y`%M&015LU3(,2)&;60(I9RB+*2#[]]%68B+%RE!5R9))N*@4Q%8DJ
M@JXB0\.286D:*:4P%5LEISGUULDQ'65)BHF$FWO%T'4;BYI$=,T4P"*RK9=>
M,:E&Y=,*_:\<:4F.['C-!L/;R-1-S5:I;.J*3&Q$%;UTA*0@``5&@Z_5@;.N
MI^-9>>PS\ECOGP<N>_X7>]G$]A+29%F6=*0+)E$D546H')@JMEC-45:.M"A'
M.!J%P742#K\O?0>T(M3D^Z_D],1E0V\$LPY^^MF>DP\;JBY1VZ"R2C2+*)I-
MC5(^C0J@2D8%>5]E$,(25B2!"+@B[QJ)%H2W/9]%!CCS/HPV,:%EJJ)J6X3H
M6%,T`5D$E2*:B)CT]!/D5LS/@@ES3_+>YR6K#+<@RC=VGWTQT@F2GYW1)CC2
M-5E3P4A$H)*FV391*)FZ4Y?5TT^?@;<#YT3WP@EY__WD/!A^F!>H.NA4HIO(
MR8QU_3*Z#?U-(*VH&O`;QLA09%L1*5!+*8HA6#:(HEU8DX$K?><CYN$%[!:E
MV?<U'P%M8)VK-!H^.#&+"U*L2C'Y+!V=Q]*`S`E$J8`TX'J5*K(!YL`2D6U+
ME&Q1P`*VA#DHY<$)YOE&4KQ'7K#:2GD-)*FR:MB:92BB0$Q-!JOE\F)+!)Y<
ME!?4@_\U%SH(4L>_=#P0+<B^1&PS5BOH&S_2O')J(YB^`K6)2FVLJ*:)X9\Y
M0&01:1`-%O7+U9OJ5R/UG$[))10X+#F/XS2[F#]=I=U'C&7$&1<?K_P<A7%\
M%85#QMR:.%6L"Z[6^N)7(_QP<0$ZNWF/T%\ZAG\O*SZ0YO0VB85!=554B$(D
MX%N=(@NI1#$5K*I$K]=[IGESW38V#,2RK%P,[]:8IIAF6[&+,,\7,M95+$F`
M-1D!01BF(F9FH99`#$VUYLQ2)KSH`R*;6:5>L9E=:CX7:#CQPT_,=_67_,>(
MN1-%E^+7=CYVO0HMDB@:FJ%+DFKKNHYEF1I*.4M4$]-%M(@5L#30:]D8$#-O
ML\(D6SI@P_`^\/X"1BD6*)SIYX[+;D#S"_C9\V$8L#TX8L3<R5>.Z_ED(QO]
M)QU#P/JKQDKS7"G*V!8ABY%,%2-!@BFFT]Q*DBB(6+$6K:1@A)>MM#V%9\8T
M'K*OB9X'MN-%OSI^RK[<S>4BOSE1%FCC#+896QMA$+!A)L!O7O+PJP.I91I;
M,%R6)V0\!]BJI:I)\%UA'5.$K,F"W(1BI"@"UG1[DA5(!(/=M$7K2!02OJEU
M=J#!GLTCKC>/K9J"ILL8V1EZ#$T7BRI($D1;D<Q%\T!MAL5#V@?P"#]"Z5$$
M=?@E]EPV6>5KC`ZH>A1(I@W1!/+5,<50AA3JRT9-/`)*DE[1?JV`VU7N%=_*
M`N@!/B6*:)O4M@0#E[XU;"PL)7T#@2A[5.XJ\H8;N._K6O?!;!55@B#QAPQ"
M,$2,)P&"``V2I0!!5=10P64A=Z/E.C]:FF51<)XMB!+%D*]3<4)A,E4,15\"
M:7.,[D5+\35?FE26%6(:LB)(6+)TV2I\:5'=7`IC`X6T5,MUOC20(*BB"$J:
M1"*61*`R+7VIFM9RXM]X2NY1RVD6,^U/?YG^^9,'=T./+Q?LD?F5_:AIF_-@
M#'ECWH"\DN4(60:H$5F$4&7)D@T%?D%FDB12T]Z[X8K@-I<%-08#5I%(*%2V
MLD1TV19DF-L3,"!=L11E4:=78^^R3%M28;;GZ#MQ/+WS2Y2G?+.,51M'GG_S
M%-X\0&2''-'RL]=Z%*U?\;"E(LFDX&+95A1$B4#L(MM'IJ5CO)3'"NVVA<F&
MN<)SYKAY8OXCV\P<A@(I*I44JB&#((M*&.N%.0PJHZ7HC9'<;GM<9FSP1FQ(
M!I8%@=JV+@NV`*DITN32&+(A2\NSOUNVL+V[A$V-$;]B#5T43,O0B6)355"%
M+)*@TAJ"CI=X0Y"DCMGC9E-@&*)A0M:G*Y*@&3*ER!2$TA2&K"XM%`Y:3AK7
M;)PLL<:#%\VAXQ6+F";4_4A6L8:H9&%+TRV[M`ADALM+;/0=)JDH$Q?:Q-;S
MV)M$T/H=*/J5?-W<)%E(3OT$+E6GQ_3^;YG,E02C6`@L+35;!B=(P9)*#"@7
M+*+:($H1<#$BD&!G"XX"*K<@-U>Q`Q;Q@EJ+Z`:8@-BB;DL"6$272;'_"!;!
MICS9?Z0'L,@.\HZY=46H^3%,#]-2#$T4;8E.2@W)D#-(Y$K+V1/X!+58Z4T3
MC)FSL2K)LJA`/2FK,K%5(,]";X0T$15ZM]W9&R42LQ4NJ)8Q),XP\:E*11N*
M+[E0&MLVGCA;&B#2+:579`RSHQ:J*2FF89NBH&NRKNJFIA1J*SHV44%UH#96
M.J3V<F(PF]6ZJ2#%MB0=6<00H(00U!+=6%"[XN@&&<!4=457B*U;%*F86$0C
M(M0'I;.1:4Y.<"@#I+[/V6'9/"R$?H1"^9Y-=I_R\OF7F+EV&%G/+!IZ14E=
M,8B9;QH)E]KORCPQV9(AZ3`Y=:P;D,%)*B[D5VQ%TB`N7PG(G)?\;:*\HD^N
M/',;U_&2H:JRK!DB5&F0C<NBIDW2"@E^T\VZ@QK5Y8DUPKQ/Y/=F%"M5UE33
MA%B!B"K;1->H8JE"J3+"EK1#E3]G?[_!2R"D)JA4U465`M04157L<I*H$I+K
MCM-0A*17A"[$>9_0^UA?H3HR,<0\6<>:1DT++%!F/8I`[#J4MD?QQ@"E5+`T
M))JJC17#LA$D>67\PR*1K%9K^\ZE(U&F$E&("9DM,JADHVP!O=!=E274:MW?
MLTQDRB)6=1NFN)XM"2B*88AE8I]5-)U2O-F:D*#9F&@:P<C&`L1,;%EE"B`;
M6F5]O+7L]N95(`+5G&U(B@``L"U#D16M3/T4">NXU7Y__Y(/,B1LP9Q7-`4K
MEO1?[JZMN:TD-_^7O&>J&WU_255?-TZ-1\[8DY3SLL61*0]K:=(A)6_T[P,<
MGB8/=7@528GR5JWG)I$`&@U\:-R2E,97Y!M`A<NP_VDX^W8`MA-,.H;7,%.Y
M!?,N!K`5V^%Y.<1VYO,N:NA[NJ0T'1L-G%LK-MA=9_-I=#_&GW\W:5H+'@;C
ME?Q1[/\SG#7__TBFYEW3-C3Z,?PP'DQVUVT9KH/A401`?^HQGK*NS5F"!\N?
M)*56S1S\%[,Z@"W\=%A>_<LX^#ZZ'XP7-5>_#^?#V8\&Y9:'^X?9L!:`W=SE
M;]_'T\?AL/FE98(+^3FN#--BU&RI-#Y3=T"R"F1K3[TOUHD-BJ6-[)B4,U+>
ME<?^U-UOPWN4YJ+>\\-TUL]B[JN810?*>>8R430EM`0C%VJKHB.(VTNZ:\6[
MC#^+Q`OPN.MX-0#&+&@I,7!1(G",$=O"_^AS$KT\`CI4=V8>9T@':0-9_@^#
M1RHT.^Z<$-0*-#P:]0ZTC4DZSEKS(@#Q?8\'I\TZ#QM(>`:-N^0L590R..L2
M0D^>A?-95AJ#2CTY*V/<,VA$JW;SYWCTM4J^J0.E$4OSOZ;C=3>UD*KXCX<Q
M-X>_HV^K9E:^>,$@<%G0OD=CHRLE2XSC$W@A33]5N5[6>Q@#+\+P^C/Y-H9-
M*7AR%H])!L4R\NE9RS">;K^R"B[`[X?I/;FIP1CUH:GSO9M-O]4/V<K[FHZJ
MKJDW6B);I7@T^#&@,\L!66*43;(01>\,M=K+TDX2.^QAS-]TND[7:G7_&DPF
MP_&RBO]9?0_"::6<D\*"4V@=N,^QWCR+YKW'E7/="HMC"#L;/[LL228#;"++
M.842HD@A\<I/<G`9?M+PS_MWD_G]K&F]HAIJI(5R@8]/VR7>M0AP\&BW7QX'
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MT=_]]W$Z?]J><$@%HTD%X4S*##Q&`8GY5&,>A]B_5S&N5+=0ZW2"S\G\?P\I
MP!Q^:;,'BW;6F[NV`6)W@><*#`A#(4)TH%A)1@?N>!6(9P(H>?%9O^<JG4T&
M^^GN2&E^C\=(/]RTC='G8=AU-QQ1W/4[_@?\IYOO]#OS-N[_-*T4'J0=W8`8
MG,-@'_\`[D30!D+P5186]&8SR:N5/(G4TSC^.)R,IK/W@PF*L^<A#F`<O;*4
M+),;#L*XD)(U]24@)9DV^P=[`N-/*=[`/[6(W]Q]&!`*6R7V]KY7'=ZWU<DV
M6Y7Q@#,WFF$\9J"MJ*!^1BZ:PAKNGG*[F;X5(]NKD!Z;CJ.%1/`WA[<DDJ?O
M41LGG)VSCB0I!`,&(TZ;`P(Q:YAN8\\<,9I>W'SQ'J#>_.,9>DUA'%U?H@JZ
M,QZ%M#:JPJADLT6GV2=F5",/SM^#>)L".:[P)*FDN>#<"P'><N5%%%4[M'6:
MH-AG>*]^#EGL*LQ@S`G$R`Q1G0X%,*:$*@@.T;6"`/,V)?&<@@V`HI@I(O(,
M1C";A$[+FP(EH$C$9_N>NVL1R27+\82)OB@G41Q.4\*2Y38@3#%G(QO]<%=D
M1B]<IB>%"IF:516HA$`J!\NK/`IJ3&-&U159T4N6[RF)YZYI7@"S.9EL;=L5
M0L+(FI3#7H\-O6Q-GRS2&%>R$@&HD@7O36M(4T"/&U$6\@U;C2-<2F**!9$$
MQEHYYA+MLI8EQ8!&H]&*ZW$HEZ\`5)I)SW/Q')CF%J^(KC8C&-LZ%+B8:FQI
M\>[D_R@VG7W!"&=.$>S-W:+M^_B6.<Z\Q`O`"P2I(TA7Z\XP^,`_^ZD&<)T:
MA_-1OE,:6QM"]KY7,^5+='AZJB!T%$FU-:P&05.PO<2"$MTNV-V4G$3Q2Q2H
M>9N9X7C"I5BP`73,J3*?+.NED32HJ^+]Q*JM#.CX<Y#,<JDU]REI4=EG94.'
M*P-S5?R?4KDE=&`&4,6#1F@LI)=65>85@Q[S7%^7WI]8O%62*=P*4XHN*(#B
M6.WUI*EF:MMXKBMD_.":K2*Y@(#&W!I9'$<S+6J[;PAXYKUVWZLZ[].+MCB&
M/5DRQ55.T7)M):M]>LD(W[_NS52'2XM@5X9#2!G`*9:\$\8PL$[(2C':ZYZ6
M<FN<?!&27\([8;BA*"N>7+%>EI!<K-Q[[V+/-1OV`M;Y"-Y/]$ZZ%&9T8DY'
M'UU!2=0L!\M"\9YS!BZNZ^Q/\4X^V@S*6!_PKU%['\W2/N<L>HE*;G=CSM?F
M_3CO%$66T62:46N,T`X"]\LQ%;$_)`EMN7)7S?_!3@H0E?B2$R2?8S146E:-
M=-`E]MK+K^O83W=268%P@FE#<RBL!OQ?Q:01'4#_UEL&9Q'!LG1H_/AQ>'\_
M'E+)V[MF@-]Q$57R0NN4E-&2AR(]7MQV%&M,V?%>7=/>B&H'96?EZ)S#=?B3
M_O#.1[Y?#!AOYDK/AO_[,)S</F[^O,Y/TJ:$AQD5)^S1'Z<0WK&,5@)!O0TQ
M%=T^[5()4.R-._K)Y`ZO)?>`WMI!!DNU>\H6SMM[J[6,*O3JQ'Y*K1>O)7U5
MJ$X,BK.<`2]6&F6KUEOP/:MYI7*_K)``[0&5$*F@N68Y:Q':%TL:Y=(W#=>A
MHCO+O+4SQ1F\;<GPJ)6S$5I78UR0_3>,O?'12['T4_@:9I6F#0HZJ*@AH`[5
M*GL3T?_T.@%^,KF_FJ^18(S#H,!EGZ@!T;/:@4$+'4*ON^'G5/M7<S:<*RTA
M)73Y@&C+\67OH\E&FV/>#E]3[I<54O926;0')DH,XX#RJ*G:!N9,+XX[MXXN
M>QKGSYU>D%QFI0BM,C7VT@Z'LHQ$%:A^?\:6Q%>/DE.H?9GWAQPE,(@%PP=O
MC!!@(UN^%*MR<,[O55@_/0;W)?&`4:L/5D5;=$:046/P0B.Z]EWP9_']O6U6
M/:158FV5`8]%@8-()4XNQ.)UVW%3;!'^R;-^MR76B;V$5Z(Z#(SPTX;CT0]*
MX=X/)E]'O5'UJS[%[4-M-[:'+3[[UTV?C?:JV>E'9[]FI1*MCQG]^;#8.4@3
M=?8EOJ3PF7$;G(@B\QATT24+&[UC1H;^9$O5S0(\F_MS2+#M7EE4G_=Z4RXL
MSDX3"63E6$)S2-,>Z`]+`LQ2"Q6;V4%B.3OH3,QVI->T+[\?C8?S^^EDN*F_
M:.\3%>41LN?.6H&ACT(O54<;6RDB[WGPIL-ZJ0(;"3B>P)U=9PHU47"3HDXY
M(LQ0MO:OHA=RO=<$N!"!Y]["`]'&*!&WNBS(:DD![;.^XAF9WKF%9Q]?M.%)
M,C[;L@1DIT(PZPN5D)-2>[2FMFV[5S&X5'H*X?!$5H2M??'!].PZ_P3&T>AY
M$`H1E+%&IF6?>`REA_`/HN?=I%E%,Y_7ON9.G].1+>`(>0,-?V.&.6><]KS&
MW8GI?N$$S4?I@+M=A#R7W)V[K1!STCRZY!('XP-CI;Y(H]'GO0:J9Y'[ZY16
MNK26[/:QW0$T^(H^M;E`93B<?QB,ONPE?7U-$4#,)2>CDC+"::MDR=S'9#3#
MO]O8Y&)KD\NA)*TS<5-14OZ_VV8X[=%+(B37R7K-DDF:"B8=7J:%O#."$M_#
M3T*HSD/31AJ>0^+.T6391&\2^BPO2V(\^MQ>^&2Y4;T+]J_K6VK.0^.>_0PN
MBI1IT!L*T2)I5*!<Q0@J]FZ9A.Z@A;.1N$N,0#/-\.<4&G+$RQ@>U`V`R><-
MRVS6Y^GO(;'.0AB@V4??LP`"GZ85)/CQ^-_1PHT??QTACOBRWEH[]W,*#-%'
MT5^H@/`'?N1D4_?E8A)P-[XW$AV3PR@`@'-;:#7EPOE*$Z2D)B.WQ#<7(;(C
M@]'\=C@>#R9##&1N[O\:SMY-;J??AE0F.ID??S6MMP@E$/,DIE"A'+J\4O>W
M4!]M3^\[O;][:#F-Z)V7561ZT+4B@83(7"[0%H)(PX/O:=GE"=YS<XORL1B4
ML$WT),242FXI9=]/8K\(P;OO<31(GT[.42HE9B5979*"WG!KUO!@@G^C&:&+
M/7AE-OU69X1N7%YUM'X('1T8O*J6.YFRL1[:"XN>);'>QC'.E.V8H6-H.Q='
M>\Y#9`O<4*UUSD5%6;@/M>A:J^W;0Y_)2@,=ILT/H?VBE<OM(OB]8&4=W@LM
M50@84E,<#5GG[&(+[VG01!?>KY;1USD3VZGH4YH&C_.V%?O+W?'3;YF3VG`I
MJ;:=T109+]H)U06T2&)M^NTAW[F!PF;(V,=VR_VQ@DS<4#)98X24+4)JQKVL
M@L1?[1J0+\T7_7W>?M.__)M^2O<Z)7U2%Q/"T'/]0>O2GS[2J/_D[P<SOF-2
M1X"D($;J>\@04&FSK3/+0"$CFX;A_:+8$S+7J.@3^6GZ'?\;ROT;S6Y;;(+?
MN/VA[P#7J?4%O;H$-,O2"4':FE5!&"A2""RH;JBW6DDOGA"[A9K3R/Z\BVR&
M%]\'+>GERBFI%"^V(3NCEZ$Q(Z]#=M\1KI,=,Q>:H\?6`<G.AD?GD&P;"J/-
MF?'UR-XI;9Z:\O`8F6".FRBI"#5+DS&NQFB<GX?L=L#`UME\?]`+"XVB&$SP
M]]:F)![[G"!ISP3#,S#!2ZE\:=V)#X)'M>&&(N[3G2?]$TA=\?MA<#_"?^_G
M\Q&MKKU%VSG].AM\>]:@*5]4X8:!X$6Z@'&Q7CZ187#73S"!E)V8?@\I)]"\
MZQP,8E>7N39X%"GXX`3H^JP'3/>>OUPW+CZ<Y`X"J.<SG=$(L&G;2H4PH3FP
M?V+(0O-N$,5-'Q`2D.L=X>?C20\F7V[N[H:4Z6O!W+SG6)%5_WU&@W:VC#AC
MWO(0,R2K5>*T$[:V3WKKI>D71<GN>]^E^'@=235.]--TM\`4FAV3A4#@FK@%
MYVRL%U5$T5<0R>P+2ZP=/+E<=KUQ)BW>V]^F/[A=>X.3+BG%0G0B,Q:,C3XS
MU(*$"#T8FLT@=!V3M?%;5D3\/KREO,7H#D$BF:5^0^4?WZ>3"M".#B>B*4Y3
M%[0,,0E&447M>,S2Z5Z?#)BF!+<>PG'4K;A:+!&??.EF8.;;-EKOLHR`<HV>
M)R]`A)03,^V0%!63L?WL!FTW[=B9'70\D]B=0[RR]C097_C$-6^FJ+E*;`+>
M+_07B-W/1VR[\/LX`1O45V]#U*@H&-@4G>KC88S4/[I[__=^:DZC?)>TD4#1
MS*U&,"-YM"DX7_,<Z)MZ3O,$RC?.V/)T$1;3D\+CZD?:5([_YV#V9366:$.:
M<U,YP*F#ICNS[&U.EGFNLV#%!XO@M4Z4,CDTXV-8'9Q]-O[.(+*;9>LXI5/?
MM1_\;H*'-)F/;IO,_O%]WT(KY#Q1>[N-B%98[0T6SB..[/>'=A3EDIR<3V!_
M6[2CM]_2_!/MX/%?T>U\Q;\Y48)>9W0=7!:.!DZ+7(K258(RV9YIZXYZ?EG6
M.B*E%Z)%@_YB%N+B`Q;!^0V]?HS'TWOZML47;4`Z_><"UBT>X`2!I4;?)!"W
M9T#L7A\+LN=^4RAB03NHT=6Q%)Z5MS[>?3*7F5LK:()Y-HZ&-(*%]F')(^;1
M<@-W>,V$E?ID[EJ0\1'/]1\;'L(N/%:@F[2TF3;>&2^DY;3J,F9CZZBEXM*3
M]-^J((G]HNM<PCXS%V/T^"[-+J\\^!Q42,)G!.@`)=<()P=4;[V-5_Z+8R_/
MZY$=F6OC%@4&9T$;SU+1G%XAVQP,,NH5]]=UJ,>T'W:Y1`U%R`R:%<B*<ZU-
M.TU3(S*0H+9Q":N1FB_(Y;,J';OL2AE9"#YX:X*PPEI*>K8W5=N\57MA]7Q[
M*KN7ZR7O,HK@-LCBM3!!`=?T\MAV9R6"=N8%M/>BC>.P!CLT9\H8JX(4J+X<
MZE;&%#A+.TR2%2_/ZPDFR25;=/'>2V\T#UDO%VY2"ZJ`ZSK4HRNRNZQF.D@;
M1)9"QL*$CK+J;\`@=*OUA=7$VU=D]5#KZXP'C*F-$S&S:)"]%"N7'L(N+N'E
MN3S9^F;'E<3PP,54A&,R*;?47R-4/(_UG2^+NS=,&?NOZ1@#BW%O+MAEP:+L
M/E8QQ?"D"\N>-B<$F5B=Z!MX7JMT756X&0MR70('<ODJTCG>G'<%%&G\8N1*
MN2A8R`I#"UU]=,AKN9N.@+15;T=`1_H`N?9@7FS@`07A(!HG,;2N(W\3V#5G
MUY&.$?;M2F>7->V*IGC.(4H*N"6CJV66-\N'LE;3TQ4-A[<CFF>9X*Z,M$G9
M*^&C9#)*DYUP=7YVI`DTFV6D-'ME&5T.-7>E([.@51IH<Y*6J$VFM%4H!+`2
M*ULTB(FW(YW3;'-0>+N,<^BHG#+)Z66Z+H7$U.;R;`/L#:G/";;9(0@O2G%6
MD@(C)$,$6T?&&ADWVV8M7MT`71+4=^5C"R^(<C(JC=6A!$2X:HG_[#;/#NZU
M?=>%(@&YEHH!1BTLDJ?$90Z(D76]6.#7>F\[JB,M?SNB.=EW`7@'TBOJPY$V
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M:M=@C5XFZF`^N\+_G[UK[6WD1K9_99'O%TL6645R@;T`GXL%-CO!9K[<C\Y8
MDWCAL0+9SF;VU]^BU)2E[M;#LB59GF2`&<3CD8NGV?5B\1P571&:DHUU5.NI
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MX\B(9%,0-I3B:B>XL]:*C(.17FD[.H!]3'F!S=O5`2(D4B7D$!,YT.RS&ONE
MSFHH36XW(+R/S;/'R?4*E?1A6Q>0,Y%`,A17B@V<"K>Y:2?1#'D+D;.<OL7C
MAAQJ[C9\A0]U_*>$*CV02JP'E.U-(S>DMY3@0!UN[@_L,R;S*Q@+9HZ#(#8A
MR\)1W>>2^,6/RF:W9#;R<D!N93N)B_UL>9'9VZ`.T?J(=;[!>0,0A&X1U^JL
M[7`K"VM>:/>_IE^O;@_>REXPGAA]]AST0`#FTO5-+$;2`YP7%W4&]O:-.,S0
MK12YC*PKCD"SL4IFM@Z75\X"#;A8M!I$B]V&7E_/-8NO;BN;3*5D_/7FX>IV
MY<[Y\\!U7LOHC4Z<IUKO'42A&_N1%6'PX@%2E4=9,WNG22]>P3;4N183V41R
MKBHLJ4HDV,*)IQ@'J(/3]J4K^/?C_7PP^/[C=,.__7CU>_[\>?+IH=X/&Y\P
M?_:0>_`N.$X`;<*LV:=C[KA^2.@8S`BWDH'>.E_%\%."L4RP?WS@K+3^F,7E
MNOIOIW=S8I=52KT-!NPBE(\I)9GJK8MB+5?YN5.H(J%R'.&V/@FPM[?33U5(
M?/Q[#V6E@21\$F1X&SE9M!51=C=OI,PPU*&3&GMKW<NN5US*\N$N^$Z6&^$?
MT\6EO[4-T'C#ZM6I)^JP[B?LDH+1.=8+(Z(RDC(<41C?H"DT`DT_,+YI9'Z<
MW-[>W/W\M\E=O=G`^/CK+S=W]7K95;VFU>Z?[E)*BB@,EBPSU4N;%K%C0&6,
M=*(!6XH$PC."M,V=YD1>>P]`-E&)$%WNB'CXR>LA\ZZ2BLZ[E).]"2EKD%EJ
MZ;!RBT7.$W6#1@4<B"(I?<XWX;G(O-*;D$T&$[C2(T5%8PFV;9\@82@<!<:Z
M<X&T@T.K2I%6B@<*+G,V&.12`8QC@QTRE9%6YUW)R5X$862I7&T<$G(6`."C
M:\A('-*AN4L"YI7>`Y+")<7IMZV3:Q&\-<N((/N3Y-_]+Z(X(T;;Y9=!>"&5
MCI0=U#O;136O!\Z/Q+9^&GCJI9PN-8(4N;K*/BGA*U^CL-2@D3#4\Y3FS`_Y
M#"^"LRE(C")7YN7:=^7?&D8)T[#E)L6K;)__5.J1,IVEZ>-/#Y\?;X>MQITM
M@=46/<?]H*TNV17D!$DDTRZJ:5<(AJVX?EMK+Y->916]ML#J*A+7R<CUC.9T
MU2H!E>*M6P6&#,.'\0JK^#*=/=S\MR,BZ3.P/[M0\YQE<RA.)L5DD*N2;);,
MOH&+LD'HZ76]MEKS4L.W$RH&)Y%?A:JO"$X'3BPZHEIC<<2-]O.BXUF^(P\R
MG/;ZK`,7@H+?6$Y^.NXNY)>AJ,')A-9P0LNW84X@A:_:I9GS49VML-W=:,8\
M&3>H9=`>OEON'FZN;VX?JV?\L2K4S)OM^?=/MX_7D^O:W*A.Z_&A^ZQ\-;MC
MWWK?[E3Q3WKL-U;WV%06YPV+R%DVI]N<@.K46%.#M6OGG\N#0S?H!+^&Z:<#
MXZFK];*?$KZ.?\!:#,Q??KV=?IU,YNW.!>'!+FDL*VJ#53+\!206K46G:J\]
MN36-\_9(G-5_/)%]G\C&N8!>TPH+A^6<J^2\S,;@\BD$:=P8WZ##?K"[E*>P
MDUJY,HL&]N+LR4TE6FX-/,U?+7($"Z6,=)<,QAMW$L68PI4RIXZ1\S'O%'2W
M"]A))(`Q)U'+1OG'(WE5+\$)9+097>'*)+.C!@\M?'JO<(PW&$`=/WR.9#N[
M3BPSLO6!0E!`15L*:JDPDJ*!09>^WMCHK6,DJ=E@R-:9!0?%Y5R9(Q/YR`63
M7DJ=@!D22$HA'9G]+#GHH%S7"TXJITK)8&*>RRFTD]#@\Z!(!R=`C]@S>NZ\
MW:RMQ^):%HFJJE8E$JEHH^12I!S+H%&*4@(\RZSE4%OEV+R=5@'%[1/HEZP$
MJPJZE%"5HK&JU^MDE_K+*O1Y<^9I</^X>Q-H;P3:LXF]NBBY0@65!)<;Z%RI
M1T.=L'@JHVJCEX+IV11<"T9(+@A.3F46QEN`IH2MI?9C<A>GQO2X`'B=<L[\
MGF8ROG`:&IN$+4'B5_D,[^M[$<7&!"E002&M@`Q`G&$N1;&U&/9KP$EU4=">
MS17*8!+GB#8IQ8O*(*U>ZEZ#-8.&T@5A>C97R)FH`P(.)=HQLI&SM:;AGBV*
M02)T!DR/+&*O7<"`:*4(:1YKS5+$GD1?/O?P]S4\WM_<3>X7JJ?W\V&LQ=18
MN^&P8/W\,)L3M_]T.VDW(FY^ONN+(O?!&OGLIVL>'35S;X,M#Y^Z2R+SZGD-
MU95)PUV3&?P:.A^#I^`#P\/)2C>]BQ#<4`4.M%W/I5^&S2C,;/U/-W?SJJ]I
ML<W_YR,7IO>?)YRU7\LQ\MJJH&L_3K^_FBEY`+Z;"PZRD8I"2KF@+T9&ZK89
M2B/3X`#"@E&C&.VSL$,161E4__M=?7TF0Y7A(V)$7(T&KF"CGPLQ*Z'0MWUD
MM=^H>OLZ*ST4M+GLV4GW4HK%BV0AACH!8`2:DMM>XE=OI-IR>"A0B]7MPH:=
M[?3GNYO_3J[_?ET9UC_?7`UDGOW=*NKSJUZ3ZT[_<*-`X^&>;G.MFF20@KA:
M#>RJDO&Z.Q+G7::\&M!R*T3:A=XKKG\-ZG%Y2/\0KV:SKQS;1HC)%Q?>-C=D
MR!K-%;K/M5BO2;T';-)RG$8-CM+Y>WHCI7L9]1K+T-MT(VKOUO/CXQP[0^`(
MI)I"GDEV>&%+.4EPKF5L45*.WLSE?8,Q+O&2),9VQRAC&`[L*>J-*IUL&=O:
M:=):5YNWEC/SHD*1)K0NGR./PTV%8-Q1EO%-M=W8WV-"3ELQ^*J%56QWML1E
M/.^JX;6I01F_-XAO%/KSM>5R5HEDQJJCJPHEHUL+B0.,'$#_CC`_7ZT*X+-5
M8.HU,$V4)(JVW:-PEX#YL6M9+C(L9JELU@8C19_:IO0Q#D]_SN\/WDO;3]4K
MBE!011E%YO0*H/6FJNK68+9OV$:X=.C/YHIC<`G)&"`,NFIT"D>M+9A+&4#_
MCC`_FRO6PIA0AX4A6%&$54&;AGG5`[X`S(\<JX*.)F91@F,/:ZN,H&O^@'.T
M`4#']0=-1^O3C)<R29/%G\\>>,2B";PB7P?)?8C*EL[)*=!)#AI]_V,)<(]%
MC9OWBNO:I=2E^4%YD+R,PO65])2;@+S4<:0*XUIRG_)EGW6-<?2L:8LO__*^
M^]O[]6;3!H:;=6&J4KP1Q1%)3A$X-GG1R-5L'A(LK&H-:+.RRD.,/<)R=VN2
MR\J!$?CWC#ES10UF*<0%%DK9O-[*3G3D]2X8@CY\?II7BE>WMY/K\+7_89L>
M]-/]F:H'M^:UOK_Z_>;+XY>A>^IMB)P*%^LV5GY=&X,NU(A"2N9:<@OIT2NM
M[:@X[=XAPA<?@`A)&E6<(^>Z=]Y+)+M5B.YD"'S@0/]P=7?-\>:Y5#M1%/+!
M9L6IJ.1"J;L23=$:)<<F<"WVVNF[+'JY^4=BE>S51&B%S2%XS1AX*$YTGH`S
M=0[0(TB0Q#<*1.W2/][R)SUL)OI;3T.T*#$EZ7WFIZL#2-4=%40G:,T/MM4;
M>*O;X/G4F>O=,A.$T\X63F$"\;Y(NNN616%!Y!$LE.C1X;P=,)Y)D;D^KAKK
MT&,]\'`U-07I.VXVBF3&9](YE%X($#N9,-=3/^6\5J62J!GO46?ONG/9:()=
M(W)J4%P$"MNX+GL]9,12DM'US%7&PJY"MDBAUR50EE/8;]4]'L1HV==.#U47
M.Y%57.)H$9L@3!3*A+&9=.5Z)_5'QF.KOC<FQUF*`L084BCH91?VJ^2/CF,/
M<S!2?WS[3Q'WK5,2)"KIE2'I@D\&V[Z.8=3'G3CN/P.(9\?]*-C%`X:`)3A(
MJ9)O-K=&DNS(ZOM#.6]G]2^,^SD7L$+'DF.D*HS)&5#;"9[#X!N(^\>CQE[W
M]9I#?N5X#JB"3"5B8[J-HMXR/G_</R8#]OJ)=>0BES'(5BIR6F#H&/IJV%-K
M%T"64'`&?2E@[!W^(9A00A5J"E9RI436MJ2XY@-C^<]IP_^Q":U[$\;6%E'Y
M#:S1@%PJMZ9`E#J4L1O=+PS_TR]?;A8D?;5]R(OG[YC<?;J9;+J!]E38QE1/
M^[FP<RY19;=?LNFF@+8_<_&GW^]O_G)W<_O7[QYFCY/O_O3GP^V89R!/.TCI
MHEUMN$E!G$`CYL9UZ3+*Y]O1#9UV%(4+&NW*$S/[;7)=IK/R^/`XF\PG0>\V
M2+AN3@I,R*!D09&*(`+.^E7+C[3T8V^]UAI[O=[GVKAIA3]<S3[,YH.XU_.6
M?FM#[FSUK'>R4)N8.)01<%5'B3TY=#S025OMMTBS\[+DZ+HV6?;RE?2>SOI*
M-->?"1,YA\Z1-XXPMY40!G6"E2P>I7]\^&4ZJ_-\SWP6LDB=G0PE\0*D2Y6<
MJUN!<NM]]J4[%=U_H_;W[3G<[NW("U,*[R+ADLU5NY#7T>R.0*-V&SRVW?MU
M<@/IQ&^`CFB=-UB2ZKA=R+L"<O2&/:'BXOX5+%],IC]SEWBC&;PJ*Q4\..WK
MS$!#6W/D&;V`+C@C-1MV^:HMA]F[=7=4V6%;LO$9G8S:%TX*F[U`:P/^2WM!
M:C12VA?:^YP.^+K1MNJ'`\I".B3+V;_N2&6K6^1<;LQHX3CJ;P=Y6R3?W_*M
M<)L45("<7'`EJ@34))\Q032C)";[P+V'Y0=,L.J4.0.*#@K*3%C8S>5VX]SG
M-!BGEK#)98R,>.ZT;%NP=\HD92DXD645&$`*;;;6!CVD/N]7_]LMX[A^][`8
MEZ]:)1Q7ZA>N?IZL'U>.,>,._G'X&CC7^N7+U6S]"LZ0W*LW[S'R21^__KI^
M(/C#;'K]^.EA\*W;Q>E32L"8<3J1'%B,PI:.4Q>+<&I<KPQ7SXJW('0&*'_D
M`H%QY%+Y<?*WZ?3Z_I^3AQZ8WU_]>SJ+C_</TR^3V?U*\Z7[4KGY;822<!4T
MGY3*(I0L<A3`U;;R.0N?N7:(7&N/"^(H^:Y!FS[.=NPT12)P#HLF$3H?*H%M
M!4T4:6LT'P5-ZO<,VH>['1O-:2$"_\H<C&4J(#B#F&,F;;#KK/LK&\V^9\P^
M_C*;['H]P:?:`I-1%<YV?0QF@9J/0FL85\P5]*Y1^\]T.V96B7KEI(J:U/B8
M`Q?U<\Q(9Z_7#D16,,-38/9_%Q92N3!'A0A&<)+OBC..D]-<Y?><27&M)[\2
M4MV;A?(D(347;<AI#J22(;)<H';GL_6KPHRK@@*\:]!VAE07`T3(-0,Q5+<:
MO[<--*&$&']I3Q(>S@7:SI!J)"<AR+5MUE[)&(*D3H.$K"YR/.'5;]?1G2:D
M1FU4$BJ:6@9J+`ZS:3LM93TNE2G%NT9M5TB5@8R)RF0,F"$J@B;20-9',ZZ^
M>A+,]'%"ZLNC0")9P',$<-E$J0P#V$4!##:[<9EZ.$5A=2[(=L:`4JJKST8+
MQ'K::XMOD%614QB/`>K]0K8S`OB4/?+;F&L02-J*T-V,YTV6A1E/=>D=([:/
M__=5H#$ZY4)01+SAA&R848%POO+@7)CM\OY4$E41=UMT,IRA^7;24EU9">,]
M(G%\5X87V*,TUH0B*.4$]1`T)^%:CS(E&D]S]?%[E(=">9H>97$I11^=S=X%
M2J9$/^]1BIP8P@U-D./7!N<$;6<P52(JI80G;3'PWE*57Z%V0:(.'#;&09/'
M[QR=$;3=X=0&400(L-[GJEU(6C-FJ61G>?^-OYUP_-!P1LSV"*@P%QR/0HAH
M!,?62IX_WVDF9<`U>?<5U(Z?A)P3M=TA%;5*)8GBK"(I@Y>+$P2E2B8W_G;"
M25S:I?4H%>\_,L&A(96MQ>A5F/<H7595Y7J\1WG\=MO1H'QY0+7DL^.XX*6I
M)\Q!%=FRD)#$AC=6GB2A>ZNUJ7.1@P+DA"52U,7E;IZ$:]/DXGC5<()R_FR0
M[0RF(B708-F;L6<K(H,QI2&&#L=KTQ,<DIX-L3U"J<BA%,FYKLE.:2V<Z)C3
M^<74RHWW)M5)$I`W6IOF'$)$D"7[:"/:(+N[LHR80]J0YK[=0'J2@LJE;+Q0
MQL:LK;(2*UE_UP)'G3<<MKS=5_,D!96IX_7(%8$O!!9<JE15'6C!V0U#'^]Z
MI^V,`8ER44XJE_@/TI&PDX\T9%&1'H^:QS\_/B-F^Q14[/:3`R#MHN%B*LB@
MEZ<M"C?D&F\WHSU%007LSNI442;M/==4H4YR=F^G$G(#9@>V.Q8W36JA\D1`
M/+]#<_/Y9G+M[Q=,X-\4KV<6*9`M6.H5%5_)S0@;CY]4>1LI_TL`O9PG<S:N
MN<!O1HG\BQ3[%7*4N_-N(LWES!]/1NT2?=,82/KH=#`V.9E#NV](O,?]8%R<
MO]J[B?LMP7CZ#>Z=#P64J$I37KJBT(>VP9T9"H9?^/,Y,C^SMS)[ES&9**$$
M+-#`A**'_,R7`N9[(6U%%07Z8C4X#$)F,"@;BZ5"-^#+_>:>S-GB+/L:+RF"
MJW?-$BH;"-J3B<%NY1?])I[,KCA;F_603()4C";O_I^\:VMNZT;2_R7OFD*C
M<7U)%:Y3V7(B3]8S4]F7*4:B8]9(I(J4O'%^_38H@A8/#L_A3<ID\V1;IJ2O
M&T#?+S[6JZU4$NW>365,M\OY3\3&M[_@UD29@"Q(+973`KC*6/=NI<";?4!_
M\/-Y769&$%J%S)QVT4,"B#;48;L\6_>6S%P]7G_<N.?[.CWV2SV0@8729QND
MS.A3A&?O0B:3M6SH0-&9WO[RMQ^):V@^;HYDK+!HDB/)81(X5[<*1\,RMG:,
M-I?!)8?Y1:Y$\8YE">^X0+K<6%/Y%9-L]+=0E\,UN/-=.EN&<4B0/GITFKZC
M\LMGVQC11G7-OB%<94)'^O5A.E]UAW,<<,6B-))AL$I[KCP8Q39[*V2RQK9'
M"09`-.!>0C@>WQ#KDO(I>>":&=):1DM4N&&=10OM$^"`ZI+X1J^<4$PRH2US
M5BOAG<!ZY5*,H>&?:&WZ<_$-\<^"E]XECJ4'U5DLRF3#/VUM;)J>N2D-20?C
MB].?'[^;KQZ73^O=@9OE/#VKY_N&%;];S']YG"[ORP_9UBNL(Y-YMEP]?EA.
MYC>?>L*Y5^IE];PRX&P.@:@460@1-F]+F11,;B]P,UUCB(8!8NLNPA\GC]/G
M@2)?@YK'#^0V2M(%-V2=H0J@/0D&4><OV\#ZDY/,O&PX.1S>`%4?Z#R:W74%
MO?O)O*SSE;*,DBTM_@H<DJN$>3LN.GCXYMOWR+[?AZW\D@Z&Y^UR'R:_/B])
M>[$9[8?IXP^+YYU\QRZ;=U@F$21MRCZM9(FW7M=9!-9"(W>O))/8N1L'`KL4
M.8/3')E*9;60*]N%3-"&Q/6&'"<%:V3-Y<AY6*QFCZOG;SGU,("N-QFYMK1S
M"\UE@$VD3P9C%38[P3I;YO:!.!'IX/8R1:)1DUX6EGF/I*1EO39&J7;\?\>Z
M.13IDG[[VJRDO]]-RU](RI+863[.?EM__7B[3(I4YK<J,F>3%3DA;IP\G@2P
MQLD3'3OC$%`7H&)$96FKBHGA,`0!(LL4ZM#2<G52(]$-J/.H2)/EG"3^JLZ"
M\I/5[(:^(<[NGAZ[PW'Z;:K=XF"7>4[&2I,L=VAPLY:*3`++NP/0ODZMNF)_
M@1?%Z".HSJ;@I_T4",&48I9;PU/6D7'Z<V,TR(!YD`+[1A2T=ME.K8\CLZR\
M7.U5D@*`>UO-6F]3&**`O1T%`V<0G`9@R,BZ\9YQGTC6US-`M(,4F!,IN'^X
M6WR93G^<WA5[X85N"*<(?.U#3J6YQ>5DZ44[X-6D<5;%9I,V![LK2$?QG(M^
M2`FH3)9]F94O,7G!L^%UMTVI*4Z-XP%6BW/0__FRVJQL1C-<YN3)1'-D^MIM
M5IMSWQ@$+WE[4/#E3YB/9E(AR*2!<ZE19_I7J!DFY5@31I2DG79O[7\X9W^W
M`*W6T808%$F$6#9L&Z=2381&!FV`MNOGOQ5G7[G@(9%'E8D'@2$9F5F0-*R/
MUKN=9O4ZW@W%Z_+A_TOV$02*2"H2M<WK474YI.W>0N$;Z_T/Q-/?31Z6X;[>
M6Q:X]8;1B^1ZFS<T3C>O%HRV?ZSK^KL)1,8Q9:L$,V1BDSTK?*T,T8$\AF;C
M>I-D>2O.OBX;,FB-3#(=4K#6N)1BS35%%Z')3'/RSD]1N=O_=ZO5T_U#<6)7
M)21[0[9EG'V>W4[GMR76MS]X]Y6`EV/#C7=!>N7)V;/"6<PI;XZ15%S&/1W[
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M+YY_R+N^'T)B<ETE7C+<.\*1Q-'C<O;STW/E=EE3.)*0B8Q;00:+\`J"(`]:
MD3V34+E@720;L7%!NOF80TB]`&\Z!?=OPAN14)*!@4`F":(!I1P0;\C[!7I#
MLAV.?#9O2DO`_\[N[HX+W4@/W$+D$33+.5COMID&;7L*SA53N[J]_MH#L0P%
M8C)D+J5)R914'X\D5+;[)*(5;>72^5@N*1\\]Z;T?1DE7=1>BPR;`F?)DW;-
MCF30?!Q]=X7P=_/:#/A^\J5T`AZ=.D`9R(WE"@3=S<B=UM50YEI;U@1CKA3?
MM9-'(9U+P$C6(&EA?8J.2S1&@1=DT6P(B*23FEQ?IU3F4O"_-F,>OTV;<Z#+
M[54LX05N2V/!AH(LA&J$PU799G8@$5]A78".D9/`;*-"G1)99D&GG(G_=2NX
M":$1'E?\-:A8/NW$7(\^C9B"=W08)GB421B?ZW90GET232T1`N?C9'1078",
ML?J/LM<X1:!G0>_;1Z6"J.]:1MU(SRO.A;HT'=_-/Y-+M5B><@Z\Y&Y0\V),
M<I.3$W'[KAGY+4>_ZQ=@SH$]PG<5,4(@(8JZA&2Y<])L8$N7;)/\T'KL$1R.
M^_UR^C"9W=9D_Z9PQ\UOKQ\_39?/UL+1YR!('"GN./>02E)0L[H@#5GV;20%
MT8X0=`C,5Z%TY.B<P611HU,>@U?*^+H"EJL00A/B+"VEER?UV>>A'[6XGVX^
M_\/TL??8ANK3M/1EOKF)DHF(2"<5-Y9<*@7UC35^A=#5Z_U(3H<[J,5=63<O
M'(8"3V$J-2//64]G`VN"2E=E6.HKPAVI_E->9])VY/F)2(SE*85M@2Y]I7GE
M5YQUQ=.EX0Z^81$<VD#HI$]D:$I1-Z!$J["-,-,W=!_Q$7#?TXT_W@A2PD-V
M2C&=RW"U%/A&;B+H8!HQ(SCV(BR__`A48R(A>Q0D!BP'#8)<>&^J=9S`ZZ;R
M"J%K"XRB6AN9)^79'?E&WEK)/4,!SDBVF52MRK8WU>;\^J_@+H234`YNWW$N
M@R$)1!>0S/.L=.W@,5+KU#P5T2^&!E$^*\@OQ4E>?9K>KMOAC^-EXL9B(-V=
M.'F7]+ASC>8*Y3QKO#7.NJ*_#\-),(>8&:6QFAQ*@<F0`/1@JW$JM,VM402J
M>Q\/A]D(FM'[Z%,F)\8+*Q/7V6:1<W78<^CIOI"R'UPK6(8@#?&+7F\RCLR6
MS$F\Z,1YWJB50'YCZQR"X%TC>`S3/Q?+?Q=%O[B9KHZ]=*7",`0F,OAHG+/6
M0SU-\J&:$*+8Q[`=#"?!'&*BLR)HY3GS-@!Q+J>PV2%=`.4VE\95]PV/XMSK
MZHSQT%IM'2O[J8P7$)-74*-$FGS.MO01!=_5;?O<F4%(@X\4N-:*-$1T$`37
MT3JLERY*WD@\27>.'PN);,CU2K)/B[O;Z7+3E70<Z\B$TE88Y5U246N;I-N^
M5^]<VYW"A#'[</;B.1/\\,NV0&*%G@^4V?DV>@T5/.QF4S815;!*7P3]2<K:
M9.[(7S(D%0/=`\\YVY:D,].NQ^/D0>(^N'U:\-RZ-[_>CTAB!T02D$QDU:2E
M5\12X_U@TQ`T!G`Q_^7#INOC)!9&)D!)EI"4=<1L-&S\LW+DLJUQHANRJZ1[
M$!R/<(B'+*90ZAV5DBHP[831K/*P-)@WPHAI>S+"4^OQ4T2AF%<A`I0<JD^U
MR+?D4EU39DV^`-\+<D^5^Z$XAY@9P`AZV<SQ3/YJRJ00M\RTI(?:!'LG@'4`
M3M+J8;+Z1!JI9*MO_9>_KTJ"A:RCR?RF-`/=/,X^GQ9'#`:M3BZ0EA3TV!&@
M%DPAD]`&@D#H3N3D<'`7HVG$'8J.D8.>M4M:FDSBP6\VEA!-UK,V)B<5X"O2
M5`R+U>-YYV2S\=ZI+.F3@LQ$^IX:9TP)34_4!SLNRN'@+D;36!#2AER:5S@Y
MT2YZXPW42#QF)1M)2=[W05?O1)*N']9]U&<=DY#,)NM#ADSRE<NRW;X&YP3#
MGF."M5$U3E0/NHL1-79.)2T86`3FE/(Q!X\UO*#*=*2^N]?93GLZ4<^QG'>+
MKCMP0'"1?"H(S+.2[PG2.&GJ?O9D$VN'`UV!M0*ZN+\".!+:$$L!R,@R'D`J
MYB1/WN>ZP%PZ'YKT3<E[:'T9:"-!0WJ#3@(Y[Z1OE<-$<B1L6X9W-R[4/)]2
MS14^&=J@8"]B`0!(3I"O)Y&,K-HM3':UZ'E=Y&9=CFLOZS'6/:NE$N_9"`^+
M^X?%O!3F[51@_#A]G,SFT]O:YC(V&(($NQ#(N$I&9D`K\Z92B0F+;1'W4?1M
MW]H9+TH(A]HH@4YH$2!RN<D!EW`]&4`]=T-WR@E[8)P$<_">"!]2<N@9F!BT
M5TS70+*CB]V3XM4*^>5ACKPTXPQ$ADFC5M(:$@!U>$`BF\RTX7D`WM&`EX(Y
MQ$WFG%=(=A^)!-(`%G5U%Z)+0K4"@7.ZN<?!+'DF,GX7NY_;1/"/OJ88H!R^
MC9I\APA2NE1;'"VC/]I$@MT5^\-XSH4^V",;N$0T]+PD^=:&E\&FV[ZZZ%KH
MY,.]%?31;),BM-8;+,V!T22H8U>2P<C;0`V^(?!!GI?"'.LBR=ILN>7%I=OP
M7)7(;(]]8\Z"?MW[N9/RIY9EA@:]3%*'P$@DUYONA.PQS<@PZ\&^%]"YV`=M
MY1PS2]Y)<MVMUI*E&HB/UB3=V$!DE,BW@CYVU8MUGU2*`)$$(AHN964[R9QV
MU('`/@GS:M@'/7Z":5"'LF2W;`KT)&/JM!^M>K*L=-GYJ=C?3[ZLVQ4^+#;U
MG[5D<;KZZ_(4U6Z#"5F5DC_C2$::J#8#;4KU@VL+!CAV/)$Q1&?"'RL^4]KK
M6$HKRTH,^@XN:OZ8(U>-`?4*P.F(KC\69VQO.3K^35R'#WNKA&T96\:2*L$N
M1_>=!5/7+K#(0IMH:4;:'(/N,F3U;=F]0/6LU;*(*I<SV1C")&7RMAQ`DK=R
MVG&^)@_DQ7E0!OM;Y\C0MUZ*N&;&MBY4RZ8T5[[:97B_+`KX\<O[N\G\L8R$
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M.68(GIA,UB=)(L>B5;[F'%T0IO%@^'JRY"[X,43G4S`XU`H2T@VRI8`CV@R(
M+-3$,^^9C<G1VC,I6-Q,I[>KO%S<;UOXU@7\APTDVG5EC"=]G[/+3#E!;GJ,
MM3<BTLMN[`#H<G\_EC-`C^@$8`)\D:,AED'OD9FXS55PU$UM`K\`YM7J:3*_
MF9)67]S?+^;KIW(TM^F*E*ZOTI[D;-`9O:G:&9GPS6W?A[H/S+G0Q]J`R-QG
MS'GON26UBUGG4`T+QDT[`E:+SOBP"U"P+$MYKC_VU+-LFC)_6'P&\Z_;Z>Q?
M[Z9D":;Y(WWPJUWX;D8NW]V<5,R_P^1A]CBY>_<N]%B)\J65R.A96!"9_#9F
MN<I)I\1,"/1%K=K"DG5E[RC=.Y3\KH2WB8%U/^;UQ_69["0%7IQ5R[2.7D+'
MR4?'&,@`9<HF4)JX9K--EO1K<]-EZVJ].MODW^#[R1+,7G]1EA'7-D8H6]3(
M44@:-W?>,72AL3W7P;4W).*PD=*HF,-,YX$,4\G>U=&%I;"^"3MTHCUO0,!F
MX_%%'ZW+9#Q$94PPO/BV+&A'UR\R;SRY^DVY\;KBX#^,[N_?_2,L_D*T3N:W
MWT]^G=W_=;EX>ABGW3M9V@-]"@AD?\@<JPOH#&+KVJ\+_=^>]L%)E<Z))#U+
M9;:L42Q)Y6JP"51J/',8,DN.HV`MW:[KZ(?I\F:V.L&L0F5-5B5B7?:(6<."
MJ%YK0G)A>PK5]E/0"^E<`D9.P&L>9+0Q6#)2N)=2IEJUDW,RS0/:+S4.0M_O
MDA]=(2_+^.1$#UQP))@2PV;R'=GBR;5-+K(3EQ]"<@;D(?>!G(=DP43!><BA
M%.&(6B0<4?/FIDALK-DS(?]]-?WX=/=N]G%O_NGEKO/^G_%B+_I:=FW_(S\M
M"?[3LO@U>?9K^=NJ8W?\.)G_LKM2?2WMGNZKG'LQY4&HR&.2SE@94,BPR;LH
M408^Z&^^?2]_.H`U7RG^PW)H-N_E4(@F>3)*Z;8'5N:!*B:V'(HZE?'A9W#H
M1_)4G^-IUQ]?5G\>WWQL#!J5F-">(T$+CM5"1R&5:KR)W5*1?3!.Q#HB"HTU
M'#P]4P8(HF1N?!V;+)VPK3*RG;KM`^&NIF4Z61DA6\:/+=;G<&H=0?!&:,P6
MP9%4(?N'SK[6$412J&WK02=N.@CG3."#%R,5DX4E2,&!<Z1&A:IK%<#W,%L8
M?"/D(YE5KJ)G=*')N5&"[@5@Y#6SRDR;G=3=[N;7!#YHJQ!8GC0K/<$(4FA6
M1SI':5W;:PO8;<X["OGC<E;&::V3(_/U'T7J?":96&K0MFLBUK'?X[0_S\IE
M3XB%$+FT:$*LA?<FTP,>ZS$\$MQE"1ML>'+>`8"S&@(7H,F;YK52W\6V>?N2
MA*W7()?1>>M!(?\]77Z>W?27%V/WDKUTI7.9T>[(%6,!R!A#KH/<]KBA&LHW
M]B-H06[6^)Q4C)()#A=:>I\RA%P&C-6WB[&=C,^Q,R"F`^!H<(.1-PO@R7WE
M`4A7&E0BU#0+J4K1=FY+)BX';D3JD3)!DX3UY*AI%:06J58">JO:WL52<7)1
M<"-U.L#!VO]C[UI_&S>2_.<[X/X'PIL$">#Q]/OAV0G03;(7L]AD<A/O!G/?
M.!)M"RM+!BF-,_O77S4ERI)(/8>2-381))$LD:KZL9[=U57>G%D;,K_+4-;I
M6"HK28S`=`?BTGX?-.9OZ2#-DKX?@]"]\X=^BV'<G_>N`+12AL*?6HUBZD*)
M(8N9=3Z0H#B5]1JQI.S;T=44*VOA!YEPS.]S(JZLLIB8TK&(D-1TZ!*,/ADO
MF^JFJ%6:`=4V,I1R8;B:C:.B)*J4DH)9PT_(RMI.$$QS)!E6H0"!4@1LR"S$
MXK3:N0A3M32(91]>IC,2P`4-[_S'^PUBL2&Q$*58"*Z$0]9H:\M#7U007!$I
MNCRTK)Z.O4C=M&$2AA"]*HBLP";&#(<1GYT1(E%UKP>3I09U>Y-JLLPGC).L
M\_$KTU((\Y!DW>(__YJ<-?HMS7K#+1HY7O5&?OWLW:#K6\^.D_YC,GOU,/R_
M-"O^_=U;RW<#/Q`+1,$GEI4D%3*HB"BC0^9P)`6&EY/D3Q+#G%&0I+*/FW#8
MC\EFT-NK9?`*X[^X;:()-KY[(8;X51!M:"A+:&PL7&T/VP:0VJO1\-/`]W$=
M?`1%A,7([\-'2/I9`M,N(Y(X;!EZX?!5?=R2]$'()B,)>:RRD6(^^U.E]!G'
M7[KT50W^4GT7&#:("R1"Q@],C4$&2^5U2BV<@'B>\*WIW[V5]>,R5%((\)>A
MGP?"XHCPF?4SDC\!@&NZ?C\5A&ME4&,G?(\@`D$=CV6$,(Y+&;2(U;<,EXK3
M%X;C)E,8"TY"!-`)$R+-_'`668IBR&E8CR-$=B\/Q[7R&/D#`R[4E`@'.9$Q
M5,X\,F<+`?L<CNRYP+AQ"L!6=E'Q*,1^#"\Q,4`7:S0#$?RRJ@7Q0`!NG!WP
M-/"ME<$8J]AW^XFM+R:7`O$8SVQB)%BM#"*"Q`O"<),]](M[2FH*R2O7-")6
MQ6+FFE%8&UE?("STR\)PK1Q:QS32A(<:?'/(D(S9+#[$#*V8"(/Y-P?AKP7U
M[Z^WJFUO;'UA%>Q.:V.4<2$/!;&,L5B4L&M!75V)/!'+9WT:Q^(@2'].>GW?
MQ=,-L[_!M?6E*`<'7/-8A\SOUT816(S(.5?&3@8[[6H`QPB);1;JOAZ29G!?
MK&?R]Y_\[&[[>DK%R"CKI5)$40BATO3P@Z0:@GA3`Y3`2QOUC;-P*(#^2/T@
ME[1K/J=9<I.6I6"_9;W.YNW0^0&^$$@J0A435&$>.HV<G(H7M9S9I8+LQV-'
M](+A@^"VCK-#H)GF[P:3]<RKX2CI@_W.>H.\UZG96=[F,`481H8H=X;Z8^'2
M2HQ*(0Q5M501'T+\UK+4*(9@!Z[3HMYJ]I.[0Z:(4)11`H)'L+&:3EOV2VJX
M6SC_7^JM$@WYD]5L-`I382MGM][OR+@_::T@LI'*?]O)&)=^@!JSV.^_A(F*
MY>WAYOEX*IP.[G>M\?/E`5XA!.>:4R=IZ7<MK@UT,&:X684^+N!+IK?X,((X
M=A;O;I/IS#N7R+"(<*1%2+6.)"6$66<)Y#L84L?E*JY'YX(O4!.ISGY,GAS`
M'U<#+$-,?=\%BPR8!A)AC<M$$H+TY;-[\P!C]CP`?C\>Y:,$E-]W(%GMNC=5
MNS&J'1>A!OQ"'.-0,DU*Z^I4]>2F(LUZH)5L/!58:ZOL8\K#$-)N'"-P1X):
M2TNPD-25N@&EFW5#1P=K53JR3J*DP[%6W!BC8Q6K2`EKRTB0(%J7MRFN#R95
M!TA'M@!H;?MIYE,/1K!OE@281)I/S](9:TU4%_<U[V"/AM!N"=N28,V;_)@I
MY9N>^RDJVDD1&_%HJ>ARH^GYA(TTL?:U&V>G@>::]!<I"Q:?^;1784))2,(R
M7S-8+K?:?$237*@F=E6>$$U?R@,_,^C.ADL/_9_F,G%S<Y.E-^"YO\Y71,[W
M=I:&6QF+F$2J%%=-K:GTX)2LV169O=G<#>Q\U\Q\>PG>'`4Z)HQA&-0?\A5X
MS1TJ_;$6Q.%50HPNU"XFH5$>FX6W)H%O$N`0@)6&`JK(.0;)-K5\!K#5*VTN
MN6"J08!WY+)9B-<&^5^%KG9"QCRR!@MJ6"@C&:O2!E/'S>HD1NY2:-$<@U5@
MJWR_:[*%QE)=GC*^Z#4.-9$8^:GE&/L>&M@*$5J,5DMCQ;#NQ$Y=AX>%;!_%
M+A3<M[^Q!FGEFU5/`SKB%_=6/T>^O#F\@JY/F_W`IUT*%_S9P=IY])-%C<<H
M@7/E.S-"(.\X&`!(=V:%I(R;\.SGW]!RC>U!:'U*2#XN0$+]II1Q`A?MH`7$
M3KQ<>7`N%A@@$1_I+\\:%+XL)]C)V#?RD2`@@D?".^-23I15HCA2K7]AT7.'
M95%6C-*,"[\ZQ8COH^'W,&>EG)'BA:S@7\@W!,O6T>62'_F0WB4]/P,@!-0R
M`&><]-?"N,?!?B'\2#3,E+1QR'W;>UY6+2H_++R`NP&H&\?@&3V:%1T%'*=A
MQ*4*8^R4,RJF9:A##*-&UAW6.`D,MG@TRS49_QQTP<4_]BOQFR[Y0AQ5X#:7
M^TZIWI(FLH7E(9#<4Q7ZT=^:"&8X1:7ET9A@KPIXL^<^.F=5M.>7"&J7BW:<
M2+)#\S$;4FE]+T/'BRX\#./I.AW"CL:Z;IV.`DV"5BH$YKG8E<?Y6IO&><1:
M,1=;Y3>A"4B(C*8!GD"$1)+5\2@(U9BJ[7GTA/C^26DW&F>S4U23BT`"0"9R
M$!+?Q,^_'O5`/7]/._#5==.:#H=)*"Q1Q!'"7:20%-:4(^$04\+4;3C/IQ=?
MQ>WVP,5W]_WAES2==+L=9YU;T-Y"(8^/F(4T!YF0^[%S(2<\BH4J$?.:4[OD
M3R79$K75K&X/UZ_I0_'1(CHGVO8P0B+&D-=2;KEUQ"@LF$]TN>^B)</:BBZ*
M"<%;`CH#HPG\ZK)C-!^5*6,H0V&LK>9(2=]U=9H=8["NN*YPDE$_09L=FYV#
M-1(4+HQ5*#GC"IE8,V41\HT$.8L-YZ+.S!*Y7#MZ.A#LVU/0&1?A.%+*:=];
M7H-PSQ9*`!-:YVV66RHV#4/1)OGX)I-#P@Q0("25YIRP*.33WH2(2EP;7%""
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MMC+@W[T!K5&191`V8X.)59)C-<OAF8XK/<^66P#O1>7A^#R*9OE`Q!HPPP!:
M2&T$QHJ5H8D_*?&TF*V-UU:+/":20T0=&2X,C;25KA1YL!NZ4N98G3NPD:9F
M.#C*$Z8QL2XRQ,\2=I"LFXBH&1J0IM6A0;\!-+8W@3:T3E+.))@'2$FM%'(6
M?@OC*OWL#\5],S$FQ!(4"(\B22"EUDSCL.S3ZGN_5;C9*L!<3=]AN#N*Y,<R
M5M:$#I(O(S"*(F%GD2:R825J:!RIVV&_"TZRKJ/]QL:D$>%.<$.DY%H;YJ0I
M>WP;Q$FU2:)$7%?I7Z!@9P+7E;S96"`A-63LL<248JJCV0PC\+75<0D@M?SK
M"'PWZ/3'?L7YMV%6;!&-1EGOTWCDMWBNAK\.!YZ!;%@TFBM/*.^&.L;$[VEK
MI,,8"0$YRG3F.@1+D(Q7.BEN@_H^5!\+B*.HH49.RU"*F$?4RP?@.'-`%JEJ
M*UHN_-3M%X/J]HX,PEF,9&0B`8[<&(Y\B\`ID@["G&I_P)>#XH=TE/0&:3=.
M,K_9F&^`TIC821([QYCC2#DA2+GO@PVMQHBO".9,U7B(YXKG598F^3C[LI5<
MQEBHD%G.D9&4,J-FZYO,QK0*)E7+!=#?#I3KG*)V1%K?-8);XI",,>>S9)L2
M5(G-MG&*IPS$4?R'="!8,0051L$_3-JP'".'`.3J7!FBF?IV_4?#%0"+'8FY
M%"BBC,5::=_HDELS"V](5/4?+T@V=_0?L:`*60699(QC;$QDIX-YP153J<*J
M_V!8+/=$?LYX[N(_(*IA,;@/A5F(61PCBF=%&`+,Z)/XCP4&)KL+.PX)CBED
M$Y9HB1PC%",_K[,<=HP5K:LM$7)1Y6J(V)W(M=.`%8XAK)'*6,`<"*7(E$02
M357C1.YS;%EA[EM4$F9\YXQ(,E7.LI",J<HF2D4ZJ@3L3-_:GCP`&5?"QY,<
MF\CG-[(<(B)1M6WWKO0M%=0M="N:J\.R2=[K^'DJO?YXM&(`W5(;@_G2#<(B
M(,JX"(4Q#D$(.&7E_)]8V[K-68P54E2KN>,_^]%Z*'8_KF97A28.D1+4<:*-
MT12AZ?R.2"G-:XOAL(0D`&E]DNQ6FU3,L\N(U1R4/*)@BYQ&DDP+<^#I:M#_
MVMH_3!6%QWNJ[*YYNAS'(24"68AL;,RY820L!Q;X&1.UQ2=*,,GG2QV_@EU?
M(W$9WOH*V?S=8%:O__[ZC\07-H_^T4L^%<U$KPJ'!*S9_MH9R_.5JM@/5C2^
MG:*5Q7F#B;-T?D`:/?OYA_[H3;?W.<A'7_KIV[-KN.6KZ^2NU_]R>=6[`P_Q
M:_H0?!C>)8,WQ6=Y[S_I)4;WHS=G/]R,WBQ=#@XR?75;('&)"?K^C:?O56_0
M!9=_*?C]GRMOXO]>1T1O<)MFO5'M=5>W8'PGL`6]07`-P`6?"Y,\O`Y&\.'#
M!+^@7P(87`^SXI.\]V<`@?#H-@]2H*X;>!I>^Q_9DZ#.L#_,+O\R&=`[81ND
M;9@5Y=*7`PAZ)C3_?3Q(?TCN[M_\!0OTAJ+SP#^WK_WUXM;!`P0F09(#D_W^
M\"$/?@101K?#<0ZBE_]T6?F1U_#DMGF(CS^F]WMDCY?-.&^`F)52>)]TO:J]
MZJ?7HTL$0C<OA?[]_$T'PPQ,PIORFM'PWM_XS\<;%U%@T$G[_>EW"NOAW^?W
M2:=\O[O^//2ZHUMX"3Q]&F80C+X"&>HG]WEZ6;Z8$)[T>S>#2\_,'%'9[)6W
M=YZ4P=LS`N%#!D^^>(-G7WX]ZCZ^S&IO41`#-V#?+]SA\=:U=WN\$.]YG3KR
M[QW[NI:_TZ"SY:_E[Y3I/&W^5GF-J=,K"KHZ27_JJ3X-1Z/AW9L%+TS`H\Z[
MV/GWD^\O_"DK7+/_RT8RY_S^$`BYALCG\K;7!5_?:*RY9>2R"/:,7'JV'JMI
M`#!%`M__&>3#?J\;E/'D`;"LP6\NVO!M(=-L#@FU'X#^LN+=PR3:^C3L=R?W
M^<5/="V"WV":YN0[('MJ:+:2^7PD\_?T?E2L06^;HQR5.M`8>I*$M5K<:O$)
M:7&4=DY:B<E)$M:T$K=*VBKI&G$S]UFO_X@JJ`5NU:)5BY>N%D5N=)**T&IH
MJZ&MAIZXAJ*3)*S5T-/7T#70G93Z%5.<M@5JM]5K@.#-IZ3S[YML.!YT7TWW
M]3N=-+V^?@*96]X!?D3G:_?B_U@NCC@/_IX,QDGVY5$6\8KRA".J[,IG,97I
M8L.^(M"G`?%WC:V%;1+(=0`>`*="EANO"U$$DUW,WWZ0'4%N&G`'<-VG+.CT
MTR1[>^;+A\Y>ST`XAD!]G85K#..3<[FM?6OMV^Y`D7,NUD?EK65K+5MKV5K+
M]NU9-D1D:]F>@65KC5=KO%Z8\1*DL:6-UG2UIJLU7:WI.I;IPF)]%6!KNEK3
MU9JNUG2=H.E2K>%J#5=KN%K#]:T9+GY.51MU-6*\=J_)>$ZE%VZA4\6T2T4>
M](H&PCL(V./!_PWU/_N`MT/!3^/)#3HG6C2E:<]%9]J"N!>K$`>HCVFUHM6*
M5BM:K6BUHM6*5BM:K6BUHM6*5BM:K6BUHM6*%ZX5[?)3>XQN:V&9]&VN]A]^
MV/VXZ];ZM.DX9Z/`/Z$BDG/18)G+OJ`]%P4^&$"M*VQ5MZ*Z;'V#JU9Q&U3<
M5C%;Q=P^N&WNN$ZKF*UBMHK95%EDZS!;O6SU\N3TDK09:*N7K5Z>G%[^^/3^
MLBIBNT+V9,N6/[4Z>THZ^TQTDI[CYKK%/7MW^+*+X.OZ#VXW'+$1,T_!S'>'
M8S_;[VOZU+ZH\SW;`OB-G_/!Y%QS?3347L2!GR=1SJKI>Z'MNUK3UYJ^+7?<
M%3I07M5:OK:0K+5=K>TZH.W"E+6VJ[5=K>UJ;=<W9KODH:HR6LO56J[6<K66
MZW"+9:JQDQ*MY6HM5VNY6LMUK.[/K=UJ[59KMUJ[]8W9+:S.I6X7N@Y5BO%Z
ME`#[M=^O>?W7US=)/[V<G`+-WPU\:[]_^3.@[Z^G!0[_*.L;KOQ]KP`$VQ]V
M_OWS__SW?_UU<NWP[FXX^'T$?S19^B'-T^QSVG7#S(U'XRQ]E^?C9-!)%R\'
MK`<>T`_I]=LS%_DZB?\E'Z^BLZ#7A3\DG=$K8QF.:(@1$TPK$S&+<,2H-,(0
M2;@[^WGI`<V#?=6[2_/@U_0A^#"\2U;;SKG+^[U!^NIV,JH3$_3]TS_@=<05
MTM@;@%\870H.JM\0M9.W_NN7O1%(>V=RIV)@<%'.$OP3?C1[@$M'Z2#X#72M
MUPG>7U_#S08W%7;VP2IX%;P?!)-?!&,Q^=71;0HR<P?J^050'.9I-T@&P7B>
MEOL)+<,I+?X4<R/T$'9.N3K7LFJT]F)O/.B-\B`9!4EPG_4Z:3`:%NS-Z&^&
M[._P!:_&B'M1?)]F!=7!]3`+;K)AG@/EPTZ:=O/FR*4J@"_U>\-!,T3_Z#$]
MFQ/<4DC/?KH(X@3^6K`$ABCOY:."$5#+(+]-LN($?*>P:_"S8*[.0=A`X,I3
M\?Z)W8_AQDF>-L,]NN#5`7M[L0V4)_5,%"(W"-(_TZS3`\(GPM?8\R,7J-H:
M?6]Q*SBX"*[@&=8\PJ`WZ/3'W8D1\'$R..;^<'0'UC`8WH]`A@I1]1(P,Q%I
MEB\\-[C2!U#^RTF_&0SHN>#T7+&&U*[`(*\^QD'W-3`WZ[L[S]3XWK]MY.?Q
MN2+B7-><'VF0F8NJJ3^O/K929+O^HUZVXHG/XU`+CG_B-S=9>I.,FI/[X\%D
M0&'[`48-PO0-2;W7YSE]':2C`_@@?L$:=4(3`S;RX]XK%(_J3=OYU+9Y*^>_
M,C/7TTLV/U3_K5+^SX.'-&OH.7_'T$6S/AK<ZC5(;@"&?-P9>8YG\NS?='MY
M9SCV6NR]KY>&7I[#;T_>S^*\],_[=)"#R-PG7WR2$7SZ,A\N7E2Y?^H@^P@I
M@6B8VM]7:^5UD><5[=]]HA?XT".;IH$3M<WA?R"Q#WGP8P]D]78XSN$)YC]=
MGB:OC3^9+;+/A=4Q!`S-<^C?S]]T,,SNDO["@A#VWYG=N%@#"#IIOS_]SMLS
M=%:\S^^33OE^][SYH=<=W<)+X&FZKM*!!YO<Y^EE^>+-\CK)(U'SAT1F:RVT
M]KS/%L=,"EK>GBGV_<95G,7UI.F%F.][X4[7[79*YLD6FU>O;JG]U.G_V;NV
M'L619/V\*^U_2+7.2#,2S1@PM^[9D:`H5K.:/=W;56=&>]X2.RD\[0OCM*N:
M\^M/1-H&4Q>*2YJR3?1#%QA?TI'Q149D1GZQN>Q-MXL6(,G=TK,`L"+4(S_U
M[2'!_"QP[>0^(V6&3]ML=)16EFBO9)&3L;]GL4,01S*"@>JYB:TR;#<]QVS_
MZ>)LMQN=9V8&J.Y0X5LN2SB8:'!$E=^9A#V%0/3D/<MO";96JV&V6KI$498^
M?Q/87,AH]RE%TE;$]CBD4V&Y"JJODJ!ZS;S=_RC!\3#Z[!<?/1_G7K#/+G\Z
M/5"&\;(\*#4:1D]?_@X1#=1_U$NF7_8$Z;6W=(.5$"P9+#]G,X,ZD5EI`/:>
M6<NE,9+&R!=D>ZLF\'>!3YLM?S6=Z?("2--LF.?DLZ`(,_MX3";9,=E@^60R
M'Y=^P).\PKP,D#=']_0SR-I:)?\?DD/6NYY.KEI7G5:_9UX;HZDY[H^3'#*S
MU^D;H\)SR,Z<IK417V[05VD>6^)\H@S':!K+5=]AN0=;^2=A88E9+$$L4N+*
MT<SQ>1)O..C-6`@I&Q-3U%*GC!R/1VAA-[4H^'JQE%M_QHY4"\#,AM.2Q=7M
MLA7)NM]+;<%'OO<$EZ")ZJD"TX!"L0Q"M>"XA)<-<)X_6C!,-./V'[%4ZZSR
M486,=?X)'`[B4#T([8%JO8S@3[(ZJY;+EJ%8"&@(Q$9N(&5S-Q8?XVE_0&Q@
M]!D:`(T>^7;R:;1<PIGJRJM`1O)8/+7&PW'OJCV:C(WK[G!P-1KTIRF>NN/!
M&7(RSXRG5(YJO3GYS'*B9$J6^L$T<G&)]&ZQE?0X$ZXC[D&`T0(4%S,(E[G&
M*=_?7:FD`6$M?!BX[E9LP>\S.,3XD]+=)'&$>[BRC@J:>C(SX8NYDV3,S`2#
MVSG*UPD#+\E.3)\&((K!@(<1=_QF)A0+!8$+O^KFH0`/"3ZF"_,V8A@`$X>`
MNH.4_R@UWJ#@QEH(.W;%I_DU#WT0P&<1JD#J-DB'*?RR"%QX67EP?G*WVYUV
MIU.C/QCT>D9_?'4],146^N;5\.JJ4UDL)"XOFE:U:*]T2JTG2Q'A2GX8)9JY
M#+!/'.ZZ*V8[;JPF?[+L@"1>%=]2,[E6(_#'K-A-X`/*ATDQKLHG%>'6M:"#
M%H^3;!:PNLK>8NX'>PABUT8-Y?#L]^OGZDHLV,A"3W&Z5]<]*6_@N+R!WHEY
M`[U^N?,&-%Q'"0X52'#HOD&"0ZG2&3;BNUV$0BAWYL;YQOX%9R\DN_9Q_,!L
M!]8Q&A<S95SNK)L:9M7HI.JEO<*7KDI[+R_4M"RIQBRL?&I[/O=8VX3PY<VH
M4TK6&9FARP/7T@T2A,OMZX:-;N_I-E""Y<45I]"7UE7XZ%ET>%J?;,K71%46
MU2EZ1*2![X(A-6P,3'V>YX4@BH+$78E9Q6A3T;E7I4%DI]/HMTJ07E46G:*`
ML!+CXL7@LS5LF!HG:RX>GZ=F.)Z05?)<:DHZSSFR(N=^S;)W:"Y*>]##X[V.
M.>ST.R/#G':ODKRL:?]JVC+JE(OB2"2XBCV/ARM,(<DXN7@JP37SDW2^,2]9
M1!1J$?&)AAS8F!0/*5#4*]N8PJBR63Z@)B;MW7-K]C&BH#R72\MS:9LG)KJT
MC\T?&50DSX7:2>VD=E([+S*MK70A'#'WO)P8DJ/[R](;BHGKSB)-TLSZ:.:-
M6$;"FXEP7Q_^W`E53^E5R]`P0C&AN$0HG@BKU"#>79J[+B`FD!)(=]$W(HWW
M1JH`B]T9)@0+@L4%P$+%1J4$`B&4$$H(+3E"=Z=-$T()H1>`4*2(B=T(-*Z4
M:,"=O9^^S:%?M$]_$C#T`Z,J&\@/2@*M+\WAJ3O&/VVHM!OLG]R/,;^F=5A9
M@=KMZ=*S#5_1.A4NPXO8U_7&4-4FX](-'X3;_&6=QK"_>\F)$%M&W2+$7BYB
MC8Z^K9J$V&JXPP3*4H.R=X;0@2!)D"R)X*H`R5:_^,(S!$F"9$D$5P5(MFF0
M)$02(DN$R'Z;:+@(D@3)$D%RT.B:!$HMH*S(UK;BECJQ"I6PM2E3>?FZ3@X6
MS89AZ(L7+X2NJWQ0JMC85E]`%9$/0*@B5!&J"%6$*D(5H8I01:@B5!&J"%6$
M*D(5H8I01:@B5!&JRH,JFE0_VZ)5B9:7"U2HK9U[U]^63GB^Q:TR<NY7<-BK
M/>M^J?2,!E(",`&8,KD(H`10`B@!E`!*`"6`$D`)H`10`B@!E`!*`"6`UAR@
MW[<[9RM$_JK\-DI6G``U;Z+Y@5!+J"74UA6U%[])<)L/=;^2OD45Y:XP8(O,
M=GA&4A?CZA:A,I<[>-8+<WK92PER!+GR"K`TD--)/TJ0HRS92T>43NY0PA/A
MZ=+QI)/XD_!$>+IT/&ED[20X$9PN'4[F8'=U<,(3X8GP=,#PU&YTC(*6RFH,
MJ1IM,]2\'J8V%O+("?P#E&K=V%>+4IY1A+O%IK-@I;I,U4UF;>,,G-)D\$GC
MX+(;L8R$-Q,AKE+K&P-(ZTCK=FC=1%AKI>N3TEV.TN5(TU_S#,^LDJ-EZ+BD
MCQ>FCV5P]EK%5]DBC2.-(XTCC3N[QOW&0T=(5#GS/86UI'?E%5QN-N_'B(-7
M^NSYSWS^Z<<[[HH/-]9"V+$K/LU_YV'(_6AD1<Z]$ZUN\6;)?P"TL1M87W_^
MVU__\M/S5_W&W5C-G(VDC+TE?I+;%T/_^@C9+V+^]W?3"2:7_[O]G]O).^;8
M<(!;T7MS=-T9CCJ=<6<\:HU:XWZW-YB8G?ZH-QWT1M/VNY\?=45>K+>.!XC]
M;_'`O@0>?[E;<I>[CB_>+X3J^5;;^.ZC,BF.#[T:?>CU0!=T]NWM0K`Y=T)V
M#[(2+)BS"(X\)/*3S)%,R,CQ>"1L%DO02<9]QI?+,``7'XXR^&/A82^PA<L>
MG&BA[C`/7-!&_,'QEW$D/^Q4G5VOOVGU\+B7'1ZHQ_LUYL7^V\*[`=V5[S_\
MGK^I'X0>=[=,0@O/6=]8H8=9PG73<_[^SGBGOH,QL++OAVO>@V-'BP_#87-@
M=(W>H-WNP?L-NM]E0278,)<OI?B0??CX>(9[T\3P67MI/FNR]ICR5TV#&W2^
M>W7DV+;5Z86M8Z\SSOU`>D%Z07I!>D']#[SX780G.ON=U[S]HFF2SQ=:JF\/
MB3LR"UP[G<&5Z`N>MOV2E/`D)7P+'2S-A,?S6KF><^NR-,23VB9!SB_-RLZ%
MD&8^T<SUTO^^H>596P>(V;TO]:T:IAO%A%)"Z0YURU(E2HD%`.GN5&P"*8'T
M`D"JDD<V4@58[-[@3;`@6%P`+%3L4TH@$$()H830DB-T=[9(51!:WVU"IRYN
MWT2A\S59CA=O:>]>%'8N6[FH:GFGRO"_M$TFOJ9QNP18@)P>;W(\55#MIL8M
MCF^H,&^_[_&-;9<V&9?.42'#1H;M&,/6+3ZME@Q;N9PRLEUDNVI@NUK-@3[R
M6;)=9+M*;KO(/.GFOCE5%D:SIX^<C8HJD9$A(T-&AHP,&1DR,F1DSCW!K8\6
ML^Y&IO)Y_J=JR_6WI;!PAVPD0H]]OP(YRD/*].V]R;S@;26Z460V^]I05!>P
ME`\7I1MXZPJ'3K--<"`X$!PR'\O4ED1`<"`X5!P.K>9`6R$S@@/!H>)P,)H]
M&AT(#@2'#`Y]D^"@8=ZI1#/>Q4U(_1:X/')<)UJQ[XH`CU8AOB&J^NWF\'P\
M_1LM*6XB7+,B':(]58%==<>LVL"NV^P."78$.X+=F4<[XWRDT00[@AW!#F'7
M;QK%)V83[`AV!+O<9;U.\Q4^)8(=P8Y@IQMVIL9UK(N&W<6GU7UQY-?W\U`(
M%F*EB4)F,BN&KE:SJVT9X!(P5#ZX5'>$JAQ4]'&4$%0(*C6&BM$<:(N4""H$
ME5I#I:NMIC%!A:!2:ZCH*_]-4"&HU!LJVO(A+@$J!]>7S36?"HR>L<!HRS`T
MEA0U3BPIVNG5L]I?[<L9T@O2"Y;\!2N_6O.VQ0Y;0ZJXB14WUQ6J-E4W6ZKJ
MYM[+/J2(-:AKL3_-YENK+14^I-(T)9L<*`>$2X52*GQ(("60EARD5/B08$&P
MJ%99-4(H(9006F:$4N'#,FS,N.#"A^40$[$[G[G*5UU8=BID9$KG-)"1N5PC
MTVH.R<B0D2$C0T:&BN&0D2$C0T:&C`P9&3(R9&3(R#PW)],B(U/H;'"=)GVI
MXM9+)8:HXM8Y!I::#;QUA8-.>F^"`\&A\G#H4(DA@@/!(5NA:='H0'`@.&1P
M:%.)(1V!=HFF^*C$T%NCJM]M]JCH`M%05V3,J@WL>LU!\?/)!#N"'<$N#[N!
M1B>28$>P(]CM66*H0W4L"78$NW/#CDH,4:T3'9*B6B?/S$=VM$V<7`*&R@>7
MZHY0E8.*0?S!!!6"REZU3FA4(:@05/:!2H?*`A%4""I[047;:M,E0.7@`@[9
MYY]^O..N^'!C+80=N^+3/"72^8V[,8^<P!])&7M+_"1O\<:W\+)C-["^_ORW
MO_[EIUB^O^-\^6%D64'L1_(S7^%)\#6,A?VKPV>8TN`(.?+M3Q&\9^[0Q)&6
M&\@X%%=Q&`H_6M\:Y.VC4+^(^=_?32=MH]7]=_L_MY-WS+'A`+>B]^/N9-#M
M=(?C<:L[GO:Z[79_,C$[_5&O/QWW3//=SX\Z*2_Q5THM/-?'>Q>6.!#ZZNM3
MYL)$?@RW9?@2VLI]FRGYL516+"?(G4JRZQWRA2YZ7=!ZK?;,/2)5:._6]C2W
M-I.XR$L\4!*W4HF[&XFC@DI'1L@P#N>P>>#"J``FA'WO^'`DB"5<+W_X4,Z7
M+:9K7J#ZJGC=%8^'=XZ?-)+'49`=2$83=:2`TBR#$RNS],]>A:)3E?(5QU[7
MIK(757"$B4[RB3?QS]@7N?H7AJI_H=V])N4CY=O%E'_>`BPERBLH,A__"GPD
M?'D6A0[\;P7R;4F*2\\44">*B-.ET6WT^]H6NDK?]T>%/93+=)%4-&1I]$JC
MUQCVM%6O+GW?GVII*A(%%NK9A,)V(N8)+Y!L'H0X,^>$.,7VO_'2%?[_,6O!
M?5^XS/'OP8L-PM4Q'GO)UDU.EUNK,1QJB^W*H@Q%C]PT0!,B+@L1%%3O&'H"
M#Q>!U/*G6@<*A<N1'&TF?#%W#HJP*Y?#KP5O_>+WK)5%62BHK,"851]PM1LM
M?11LM0<7Q5$?/X?!7$@)0QEWV5R\DBUR.3ZA,=`V'5&6KJ8HJ3PC3N40,=#'
MJE,7/%",M&-8@>@(D^*XQ#PX[EM8,3"X"[DGTY!I!B$314H[A3CL=LB5HSBI
M/*-6?:#5;I@F34)0G+2W"+\$*^Z^FDU_*=Z@2<36%!U1=+3!@T',UA0=[2W;
M7[*4!+:,0VO!)45"K^"K3;5]*1(JT0A5'V@E<AJT6^WB-:PN$*-XZ&.690<G
M"AF!!-F2KSP8U2A`4O,+)DV74X!$`5)V79_P0`'2(0%2)$(85S*^!7+A=D9'
M-)--P5&)1J?Z(*M+>Y+.&!,951^V#F,)TJ9:6ZP!G>4W9@<QLMV<0AN0WE01
MZ3SA(2B+O/7MH=Q7A&>66`&9C>W&L*TOK>0UN55"C2BR+=QW(`-&!DR3`>LV
M>CU]I!1DP+9]MT/I08MA^-PB#QW'TO&%E%>!-W-\M>UN<^4AI*##;G_<-J^G
MU]VV,1Q-.\;P>I"0@G;-8?NZ5VU2T$Q,+">GX[D_WUP]=S6N4/;+3S[[9^RN
M6*N?\%`I!D_<\\G]%5-\6.#A.WX4,,YL,7=\T.5[`8Z]A3Z_<OEEO%S"'?A=
M*`2NB;`')UJP?P5^<!.XBJT`[_D_S9LF:*WGB=!"=B9E*R6#&Z>+*T_D<ZSP
MH3TOF$&P:Q]W]'U_&>7'_+Z9=!/<[]G^.Z9][/O`MSE(+@H#_P?V*01)@)24
M$9XZKL>^3Z7Q0P-DRZ:3$>/+90@>CHTIY79L14UV"^*,0K@+P!QWY3YPB+T2
MBP2GH<#Q`)ME$+$V$&$0DHND0[CU9^Q(1QWU1+0(;"1P3>^#U!(S+N%V\.MH
M<^PF@A[GH8VXLYTYR%9=/S"Z#?;N5`DE7_'T#TX$/6;M@'I32W>\4^\6HF_@
MKAJ)6"1TCDRD@[J/&IXGN^5(`0W''P`9+!1X-9X5L3EW0G;/W5@TV4AF9+@.
MG*XV!-A8>2D]",;;1OC8BCH7!UFUHQK0!:<B.&0$!]3ZXAH_?\8\!#0")O%Y
MR&+(,O+"QA9H\2XNO*:MCMYGU-79LS<OEK[HH_?+GI=3L":[60I+];:+8O*"
M$-_!`T6%=W+\.=+1JF?@Q=:+7"5/.$K4PU6C0+LL9ZFD<!<&4H(+\MX7$9@<
M5'GL<%1$/#442Y=;B:'9W`@A@#!Q;&6NF/)CT+ADTE#7/HN(C<8_U2D:/UYK
M[>T6X7/".PP`\7@(YTDE]2SK"SH(1HV$+1IZ9\,H`%H56&LEW3[]>-+H\O?)
M"ZR3+WI86X%A]3FB>V:S,S3:YOH_?8S1W5,9H[L5(6)N$Q%S92>"2#YUX@H^
MH;K)\Q'N;0`^,/BG&R]]@B[D%-U,+$BR=YH`I5X<,*_P>8>SLML7H77W,YN$
M,PJQ](+3,$`/*HQE==T5EPL53UCX08#=A.#WP!Q=&K#/+)^R*(^VM:GBWEG_
MZE*GT>WV=+UX67KRJ%C]3.Y2]6ULX'G@B<HHL+Z2-T19B,6050RT58:E1,0+
M</Q^?;H\HRU4(QNT?T1&@9?6$<\TJP[,JT"MJ^%2W=9$"GD.Y#F4>QLJ^0VO
M&O@:F*?],Q7(G7@#PU3`FL];UP+05WOC->F4!60EGH[I57X+5K)&2+Y5F6;!
MB]G?\5)O5")C_WP;/TXI#UB-'2&#1KM_QAUME=:[MW>2W\0^IAF`:H=QN6TE
MR:I*,VWED16E-!V0TC3"1/]UWC\E,94)R)3$1&M96]=E3(/)]KCZC+-O#DG*
M7*I3YM*@T3*(E/^,7E'E#>L_@L!^<%R7W)\R3?'79NVQU:><I?/Y>=6?N9^N
M=XNK7??;F\[)[:OR5'T59D:)BJGL$^]5T"*-`\'+3$QG:YB>_?IE:Z[J],(I
M(/@,++\BI7HNWP]).T(A%9\)9Z$COS)N_Q%+I/M`EH_TQW0\#(7+%=E,%"1;
MN;):"TRQ=2P<<9_0?\#`:0&ZN.-O"C,\0PRSF\IK/[ZMURBZY&<`J+7:@Y;+
MF,*_P56GV[L:C\WK[F382FFY3',RN&X53LM5J"ZDS#=/^N#`>Z5^;VKN5(MM
MI-I)MN$B0)+'(0W.QBW(^'!.?;JZ=8,]"&8+@+H'$E0T-:%(6'_\`#0U=!1_
MAK/F;@?55QGHH4@)=D!]9V*+X>=X@IE\IW7:NM=?"C$_1:G8[V!M7!FP)7B:
M0>@A31;WN;N2CF(36W<9<^9;A$Z/>9PR'B3'5[?([;/_,P;3.5\E+%KO,M*@
MYCM%O"6^6<@@E+(I/>*V0?=7'9]ON?=X!.W<8VXI"QX<^.X*]02II.Y\Q=L$
MS[U+9RM4ZY[E+4IHP#+2IXR-23(''K`A?5I+!G06K*IJ'3PT>A`NV&L/Q+N0
M;!X&GFICGJ,J)Y`ZJ>U>`T!JS;>,/NXN'ODV_KG>;"U.3CR$EG%D]+O]\=#H
M3\>#T6#4-ZY'_=3^]\?3R>"\]K^KKT^2KWCZ%GO;>E>V^G"]8U?V4>--KJ"7
M`H2U!D3B?TADEV(+>'V`F>O`XVTP$3/D#I-1&"=^A2(L1"Q"U(!\8<SC40R/
M7)US+!L^35X_2B(V7\G-F!B$S$7+D0Y&CW;&-Y->R1U)!"?1)W.0Q,M5,N">
MHCM5^=#*:T.7"UJ^`DF%7]7J<D*(JGK:%E[R9QF``3G8(]L+:7M@\PLT%:PR
M-'?7'?>`K#D<=COMCMEOF]<3<SH9#@>=%+*#Z\YT5#?(;@2GU$,_4',/4!J9
MZIS,//J$6%*H[ZD6H>^_0*U26(TV2%_?M_]1YA@4$=Y.%"?4@1S5VE7C'T\8
M21VEZ>$282@RRD(+B2VU*.M^JK>MPX'G.9&R1WA^%DE96\S!!_'_]LRV,39;
MO=;(&(V-R6#:30>:H=$:M8K7VD<S/2V-X[_Z^B31Y5=Q!]W[.0PL(?#)LL%R
M4DT&H;Q<M877Q<+QR6L]'9*TS`MH-"S5GM5XH1]^P7D,]@]$,&=C)U@N>.CQ
M!OO%MYKL!AD1%J"*X&)/X*;W7/$D_PH.]-V&Z1)N\>7%6SQ[F39A;>_=PN7<
M^G2^>AV=K4=6;.['/%RQ=B<CV54,UF"+E64'2Q*'T9HM=WT81JQ/H;C#T0K>
M'&*Y\"Y.)JL2^EI;S`4R0$<R-W"!+Z54!)PT&?&$%G=SR':DYT#\R1@T:RIF
MH6J7F>?^?=2JNY#[J9>VY/`=3WGTB-E*_<5I-G27X1D6!J\KAE2X;L*T&[OX
M<]KP%]HSBN]B\!:[.UJ#%,C8&##!X/A"3`FW@<=#SZG'9XW$EU8-SQ]\35QI
M6[8O7KK<@4_SN03?EP.<%`^P*U2<[R4$RBI@QM.::=B`+5UP6TDEY4ZV-X!<
MKJTO6\(-U.PDG!'$$=QH'3,_;9>3"$\*"^,)G'>P7([M39B[P?L1S6+,N79,
M5![1J:HB<%K(5YY3D[2;[@,7U#^)>M(>!%68")<_\'!+']+^6Z!VH6H!T+/>
MET)\36>OE=(EC.M2P!C.\[=8:V#V]&W8D%J<H_6_)S.XOIJMO7?N@C"()?:^
MLCN,WW$,))(R!]"OX`!(T)$,Y6JF+T!SKS8-0V]Z:!:3.?!'%.T/(M$6/XAR
MM/'^TYW%6ESADV<MU%WR\Z4J[H+77PK0T/3=DS=6?.MQ^#J7/8@&Y#T3+J[@
MX$1DE-V!*T+Y>U5L(L$+WC![_`JCN3A$&OV&ZHJ<+"%4Q"(%</;Z'(SC0@>G
M?C*Z_:QCT-*KT_!'=0=\H4`-"#`BX<P]!&YJ3`1G"7M919(;?GM\N#I1BO`^
M'02<,*MEL:FML,3X#J36@*LM-UZ/%YNB%SCZ):_,[S(;@8L*H'[)U2N<:79C
MJ8H=,'83S_[82!Z?J=JP9DU/[JS4#(4Y$_C(4#C>+`YE\GIK(<&CT&^1\0SZ
M!BP@LOJK:3)711ISH58Q-HMP>.'_M_>GSVTC2>(`^GDW8O^'"K_I6"F68O,6
MY9Z9".J:]3R[[;$\TV]_WR"B**(-`FP4()GSU[_,K"H</"2*`BF0RMV8MDCB
MJ,K*^R2"4'(>I+^9DRA,"K%!.=I5[!`W3*>#&$RB9WI`"'$8F;?ID`D^W<^T
M9ECWP]@;CM,SIP?1E8Y[3\<=24?!26$T)K<!:@09JMP$A=Q3-;SM.G$<@[=B
MJD0EN=;>\MP5EM7-U0680.A:+-OJX6-X-(X&G$*K-L2,D4AN,DT5*>CJ![;"
MN)/:D:)(=S^"XSH&K=YX@^G(4/S94+P3QS(J<A!\<J*YA[T,5&=TT)N'A-&)
MOA[==:!LCR2]R_$5<H`D/UMTFMP"XACW'ZQ32Q7B#;=2!D(3=`P:6N8K1`0#
M7C="Y@42_FYL!%8"+,W7,RA(`H53REB`1:>W>GF\+(\_,!ZN9@>#7R\'VW"!
M,#-8N?KS&<A.I%NAU;=+.9236_AHW!]@-'V.Y(_0JE\@N*5W3V;/%P=4F,B9
MCL6'?^6\]\@I4#\#`7WTJ_[W([WA&&Z^<VCF$AKD@]O;2-Y[]%;T-U]&R9T8
M3*>^?<@1HL,Q:BL3+\XI"3@;"WC#8!@[]\",/CJWZ,P/(V1=UQ^-3^W(_'Q<
M4.YHHA8H"B6%]CH-_'\-2%B<#.Y0IS-674GO:/7Q__4[)B4]L]O#_]?/=!;)
M[.4+34;`A4'?+.G1O2'^OTW/V<+AH8C:`FQ1UW;\TAZ=7S$(U#L9P,5#`::$
MTH.RM(H^`.T>PUT*Y65PEY2'[_DCCK>!BUM8)U@'+T\Y6++6;1SJU1^B46]N
MA7/HJ7[[0H\$B-:^L-"[;8"@ZL>5!\#5%@[JCVT`M5%O"T,*VP$$XFUG&RO?
M1P+N65AKBQ*_ZMNOZA@216E54!%KJ597BAN3<B4"5V56+DZ:1%?46/KD&M.Z
M+3J*K-2D2]$H]#V;\(0W?H[(&CX/P^_BB`*"7\RC>K73[EFM`?_#/WO-VEFS
M01L^Q;]JS7:K9CQ9Y/4C^S74^96JAJ^>)-;^I?`?360E88[YB7?IPD@!I^=0
MMTK2,V_D-#;J>J-Y=IR[1N]@J(>-@FZ:Y+V4>M<?S2C?@?70U>@NL'O!^'!K
M<+U$#^A0DH<-'OTS@(ER4]&5?4L#0+%IIG8R4AC,":SF5T.SOR:L!F2S9O4D
M6X%]2>#18&D;\**J7U\>YC1'9&(M^@#35U.$U7<>5.*EX91UP[5H=/P=="<Y
M2]W]RVT*7]L4@)R!&_V`)^KT(3BR%%_M%7@`]B%?\C%^,0"X&2ADL4U**IZN
M>J^U92CW')VV:,D$<3Y&54]O'3O*`@G=U0IN,JY0G`X<D=]6ASPMN%(G?@Z4
M9H7Q&%#"$@O&>W-G$.<>@<X2@'JG2\F'63XQ68G3]'$%&J=59;CXOTX\')_\
MYOR8H$TXC'4DF::WYJ8@.P0\L]=\1)A<!H24@)`FA)M,$>/;C95ISH\MCSW!
M.UC]0*CA6+HZSP"X]`@P'#WZ.,V76'-HII.?62ZP-%2JG8-VD'GCZ50$!RN.
M3N`'-(^R%5#)G28.3#X@'RB5>SP8FY[$P$.$;H@@2YE@5-F=MSH$6_:.?$6:
M=:P084CX4V=&_+X4%:+?_ZF4YUA>HP-5.CYEA>)JD:9=W%F@^B&,OFL/M=X_
MQMQ"S'U)Y%P<VXANNM?W)<AD>"UPTJF,XID-1\Y%WZRF8>?-[P>";!V]2UJL
M_KA8)I$EJC*\M[_Z?*F(*<=2MCQ+Q:;PRI7WT@^G1(DH8BC(K72,&\/O3C0<
MFX*'W(41F0BY4#?H1I&;2A0R+,(12A!3*9@5K]+#HG#F^$"<:=4KVDFN3<,#
MH@0FEQ6@T9K3J%9^(:`%W6%T[%/Z]/2)$\>4G.DZM)II?N]@#1EH[%/,=,CI
M6WF5':_4-1\H,4'A=]"=CZ9+&*$"#?)[1D:=C?-E@?]:/FT?XX?Y2LF)\UVN
MVKI>$!;\8>TU^M;-HM"FX)C]CN@%[?<\;ALDFF!5A:ZX@-5Z;H+9)-H",LI:
M$OC>=XG"Z)Y$,Q)`5J^M,2KQ8P^0SZ*92K.!M$DY_VXRA2+IH.Z6YE@Z$XDX
MXH6NQC3G[@XC35C?`2;8'8E&L)E)4P!S""W_W/*-\`/:@K40>9E@,.7?`$+;
ME*#:L@5I@K[S**\I0W*R-D!/C*1-&4L"S]2A`$!TI2JN,$^X18JS7H/\8R>(
M!<+5'HLA8`8VF*AE9:+PK8Z5Z]0899_Q0+N&5X-&6UAF*)S[T'.1"FVJ4JZ6
MWY)CB2F)Q6STQEPV.A/?:F&%D5$2(QJS=%T0(LN]I\,_UX.;<S&XN1#?PJDW
M%)U>0QQ94[G5^`5_@>_2;YJ_'-=$[O<7Z\LK%)R_)0[F9X=1H6!KH.L&=2S8
M%5FED_BJA8,F+\1S\P`IM9?%9-5]"'066>YG)"#X6MZ"3AL84?D9R:'DDE,`
M70U)!Q/;<^EM.J\1;D3I=V=7A32)^#$)LO#XT'<2A2(Z?\!TDB[LXL@[SLHX
MYVZE/=T[$270@QDZU:H#KE3D$O!L;DTA?<;H(<0ZS'4`<EB'4,EH1$R7UCI,
MHHP!9VN76I69F3R;0.I,:-)T;`)C/)M*HZ&`ZG.BK[>IGK"2(V_SO84CN%":
M+649A-9UERE;V1LCCSRHJ?^'DC>'FHA2@&OO*)V%DO-'I31KAP=)7;!OI,5R
M"D07U<U%MD$@-WAN2'ZGHA*$WCKTHJ;0UA8A-1[0DLA(`Y6:OJF'V`VEOAEE
MFLX,I<=D(DT_S(C'48+^V#I1'"5?H)1>MA9G.(P2G9M<:)B`^!2KI8F]<Q;D
M$O@]NP;X6=60\X64TTB.0<S#D0&C""=2EUL^OU;_K-%JG+?/3D_[W<NS\V:W
MV;INF,+?7N_T^OK0"G\+H!,?@2N4RS&Q]K?X#N0\A?)?S,O#5AGX0TUSE2`T
MK&M8N-6CHP6<E),LQU?K?\IV%'JJY<I2Q%L+>^90+D#+1&N+7SWU74\6P[_6
MP+)^I]D\/S\;G)[W+MKM[F7C_+)CL*P[.#\_O(X0>6C1H9M!;`BO\A'NNE`3
M;EL^D)2>ANART_GORB;8%_5B!2H>L3'=TVINX:9P/#(';1LGP.NF]%"\Q/:_
M6.R]D!?[$ZP$0A&FK[MU?,QM)ZZKY#W5K:<]%K17X2&$JX+OJ7*/H4U"!AV]
MRS6J&4G7&!PZ_1\;X4RP,<,A=6M:U1)@'NS:=ES9R&*2D(MTE`1N\80*#]6W
MD[5FBC52::RMJ]P%U%]HIIN.Y.H`(Q*8NC<'MN3)J>"YF^\BQY4YA1/5,=VC
M!A:I4Y55JL\4,<K*<U0/(@_C*D:F:V4O#$Q%IF[2L1&J%HACU<V$F`_AJMX,
M::!]/93=V&)[=7-RF:Q9*38>%R^;-83H7U\/6OU&KWU]VFRU.X.+ZWZ+Y,QI
M][I]>KI];:9,L;)0\7:3P\6+!*R>B342"N![2MQLU.)L/XKGM]G_,>?5S85*
MD2=G3JF1]7)9:Q]N@D-"EN#]FRJK*5-B*!-JF)KZ`NO+"RKC7/LS*MQ&9[`V
M\DH1*0#U<I01K!76];YFMYEKSX3::L*Y=SS?-!0L9_G*^U'.\MV0K&=8*)QL
M/%;:MXOE@AKB$4B0"&698>*4>Q-X^,T-6H@O==!O"VWWB\AN"-9IS3$J&90T
MD7*ZM,4JP+V4@V\VR@IY1Z!B112T0<LNPC!`(H6;T*AED/YP`J`W5XMHK1/>
MV),.>7@L?#''BHY`/3Y-J]+Z2#GMCG-/*?CTYUWZ^#G_F@!KJOU"=_`F7I,^
MF/I!BZ'T?7/-7]XUWM%G-76&]O/S-170\^^\0"_22>+0?J'[W=,W#YX;C^%J
M`(1IPTW=PZ9*OK=_+`0`LG7G)QIDK;G;2Z=3K#$4@1;SEW>=QD]/=OTN]A\W
M-S8WO:^]ZQ?R0M_60O=TNFJIC+L2D\P.##[I<KM/31\J#&%8'+.PY2%$"Y*U
MOQFX^BMMXF^4O_TII/3G*VIS8HVHLO!M&S!D?#Q0?+SQ?KP,&S>;<%<Y%'T,
MZ&>;`?UL)="M,XPE3/D4_>1\NYV@WOJS@EZ;`2R-][PJ'I8V9XF1]("0M+-?
MZA$C<>4`70$D9D[+2%IY)%V;TVYSN/6KH_0VN\-9_5\,2A-J>P+5RC&*W4%U
M/T:JMDH344\"+T.O0QGANQB=K0+B'9BESQ1;O*_=9XH]>(IE`?Q6R+EUQN1\
M\.3,%'M`%-MAE7D'%+LGJ2D[<1N<5\N->+C<[,7A_5?5)$HS##9B/U6AFM)T
M`B:6`R:6TB,S3"M,*P=**ZT>$PL3"Q/+FC5;3"Q;M_,JY*[9B0%X44EWS5OB
M2:4"KC+,JM6NIBNK*@3(_F6FNVW076D*-9,=DQV3W=KBKL5TQW3'=+>_-O$;
MISL.BF8V\26[X]@=]S3K8=\U^ZZ96-8DEM**+IE8F%@.G5@XW8:)A8EE/7`P
MK6S?SJN0TV4G!N#BK/LJ.%W>$DLZ3&]51>OKJD)_["1FLMM*76N3Z8[ICNEN
MUW177J,M)CLF.R:[->'$N0CEV\H_T\2"I=?G_LYM@,>=/#Y3Z*DI)\W&3_G9
M(G$8YX?D17(HO7L:(N'0^*!TT`ALW8[W,&/VA!I+&=-\UMSHR,UG>^SA0:YH
M^59\;>XI!?;'PSX*;0!/7SCKXY1G?;SN0O<DTV6_-"F&S_J-0K<`J\<UJ.WW
M^BQ,[V.<V@I.I=NH1B/:5\>Y2]`!)[<R$NTFX=V6F\WRG(DRYTQ4#YR5IOVJ
MP?*U:?_HGX&3N#B&])BE33D85\7$@+WH.\8MN*N!P-Q/<(M9M]Q/L"*(=T@B
MAREVL7R[HFT3#HMB]\0%R!U`#XF;[75,F4L2N"2!B65=8F%:V;HTKI!2S7W:
MW@1+.LQDL79%1PY4A0#9"\!T5^DNX6^<[-B4Y[XU;)T\*SV<S1,VY9E8UE2/
MF5;8E.?N`@?&D@[3I&ARF3.;\DQW>ZQ0OW&Z*[_><JW"MXUHP]]>G1X=P%:K
M##\$`M$E]L)`Q"&@1H`@BAS\0@DO$&$2I769XM91LC9_D>.K4,@?GHK%@Q>/
M12355`YC?!S67KH>?`P48*28CIUHX@P]J?#'A[$W'!>>KX22OB\&MPH>[M?%
M=1C!@X'W^%(L@'.3W79.%S%PD^<()W#+65&WK!6%(P(E5K4.(V]*1U/#8MB'
M<>A+Y?AP?,[PC\13^K"'H8IKXD%&Z0E)5]S.Z"'`2<K9W:+-M-'><G@S`I1`
MK(K'D91B`E>/Q13N#%TE9(!\3Q0JD.BDL"2D9O'2NY?^K"X&!NL=WY_52CK+
M5N6PZXRQ:Q/L4MX/C5MJ(^1Z7,J9O__\<Z).[AQG^OXBST^_>NK[I:>&?JB2
M2'X#WG_NA\/O?_VO__R//^=NH+0[NN$+_#6<I1<B=T:)\56._O+N^A*7^8_6
M_WV[?"<\%[YPAO')X+)]T6V=GW9.F^WN:;=]V3@_N^RT3P>]SNG%>>/LW5_G
M1%0>E$]48B_3*!ZOF^^6)]'T1[S\O1>#!!WJ)WV)O&#H@1"A_@`%X)6#05H]
M[K>:K9RFC*T-ANF[`/U'7N#`.AP?G@]?3"2V+X"5^8DK">O2G@:PRK\!204.
M(9@'WR"9^4`^#P$\2"6WRG,])P*4!48&$G,"SXOPR1ZJ-\-P`NK=+'O>V+F7
MXE;*0$C?F\`R<#E>D%L>@&(#K%V)A`5LO92W\1*,7@-16V?-?O>TW>N=7K2O
MKJ^N^Z>7/8VH_>M.\^QBZXA:)EXN5"Y]#%%IE]%$((1>IBYN@9BVJ-QN2YG]
M'(A/SDSTB3NW0?P(4O<)V4'A=(0?.@'1E)+#!)X"-'('>@22HM9=/_\`$>"*
M:R)5*3Y^O*AA6Q'J$`%/PL8C=W!QC1X229\H"2C51>4UP7^,6@OOO@TCL+K@
M=Z3MD1>!?@P\/AB.J2W)2SF/L0I-WC6!U97#4`N1]WA2&B9_:C8$/,<OC=D=
MX7;>?01(OCNN"^1R^+>8.C,"(R)TQM9VM<OF8J.CC39GA#Z<#W%2J>*3,`#&
M:W:G4.71Q_E#8EUF,@5E!U:STR/MUSO=<O2ZFFF^HY6S7:V_O3BIYX6'Y4S"
M*/;^32_"SU,M\9%<`S<]2B#0V"-AJ6D?)."OX;VN'`>&T:N+#R03`U3DX$'$
M$6*#X*C-`AIXFIPUR0-'V1F"EZ3(#QTU%B/0=GV$P`AL*(30[O;1K9>$NF8G
MP*C]E/?@5NZ`Q2)3-MX'RYMWM3\E[V4YC/9D!C)7/#@1;H@<)M,D&HX=)44R
MQ8\[0[U^J];L+XZXV>C4%!A;6@\GQT\X`2*&AZ`^Z.`!"OD#%%@/-@DT/-RM
MI&S5.Z<EL56M!,@_$E#C=TE>K7)8ZXD+:A08#1%H.\`OH^\RSLYCX>#@%[2;
MC;O/"$/\FVCQN7;%"G.A:%*DOW\>78"U(P.EC6>MD5V$*E8WB&GG0"[N%R.\
MGV-ZG%VC"GG6.^MV&E?7C;/SZYZVD4];@\O6Q>5^FQXW>&XG!!R1A]];-$*V
M[W_XK/UE2"%?+`N_2?G@A28E.I+2W1%">R&T/T#K>HI(<QJ%]YZB90UN+C*O
MQ6FS;[E7!.S+PT7B]1/I(+FE8C8"[G,7>%;A&N:0"%@X.?S(F^;XON;Y)[>$
M;:FH!L'F*N`MZ/L(A9Q,_7`FI:H).-\3^U&XL(!A'$;PO38IT`>7_JK93ZC!
M6]<@7+X4_7*,<5BVI!G5R/$B<>_X"9B**O8FUC."KI/()1LPU0)S((,=ST--
M>,H"Y=_(\I469OKU&)NE9Q!,E0=O5C*Z1X:J_8N/,TFFO+56B^&B`DH0IJ8:
ME-4,C>/+`[U0(PGBJ3D./$-4&+5!E$=%P,`X1TOI4:OE"+<"APQ-:5M28Y'X
M%DZ]H>@VNB?=1ATLDASZZWWDMZ%W@30)ZI(;PA)C<8^VC3>92-<#_`5KE:Q2
MC>5`>;36R%V-E'@_A><T*HJ!MG$!$+A$Z0S'.=]E)*=H:Z679]+?/$;#2=.4
MU@.47'H@VK/B^,-$NU$2BA'BS>>^`^+I9DBQ!7/O">H?>,$D=*5?T^1V8MA2
M_N8<21LUQ)Q9RA9/?U%SFF>@K3H\;S(K"D>:HVH7#$?S&K-[6(;C_IXHW(`^
M<+@`XTLW'AY\NB"C1*7K>A1#X["(>O@6E=S^;J*J($&".T(Q>GP"YJS44`<[
M&&Q<NV_]RW+\?/!\/_72Y$"6P53CJ#:9*2:RFK(0R48).J@1!R1SLS)66VR-
MK#OGJF0"B$1<QR(V[,+P$CH@(V97\21]%ZY87Y4+3^2"$D:@1W*,@?M[L*)#
M-1]Z)2]J%B9#KEE2T!)#;)EH7=E*<B/5:'G`3AP1:,)$P>_JN*2&T/N!OMP0
MNKR&T,W>"SM"=[J[;K2\\\[.O$'>8!4WN"?5@Y7+\LUWPW\\HW4+O4DKU8GT
M&^E%G[0^=$7ZD,T6>@8\&=\8W];#MQO0OE^$;<SR7HB"[4JT8UZ_(=]K8VSU
M1@(<;@-<1M+-D;2T7KG,+!D/F5DRDAXRDFYYV$IU"FRW61CY52KI1,,Q.:A=
M>2_]<(J^^-=D`"M!OQ<=H/]4%NB>Q,"][S1^MOU.XWN!,GC?LP,LW"R@FGV#
M]AL5F7L]HQ_Y8M(NLR]F7\R^F'WM`_LZ74S99_;%[(O9%[.O/6!?[24E4\R^
M-F!?>Q*,W28(;Z3O4P+YG0RPUEY7V3ONQ`L\1>U1[N4F3MW7F)K[#"_M%CK*
M=\O3*9Z`355P9]O:`RL);YB>FK56K[PI#4Q13%%,4<W&8LL6IBBF**:HS<#5
MJIWVSYBB=F!T5<B1M$W8?@MC:E6XO*AP.YC6!DQSPP1KPEY"B/OM22C/^_04
M;`_?/=7KE)?;L#$T]P+KMJV<5(AK5DYK80[)'/+U++%.=TN6&/-(YI',(YE'
M'@"/;)TRCV0>R3R2>23SR!6)(+5F>[%',//(+;LM5T]'V]G"'FLQ]>I06[M;
M5]FS*/*-5Q-E&K8]W=@P[468M7[317?2/;$-F1VEDDG64]:5.',!-K>D_2&V
M7\7Y,<7F?:;/X.9]SK(-GVT&I[-GRKE-<&SOFI9MHR-9Z]4ZDK7VI;\4+W0_
M%[HG&9.5LQ+2Y7:K'2/GCEV,;X>%;]RQZ[51\#72@O:\OT?%FM`P'I:'AU5#
M->Z[=;"HQBQO%[!C)'T[2+JEOENP^2K%V+;:=,M3W\4(3<!T0BB.<BV+^$N%
MXGX$@9KU7GDYZ$^!+T.H5X)?Z0BY.!FU"JAW8(H1T^PR(-*T0"9=)ETFW1>H
M*-N0J"76\I=*EDQY3'F'3'FM>J.\?*:W37G/MT`/R]#\5^@[L>=[\>PU'4N5
MH:S3=KU=6CKUVZ`@=GB_87K9@H7&5,-4<^!4<]JIMTHSG9A>F%X.G5[Z]6YI
MS1+>!KUP9&T%!*]^X&QUZ0K?NY=*',VD$ZEC]C<\VK2S?KI]?T-5$`3OXRK1
M"HJPPZ2M[;O0F;"8L-X@8?7JC>TG?#!M,6V]2=IJE==T^M!IZZV'F%*+"][G
M`<6Z8N9)WV7/!FI_]08[`MD1R(Y`)A<F%R87)A<F%R87)I=](9?]Z?95:*C5
MG9;;4&N_5HOMOQ8:=Q5[<\UUXQ)N$@&J4A.OF!J38"LPY?T0DY!:1DAJ&;&P
MW6>NSIC_IGR"8.#*81C15(?W"%:]`6Q-D;&N=J,FEA;&;@(;`$PD7[P1>M2?
MFLL<D!LM:BHCH<9.I.&^*S##!I94<KYL`S41287N`.]>^K-Z-0ED_\C9=/-+
ML_%.?P&:M&X7^!'(5.@^>]C13XK[-.LWU[%/>$KH:2K)%#[%V7/_6XGP`7Z?
M3'T/?L[=[05XS:T7$/*(!R\>TXU++L66?_C\[S+&O^G1D6Y71V_QI*H+W(S,
M(O2C8D?!41@)"4\.9\""B#<I3;!SRU;T^A$N8"+C<>C"MD/T/;GTB`1.(A*#
MFXN,B9PV^R=-8"0/8V\X%H8I*@.#((Z<89PXOL!NAKCX>`7,+=^$2W9%I;$,
M!.4PE,3_[`E:P7`O54R\WVQ]5_L:A4E4YL;PX)T@W=8.=X)RLKR-K$,C\.X3
M2R?+*6054FL$UN\HNFOG&,6_9136Q*T<.HF2>7H08T>)0`*8Q=3Q@/LX:IP^
M2I$`FX(,`%;HFVM#JG$/Z,G8,S04*M0KB#SU_62Q"AZ;EFI*E@Y0*S$"\0"/
M<GP5YG<*+[IW/!S<"](GC.(3VFKA68;GY!>/"#]Q$+B(+T$`,((CH!>.I!<G
M`$U:Q0Y1J-E=5,DWIH)YY0Y@CGU84X2I[6Q;_>WN"I#,@U\F3@`4/P$,(^Q#
MS%V@$L#0"`@JC.;PX<'S?5!98.TX[=GU\!U`,DA^`>"]IZG&$%*&(("*@"5@
MM0,5Q&-`HSQ.N<6GTA]`+B0A03PC6C_Q>(VY](XQ:!D++V&]JH35#G8JQK=H
MT]00B0!5D$/NS';HUKK]5JVQQ*&R$87#220!$LI=0+PX/^\//B`SE[YCZ#Y,
M8A4#G2'?MVP!""1&N94*3KCN5HK<(U%^T'-A$T'\N)8G<</P=$.H\!7*.V?1
MK(8K/5`_=XA(K7JW)*.-=!9F)<Q*\JP$5:*[NTC>[5@#:O5JW4:C/(9"W@AE
M#-',/"9=&=73Z-ZHF!ZHO4X`-K.V&E?QA%:C<2H^!-A>R[N7XHOO!#70-(=^
M0FQH9XIBL]:!_Y4-)I7<_@YL<YZY%D`WKX!E\)KZI$COSG,%EGRCURL="@X:
M$^2Q0,08):2*:3>$UAH==^(%G@++*D:-=)3M/AV$H'T*,77;?QA+A(N!'.BI
M,S2HP@F:=S(:>@K?51?_,A:XEB5JF7\6S28DR#'('=!K8WC`4,I=^F1+-M<U
M/.TV25\&6>NA`S$)?*D4V79>F"BP(@VTI%M#8Q+5`*,0[ZD/9A2%$T(3;=GB
MR=87]U()R;9?<OA;87B)GI6ADLG$B>`ZZ[U#<\N[-Q[+'+O??"3)?IW`JI?D
M[BE$>2L^L^3LK-YH==L@%=N-7J/3.BMQ@DGSA1-,NNU-IU%T]F7>QJ;W;0R9
M?;EO-QODKOP'T?VW4@U^OX6QXZ\K7G:ZLE^3R:U$Q;N2J[O15D0EUW;T(0"-
M&]1I,-/*JX9F1I(MM\V,9![I?C/>TDI2Q$![<"NYMBMC\%9R<5\PPX0Y"'.0
M71"I=457DA(^!''D!<H;5G)U_\)DSTJN;#-EA#O>K.`ZGW,>>R<6?W>"Q(EF
M&2]JK@@05:'B>3_ZU/=KW;/M]_'8BV;S&[DCN1%!-2MS]AL5_[0SG-M[!M;>
M13^'O4`:YE_,ORJ"BLR_UE?`RFNGN]\X\U+V]=)>-?U]-Y;^IC-J7I-K58:J
MVK5>O[1A"%4YX&T+>);CZP=/7TP=NZ:(9OVTM#[43!!,$'M/$/W26FP>"CEL
MS0V]]ZJ5C5J6IEP=9F_-H^;.X+.7S6FJV:O_K4JL[='@KNFN4>]S3UNF+::M
M;=A-3%CL@%L/@!=8;.G[)6J)6TB+JHZRV.^5Y_E>$U!O6VMD`7;`[HQ6O=-G
MAP83!!.$5=Q*F_MV*.3`::9KIIFNUX6D%%VE#;J*&R981FR5E</T#>KV'J\/
MQ*K@'+LQWD*V5E6PK1()697A1:UZ><DAE3]Z9C3,:)C1O%:.`?.9[5DG!V:$
MF(YAN09J%3!&]MKFZ-6:O?(&Z3X%JJH@$GO-]D^N5P5W2A/?^\0FVO5.:8Z)
MJAPD,P%F`LP$GK'ITP[G`Z_6R'E$WKZLEIHYIVW./=O'10_(TQV8\]&.P"T8
M'+9M,1@>"]M[YFHJT/-=]T0'^APF>L*"'K!C!PGYH4(8Z+EBCPQ-*/0*=Y2(
MY#2,8OT@!/>O@YO+P3_$A3/U8L<7GYR(!H7MKHGS-D&XPT;Y?VK63TMJ>YY.
M[3/=S5<1A)!_)(ZO.YM/`1VH`[[KC4:`.-@Y_U;&#U(6\87F34[T(:=C)]?#
M':"V>)SV2)=%U*.N\_[,RT9_/#[!PO[]YY\3=7+G.-/WEY["12:1_#RZR(T9
M^:H'C%R$*E;4RO$<Z>"+,\/)0NH;',BY#^O[ZW_]YW_\V3[KRHD"6(KZ(B.Z
MY4OH>\-9>BV-X8(/7^7H+^^N+Q'?_M'ZOV^7[X3GPA?.,#X97`].6Q?75^U&
M^^+JM'UU?GY^?=EIGPY..Q>GO=[YN[_.,<K\Z3[1('F9*%V['?0S,8H^+C;L
MA-/_&"HE`$""(%1->;!_TLL.L'*&PS#!.8EZ_IT+=$GH+7%(6RQ\!#[2N24Q
MFC+J!71?Y-+@"QH)>#VX.<>1B>);.`6Z;_4:PI)H:XG"OPEVT.7OD?M[0U,Q
M9,B'5DCH44]?VGSQ2S63`RJ&_3P""V(_TX0DWTQ/LD/NDM[AQ,`,;Q/=Q3P.
M"\QJ#)@N(X4WQLNF[@:V86WAG2JO7=3%I>?3VRNV1IJH]!`FOJO'3MPBB\^K
M1;FAP68,$HT0M-^E@U46GDRHZOL@2V@L(&@#+H(`I<HC8/J27EV\"'BL\A0-
M=#+?T)L1$NDXQ%26X$6%:28TKLV)S)"/9XJ2)]C_HZ+B.4+BZK)W/>B?-EJ-
MQMGIH-'M-=M-(R0N+\\:'182+"182+"08"'QZD*"N=/FDWJDYE!F0'5Z\/YL
MU='+'SA_#0>YV8E*UHV!<W[@&%=32VZR,1BJ-,A-T81SPN5;L(;AW2?I>X\\
MQ!';LG;S44$9+,XV`V%VVWK>^$VD>NZ>@H>^XI.`FHU&>;-_>B\<_=,[W73^
M2W=?)MSL9J%[,N%F=8CB!>VS2ZA8Z;Y"4_E*M9#/P/=MC)/F49;?>#_$)[AZ
MK,15@/(#?<.BW:AM$/1AI'P^4FZCC.H)2+TV&I:9C\9I!6\=E18G@',UV_.P
M[C=CSJ$A/$VBX=A1LF`1ET6L;W!<0JM5:S=*J[-^VPU[N;!D2[EG;Y`NSVK=
M$KN)O&FRY#H,[1G=NO0\Y.8^VZSV/ES28^N(2>H1$=<OK\//6Z$H-A)71:F>
MG(3-+4V>K!MJUTZ;NZLO//@*8#8(=R(7WPQ]-L]JG1*=-6^>/M>J!WI>6N'R
MA,)KQXMHQN]'S[GU?"_VI/HD'4QL=S\'7^4PB3#U!E.;U#^#\%;)Z![7\R&8
M)C'\'`9#N(M2)9Z3B]B_;K7:UU?=;J=S>GTZZ%TT&QW*1>SUKLZOFNVMYR)N
M-2]E(*("9&S9P:V\\X(@+0;2N4T?Y;WT15OXV0%0VA+>H+P?8J)#C))"C`OX
M\\SE5:',Q5-8V:/S=A3GQ.Q!3LS96;W?Z#9Z_5:K!_OK=\O+D.F\,$.FW]MU
MPDJ+$U:JGQO0?H6$E8H'?%'2"Q+UZ[*UG2[/*!U4)E?)!?X3*Q(SK+R!MWHC
MP"Q89267FU/6*KE`TB"K>=1'1B=;NQW\\[CU!`Q97U;)QMZF*73N^)B;7Q-_
M=X+$B689"37+;;#%3?Y>Y-'9!S=#K];K\I28K7*EPV(^%V,GN*,J-*K-4;$W
MH>X4U%A@KJ-`$,,>0+9DL6C=,X"J?D!;)!MY$V7TR0E.KYL]O874K39'SW9!
MJV]+@]C3%IW[G>)4GO[QXL#(WF?.]6K]\B8A;P[/O<"[$OGII@&4;81&EL=>
M<KX/W?SA^1V`KJ_.+T\O.M?7W:O3]ME9OWEVT;4!E5ZGU=_OY@Z9[TILXB?:
M\QKJ.8;7;,U%"[;:]<'&:08W%YG@[;=`\N::-JPX'PIS99VR5"W7<D$<Y>['
M;A#PS-S/QVD,;%FKKY$7@$:`!?J.HH)O?%$^@$8=!;!".Y(G$T.S=%':4`Y^
MSQD!\$DZP['Y&<-RNL]`C6YZWH/@W!6\/`@2JCI/J).9D[]H[($U`3;&3*_3
M4^(V"K_+`%CX0X!]TT+X`<L,??1#J;J)$7KD,:/5N!)`@"]/`VF;1\Z6H5=!
MT6DV^B4C&.TGYPC*.?OM,;=^$7\D(0*8K#"E.XE0&;UN"*>CI!Y2`$I'BPGP
M70X1'F_K5FVHM)9#)02BB(3*W,\B$ST612SM+(4)XE:8W(V!LJ(HO#7!7]V;
MQ?3:<YW8053&9TPR@L;OY<M!NAOPM9>#+P^X)%@$'5%D)$>^',8`CL"YHZT7
MV,^M!`*WS@1T(#S@309V4P?5-6]*=6&Z$02UB`B-.V'UN90.\+R0:#9Z59=S
M!9E6]FKS,FT(4+T+([C`%1Z<P]!18VQ/Z0%[UG)+B7D6I;M;(O]V=-$"TMC\
M1;H+JBMC&4V(/Z==4)V\N#28XDRG40A2)R\5M;38A//520#G\TU4BFANB$V:
M0D1LV"4LT2G0@2OO4-K`7;\G[ATBGM[M*GC9+C:%[BKPHAA009.2!NDB&%N&
MS/3ST^>@2,ND:SS7\A.A%UEU&T'JJ50LWTK\CJYWD<;,G23,_TB`%,'2D7!M
M`LOT$2@SN@UWYL,QI>MVEZR(7N]:`1[H\X(S0:+'HZ$WAZ[T:_8:;$ID:EI,
MKR`D8N*L81+A`T"O3X^HH%*=-OL6Z&LY(JE34^Y<+*Q%.]438-MP41ZN>'C+
MG:"K8(S_N+\GRF@Z*^#JQ;9QU#*@/F-'!N2%YL'RQQ1X,1ZO1QV?`')`[;`-
MX#BJ5KP$#NA6,]09-6!*P.95FEYHZ>F-:0,S;&DF8`%`(#EB!=$X1<&(Q'P;
MHTH&A*WTA0)9U`_8RBT<)NP5>T#!5A^W3%=;ET\9?\M-QL^C:ZL#?PA4'"6D
M<.M;US`7+QL7E^=G@^OK7O.LW6HV&]?79]I<[)SVFJV+O<V_TQ_Q\D+[MYR!
M`FB1@D[D8+=P?IM(&9%7-0CW@:%0GV%GHIOGI7:#B4G<&N>F&DO@6XBH\]*H
MEG7>`PJ5'JDKN2^GSLQ\`R@]-)VQT0A!E0)9U@^MI^@F51G1@UA(2"_1/Z@Q
MK.L$)9<(G#B)-(D8?JH)!$!G*6%C='\,<8NHON2RS)9\CF^D=WYZ>G7>;+9/
M+]O-B_/NY=G%J?&-7%Y=G.YY=V3VC;!OA'TC[!MAWPC[1M@WPKX1]HVP;X1]
M(^P;V1O?R`XLISWER7.]K8&G`*`15;Q@A!5AA!G.;9C$FH26Z_MY)'\*K8U3
M`G`/=H4GCEB("2)FIE?.5[&-TKU-P;9.[=Z>UMZ5VH^Z^=*&U)V=]X?>3;G=
M*]['&ZS*0JN]P;=<$;K@^9RO7-<#_3Q;OGXIU3#RIILF['/UZ(*7>;N)U]Q5
MAI'O$>3[!YG\&5B_D.V???X0S/NS5OZUIHZZT^T-M`-##[.M=$5L<^V*6*9X
MIO@7X%N^NCZ%[6?T[E>2/#YGI?8YIE3U^O864S-3\\Y[451;%E>?:KDK12DM
MVLA7^KC/<E,"WR$$]X$S5@98ARM2&.,8XQCC&.,8X]X&QG%GGU\NYO*27M.4
MK0I,2FO6L4\]P3JMVEFS7=;.JW*4>!_/MWD]F<UL@-E`!8Z2V0"S`68#ST8!
M*F=@7L"\@'D!\P+F!24Y$-9TP?3WW;5``_ML-OU<8>L0H[=SJ?2E^0FY_>C6
M^!:W'RW90N+^HR\#'\<$F$DRDV0FN<^(QTR2F>2^X"HSR4H;ULPIF5,RIZP$
MKC*G9$ZYOYR24Z-^R<TKV4J"^UO,N./@&>,/XP_C#^-/9>'#^%.V6E0AJW*;
M^M)OZ[5L?$U2K?RL8IY3G;^OV:^=GG6V#I*J'#Y[MPY(*Z@\MC&KV;:'J>H8
MP/R&^0WS&U9MF-4PJV%6<["LAE4;#G]M`,*+<*V1"IMX%ENOT-OM&9W<RB?!
M7JW?/RN-^)Z`3E40:-LRGT7[&Z:HK6>$,%TQ73%=,5TQ73%=L0:X1U;8VRJO
M7CZA[,!JK*L"\OU(Z:Z,XZG5K?7Z%2@"K`KZ;%O!8"<X<S/F9GMK&3%+8Y;&
M+(U9VMXF(3`W8V[&W(RYV>&YV-XB,\LYWWZFV>Q+K\_]G=O7%F;3OW!CFRPN
M=T^!O_"H>QYU?_B#TGF#^[Y!'G7/H^Y?;\[FI1S*R:V,,FN@W:1Q]Z49G&PU
M,0+RN'L>=\\4SQ1/S^%Q]SN@9AYWS]2\$WSC<?<E4BV/NR^#QGG<?47B0=5!
MM\H!CC&.,8XQ;B\`5QE@,<:]!8SCHO:MC;O?>KW2X:6AK`;2/B2;-,]JG=/3
M74&F*JB`]W&)Y.OI!,Q&]FQV;KELHBI'R6R@2NFPK&T<O+;!71F8US"O85[#
MO*;2O(;[53S9K\*A"!JWJMA3UG:HM4/;=.>\Q>(A#F[L1!WC0:M[P^KV8]!J
M5?C@7B`>,TEFDA62V?O!!RO#ZKB?#[,T9FG51D=F:<S27INE<=;4+Q^S)K-;
MR7U_B\EX')=B_&'\8?QA_*DL?!A_RE:+*F3^;5-?^LV)(B>(E9B&L0QBS_']
MF5`RCD$'1=W9"\304>/7)-7*J^T\PS%_7[?6+K&3?M7/GKU0!Z045![;F--L
MVX=4=0Q@?L/\AOD-:S;,:9C3,*<Y5$[#F@T'OS8`X05\!RN3<.<TB89C1TDQ
MQ5:BL*9`>:[4#84W\2N^P2FHO6ZS-.)[(U4E[*EGBN)J+:8KIBNF*Z8KIJN]
MIBO6`+FNN%S@ZKIB/TM1Y.+B_?$KO8FT[&:KUFCSF%5V@E=`\V!NQMRLXI81
MLS1F:<S2F*7M:PX",S-F9LS,F)D=GH?M+3*SG._M9YK;ONSZG2TL![2%,?;Y
MD?2]+J#DJX/QU5;[;8S9&1/`N)EP/5<$82SBR`G42$8"OQQY@1,,/<<77J#B
M*)G@,`CX.PY%&(DPB44X$F9R&FS:48KF2F*BAW"3"&A?Q/".>!Q)26Y&Y?T0
M$UC)6`D9H+MQ`3#/W(>A)D-F\].K\0#T5O^>!+GI>.T&C5CNOO3M]&@$!<YK
MKHL!N5$!8+ZG80#0P?W?RCLO"!`:"`/8./YIP99WR8[@47C#08+)4\+!+?J@
M2"AQY`6PU3!1`!)U_'B]_&,$DKWJ;#-R.'NF(K+>8HK$F;NGH'LT@*#S%(Z?
M\P\-PFCB^`6YVL1KT@<3JQ5#Z?OFFK^\:[RCSR!'AO;S$CA\\R:`;[_*!_$U
MG#@+&MV#Y\;C]V=G]7ZCV^CU6ZT>[*_?_<E*.L`GWYDJ^=[^\<N\<,J6F`_%
MI`*NLS2\MD8PAU;VEW?]WD]/BLZB`#<W-C>]K[63%SXOAO5JH>+5JL@+)G.6
M$"CF^;`+DTVO,9KWKR>C>:^UO$\Z"CEY<LS4:RWPGPH.-\/*_/#L2BXW/PZX
MB@OD(<#5\>MLTZ(\=WRP'61-_-T)$B>:92347*%5<DT*UZ3LPEE3];,OT1?S
M9JM1QDYP1QU$T)R6*O8F3@QV=);:9&USL->Y;J4DJ+?:_>UX5#EG\0UK$)B2
MN*9?:B\"1GO1M'T_HDG[,2V@5^OWSUX?GGN!=R7R4XY#[<MJ,0ZUL6:&<84L
ME3W6"E_@XE.D,QR+2$[#"!\DIK"`T!6)RH=?/')'H*;HP-/#6QV,F1GG@'1K
MPO74$,@)U4=L1W<2)C'F0HA)Z$J_+KY1O"9U"HDDYX#!.5[)9(K+Q%<,_<25
MM,#<FW"AL$Y/WN.R:,D`,%!9X=!J=+$+JJMX@%W]F,HA;#"$/>%E^%ON4HPM
M.<*5L8PF7I`&H*:15`A##=N1,XS#2`$08#OP)+LY,4IB@*!YA]FJ,%M5]<?)
MS_S]YY\3=7+G.-/WUS9N^"$+&U["F_P0C^D;X-*Y'PZ___6__O,__FSO^5L8
MN@^>[P\"]T,0@_KN`0`'-`?M"["JX2R]C3`#/GR5H[^\N[Y$3>`?K?_[=OE.
M>"Y\`3L\.6M=7%U<][J7G=Z@<]$:=`:GYY>=]NF@U^F>GK<;[_XZA_#/B(TL
M8XD+]#(GK/IS@9XR24A_Q,O?>S&PY:%^DH4GX44&4:%!NG"@F]"MR"6YBL+[
M<)LC+_!B>>)[]Q*_2!=@9MLY@&T8<'8F2)[_AFMNDYB^C0&CJ2PE2*@E)$9%
MO<D4&`0BDJ7QC*X3>(_PD9YK&(N%YP&>1_*/!*Z&VSU@!/<4N,:5#;UHF$Q4
MC)HETJ2+\6J9?_[$F8FQ<P]\:#A,(N`J=7%MJ";.!<PM$U)X+ZP$:3\>P^*`
MGGR@+=`C[BB,CGL'$$Y@Q?<>(-7<=@Q;J*7;1Z#XWL2+B4(U"]!14]CLYH'2
M@@[;.UU4J%(<71;%RZ/'&O>M@4%S=D<_#6L:G&KU%J75)DB:<]B+(;D%E/4+
M`'$'<$3`)+V86*+FQ7\D'LD2C:<V)!^#N)%W!AOQ>]#/`#WAV$">2*4VEZU\
M,K$(Y!U(K'MTV;@)P'J&<,=DBG#B#8&80*(SA%\$85<.$2Z(^Z`P@!35NA2B
MLR,4P-R!7UVC)/V"O+)$<*\%V_T#Y,2)ODM@*\Z4).^_M=(525_C,NA7`?Q\
M&X;?M?KUN![%UL):JRTH&B'PYFB)=O'@Q>.<%B)0"]$ZA\23T,[@HB`>>9&"
MPYH!.?P!B@><*!TB/E`IN@+U9:->:S7>][Y+WQO#@DB(I,^JBP\H4]`T26]P
MM7:0E_Q*ZRKTE!G^'*#PKQ74#-HI?!&@S0"&/&GME%3W$`+DY#3_1-2<M$6B
M-Z-_5W@+/2_2RUZTM>:4*?.*H1-%,TI;FY"-L/1BVNNRJ^4/7*Z:>V,-N0TR
M=E>O;I(@T*V&H[<W=/QAXA?5LKKXC$?]X"EXA#=:;Q_Y)<PM3T/YSN(2``GU
M+JO4Z77<V@60-F#?,<DR%L@T`P`$I!$8_2Z<`T=A@>D+K1J!QJB_L'#2H<DL
M?4J/+F)+BFTJ!QQE-9STY=H$UBH0<3!G"M@%-F7M&6_./05TV'`BTZ>\23;7
M*WFU'Q;@/8>@"R>$Y*UQ<)&Y/2`'0>.?%-JB$:02L%24L5Y6HJY*UX$&$J[E
M5E*^*^K!L$K-=PPBIH;AZ2_8WA_-=\.'/(26-YKEN@[DU^F'R&Z)P@,)BU-.
M-`.K+EC&XG%+3UMVZ:[LZO'\BJ0=N'1!$LRY>@0Y/W+A0\T3[F2`OB>T6)%K
MAZI@T_JP:,W+EW"=)SPIKX9L^T4:^;QUT%<!U2?2S;/@.>3/&-4*P8[7@T8_
MSCCD>DZ,&HJ%!XG7JQ54:L3(W*,TGQT[B_H!"CE)O]Q*B?I`0;Z'14K40NFE
M&FX%DL.?ZV!<WUE8\#%^(#GUS?FQ@4>Q<WUV?7DUN+X^/>M?770;UZV^\2CV
M^I>G9UOW*.[8?:A!)0!6<@O.PCP%HQ``Z^K?`*%\+03:I1K+;54$D)",B*:<
M'T1BY.(;:OTFENB%`VDA7&\$U^D?;F7\@&1$"C/<=>LHCR[/G#OY=QI)`(J3
MUL=0.&B^;5U&644,")I8VH(8X0Q1DE&XFDR/Z\'-N1C<7&3T<MIIG#2!9E+3
M=$F&<SE'-QB2$$.>AZ`KG*1]>?,7<91;":Q4Z`7FKCA>I,J-#OX;L:SE!T3,
M-I(J\6,"L?.#XB:P;%>ZR3#6S#8[`Q.FF(&<,AI`IO;G3LMHVRM..4H5%[@%
M?M0SA]SZBSGIJ@/)H%L*0-&W#9J+TA+#$=JB1=>#@T848>$MI3T!,#TUAET2
MJ(#U.'?&<,D,!6V6KC1'S4O@F,A31&:*CBPY&442H/5AIIHA.D00J'E:M\:W
M,L=&3I,L#H8B'#TFZ7.-88&D:T4>D.B2_9(LS&F,#D8$'%!J\:+`Q!(T^=?%
MI2U-@RW+]&%%2TIK$HJ6!%0D01_4>&66A,.IPN#W)!C20HCHM3-B&BI/*QBP
MU-2O"8]S$>5!VXXH.F]5DJ5`>`0`!2>$-UIQ_)ZR6`(G,'!_!RM;\RICVB^[
M1QO"P1!6I`P)FK_C%9I];G5@^=U[BC`#="G0D$>><448_JY?!B#)V\^P77.M
MTFZSS+^Q['WT(@(O!E13,LB'7W]/W#M\-*EF<#HR0L>FEBBC&"V&'YZ*]7G!
MO3:B&H!L]IT'T.CP+XK83",9._I-&$O&V_#,]%5DO20@I.\460'.#U+R$S`'
M(N(R@&5+Y!!H$HB'FN&E\F;I7O.A8S39BJ&+I^[(6*5VZ&9<C[J\F:>8B#C\
M.8,ETEE^#\*'@`WX<JP4`/D#\J4P3RD88@\T@1G<3S6<I86R]@`/IQ(4-Z@K
M9G^S:1X)><LG2*H.Y6*,$F!&R[B4<^=@,;((DZ@H*S(>^5QK8I59,&<[%.V,
M)?D,:Y@1C7;W\KI[<7G=;O9;%[WF]77_E,R(TV[CK-MI;=V,*--J6"B@^>@-
M";4'=X#'SRKI.B1&4O9J!\`#G"BVNH$-.!?U%2J.,K7Y/AT#":3T(+3$`Y4G
M<NEIGM7\M%0TLC3+)](2+IPY/F@E4V>F'P(*%*K,@4UB@L>K5-O6K\TBY\#-
MPN1N#!1Z+_UPJI,WT%$73B8RLD;4'<K*3^EKTU>AEY'T2*W%U(A)RA_`DGQ9
M$\D4F0+ZFX%'V`7`)[09Z$KMV$884$0GDG<840C!_(`W!L-9;5[XSK]0\Z/O
M<A40]`J0.V-A&CP45X$,23F^5'-+TIH0<7[70[&<J6?H=I21]>O@1-2[G%FI
M/5PHI,WRT!$9(>@HW2NGKH=BY">H7L28_1).4N$>FK_>I%#?0JKB_#$ID!TQ
M<>8I:N5Q`:D`^DG@H6(;42Z33<Z3!:J8PU^#F9%$U+T//=?J<OF42(.-OXAQ
M^`"/BHKLP$/E-T.-(:GQ^5=ZH_1ZM$;`+!FB\81B=V;R$6%'&.G&'&2*+"(Q
MA;>_@\:,P51&IU*"/(M6)#DN,`E)VSF('+_*Y%_.CU*4+[Q/)=,52>9Q./WE
M$97A=!IK*OA$:X'G+`7M)NLJHF^:A$6)'=I0(O,&I<\M+-489IIW.E;T9/(.
M/4&`KH,ITI%#]R,'_F<`J!LI8VF#X@;:^2<PU<!&QB<I`/<%:IF1N""!6G"2
M?;H<7%SD_6/I8_]7!B!8X$%_=X;?\2'72%-:<[6Z_<"]QR=;>O^$]CYZPSY)
MUQMZF,`+:FB]\,+__?MUX74/8V\X%G=Z:+;\,?1!$[@'$R.,?/?!<Z6%%A"\
M(_Y9OZD#E\#)VH)\7=;A$$C?F\JI-TGBDQO@66`QNL;HD)33IF_%+]#Q`6AA
M'J./P3P29*]O6OVH[/G`"<=HJ\`&LZ!+^@I%SHHA[K8.1V'$'O%$(S`]98^R
MAAG/VF;-Y#$PO9PWAZP%&9!5,))REZ&0/[4:C1I<4A+J.SF]RS#VO=V-5HQ(
MQPN&%@6^4/9^6WSY>G5S]>LWS([5:IOF;+E4GE3B+$"D&&U;K9JF^I=Y-G:J
MHD<3*YC*!!B>%;7*RD2,F*/25-!C8SD<!P##._+G5%."[)>\NQJ-M/H@+B7P
MPEL9Y7P,Y&)H$>$3\]41US#/WDE1`<XSRW%Z$IJ#\P\7XE.J\W_4^=.4;)3<
M*L_UD-42R[]W$!NCB3,D3'!\58R$P(/R3+=F9(SFO;`T8K^P-'ICQH0SUJND
M_)XS/U(C!=3Y#RIRI,[]0?>%05"K]@UA>QX5>U#\.H@C!]X\H5M)Z\I)DSB2
M3IRZ4"-R=0^UY$ISQ<E:3%]/N0I27%\.;$KS51(!X@,_M2)(@>&>LXU"LXL:
M;,F$Q%U/`>G>)K!&L_AL5R2?\;6@2HYSVP9:O-7)I761AR[Y+*U\]U68%L@X
M^EO<F4YCB^0H40L0Q)"$T8M-L@?)(OQ)'Y99H3&<]()P$9GD>0RO:OJ$=38`
MJ1[D+\;(OO'5XYMR=B7\Z5&6>$%IRQ9=TSYRMQ!$A)>&D;98_1#97DY'K\U9
MRT!*!3/!L\&O.RJ#0M>V]A(;`_@['L8"GT2+),<M#03GF*8^*7TL!)'4\?PH
M*:*(MJ5:Q$X31<=$%WH%KDR!*YV"G$N!T&%4DAI(]^B>]T:>3F>:`*`W-SKV
MA^>6[8?^'"!C'(YS#5CZQ&K;6L>RJO;@%K'7KXZ5819\VOFE=&M#'(W0:1/,
M_&-QD]QB'`<URF\8?"9%0_?!G"3#D!@/D""(D%B>1-(G4]K>+HZ^??AZ?6QI
M4GNID)B*[-(0:*Q-$!0?-S&%08E*/D?R1P@4)XX^?_W_U6^^'2/E"R"IZ([X
M*5*!)N*"X$JM)4W,\/R;!PDXI/E&*IJ`0E.-QH3#*,#E^U)'HZ8H!B)D:-EB
MB$O(6H[AUPK2H`:D/")A8[9KL`?+BO&-2S=KI`H0S$E^=1,G2#`U$?F0?0P^
M]WD+H(PMJL1:9RWU]*(TU<H*""LIR0JZQMQN?/1EE(`YZ0*;RIC\$0C3)4D2
ME:#Z_>)16B2C3C2GUQ$V:CYES/\E0C@]K;RL3.6P/6ACT))`RKN#*0_59E]/
MG-CXT;.G_B9S@I`P.,VLT`%M&[6R#F\,_(BC3`74_M?C@D!#1)HDD[PS'+[W
M:8E#^93RE=^3)M7<@WS411P5!I1*(T?P1"WWL[+A;!U:\*?&%A"&9@"8&A'$
M'N;%V%MUA"`%2Z;QID1K1#Y".0CGR[1'>(JW>@UXTGD_SF,P-2X`A64<>K4&
M1!K:V(4XRV3/P$WGEI5,IP_$5^O'6,C<REE('E<LUZ"$_M_0F3#R##!])PF&
MF$0SAV.9TF0!`(__/(Q#,&M(OC)K*,=%6M!K5^-?31PUCS,MYP$]!YYK\'EG
MOI1F`ZG)7]8S:D-W"I"5-0:<1]JC;FM#W7+WL^CIPE0JS+:?HQ[M2")O^#(;
M=E1@IX01.44BRI&E3C@X:A5Q(^/FZ%6$?PA/WHLC)W>=3LB`Q9Y@A"<-P^!J
M%_U3F5%E<Q/F&819R6WN#8[`7A*ZA\N)Z]UY<6JR9=99^JRZ^#6$+R/R9V4K
M0$-TWLXCPQ7L7C>!O8YB8_&2>P$C#60AHR@<^HXWR6*X#MG;R"TIV<DJCM8#
M#`P5A<`15<93>?VN\!!08K&)SB88>*PS;TP6'Z`5^5Q<'2<VWFWB_J!Q#N$D
MXUKF0KQ#1W>``$;A2\X2A!PJXI)N_#V)/.5Z0ZOQ.V3L:T&->B^@LG1\$LPV
M4XWJQU(6!T]+/>!_@R,/G#E,);Y[0O^UP6=[>":SR)3#A(IBR+J'`=T=A4H.
M47U`HV'P*U"10PNM'[)9G2LHWK:9;3J="G1B8GY3T;Y>&J8)\'!]_!)CNU'H
M^Z3B:B/SZ.+KL?5\Z`S5U`L)Q.>@-ORWP<>KDTZC64N53U*BB^'#3\`*U+S7
MLR8^?KP01^_HQW<ZEJ4O!-IPL)H/WA:B_A,^H&LF\Z/6T[?2HC$=RP0M304_
M;,GU=+:'W1Y9M,"W3U(KRWJQ*`DE-<*`9%"955XP-"6VR+":9V<-M=SW*15V
MMT%M#`$PN0V',[AFXCGBZ.K;<=UL"3:"*9!!SF%K'5F43TL^MR7NMMSY7'PM
M'L4TB53B:*?7L@`DF2_G7O@O1V$Q:V3B>TO#7G+Q_II=.4;-"@Q@\9D8/G)/
MXO`$18DI*%T0)2A#(BR72V06ZB#+.6,Y;A87R85:UI5Z&@<H<\">3B:@<Q97
MWMC0F_2,!SBU[7RMZQEN;!E7FD&<!?Y>J&+OBCGLEK65';5!UI8`(VB>YOC:
M7(C&U+?E*6MUM.93&(0WH;_*>,\QR/^73$$&_ON-."7!#'4`<B`'@F/01P$2
M`"7J[G?M^9/5/-3"<4H$;MG^&/;A:P<']BK#DE7X",<0AZ"Y>$,!1NTDU%'1
M&2)/,H1G!@XP8)TQ<1]./+*HCRX^_/JOXYJ('-=;[X:O^@9*&`!%Y`0]C+H0
M8NGE7S[#Y45%:(6M9Q#"%*I3^DP@Y[)GI(TR!HO9B=IE8H<<Z6"(N0(3:[6;
M+\MM$$>@)I$0SMYL#4N+Q0X\)M;A[%+PH&R+R]I71(^@!&B3!/4$)+G0]H.!
MRY"XZ;)R]M&H;VDG>JE=0ACL`$,GE1;'9OD"#Z:H!<6F/:VRMM8J>6^(O;"O
M4A[6+BF5PW5FRAB/!GS%POXL5<6D`Y'@EM(4\Y@X'B4=A3&&^O#*K$1MMB1&
M\,6D%V%F%<:_T:TG/I,YIFW^?%X343RE,!IEUQBS:3Z2H5FM9(*(Q,:0QMW7
M:K3Z-7'D><=/*3B8S#35VCH(,I!D=V1$ET7MS5[99%+P0ZS4R'))#ZE_(5\?
M"A=;\*$A:RHK,?&5*DM1A2P'`*V2/6;QR[U]UI57[LJTT`*4\S`6L(;?9]D1
MU7-GM!7UL77&RN]":&H=@^WI(-72^)0ELK+B4VLF:E"[PP0]89@ZE.G>N7@1
MS2TL+#K/4_-+6%(![XC?0R^(E^QYZCN!Z8N1+U$VXB!-`0Y2#6LQ!`?L'!.S
M8L\O^EGMVG3CIZ4!-]O+"M.&M=^.8D9&DUX9#4:?,ZF<"M<_M(9/KH>2C41G
M:D>NG&UQ'4&"Z6\ZR0GC?OG0UI12D0/I4SYC>BLAX'8L7B;Z%43_>(J852H1
M;;0'MI`/2.F`YB;?MUJWR6C6RD7!LE`)E5?HB@V=J8&=TG2]\_.K&I\L6)PK
M<$3;$5C.\YNC7%RT+WL7_:M>[^*ZV^J?#SK-CFF.TNF>G[8/KSF*!I6WC=XH
MN8=3`CPU&DE;FV.3O$C''!1Q,<-]=*LN6Q262ZG+\O`IF1*@5#-_8>3\Z-WU
MA^O/[XY-YGZ]\'8*X"M2&Q_"Z#O<>D)-")6.,*##AS@W=DTJV)1&E%AG8K$'
M!-)*P7F4A>WLB-QY0LM\O_E<(;,&?)$S_.Z06CJ7[V'E07&I=3$XE,9)Q;*9
ML8,@S0YPES4$S5JGU2NQ)L(@GSG4'6ZCU>N45PRQ@G1VMYU>J]3-S!/2LV72
M<AE3$$2?J8?%!^#F/Z3[+?P`.C7H0U<@-./9I53#R*,+GE5V/[ANGG>NSJ[Z
MG>O^=;]S?GX]T`+JNM^$`]_OLOO?J!Z5B^W+ZBV8JZ!05$$RF9CRD0<-:1WJ
MS%MV!SFQG6>T5W]&>[/1*&\J>^NE8]E;FXY7[^]ZG#NOD]?)Z^1U5F*=SYL"
M^H*YUR\;]HE1-6R)_7[LN2`+R]42UY/L%1JU^P0LE\!OI\/LJ>9/EZ*L91^4
M.)R7,9,Q\Q',O)'36-?^KZG#[W1U6'I0R84Q%3,55XB*TP8>5:05;"12R865
M3<1,I$RDCZ#;8!IY?@95((LFDP63Q5LG"]T/I8J$P!3*%,H46G$*70RG5V%A
M3*%,H3M$MXLPP"$F@'&5I`;,LOG\8X3C)9DPJD\8CX"N4EC_#2O]U@741F&=
M6V?X_8XF1)V8')#A4,K1Z!70;NE`]I?"E6[[G,0XJ!775LO:)JS(7=G4OUDF
M(`T>4W;'`A)O"%,ZE!*!FDLBWCH,MP&/.1Q[I<RSU\*P15(M#<:5$Q],M_G;
MVK6ST\=#3DRQ5<0MIMBW2[&-]N-N.J;8*N+6@5EA3)3YVWH[,!V8))DD*P*X
M?2#)YFF/29))DDFR.B398B')%,D462&*/&T]'D]FDJPB9C%)'C!)]FO=#A-E
M*42Y)Z5MVPMU4OL*MS1DVD*B246(KHEM5\JS%Y\`U*'05_5(:<]DV^$2U#;R
M`9BJF*J8JIBJF*J8JIBJF*J8JIBJF*J8JIBJF*J8JIBJF*J8JIBJJD-5[%3?
M6="J0N'E+2)4H7+OBJ:![RRX52J$*P+/5Q![*\%X*.1;*3QC0<H$S`3,F5Q,
MH$R@3*!,H$R@3*!,H$R@3*!,H$R@3*!,H$R@3*`'3J!'K7:_,O#+D&Q[`"RY
MB.:8J9:IEJGV4*GVS1<)%ONAKC?2MQ1$;`,BNF&"$VHYV^&YD'HSJNXV4.;M
M"L_#HKERNY<RR3')51>`E2&Y,MN/,LEQENQ;IZ@R>X<R/3$]O75Z*K/Q)],3
MT]-;IZ<2NW8R.3$YO75RZO0?GP[.],3TQ/3T#/'4JK4;6PJ5'3!)'5"98<GQ
M,"HL=&(O#)Z!5.EBGQQ*N4,0/@ZV,@=6TFTT-UFT&COH*<T,GS$.;KN1TUA.
M;F6$4>KR9`!C'6/=(UAW*8<ITITRTKT=I,LU37]*,]PQ2@ZFD><S/KXQ?*R"
MLM?<_I0MQCC&.,8XQKB=8]R_G,B3"E&N<\)F+>-==0&7\^;]'#N@E2Z[?F=N
MQAR8?"^0)V-)8&VV&C_]0O3J!0"R^'VO!X!^=:?HJZWV-R>*G"!6@/.!\E0L
MPI%XL-]-PQA>ZCF^/Q-*QC%L"8T-+Q!#1XUKXF'L@31T(BE\S[GU?"^>G0Q]
M1REOY$DW?4Y-.($KY!_)BM_KI8"FW7JK!ZD_XN7OO1CXTW#^:#.0.RH]*I`J
M&^_D38*9[OOX&*(O):(X%-,$M$9'2?A],@D#>&<X_"X\&HQ%U!0&@1RBMU\\
M>/'8D(H8>8$3#$$D*+PH53V[-5'P.;9K(N\-:M4RUIV:Y,W<E^F#\E\BA:8_
M-.KBVUC">M--((T_S@V(QA\D7.=*T(`F<"JN",(8]W^+5[GR!WP#G\(D*@""
MR;^$U<)Y":EB;^+$`.61XT7BWO$3B:@89L55N1,=#D%OH8O#:(XO`&KF3]&)
MA70`,VX='_!1"C66,A8NO*DN!L$,+AU&$M$;'N0%YF]`B_B1->%O9BV9\!#*
MP^?C;Y,0R"B2J$XO>2\N$'Y$5YAKWP1$!*!5TB4JQ-I">BWL'$@%'P-O!;2;
M1G(,EWGW(+1"I7#G(=Q.*P\G4AS)'U-\S#'1P.I5$Y"RW24*H>L$PIE.HQ#(
M#E<)_R#YPF9<Z6O2QB>,0A^4-OS!"Z9P-N]+X,-GFR'0V3/5O4V$0NZ>@EK<
M`!+(TP1^SC\T"*.)XQ<TYR9>DSZ8E$PQE+YOKOG+N\8[^@PZ\]!^7@*';]X$
MD/Q7^2"^AA-G06]^\-QX_/[LK-YO=!N]?JO5@_WUNS]9WRNH^KXS5?*]_>.7
M^4!PML1\6#LS*SI+-?LU(N.T-'A`^Z<G#:RB26-N;&YZ7V/7+^0-\@9Y@[S!
M\E_XYHOM7^@3:S_E%-OV-(''@56F!Y8^/6AUY#;T71/H5*@+OJQ+`2/ABY#P
M-7"P,G&!Y5B9^0>$]?P\`[)5@^;>A@P8,Q<P,_56K6M:[G1UZ$&KY,+*IF*F
M4J;21]#-^I`K20OHUZ[DPIA(F4AW:7I@0">#*@9QF"R8+-XZ69#M4TE"8`IE
M"F4*K3B%/IY4N2\4>KC5M"\-;M_$D?==A^/E:_*[E<#.%?5L:ZCL2V'XI]*<
MB4]AW&,`W`*<YGL!O!10K7J)G0!>$6%>OSW`*_.NTF!<.46%&1LSMDT86W?[
MU2?,V*JEE#'O8MYU`+RK6>^7UZ.=>1?SKHKS+F9/9;>(>RDL&O5>>3U,>?8@
M,QEF,LQDF,DPDV$FPTQFUP[N\KI''SJ3V?L\_Y=BR]6/J1QBA2R6$XNC&<!1
M/6>:[=J]6+9<5E(V%77JIZ51T:$02_7HHG*"]U#)H5UO,3DP.3`Y6!VK4UH2
M`9,#D\.>DT.SWB]MWB>3`Y/#GI-#H]YCZ<#DP.1@R>&TP^10@M^I0A[O[3FD
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MY`U6?(-['ZUYW6&'S3.>N(D3-],)5=G4S29-W5P[[,.(>`!S+=9OL_G::,N#
M#WDT3<6<`]4@X4I1*0\^9")E(JTXD?+@0R8+)HO]&JO&%,H4RA1:90KEP8=5
M*,QXPX,/JP$F[NZ\XRE?A])E9X^83.64!F8R;Y?)-.MGS&28R3"382;#PW"8
MR3"382;#3(:9##,99C+,9);Y9)K,9+;J#3XDIR]/W%HU8H@G;NU"L!R8X#U4
M<BBSO3>3`Y/#WI-#FT<,,3DP.=@(39.E`Y,#DX,EAQ:/&"K#T*Z0BX]'#+TV
M59UVZST>NL!MJ/=$9AT,V?7J_>W[DYGLF.R8[/)DUR]1B62R8[)CLEMSQ%";
MYU@RV3'9[9KL>,00SSHI`U(\ZV2)/[)=FN/D+=!0]<AE?R74WI%*@_L',ZDP
MJ:PUZX2E"I,*D\HZI-+FL4!,*DPJ:Y%*:=&FMT`J:PUPV`@K_0T2/G*P61C(
MD!^NT.L"I$NEH;U:[;>Q%-(67MQG^1^.4LED&GMAH(0327'K*+@@#$0,-PS#
M"6#B[+^5\"93WRO>Z07X^ZT7.'BW>/#B,=VT<*DGJ3NV\F"13B2FR:WO#?V9
MB"/'A>M@NW1-7136Z'LCF5N=\%1Q;9&<.%X`E`2K".!1PSAQ?"HIH;?A)0^F
M3Y-^<E3TTLP_[]\R"N%1R10^XP4*-RA'(UB-<&*Z)/8F$I]][_@);5H_&,[4
M@T-SQ<R3OBL2?*BG'XJ-C7")D]"5/KX2WU(3MW+HP&5Y&(NQHT00PAU2`43@
M`3$"!A<'7SHS,734.'V5JE<3R_:/)H9C)[C3ASURO(C.5LXA$."B<ZN1?A1&
M](OR?L"A!O%8`?XB%B_L\)D+,FYCTV>.MNW*81@1GKU'2.HU_ST)9*Z_?(/Z
MRR^*KTW`(1YDA"0'F_1![U#BB+`X3)0#&'?\?N-#+$]&\9">;.7;&-+3?^&0
MGE9GQP-"^OLRR(3WQ_NK\#IY?[R_[;UO3R+$U?6X<-_BY7V+2?D597?,?@5H
M,F8>#F;R5*5*]+UG*F8J?@$Z\M2E*A`Q$RD3*4]=8K)@LCB8F2Y,H4RA3*%5
MIM##F+K$%+I["MV7>>W?PMCQUP74\[S7`((J%1IN+U_LM_GDB)KXNQ,D3C3+
M<+&Y(CVA"FVDUQ_3_K9[3&\#3F6G<&J,Z[>:K>>PO\U`M@.\>?W>6:]<2ET:
MC"LG<IF_,7][/J!:M>X.&I$Q9V/.QIR-.=MN.5NC=<J<[0`X&S,O9EYOC'GU
M6MMO4\FLBUD7LRYF765WG>D]G@7(K(M9%[,N9ET59%W;;Y;*C(L9%S,N9EPE
M,ZYNK=UGK:L4YO7\G(Q#2KVX+G2JL&U.A*=4(MUG(-BA=G1J-FJMLUY9E'8H
M-,,)<6^6(+:0'\-4P53!5,%4P53!5,%4P53!5,%4P53!5,%4P53QQJF"W4]<
M1K<VLEQ0`^+%_L,/SR]W79N>GBKG/)09?ZU:K\0TETV!=B@$O#4`L2ADTET@
MW4YYPSF9<#G3@PFS-.6VO'(=)DPF3";,LM(B66`R73)=5HXN6VR!,ETR75:.
M+H]>7UXNHMAS0?9J;LMCIMDJT>R!T&2[UBRO6]S!B\.WG02_K/_@>L,12V'S
M;6#S;IC@;+^7]*E]4_4]ZP)PS^M\FJW:6?=L9U![$P4_KT*<BZSOC;;O8M;'
MK&_-B'N_L26[BCD?)Y(Q[V+>M47>U6QWF'<Q[V+>Q;QKSWC7Z;:R,IAS,>=B
MSL6<:WO.LGYIE1+,N9AS,>=BSK6K[L_,MYAO,=]BOK5G?*O9KYV>L:-K6ZD8
M/\<.;'_9]3M;6`YHOA?(D[&>?]EL-7[ZA:#H!<#/XO>]+J#LJX/Q-5:K/^+E
M[[T8<&I8R"E1L`-'*6_D25<X2L@_$B^>56X3^P5RNN^*('F2`V_:O7(8!LI3
M\9*.EE@<#;\&<AA[82`>O'A,5R=^#.Q7*!G=>T.IQ#0*[ST7KH]#D:BZ&`![
MQCL<WY_5!-SYR9F)/B4%M?%8'3%U(GIAF$3B8^@$8N0%3C"$I];$@Q1WN`IX
MWN<?(V!BXEK_Z/CBX\>+;)'PMFD2#<>.DB*9XL<%V#\35"9=S?!(.A!7#L/(
MP=V\QS.VG+Q56V8_;W(R0HV="(`(T!B&DPE`2\7A\+MP8@%PD3]D-/1@@],(
M0(T7[6J/?VK5.XN^S4UV"$<Z]H9CI&;'UU@2C^7.-M):'."WR2Y.7$!B!V2Q
M<R?%Q(F^RS@[%,3CPNG!+V%D=^HZ,5V%?Q-JU\4W^#-%Y`<92=V`P`7Z0=*"
MDW>F0%;P&+P7WX-?3T)7^DA!KE3#R+O5)/IK")><U<2M!)U9/SK7T@`(/IE,
M$29*C'!-=A%PZ]!/D&P=<1_Z`#9,YMLEBIUVZ^W.3R7AF/PQ!3Z%Z"6CR2YW
MH>2]#,IA!3.0):HF(D]]/QE%4HK(8,[.&%L=)%%)!^($B%D@\4`TP)^[WDJC
MWBAI*PLD94@YI5\KKAZ`,G?&GIOUL\4"IXVP;BHC+81HHRJW,?A.1/AV5W,:
MK8^A:,I!(YD"UT.%`62TU,<>A#%R*9LA[$EET`&>A[^IY/9W(%;DCX[[>Z+B
M"2@]^"GW6'@=7*;@E?A;)*=A1%H'K-8+755_W$(P?__YYT2=W#G.]/UG8H$?
M0+WZ(=UOX0=4<"*EU:)+XJ9TP3<`^+D/'/RO__6?__'G].;HS@F\?],97``C
M15.*/@P"]PL(;U@A??P\2E65&_A&XK;4I:>&?JB22,+5-V!%@?XU!/`.AL,P
M"7!/7^!Y0P!2^G+4LO#HO\K17]Y=7V(R]3]:__?M\IWP7/C"&<8G%YW.X+1[
M<7Y^>=9OM#N]\W:[?]EIGPYZ\'?SLO/NKW/Z9AX=OGD3T#A^E0_B:SAQ5CM8
M'E-7RS0('O1S;T/?-3AYCG)0*D5H<^Z`@HI4EX?UQGIVI8V`K4+U\SUJ[/*A
MFJM;TS/WI`F5\U043*I>R2;5WT"9#1QQ[H538)X3IR8^!,.Z.+*]^5J-7QYD
M+?W4_$7D?DG4JE]`E5SUDWYC_D>CS^6N`2UTZ@2SW$7'P)Q!$-_:=0YE0NXD
M82X%K7"8*&#PP,9=T&7\<*I54)=46K0_`*3_QN^\(`CO@?KN@<_'3G0G8[H-
M9=;=#%<2.5-Z.AAG8S1@7#="(IXXO\-*)]*E]P92NK"B810J1<L?);XO%*IO
M44*JVQ!%"9`5R:3BKINGORB[3)(:*!=&P$!#T#"".V!KHRB<B(GGGJ!``;56
MGJ@8=?8AH`N]'S1B&8-$TOHO[55$X2V((>%-)@D(*-K(#.U:$.T3@4;+[0SX
M9?(OYX=92*??^D4<!=+WIG+J39+XY.98#),H@C7Y,Y1>H,-[P,6CP-&V<$U\
M(5.UG:TD!O7>U^K%W+G1-C/P"S=*[I35V,7@5L61XY<B_O$^!>;SZN*E1]C`
MZ33.T^YI1Y,K/&\I%]Q(/3D:(<L/9OZQN$EN83%W8$:*;^CLB[5\^'_)%%#D
MWV\$'&'@.@%@<!0&Q^(SH(&X"7WR_%Y[_J0N+D+?1X\-D`AZ7]`R33&_0-,"
MD2B6=Y8#*.0`J*S'WFAF68#CWFO'3)Z\13A%LDL"TNV`SC+>[4W0&R3S)%S+
M?B7:=+V(E+](.EKQ,_JTZRF)!&*LYDBZB78\P>]>C%1/VJ2CG4^PT!,Y&L&3
M0!<L7W146DO8TF(7Y/*\^9&`*(UP-?H5O\)!^^)"G_2''.L$I*C:WG9S$%OU
MX7X&4DZEKJ&OHL`BGY$S'*/$OW50II-Q-HW014%D`Y1',DJ[K?1#K'\.;X*S
MGFA)/P3R1%\4"K,)4CNZC!PML(-D<@LOSR0U6#?WWGT8D3<97I005P##&!U2
MXC.^#IV^P"T`QGD1%R<3T`SHM7#+1,:.0@(?UN@]81+C#[BR24@NZEABO\X8
MI>G$^6[84KI!S2MR>X27AC'^@JYH`49>IOG`X6O6@]%F^-DNSV@=`J%M%`#T
M<'L3)X(#,@=@+T:13"M`,_8>(73DP!JC$P#(G8QFQP(8-0'^81R*L7./;,UW
M-',68^GX\7BF#U$*-5-@,H)B<IO$L+L9X(<'ZZ*[D/)B[=^"\X'%^/`@X($H
M"@W??-PBK@P6'P`-6AXG$O29_EL:*@0E&+$+#M8A\2M`,XQ!3)$B=PO+=G4(
M!?'%'+E%FQJY6?`BQ*%Q`D8Y>942/QS.8O0W@[8,ZON=I)+Z@'!CDOA:%H[@
M?4!%1]'X;Y].+FZNC[6WY2&,OJ/>"EH_FM(IL2PAP_`A*&(A"6%"]1J@L/R.
MI*CU@3AV,#H!2T@1T,IZZ?NJ+OZIM)N&]FY`<R<#!>M`2P!N3&DRIYF@FH%J
M^IQ>/G*`JZ"J)Y0SDC'IY"//!_L#W@($'I/#2FO'2#(^+@YW&8<_O*%13V93
M>@?0.G$1L]ST&$D!AT/SE2%1@E*Z1H"$O`^_2P%POSOQ@4'1_J(P-G&Q>!R%
MR=U8G[ICN5#NE"U([75D&$0.R%*D8W3JXPTNV!+`BF;`>WZ3Y"K+S`D9W`%L
MR`<WP>@;Z+MS5H32N+5@H[Q4Z5SAGRE%EYTWGQ"__C;X>'72;C1K:-M>8UA"
M@HD=$#I\09@#"(ZNS[\<6POT21D`-]RB+`-,OH/_1BA<P(H%H`7T1AFX(&,(
MB`8UGG`N'JSV4DA4:K>V&?5?CE9/6MC5W^H!R+@G3T%;E;`Y%]D@6FE(."[Z
MQ($QD[?I"3T5R(ZT321>X\R!:VUXLDC*Y@E%BM8B$E9DF"AJFL#^C"2$:T'\
MH$C\WZNOK6.,#49&`EH*-YP2EY%RZM!%Y1<E,!R9<V)%&+P"&+.K'4MX,0`_
M<E#:@0".!-SD>"G+QQ=JX>`%((;%`UQV(A7F)GEJC.%)K4":O:86-;F*[*Y3
MED60,EP+%5,PQ.%M6F+9'=P[0_B:E.2BGJ&5`7J3%_QNA!69<+12]1U72#]F
MPLAQ4;TDQP!<71>7H&N3X%9CU!&T5R^PYH%$!$"7O#$GO&AH=1*MV)-*((XN
MOEVH8Y+/MZ231^@))!7)'!C<?&FL_VN,>]Z0/0'K.;J\-H+ALU'3LY\^PR\G
M8'K<@=80:W7!#6$7P9"BV)XBZ8$*,RA/QK10J&"0N5,CQ5^`&B5K6G5`?`9A
MGR%:70Q0F1>W1OX8Q\3_?AR(0:LF!FWX7ZN#(!RT>O;0R8L"..2!SF.@0XLC
M4&BSID!-0H>X`()6I0.5!9VA&"82H/V%I,J(;\*?3:9CK0\"1#^J8QNO,XH'
M;!6_)E7R+@":KL&;$G04HHZ*,`1=-(["62U517!1\%SEP<H(<Q<HQ:X[4\IR
MID@XA/.."U?2>_(01^0>A4-/XVQNZU8[@O>!,:;(9:25,("<I'`Q;0>@3HPC
M4R7AB:EJ;7="]'.B.0OB\XDY`K@67A<#?P&@`L[B%MA2VL'J08<E93K55XV:
MFBFUH$Z'9+X``6E>5@>-+R+A<N>'MT#C4^\^)&,?0P2H!D?HW'0S5_J7KU<W
M5[]^$T?;T7._E*+G%L39=A;ZM92%%D3L=A9Z5<I"G<B?G6QG@3>E+!!-V9KX
M%4R[DR^A\DC6G6N1;ORE)*(_A@_(WSX@\\+P&#(]XL-5!KX1$38C=#M+-4IH
M*2&3[:SP6TF\00=!CC5_K.7UTH)]VV[4&HW&28?^L=IF2W\K1A*4-VF51B./
M4Q^E$P0)^:4`P>Z"4&E'`M[_S_I-G5R3Z&Y`U4Z,89>H;7OJNWF)%\T]5RM(
M.E>7',</*,1'DO(=,04JBT;;D$ZF4Q5BV^0K!?5E[,E[W&?NS@"]+AB,TJJE
M>5#^YJ-?KRZ/!6H8">@G1]:-K!7!W).L;[H0$B?,A7L#UXG<DW!T@EY?8>V3
M(^.^K8GA6$ZLV5(3H"9[I!BGJA>"ZX2`E4*;I)Y.<?:&9"%,0E_JOQ3(7EAO
M9-0Q`QV]A_>:\C_\[X5H_L_/K?_!2-\P-%HE!JU!B2(EC];NW-T1%:*[BE1M
M;0&!;1:@/VEJF<Z1?8E115.']0_/AQ7-M%9)-ZDL:]6ZK[4C42N\/P_:XDC;
M7;Y,OFM%U"JZ9!OI:U)`I"YOLC:<"7K0AAZ>)BIXRB!/),W*E`Y?_/`FL$M`
MUE[W)[QV&D[)IB"@&^)`@X0TQ5L)[S:F24AZ.OZ+2CFN&[7RQ9<$F)9@\M-%
MLW'2U._13C_[KCR!:(=\&@3!J&KN>3KS_+2QXB%_=Z8.V%'_I*M:^E5XZY"J
M5?1IG:2GM9R`:PA&Q.L@)!3$H,1TC)KM(H6`-N7[X0.%2/4AFC"NB4\00O^<
M(K)(<1OQ/\NA#2E.,<5D0,`V`@;:992@FGN%82B>L4@Q7D(?==PI;[(K@;Y-
M`$X8U84AGGD^A3`%_+KUL]"'FYIQM;SAH5$>S4IMDIJT<F=I?,N>I0'N$6`A
MA4_LE<?:"`8X:3L#?R?8'.5,&`/>8[8==I!:]5O>]VWX:19SM'8#G-K4!]F&
M7J8Y7S@P,UBI1@I`:J0`Q(!"(L2=3.EH%(8Q\#X=#]0\YOU6(-5N5^&<B?60
MN6[<H']YUWBGS?>I,[2?S4KFBBV;J:]T12ZI6+7,9:V2'SPW'K\_ZZU3(%RL
MC5S_XF=W:WY.;>13*9(%/S/120G5RZ##]!X_X77J2#&7Z45;W6:LP]KWGS6M
MOZ=P/!O]VS;ZMQ0M+-'HWQ(HV>JOD-4ORC:M59RX,[(:,//'I\"4]B7:_,/3
M;C]GN.`&Z4":_T.J`AAC.F[BB!OTS(,&@;'H$!BF&"@%<*'G'-U\&1RGU4"W
ML\S$O@Y#EYYT&25W8E`(LHBCZ\N!-BBULS1+&*:/0XEX@L8G!JIABZ`*ZU+_
M$\R&Q=(<RQ!U$!MT[:*[U*2=T(^`E5+IJL$(OAQ,`'Q#IR9^DPISE6F15X[^
M^RJ)PJDIZ?F@(D?Z^=I>>,@(PRV:QVD56P,:'?FW:(DDE##R8EQY(@WQX>&A
M'D@P;W[4X7A+09TGJHO6Z#_`.A;K6'NA8[5N,R5K4&`R!>[C!?<89;USXC`Z
MH8!=&.%%[48CS9Q,'U@TQY`A:5:$5IOAJ^C@*OH^D,MD[C3Z+9!WE"N9>:!^
M'K0Z/Z-?9X6K$WU7Q(.L&S4P07$G:V$`?!>N^3=Z&L31_\H(<P5>KOKL1?7`
M+^)O$O->Y7#\\]=P.);'"PFL)F$5Y1'ZH.T!DCN3G,BCA&0.B+>Y9S'3W%NF
MV66F^3RFF>.9P0K>F-&.=5BMPYQ2?J050GW]`SI#-0L5S8SAJC1T$\C0$C#F
MJ*/F*]VY2``59J<,U88:VO^3<S-3W78:C:&,_;%-:TY5YRQAXVAZ\96<IT^^
M>]GKZN*+YBG$46PB0)QQ'5T3D&9=74KD059AOY0C26NX#"^/TRP0O.X"P&U,
M%>)7EU1N!$OZ9.H/OTHEG6@X1AV>ZON.+BX_??URG)5!&!9GGYIFXT28JJ-B
MLRC,"KK7&=`3B<Y)JE&VKS>Y4I%,F]WH3>AE#]+N'M288S",P4B`M^J:^W?`
MA(6#)4[OQ%$(6OX=PI1X-?H4(JF+\"G/&;@</AS[^F`\"XL>X/U4>BZ<!R=R
M-2+IEA_8H8"^Q-(08]$4#=1%X)Q?(&SPJN\6(`-\A+B#DPUL4A1E3^4)(<WF
MTT6.+!OV53:P0OU<V?!%1R7>BP\8_PL2#+.V&LT.];9";A#(R%KEEU&N>O&K
M=-UB"?!'YQ:MWC"B'AH?8Z!F8`(?@/,X*8'EJ[33\H-,Q!`?BN2=SN=\_'6>
MLMS=0VK#-P!Y.'=:'-C]90FINI""N'7AG7J!\$>FF.,J3'8A58_XF/:+=Y%L
M.&K^3TVT_D?[&MK_8]PA^LED/^0BDQZ6G:+/#)X/8.W5%QT,SV4NE4@=UQ^?
MSI*W)1+B:*3K(VQ^JLT5P,J)\R_E)<L?4*1R&_5@2@Y#3#N=[QTPGQB?E;;H
MS!X*I"\[/YN^#KN8CITTB_S>H;8SI)ADB>.V2HN4ERWY[TNQ/8&*T;S'Q$]@
MZB>&%\!NCEJ-DWX#@:%5'%.<4RM4YB!?*-C\H#^FA.!16L>2_&!=\>X$66YU
MFE.<9DGG,Z.1;DY6Y$#GWF=:)I*^!P^'F](7+DO!K]F"AV)_",M/G7E_R?(Z
MB&(!1-%9_50]D[C0;\Z*[M-F<"HMO->Z)\;!A]Z45&?=\3%+@=(8Y]R91!HW
M6X5*1B/2)O&(\TO%/.Y?\-J:+KY+[\CGE^A.A["V"2;^8(Y(EDI2%P,?K!!4
M.]$\F88/)#QQ]7*$G92&LQI>/?%TW2$\U\,JCH@*%!,_SID0JP`.T$W/EIKQ
MF>P>G2B'W2NQ!9-5N8W//!`WX="3NF7>A7W@9]L-!7`$(**KD`G!)H`TU'!!
MYR*@HHR93K23-'D'DVR4K7#`]SV$)ND&T*??K9_^!*(2,_XFPSOAA@H5^S"9
M'HM[`%3SK-[Z*:<6!(#2OKX`;#7Q%]&H-\Z.:W2%(T[[/^5Z+!#;T97):?)?
M+FM/Z!0*`P'"`#(FB#'%H2^C+#4M*Y;^&]:5B*:.H>1+,@E/L>E53.T'D?8P
M_:\,[E40H)KQ!`(3`$MA8O-%"W6LU=3*"?4C-4EV#B![A&6[E.OG8A$-FG2+
MB*CQCXS>:ZQN,0#6D9<<BN&16?LU1;'T*F.[I:8G8BLG*KUJ;XS_E7#X=$Q5
MV\D;J24EAMY!+1D-&)0*;LH3,28*WQ#+/;KX>KS-NM*M)LKM5GDN>_7+S&.P
MG,,$N)D6DL[PC\137KZF_B&,?/<!#Y/Z\Y,N]_0)%U+5`V<B3:5YA]1QX];"
MPJ.Y-W[RL*;M2Z%Q&AKB'R_JZ0/HG0Y6_NDEDPSUD!6[%!;+K>YH<!?-_#<2
M;*J)F[$7R7GH45*YN+X<G%"^][U,JXAK.9]AKC=44=6=S+!:&([8&Z'2@;`.
M9#CU'351XNC3EU_5,35^0SU1.+<!IBA0,H0O=8WD%,T`7\;:`V$RES/-W+EW
M/)]\C2#J37).BDD?OAYC'K,RV)''.X<Z:#DN_@PJP7WF]4"M^A:NDO?:?W$K
MM>9&"C2NVT$,PD"K20AQY502R=':(@E0D36MJ]EJD(GS`PR:R=R-1Q<E(M;M
M"L0R\R?6P*V)*>"!9Y6&5-3-<#R;HD6"/YE<=0"-J3/`PS!]P73B/NEDT;U,
MS84G_$6588_[S=P_V;I/K>LV*93EZ=RCLW[:^\BT`C9E,[J4(V6L^EPU7SU\
MU)[C*%F511@M5.;7L%B&[$+-4-`.$YD=9LP(9#,JO5-2PH836"8T=*;$Y\C2
M,[QE*7.T)VC[86;S'O`=0(9HD'_Y_X*-J3E]^!T`"'`]MMUZ*`T_H)=1LP7M
MP,T)=1LAM1YFN"\<45D6\K=I;#MEYI;3J@DP?@(!O%KZU`[HSL>V.1-C4Z7)
M;\W^0K>N?P9D>%*/9K5<Z*!.,+G%(J>0JN/1W;`@0:B!LUITQZ`4JJ>;`4E\
M@BAE6QB1\6MXD;8-T9(NN!S^CC9FWN>0FGJ978&9AU02AG!L->"UUOY[F5%J
MX(=[-.%8=$#4L0NS;A*+539WZ$P+07&;2%VBF':V`L%>,SU;K=3#AB#=1O?H
M]OBH=9R_&7"#FLWIJJPAGC0A"<:='QQM]>9[O9+$3!LS:?4AY[XA92Y=")4D
MDO_%I:3+ZFI>HG35*V?S_+)""WNC/8Y>R1UPD75=O4"V:]KB5VU;;\0W4%+_
MY'5?5V%#;=TM/-Z%N?J8<0`*-88:1UZ$`;",F:26,[<$M\A82\.!MFMM3K&C
M(1^F)9;CXD0JJC7/>8UN\XE.:7HQ=AT\_S;\DCJ2'&UB:I4*S/P`-!PJ[D8O
M_EQ6<MV>#JW,.CU,?0CI2R8^Z*`Y9+=SE+7JBD&Q2^2Q(.TH[1VF4S.DU5@+
M"Z<5+^BEMM\OJ,0ZJ(3KO=.>""!UW0K8-(/PL5G2C&+1WCTU>Z">HN9G;6K0
MT!;4P[W0LU'IF5V>%^&L%HR3X@*Q'3$IP3F0:NO"P@:+26SAO.F%:3QJ@>/?
M@94QU,$_T^/)-B"[]4+CLDGG5U'[J8"<`Q91=,`5COE>!N24RP':0)5\-5ZQ
M=MCU0,?V3?_=_%G0>!J*^YM`J#:)T%/DR='*XP!#+(GE'$)@0GJ@)LDP5/C-
M@M<IW</1MP]?KX_3U`(3;#-Y!CC9CR+K"JG28A?>(;YB/.\*Q^IHZ.*"/WF4
MIX<?;VP;^*.O5Y^PVQHHXDI9:Z^P5L"X!%NV)38$FRA\$Y$/?)W_/=*`>:#P
M,I@4MTFL$4VAJ9H^,]>').^&S;&X,#=\AUTW![?Z:I3$5T))65<9*VG>Q9M2
M7Q^?FE%]W#B`7#D,]R6^CO6A7/"QN(Q\2ED2W3+5EL>[9(A:T^ZZ3V$0PM?B
MZP^*1>:BF[Z3!,.Q=M1I:)_5=#Z(A>,*)90T)!?;>:8ZX_(\-)/$1WT^0Y<<
MSAA>F\C8Y-[E>V8A,B48S0TP/N;07??AQ".?X='%AU__=:S;:JUWPU=]@_8#
MJO@DG*8QP&67?_D,EQ<WCEVCTMVC@DS*%F8S9ZG*IH1%AQN7;A$77A>_+GDG
M*<</H75LZX;S9C)L;F0-N6<C3U*D^W:F=V,;-N4:M[GYA#FCB1<`C([IM)M3
M77P@%=;FEIF4K7*&(Q-^GI4T4Y.Z,^6W@5O5Z^QK.RJ/%'DS!BNA4MC10="]
MB!DU2LNRLX\X`6H'J_^693S,39?+)4``F1D2Q&G@*7O3$XN#.YW"82V8D9D3
MIPNC<)Z&1)L!VRT$\*#NR?^6TQVBK$A@N_PX8-J^G$9BA`&E&MN)'F1PW>*4
M4)L+X*13LE(P8<XX-1K$C@_)K2D,(V:`K:XI66$9RZR+S]GYV-[HQ,,PXP9S
M<Z-T\C1%5<A^P\QF>WC8$/`$.:4W-$-?:;;@;10Z+DU&2:?^I7,#[>2_`J.V
M&;IP#UCX.'CV'F-*%-#*X1#%1JFSI<(.T'>1Z3Z.)KT21Y\OOYE>C\[<`!&Q
M\I%OFF]LRZ2T)VLFYBBKP12JCW1)I(PQ(8S"54M5\X-4^["*GB8(S2@[BB+^
MRNA]@*X33;O6':5LOY7,&>6;DM-`M!O6,Y41E,F)CTTNQ6T2P3$3QWAP;);!
ME%+=W"3*35G&2X"8*0)NV_?;23UAHC7$N4H$\NI$D1?;/`74$YU9ZK%+NT4X
M[CB7'Y^;3/3?P.R,,P\H\[N44\V&4K$@7,P2P=?A5**,=UFMV"@)0S]1>M!6
MSBV5@L1XK_`?A;USG^N)VIC.*LT$RO1D+%CA2^<XT^GGQF*+;"ZVL(.Q2^%I
M>V*-;XL#:TW-C)DE*R(=9(Z^7#NW7*AT<+D=-^L*)%0<NH(I6M1R%]2`J1.9
M+B`ZUV.:1#@"/D['=R:^*?0P"1^DSQFSZ`8K2[)2D*L?PS$.[Q48)O=TE[&C
MFZL+L-W^&1C.)NU0=#T-XL%3DBKPA\C5:EFVATWR431J7L\AC)?.2%XU9OFQ
MJ<WY'X!SY'X#7I'_,6V(K<&C1^8\C$-45H![H4X+>ID'AANVF1Y,R=+1(Z1K
M<T^V/Q8Z9P?NXT]<G;B,3W]'/]??E8.J^Z7:E+C:1?<C/>F?-$MW)*Z,&4XH
M^85()LUZNTX)[B8EN')4B52E:OUBFC(77JQ)8QWB)W81N60Z:!TZX\RF2A!)
M7$]KT6,/T6[)=9<OI-G!NTWE'/71\"*I\A%,()6)\SVKB].<`:R*9#+5O$,G
M4Y/_Q"1X88`7LQTG.@]/M\&P4Z%]+TVSL=W6AWZH4`=`YT-(&R%%9,4])H<2
M0W&&;2T%E-5>EBV''&>)UG#0:Q$@9A@5*[LG4[CJV`DDT<,]J701`.[CTJFZ
M$L$2F29,.FD/T\A3@+W0<&%J7D[-7S)4U^U=#.$`3I9.L%EOAF_C]8A4#X2/
MC7"W>&=D,D7*=9N@)5*"1E\.0%6V>*6'*!GIF#TO$_NI&>'JWD4Y4##R;07Y
MODKRK)!N3%RP?!EQ`<8PIB?HX0^8%Y)RL.SDHW0=.C$"JYO#B,;$FM(9?><T
MI]G;&1G1_!ZHKS\.^-"\'.12@!GGZ!B:XC#I,4Y@KMP)'00^73AJ3&R!_KA*
M?6!;TCTL+Z&&"2[EA.!8!QU!\CUX/5;&WZ*+6*$+,/,CD!/$N_.PT2QEK)O<
MGI>N$WV.T?O_3X/^;R%K%P_4!CK*@8CKS%3&U</(.&I,`0:<0>:'Q#8-<]_8
M3A.YFGI4<B:V[@#;;9FQP+!R='1$W[%UF&7=IO.`_H>ZL;&6L"U&33V1:`@C
M'&+YY)1[`>%-O@?)$/V9(VT*ZU'2=-;(6<<4-[`U$88>"U[73+%`(O3B1/-H
M:I;M4Q6(:4GB$3Y&TY!F,PXQNH/-6"*7<6H[.'7M>)'XE^,GLF@Q?LB8Y9;8
MMA-%Y".RG":U;>PH'<<GLU"-I<E'G>=EM8P)Z<"U'G>4?CEU9N8;ZM`SQ7T+
MW[2AR>9`F432$4("$QC)?)+&I^.AK@#K.L$^^B(W6,NPP<C2`^FU0#^,IUO!
MTX$]U*_I28L73V?4F)E7(G#,LJZS-[P'K1&3ID)9UXF*PPDJ&;>4&4PSJ)2\
MUPR,!@T7!MEB<3"V%*+':+4VXX480/%2_S3.;Z:(1`T1E_P58V"^(7K:IHD=
M[6R6I8E%V>`G,6C[BW52UL6GS/4!2B\JTXHRG7$8+]5+ZGQ=N8R.]`4!^3*P
MCQ7U\\QH=>2C6ITE@:!V'4EJ#XA'0W14Q\:U%/LA0J9*NS"YC4>)G[U1IY*D
MHZMO;06@;K-*I_+?.,9;96^SKA*]&BK?C\);W;O3G%J($Q,L)\D>LV2?L$BU
M2Z4/RRXS9:W=T)E3Y6`R37^`G=$4JW:SIM/@"%1/G`)6AY:RAC_!KG!<9"D/
M8UZZ%5[Z`2L4=+_/\F5[[N&4J$:>I+1:7+?,(-\H$#2U_B0Q2OQ">V.Q;EBB
MM*46=XFR?DRJ2SK!O!/]%\9EC]Y=?[C^_.Y83&0\1M=F_NW6KH&W85(+W'H"
M?&*HFX.2LTNSG+O01*'G0K$F.=1V[S`2`B>\T+P"TE3(HVP#OZ3-("=/IE-T
M5=L>R2I?39,&B<T:\$7.\+ON?XK^:U.U@#^G<>3"4@^(8]7R%H,>Q9@[P!WN
M\4_-6J?5*XUQU2SRF4/=X39:O4YIVUA%.KO;3J]5ZF:V0TCT>"MW<Y1B!/!^
M4(H&>*_;+0_@Y=*`7F"GS`5N";WU2EN-\A2A);A;CK*Q'V5=6UCM"M4(O=59
M'Y#K)$*8`P)O05$JOFJ4O6I.;2)-R7A7(VGF<V=J$6H+""[=_D7K044K*C/2
MP%)$K1_K7I4XRH+JN^+G-."Y'$B64&RP[JI'`*YR%DT%T<?6?*5>N-(UN0%O
MQ=:9&YO1GV]?N7WSYV_`/RE]DV8.8MWS'4TB&-`YE$_HA??A-I&3Q_($R9!L
M"+L`FR0223TE9X)Y&UAACEXD*OK1H1@G"!*=H8$><]`(O$CSD7@NX2,)/--E
MB_*]J(_`B`;,Z`;A(]M#D!RD7C1,)CJ-7Z5I;_GG8XHMA6O#(05DP=ZZUBZO
M@G*2!>)R[1'&Q,DPT22.O+L[*K'7/E-O@BDLGGR8WXY)/*BEVR\ZTK1&E'8P
MVWR8=G$4R2G@WRH<S>7=+\7)->Y;`X/L4ZCWZ/M6/YV-\LB,DTV0-)\0JW,C
M4X_9!(>+D)V.SD_C8*2VI5'*L(2Q:94M[;?QFY"\H3X<&P@IT*E>SBO>\LFD
MX[2P:!%@3=5XF'L?3G`R0R0#ER'\(@B#T"?="=MMQ.'P.P;"C:,4FZ4HC`=@
M1S[*GB,G:XG@7@NV^P=(X]8S03<[,RCM_@_:&P8,;L/PNPD5O!'M9ZNK+2@:
ME,&^1+N@.'VFA1AC`,6KC0:Y\X)8=X2ZG0$Y_`&*!Y7=W.L'FJG4V,;&^FRU
MG]?[+GUOC".I48BDSZJ+#RA3=`^<U,FKV^+D)+_I>41/F>F2(Q#^11\([12^
MP*PRL-UU<(T*EAYP!J*<YI^(FI/VX^K-Z-^53C.;3$FYPA_3&'"FI!>4*?.*
MN>#U\HMIK\NNEC]PN6KNC5A/:3H4T.HF"0+=:C@F)<[QAWK$3!ZDGVVQ0@U5
MNK7VD5_"W/(TE.\L+@&04.^R2EW:7EHO@+2!M!!=.A@N)(!C0BFZXTDC,/I=
M.`>.P@+3%UHUPG1;G5NX33=]6H\N8DN*;:H0Z#<:3OKRS*ZV:4Z8)^`,Q[5G
MO#GW%-!APXE,G_(FV5SY+?WGX3V'H`LGY%`,&W%PD;D](`?!F`PIM$4C2"5@
MJ:@X&TJS%'55N@XTD'`MMSIDCGHP19AS\:-B,2K6GLT,'_(06MYH9NJ9,.*>
M7Z<.:1.%!Q)=E52"0U-U%E@\;NEIRRX;M6-6KYMZY4G;E!W@[%1%D6*;&38"
MEE3H`4$\07N48MOS(U0%FS8K'UW"==BA658!GN5X)N-#NGD6/(?\&:-:(=CQ
M>M#HQQF'7,^)41-F<!/^NYQ*C1B9>Y3FLQADG=</4,A)^H6RQ8.P(-_#(B4Z
MAQ(A/=`:X!V[];^:&JFO>B!?>74U)X7<@'3>GTJKLM+.YU0`GL7WZ^+7,+TH
M1>HTT6KA-IL*4`YB;QUKA84X37LU4'&U9#KRCJEK9^)@Z3P(*I1\0VD&'8)8
M0%<44;7\@=G'-;@#;C'].G4&AO5`:A'EQ;X&XA3)WZ4;O&/35PIM>9RW[?W`
MD$B4\A7*%\/;C[S[8\I#ED.;@J>7[:@0KYI1A2"Z.RN'[ELDSEWU&/E-%KMU
MVF:C2^L[@<UCG9DDJIAK!I2V``TC6Q,>.YYO+Z/AQG#\F.3S+DWCK+VSTT%H
MQHN>]D1%E7$2!33D(!OB.;]$7(4J#$G7F$B]5D=2#\Z@I"+SNEJACVN:DZ?S
M@S)E:I10@I!]C5Z+TA,HI]@[C7K1Z,R]6@:0*/]M)&]UT?IPC,-;;YWA=WR"
M[8N137*W`S=N07<;>49CU,X#UTYN)'D:@,$HW6(R%)&)\0K;XEJ5\PC]GKAW
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M%THXD28S"\/Z@F$0N6JI!-][TGUE87%HPN^W3)_+D_:W1;+-4`B+D!Q_3D&.
MTIXDF5Z<BLH<%ONSO*\ERJ1.KDM#E)BV;BF/F,-:/<H[K1UR\Z9O?D6Z8&IL
M,M]L'Z>TI6I.O7]:GT\]I<;F?G)]!:I2SB0EK7PZUE+*8NJHR'Z^:KMFCB"F
M#C9;]*;6N!B:?A/:"K(V3BK+K`66\VKG53\BHPEE<Z>ESPX%M;&<#CW@V-\G
MUZ@/'@SB)9EB@S+0ZI0>J)C[72N04\S>]+$_:(K"V'S,3/V@+A9SRXT+>YPI
M@Z@:!)DXQH@GD5(DL95J$(_AC:/83!.1@6N#;'\D`"@*"Z>0R&\[9PIG+R+?
M_<C#'KGU%?HXU>UD3$)E:\SXC>G@D8[Q(,<,;#&GL^=MQ,P*EA%J,\Z=CM:E
MMG?HDTU'?NL1!1+TB<WSA^R!>MRDKM75J?,SRPM27H.LPNCEZ,/2FW"BG!=@
M?54[C:\\REE6R&S;)6IFFF0!;'/MG3(;W<(UUU6*>55%]G.1N5[F^95F0'D1
MGG7?P$[523P&HOBWSMF.T@C[M72ITOA&5YC=8!?^!&3ET?7-39I7_#?-%\2-
MC.Z1QL2@,-;5S!G"^=@W-QD]!O(NC+TL>"?%)?9T2X>5_@M5!`>8Q&"$`72-
M@_>P8NS16F1V^@6?J)>J1SY7_7>4*<\+71MM(Q\T7*@UFF&EJ1M,+=$GYG0$
M'#]:8.FP^UH:Q%QQ%V60:">9P*-*4SS,46GV,+)S/F]E_(">>KK$T)Y53,C5
MG#::I4^:_\9(QU.$13;N@#:U#D/-.?`R=IIQM9S[+V-KFM755G%='6,SC#?W
M`MUF'19;%WG<?9S_+6I6ZRI5;*X<`)/[8ES*@\RE_,7H+X];+=36)=5UR(B&
M37AF-F\V'20WQLN:OZ&2\S,K9-$:TIT[,H=]0;DC0Y]PVIO<)I'*6)Y9ZBJR
M)#]_B%U$C&N/'I6YFE,2N<WF&&?ZB\ZA-LYL5^J6DY@:Y)N&9X^K)3D3R&@H
M&]H_NN<E=;]:JD+,Q)$"/?+7$'2_SO%KF$MOOIORBC#V`#/PE9>9%!^"DX\T
MX0CY9K['8RE>LVO3],0+3M(Y2JDT)CEG.\I3<.U!VIP3BN/F^HQDN:$/8TDX
M!]>.48-W2(6@4*QMH",H[]I.R\2-Y;M'F6MHU.+BK5K4XH0)TT+(-`/'(!Q=
M-$4*RN"'H]^Q@SN9<`]RR4(I/RH#NQ@YV/,X&]4(:HK-;5RUG'Q/6\J>&8'U
M4DM38>@Q.J7+M*//]>2<?_]!U?X_R&*2#^;W/$@J]%D%3$\6(XZWQ0ZFS'?*
MB<C3"*LGB=DD&Z_J;6S+A9!6@P(1&:-=RZAWMDZH_H[$+J8FJ]3BR9D!J$]C
M3N6*#&<L*+!+L:\>HI`+_-F<>'9R&;_$2>P24.;?8O=9VUK4]@[240!)[B5X
M07[.J8$,X"PULC,9C@\21[H:7TQJN>0;/>>I^BVB[0X:D89I_^TO%HV^$!I=
M&-Z[G0[+(O?B8?Y-B&S+4&TNE!O/Q9%SN)XEV^?I22?;?UM*%L.5:\%7GIB<
M?7JK=$"[GF\7;ENES@J9$UZ0?U4ZQ`&^UDUT<DVETU;2NNW/!$3P&#66>TDY
MS6\R)7X''<6=.,V[T7^+`5H:9KK-1:BV4>H\\'%>SEVA$2A.8//DO32&ET>-
M&;/%D2KEDP,W&U"DRXPUZB9IOKWVAV=9%<9#G&8N:7T`'D<YR2G3M6_S4&\S
MOORZ!0IV5R`/1TTK("#QX$_C:'5UJH@I=GX#F;C;Q\L;;+Q]HNUCE*T`YBTQ
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M5G`P[&`4S\0YT<X73<TDA7\%N(@K"YA2.%4]MSMZ?LH7PFGJ'C5'J4_2Z!MN
M2(5']^0UFDQH%#,6%5,BBJ9TI]#B=CEAXOV%&3IQ/K9.FG/FIEK0H?7<"X",
M>8S&E;DBPF5(24FK:=5OON_3N>\`)[T94OC'W'N"1C*%PD,7>[[,J?BY7II+
MS(3%\D0[4YI(QL:U$.=-<_@<6N<X6V[TD$U<4\9VD*Y!>BSMG0%#]H)AKO"Z
MT`L4O7:/42FV$,B3'[XEE[]@AKT5LKGG]<?LE^4T:OP#>OQ-#F093#7&HV_/
MUT[R(G?!Q(D$$S3T#`5FXELJ[E*P\N'8M#^^EWZHL\NN3+I$^;IEX95N[I6I
M.;'<A,#9>ZFE'#W]D`=,>ZDMJ\TP4^EIQB+52(V<H?&\U70#6OH+3D)&V&,V
ME5_T".!J8^FX:1#'U*FL7)&;I@)8[<N,3L9N3HZ?)J8PAI>1-K(<MBDGTHJP
MQ1*E0M,3D)2(--*?GF4Q-^/HXNMG=5RHA3"1U!.+#.;!L&XOUO5-V@A`#*$E
M:=R\E6;")\:#F+F5LMK+QXX6X8^G1]#/DO_,E`L=;:8J-#V>0L];4SH(1J5O
M5'UIDQEE@.&UU(@#0>]A.@@J#QYH%'$8F,PW4&W0?0/,R_#3/-=PLJOG#)Q'
M<M<+M]C'XP+3JPJA..,V6M45)OW=QN'3!5?SC/<+([]1$Y/[4.N5Y%.;X_V:
M2V"DQ7?NTED8.O)!!90ZD<DHN63;:OQ.;6Y$[/QLAV0*[\&ERO@DF9JK25\G
M'6L821F8IL*DPE%'G[2TT?BQ\459\I?]M<CC"BOX'H0/OG1UGH:]/D<EZ,=.
M5.'YC&%;4>@^Z*8YWYP?V]#=5A3LYT.7Z*S2D42;K^?B5!6*.3L_R#M`332'
M.B<YEMCGTHEFN41!5<@4Q+O29(2L?>+\^%B=M;0PY-4:,6N.T+4^@YS[J=,X
M:39VX=3,#59'T!5.,F?`+[@=:8%Y!\8B:6UT\#JI=/D!D;S09<4$8N>'EJ-I
MX3,U",C.P)B*U,17RU+ML5D<R9N+BL^?<I2V!M(B#RZ**;-^6P>20;<4@.8\
MP91OFXN$IVF;M[(PTH=`E9O"G&O%M99H1[\QY0214T4[F9V,(@G0^C#3WDO8
M<G"A7,&TM[-%%'I6D4YX,VW`,(4@?:YIW86DF\MP6+)?4QV?]F1R8AHR1J/Q
M*'<"N_5J\J^+2^L=P;E'Z</F?8>84J0S#3`>-73,##ZS)#T7]_<DT*E]6CDD
MJY!&\E$+G\#-.H>F'3846*%AHK-L5P+A$0#,9W\L/_Y<4X"Z&"R4VR^]Q[I:
ML.F&(4'S]RKG5&YUJ>,=;S2VLC[[?&B"M-Q<Z`*VF]K5.8UVU?OH1:%-ODO)
M8%FW`[*NTE"CEBBC&'MR83\3?5ZFY$UWPGP`U>D!XQWPUWR:&GH7?Y@I"OHJ
MBKDD/K6*Q[Q5YP=EENF2`2H`$9=+Y-!<'P6K&2W;:WXB.C9%*S8'?NJ.C%5J
MY5\5':P+2>(8(::S1`WL;0YYWD(?,/(>45I2CE)2MW9*)ZF&HXO'J$[-^V$3
ME^P!8LQC=V-?MCTB#8>RD&5B$@RD;@ZB)_\!4T.?[5(N9>L1T%PHR(J,1[Y)
M]-U)*A=FT4<94[S0D_Z^>NI[^3;"=6%>K1T:3=K(-,2\$8]<+VF\(5\O%!9D
MPG!AX79.(RP\/WHYP/)57P]?'MH)VHO3F_,:36Y8)5YG!J82`[9F>#;@CR*,
M#R%<%7Q/"V$QU<R;&+T4G4)I[N5(5YKAE(!`1X_T),R#2D!>&?B:'Y%-6<DK
M1V%/$I*L(]"LU.IFG_IV/8Q3]_UT0ZF[(A*'R5]`*;,S/;9<R6$2F<QG4\=J
M^VCFK*C<S7>1X\J\M861:H(KBG\*&J@T'K`XW`X7A'(B\E!_<&DA9IYF&!@-
M48_YW@A5"\2QZF9"S(=PU=SHM()G/93EQ*V2TI6RS,V/@!#EL]V+A>S0P@AR
M*W;Q!U,[".J-*6(JW&H-)3#\,Q^.56:P&DP&3X8L[-]__CE1)W>.,WW_.1=)
MN4A37.'#('"_Z(?2Q\^C5'[<I)X:[.4!"P>\A*MS7?,SC\D7Y`I`YM_@8,_]
M</C]K__UG__QY_3EN$WM3X$'T"?CC\^>G-Y)F@U\^"I'?WEW?8DL\Q^M__MV
M^4YX+GP!IL!)XZI_U;[N]"[;I^=79U?M5K?;O.RT3P>G[8O+QJ#W[J]S")@_
MT6\D-'X%<^5K");]2M3;`7'1QP?]W-O0=_6#"#[6_71D`'7,C.#9J]6`-/1T
M9.R'8YUL,<&"=9/,9C,LC\B\"Q,%;%T=;SZ4)UO+V69;R&[+<BO+/O[</86J
MV\9<T2U^SC\TP,9R?EJI&X=3?/"/[,&Q'F8M?=]<\Y=WC7?T64V=H?W\?,)\
M\-QX#'_"GF[1&H].L.^I,U7RO?UC]422.$K_P@`*+B7XR[MF[YV(X.3UA_3B
MGV,W^S-:^@A:S%_>==H_%9Z0>_2RIV4W-C>];^,;]^6^O5GHIO>U]F6AU=[@
M*LHTC`5,2&JM:[B!GNQ4["_0RDV,0C:6_VPF0>6_,M.(D-4]M<P<;UTZ_HB8
M6G\SV=!_IFPH@CI=[.F[QR%E6*R!0W/Z0Y#***S5NPDDES+;Y;!"OX.,RH'6
M<BWK&_D,/VE?X17Y"-%>%V"F/P.>%<,VC,WA>(OW8\\%Z5VN[L?X]A)\N_%^
MO`S;F.&]"`';KX"`3T#RM5%RJ3>2>1VCVE90K<.HQJC&7(U1[:!0;6VNMI'Z
MACT,[RCMZ<0$'8=#*4>C2NEU)52-I`5OC_8`F>NGD_9\>TUJ7WE"58'MG\J"
MSI.XN*XEMCXP"%-+A4:_O75P5.7@\;YGQVK*Q(<W+#29S;QM-G/4.5O,6=\6
M0#*:V1Z(2L>7Q^/9S(:8#3$;>CD;:K7[S(:8#3$;8C;TFFRHU^TQ&RJ%#>U]
M$/#EL/KD*4PF<P))TUN6YOAMXM]L53M"73Y9YK*72Z/.)V!4%1S:MF^$A?X;
MIJNCYJ[(Z6W(/"8V)C868BS$F*Z8KO:!KCC2_TAS!YI`]V*C[1EXU@8\<\,$
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MPXY_XA@I6`/=.<VUG*N;3O?1_![@N2YVR0,:Q4ZE</"V@Q[VPQ,*Q[$^MP_>
M<W%M#E%Q=%4\^^)C\[O`Q2&"-&2*VM_-GM/"KC]HM,\NSOI7K4;_]/)RT.R=
M71L$[37;[?/=(FB)/9Q7(&@**NJ9>9U$@:?&P%*W@*C%5XVR5U';39H_02/#
M<8Z*F18&Z&BF%65S!E4<.0BN$P2=F,AX'+K%6:O95-5$R5'B"]_#4=%'V7RC
MEVYNW4ZSU`"['$@"I>YJU2,`5SF+IKD6Q[9DU';$7Z>K]3(.L1Z1%SB#':H'
MU^>F^!GYIV]<@RF<GETV&J>-7J-Q>7U]>MH^OVRVK=1J#7KMPY-://V0IQ\>
M3L-1GG[X9H^>IQ_R],-JK9:G'VX\_7!1*5Q#OYO3!^]ED,BOV0RGYYN(UXU!
MK]L=7)X.!H/>U5GO].RL:TW$0>=R<&@FHH&9R`&M'/WO9-7<Q,B\D8B#,-3Q
M"8D&MVC]^77Q:YA>A/,EK(]#3X-:N.W_)5-?!O]&T5S"F!%:_!9GB-2%A7B1
M_Y.P.?*.40*HQ%&%,6PXOP[$%0ZT-R/Q:,(7B*DC#VYQ)=K`D9[&$0ZU\JQI
MV8M]#<0IVF4NW0!W$(U3/Q]8Q<C[H>6)E2$D'_'V(^_^&!VI/DA9._2-ENVH
M$*^:T1BOJ#394?94J^W(CIS;>*NR!&2!0IW3T`5.K4/=T:H*_P1JA7.C@1$T
M*N]A'(*B@%0Q'3O1Q!G*A#SVH`'#`[S;!!06;=#@L#C/MY>1Y0/'CUS]W3`!
M56,".%A[ETTK`GI$&!"!P;U)%)"D2M%W88FX"CV3!0>%H9*E,1$N"M0(GFY-
M*/LZ+7IH+A^H[+E)B3B+(W/YV#%QYC5Z+;!Z^&(R1:&&`SN5GF!4RP`2Y;^-
MY"U"K(93ZJ([B0$*?(*5APJGA]#P+GCH7>1,EIF39MXG6@@TRE&Z\\,C<S,-
M];"P[W+IZ#_]5+M#&L5DR1!EML)D72VX51XN8!J/Y@?TZ5&EFD'B<M.'%H=%
M6KUO87G.PN3%PBO3J;)T!B^D^%W1T-8Y0"$42\O?ZGZ^:HR?DZX9^A@",821
M:6QC0&HP5X:$+O@;G";&",PPT9QYF_L>+KUS(MP>A0[22%#^$IK_![>>Q.,H
M3.[`8HEDX`+*D<?&UQ>9*9D9'>L8!FF.1::F&0?.CPRDKRQ3H"O`L/>T-U.X
MN%=-;]FL/>04=M]&MI+"`'MRX),A6&)F5@*OMKFB94+:C!!R`.X1CN,,]6#4
MQ7%_Z1`UN%=Z]RA/-Z>7(H;UYC&L\C)SQ^O_HD7!%Q`%EY;I`[D,$)G0)X2S
M^.XUMF120P]AS7/)<$1BRM&3QJSXT"$U*R$-O@".[#[XT/JI'#4=2/`NPN`>
M4=[<`.0?.''63D\#]I!N70L1O,Z?F4F!IFMD9(02BC`2(X!&FLPL#.L+AD%$
M,[86)?C>D^XK"XM#$WZ_9?I<GK2_+9)MAD*`-EJFY!5DHP87].)45.:PV)]E
M?C67ABG.48CVU:@"?L]C+>G,%I=@:7G3-[\B\MBHL8FB&I%IICXCQ\K4^Z?U
M>?-M:G,_N;X"52EGDA^WG'J!EE(64T=%]O-5VS5S!(&!*`\GQ1KCPOJSM15D
M;9Q4EED+S"*+=`NJ'Y'11$YN$6%QF*=YVL0)G#OT$Z('O!!!J:%X2::VC3#Y
M(0L1%E(@IY@)X,>S'`K7P<!U963,D(7EQH4]SI1!5`V"3!SC3%`B)9P[8V94
M.Z-8/Q>G5%NOZ!\)`$KF?.K%;>=,X>Q%Y.\?@22<-_XR?1QWEV,2*EMCQF],
MBDX:BB+'#&PQI[/G;40W-RP=M1F,>>8U:17Z9-/!CGQO-*,0!9W8/'_('NBC
M=Y4>@E-A`WCKS/*"E-=0"IC6R]&'I3=AY[0;)]:Z\IH4BB<YRPJ9G7:@IJ&W
M!%LWB_IE-KJ%J[W>>W&\E7E5:3';S/4RSZ\T`\J+<*`'G!OITZAL)XG'H1XB
MF2C#A1"3KO4L7W&#L?R9N!F.`0U!5AY=W]RD.2I_TWQ!W-CH_L!%/XLRT[9%
M0AP'[`2X*:/'0-Z%L0XLWL[H.9=I?!^?_"]4$1Q@$H,1=E+7.'@/*Z96605F
MIU_P2;I`U1[Y7/7?4:8\6]E]EVCC6=E,/31<:*ASKB,[4;Q:HD_,Z0@@](LL
M'7:?17M6W!53_)-.2N!16>:7#BXG]H`*%SFI;V7\@)YZNL30GE5,R-6<!I?H
MD^:_,=+Q%&&1#MW5FUJ'H>8<>!D[S;A:SOV7L37-ZFJKN"X]WS+>W`O0U^;=
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M+#T7P84\)TWYH%G;*$'*FK:]7R[HQ^83K3S@@K2H[(!NT(SOO$`O$G3CT'ZA
MRZKHFRW,\.Z_<(3W:6/7\Y%W/C.<!T!S3[LEE,,#W18&NJV9;<4-%1GYRD>^
M2["1T#F:0\`F(2#/&"R_-H/2B%^3L-]0OZQ#:(?5K9V>GFT=(E4Y^\UL<.['
MLO5^+,QI#I[3]&IGO5/F--M4>0Y,LXFDZ\4860]-DCJFIZ*+S=:C6%=TZKO>
M1&-_J@7ZWK4X;];.SDJS[:J"#-N6W"R@F2+>%D6P4?V(Z`DG&`1R<K%/'7"T
MA4K;(*M28?O:]':ZMG/GS:MZ>T1S^RNS#H>X6K7FV?:G'Q\*<;$=A>5:(ZD4
MB#+'%R.YI/O4V]0)&_W2W!%5.6JVDJHC<?:.(OJ]!M,#VTAKBY65[1QL?CT5
ML+`R]Q@0S[KE3=TZ=%5NC^AN?Z76X9!6J];IL!."[:3UJWO#F>-C;C=K@W!?
MIUW:F+2J'#!;1]61,_M'#XW2G&Z'0@]L':V&[8>TG,[6$K,E]#A]M4KS/AR\
MLK9'-+:_$NIP2"LW)X))C.VA=4%HL^RRYOBFC1\;2.1?Z+"[G`TD-I#L?:=,
M#VP@/<=`BF4$<L7V6V`5[E'KB#W9;!Q52#H=#F5UN29IAS918]_%UO.Z!)6&
M6EL95[\/D[YW-Y7^E2"VA<S&5NVL55Y:R9/CY_<!C=BRW;KNP`R,&5A)#*Q;
MZ_7*:TK!#*RHN_U,C?*67K_D[ZSSY/J])%>TH+R:3/UP)J7I#7TS=B)YCLU*
M\^5V`Q^>0']]'GU->WI^H=Z?%]C<YCD=*SN#QF6O?S8X:_5[EYW^U?G9I1X\
M?MHZNVY>-O9V\#C=]ZW0=U*W/U3)!#MYVXZLV$86<"70@^54#&`[T?UAA_D2
M1Z/-VG:K.$)9CPK'+I=(#U3\B/-&Y<0^#!\0R3%<APUP?1QP8QM,ZUD`-';`
M^V%G`L@`1T4MX.LF&]_B\$A:-?:FJN4&@_BS[73UW*?VSMS5LXRNGLW>"]MZ
M=KJ[[GJY-^TY>8.\P6V^<$]2`BIG&*;+/7V%WIB5ZH3YC?2B3UH?NB)]"%49
M`1H,.R(8WTK'MQO0OE^$;<SR#J(=\/H>CM?&V.JUI2[-.\1(>D!(6EHZ!C-+
MQD-FEHRDAXRDW.>_C.IDJ:03#<=ZK#:.6`QIC/5K,H"5H-^+D%HEVG/O1T3V
M;/M=2O8"9?`^SDVM8'X)<R_F7JOS2<IK]+??.,/LB]E715"1V=?Z[.MT^YT1
M]@)GF'TQ^ZH(*C+[6AM4[0YK7V6G\%8Y&+M-$-Y(WX>5U<2=#&3D^#7RACGN
MQ`L\%4<.)FMNXM1]LMSQ=3,%ME#UV"U/IW@"-E7!G6UK#ZPDO&%Z:M9:O=)B
M<4Q13%%,4;5FH\44Q13%%%56P[+::7]+596'2U&<DO!(_6$8.[Y8552X'4PK
MJW1\KST)NZLI/WSW5*^SPU89>XUUVU9.*L0U*Z>U,(=D#OEZEEBGNR5+C'DD
M\TCFD<PC#X!'MDZ91S*/9![)/))YY(I$D%JSW7M]>.X%WI7HMGQYN[>2^[:M
MZ`YW[7C1OQP_D0.E9*P&0;Z_W"?IJ"22[N<`GIU$$1``K,";ZSNW1D>XB^OK
M1N.B.6AT!YUV\[+7NFYUJ2-<KW=U?7%]M=N.<+WIUCO"*3&-I,*^Q%XPPF9;
MU/#-N0V36(1)A..;`=J41Y-K7"PF!N#"B<4(3D;<X]$(O%5$]@C$+9[!$UWC
M;AV?AD.KL<07E=5([>5@.UM#DNY=6[-*]BS;>4.HUKYTKN(-\@:W^<*]SQDM
MLQZ=WN*";A*1$'P/NJ&,D&OK-UQ*-8R\Z3-CEQ5K#%"IVO\U^[1R,LNFYCPC
MWVKD^T<2@OJ9@?5+!+:+RCY_"'(@?_RO-774G6YO0)V)Q2<G^BZ?F,CX6DL\
M^HAM*D3SF"F>*7XG[0[O`F\$H`!`IK#]C+-Y*DD>GV^5C.[).9-C2M.DVM3<
M8FIF:MX%OOTS")<02"5)H_I4VUZ;:I]G,4Z`D'Q9I9#;5H>_D:_T<9_EI@2^
M0PCN`V>L#+`.5Z0PQC'&,<8QQC'&O0V,VTBS.RP%[L)18R'_2+Q[Q\<Y9J]I
MRE8%)J6E.&UOS^7G(G5:M;-F:84_53E*O(_+AU]/9C,;8#90@:-D-L!L@-G`
MLU&@WVJV2L.!JIPG\P+F!<P+F!>4P0NV&1KJ[[MK03=#,=GT6?9\X&*Z/$9O
MYU+I2_,3<M$6%VWMBX7$55LO`Q_'!)A),I-D)KG/B,=,DIGDON`J,\E*&];,
M*9E3,J>L!*XRIV1.N;^<DE.C?LDU6]E*@OM;S+CCX!GC#^,/XP_C3V7AP_A3
MMEI4(:MRF_K2;TX4.4&LQ#2,91![CN_/A))Q##HH*M9>((:.&K\FJ:X\B:K`
ML!)35"MC]C7[M=.SSM9!4I7#9^_6`6D%E<<V9C7;]C!5'0.8WS"_87[#J@VS
M&F8US&H.EM6P:L/AKPU`>`'?P<JP3_XTB89C1TDQQ8ZAU,S><V7TW*&FZ5[>
MW*#A7JW/@X:YT(Y'=U=:J#%=,5TQ73%=,5TQ7;$&6`&*XO+J)\NKET\H.[`:
MZZJ`?#]2NBOC>&IU:[U^!8H`JX(^VU8PV`G.W(RYV=Y:1LS2F*4Q2V.6MK=)
M",S-F)LQ-V-N=G@NMK?(S'+.MY]I-OO2ZW-_Y_:UA=GT+]S8)HO+W5/@+SSJ
MGD?='_Z@=-[@OF^01]WSJ/O7F[-Y*8=R<BNCS!IH-VG<?6D&)UM-C(`\[I['
MW3/%,\73<WC<_0ZHF<?=,S7O!-]XW'V)5,OC[LN@<1YW7Y%X4'70K7*`8XQC
MC&.,VPO`5098C'%O`>.XJ'UKX^ZW7J]T>&DHJX&T#\DFS;-:Y_1T5Y"I"BK@
M?5PB^7HZ`;.1/9N=6RZ;J,I1,ANH4CHL:QL'KVUP5P;F-<QKF-<PKZDTK^%^
M%4_VJW`H@L:M*O:4M1UJ[=`VW3EOL7B(@QL[4<=XT.K>L+K]&+1:%3ZX%XC'
M3)*99(5D]G[PP<JP.N[GPRR-65JUT9%9&K.TUV9IG#7UR\>LR>Q6<M_?8C(>
MQZ48?QA_&'\8?RH+'\:?LM6B"IE_V]27?G.BR`EB):9A+(/8<WQ_)I2,8]!!
M47?V`C%TU/@U2;7R:CO/<,S?UZVU2^RD7_6S9R_4`2D%E<<VYC3;]B%5'0.8
MWS"_87[#F@US&N8TS&D.E=.P9L/!KPU`>`'?P<HDW#E-HN'845),L94HK"E0
MGBMU0^%-_(IO<`IJK]LLC?C>2%4)>^J9HKA:B^F*Z8KIBNF*Z6JOZ8HU0*XK
M+A>XNJ[8SU(4N;AX?_Q*;R(MN]FJ-=H\9I6=X!70/)B;,3>KN&7$+(U9&K,T
M9FG[FH/`S(R9&3,S9F:'YV%[B\PLYWO[F>:V+[U^R=]__CE1)W>.,WU_,QQ+
M-_'EY]&UXT7_0O^3'B0U"-Q<:>TGX[;Z''R5PR2*`,'.'>6I;_C6;P"B<S\<
M?O_K?_WG?_QY\<DTY?#7,`BGE(\0W'T(AN%$7OV8RD#)XB,P<0%!_E6._O+N
M^K+5:';_T?J_;Y?OA.?"%\XP/FE=-UJ-T[-.L]=J-<_[W>O!Q>5EIWTZ.&U?
M#"ZN3]_]=>X(\\?QQ)3Z91B`@YA/QGIV6;/5^*DL%*"/BX,7$5A"0T@<&1@]
M/B!M!VO='%T?6QS1EA>`<(O?][K`J,I<K0:D9P`I#2"%IX1*)A,G@JM=X2@Q
M"GT0LDH<>8&(QV&BG,!5QX_7DJ\'\;/-MG#V3"&]R?'G[BG(Y08<0OY4\'/^
MH4$831R_('.:>$WZ8&)#8BA]WUSSEW>-=_09>.S0?GX^8=*0>?@3]F3X/K!M
MWYDJ^=[^\<L\J\X6E0],9.R^MS3:M$9LPTR\[[2?-?(^N[&YZ7T;W[@O]^W-
M0C>]K[4O"ZWV!I\7=7RUX/YJY?$%LU1+".V?5CNTO_W)L]_&D93B$_PV5N(J
MP!CLWY-`BG:C5I9YP@X#QK?<]/<?+\,V9G@\PKQ<E$33FGE=^;R.46T9JI66
M8L*HQJC&7(U1K1*HMC97VTA]JU`L<JM%C&,GN*/&4UD.K`A'(AY3&>.*`D>;
M5#M[36JO?(2)JZSS]W$SA^?P_GWA3943FLQFWC:;.>J<-78&D(QFM@>BTO'E
M\7@VLR%F0\R&7LZ&6NT^LR%F0\R&F`V])AOJ=7O,ADIA0WL?!'PYK#YY"I/)
MG$"&B1+ATAR_3?R;;Z[9`3<1X28BW$1D"^)N9QU$WH;,8V)C8F,AQD*,Z8KI
M:A_HBB/]3[7#>K'1]@P\VW8=LGD;U4%5%J7WHTAY&Z"L=`K!QL#<"Z3;MGY2
M(999.<6E0@RR*NBX'SRP,FSNJ'-6@3X-[.%@3K<WG&XOI/)^L,']4`5+S:_8
M+8_<"UQE!LH,M')(R0RTHIDAS$!+R2MY>1^QYW3[6M$P[*L<AG<!-FCZ@%V(
MO)$G7=.5;/A'XD7PJ="=#'Y+)M)]=B>Q3O?\O-?N7EPW.LU^Z_3LHGO5I4YB
MO6Z[U;RZW'HGL4(#K-ZTW`98W\;2-+>"0Q"Z,5/:^DI1>=5C0^-H0H$#MP_U
MQW`T=WD9+;*JVI1L10WAGC?1@J._\P*]2">)0_N%9GWTC>ZSU>O4VV>-5B?]
M3WE=M[HO;+IUVMV33D@M[H2TMXHOP^>0*K]?T(>1/BUVCZ(X)NDBRB/A>.G$
M4F`'5?&OYXSPX6#Q,SJC?GE$67E<%V%?P8Y9P@Z!6'G`E2"@]WX.VH6CQF1/
M#/$/"7SSWO&!32L6V-55:*J"/*6YW/8I`-NN=<MSCE7E)#>RU7>D+NT_CPTG
M$]!$51P.O[,V5*7LX#*!^*IIP:U:I]_:.FY5A:!>A5L=&%/*.>F%H[WTI9EJ
MS(/6M\C8\"I5XG4Z^TZ8%V':6*_@2&'-@36';6@.G>UWQ*H*:;V^WG``["F2
MKA>+B9R$.*$I$O+'U,.I8V(X=H)`^L(+[H%YA=&K]O]\LXSIT`H>F[6SL]+Z
M1G.IXXME6J^Q[QQ,QPA9MZJ2%YSS63F?=9NUH;76*9>'5ECVO#Y_-!F`K4;)
MN9[5B!@>,*PJ[FFK#JPXI>D9*4V4U"X<D]3.24Q5(F1.8N)85N&^_Y=,?1G\
M6]#*.'.IPGI(53#F368N]6O-1FF](ZIRDA5VE>T_8_U;&+H/GN^S^E,E%__!
MQ!Z;IYRSM#L];_\]]]>%*80.U1VG-AJK??OLJM\'S^CN//+L>-_,\;X/6%2B
M('AY2XA2^CFLZ!5Q,W8B>>XHZ5Z$$VPQ0:'6&\R"_SS%/^$=L7?OQ;-GMX?H
M-:ZOV]>MWF6CW[QJM?MGO7/='N*T==8_N[K:;7N(;LFNW2?:0X13W03"`"\;
MR#L!A)YMWOMAJWO:".LWZ52Q=ZT?=%^'L[-ZH]5M=YK-=J/7Z+3.RNOKT&R^
ML+%#M[UIOX3.GG2$V/B^C2&S+_?M9H-[&C-^=47]5=,"GQ\Y>:P51'\S`/8?
M;P6QKGC9Z<I^32:W,@*Y7<G5D=JF1"77=O0A$-_&8:*<P%4\J.@U8J]OCY'\
M1E\\X6!ZK<4-X)B<N\?;VKS6VJY^R&CHJ6HN[@NVJF$.PAQD%T1Z=Q?).R>N
M)B5\".+("Y0WK.3JGN[:M5_*R/-,'<#Y*@5-M^D7_9S$*@90HL_+B<7?G2!Q
MHEG&BYHU@:[`LEAVJ5#=%V=\]VS[Q9YOP@G/B0X52BK;;U0L+ZIX\&4\[7IK
M^_Q_+Y"&^1?SKXJ@(O.O]16P%JM?KY`,AT;4H27F1D[PE$NRFJG\VVC(V2NO
M]UU5#GC;`I[E^/K!T_W+JZZ7EW3'!,$$L?<$T3]C<GBI!O56:IYLU+(TY6I[
M]3JO.B*PO"G4/&2:73%<,[<FG!KU_O9]H%4A(G9S,FWMTFYBPF('W'H`O'`"
M+/TH44O<=N/65U46^[WR/-]K`NIM:XTLP`[8G=&J=_KLT&""8(*PBAL/9-N5
M?V_?%;?Y--,DD!DQM1LE)YF^N/7R7JI[S6:MTRS/F-H8B%7!.79CO(5LK:I@
M6R42LBK#BUIU'HS(C(89#3.:K><8,)_9GG5R8$:([G\EI,XUH,Y"KV^,[+7-
MT:LU>Z5E^3P)JJH@$GO-]D^N5P5WWF0/]':]PRW0F0DP$WC+3."TP_G`JS7R
MEW>5W;3SZY.-9+\XLXD,XL&#$[GYQV&3$'H']:?5WSV[J>S9>:/?N.Z=M[KG
MEZ>#]NG9V<65;2H+&'.^VZ:RO6GY365-BUB1*%@K]HP]]\'2/`%(AW[:6/9D
M&GG8SE1,0E?ZP@E<NC1K2/M@^F&=.+KW%#9BMT`7<2A<&<MH`IO3]Q5[MON^
M\&(%B\<S"<U-=[J:;?/6M=F&SS:#T]DSI<-ZBUEY]`6)4?'.M,U&H\1>M*T7
M]J+M=#=M2-K:EY:KO-#]7"@WL7UA6DJWVK/M=]"R=AQ)*3[!;V,EKD`:N.02
M%.U&C6TYQK?R6_UZ/UZ&;<SR#J)O]_H]0UX;8\N,AS`>5@T/JX9J'4:U0T4U
M9GF[@!TCZ=M!TK69):>FKT#9KY[Z+D9H`GIX7E+%(GJJ:3AW/'Z\$5*).2&E
MMJG8BS9]/U42]0Y,,6*:70;$?JO9VAT4F729="M-NI6ASF:]N_T>MAN1)5,>
M4]XA4UZKWBBMROF-4]Y;+S_X5^@[,4[TGKVF8ZDRE'7:KK=+J]UY&Q3$#N\W
M3"];L-"8:IAJ#IQJ3COU\L9_,+TPO1PZO?3KW=*F&+P->N'(VLJ>[E,YC*4K
M?.]>*G$TDTY4WOSXP_0W=.NGV_<W5`5!\#YNG%)!$7:8M+5]%SH3%A/6&R2L
M7KVQ_80/IBVFK3=)6SN8OGPHM/760TRIQ07O\X!B73'SI,\#2TG[JS?8$<B.
M0'8$,KDPN3"Y,+DPN3"Y,+GL"[ELJ578YKV]EK8-4Y]'%V&`E6\1W?UYA.55
MYS/\+[;["J/G]`8;7#7ZK<NKUD6WT^MTKWMG5WW3&ZQ[?7E]W=SOWF`W#K;_
MBL.Y1E_#1`&2RDB)2$XCJ;"*T!4+:++)&YN-173;Y#DBC,0DC*BW6"!C6.B]
M#!(IW"3R](`7,.!57,ZBPV"Q%F^S18\(TE.X(G25``H0&7P=98Y`E=$/[94\
M(4^B\HK"U#WOF#9QHCLOT(MTDCBT7VB!0-]LHZE:^Z5-U1J[[LC5WI?68;S0
M_5PH=R:JB*)_8/#AYF$[;%;W"EV'&!_W%1]?IYE=]5#T,:"_H#OR<J!?&!.1
M)4SY%,T]B+A1%B/IX2%I:5T%JP9;1N*W@\3,:1E)*X^D6VI)N)OTV+UH,V7U
M?S$H3:CM"50KQRAV!]7]Z".W@V3EC>+]>T'7W,2**7;G%-ON,\4>/,6R`'XK
MY-SBULN'3\Y,L0=$L1U6F7=`L7N2FK(3M\%YM=R(A\O-]CI'OU6:8?`V,O29
M6-XPL90>F6%:85HY4%IIE=;AC(F%B>7`B:7)=9+;M_,JY*[9B0%X44EWS5OB
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M0:YH^59\;>XI!?;'PSX*;0!/7SCKXY1G?;SN0O<DTV6_-"F&S_J-0K<`J\<U
MJ.WW^K2M_D7U.M,>#$ZEVZA&(]I7Q[E+T`$GMS(2[2;AW9:;S?*<B3+G3%0/
MG)6F_:K!\K5I_^B?@9.X'MAQQRQMRL&X*B8&[$7?,6[!70T$YGZ"6\RZY7Z"
M%4&\0Q(Y3+&+Y=L5;9MP6!2[)RY`[@!Z2-QLKV/*7)+`)0E,+.L2"]/*UJ5Q
MA91J[M/V)EC282:+M2LZ<J`J!,A>`*:[2G<)?^-DQZ8\]ZUAZ^19Z>%LGK`I
MS\2RIGK,M,*F/'<7.#"6=)@F19/+G-F49[K;8X7ZC=-=^?66:Q6^;40;_O;J
M].@`MEIE^"$0B"ZQ%P8B#@$U`@11Y.`72GB!"),HK<L4MXZ2M?F+'%^%0O[P
M5"P>O'@L(JFF<ACCX[#VTO7@8Z``(\5T[$039^A)A3\^C+WAN/!\)93T?3&X
M5?!PORZNPP@>#+S'EV(!G)OLMG.ZB(&;/$<X@5O.BKIEK2@<$2BQJG48>5,Z
MFAH6PSZ,0U\JQX?C<X9_))[2AST,55P3#S)*3TBZXG9&#P%.4L[N%FVFC?:6
MPYL1H`1B53R.I!03N'HLIG!GZ"HA`^1[HE"!1">%)2$UBY?>O?1G=3$P6._X
M_JQ6TEFV*H==9XQ=FV"7\GYHW%(;(=?C4L[\_>>?$W5RYSC3]S?#L703`./G
MT46>M7X>??74]_,9_O?:&<9A]`U$P;D?#K__];_^\S_^G-X/&Y#GP)K=BW""
ML-9WTRD-`O<#/1)6]L5W`O4E]+WA#'DXRI6O<O27=]>7N)E_M/[OV^4[X;GP
M!;SL9'#6/.OV>]?M7N?\LM$XO^HUSR\[[=-!K].[NKP^>_?7.4&6!_@3]=K+
M](['J^N[Y<D]_1$O?^_%(&>'^DD$Q1.4<*[(P[$<)-,:=+_5;/TBL.G!$-[@
M!#/3_$`1UDVC\!X("&6JZ5MP/;@Y%X.;"_$MG'I#<=KLU](GM98HX^5`HK#[
M3///[>`F!AP4B]?!JIHO7I4&V%%NGP@!V'ON'<<UHSY$$IA.)#4`)])1220G
M@#%$FI$<AG>!YD@`T6%NO:!7$%<BD@<9`.N#+9GCGSHS_8P')P+2GSBN1(5%
M@B(2SJ0$S@=JWHG]"!P.7@34B1PQP&JM0"5^[`0Q?.$%0S\ASD$O$.'4*$UP
M(3P]PJOJ!IY+UZ=7A-H9;/`.KZ?^%6+D>)&X=_Q$"JEB;^)@JPS0U[`Q1N12
MMPO2QA81"Z"9G2J`57C*0NK?\`P'%Y>^'JU*>@8!&K@[,$<9W7OP>,T9'V=V
MKT'?6]3*M[5:5'17XX<^=GTTB%R>*[6`(.0UQX%G"*N+M)S-XR=@89SC..E1
MJ^4(MP*'#*$A71`6S;&F;J-[TFTL4*W^NDBXN4M>K`>LX&!7L-9X)D@FBB^:
MFLGF^!7@(JXL8$KA5/7<[NCY*5_09YD_2GV2R*Q`=7)#.*98W`/Y"F\RD:X'
M-.S/1#*%FS2E@T2B\XK<U82)]Y-QI<E1#&+Z&I`!CTDZP"1'7@"'Z3D^]M4)
MH]SEP!H\U'E"^QB-*YJO:"&DY%*DK!$V.OXP\8GU)&3AX<WGO@.<%)0:U`S-
MO2?P'NSO`EJ5*_V:9CDGAE_G;\ZQ-2,##=ZFXN?T%T)<4,\,R>"J\$+$^:&C
MQD6TSG$V-XGL:\SN81F.^SM8GPA>0GJX`*V#&P^1/UW0Q(F^RSA;UZ-4&H=%
M\L.WJ.3V=V,3#\=.<$=D1H]/8H"`AKHSP99&=M_ZE^4T^N"!Q-*BI0"R#*8:
MX^%QGJ\UVB)WB?#Y8/G0L<LGF/@2C?7Y&F=18\75`'X`OU*:5G\-8WGIJ:$?
MXNI3/7<-/;77N[YN79P!.^GV&]?=\^[UU9764P?MYL5U8^MZ:IEJZ4)Y<QY2
M.1(0&FK5E&9[(WM72(\OD1S)"/D207^[!L`8V7H2C\.(>%0R11[QTE<:E[$I
MRB+PN2A&B$S?XXD8_T`-?L?_E;+'3*M4R!](39BFL"0.]')/R[I;^U.C#A<L
M^N-?MK&I8UDM2!!!VZR1%N8IE:#"5*?#G=NUYM=CYQ[X<()&"Z(V2%!]F83;
MZ(-W[_GR3BICNZ@89*;QM&1FQ'U(XML^`L@&U$&\WGP!#!,T`T6BSWP%ZP!A
M1`)D[B6^!VS$=<Q/N<4`4L+F8-&W8-[(6$83H$G2+%>)Y/,0;"4\\4MK#6E%
MQHM5'C@A62]%C11)`#4AO`P%,7R5`R"A$EL96^%T%UJ/.G0VUSK=/J/+JZ2'
MS^4JA^`'08Z_@E%'?:S0IRR^)!'8"J#M#^XBJ9U:9(U_!&$0^@'8M=%W<>%,
M\0DU\?'CA3@IQZ_^.1#I2M#CJ#W<>8Y-453R-P$5.V)J5^JLN]*CCU\NCFMX
M(R)4G(4#Y^4"N1[P0/`2B@["OW!S21Q$$U&W(>`BOS1G+]AV&6/([>B_U1R;
MR)N%,HH=N-'W)@"FS+P$>:X#52HS^<N)GBP.K=QHLSH&ARJ"W>TB.M01F=.3
M7GY-C8[50W<MQN32*TH*A;7JW7(/>9T3Q@A9.2C:JI<DNS*6GCI.++T9_:N4
MU_3:S5IK23K,"T%=`*[A!*A9T`]>3*QG)*6-#CPXJN@_H\`D/4ASH[H8X+?P
M],0WGA=/621,Q=V"`U5Z]\3]]&6!C-'%/I32I466<^*=^EFI"`M*_0BH%-1Y
M-QF2#4$P4RIE-2'L,H(-@.:-/QMGDZJ+N201`'I!];=P2&G:1(L+AY6@<WHE
MZ>=<<R,O@B/Z(W&BF%9#D5:,)6>`WQ;`.^5RB%$43A:`!2Q?R3\21%0+"-VV
MW#0V+VL[K?KIMOC=_-G6`%6L>6H()4>+UH);W-9K:V$'H3,.8O%)>Z<_&&XE
M;AQTO*=:HRH'H4X$Z(6?G)EH=4@E;--97RS3"-=9T]'@VZ=CK29^^O@O;3?B
M_^")=5(1D2-]<GYX$_&W*`1MC]1&?.7@#A]P7!?72%^Q-Z'@+/V;8R-YA01>
M10QDXA@A1P_7VN08'GZG]4[]X-JCF&YEIKX64RE]5.`<PG2@:\<O32UMEY>[
MHV/'H5(9VR3F1)$!.!F\1N^Z9A1KRXY('2V/Q[;*U[2+^]+^-SAPBNW<.YY/
M(P>,UFE%N(Z+>.AR$MJY13$LX]XR9VMR@<P]=7'Y+!E5EMK7+AU@!>FY@`:E
MO*99MBA=39)%"O[VB1``E%O*/0M"VM?R&S.-!-$ESSJRW$+*^X+3+*9]`68L
M7$X<)4L;6[RML[G3A.5=)N]`L(!B3\?P3SS`![@UE@$8F+=PC?ALM-=RT,[(
M/'RC<81T"WP$PY7DL=;(9-<RU6M)->G2=+I.K=WMU\Y.%YMY;K2])$#OO(/B
M"^/S,C/.S?I+XF+->K<D9P,:K[AJ\D;.2;32EMONE\N\2&MYET-<BZ3O0(FY
MP@0-VA*E]BB=78.SB[21ON!:1D;CI`DE<&*I/57*:AOU;DF.!C)JEFZ"4`ZS
M&60T])0TR%>>DE%O+/:HVQC=:`=:K5ARA#8+@Y@`.NA.'-\/M?%C\G]L4G'*
M(K#0(7]N3F9>@\95CNY8ZW7;M7ZG)+);X8`!5/P9-I=FP.0W5:)_MEGKMWJU
MLU9)^=[+-U-?9/6UQ6.S*$M&@!>M./$\')8"!T_\#FRA.\SD+$WIVAF8!D"P
MOF@V2@33'F$]90QG]+H=9U2W9`U:,S!MT\VO.%[.VO)9!Y11:-FUN>7I0\6K
MLGQ!TLA+<M4UZN7*Z$7G:(K/^,'UE!DWJ$,R<W[3>8\I)I"3V5G,EWB;+K"R
M*Q9O5E.E29FT;GN3/HL)TL")B&Q56G!Q1`F88:+@!-7Q6YD!N>HEN7L*!=B5
MG?BXA7&.[1>.<^QW-AU:V.5IA^O4G[]@=M!<@LNC],.SEQ;A1Y\6DI,'Q(;1
MR96!]KFC_[A/T&KV_YNU'<(D5K%#%:C/0-W=@7`_)FJT6K7V$L]`V0#<BP$9
M&VD6AR1,2E!$"R4U6R#1O6Z%TVS6.N6UH:K*F;\*V;P1:??94%+!8ILWZ;*@
MW<62(H16HW$JTNHS@>5GE927U:'21JW16W27E0VCJJ`82[VRW"]K$JDMM38=
M#M*4]C(I<Z\)L+<DELLRDF7D"MA^(P?^8\17&B\ON#/:8,BX88*^/&O)O$$#
MLM.I=;IGKP_AMV9AKM<"<DF;@G7;#!2;$Z09VE?WF`CXG&8$_=[@<M#LM3N-
M?N/LO'O9;PPNJ1G!:>^\V^YW][P909:[KD'SZ%D>:#RK[-7FJV0E5EU2*BK6
M7LO[-`\U<@+EZ&)PW3PF'`X3JH_6<<N%K6VRDC4=N9L\FM)!<HF:U,)*-Y?)
MFM.H&+[5V>$4*];U2'7QF>I28-L!!O!<3;ZP=>DK^4#)GJ:92@#4K;)<7SPP
MO`X3JY!%$F"7O:Y8W^,",\5R=*K7QR^PMU:DN^?H7C(4TPHQ$ZWP3:ZT0Q_=
ML]NJK.(\!?[T+7)<.0A<`LM@J`/37RGO&)>Q=H.__OG9%?"JP67CNML\OS[O
MG%_W3(._;O>RUS^T!G\65"*#E3@I![OS-#QQO``K.948`GUZL4ZA5VFCN:S9
MK6[M1ET2%"!,!!@V<DPCN2SUXC:)"1WI,;J]4(;#:76HSC\&.>GY(.9J:0N[
ML0=OB_`+S.E48R0'O2S="DIG,"0ZJR/]Q3:"J(M/3N#<Z9+>J8Q@#Q.\P_%G
MRB-*LQR+VB<1=*,4NOJ"`"5MK@IO8B\;4>5$UKP.TU(B">>EJ8D*T.MB$"#4
MP@<R+!&&J"3%H\3/W@@KD;AUL[]"Q[R+M"[S%OMLV;?9'):LY=(T"F]UK-J<
M6J@PD\.;?\R2?5(180F9/^L6_6^33R,V7,+.J/B[W=29ZQI43YP"UEJ6LH8_
MP:Y*:]7P7!:\%G,ML.-_*OEY=&7P2JW!=Z_..Y?MJW8/6&[WHG7>OVQ>7UB^
M.[ALM@Z-[_[35#AF,`*B^@+LQS%=#+&;8,K1;E*I7`Y"SS<DF19?K'60)S6$
M95T1#>93,[T(^+4W199W)P/DY/X,?Y=3TY43">B?`?%OVJ!NQ`E2`,S"K(?I
M)&.VP#DGSO>LMZ?FTPYH1)-I3@UT1B/J'T`-&I&?YS@LYE\##XMMJQ\M&SSS
M*#>U@G0J%6V$FIZNN"?.%#?;H6X9H&R!W++E1*@6F>J[-%<N5TDSWYT0&.LP
M3K3#(_&IW"[Q<>F8<)>J90!J4\4$6F$&L.=2?I&.B<2!<KZ_'X5AC(KE1_@@
M?M!748@H.([CZ?N??WYX>*C_N(W\>AC=_=QJ--H_X\\_XX7OS/7Q;`K7`]51
M5=`[>O;/"P^'K__\,S[)>X__A8__?U!+`P04````"`!'AP9'?D:_)]47``"5
MYP``%0`<`&=A;&4M,C`Q-3`V,S!?8V%L+GAM;%54"0`#9LK#56;*PU5U>`L`
M`00E#@``!#D!``#<75MOY#:R?C_`^0\^L\^,2?&J(-F%X_$$!B898R;9+/9%
MX*5H"VFWO))Z+OOK3['=]MB>=K=:+<EV`DQL=[.HJJ^*9%6Q2/WPC\^7LX./
M4#=E-?_Q%?N.OCJ`N:]".3__\=7O'\C1A^/3TU?_^/O__L\/_T?(OWYZ__;@
M=>47ES!O#XYKL"V$@T]E>W'P1X#FSX-85Y<'?U3UG^5'2\B*ZN#ZMUDY_]/9
M!@X^-^7WC;^`2_NV\K9=/OFB;:^^/SS\].G3=Y]=/?NNJL\/,TKYX2W5HRW2
M7^2F&4D?$981SK[[W(17!RC?O.G0_ZKE]Y_3!_?:?^++UBS/\\/EM[=-FW)=
M0^R6'?[KE[<?EB*2<MZT=N[A%6)P</!#7<W@/<2#]//W]Z?W.CBW,YA;5U97
M%[:^M-_YZO(PM3L\\KY>0#CY?`7S!IJC>7C77D!]O*AK5,3;$FEF95M"@ZPE
M#K^_J"'^^"KUAX`P216G"8Z_[=Q1^^4*?GS5E)=7,X3H<`H97D-KR]EPHCSH
M[PDD^LVZV8"ZN=_=</+\M&C*.33IR3_9IFS>Q;,:&GSV<HQN8[\;]53<'H50
MII]V=CJ/%1*F/ZXM83]!.G0\E8QGU:ST'0;];KT,S_UQ=>G*^?)AG7E=1S,N
M9QVGG0ZDX_+9;3+93CD<E\?5/*0I*^`O#5I32%[!3W:65KT/%P#M5FZ[]S`E
MUV<V3;P7T);>;ITU>G8WLCP?<(Q#<M;>Q0]MY?^\J&8!G;V3_RS*]LON%+U`
M&(F'J9##Z?+8-A=O9M6G?G:\L:<II:@NKVJXP#;E1WA;-0-(\UB/PTEU$VS@
MVG4R;U']=U;=;?QWH1V.TS>VK/]I9POX!6RSJ*\QVL;B1J*1>4.MMACFX:]G
MB]I?8`QT5I<>DK)+'&Y+F%;MPU%[TK3E93*`V[[>S=^#1^<4^UBZ%=V\JR=@
M960<\='5W*-OOF3S77P+'V'&OPE`>@&S8]\C2]K-]>A`.AR?;P&_.JLK#Y!R
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MVMOH*UVO[L>4=P>[WT`W((<+U\!_%N@GG'SLDB)YK/UP'/UAZ^4LNXV3A^V&
MY^#XPL[/H3F=?\T`Q]5W-[G1CI-P_QZ'E^K;1^."=IOL_KU)V>V9]7]^\&B`
MT%PO$BE1CE_\4@68[2;RP(\;'H]40!46LZ_\[;:^[MC-\/QWFU'6MQZ>FUM+
MG]FFP:`$PM%J!NOH=N[<T5H9O)WYQ6RYEKW%1JNFB=.12N&NN8#/+<P#A.GY
M6`O*+3M+9I`=]-WOP;]B85FK&&WCEI6%BX:<6WMUB&H1AS!KFYM/DJ($H6Q5
M]?BWU<?%BLD[W*SXN^%F9AW,?GR%3R^VTA0L&"YXEI'<"$\X0$:LL)1DP>?4
M4:JUXO?%7$8D57T#^AHYOS6S]$F1-B%JZ]OD%]C:7YS9+VEXK&%[4_/"<PH9
M%X+@/TV\=(8HPR7ARD+DAJM,PC:.[QC*4>T/JAJ7_A]?L5<'GZ`\OVB7OU[W
M@$_^QG[N%YNN6AQB_'+MSI&RA<L;^E0\.XHNJE&@0NK=%7OMW?U2XE375G/`
MIU^N-\<-K0MNLL@$<IAI+4B4(9"02;/BU5H%L:=:LY>JUL&0ZJ75ZPS6+W!9
M-4<>EX)F&;@DGVH.&+TD?[2JOSP^]^S>2>$5U1$B)4IH2A@#02P7.<E0(]0R
M,(QF_6R`OU0;&!O`7J9QAF"D&AQT%:[KX,_JZKRVEUN,80M9H5QT.N:4Y)9E
M).0!3=SE?&78(6/*])P"Q$M5__"0;5;X,"[*"7J'U1=`OW:6PHZ=7)6MM$50
MN9?>2Q(]&CEG%I>VS#&29P(<5]QIZ?J9B7R!9C(F;E/8R@H-M.L(3;-,C;V!
M'7S:1PB+S'B5*:])3C-.@--(,A"&T"A"8$R&G/5<2]0+MI+!09O01-Y77^QL
MIWCG(45A>.Z418?)."N)`9<3E3-&*`#D4CFEO.EG%/KE&\4`:$UA#:?S%FKT
MB%=!SG9C6$]0.*=U%E6&'K15Q%FG"62>$2,B9R+DCIG8SQ;,"[:%P<#JY5BN
M9+KU:V\JAS<,^4YT!<Y=^LWKD]?\6')^I(PP-'MS(M7)L>8R_^EU/T7G+U#1
M8^!U1]<_'#Y(PDV<F5N7<1T\3[C+L<B)']YY@W%BOM:?2!R-B<>/&D[RR,WY
MX3&?/(G][WJT;Z+,^)UI`(WP\6J!-3["-M+"0AZ#!$V,%HR$Z`+)!`/"A*+@
MT64V:FMN8G2INPE8,.6!"JX(=R8C4F)(&$RNB/3."I]<?Q>><P9]6&550P(U
MA0.\4SIEG=<@M`::!>)4,(2'J`AHA@X^5R)"\*!"_D+4OYN&'M=T?V@FBG^K
MQ3P=-NX8\:PG*%S03O%H"<TM#@9&*6$J`I'6TTQGU$C1,_J=7/&]%/9MV#L,
M2A/F0)[1KN]3;K8-;PF#`=5O!_7;LIVS"GVFMK2SV9</T+8S2#9Z.D^'S1_=
M6=VIE\):';UGGCCF.:'.YVCH5MSL'0B@WC_GW;:!C&`:Z"9Q#.X<L^O@&7S;
MNJ"*LJ!R39CDFGCN'?'61IP%F6#6YYGC/5V#:7;@!IX7AH%H"M6_A@C(7_C-
M?CYJ&@S`[B#Q*[2_5G._U2`Z]U$P'0(7N#JZX-#ARD1.(L/?J!%<JQ@C[^M(
MW%D^R`MP(<>$K%_11H=+%Y"Q=W%ESF=5?3=EM:X&JT=W161`(<\8\=%K8J6V
M"*>^*3P*T@%C+V1IZ64?$X,W]>+2:3I93U"8W!F.0I$8G2?1"T.8IH%$XS(9
MF.(@Q0M98O:+/H>"9PKE[Y1+6Y.0R11(Y=&0,V$=`:-R8C"\(E32W'N''_1-
M.4P>;PR?<1H$KRFLX*Q>+7=+CI?N\@8S6-.Z0)!TP']$Y@J(\#H2@3$4L<Y%
MPS@-3.KGG('85U75&!!-H?H[)[NVZ?UATR+&0//<Y$1+:XC0C!,'#F-HAC\<
MEPK]Z><\^`=6^@#X3))PNMU(/+-E2''O5=G:V1WN-V6>MA(7W$MI*$7,+!BB
M&;HZP`(C$H21N9<T$SVM8AH7<6"K&`6Q7B$$QC2E+]LC[Q>7BV4MX>M%NH3M
M=;JFK+I*)>AV]J&UYX^>W.C>0V&DXMQ0C*9-U$1G``0<NZE?S8.)ECYG;W`@
M*Q@?MBFFC-_JY>5P7SHM$]\V+C3+M:`@"8IBT./5.`<:%HGU(OE/C#+?LV13
M3I-6&'A.&`2BJ;R#1RZ;V^(H/$)56.U<SF0@H(3$QZ(_I%T&1&5<<R:DB$(^
MY]5AU(!A6.`F<2:6R;%-#L.R0>$DTU9$1H3,-7$T%R13U"3/*"I%>69@:]YH
M3`DZ[+G=;5<H'44.!CN4,1#AJ",6I"60YXR[7'NP/6>TB<XJ]E#+0\=F3T`F
MF;]L<Y%&$OY(P_-CJGO"L=4>V[K^@F-K:\C3A;[(\3]%HR%*TXQ$#;@4F!!)
M],[0C&G)W`LPAEZ:?#B!C837%+;R'IJV+CUZ9_M:S8X]%3(/SE$/!$>;)L+H
MA+B@!+B5!KT+;?FSCJ.'LY_QD9NRK.<]>$#.W0Q^A0[[MIO(BN`Y93:S1!O'
M21:UQ^C`942AK^$Q6,AYUC/!-M$)VL%L9&"8ICG9LBK'1TXW&,#=9H6EU,H,
M*#$!EV;-I"*:ZIQD7F7&6Z:4ZGF*9:(SLX,I?$]8)DJ@7]GRYA3#S2&&KJYE
M!^J"9YE&&\Z)=WD@,5A-0.;XIXK.Y$X"U7;O$/I%F,,X:$UC)=45U.V7LYF]
M?L\%+FS+[,_F:6$366$96!MM1"2E(R`R3HR$2(3(1,3X,`KHN>LZI>^P5R`R
M,#Z]<JNG\^45_4US<U/+G=S>8]G4330%<^@'&Q:(Q.6,..X\LAS4S0TO+LM<
MSXW5*=?[7GH=`YQ>2OV`_TN)F-=E\DK=8GD.YWV";EW&8QM)02/-@[&">,$]
M"3HWQ`4TQ6NNO:0YO(`5O;]*A\5F:(W^>W&%(<9_>RAV15E([:/@P1(EI![T
MDILIE^A1]-L?HEYJ_OGH[8F@K-XX5.\U*CA$S7,'A#H`PD7P1.6>WAB@$,+W
M')P3W2JQI_+V16,*_^GGJ@J?RMEL@Z]TTZ0(+#-&\`S7?88+`S,&G4OE2.8P
M4.`<\9`]_>6)+H38WR_:`XMI*INOJJ9LFVM).Q8RKR<I`C?`P5)</C1@:,@C
M"<PSPJCC5+OHHNKI!4]TY</^VAX0F_%/_>_U_LUI3CV/^B+,B45X_%V6$QW@
M7I_-/8.ZK,+IW*?M<'@-US]WWHY9WTTA%(;ZTF7$Q"A)#ER3(#PGTFFI1.Z=
M=UM7@''02/E*%`$#G(\E8O_3E]^;=&7'FW*.]E_.SU=7'F_>9._>2:&"=IH[
M16APFF0\:L(US@6"Z6A-]`;ZYHZGV9\:3^W5A)A.E&%*[PELTKO";B[E7[[Y
MM4-IWU;:`B,RS[6AQ)C(B5=<D&AD(-YQY9Q5W(5GO<\YEGJ_S4<-#N34QG/G
MQ2;-R6>H?=E`Z&@\:VF++`]:R<!)[E!FE:-#$I6V))VZUAZ_<OI9GQ1X`N,9
M"LA>,33*>Y>7F^??,^2'[XYX&&+OTD?:RY4BYAF16C*2<ZZ(\5[?Q)Q@I'G6
MIY9'-I`I`'VR):I.N:-W<>L)I.W$N/['3%N,<Z,7C%AO<:"D<$<`SZ,5/O/0
MLYABFBSK4RY2^R(Y39G.U?5UZ1C4K'L?[MIZG/4DA9322`E`E(Z>`#>""$\C
M\9P&+B!@P-RS&'6BNN2)C&5``*<PD4=0274$3;MG?+6FDR(ZRGB0D6B@GC`K
M*)%69$1D+AC/+0NRYZ'H:5R;IXZOAL'T"2WKW=7RU/=^EK6FD\(I)WV&0S5+
M%[/:3`FB`E6$L3P$*S.MGK=/]-26-0RF$UG6]6N5T[NT-QO/UW9%M."]H(8(
M!Y8H8)P8#!Z)9@[7YQ"B$CWMXTDC\KW5]JUU[`7:1-LA-?AR=:WKU0R6"IF'
MH\MT>\1_[UU`NWYK9"MYH554C+E(E+>>9`9'&+H%GG":F2`,>@&\YPL6GC0&
M']I<1L)RDOL<+FP-C[X%>MV=#FL)TCU8ECHOB5$>0>,VO85(*Y(*]YT-AE+=
M<SO\28/QH2UE,/1ZI6BN7X-Y[RV8:_(`UZ]9/IT?5_,Y^,3?'V5[\4^+:_!B
MM3EU&R\\FLD9X5%%L*"E!XT^G;0X^[(<8Y.O55S""=WSKD+QI-'74$;VC(`?
MSCP?WIQT[]*DG:QO8T\%I[C$BVB)SV@@8')-/'6W,FJ/<_=+#.W'-ZZA<9WF
M@,7]6.)T_NTID0V+8!?R(GK-7122..TC\287Q$5N293*YX%C?-*WTEK])2QJ
M9#"?QHQNSIYLCN@WTA4AL^G:AD@$#Y%(QCW15CN2<Z""<N$<Z_GV._T7-YS]
M4'P:BUD=3[FY0'+M,96=3*E+AP7507.*X:SC&6*"HXBHE-WU43K-/3?&];QN
MQ?S%;6PD>)]VU7O\#<R=:0N71V=DEA$M,PQK,YJG[4-+%`4EHLBH#3TW1Z9Y
MN]*3+W?]@7PRXWEP6?JN]O.`O)#>Y5:#(2%DBF0ZO7^0,YXJ48VF'&R`GD78
MC/[E;6A_,)^HCO=>V6EU>57#!;8I/]Y+;4]:?OITR?5QY+FUOTY2K6E=I$/Q
M/C<JB86K6@BXEGF=$9-6LH!>>._CA9-M'/355#4&.I/D=M/YJO>`+O$"-I\8
M?M"RH$9Q;90CRL6<Y$I%$ASZSD$JKJ+AE.?/N@!X;QT]3-ONC<\4^CZNFN4]
M8#?O1MQ4&/^@:1%3,6"Z(8&AJT$<:$M"NE(2O#)`';5YW/\],&/&`T.K?`"$
MIM+YN[@RS2T*OVU7.,L]`,;&U&GT#Q05)`B)]AM4R&/F,\:?=6'V?LI9H^E]
MH)FFB.WZ4'LZ+?OU7/M*_(V5;!OH"AV8\U0&PCG@T*`8:`C).7&:(@16B^"?
M=8GUH&8P-%23K/`PPS[/?X8Y3GZSM.,<+LMY.DZ-\'V$[?;1K8-"&B999B/1
M%C!"<=P0"5&2R-*+#0SS_GE?+C&HH8R&V106<[<DX5T\G;=V?EZZ&6R_EW,C
M8>&9TXK+G&3ID('U'!\.%(A13'A#E<^?]_7-@UK(X%A-81G+].4#+VJ%QN;@
M83-AD><8:C&=$R]C1M!KIB3+N2::^BR::#+E>I:<359#-%3D.#10O7;9DQCO
MYJM"@)//?KFE^]A&^MK&A>4JLSG5:,!"$NI5GB[6R5=[NI;3+/:L7V83!0L#
M:J(:`:YI\KDMU-"T.XSTQT@*RS(O/,Z35M+T*D0EB:0H:]3"X3C!+_M6?TTS
MQD>PAQ$PFVP5^/_NKJRW;1@&_R)A/B49V$O68RC0"^WZ;$BR7!AU[,VRN^7?
MC[*=.TX3-Y:#/J6%#](4*9'4)_(^S_*=POAH%>A\,'0()U[L2\2%C1&-+(Z<
MB'($XN.$L-CG\5DW^1A00TXNN>'3^)>YJ'1TI!VFK$S*V4T6Y\5T#9,U4.&*
M!?3HKFZ)T.P;C$'SD*9^[?W1I+Q293+5FQU+Z%3V)'7)%7C'#Z82=2E+EG15
M+AG6Z%O`WYRSRT2)-->,[['WSF="6,\8E@%%@F"P!1O'B-H$_I4R\BUPJ;V/
MD70'^C)?K%NRF>39B4;NRS5-7AKTF@U?I$RI)$[`BE4?0_G,:T,W(.`/$(A"
M&<C'<YB$L9$Z^J!2V"!$O^]Y'3..U6EU;221&LG+U*F!XS2K\YF0<E\?@F,H
MPCA"=L2Y!A@P\$XHF!VGX@!TUT!&MO.`WY$6=>@[=-U7+%WNPS!C@JCEPY0C
M:(2L&'X$"[@5]<63&"SS]ND1/JCIQFGD-[SON=,9`U<JST22)FW.[59G\-T5
M-,Q>[VI0/_&77OB&]E!O)5QJ2S3H(QM[&D,UDIC_G`]?]^`P#,X...@:K/E:
M2".!PQ:]97/'E8C)B&[N*GUA@)09-8,07*?>'F51'[`S2ZT]7J7_5%?_1%H!
M+5TEI;W-R.ANL&1DSJGS%NN9$`,FO$VU_E@S>M9!?&BRS\EK!GZM@+CJHE(E
M4"_:Z1.FE[)HU[R+`N;8\BE1;V:$<2Q7)K3C6)Z.O=_,<.N3FIUGLHT2'6^]
MZN`GK1WTMD_ZUF5#BK^;-05>?5-[[SHOFBI\/U<.VXXHM96Z@"T`?38B-^9L
MR&1!Y6V"(]O.1OWIQ1'P22$UU*EX!R\E+ZZK$@*5>4&W$7/0*QRV'<\;CZJ3
MU[TIMR/?%3+?YJY+8A1+RI#$A"#&J(]BQQ/"YL*-X[$2)CJIM4BK/A1U?XR'
MJE0ERW1(M4\,'SP:2LL31'H$6;H;(J<$PGO,)>),V,1CF'I6STTY4S#00<=Y
M,VUR>G&.5^%EHC_BM0Y*?\R6MSPV9?LF?UD1M85D5[[POIIR6>R#$YZ:5LC=
MP!&88621V-*]TF'4+!(A&6.'46HQ)SCO4GE&5?0<Y-\+E-32[Y3*"ZQ`A?XF
MEB52W=3>>?(N=0>WKEV]3[PRE!0'D:L1&;$;(,>C`0J(.V]GPS"CN*?6F<*[
MFM"Z$<3<KZ[,L=)XB*^FO]-\)F7]T&)_?X^VG9)&*`0C-/)`&M2Q463;$MD2
MQ-3(A3-"1$_U,P6F-:9^(\M]^.V.;5_>3/Q4<27_5/H$Q+N!1/EF8?B!R31U
MC-1:(:/VVGS/R$R$/&=H!X#B1BTP0R]*@X12)MZ>!:B"5,VDJ_%&<.$NCV1J
ME%O@0D95NF36:%9ASH41.Y@36VC.%L;@@)S3]V_Z$H=I!O[Y#U!+`P04````
M"`!'AP9'6UD[F(5"```K#`,`%0`<`&=A;&4M,C`Q-3`V,S!?9&5F+GAM;%54
M"0`#9LK#56;*PU5U>`L``00E#@``!#D!``#D76USVSB2_GY5]Q]\V<\>$V\$
M.36Y+;SNNBHS<<69G:W[PJ(EV.:-1'I)RK'WUQ]`B;*=Z(6B2(K)5:4JL@0T
MNY]N-+J!!OC+7Y_FL[-'DQ=)EKY_!W[RWIV9=))-D_3N_;O?K\_9M;B\?/?7
M__[/__CEO\[/_\D_?3B3V60Q-VEY)G(3EV9Z]B4I[\_^F)KBS[/;/)N?_9'E
M?R:/\?GYJM?9\M,L2?^\B0MS]E0D/Q>3>S.//V23N*R>?%^6#S]?7'SY\N6G
MIYM\]E.6WUU`ST,7ZUY;6[B_SNMFY^ZK<P#/$?CIJ9B^.[/RI44#^JN6/[M?
MI^6ZP^O&Y&+YX[JIZ_N&]!=4M05A&%Y4OZZ;%LFFAI8HN/CGKQ^N*S3.D[0H
MXW1BWEFXSLY^R;.9^61NS]S_OW^Z?$/@+IZ9-+Y)LH?[.)_'/TVR^85K=\$F
MDWQAINKIP:2%*5@Z_5C>FUPL\MSJ[$-B^\R2,C&%9<UQ^/-];F[?OW/T+':`
M>#[R'')_.9A0^?Q@WK\KDOG#S*)Y,80,TI1Q,NM.E*_HG4"BS_'-K$/=O"77
MG3Q\422I*=R3>5PDQ<?;J]P4]MG5<-['?K/>0W'+IM/$_1_/+M/;S'9T?RPM
MX3A!&A`>2L:K;)9,&@SZPZATS[W(YC=)6CVL,:^;^O3+64.WTZ!KOWPV<R;[
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MO/U@'LT,?9.`M`+F0-H]2]HL]&C0M3L^/QC[TU6>38QQRQLNWIDG9?5(.^S7
M=C5YR0,;QGE'$SZ)C+]EY7X%M:77H41V<-N)A=WEIIF?W-JA1YZ.2"';T.I0
MDBR]^VSRN30WY5Y.-[3MAY.FXVY[E^[X^LV4+ERY,OFU_<7LXVE+\][X<0,R
M2ZN/A7J:S!93.]?EV7S5K)D-'D.S-\F:S2`[.W7'6[6\=IG:O\UJT:V1^]S3
MK4_^*B0:#J1FO7OGMBV?/7!XG=RER:W-OM-2+(K2/C!?37C66Y?Y*L02-L9,
MRD])\6=#H(\D>SKY&EG[441/)]NA[9O9ZK!<=(B>6T6QF9%+Y>=NC#7*GW?W
MZIN[(\*OU@1[EVDV<YNC;A5ET\]-'4X'M'N7M"@6\X=JV5EG^<?JT]]R.PZ*
M2_N+F1ZER(-H]RUI]>V2"38ID\>D?#Y&N+WD^I:GH2=LT+=C3@]:B1YBW?C;
M9QSKLPXEUJ<LJX3!?<]R2[`P^:--&;)<+\I%;MQ0<WL;;:5K1;Y/>0^P^QW]
M.N1P<5.8?RULG*`>FRR1;&O?'4=_Q'GE9?=Q\G6[[CD0]W%Z9XK+]&4%^';U
M6[TVVM`)MZ?8O53?/MI.:.O%[M\+M[H]BR=_7D^L`9IB.4FXA7+[PZ_9U,P.
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MRP*:U5*VJ+8FZXI%*Z.Y+,U\K9%9?&-F[]_9QT7'$8Q8Z+.`:0$!HT1@Q`.J
M)$:4!9AJH?1;@:N%ERROU="?Q)4!=B5M12P*:!"2@&`&`-.<$B1"7$L:A!#L
MD_3%Y%@^.<MRFQB]?[?NM7*8!\WO[KC!L$K,!D;1"FV_J&:"GR>SK##3]^]*
MZX)>OLS2THXB-:MVC^TD8.[<AQT&]AK?V[BXJ4!>%.=W<?Q@9QZ`+\RL+.IO
MG"GB<P^L#E3\9?5U],DE0>PIV32BOFD3*1*$H<;4DP0"+27$R*N%9ACP@4QG
MQQ1ZI"D=J-NL&Z`JZQA"T;^^B8^VJ7K9*J*""A5@#`0)E?8"`N5Z,`$=R&AC
M^-J;TK>&S2\J/T(/FS1Y%`[?ITZ'U^6;M.+4JAQ>A;]:..>+^5XEOFD7!0PP
M8EFW2'`J6*!`J%X<%!K*#V_,NK;H\%`-9-W)/X@>XZ=F>GS=+B)!`!`66'/@
M,^P!QE[D("@@K?0(1ZW'(^0?0H]7>69CB_+Y:A8OR\C_M4@>7"3&GS];)O9$
M2@UZ1P`3RGS(.:`,.<FI%+7,%'EX()V/-8;J'L*3FHWC6;Z9XPXQFY?>$1<>
M0SZ3(?05Q]IGB+-:9@\#.-YHK%.--K66HY'[_V$UHXOWQFXLAQC)EB6@]6/U
M(K?8+G)C>=')D_M4;`T@FG:-`+7`A(#9?TJ+P#I?C6H)E"`CBPT[U4G6*U1#
M>`17TO7%54'H+)?9XJ:\7<Q6,ZP[&622QRWK@8<1B"#V*40`"JJX@A)H+NMD
M*O!@RR"D<R,9>#6P5PQ;N8HZ6HZMU29VD)@\R::?L_J4G&7T[\G=_>SY0V*M
M?>H.4%RF19DOEB=0"G?VU!6?VO_<<'ATNP#EUK7S7AX6A10R$@+E8RF]T!,V
MRB<U2L@'WCA2G%.L.X\![R%\VF7JJI.R_/DW4^[P7*^;14I*CGWH>Z$D'"`N
M21BNQQ8)VTUBZ#NWF@Z0&E3?[@*IR[0Z=ECLRIHW=XC<LH`G*!6A5+X",$`2
MU))AP-KM4^$?S0:.P6Q0:]!6&86%Z6]9-FUD#6\Z1*&"F$*M`PN1%,I:.EO/
MMCX"[2(6\J-9PS&8G33C_;TP-LKZD-SN"FX;](X4PT(0)A0)&"$<*4KK=:>`
M,^6WLA/_![&3[@$<PFBN+5B%3(IE!'YM\L=D8G:YD,T=(B(Y@*$=#IJ2,-!^
MH#&O)0MXRU"4_B"FT0EF@Z3(\RPODW^O3M)=IF6<WB4V'V-%838F-\TZ1A1#
M224,L0]$0`.;BL&7J5/1=N%&\(-81Z?8O;*27R[>%K`-4-2V^?:[O@KKMM]J
M-\03=Q=3]CM.UUJ8V$FFJ.7:6K[7I%ODPX!0CTN;[3`B@:*P7@E$"!"\=[^T
MI_EI/1PW,%_PYU=_;2OG:TLJ4AZ%2/J:(Z8A#S7T%*T1P9JQ4Q;S=:O2K^>K
M?I$:;<'>!FGW;$IOZ1%)S7S@88YM;A!(XG/KK->`^*1=\4%/Q7S]:SWK`[0A
MXJ%-G+J/N=F_A;BW;R2)9(Q!Y+;S!0T#B7Q4RPLI!./==CY:@PTLH@NL?GP;
M&=TF\_A,HX.]HO]9/-C(\-^[-Y#?-(J8U!A30;`7>KX/*`^]M7.T?PQ6#=IL
MJ[A#E+..(!ED]:.^?K4Z?;FZ'W?/E+^U3P2)30$]7V`MN&#VB0*&M7S(!ZB5
MRGNJ/AM\TN\*MB',XC6+>WWXMXTCBGR.0Z$AX=(C`41*K^-NI8$>[\3>@9:R
MGN#Y$10_NMEZ%/H^@9Y?KDO96U7^3=N(4NA[F@:*06EG,1SZ;#T5*C&V$P+'
M*.1KW1X)Q9#A^*NE.G?M\UV:_-M,+Z?6U)/;)%XOKZZBG"E+IZ^.)E=W8IGI
MJ@QD=WW/,`^.L"98(`HU!(0#S@D(>8VTA)X8E]'ULBPU*H1/E%HNKP:Y3$N3
MFZ)<WM#V,:_N=[*"5Q?06`F3N]0M?A^2=QY`.%*^\%'H!9AKMR>A"85RA136
MGFAGB[T=K>G5%@=!\$1^\\T+`S[G<5K<FMP.J%>CZ3)U+PIH9&OM"-LX1!*+
M$1`>"@.A)?4"OT8J`*)=2-5YM=K0?J\_!$=F:]7=(:`;\UK2BCQ.H9(`<,%9
MP%3@#CC4>&""PW'4OHW%HEJ!-C(CZLA^0!00(GWJ^Y(`J24C%.-P/92T'DFA
MW%A,YU"\6BW-M@P*XTU!X:?D[GY[#7_W3XHPE<0/W5&':ET<>0"N1Q7P8+M%
MXLX+ZGJQIW%`.H2C<O6B7Y*73?P-3JAN8E'4FEKO2CBD5`(M(:EW2;#%=21E
M=+TZF)98#*')5W=\OC7(':K=VB<"2'A<6"_H8Q\B/T1,H;6E$MDNB^J\**Y7
M77<%SE!5;_O>_]EUW=FA;_(<_OD[7L,Y"#.]O@YSH&J^-4?K`=5D^_%E]"$>
M`IO2@1!P/PB(SP!7&@LJI9T$Y>'7ZW4LU=ZZO#<-(R"$3T&(&:6!5$@KZ(<K
M:6P&0H=:Z-Q9=7>,$K;MB[:1?K25=&NIUM?3/V1I=;:RX>;ZIGX1]P(*L6(6
M!\)%Z+8M@AH<Q*`:955=2_UN,Y,.@!DB5/J*S;V;J1O;1Q)B8!-&AIE4`5-4
M*,EJN2##([XFKR-]9?VA].-8P7AWU4>@_.]M<]VC`')%,45>=26)1P-8SZ,B
M5"/;YSQ2)WOWUP]#8Y`C8NM[JZ_B9'J9BO@A*>/97DWO[!=A*45`A%+(4T)*
MFTA*6LO)`&QWLK2W'<5NM=XE,D-8P"=W\"DU4Q7GJ7OA\?Y+4C=VB!CV?9O6
M^PC:B-FW(#'NUY)YL.6I\]YV]KK5>2>0#*'LSWGUVO'G9NY\0VOKPJB/K`?3
M6D`EJ-"2UQ`A"U'02LV];;=UJ^;C\1CF&HF)X]-(L_S_,OUV8>13-IOI+/\2
MY[L6.P^D%-&0`J4`8A30D-FIS0^\&HLPH.ULH[?)OL.LOU^@!BF=K]Y]_7%1
M%F6<NA??[\KJOVX;,>!AZ]F(\`CV."*,XSH-1H'G#76TLJ'B>]/6UTG^D3@-
M<V3B:\DM.K/%M#H2GU<:*<L\N5F4;KWC<_9;EKI%*`NW9>6NKH[:N034Q0,B
MRIGOAS["!'@6?8(56"/'H-_.PGJ+*`>SL%.`.YA9KEY8N\B=.-65;ZL1Y6I8
M]IG<SLX1`B'$@@D4(NEY/M&8XUIB$BHZKF!U4'/J$K@3FLIR'[*=I;STC8#0
M-F&G!$@AA$242+(>&E+(=O6*O86[)S:4UKB=W*6(+'VT"%57MBP_E^[.EFLS
M<1=.)KNO4#J*L$T@I,<E\@+)!'8G+GPD5DC9X,`?61':*%Q1UZ">VDWU8'W-
MZ$;*XXH!!D(/$*V@LNJJU8.!]D96L38&]]8UIB=W?6K^,,N>C:D:72WRR;U%
MUMUZU]KG;:<8A9Z',0TYIL*W'W2H0EUC@U'8[I+]W@KB1N'L.D/SU%YNJR`M
MO=M6>A$BF&B/0A&$/A1``5^#&I?`:WG34V^E>&/P:EUA.<R6U?\NBK*ZVOMS
MMF6WY7/\I&YOS:34%NYJ'/&X*AR;N]?8OGE;[,;-K4Z>$`4:`U]IZKM#8%8S
M@J`Z",:<L78GB\/OW0Y/@^[)Y]GJQX\/5;&I>C+Y)"EV5AH?3BSR*5(^#CT?
M$9]S&F!-^0H1%A#:\IHR[WLWN-Z1//7,VI%I;:<5$6+Q0-IG6C"/4>;9'*K&
M`Q"_W7H9^/Y7^'L&<@C#^LV4%JYL;CYD.U\]\*9=!&&H(-?,X]S*P7PI_&`]
M0$3;M^)\]PORQX#4]ZF'W>7SA4UGX^)>S[(OI[D$]]BR>6(!#;F'&0X)HAAQ
MP*#R;`Y.E`?D_CLZQU4V+PD.K<T)&^#8]`Y31I1:2B-U`-A0;YTZM&R^L1)V
ME\T?)OUHR^:[NX`6`Z`DI`$7PE.N>#`DNL8U`.%0E17'E,HWUFG#ZV4/@^1$
M][MT>'6HAI@*!CG"&M@`(J#0"];R*LK&6SQ_M`8/OD.T'58_OHT,;QLMKY<]
MG6D<8A(=7B\;^@*'5$@@")84*E^NN8+>_MOZ3WX=6%N4=UPO>Q`D`V5*+D2^
MRK/'Q,;#_/EW&VI<IA\?JKLRTCLV*9/'Y1T&-T69QY-==5&'$XL4=)N7GLU,
M``M#IE"XFD%]A)#F(ZNRZS`Z[!VK\>;9E$O)M5;`=S?8^4QI*&LY*`I&YACZ
M5-3.3/LPF`;?I7"WH*239&;></TYZ\Z=]/&XB&'H">UQ#@@,-/?<90TUJD"U
M?.U%;VL\`QK?"-`>PH:E><C-)*FV6^SGF:E4F4Y?O^)JATTVZ1Y!C*FB-,">
M'TH@?8[4>N2&-NP;EX,[K>*SWO$=[*C!(=NQ6_;_"$(>(P(&"-CHP8:)@<T5
M5I()@$;RNNQ16DXGB+;*C<1]G-Z9R_3554&OCLG^$>=Y;!%:;JE<NJOH4C-Q
MO/V1E/?_B/,D6ZQ6ZW62QA;"]&[K!6\]/"JBB"LHI/`"YB$0T%`)5"/$,6_W
M_I;>ZL9'87,CT45WUEJ]+])B6I?)O+DO\2!CW$DI"@D/?.A1$6HKCT2:(K:2
MS^;%J-WU*+V5GH_<UKJ$^C2'.-<XK4ID&B0%S8E$E(:>YH(&&O*`:`3Y>C!A
M`&6[0N#>'-N`H7YO&)[&BE9OO"WL"#7)XYX]R2;=HX#;X`#Z`!#BB@0!LQ%F
M+;7/@J%V*EL7`AROSKT6<S1JI[&5R_31>LPLWWT`86>_"&I7Z!!X*`A\$FH(
MA:H].$8:M`N8!BP3&<`ZVL-U&K.XRLU#G$RE65X+K9Y<`F%LWEF=_-K[;O%V
M!"-/`I\0"CCR@8]\"*3`*V2(#ELN?@]X8G,`0^H!Q]-.4E?Q<^L9:M4W4@IC
MSPXI*QQ#'D&:*5K+*P/8[@*J`0]P#C@]M8/L9":2+]Z\(.-0*_FJ>\0]0@.;
M8C"+*_4"A;DBM=0!5^W>(S'@.<QA#.4XU,:U2]O)[FP$[&3M!9H1@`))@-(@
MK'-'HI!H=\BC-P<S[`Y=/QB>T(I<K%9TM=>_@U@$%6(@4$PI)C"B/D9!#;J/
M`]TN'^\M;NY_K[\[K(:P'CN3UN>;EG4Q=<6,*:Q\RTKK!B\;.(1,1#GW-15`
M^)#X6%OAH:Y14!2.;".M3S5G@Z%X8EOZ6[Z[E&1?UTA*Q&0HM=:!@A00$8:\
MEA8B-#(O,PZ;:8/<2>S$XF2GVO+9'>,M5R_'?%C6O3>WF*U$HD![OM0,5IN&
M-(#N.-,*`1K:T&!<"?DI;:<K#,<5]W02[T2!IY6`/(0<:)NB<(DXK!%0"'P?
MT7,?5M0;AB>THO7F;1?1\PYB$;`>V(,82$$]YMNL10=URDM)2$:VF]5_]-P=
M5H/,9'DV,69:N+/_U?MVT\G;>H%=$]C_D7=ERVWD2O:/9K`OCUCG.L)N==C=
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M*9&)&Z.BB%/+)+9"[[9(B?*VD]XNG"I*1B'$AG70*7+`"0B`>"HP'`..F;?2
M`R=V*T++O&"KWNIU5I29WC"L(45K#_3T+OU(.]_W5,%EN=C4$GIY"WM$CLYY
M39!:2`.84=XI3:`R%+:.;@FP'IA>*GA$[A&EZ\F*BM(_GS]&05]'/)\M)"_&
M!P"XPY(A+Q'6+&*`I&GI-DKD.5!ZTTV]2\=E\%1)JEI]^[8I;S.:M'6<WDWO
M9_.'=83["6ZV$]\0D.8>"BVX@S2>^A%4K$THD\Z1@97P+5FCJ!>`JI]QMDT_
M-K'()SM(7@X+7GBB'#)2(R$()(;H]B0G*6%YV7?]%2,HS;MCAYG+H*H33[>9
M8JJY>C1N[N=C@6GF((=0*XNUC(:3W5UD2`5]GM^TOXB4GAE^`32UK(1$<FKX
M$W_]>6LTO=MC$MOQ(M5-6\V;$_3$I:\.G`-D.-,6,1B-?&ZB6=6B!8W.N_+K
MK3IW8=NB(G)93M4G27/'LS*?>/=2ME_DPIU:F-EB><1M5O@+(9I?E'(B"(=,
M*`@$0FVVA-**YGE0>M-!]=@_&P+<6>(7OSP9+1;C^_'M>I_>3;J-.7[\^]ML
MVOJ8#XG8>6\)DAJ#D6&"8DFL=ESNLDR5%"(OT;8WS78=,>H5TB>B<J7*M[.'
M;_/F:RI:]_U9?:87%7#;25XX'SN[7:4OIUB@Z7+=M6]GF?3[Y=UN\&'=R79#
M_Q4^^3HA^\_Y^/9Y5O;V^3NU=%'`'Q+/?FYFTX^IX4XJN:U'B_'"I@;,DP.$
M]&MJ[>:T2;"*/'V2']'2\&2^\8&X=.?/IO_^A)+'1;\3`-5&"\'CH40!06TT
M:)@EF"L!E1*X,R]SN%AV%5HN]HW`L?74*&VH(4))*N,Q8HNAA-#7JL=WM$;S
ME:1F-@S,1T.M#+T#1#\^V1;]O/G?53.]?>RH$GW"Z$``YM[Y>!I%%*JH@15"
M+5`$T;SPW)XK1E]!3`X):C%D:YSV]ZG8W9P[RPJ?,#K8B&3$$#$5C3I/E60"
MMC1[Y\APBT\7Y>@A:2F.W.\A-?6EI:,<]="%91A"LMAMP`=+7)\S/&B/A+:`
M6HY3!2:(I24MU4AEYCKVYL8IRL<39.1"N*H*B7[<_?JO<3S&Q:/=X_OF>S,Y
MW:`Y\H)@C-<*<XX9-9A*%&G?P8H,RHM9.-]1\W9MFG+@7FWO>4U"EJHZ^)X@
MA8904XTT`]):1@G3+0Y,>_@F3)TBC#YE<RH,X^\K5D.VA88O35>4HG?3;ZOE
M8@T(/-T>>CTJI!!GQZ&VBE(*H`!$F);&2/[`"NGUQ+]#4G(Q7M>2"90E$]M1
MP5-NT+JIM_5`(VL%=:W#S0F=Y\7I[6KJ>C*1A]>U9`)GR<1V5*!<4P4P,H1&
MXK"E/)X%MC3&$\'`$N^O)Q-Y>-60B<U18#?GL\)O.L<&Z)1&D,C4KUU`8QW#
MH*4789]WG=V_'KGJ!45I5*\7";Z'AK.CP?>\(WA,(1*,QB5I/&<>(RY;^K7R
M`[-."O+SI`#QRQ&[ZKZ3L]\$BJC5W$D0]VCMC.#0H9^Z%N5=?_;7?Z,WB2B%
M4`T)>+*WYJF?TUX0M-?8)=^X4<`:#`%PK6VNN&)YD7G]VZU7U4&]0%LJ"/3/
MV3+N<^/19/+XJ5DN)TUR2;Z;IFWPC$#/(V\)P`DK3/*9QU6BF`$6[NC"+M.Y
MVYN"*<VLCI#-<L!5L4QVT5W/`KK,-H(P!99NN[F<9ZQ<\-K`'22&1V0P`M0A
MK`!O_51*H*&=I'L2KRL@64/><H3I,'V0<J0(,1HQ2"&(5IQO[UD48"#/TNWM
M?-VSI)2"J>\0WT,WI^LV1.-MR/+&+?`$L2&$C1XW-=:VQ=_3V>=%,_^^V?2_
MK9;/"7M_3O1HP<\%XATT'&NLN:4@56UV=B,"''E%.G,`!X_LR;&DA3X5#.8<
M^HBGD:D8)":TW5MY/#G`6D;0:2&E5Q&E0XZ_ZW#@+028]AJ204%DE;16P)0#
M:3%`F+9P.<AJN87R0C*JRTQ>9,9Y&/^Z5^@(81/M2P"P9,P1;IT"+0Z$(O7F
M(S-.9O1%=^EY,/Z^8O56(S.&(4V_PHUK1-%)`Z1AA@B&J<$2M31RX%@M">GC
MQO5D_IUQXWH>7E5EXG*5;T:3V]5D_>O'V63B9_/_&\V/5='H_=M!<(P\`4H*
MS[V*3$1N>]/$L21@J`'4O]CYH0AS?E?W+-%,8:&\!D`S`3B"0K<H>6\&YOT?
MD-24].R>QX2LJZ63FG._S@4_=,>4^;H0%1NC3%/L`1'.(TYENUU@2F5>#9K^
M[R<'(VX5P;^*YWA]KN^Y,,+[)OYI6S@L8K9(!5C&R_7G4X!)B^3MSD_=_KB*
MOSI5Q7@VIU.\SH<'!>LEI`YH*CB@7D%)XWG%00$59,ZISONX2E1V>8#W#PB&
M>1!-::.(85QKJ!%D6^JH=YG-D0K[<4LPYV4(0PDT!NM3W56,V6C05#1F-ETO
MU^.NU*/C`M;0,(M2"1Y'$&;>&-1BK8G,JZ?9LP?U4CZ_K*Q9$*!Z]\V[:7;Z
MH_8^'R1S4&N&D!.6`^E2RZ_=(C/&#M>=68A?>Z^:RZ#TZTC!X+R/0V+^-<[.
MNRIYG2[%5\\&;Y"$R,13D:`.<D80PRT]'K"!A>9?R)-7)]/+T*@2('UWMT8W
MVN6C<:J0N&FEWLGIH^."UL8FUZH#3".'B#5B9TU9X@86>E:6ZR61R7(X/#=5
M'O^,1DXJ"OREF=VO#V"^:18'RB"?-3YX`+2GE@H,B/46$>!UI$49B](1>F!]
MY0H:_WW"5&/1]]E@&0DJF.!1FAG'2#B'&&VQ-%3EA4?T%W5:_D18&*$:\K!6
M49L:N7:5_&J;WB"?OH[FS>)F^?6H)N@>')PD&CMOH982."X1XCL3B4"1=^#K
M+[ZTO$P4QRC/$SV9+=*WDW^RJ[OH\0$!<H@Y%593`IV'%B&LV]ER:`?62Z?T
MUE\*ERNN[8WW.F]I_QP;B&"`@VC4`$69Y18IT1I)7#J7)P>]=<VIM[*S(>K;
M]W^&"_Z/V;+W"X&X@*:+1GV9-S4*,[_ZW$];_4D]ZJP0^4.V^/:+"=I)7&&S
MS870SQD<NU,X\PU!F1020!D3BC!(0#IA>D<`22T^3'<!U%(T';I!.&-T\%Q`
M+ZD`"FJB`.-2XBTME.EJ*?U[KQ-ZX\NL;YP&>]'@$[.:]ZEYT+MXB)I^&4?B
M-KFI^O'#Z']F\_5]?E<$]^EO"2@%+.MX'@/:L3@II9B(P"'MH-0,U.JD<=(E
M1"\"\3(LJ#?LJD2['9[]S[G_,7IHNB-ISWM34/$\#[FAW#M#'-<2:;W&PDL9
M5;X<[IU&+QP_7:H*HOE[2]C@[DO>HF#5%R@[7BSGX\^K=6#2^,O7./$NI_NA
M(0%$K(A#-&[VBA&K)%=@@R*!@"!:2T1.#.[JBW>S7N"J(0P?4UQ9AW6S>R98
MQ:D3$CA%O&/<&XUAFC\E"B'I\SI1]E05N(;MDHM,-<YVKNPG3P5F"'7(0Z<)
MDPH+X+%?TT"%0$H-N!QO!A_V<?(B'-XF3P>GP^NRLCX+/T0X'U8/G4Q\]EP0
M%!E$!(^[D>`60HS,VEKAW#)&V,#T;!8'9N7HK\+'T8_3^/CTN6"B,2&CIG<2
M"8B543;%[!`D$5)`P[STMMXN*8OP\0+Z3^?CHKG]CR^S[_]YUXPW+(R_O.1<
M_*^P]D)O&@$>,'KV/!4<I5'^E*1`66R<@`;(UCS@,+-4Q/G7B%<W>R['ICQ'
M-U,Y>/9]^4A`!$MC"4"2&<")Q-SI'<U*H.$9.1>A/BL*P_#9-QA[YBI<*W!7
M_\'&7:.9+U+^TO2VF9LFM5\_J.8ZQ\0SKX`,:J@@YD![AAENB68:D&I>I.,J
M+Q_J63]`U+!AV@"A=;S08H/Q<5?`@1$A`F6EC*K$,F4E\A1KV-(6I3YO69X?
MEG%U#5D6IVO)P"9\K-NAW#DV^'4@*Q%>6RDX$DX]N8'4'`]/VQ;CX`D240*K
M7U]&!J/2ARL:!?3^S;SY,3NNYI\\$I1#UE"HK#<.,PVQQZ"=$8=H8"'8!1&>
M%0$DBT5J.EV-)A_B=)?---D7OCD8[;+OV2`9(=)ZIB6A)N6$`[`34`_L0')B
MJD2Y%,`GBX=^M5S-FP_C2;-8SJ;--F;[$!?W/QVLAXXHJZBW.,HL)8ZZ'<5<
M#*0=0!4^%D'HRJD/?S3+F_MULXO-7XY5.#KG-0$S2JB*>%+$J?:2*&U;%!C/
MO)TM'O[>MYQ4@"YK*]BCE-(4_M5,[O1C.Y'-F?30_G#&*P)!3"DGL70.(T$9
MC>BU%&''\^+.BD?.5]DT^H,M2Q#<8CE^&"V;NW\WH_G-_9^CU(#`_?@V/EZ0
MIV-8$%2E%!]LC0(0TZC`],XB`9&<+(87#Y&OPO"R4+WU3#D<CRE`">T8`D9J
MXXEHS1SN%!19@L'>FF#T!%>]D,#)OCBF=O>"1P3DE.%!2><-U8ISG.[JB&-P
M$_MDC;/`Y@D)?ZM"T@-D><>'[GD<*$MW\(B1_<:@4W!&:KV$C2382\.]V]#K
MX@':Y,66B+<F(G51K"PUV\UQDUM67H2>O3[H:&D3XSQC@(E(/21(;I#P%%B5
MM^7(WTR>+H$T+[DWSB/UO5F-)C>?)^,OFUFT3;1:[9KPBZ>L3Z,GM?Y>9?V>
M_:9@H,7*:F@Y1DH)"A%0"5S+L&#49A84!V]29GJ'KYQXM!/X*PY=?)U-#FXM
MIXT.#!%)*5%1YYIDN5N)UG'5B`GI*,N\8WZ;GLU>(.L].W@V_?)7,W^PS><7
M]UO%4W&??.F:13[3]]]-%\OY*C%]Q_,C9ON!$2&N5@#B1B]!"BCQ&A.[*0'/
M/0?8=!8^J4%?5VW//4\';+BEJ75:U%X2*1-/Z&)+%W.<U+IB.EK8\V*>O,P<
MN1B'P6;:IH6WW"Z\O^)4.R)-]CT>1#R#*P"(H\!CQ;'6#+90I)YXE43BK`*>
M%['T5='7BT&IX9]X.<W.((']`P*WU@+'XD)2$`@F//2DI4PK1X8;/7(9HSJX
M?A$ZOQ+_!Q<9,@2V%_$7S!?+O^:CZ>W7P]E&!YX,F!#M/)*(X7B>\`;S;?O3
M.#_DV,`ZI%P*\JPD&,-+^(0^SI@PS2Q@D"-/H57M_*,XUVK><#6%FXO$,),!
MJ6-"Z'C@3Z6"I9*0D)U5*B$3P]6G&7PXDA68A\/;Y.G@=&1=5M9G85YB(/<2
M4T]3@5:/L"`R[E`M'5K8@?6]R^+`T<3`\^BOP<?G:L2,YO/'\?2+>IBM]L;K
MG3(L1$LK&EK8*4&PPL1HOU-#W"@],"[WZ]RX")HLL_:%81"MOG<I/:=9+&^F
MDX,Q5L='!0L$=Y@3[[T!W#&*XW[6BK_C>?MO;QF]I5A:'IGZ2[J=[,?1LEEW
M6KC[64K[Y`5^["5!8@*QL@H@PHQ5SA,#6@0X<'DA=[V5'^YWN1<$JKZH)-D^
MW7L='P[6,@BUQ\@C2SF`$MJ=\`N@:R7$#8+U&8`4V-]31*<?I6Y\R\<CB1)'
M!P5.G+*.6R*A!I!CA:AO9^VPS%/8O949[G%WOPR84NP<3W<7V6?P\\FH(`WE
M*%41822=/KAW#K?S]HCE!0P4CWVLQ=!\9/)B`5)]M=G]?T?+;S2-N*YKHQW8
M6X\/"(H9J3$$%F!*G2;*PYW&\![D\;%X>&(O?"P%2@TUNI[K33O7F\U<_U@E
MM&[N/Z5NJNL.JV8TF31W^G'[W&+[X#$?Y85O#IHS":6U1F@@HZ`")7?B;DAF
M*;OBP8M]*>BZZ%U-TMR/:&..MYUQ=W_<D7$L2#KK?4$@QI4SQAM""",8I%R"
MW0K4>96"BH<P5I6JPIB54SSJ>S./AX\/H_D_S7(]N[\7S9V?S9_-^"S5=-HK
M@P`"(!PM8,@1-,9)O>W*'"DFV27`BT<MUM->O>#6=\S:'\TR]?6(Q]AU.YU^
MP]9>?&S;^F7=QL?]N)VLXJ?\)K(S/9;52:)07[_I<GPWGJR6X^_-3T7R=(ZI
MW]UJN0Y+O+EWH_DTM0-I"7M_0B!<J4\$P*PB1`(#K,942X,9WW1'%P82T>F[
MZP?!3[=?F[O5).Z5%Q+:%717]D-!X[@N"171"B50,VH)4"V:W(%!-.*N+SHO
MV_9<$_/!Q@9>B(5^W/^"CC"''K\:C#&21(-&"8VDH,P2*5K&,)WI^NTY4O%:
MLOFRC^E@V%+CW+)_LB?U<^@:&GBTC+346/*4_L.D8QRUU&J!S'#C/08A`R?)
MY<5P_^I"-K@`E%]2MNK+U/8$UQGG\NRY0(`@7$F+$4*>$4"9H"T=@-2K1W_:
MR;<<6V;E0*G!7/?P;3)[;)IUE\F;;PGO3D8?'!.$\-$.D(8!0`&0TFFU6Q62
M\EI1I-=F>BF`KJ<Q3MXD.\.DBKP_>*`QD00C38$D@'MMW<[$C+;G6]A-*AX^
MKP%Z92_<^NC1<S?7=7O==]/X[\;]^):2>2MTK'W]T36IQU-8^_UVSU_]-/XR
M'=^/;Z.>-*O%,GY\OFT5G,*&YELA-?/F;KS\.%[\<\ULWF>32I,YQ8]Y>%"0
M6@,$H06*4BB0LA"DS&],$%*:BLXDFDI4=GD8]P\(*<!7FQ0TK&2TDPUR'FVI
M8\3+6GE=1SV%)9CS\GJL!!J#]>&]HDX_GI#F>V148$(+P8%CUAK+&-#(F!88
MYJK%Q)_E0[N4QUTBDPU/E3OX5\2?DOQY9%30*E))D"".:A2M'N[-#C?DP(`S
MEHIPKG,#N12I7U,J!N=R&IHPU!>"/^>SN]7M\M6D.[T*QP<&YYD#3D'$+:;2
M*$N\V%+*M</5^@&==@(LPK.7]2M+`G25_4`_ZF9Z^_5A-/_G?&OAV=`@,%.:
M0PJT=!!!IB6B+;5`X3R'0,_YROV;#)=@=!V):"=\OIIX,310C;4$F!`@@78$
MD;BPMM0*#!A]4Q9$)B,[):0(9K^ZI+P%JV(@`E)?,-;5[3XVWYOIJOFOV>PN
ME?3OM"T.#PJ>,?K_[%U9<]NXEOY'M[`OCUB[4I5<IY)T=]6\H-0V'6NBB+F2
M[$S/KQ]`$FG'MD0*7$2YYZ%=:9L@<;YS`!R<51)./.).,&XL%KRBD'.<65AR
M-+TBFV'/PY7Z0F@4G\7U=3)0Q_E>%_.'=(@V2L"A(8%(SC1W$B(#!<&8&0HK
MZB2A$W-9#<;_GO`9I^["?Y>K1T/Q<47RY</!:^^1A!:G1G_8<8`(J2A*59FS
M.#Y0D]^!5,?.J(S!Y^2(O;K]9:J-9__!,8'$P]$`@'G<SJR'S$JL*_J0(6JZ
MZF$79I7#PO/VQ&!RNM\DN'\*UP]EYNR_>+5LJ#3WXL$X.PP9-<!+ZS1"6`)2
MS4Y"@$:S`K8[HGM`N>P1CD[,^O*SH5/DBP<#AM8S92&R@"H+XN&$734[HUQ>
M5<#!]*F!F)4+1S=FQ:=:KJTGCP9@-<*0(LM-*CCN+**U.#F5F1\[6.V2H1B6
M#4@GEOGROJ'C^LLG`W=,$^"PD4S:5(G+$US-C\C,ACV#51P9B&'9>'3CU_RA
MY0I[?#)80C`G1FMAM$0&4\BK+4!)ZO/BI@<K+3(4OW+QR.+7+L&]O$W9D\5J
M?CU;[)TG!UN2'!X1B$(,"0&X)R*5,61`5GX[Q>74*O;U&,[2+S"=&&G+]7SY
M]?-F52R_;NX:N?CL\1`/6L>,``PH*3%W.M7HW<_4LDPCWWA&GIY8V`V5LUC]
M'TN''2WA<&18\)9;9P144-A4?\!I5QT/"HC,`C*#Z3=C1*/EH]-I#7\I?\0O
MWY:K[U$*/VYC0*_GAYM$-0P+C&J;FGA&?1HSKH5W+OF[N;-&4<#S$DP&4X.&
M6M/]H#-T[/:I$;XCA%F?.J53GQ\E<#KEE^C9.O6(^Y["M7]I`#GF-]7-S?:5
ML\6[91+&[2_/6)QBE\#W8I8I%^OK-EQ6__WXR+XPFOHY6]V\;Q'.W?WEP0N(
MD<5:6P<4-&G9RUUJA37:-+>S&PBU.B^\D<3U(1K;UZ+H^(W@*>=8<\(,E''G
M9(35&#(MIQ%</J:H'"Q`,2[0DXU;_S+?)#3>+6_F#_.;^]FBP77XZO,!<POB
MY14@"8`S'EF!]TE15DLA,CL0#NL]/(,HE/UC.<8%Y,4\_YQO[CX5BRU,Z[OY
MCR^E6V[FF[\;75`GOBDP#RA07BLC$9/,&2EK+!#48+K^R8Z\;9*407#[9\O2
MY)R<TQ:A'N[`7WZ6_Q6O:^F_SRG(ZMWVUC!_*#XN9H<3[ML.#9BR>(N,V@#S
MG'N@!`6^HH``/+%67(/QIQP4MC'VC-.:=N$X6Z93G!?8^J8`1;2:/Q29GH6!
M@^#/KXODXC<:_T]J"X441-@(@)R(>"!N*=(5#=;3";?.S.##D?Y0>3A<)D\G
M=WZ/R\HSA)Q&.%NU^GKZ7&!.0*^(<00RHQEVPHB*#@TR<Y1&:?75F@//XTH[
MT#].Z'!.RS;)<:39.Q=1,)(QIRRO+#`1GHEY#WOA8P?Z1TD"R36K[8HQK7_;
M5B9_M_Q8K.;ES9]%*DU=W.R+4V__:&>;PL_FJS]FB_NCYLQQ9Q+BQDH@UD@0
M#2-7A$>PYH7@?F*QD.<T?TZ:,:,MDK^>([`K):[N-W?E:OZ_Q<WORR@"3PJ5
MI>O1^I=J[-L-Y>I^L][,XHUM^74/T#-(/A5)(N*?39G<8=>;>*]+O4I0T^(Y
M_PPC[Y#P#A"JL:$$**)=+6/8\;R,D,$V^',OJHMCV/D6VTNF_'5@N_FC6"?"
MES>I[M9U_.>7,OUJCUJZ[[8$YUB<S'0F&:(F0A6%!L3;`F+6TJ@2UCH%0F,E
M85WJDKL`GF792=UZ,_\^VTYX&;^;=A-?KFZ+^>9^5:2.DO'_GA[0B9RJVN;!
M2*).+PT&>"X%]81Q#B5.G4AHO==X/+%PZS-(ZN@8CR99GXOEO%Q]F"UG.^SZ
M%+#G[T[5-K75%'N3^O$YC0RIK-P&.91G+1@L3/R2Y*PCU*-DM"^V#"UN7L=U
M7XSSR-'>[@7!*X8D42Y>3C#%U+MXJZ\H)Y[D>0P&ZXIYQF-W$#SS-JZJF'2Q
M>HBJ\^OS^7VY*J[+K\NT'I[^WI3KPSD/W=\<D#`26Q1!8()B:31QI**?Q?T\
M2YX&Z\YYMDUK;*#/)&C/-,F=Z>3J]M-NQ-/8U/Y%L?G;(3D%+5#&2(%A5&:=
MJNW11G'NLH1UL$Z@ERNLO;-BTB;ENIGJ,RO($$;C0]\*5F"K:-PC+(<>RH@K
M-Q6>4*&\ZHB#M2,]]W7ZC-!/6I1?-7W_MBK7@T3#'_Y:(-H`P3R3DFJ'@2><
M@?H^B$7>3CU<W]1+E.?>T)^T1#];M0^S^2*9O.(E<4OX"'OT\T\&FOH?&RRH
M,YPCP3&&U=%G'969C9'^WX4W&`LF+>#;'\F@F]+_MFNXT0'0TV<"%90!X33D
M@&N$&:(:5BAJ3S([7[Y9M]EY8,^Z"6;/U_W/C_DN%7(WVT/7O=X^$+#'S%)I
M'8/4:L$%YH]HV-Q0][?D2#HKX'G55A;;0@5;3_'5[;X#>G(G'Q*G@P,"H<QB
M$*>%K.964,U5Y;**OV]N_/VZ>+PY[TU?``Z>1_YZ\G%MJWWUS^=L%]7*F+*?
M_SPED'^JS2J[];8UJ+QOD93<\Y<"U%PKP(CS2,<5+S04.X,C%U%7:LXM&$A/
MJK,'^J&W?;9RC]\+J:(NL=90X;D!2F$JP!Y;KCT=JY/NT<SEL\G3P33F\W%@
MLBG-NU9]GS=Q\TO?>[\GO2&!Z,BHH*E&\1B'C'OC(7$4NAH8C-Q8]5$S4XK.
M(B+E4.B.<?$\,-O&E-2CXX+`A@OOF$<BZH?.:>UX12>7`$XW*:D7[K63B$Y8
MO5W9F%QRT_1$8GQ1^%2LB_B=.[6\L<5#L2A_I&GOHR":<]N:1P=HD!02:FV,
M,)1K&Y6"BN:H,TRLRF)/_'N>!-<[3J/8+HM%?.?7WXIEL9HMXMS5S??(BO6V
M*-9#U4AXW=RDY93W!*\,=09B&2^EU%HKK3.5/@DYFEA2UC#R,B1B;RGJ33IF
MC$>&.RB]XTH;IBO*/843Z_$SE9O7(.">R4*T7M]_WSD\Z_C0O><S_J6X.5JI
M;M#">4_29-1U7+2IZL79)C-:S<*[<A'7T-K]YS[2._;WIE:KT"QFZ_75[7:B
M;2Q]KSX?TNF?:F$(C0FSP&O-[:Z**'?&Z<;P\:'M=3N)^WL[^1-J!#X?%9RW
MG@&N#8^GI(J7<\Q81:=4F>5\^VXIWXU#APOY=41C8#O6NKC^U]?R(6[K\YV$
MQ'\\%XSXJ_"^B*MU5^'G@*7JE:="U%<8!,(;K9`F#CHI>45J!#33W3R69:H#
MZ\J^,&FOTK7E9$/]LN>/!,JHL3@U*@;0<\R9=KJ:+Q)F@EW>.Z%>]@K#]-DW
M&=/-6;C6@^<['A;7Y6+Y<;;Z9F8_YIO9XOU[<[P\W)$A(=[JA*(&2P&M5G'&
MF(!JQA2:B92%RP>Z'`2'+,Y]>/^'*?\5/SE;WFRKI_RV*N]_-'*O85@@0,G4
MS]<3([$A\5_05#,GB.6MN-ZM'/UPL%\L1K%\5?:<IPI?@_/MX)C@I>,&&$&A
ML)80AQRO-R@$>5YEX?&J^756</I&:`P)>#K%YL;D+QX.'#,GD'?6,*(9AYJ@
M6J:]%GAZ"E&/7'K>IZ0O>-X"XR>C2DV*WV?@\V,L7*,#X\6SP>(X[=3$13&D
M,;`<4U31`Z`:S=?9LD=-!X:\Z#G4#8HQ6/OG+,55;AK9^LMSP0+,,:9&:J.@
MM\1`6.N2"-F\,@W#M1+KCZ5=8!B#G1_CNXK5:A\%>D(VYO&!@0K"&#*4BZV>
M"1$EM=F.>Y*76CG*&NYN>NP5FO&%(%X&KU;;@^MF6Z3O8[':TM!:&`Z](`C'
M(1888Z.H)$H):O=MT[BW0.8)Q2B[0-]"T1-$(Y_E)VP/1T8%#3B`T$B&!7.(
M.K6MD[JCD3B:%[0R7&_!7L6@/UQ&YGW&KM!B=+`\WG8A\8PB2"PG@L&:9BU5
M7L[R</T(AY*%GO`9Y[`HKXOB9NTC.BD.8+:\+N+<9]M(XE]<TZ\>%$V#`]`J
M%<QCB%+@/2.`:E=3#-3$*GKU?4CT#$^65?;C_>KZ;K8NU-=5L;V\ID*&AVRQ
MKSX<F&%*1E47^/B3>R29JH\Q%(4YBXF#5<SJAXF]P3&.$3;2N@_CN5_5B;*[
M,ZDBXNI6K=?%JZ6PLMX3,'!:.4@Y]9@X11&0E87;2VGS;O:#%;[J.2!A0*1&
M2[;?YCH>$X?ZH4`UBH)N)(+6":@H)X_:3/R19ZL;K&Y4S[S.A>'L2__?Q<_M
MG[+7?/V"H"'"D7CE?-1=A%.6,%"?5"1SL0]676G$Q9X+4=9AKC8?9JMOQ:92
M)Y(RL:Y/I_6^JWEYNRUB4^D?AP[[K)<%*YSTUK*XETD5=18#5*VR$))9[G"X
MND0]:@-CX#6$5.P[F?0A$Z^]*OC4ZX%JH341CD"%`*E/-VIE9CO8B9L'1T(K
M2QYVM7_*?>V?*)>_1W@/<?S5AP-62'!I%)02*0.D)!C5>QEVF1;?B5OW>L-C
M1._KWB5QM?J4"D[^TF&B_N-Z_]?UL;I(6>\+'!I.611<JUB\NR)HXB9723-'
MF1&IEV+^&P&RLXE274"LN(XZSV9>K,ULL2AN]-_/23I5J-J_.1#CC!"$>N^-
MP<Q"4L<[>6UU9I6(2[$HC@I>UDES5#.^2K5O%XMRDP[#77[/H4/HU/<$0S%2
M$DKO59Q4O%+K.K#*6VTS4V4G;E@<`ZH\&^,KELYR:^DL]Y;.?Q>;;4NDGTEF
MEU_M?'U=WD=A35;S^3I%WZQGRYNKV]LBD51E;1XT4P[TO6"-`@+`79P>(10Q
MOM^;!1`,9AYG%V'JG`:DH^1&_I(*]\1OHU9%2C]?/6P;:OC[U$^CPF*TC,1?
M)C=*-N+]7^OB/_<IR_XAW5J&_5IU2HWS%7.7JL:MWRWK)H7U>?I^'@<NFG)-
MSZ!XO6^?_WA@8&"2:>T]I32>_(H`+L`^S=U(ZUGC[6U$:IOR(`\/"LQ$=1E(
MCJ,6K6"JS,?1GDJAIY4&V9E1;53#'%0&3H?L65@:\@H.C@E:`&XLQE18I"(D
MC`)7@0*E&RL(]:2\@CYXW$9L,@`ZVZ6T;9CY:Z."$LPZIPU0')GX542@KV@D
M%+KI)AKTP+<VDM`)I[<I$^/+0D,.PK1$H8>[XX<XZN[+S_++77F?+A!^?KLI
MBF6EP37D#K89'#!"T#!-9>I1HIT4$*N*"J'Y-,.7N_&C'!BD/&M1\6.S_=B3
MR7RYFZ^>S.8XNUN_(`"&%&>1!JL$XLIH#>O%H#G762P?VGW1'\N'`BJ+[;:X
M?C&7G\7BH6C%\W:C`T7,.XZ4!X@@BR54#%=T`$KR`E2&]D/TQ_!!4,IS1O]8
MS1=/IA%O#@\MEW>+H0%(QACQCCIGK**4P$<*+,QLFCVT0Z`_/O</42^']@E,
M;C$T"(12137"J'(:4XR1J*[%@D>M)HO)0QOWASNPNT/4"Y._9'+X^;@HH(AX
MSCF@QADJH6"HNKY*!''>&A[:R#X<>SOBD\7;VAY:UA[J?:_H0UP]/")0#`P4
MA#OAF+<&,^=K*Y:2/#,D;%1^YIOD^@4GBYE;BNHOESN*ZBE]*A<+7ZY2BY1#
MO&W]@D`-0H`JB9"D%E&NDV-Y3PT0-D_-&E>O[LCJH;#JMHP?`TTJO\;\L/OT
M^*A@H<34"I`:Q&ED4_,;6,U;>#16:XX&'@_%C%>7=1]`Y2WMK0/KF/_J")];
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MRTLPTYS*C]/=H*>!-'DW*(Y:56J11!FT\9@TCHM*L8H+)>_`/XL;-(OE0P$U
M73<HMU@AAI%VU'(!@%%(5700J_/\WF=Q@V8Q?!"4IN@&%41YZ+P@T"ME#/2"
M^IH""?(N?6=Q@V;QN7^(IN@&-1)(1)FA5%GAK77:XHH"YW6>5G86-V@O!W9W
MB*;E!B642PJ)0U1QEBJ10EFI&A(CFQ>6=A8W:"_L[8A/%F_W'_R\6<V_'2R'
M<^#)X+571`KMC6$.&.&BQE#-SZ"+""O,-\'U`TI/3J\ZE^=)D[N4@':]*6Z.
ME3L[_4U!>6\Y<1I[8;3PU`A572\EI#QO3SZ7`S2+Z8.#UF4E/_I!7IG+'^5B
MMME.M&&5MWQ+L";*.0:1&,NI1XBQ?1Y&I"M>(?,JGXRK;?>S`PP#6.^"\&F^
M_N971?%NN2E6Q7KS:;9IVO!;OR=8Z"B.UTB-'!72111QI6]&+#-+78ZKD@\H
M##U`-I8K];&AR_XWK;J27J:+%#+%O"=,>04P441`*!UPG`(+!(>-D987XB*E
MWAE&13Q^3"K+1@'0.RJ-YY*-U6FDBXNT-:-.<)&>A,H_Q44*"!2,>9RZHGE"
M!:2J!D7QL1+">G.1MN5Q>Q?I20!=ICO,Q+4EC<24>BN\4_$R*RL:(2?D(EVD
M;?EV@E\L#Z>W*1.7Y"(]@RA<AHO460J(C'=4;8$&&DMI78T,]:-U=^UNDFO-
MC]-=I*>!-'47J?7>R7@F2N(E!=1@#&E%#=/N$@PZ75@^%%#3=9$2JJ!GA'D-
M4?QI6=2(*CH,,I=@M.G"\$%0FJ*+E".@C;=&`(\)ED1Y:BL*G,SL3W46%VD6
MG_N':(HN4J\P18B[U%H1*6<B';ZB0$F0EZMR%A=I+P=V=XBFY2+55'#`#`6*
M>QOW':=9+:!>\KP27V=QD?;"WH[XY&4@E<MUO,+%;[93M`\]'SBSTMI4@50X
MA3@7$+%JKE;2O-"DH=O%],?+GG`9X_+\*:5!-5C0ZF>"(!981!#4FF"G@)=,
MU99)ZL8JM7)NBUDN(*,QM+')[Y.G`H@SYD@[$V]ZGGD$H>85#0P9/5T+6`8?
M7N-D)QPNDZ>3LV"-R\KQ6?@APOG]_GLC$W]Y+EBB"%`D'@W8&VZ%D-A4=!A"
M)V:CRN)`V1_]H_!QU^>EF8]/GPM".T*Y$#P%+VJ@E8BBO:<C14]-R_#4"Q\[
MT)^GN[Z6+WYUOUE'->QFOOR:6QKC]5<$`;VTRCO*%#',$`NEKBB2G(VVP?82
M`7*JPWE@M,[F-'HR^U,]1T^&!F<L)?]7WK7DN`W#T"-5U)<"NM'W&D:*>`IO
MVD$&&+2WKYQ&00>%$UN19:==!0%"17JD:5)Z(IE)T243SEBI@5RM'3RTHB`4
M5UEX5(ESCI+*\:KG'>Y40;HETVG#@`?K`@*#0"+1XAJE6.IV<I2PNHYK`U5/
MN>''ZW!:J-R+3$KZ&1K+A8\,*%(6T8X&Z37U5-!0%G95/S;84+EE0)4K]^_>
M6N<9'$:(_0UBYRSA#GSP)*V!QY@@438%*5=<D(6R4Z+J&\L-U5T9L59DSA8=
M5/)_Y<\S7L/+T!_-I8_+;^;HU#2>DSJ*46@3F';)<+AQ@9%<_2HD2\*[#O$Y
MJ*-@4Z(Y'G>KY,X4&J+]I49<2%%P;'7)YQ'JZ&Q%S:>.+D/E/Z&.:J637TV9
M,`W&NPC.RI!!L<RU"O%K;83/UO%LZN@R@)Z3)HC1H`?N0`E/P4@_=E^[/&PZ
MVKC?C?,*>EO`%RS#Z=^TB=UMO._+%"HD##DRNR2@'WL\3R4*-X6ZF.8)++U2
M->$8`3CZC(3V%IN53*JRV;<T1*B.SV8/=O..V51:)<`$%3@*)VU*ED3&!2C=
MV;9_R]"R,G1%CB(;L3_\?#-C,]VO_?'E^^G#U*;\Q1S93E%!N!*:"$:\YI83
M>47,86$1KJVN#!>YC15@:N$]YMUPGKA1O'R0#AB/4D62(-`878B$^HP`IZ3,
M4+:Z3ESJ)U;#:VN+F:A*,5>TX]2B-Q)">K,*)14&<8V9QH7O8WMR0^LH0&DK
MFYA9E6#I$!U(!D%35#:Y4$T9(L&\>H.ZK+![6_+L.C92`:VM_8<?WH=C_^WX
MP/OFSR$Z84?JZ7BUQR48(HW>RKQZ1@H;Y+8EYZ[K3QY`JR@0G>XH\]J?SBG6
M5!AZ7[*S7(#DE%L:95`I-Q-"Y_E+69B[XI-H>QV0;I]G??XT_O3+X:U/7WX!
M4$L#!!0````(`$>'!D<LIG01U:<``,?R"``5`!P`9V%L92TR,#$U,#8S,%]L
M86(N>&UL550)``-FRL-59LK#575X"P`!!"4.```$.0$``-Q=:6_CN);]/L#\
M!TX]8!:@4M%&+3W=[T&BQ$8!J4ZADNYZF,+`4&PET6O'RDAVEOGU0VJ+[<0V
M5UF9#UWM2CFZYQZ2YUY>4N3/?WNZFX.'K*SR8O'+!_.3\0%DBVDQRQ<WOWSX
M_>(DO$"?/W_XVU__^9]^_I>3D[]'W\Y`7$Q7=]EB"5"9I<ML!A[SY2WX/LNJ
M/\%U6=R![T7Y9_Z0GIRTOP6:3_-\\>=/](^KM,K`4Y7_5$UOL[OTK)BFR]K\
M[7)Y_]/IZ>/CXZ>GJW+^J2AO3BW#L$_[W]KY#?JWD^YK)_1')Z9U8IN?GJK9
M!T"<7%2U;08CW=>?7GW_T:Z_;09!<%K_:__5*G_KB^2QYNG?OYQ=U'Z>Y(MJ
MF2ZFV0?"!@`-'V4QS[YEUX#^__=OGW?""T[I-TX7V0VE_&M6YL7L8IF6R[/T
M*IL3'/73;LOL^NU'S,MRXPF4HH!29+J4HK\<>/#R^3[[Y4.5W]W/"3^G,@X(
M(%Z^1JL-7DW#;R(H]_&Z_4#5@"_)",[40G[]2-6@F\Z6+&8Z^O#V8U6#5XM9
M;^<HENE<<>=X]<C=H.?T:V?D4_M-^O@],EQ;;\5U[<G9TS);S+)9(YX;SP;Y
M[)</Y--D59W<I.G]Y'M:ENEB686+V;?\YG99_58LLSBOIO.B6I59>%4MRW2Z
MG(30=VW3,I'K82.(;==(<&(D'C00-EW7F-2/GV2+D]\O.C3UC_28^\!#T&ON
MRZPJ5N6TB5\$)XW@#?2_=@A!NIB!!B.@(,$+2O"CP_G?/Y^^>+K)=C%]JP/5
M\*[3ZJK&V+)"L)K.:39?5MU/3NA/3@RSC<I_X:1ONP&*J;8&:/B<T[RD*+O.
MO-'EPG(*BG*6E21GZGXK+:<'6J[]QNFT(%G`_?)DHQ%IZJ39K4)OOVUH(TZ^
M2=FK48KF:56=7[<HSLL:PV5Z-<\F#L0)<J&/?83"V'&A842=12]P[<FR#TX'
M1Z>$&9X!N=P1+O>,RAH9**Y!BXWTJ&9P@A\UOCT#43FA;$HW$)=\XB9!HQ8]
MVTW2'@E3P.Q(5$N%)X7R;J="F\*GO)I8AF/ZKHOM!)H(.]`W8=@;#+U$6IJ8
MK!Q/F2@\)<+$QJ:$+BDG4IDL'>!P.%6B0'A%B8O6,6L2GR,LDB1`C9PBQ<5=
MFB\FR`R2``4VA#CV<1*BV`GZ!,US'&E-8K1S/%5J`"K1)59.)91)`YW*M.D@
MD\.I4P.%5Y\XR1VS0O&ZPJ)10O0<5*F;E.1B7\C7;B\?B\O;8E6EBQG.KY=9
MMNBFF5^RNZNLG"0Q-)P`17X4&Y$1V4$0)[T^0NRSB)5"<YHUJP8)2*^'W5BK
MP(\&&JM:J>1VOV@=B58^[6H8)0!!AQ"T$$?!\*Q=':N7M,;&]`:X@1G?BAN4
M`1H-H.':1AT+V#EY(R1H(/3(D4&'1X6VWL<3)RZ(U_73UZQ?WN;EFOG6>HQQ
M$I#Y?.#@`!H0V;8).^MNE'C,L4*=2<WQH@=*8X;=YV<B@J:09H:P<1R&^4+'
M"[D;8M;!'`O;'"'D.*R+A1%U[+.%$F9N=H43]>2.(:1H\*K0VB-Y0DN<35\9
M?\SF#]FF:0>&)G8=%T>F1?Z,72/JHQJR4,`<5Q39TQQ4.I0TIEAR6;(J@ADB
MRA&XY0LG/:V;>E9CE(HEJDCF""1'(%LLBB@BG2V$L+&R*WXHYG0,P4.U2X6^
M+L@3-L+[,I^OV4WFV<-VN/(L(T(X1KZ!;<<.G!##N+.;!('%'#-4&-,<,&J(
M-%J8<M%"":\,H6)H2OGB1,/FAEXU`*6"A!)N.2+$T!R+A0<57+/%!@8^=@4&
ME52.(2HH]:?0U.=D5C+>LHM#&UJ6E\1V@JTP0<1ZORLN#`PDO(XA8FRH50S)
M>*"$5X$U#-V42J]@*(@'2KB56+W0S;&RM0M-\8"!#]9U"QDJQQ`/E/JS;\U"
MGBBQ>'"Y;32"OF>X"!JAAV,R#4DBMP]"./!"X6#`;6FH2&"HC03\C`J$`:UD
M2L>`2\4!@)]2"?772JTRZ>>C6$SWMYE@%7UA!L>H^.+.[)-[28K8M!X5BVHU
M7Q(C6TOAGAL'<6S")/23T/(\W[3<SE@<P(A9XX4MZ-Y?V>.2TW9Q!ADT?1#R
M^+3\^+QQ"/<@_(D)MAB/;"J]R^U=ZBQ-TQA46=Z)0F7/X=SQ_HWTC:S>4N\[
ML1%;CF5&D6,GH8$#M]U2'QL^3)B4E_^IFM6V!B+V/@T',_L552\I?"K*QH>6
MW>>]^V^H@3A%(]E9+@"\D.T=(B.]%1.#/-"SH@093H!=;)EFY'4F7`OQCW7&
MYPXSVL7>4^'BAV/$:Z!&:,P?YYV3-0H.C7M.HL8T\GFAOS7VA=QG'OU?\D5^
MM[KK=H4YH6.$#LD;;(R\V/<#&W5&D`.97@\1>[+NRED#AG=F(,@2FPKH(XBS
M&L;,C18EV*!ACQ:(T342-1`$7ZCH,;R*D#ZM&?&CQ(&>[WL(PC`RHM`GN4=K
M!"/D<BD"UY.UU]*?I!2!CR5&1=!&$&]]G)4;/8JP3L,^11"B:RR*(`9^6Q$D
M*)![^_TL7V2?E]E=-3'=T,78<4,<&C;1)-\T@WY>XIFQ]`OP[*9TUVAWO[E-
M,8(:I)+WX#G899.6`8GEK-]*<CK<&_$]6WLD21'-(]$H5=ZPO!HO2A+CNA(U
M670FB\;D^6I)SX2EQ^U^*^9S7)2/:3F;^"8.XA`GT`T=Y"(G-H.HLQ]X+L=2
MDT*CQU*VCV`-,/A!(8,6,]_RBLH&8%FI.A+WBL1OE+3S+'0=B7[!M2^US<"X
M*,9.T<YU,@TLCV+I3(=?A>;NJ2*I7H,P25`,'3MT(+8A"B,W,(T^F3=CTY[<
M;QT7+I8#\ICD&8G;Z)@'8[_Z7*P-O8\@RF[RQ8)^ODKG]"!W%6DV%]\2B;8N
MDG5$FS&DVFMP>)-M$:K'G&X+^<.2<(L3)9%R_TH_9[-)$-JFDT0H\4W;3`QL
M!+!?RXPLQ'ZVB)05S4EU"T,Z7V,F330OUL&7JBK`X"3*9KDZR%2<UAXF52*%
M;9_-E;/R<C;:))7;D8-9J1@U$A*=/-WG)3&(3-L/(P?&V#8MW[*Q']&8$`=6
M;$$K83\J4,K*\>H>+4)IX6'F4U2]=5"I++$<G$59^=;!IO*JQ$%6)?2[?3:7
M?O.2-EK]YG;DH'Z+4:.NC."ZGA4B)T&!;R6>B4@ZC[NX81DX;LL(W8U-\O/;
M0P;YBPAOWR;%7T)(F@\'ZP?O;I[+2OE[F><R^\,[S^4CBB.)ZHU6K=6J'O>U
MX,?I,IN8<1(;9/`[&,=FX$4(PKZ*Z-L)^Z%G:LQI3JM>T'`'?GDF6?.H04D4
M2:C.KU]>Q3DONZO#7D`"BO((!/.F6(,2+9-K21+.D70=HF1O]J6,S]&D8>H\
M>I6/*2:+.3%[N<KM_!H5=_?9HJIM?LOF]`Y'5%3+ZN(V+3-ZZ^WL:_I,.VW5
M7_OF)3[$+C8CUS3)Y]"/$Q@[MD<^N+87F(RK$9I1Z%/`M;L1R0QH'3IHL8,:
M_$=0PS^I\8/.@>/=IRA'^)XD<*"6'$F*.)2WQ5&&"Z>4T!NL9ZLYP53;CJCM
M=70AU;>;K,82/;]\I\47TF7LYL(V##W/CCS'168`H>DZ;AAT`*,@X+JK:#A4
MFI/5SA$J-.MBLB$ZZ]Z`J^>W5`?4+@E>'SE@&[-%CG$V+U\0&;IEM40490VQ
M)[@,W]@CB3-'<+PX]CCCC#Z7^9*B^[R8Y0_Y;)7.ZY>1;2\V'!095F`8"<)6
M3%+EUE@4^#Y3/4/.@N:H4(.BPO$"2^R\`$'^V%1:/W5\BBO"FA;5?).8/0HH
M1^1(U$S2B4)EWY)5F>_Y\K9.NXD&5K?Y_661+);Y\KF]0L_%!C1"'(4HL-S`
M35`0]#`L,S*D]$?2]A&4Z9$@!NN0P;(`#6C1<P^4MXB@H@W8&'Q:)TSW,(*W
MGS<>*534`F,5257N'9)/I32RK4U=/A;_E97U?Q?TL-;/A"%B\R'[2GIR^]*H
M#=T@BB(4N]CSL!'ZT,"=7<>PF5[?5&9,LW227_9`CPM08$*'Q2GAE6&=:FA*
M.9.]QP)0:,T?-<#1D,NQ1C4TR6(K5$K(9ENA8B!DU_J42B['L#JEU)]"4Z?C
M+2<?JC/L*C.<]:_H8M^TK=B.HC@Q0A.9OM67&A#!RW3B]H!P=!>0&4J+!RJ+
M9\+'!PS1FHP5XW$U)&>I>*`VU%,BEF9^7VUXN&8=R0QA2(^WJ\%#DZT_:IS?
MUQ.>^CV&ZO/B:[VE\WM&MV)DL_`A*].;K/Y'NAL#IWGY1SI?99,H<1S3CBS?
MB4P;0Q];IM>YX7N8ZRBZL6'7'(\Z@"!M$(+L*2NG>96!^S*?9A_!#=<[56-E
M47=8&D'C#QS#/H+6YX_-&V(5R!>@\?LCZ'M5ZWKSE7I+'*#>@]K]]Q+YQ!I7
M1YC4W,W>>TS538^J`#Q(,_)%ZZMM-^J?5N%J>5N4^?]FL]\7I-4OEL7TSP8]
MG7M621LLOM)8\8VZO;:#OO5RRZ]O&:U@DG]&Q:+>";5*YY=9>6<1]RP?)X8#
M(QM!>EIEE/3)B)UX3.]YOS>?-$?W%E\%IB_``'G.G4@X?P=T\H3Y=^#.\.&_
MW2);@1<:P(KR`&HBVIA?EQ`K^FIAFRO6;(":CLUCD/H<X55&T+,"UF@!EWO[
MIKZTX/B=X5"Z<'R$S-UU3&G$>Z+MK?3B/>%7D7:\SIZN=F1/?V051;^8)4_W
MV91\O"SHCUK7Z2XW1@_-20PM&$(3&8X;66X<PSB*.@_I%97RF<<HW1HF^0`/
M!#[5>65YQRC)E$H]1NG1^R@^-(2`^K[@EA*ZP8;^N$]0*"WO+P4Y1J?@SD)&
MW7-'G8B,FSFF7&3<+G#L?4I(A+I+:X0+8HCF5;@HK[-\N2I)_K3,R-_6BS84
M?W)W/R^>LZR:(`-[@0^QXWJ>&=A10$%U"1*VV4\_T@M#<[COP1,M[M"#ZQX^
M*&GQE_P=%(T'W<H"5>NL<X)G[X_F1F/8<C6>]N*+OR]-]0(<O"`'W^HZ/6FJ
M%GQW!ARX+$`RPJ;BV,`UGB83V]JE9)1]DMWU)<7BKOU@PS3-&':*#>1I,7B_
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M1'X'//2\9,`XK0"MYDA^?I_1$W47-]V$IP*/VR\A-6?Y#QL<5+3S('%_X"8^
M4F;P>KM.XR@]>'O-U??71P9-,0;N*T=.0J3[S%"YRN%FT9?-*.P2_S_R'96$
MJ,V(E#>5_C>X?UO1XTC:`TK7MJE/8M^.0T@RO-@SL1D0P![J@)JA90WRCK8P
M.LTY4?O237%-2QMW1,ZJ^FT;\C/2=YHE(Y!7U4K@+N,CM"3'3NC1-N+@&YH;
MK_K3I]??P'HO[TGO:A@=;T)+=X*1U+^/2("JMYD5-<613A?YM2RJ:N)$R/!=
M[`8!C!+;P([G&OT&)]MGFL$?$]\P\:E:7?TCFR[I[H3UV_(V8M;63H:CGAO"
MV+::X]5`S3IXQ-IS_D?MW7L)6[O;1T?@4M`;WGOH4D&!UJ,X1)IC\*G50YK/
MZ8LSN"AK]!.(,'*0[<,$>9[E>[9M=E/!.(&!>8P9%C?(80)9VN&J9U;7JWHS
M7AVQ6%<DCT[4P+,LK0TY@LG61H>H/7POX>M`0PTP^1+N&^\]D"GC0=-43+)A
M](>T^H\_FO,!FM!K3J`/7<-/(M,SO,BR70M&9H<QP@X>)(R)`-,<NEHT[=IH
M72P\TEQ+J-4TARO=#39XB&H."NX:_>N!!?%QA:0W&D-'&))I\_<>>J1\5Q5N
MY!N`;1./,,"7ZYL;>!,;VVX,@SAQ31A'ON?;W@NZF.TJJ($A:=^.T\20C.(B
MZ2_IHF!&7TLB\>5F?QY\U(9BV&HSSC82B"1O;858CR31\\:6B<VSYM>NI#\4
M18[:H!S[8L;9L&*;7P9M8+;]+<KHW;6)9?CV&\-.E2-X71QUT/"$>#0O*II%
MT`,+Z_O4[XI%?:KAQ(%N;!ODL58<>;$/(R_LSOLA/_?93]<1-Z$Y!+?`FA/W
M:=Q=WF:U%J2+YW^K-I;7>+1;@E*&X#H,FWS!LB.R.8[V_!HTL)JS:P>BCB.,
M#4.A6%AZU2?7>Z'TF^@[/=\5,>2I&D,$4.!%H;3_<-;YDO]9Y<OG\*JJ3V2;
MQ`9Y+G+,")IN"$/;=Z&#$\=V+"]V38=U89WSJ1KWKM=`P(\.RM!7,VT2L:=B
M(LC82&H>HN@+)=V&M[0]O<UF*WHY:SVRHF<T3ZOJDE;5)PF.L6MX$?*B*`FA
M3](BMS69!*'!=[.=A!W=:Z8MM'JYK-[C<_4,:GC@1PV0^QHZ&4X9Z\@#T<DY
MF9=@4D^%=S=-^PJV"L@=B18I<66[G*J,GH,J-<ORR5E&DH&DOATZ?,JK21P0
MO3-\C*+0BIS$3(+`ZTS8CLNT?B;R7,TJ5,/I[TVGB%AE1XBD_3*CFQ\^6>&B
M9H^.5-GTTTWQ<$J\:R2$?-A6CC<\?T,I9/@YLC)(02_DNP?'R$_6KX2'+D2Q
MC=W$,$SLV9X;)5'W?,M'3&42[H=J'O-=EV[0\(QW/FH.#W9MK'#.4%@)43#*
MUUW>,<2%6!G!^!;#74AV!YYRZ%F^F!;SQ=>T_!.E]_DRG9^=H?:J;].S_!`B
M._#-.`J)/=LQ.GO01#%S053&B.YHWT`#%!MHP7T$!![#Q?6*V62HA0Y%)&=:
M,!X..8JB0W$I5A:5X92M-+K'_UW%4164C:$\JL2/0G%?XE'M+V=_H.(3L9$N
M9E_2I_SNU[)8W;_8=(PPL$PWP@X*;.203R;J;#J6R[Z4)6M(LWH3>.!?T[O[
M_P0$93TZZ/4\-5!0(Q56(6F&&=1\2'+Y%'W$O'(H_)#\BJF\*I[9%/\`'[M4
M7Q6-8U!^9;X4&OH9[XH!Z6SU?HJZ[-<6`>L2``X2#QG(AZ8?QXZ36(G7EP`L
MTPNXU@N$K6C?S$#+V7V!FZM2IX!"QN6!0=CC$W=.XO2L!^SB9=]J@#278UD+
MD'=D>R5`$37,VK-NIZU.>+:;^!9.8N0ZD>N9D6/U*H<CW^81'8''#ZPV?)5"
M&=K8A$8S8W(*(U-%%->8UY3L$1<)_D:B*C(>%,HZ$Z^.O.PE:I.EV";/"R/H
MAZX5V4;LV=#J#!EFR/5R.?_3=:O(VC9!WNF3!&6,$J*5+4X%X2-*CWYL\[%/
M/H2Y&XMZB#NP+1Z25#!KQ_>4;BE?=D8,V[-MB(((A2:.'62:?9G-LF*F"]K$
MGJQ9,UHP%3T,Z9Y\YS:MLLV3D`2%A),_-A'11QV?@+0XCJ4=&S3LT0TQND:B
M&8+@"Q4]1F*^<I8OLL]DNE1-?)*[>(Z+_,AVW-C`4>3%G3&41%R:(69AX%D+
M!09J9#(S%PX"^2<O>KB3F[\PT:9]#M,SPSB-X6=R)+HBZ<2>R8PH)<PZ\Y6T
M?5:6V:PV]^J@2N@[KFLAZ/EUZ=>TH--;];##=3:QI"G-RM.C:W*4C\UM=!5(
M&0Z;U<(LFQ(-2"J?)+WP>='P>>S#>_<SM4>B%%$\$JU2Y4VAI1]*J=?7M#PO
MZ\KR[(]TOJ*GPM=`)G[BF;9OVS8*8>"$H0]CN[6.8R.04#%ADT.KV7U:@@>*
M$/S[JIK1HY(:@?L/*5439UQ$W08A6U+E"$8RAD&#$M0PZ=D#C?H=5?%VL<>L
M?-+TCU(!Y;W:JX2*2!.I3[\2X<CP#--$@6O[;F+!),3]BX#82:`K6*GFMC-,
MS5I1&B=%*'<=6RN7XA7MXV=O>SABJW(+,SL2U5+BRN[*MR0](OJT4QIC#[ND
M%V`76J83>X[OFKWI*`BYKAQ086]0O5*5J"DAFEN_!N%81L?&E)\Q\,:F;=*L
MCT_CY%W:K76*Z.*8I1;3+)M5F#C\N;VKB@!(Z8O0S5D-$R,*+1A"U_H_]JZT
M-VY<R_X5?IM^0-X;+=3VD8LT"*8[#M+N-QCD@R"[9$?39<DCJ=+Q_/HAM55Y
MJ3))D9("/#20N&.[[KGG2N=>7FZ>9R6)#RT/QY-E"WGI][R^J<3'J+,-RKR/
MI]@D1DX]QOY<Q1%E]VYF_3D`/5+I\>E\KD7'IHN2+#LNG<NNH1'I>YQ='(UJ
M(WPC>J?3HU>C4,UDB>WS^3S,]Z/[.N_6=U[G]4/J$Q]%@>M:"?LS2)S(1]-8
MUV%J*[R[1^WC3??:QC4.$RK`8<EL,E&D[;)0+<28I#"M1I;$/ASSI*GMOI$F
M3VR;S9ONOB'$&KC9PI::F1Y4VAX4Z>TSK';E6I[OZ*&>#A;O1^XCDJL[U#1Y
MVZ2N%6,4VU[@)2Z,D>=8T;CW/HDB*G?GD5;+AN6X7P+1HP4]W.GVM1XQ&P6.
M+Q(KA'K4TOMPM,9"K.)<+PQR&J\[`H8V]$B0>:$J-1.4C12HAIQ[M1G('(5R
M-_5T!X:F'G:8:)/(L6D<VL@+X+'UR?Z0VA@D\;&F=;$[)KV#HG(=CB`U@DIF
MAA5)F1(AQ-SU,9WA2\(BS]%65$,!^5L7KZ@XKZ>:^I3_U7VK2;'MN`P`BA//
ML<,84>A;TR`9:BRCQ$T:UHECL^CYT=;C5*K.2DF"9PTEDAF*]==&#&?_$YNJ
MB2;V5(LA>?JWHF>:O9(I?U1)$VO7H?:WK/XS;\=WGO<'FVDPVS`@M^SOZJZ[
M]G=L*:8TC*.$4I]58!%*$I]8:&H<0IA`X7:>&?.&]1&UH$=];*MWN(]-&3Z\
MZ:%S#>W`@Q&]3*/+4'0$NH;K!T9.57_ZF$@T)]>/C5KSTE2,Q'J<2JR=ZX&:
M#<$6>J2&/:P6>YXU9L/NI*3#PW,<B9MXH8=#C&$80QLY%IRZ$1Z-A$XN,F9\
M"YEP`&Y.<M7",C\)&H^(@12XT6#HRW[&@V(P]\D&1TOB>XLPQ;0WB_N?(.G-
M\T\BY6D@4BSA?3KP+>S5W=!IS^L_RJ)-7>2$0420'44.(E840=>9!IIN++1;
M:L;'&TY:/:ANKW2_I)VO_N3`9%10D3B!I&.>,[FTLB9=$FG!/&UJPJ]`GYBL
MO^GP.>&>Q\X6I'FF!Y6V1T7M&(_AR)"K^DMQ_ZV-?[`Q3='DP_6$XWDYPW<;
M.PUL$G@^DW6*?`_'CDW8&&?4^L`1NJC(+`+#(CV=9S&>BE/5H(/V`8S0AZM,
MCS_33#\D.T5A*$AB,Q;KQT<N(1@+C<GC2.38O3#!839:&YGO,.SDV\>=&*5T
MGE[W&>/J[O?\]E`7;9$W)-OO\QU^>HDKA20F80B])$D(<7UJP^GD[`133&8K
MMT8LBQ7:XQ;<[UG!W>SW)/PUP-6AU3H#-$.U5XJ--OT^*58G#T#O`K^.<YMB
M+DZZK*P;".>6!=Z$NR)2;XQFL1[(Q=GWJ^]YS<!4+1_Y73UVXU#BN0Z*["A)
M$!N5Q<C#TT6E"<54Z!0%,Y8WL+#Z&6S0XY;I%.B/AD#/9=5`Z%\^M+T82#1R
M5HV%6H]'?TS$6D"R5)WK#AFC?`N-(W/.54L\M5)[+]_8\EEU6SZK8<OGI[S]
MHV1L_\7S;'E/B^:V.K`$R_?&%TW#@#59N;NZN\NY#_&/Q[QL\B:E!%FA9?=7
M<D/H.7XPC+5"*_1MH7;4N@@-9\9IMW5R>;<U7]K9@E,'P>3A!W#B8W>KUN@E
M&-V4VB2YVL,@D'!_BN=`+C'_ZQ$X>01DMMK^#(^"XF[=M1\)P=V_AB)PKMQ8
M/>);*$O6)Z':TDLHV:6]:K_E]<?RMGK(4;D;K:&;IJVSVS9%F%#(I_"('44D
MMJ@71A2Z`0H#ZB/GO8NK-5DQEVLZ8*!'UFG"B`U\'=$M?>S[9:XN=-XTD;R1
MQIHN;RHC3^*LMZS[O\$T?_WW57.H\^O\1XL9`W_R.T/=)"00)S;QXHAZ$"4C
M"(=:5&;F0Z]EP\7_L[?QEP&G[&E]FKE6$;@E:9ZI=_T_#%C!$2SXRN&"#N^Z
M"O@.F<*"J"LHF]1';<Y=E$N]%(JU8N@P8!C_YJI=MJR.^EC>5?5#-XZ8Y-M&
M`<&1@WP["@B$.("ATP-``;("+#*BUFK0W)L\P@/3%XB7+QU2<`)5J)`Q3;O$
M*'8U^M5&IJ_#D*F'06R4*</0N9&C$9:W,!HTXUAE^@$55,1=7J2]L2_Y?<%M
ME.VG["%/(4%A[,,X#CPK@E;"+`:C'4ABH;ZR\H<;K@J'E^D("G!4@F*FSMCE
M5+$(67(909:G"[5;D]_^X[[Z_N_,R[YL8U^\K-;.,?"&Y,PF:V5EF8^_TO34
M2.C$=9WMBO+^]Z>'FVJ?>I"X'@PL9L;R(700BNEH(/!])"H0<I]J6!D&,*!'
M(Z$(DMR\+P7F:)'3`%%&-+S[SUP^\]*KT;*!MUT1>#7WB9"N`PBK0.IL_['<
MY3_^,W]**:9>$F/+26R+(.HD7A"-AFP<"QVRI/[IRU0"`RK0P0(,EW0M(,V:
M:#%@DC"E:D""*VWUP`L2+A8$JH1M0"-F.O"J))A'A9!FD$-=,RM)T=QF^__.
MLSHN=S1K\S3V/?8?)"&A%G82-E2AUFB+1+'0/3&S#!A6C@$7Z($!CHP-TG>`
M8Y-0#W7^WA>01:B3TQ`UUC3HR#DNSDC);.HVH";S?:@T/DO2=4A2[/.:,!/W
M5?V4.CBV'#OPH(N#,/1#8IV4.UCL6#/5SUZF!NDP@1&4=`$B29=H^6&.*:7B
M0Y0D;97',_\OUAUJ3&U`)V;!?U5SS*%!2!W&+NDU^Y74\P+L(\>.V&C()S"F
M0>`=NZ%$:$N?](<:UH.I[\_!2.B`'#'O"X`Q3A2GI2[3H>&-/W7XS*NNQ,D&
MWG$UW-7,AT'AK>[7YH_%A1T@Y,6.$P4DY+._P33]BX(HC@+9UUONTY=ZSWM4
M*J,'1=;$WWUSA"F*@#!7&O7@&0GO"(,:81M2"$4'WI"*.51(:<9Q4)*P?VG2
M&`8T(4X4>@E&L>M$K@-'4['M"*UVF_/Y2^G&Z2"Z0Z:@'-+<B6N'2=H4U4."
M,8WZ\8*(=Q1$E;8-:8BR"V^HR#PZ%'2DEZW>&'8MQV)#F,2-L(U"*PKCL;D1
MNK[864_S+"RL)4-ZG:<F4@S*ZHDI\N8IBAAOVC7EA`PA55$A;W.ZHN3$6651
MIT1(6Q"SM.NL[;/[U$[\T/-1Q*S8V/>HFX3V:,#!1+B+*?>IAC5D`@,X&@G5
MD.3F?:4P1XN<.H@RHD$/GKE\1@/4:-G`>Z\(O)K[1,BOF3C>7S\<*W!HFS8K
M^7J--'%M"SDX#I/`I103+PCI9-6+0LD%%'-,+;2:HK^8ZO?^8JKA;-43F/*+
M*V;1*SK5L1BS2C,?ZJ3J6X5Q@:#+2S)T,+L!/=+IS>O%&OI(DKAG+VN[8\VO
M[CK#WZH]HZ_IMQ5/2\Y=C&F$[,!S/->)8T2I;2>0!)0Z-HXLX7LEM1@S]Z)-
M^+I#]DX0_MMP%L!Z.WB%J'OC%31#_4;VJVEVZM7%;_HIDW\OK[.;?9[:A/B!
M'4$4L-<^=I/8\:/!BA/30.K@4LF/-EPQ'-^YKQT>T1UEJD1)*I5^CE0EZ5UZ
MS.I.9UU$8.08VYJ22*(_)QDJ),AK0R]%K&QXK$KVOPWZ430IML+`@4R(`N)A
M$KEQ@L+1J(L<H667>BR9'FOT*?D(BF5G!DM90-38E-03XT1*#BVD.32K,F_1
M(R(ZLVC=F@;-<^:<)&F@2%BA7MBBU4-6E"EUH!U1B""B<8CB@,04C<8<!*7.
M(%&SL+`B@:\]+EE)4J1/3(K,,S=/@@1(,Z)!;_)R07OF\;@1S9GI1*7ST9+4
M&+3;%7Q??+;_G!6[CR7)'HLVV_^6\_/*4T@I"3T2QZX5$TJI;]%@,.HBVQ$Z
M!ER/)=-S+Q,XP-']O2C!@`]\[1'*JL],8L54:#E.)2=NYM!I1)<N,G5!G_0P
MO!&=TN1,9>(AE-2M+WG+5#'?Q5E=%N5],UA#T/==%/NN@_W09]*(L#]:LQQ;
M:&)XI@G32G5[>W@X[%DYN@,TORMNBU95HE0Y%-.F!>B3$Z41$!@1K:5%;S-S
M081F4KD1]9GK1:7U^9+4F^LZSYI#_=3UL`=35A#X;@"#)"%.3`*24#R69"XK
MR80FI.=\OF&E&2'U<SBJ(J-$G)C"F.9,3EZDZ3*B+6]P<D%8YC"X$569Y4*E
M[X%2[3[_RC3L(_NR25T<V4RQ[,AFRL77U]@X'BUA*G92V(R/7VZ&BF,"'2CE
M+K,$:Y*M93.$*4]7"7%EMIL\,2+20I:G;R,Z,L>#<\UB53*$5>1C><LE*Z=Y
M__?'\O4<^Y=JOT^J^J^LWJ5!%-AQ;+LHL(,(A4[BA]8((PH#J8I%MVW#^C/"
M!;^,@/\&BO+,^A2.&PS`935*>TS$!&S-<,BIFXE(&%%`24HOR*.IX&Q$.XVY
M5RWSC,O6;J^6%2+;@FR4Z1'+@Q9V/83AN$3!#2T+I8_]56EM5K>"!9RT#9D7
M]B4<X7<7Y_=%R8?;X";;\QM4/@P7'\L6<O(4"M9Q1GF3+./&>Q%GKBZ>4<,)
M+"^>S]Q&5&B&`R\+N)E42(P"7\H7D[C]@9O\7-7=>=5M6Q<WAY:OA+JN/C$F
MJK)EK+`/O?]8LCHH;]HTP,CW(]^%GFTQA?-@;$_HD..KR,\RP-;1+.E!YS)!
M$AVH;BXRLH/;UW7>!S`Y`08OP*D;H*W`<T?`Z,GBHV(=]%\<22\:WZUH]\)>
MOQJQKT"Z7)8X>_$NO_DE=>W(@001-W*I9?E>`C$<+7M1'*3?\_JF$N\>SC8H
MHQ^GV,1'D=-5DW?@MM_3U?1[NM0*4@T<2PCX<N0JB/-[UWQSC&O([D72WI-4
M/8QO22XU>?26%.HD:Z[,_3/;'_+>L$T2'`>!9U-""'4#CWJ3OE)")6=(YEHS
MW;`\(W!ZA$V&U5FZ9HA0?;+6`=R4JATIDQ<U!;JWK6DJ#HE)FC)5>@HW4I6L
M\.&W"E_=]5^W!2LN?\]O#_S^X;Q)K8!:F+I62!&!,/*1[Y(!%8P27VHQFV$H
M*VDA.#RR+_,?>7U;--UW_\IJ?G5/8Z(,U!`Q#27BLL'27SX>\?-XG7@`CBYL
M0X<%^5:M//4%<ML*KMU;F8I5-\E:JMGW0<46CI&-[,BRO21VXB`*QIDK:"=R
M%TV;16)8^<FIVH_B#HI>88J298.RS&^[AN%?1?L-_,8"]`WPJSF?)XKJ[BZO
MQ<_,62B*\ROK90.HO>K^>9*!&-N*!;N^*&X[%>AV5J+0UTVQGD%`_/"XKY[R
MO/NAS^P]^I8U^6?V%C5I9%D0!A&&`?'9%TD41\D(![J1HZWZGX%AK;+_#>'/
M!R^&GW@<_`"/[!--#`;F1$[#*&"AH.DO_T?@PS+Y$3KHL&]#ZM]C6+7@UQ"S
M;<N[/C=E2GQMM&JI[<^B25T/>HD5."2,?(?8L>TGXQE7,+20T$6_9A'\)'*N
ML8:?$:WYM?LR@=)>LU]2\&T(^&5V%6OT^=':MGCK<E*B)M=%J<1I%_]S:%J^
M-:.YKL[L6[_.?L1W=TR+$L9<EV$P0[7CYW'D99/QWTC#!-I^G`0^3"P2!B'Q
MW'&^`&*$L-RY&,M@,BSN70S_?L-A<7&?<(&[J@:[HF;@J[H!6;F;M%VV'E\L
M>F+2OL7`R8G]B0=\A=V+4SO`\=2.;GU>]9`#Y@_`>9G?%2W@RM*7]4/83[U:
M_'@/+;&XD!J6CO9&DL7B;K\Z7&0-VO4T=[IO7CUR^TT\S%'N4C]P8Q]&EN]Z
M/L9!"!-^@6>'!(5>X&GKZZB9-YTFSN@%0+RU?]_O>KUY>J8KG[.G[I\1W]3S
M`0PNL4)T<*KA2M5[KK/#HQ@^#<T=\Y&3'!2L%;3ENSYO4J_:\)D7QXUD`),>
MRK1Y=)"II</S-A#/8T#<Q$<)01:_OC7QQT61R/9\H2M6S5E?HOB_W#7H?V0`
M/JF`)L&>$Y?Y?1SS(='>PY&.QN+M&TU"K"%`V]9A'0Y*M&QT4"FLPI_RMA]W
M_EHU3>HX4>S@!%D8,R/(I\0/)ZDGEM1R2+E/-JR>#`S8,QR26BC)CIC.F2-&
M3L,X)T//X1<.Y6^O]@-^9D5!N?3VOV?T7%`C-1HWHC2*X"L=3]+LHQA"E_C8
MPM"V8YP$B`WM;6\TY`:!/>R%CLN=8"TF;4'FI7@.1OCMB#LDXF<P;/!P`5$6
M-_).S'#@W<,%Y*A8^G`!CR:>FT34@P&T*'2<$,73FTMI*/U"+0-K\;?P7QO1
M9\5I*^_YPEZ;V8@N1_J[BG*?[?/TOX;%U__!_\QWGP[\>,SJKI>S-/$IMETK
M"B(+AHEMPY#&W<6*01Q1'`JU/S28,5RIC^#`@.X#Z/%U-QW*+#'4P>CE@GYA
M,N6J^TWQN!ON,>\GBC;"YS-0B_#Z(DMQ?WGN\2S?M;K,\SX#;V03C;2MG"%T
M>E)I?Z9DE'PT0;.G!GW/Z^P^W]U5]=C.^5P7MWD:.)X%`R^R/->B$<30\NW1
M,`DCH6Z+/FNF.S#36\)1@A%FMW9E!`HZI#*ZI(=G`9E?G&+)7LZ&V940_\59
M5LL!$Z./'!`H&M!/R%8E:+_E(.N1@]M]U?#12_]3%?M7]FWVPP]9^03:.NN&
M-CL>K\,C;[?QW]UE;;=XEW]]S^7J'W/3B0BGY[**UGAL(;GH=:@R]>A*MB&2
MK*B[J0/4-(>'<>;@,;]ER>Z?U9X]W'M^;"M[M%+;A8D?)!:#$(4)B1/+H2,"
MZ,AU^#6:-9Q\.-)^7@Z<8.4K)7JTX`@7<+R2TP0Z^1>;0UB)>KFDI(]U(^T=
M<0XOM'`,!&(C;1H3GE7&GV*-RGF=UP\I='!(D6_';&#@!7X0QEXPVN40=.FE
MD+&U59*#U"B-8@3/%T3MW&J6P<NT+JY]'(ZBXDDQ_1/HG)P_$NJF0-0L3?M2
M-'\F=9Z/[>M>4WW7CB,G##`K1B/'#4,K'.VC,++G:IN2T94TCF,%'.QTZK&N
M0E"->G75,\ZZ'O63)GPQ'7R+0$D]G!6##>OB/+\$]%$#<5IJ/UI\+W9YN>OL
M>Q@Y01#!)"(,2.(D%/NC?=>*9^NDDM&U:\$1K.[QLASS\XM#8Z1K+A(%^5Z\
M6CSE3[%J5`K!AE5RGE\25>0,XL2FL2;CU=V+.;3'O.ZFSU(,/=N'#L1.XL>!
M;4//BT:SOB^Q*D&#K>4TL;H#KR>"&<Y^"EAFCD4'Q0+S5PNSJRQ^VR)68NIJ
M88+5)JXT$"TVZ?0^&^>FG#3RN(4))YWN5&8>-]6RF18-G^$\L.<-W31MG=VV
M:81L$L8D]#TWMA"D+@R'"2X$8S<BL@6;BHU%=.H$&/@Z0EOZ]LQ+-(G48G/8
MW5K]-<N7<S77?(+$EY+??LMWAWU^=7=:\>5M@\K=KT5VPZ="BKSYK;L^/=]=
ME5_XL9I\ZQC.FJ*Y[A:KYC]:S-CY,W7BP+$H7^R.D&_YQ(-P`FE3BTAME5T4
MF>$:CE1ERY#Q;?/'4[6Z]1GL.PVKINLNHWX`HSL@:T'<M,5#QD=AIPFT!).C
MH/-4=J/MLA$74][M!EM.JD<_>)US#-H'T#O3G9%TXLXQVJ^C"KYV3@'N%>C<
M6OR:>)TQN9`7UHG]1A+)2LZ_W)RP8@CD*T`!1'^4U4V3U]\YL(_EXZ%EWV8!
M8;_5Z>P1*PH"@B&.?.AA%%`:AY$S8G5M5VVB?4F`AA/7<UA<UG[-O[/@N*<Z
MIMJ'7320DD.`K<90=>CP033Q?`"G?H'.,?#B,5@]-YD(D\C098VG8B.9:ET.
MS@V5U@N(^!#KP,S_[X'5_O%W?MK=-*2S,')"!P88.LB!291@W^OLA3"*,79%
M:V?5SS=8!D^00(]IO6;%.78N%:1S"=W(&SO?CY=EHAYBE-^<XZL:N@193@2I
MA6P<1!:&A(X&H6/'4HT&92N&:Z]7;Y'L2%^=/C7E,</<;.E9<0A]CB`)]9$G
M=:/RH^#(._JC2HU"=W0ZT)P5$L5M_O99M&C?D=[=1,2+C/NR^+]\UY^Q1:KF
M%#`E**$A1JZ+$^A'(4GL?A%FR*\H#>1N`%T-I6D!/.FF#:C9D.7T//)G9Y;R
M]0EE([LJ:,48R_9&MQQ>]3[I\=:)WJVS)X]_`$??^"\>O1L.002=?^N/3HU%
M3*B+NM93LI6TLSX19[NKZX9&(>T=$0ZG/G>'/I\>%<E'X3WLXT*Q%_U@XMML
M8!#ZE(0TC`@,B6,-*!'VB*66ZQ:!9CC!G0#K]LSWP/N%,<UPSJMR.ELF=K(Y
M;'-A4T]<%PY%?W8*;W\V[W"N^DG$-Y2G=$1%*#DM&O[-9:1EO3^;AE8(PJS<
M<YH=3U&BV[;X7K1/+Y!!QXMM.XP<%R6.CZD;N6A`AJ'@VN`%X9@>1)U($1@A
M:D@JNH.BGDA6C(>>Y/%\D/,B=XQ>;#-=R'$OF2(,!7;#:<&4QP*IP"C9<L<^
MOQX2'6^CP4]O9Z\![<GINU^J_3ZI:O[-U/<M]__9N];FN'$K^U?X9:N2*L\6
M"!($N=\`$LRZ:B9V9B9)U?J#JBU1,FM:34^SY8SRZQ=\-B5WM_`FI-U4*F,[
M'MUSSP7/?0`$RSR-XA3$&"28)3@?MO9HF*!$[F#B.A!MIPF#7P):>!A\ZGP,
M1B<O*)97JT$P%_F_$"3ST\IKP-YEYL:C="F3K;LL?,EN*[-PZF[VM8.R1A8<
M+HB[`BA-L[3(`<`$PA!%E(43T)Q%>+SK_9?#9G]PG@8%,<H(WW-WA#7PU^:P
MV7YWN>Z[H%GH&:WNZMUN.#'WP@WQOH37>4:S$%,ODMET\?+KS6(#?C<)3'(5
MO+W<)4N`O;2E%`IG&6O8\GB_&[:Y_K+OOBR4(I:@,&(99:C(<1E'*)Z@1@6"
M5]^J_>?&5=NF@E!&W9;.2`[WFG%#83.VZN^"<UEL?%GWE8G7">HMRI=.H-^(
M@&E18%C"],-A\YO?<9JA.(8EP]T!6!8"A-&$!.51<;6K[C;#S7L6/_W]$@HA
M'<H&'?H.L#4Q\NSCI,X^$RT:+5_$Q**'^I^)EB/363U3-OO;JCYTK_!/TG6%
M0`GB+`%90@AC,:`PG4LOD.?9I!5NZAD5A`HZ8E="\J[[WF[E3\FL$5XW/;BU
MN*[>A2\\"^K=>.;SE96R)Z)CL93560N^9)\U*3!<RNJ'8\4)<ED0!I(2=Q?/
MA"4K4YC`"6A(DT3I\[M.$<K/CZ4_'"HR/1X_+OKBZ-A+_5IWCB@:X3>B71H$
M6)\CRH7"F6Z-C4%W5F4$RD`:LBACM&`)S;*8%ZCE!+0@<I_2<(_.\JF/<WI5
M'8$ZKJP5`NBFKK8;N_6JZH5?KW1OZ[O(6,Q)ZJO@C>0D#0(,YR3=4*Q12_^S
MJN^^'*J;\5-]3S[3UYTKN1W/E<28Q#GDH'$"4%Q&48[9Y`F#:;;2>453\%_G
M6<9WP>3_]*739Q\Y]>:PH[%EYOS8R!HKS)-S)2\NKM6NT'$>7C=-I>FU]D8R
MO$V&[+6E=H+I6XW`X9<AI#G(8QB!*`]+&I.Y[>;M^*KG.+60.SG=>6Y_Z07M
M?;<X\OEY[2.?>NO#JXQN=%&\CC3^-G/W^@E;>"G]W\K2XK2LDYHEPV8N'[=2
MQ\XNNI`D-,E3G*(2AAE-,P*CJ:3`<1ZE1IMUA[B=O)BND(M?/,3J_XHPE(4]
M70SF,W$KFHK'JW/FXR&O+A^;"ZE.3EYA8;V6O+P&-;*Y>;7PN<O/$THQ+U"$
M,&.T0!D-*2RR(DK!Y$6:Y6Y3M%GHOF9I@=/=KV)E.$K5ZRV*%;/U[/0;3MA2
M@;69L^VLL+>2MBVQ8SISVPRBN^1]XB#LY2($Y$5>@BQ-$28E+6(&IT.RN`0(
M.DW?IL'[FL"MO5OA?'4X2N%K+HP5D_C)US+>7!J7#*[-1&YKG;V55&Z-']/)
MW&X@O=N[1C&(0`*3L"B+*`2,<-P3_*+,R(IOD&CA=O!>B7H7/KQL\N*F]?]O
M/CI9(J]%8EW3LM+FHUS8UGB)Y2)\S!*&.&C*`$QB@G),IW??,0P-;SPZPNQK
M-^3%&S%ZJ\'Y>S+.%H(G;\^\LI;'3"#=O&QC9"F]D>QKG!9[+^88#-L:[<S[
MW6%?[]KZNO_6\!5DI"P`SI*2I@1#$A5X.JN$*0C!JH=O);&N>MR6W-WM^^MA
M@AGU])5RCP[:RD;?^=%:BR'WY##ML^7QRC+HV5"YZ5@5E\<;R9(&B+#7E6J%
MYL5,>+?95L;O7>2_*[ABS]+]S(4")BG*("H)(QF+BB3+HKF5YKVT2"_J(^Z5
M^M$+&5+N^*N/G+Z0*7V$;#EW!O1R[J1C[AS_WI/<.:7.^;.1TQ[<\`=!Y_;Y
M]?2:E]%-<_W0V>AAO-GE],3+U[^LGE5J772Z^@N!)`)]];5"O$[48SZOFI4K
M-*^I:?Q_Z-?933CN,?>7/CW#'I(D85&:I@1$_+\(IV$V82<,R'TSTP?`_M5M
MU@Y$.XF_T\T#=Z%??>?@Z:&IUSWO$(F>_>T",XOGC4Q!S')B9Z/`9,#<S$;8
M'U_K?74SP7X^S<EH&I$(%8P6>4Y11J)XK@,2Y&X4H@?3OPPJ>R+9`Q)=C#K<
MA7FMR<;HX:('77&*H;D@'`XMW"V,M6<4&@O$S3SB8BALC1_,Q/\M3!L,,6%R
MN&`R.!Z<C<@92V-2%%E<@IQ`2$DR'Z6,PI2N>+A;$NF*Q[DO30_>R$%N#S;"
M11?`&VD!#1#A;"-<+C3.9.\?5=L=8MO=<-&NKKNOXS7='RT.NIV;"9,PC4`2
MT@0QAI(89S#/Y^X5E,SE7-6>%_ZUBNL=U[:X5MS,8/U8)NL-9@?_`ZY/P<1`
M<&CZ/WYVWEM_]]./]*P<<8OIV_XJ?"/IW0%1AM._J]`*SH*OOU0W#]OJP^T_
M-YT+!S+FEU\[),/_5'\<*(_9;U<1B&&>E`5C99+!A(40%3V`%)=1$L?BHUV3
M5FVGWQ%K]X&@$6TPP94:O!EE6F2PNA;)DLEKXO?#]_P&/<K@T_"/#FW0PQ7]
MN(0%XF4&F&L%0'$>^6(@M,>($H2<G0K:(-6+(9\5QQK;ZU$KV71Y;4B?;?MP
M/^3'9S@0B$I<I"1,",MHAD%:A!,.D!2)>LXQ8-QRZBDW]7XHJ1?)IPWJ-F#M
MH;[O/C`=_+WM/Z>YW5S_]@-WD5MJQV*^?^VR^S]_:FZJK99BFHB32L9R'"+]
MQ#4##A:(YRQF*'^9B(9.&G,<%7/93#\ZBGGN9<:$TYU!\KW,>B;]NYC\C!,I
ME@/S+UV?V+[?=>+>:_N,Z,=Z\[G>SOEXAE%`&I&4)B$H,H0+@N,033#R+!,Z
MG6K+MN4,."+N#@F>3(;!C%M&46W$0""]K4R_7':;F'__A/D/)YC73&\V@B&1
MW58.BEIRLQ0<L>PFS]BYY&:1>Q]RFTWW&C=+6'*G\>/FL;/3DMT-N;[>/VRV
M[?39QBN2YCDL8927-(IRA&.6C`UEF.=Q+'J!@(X)>VHYH>KW329<ZWVS\@))
M%S8M3%#KR;:"$5<:\RM/=N=^+EI[B]7-]#S7U?-:-08LI'D,D@2P;D)#PNF)
M#CFH,I?::C=GUN%P?L3:;UONVO%9_'#X4NV#_&&_KQ9ID?LANR]N,!*"&]GK
M!$%Q!K+@?X%3:G)O9W-8F,5+N[GF0^&)3MKP[/E^J2WRQ/KML1#ZY;"O?QMO
MWN(_BL19RG]@GC"0IRPMAM.E*<QRB(7NTU?]V=;/"G50@J^7+]PSPY)`QVN9
M(#FMFGJCD:,7+B4TPY%$(VJ9*[5&4XXSL?[Q>T?/]8<:E/C0_^G`;\RL#!FE
MO-`]+D:D\ZF5:G]_1<JRX+4NC<HTIVF)\I30"4:(L/ADTH)MRTI[/!S'P01_
M>JPV^_;/,G)B@VX!25Z9:3G)?FFXM=S&F0/285X[$!*ZOW)`U/+""\-XE<"(
M)0]YMLXE%XN\^Y!\;+K7N%F^"F5^.\,Y8?P?S9:O\@[959'SU!D!;K?`J(0P
M23"<(*18XB5UPW8M)ZTCDN`_%$I?8^R*MPYK$*O45K3+G9B3\G=$NR;U\AW)
M&B'0ZE;,A$*JF1'DZ(5&QS33/N0A6ZZ=:)#LT*>??WZNV]_*?=4=YZ_XZCW\
MO#E45T7(4!2EB$*&THRE*(G*$02CF"`C&4C)LN4<U&'ZX9:#"O;=NT/&\I`:
MRYJ9R#K!9G-1!S?H\`83X*!#O&X(#&4DZZ&PDY.D0Z*?ETXQI9*9M!CW/3?I
M.2>:G0Q0*+R9O+1?';IM[,5.S$_5IGW85S<?=C]7UP_[?;V[XW_AK\UN/_V6
M;MIZV+"YPE'!NS9"<Y3'*<E01E,\[M-D85@2F;UF=Z@LY[7%\SW"[L2B?1?,
MT/L-Z27X<7M4]+C<"H$4VZKV,X;*HT9SX;.RI6V,[0L[WNXCZLF&^`J.-VL_
M3*IYA#XNGA2>Q7Y_J';7C^2/NKV*081+5F9)"5%(*,,$PLET#%&DE"$T[%G6
M_@6N8`86?.J@*8N[#KN2LNV(6#E!5N/4KN*>)TI$2PW0[)M*FG#IG/X9HTM>
MV4X9+IK[3;V[*KB<<B&%">E>CT4D2])P,ETR)G0'@DE[SJK:=\&9)W(`JJQS
M.EQ+ZIPCFE4+3W6&[:K>>=I$5,\`Z;ZIG@F7SJF>,;JT5*^=R\N?JOO/U?Z*
MEC"E!4`%CG">E6&430>.P@R2LM"5/6F#Z^C>DW[PTP#5A/+)\ZTN?5:I-J)]
MDBP[4[_GS$G*GS+Q'NN?ND\"`JA)F$I'.__RO^MJSW_`E\<?JV^<WZ[JS/.2
MD@CC*$%YA#+([<_Z"W,H]94@0R8=JN",3KNOU>)8NK5U1:^Z\HDS:[N[O<"5
M6(-K@FS?U,Z05^?;7'.DZ=5\W^,8"\\LI6%($84T`5E1)"@>[R7F(!):AMK%
MG[+EU:K`Q7;!XO$UUPIK!$.C,G02!^5]&1FBW=6$YSB3+0ZUN?=--\TZ)U(N
M&J)07D7?[[X^'-I>M<.Q5"5E&C(<TH(@A$"8@CC-)Y,<C=J<4,&.987\VT/3
M':CLWTKJK^GI[Q2L@I\V^]^J0QO\J0<;A'_6[I95.):40LOTJE>(`[!WP4CF
MZCWQ]T2)J)T&O;YIFXXKYY1,FQXMW8*CR1+A'&9E&>=%"2@LBA2QT21A*57;
MN56P8UFW?JGO=O5M?=V]MC3<$?'A<UOMO_77%0QP)^V"1K5+F&=U[;)!L2GM
M@CYI%U32+EEZ/=8N:5<$M$N-'BWMBD:3"%-$0`3S&'%;48$PF.Z/X#UTKJU=
MHG8L:]??=\TYK8J,:I4PK^I:98-24UH5^:15D9)6R=+KL59)NR*@56KT.#UQ
M_6.]J]X?JOOV"B":TS3%>48)2#F^C"832))&:E,X)\@<3ND&?_JCNLM[J":7
M@F9WZ4!O[U?PJ?,LZ%U;XVBV1,0E==>[8*LKM;LX>WN&>PZ)Y7/<\J'W+8NX
M==[">6[5$`AGJ@';#+6HV^MMTR&;;[@,&:$PC+,L@7D:Y@5+(C`9AI'<IQSU
MK5G.*`/`_Y(4?P,DB@FZ6_[D1'K`]F2#[(AOO1MQ7Z3L@HB:H]L3833H4&-K
M94H*6+YIOW#E[/[!?G^HOVVV3S:$CD"NR@B%,$U0@N*\Q$D909Q-`"@II39F
MS%FU+&@=PJ`Z0I14-H/LBBG<.L3**5W/:5=:]K]8P#PC?HX53YC""\IG/@R>
M**`%QQK;*]A427>%("HH9AF($TI9GN*0P>-D%I*K0W/8;#5+N1>M2"G>#$CX
MZ?RU^U>"30_/5!WW,G.:]9M1T@S6;;X4:RI%FC"GGDB3`4=$BS)):H2E9]'@
M7BH%:4DCUKV\EQ-0Y%$(`)MVMPDF22E3B1DR:;D,6Z"4;2Y-<2JF4"O0*2=7
M"X#>]9IBY%W0,L/L>R)LIKUJK"Y9O9NSVX_-@==[]6:[??RE.ARV5;=9^W[7
ME8-7@*5%FG?O\7&Y)4D.BG"&$#&(K[Y5^\^-XKW96I9EGM<E2.''=KX-Z^L1
M9=#.,+L#A-<<J-[US7KD7Q;(M5E7W3%9W)_=!@NPP1%M]S6Y?&7RM>[-=A8$
MC3NSO_7!:&Z#?XD]"?]I_L+L2S2=2$HVR?;A$CA;KEV^)-L@?>(STH8;W-UQ
ML_Q7;<U)[1=PON5=<GU;5S>D[485A\=3K0)F89QCCB."`#$8$8"G%Y%("N7.
MA5H%8GN2.F,/OO*_\F73CI_;":Z7OL@.6*V&1G#FZDM4),>PQX`\P1T<@0>;
M-AB@^S'?T&'ZTK3610`]:2;<^/I\INN.8&%1/V\P1!B2.,XI3$(4@@B%Y73]
M&P$)B&7&O.I6G(QYM\K?==2@3TQ5W3`G)YD^::&*T.ESZHF*&7"D,;W<9/5G
ML]]Q36P_5OM?OFP6@Q80QW&41UE)61EA3`L(QFTM_I^"BIYU4?[Y%A^?$5+`
M,04]J/5FC>?HN?3TZ#+JR\.C[<?S9\<,,6(SP^-G44>SD]5?F[RYOV]V_6^^
M-%O.XO/OI$9I`G">PZ@($X09!/R_$Q[(H-`1%NL@K/=A';[A\>N^['*]?;CA
ME7ZW3(*_5H?@QZ85K07LQT-@INA+*.2D</[^\X?;8,2]4,5?FV`9IA%\,'P3
M^I/01Z$=!TIB_NA+P-2&D=8#)S:=U"#QW*C215Q\F%LZ\;-QO.!ESSA=7S</
M?4_^L=G6U[S].^;L[H;,L'M1GF5A5*(T*L><36B6A*)#,0T+%L_JS*"""=6*
M)ZO/,G3IM(X^K9Y4H28\>7Y>QQ0YPL_1A_W=9E?_>YAF-;N6F[WI?T-V-Q_Y
M0IS2RX?;LMYM=M?U9OL+_Y/AUIW%)OON9G&OPO=N+/2@3'`4LZ),BBC+(D98
M@B<_XH0)??W,6_"6*U_ZT-:[JAU>?AO>9&MN@Z6GDC,P[P@4U&;O<-M3_*6K
M[X(GSO;+8.ENMQIFAX.CQ\NS4=V_L[P"Y61&4:GSS.04UY&]D*F\762>Y#]_
M^6E>B5K(3(VZ':BN$/B9X^TNN/NX>>P_]9/`%.,0QT4.`.WN@D_2N&1Q%,,L
M+E@!A2="J@9L3WOX7^.$;X/#OA.UZZ85/M6OQYO`Y,8%9?);XAVB8((4C)B<
M4"8Q0W%!G=I\1(%"L8G'&9?/33-T&?)A4J'M0V-PR4BI[;ZZJ0\_5?=-2ZY_
M?ZC;ND\>7S:[7;5]O_O&5U6S?\P?]GO^JZN24E;F><$M9SGBF@\(&1&@HH!"
M7\6T8-:V,O=@@_L.;7#;[(/JCZ]U?\G&_SQ\W5:[?P?7`_"@GI!+J9#9$(C(
M^6KL2XK\0'P/-%@@#4:HP8R5-PP#VA6)ETD*JP5`,568#(1@$I&AZ&QJL<*S
M%PG'CF>-]44J>_;B_NNV>:RJGZLM;U26]\I,AO,HB3(&,8RRA!(*$Y(GD^$P
M!%*?+-&W9G]+^&NU:X]3D?V`-/A<[:K;6OH]8`/T"IYQ<<JLY&&7$=L/$YE/
MWKR3U3-#AUY>XNO2Z1=C7'LR@#'HT//S,(:IDMG6VS]4-Q_WS6W5MOQIWFS+
MZF@U!%P\NTL:&2TSP@AF7<4_6.5@4JFKJ/1,65:T):S@MI(^W:I+I/`>J2L.
MI?=).V#!$QH[:&L)UV6F+N^7FJ#8$\DRY<WW^Z;F2!*;$'SDQ0;_V82;:P\;
M[CPW?K??W$\V&2H0!0PG*21A'&>P)&"RF5(J=,6!$4.VA6J`U]VW,N(+O@X`
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MH7XTYTQC8X5)71#V<'C85S_5VZH]-+OJX^;QOB]6&:$98BE.>?[(6`8HGL>G
MJ"A3F8O`U"S(/"Y*%WY-AP#N)V3!UP&:E*:K\B>@Y`Z(D]/O`5`P(PI&2"[X
MDKE^RSYOBM=L2?,G>)'628?/*;$F/3[HKZX+C;G5(MFMO]_QLI-;&L^&S;M5
M(<LC@J,($XQ8TDV"T60-`)C+-.N*)JR7S@.J[A!6M6M%SWOJ\B;6L3N@3$YI
M9[9&1&OUZZ>)N="N:S+I2;>NZT5C='FI#01/[(E3!&@9I106E!08%-P0FPQB
MUGV$5.)V?64K4D(C?^W2U`2-.C-L\C3]=Y2O!X0:=S)I<"LU.[1,JUK;[L'Q
MFK/TO#Q!U*#4$U4RX,CI*:(V-<+:])>FN?E7O=V2'6]S#WR1U5P/AX\`G+@0
M.RU0!(H<AI@@4!2`%;@<7\TO,$9`\)DR:]3><S;A[!7KB'3ZH*0/]\=+47GA
MF;03$D^>4TO.-2Y6M7P[<\;R\67#E!8%KV\PQ11R^P77%#*9+AF1^CBP"7N6
M&YT?Z^NN[@C(W;ZJ9,9)1CD5[GN<TBG=!%V0P/5>`1=@[7*'9(QS3P3/J$O?
M]TZ&Z9*]PJ<=V[;OBR4NO1^ZQF+Q1T=X8R5U1,EB2F&885+F"6`9CG`^730$
M,DH+R0,9+J%9ELRIP6#+EJV'/[49R]Y#OF5S&D7A/L_7`$HWA[TCQTG5R7;Q
M&-'E-]&/'LT-Y9K";C8HEUO2-:+O2;I8R_O3=UFM$P3A)%14GP\GZOF8A)!D
M*`-1C#+,`*(IZZWA`D""13^FIOC3[<E)!\B+3O<T,Q>>:4TJ/7DV=;UHC*XO
MK6?E^&C2K,20EKP^1(!0E,&4Y).Y/$%2KYJJVK#==3:[NQ_XOW<?=``E2R1E
MWE1$Q@YEFBJS7LUQAAQAH9&GTTNE47#CHM2HTB*L-=-5AWES_[G>]>=`CG=A
M,I(PR$(`8IHE.&<D0H.^I5&402*:G;5LV'MZYEL>E[C6R]276+KP&!DAUY-G
MR8POC875)_E4'2]RGJPOKK!HZ>/B=_TUSE<,8!@524DC4D+^J$/`\(0C+HG0
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M`IB@)"4H32B,X6@X0('2#@)S:S-HT0J,&,&7'J4-75(D65^AW/%KKE5*U$ZF
M6V>,*2J8'ML+UC)-AR14S80JN>-UPR&S7\NGNW*WSB@+0T2BT$N]./813KU#
MYL:_D-H"H/&QCA5K/$CWI8>C=&6:(C_7-<@Q-6IB,R$K"F?CW+&C=R1.GB6Y
MHW!G_KTAG`8D+.'@FR;RQO@),,_I/O!_N-F73ZWHAQXA#]/82[.(^CD*<#;:
M]*/0M*"4-S1+52G@@0Z?A1Q.@53M],T-GS:J3"DJI\K9#C2II6OJ["XW4]/P
MY?TD39<@DY6\3^6F>:BK_Y3;FRT?TJK[JCAL0!V2QFU6G^T5:EL^^FU)T7[E
MWQ!7G7_C8EOOVW7(HI!`%+#`C["/<>2G>$1-`T_I:._,4!WKI4#4;13<B+^4
M1V":.CE70+47=Y<:2_/EX14X^@9.G1MW]H_N=?$_W2(Z>+@"AZ<CEWDPIEII
MMA@RM;7J.9Z5A8T\<[/Q_GKY?$$RR=2%U?WW\=#Z#4=4;F]WXO\"_9_%XXMP
MH7JHR^TZCTD,4R\),?-)@EB$`CJ@"IE'M$8W1U!<CU[]K>3MOMG\99[86XV!
M=NH_%_TVIG5[[.#02:-'S]4)C/A7H/,`C"[,7T,H\*U69;@(Y,)&`]?>OE^I
MN"/9I)81%XI6/`;=%Y]W1=W>E[O=V4&'F[KKC+%=!Q&-.!Z?>#!-"*/(2^(1
M5>(3J9[P$T%QKN;=U:GB0-+F%+5Y*6(U'MJEQERAL%%*G&$')^!79Y7#B'_^
M(D&!;+4BP$44%R;KKKU]/XEW1[(+6>].K/EK#Z,@I[Z/"<Z2+$\HH>$()(S"
MU)&22UIW+=X7+_[4O?#382"L2[B#&#A6[0[Q<F6Z)]2.,BL&Y^<38U4']?57
MBTH7DNNODRBB,8IC&OF4T2Q"89@>9)\QI;LVK!IV++2?17N^J1)D"9JM:ZE=
MAIW*Z'+UTY)TRL?BYU--!=_T!5.50+D=;IK3WL5;T]Z?JH>O8JH;T2A.8Q3`
M;J\Q]/S@(.F^%\AODYL!VT1[[78=&I4]97/$Z;H>_PPA6L32YZ>?(M@*NQ`7
M'G2]K8PS!5]N7Z1]QB]MKIPQMDO8H3FG^\TR7C'-GL#K.&`,\0(NP@%"U&<T
MB,;S16&:19Y*%27]H8['ZQ&'8EDDSXE<R>.$#K6Q\7TFG'8LOE*#*).SD/I"
M'?>%%L**CDN_V:RH=MVRY^W]N<JL?4@\3'C%$8=Q`.,49CD\2$E$E;:-Z%MQ
M_.X+8.!;M\6@N1?W3XL!OQC`*0J"`95R"C$-BVJ2T1'XYTC@JXQI8AVYR,\5
M83'G="%*8\&1QO;CIMU9IILW_JVIF^=NBJ1^N*DWS5,Y-)_M6BR<M!;VB>BI
M`),,AS1)89JC01E]&E*LM([F"()C%3MM;=)W<.W!@E\&N/^KW4[&;B3D=&X!
M05`3P1_Y/\7\0S"&QC)@OHYV>@Q?D5''(5N(QKKV\F+7&8>DRG?N/#3NN[WG
M%:NP/)2LC\6^W)*FW;>_?RUV)2[:<CO<T=<>8<48!2A/O<B+<!;'&?10T#?Y
MRW":T%BIPZ=C+*[U6FQ`!ATV<`I?M2>HZXC(R?62@J&FVR?M1;ERGV('`WC0
MH5^!#O\_[KJ(C1[,VI+4C/,K2CY5-!<BZ9.Y^[H5ZJ0T2]XS/2;\S?W_%;M=
MP0W^2_S),_X(>L1/0I0G><PH@7'.A@ZM),U2)+5[PM3&%%,!ATIV!`<&=$KW
M)QOP*+$<-Q&%)O,`<[&G<@/U-"QJWD*MR:;D7=077;^T8&2!K"4L_-APH['[
M#*GH,WDLVO9@JMEU:SX'#)^:QT?6[/Y=[+AU$@1>E*5!D$8TB!#F`$;K7D*A
MM%S;,^EZ/[$`>O*RB$-D'=@5.'F9O@C$8("LU.['(O<2$C\/[6J*_Q,QKC`L
MS,.\WBAA-P)R8X<T/Y>&$OL$+V%D<>!5X_2IU*H+;@_#W,D&A#7U4QC1Q&,D
M)#B@,86>/YI,6$#6S^6N:K:_[XO=7J5"T+.F\MJ]!B;]YHTOW'A+^?<5P.5#
M5==BNO>NX#^[*;5R7DV&5:H&][1J5PZW)[FN^FV"5IC4J2#<,VI011P6M__]
MZID5.]B*;OC8?RW'AQ:T7\MR#[;%OORGM3+C37[>+37,6%W"H&#+E3=+#AOT
M2)8=7_E#5=[4/YH^M1SB)*%9CEF(6`)]R@C*#P6/3Z0:0%LTY[K<Z$""J@;W
M;[UD2I)EB5^9LF)R:A5+BI[5FQJ\.2CHC@F6"%:I(B8G6K."L$&X9.$@0\G%
MHL$JGTL8&RQ[U#A[^"P6"GQL"@A.O-A+<!BE'O8A.@Q.89H.A4)>;\W+A/=L
MJ9<)(RR3(H%_AE2%,&.")4O<$EXB6ZXH)%AJ]$AOKA"=R:I]M\:7U=M#9YO-
MV7W&AYO=&",IQ'%&61"1T(O"C"0L]Q,_\T,_]63O@;!KU&%:<,39G<$Y0[J(
MFXB5F+RR^.XF(@M9:G?D7#/%0ZWX.G]HQ*F>$]/]K6`D9AZB.<E"$B.,?1SX
M\6`M8CF46I8Q-.&X+A*H7KV?>A<:ZC(HIWP3D*<F<3J\.5&RMYFY(EF&5"Y$
MFTR]:*P^7Z9J\^'0CYVRU(]R#T<)\B*6^6D4>8/%.,\S,\61-S.#ZGS0OL/!
MA$Y-^7'#I+D$29$XC0X=*%+1(G5>EZI'&IZ\ITFZY,C-!9R;^_ZQY$]=O2\>
MRN;^0\E_@I5E^[&HMFOF>9A%-$J@%U)&@]!CF!O/"`U@&LI=OF#7HF.U.@(3
M,\:/`AJXY]A`<_=8/72[CO<->"YD&]]9IEMB'GD6IHW4[/L*G-/>X00"*!!(
MYZ%:849Y%LKU)I6M42\W"R;+S*7Y,.O,+F%FS+Y3C<N'43'A/6R';X8CJ6,G
MC;+]UXYC6P=)E,0)\F,:(Q@D>1[$T3B@D2A3:O9G;,SU<#(>1^&#QH`0'"&N
M0`=2,04V)U@N$9Z46[4!Q)!6)TGQ>W1=28VM,;V0!-F>/XVC1U+U\+LX$]A?
M2$!?1"/DC_WF-'$&J.W.?Z[S-,0P9]3':>KE*`T"%(R60S\)E`ZZFYMSK&O=
MI0QB2Q)/&38G%[=TW:*?JL>2?\6KT^<^7BO0S-"A^'T6K[R2%D.PD)?2ID>O
MST+;)DO^W'-YM[^IV_VN2X7[B3Q($(UR0D,6QVF0$2X"_1%KQ.(<A4J]<70^
MW_&K=]K/X$-3/_R#?\83$$#!$:GNS+X6GW+IA&LJU3((6RRZ.4#\(U57I,J$
MV(5HDY$+KP_O&M.A,+=?/XCG1IC\S'\U^[MJUTD>!YGGA7GD,9@AB''LC[9\
MAJ2:[QH9<#Z??_JVK(#`!;X(9.IS^3KTR<[B.V9.=<9+@S1'<_<_$G-UUMZ`
MQX6HBYD//\S4&Q.BK2^T>2JJ>HTHI5X>>QAEOL?+'>:S<+2&LUQI`D73Q"P:
MTV,S51E9$O5TQ@%_-I3F7>HFT9H>A8+:*+*Y4+U1]>(=Q=$B17*/<+5K]^+&
M`YX=_UH^W?'"#88ASEF0!C&,_(`1B'(RF@GR6/XN`8W/=JPR'2(P0`)?>E!*
MQZ!U^))8PG-,E9J@S,.2RE$_MVQI'N]39$UR4_D/KEY:.#,@90E+9";P&SO/
MAM%,U(?#]@V/QA[7Z"CU$I]X#,.0#KV@&/(@44K6=&TXUM%7LR8FV[NT6=29
M@W)#H)JZZG$WP:S3!XDM7:9T+B1?,W;CZ@R4+BV:RD.*W>Y[53]D3\U+O5_S
M(82/(##/DA!F,"28'6:^$,FP6F-/$T/.*\:B7H&BPV*D.:K\Z0B/0^K,BL4Y
MULVO42.M/9J,+E*`='VYJD)&!,D5CZ\FWOE3=5/S9ZML][?UX_<U]1*40Q0R
MQHB'\CB".!Y-BB[(TH6DH1W'0B3P=*O@U0`*-!S5N!*N=#3>E%")2G-"+HWR
MHA40V%9@1`<$O"FY5*A')^14KS8UXU:N4KU.PJ6JU1)U2ZA@;;G2V'^RC/++
MT>*G8E_^OA<;XH\[3-<I#'V8T<P+PIC0+&<A\48$R,N9?K9I9-;U9JCQQ1E%
M'A3[KF_3??5WN06;YN6YJ<&.@S;*3,V8U\E3)R/=<&PX!$``78$>ZLG&]EDS
MVFLD2N>W5B*QR&S7CF=7<U^+Y.EN3.-2O:8T]GW,8,`"&B'/3WUZD.?$PTH[
M1#4^?JJ\]WE7U9OJN7CLVD%4K[71;$.:%(\Z4F>=0@OI[KR[SC@`^4UG*NPM
M4H;4/+B^Y4R=#)T"FQ3M5U9LNN9%K"S7*,PSFB,:IC[V?`2S(&*CQ1RF4C-]
M%LPXEAD!!]P/>,3)3/`L,<Q;YU*YM'9)HZ'4=)2.V,31OPEYU"ZK7?)IJ:I6
MX%6GIG[%@%Q)K4O;\BIJ;4\N%]1FY&AK>%47C\/!IG5*(A1$,4[BD$&4(Y8/
MEW=RDRR(,Q,15[$SB8H+0&->:$_&E>C4TW%73%H1\H[5`=V45)I)N2M*K6JY
M'+7:8G["@8*:ZS"W4#G7<N4=/=>GQ^#>GZX$R&*28NA[U(-1E.,P8_YA9H$Q
M3U[+]4TXEO&QB>K^:K%JE3,)P9Z&+C6MOG(;S/5*WRIYIE?M6"?1^M4Z2M,F
M*K?H7)@.L<35$O38@A?OWHJC08I\EUYA\-`7^+8WF/_-T\JJ+3_NJLU)T^#A
MNZV_3H(893DAC(1A&(?0B]@)&(S6W\K=72,[+>L&@\H;=0I7^H4:$8JYVTT)
M?GEIMR(?!ZTXP'WE>GHW[7IU.+PR4^DV)@N9S'3LY.LVOA-0:I!]9?PEX'7D
MK\7NKW+?P?FC+;>LV9U!7"=>X@4P]:F/`I^0/,4I'?&$L2>U6.T<A.,,CK[L
M^BNU^6A:](C!4P=YT((7<:FV6-89;R@JS[3".'&Q%2O=O'"&,%G+'`?LH`</
M.J1`P!<7"H*#J']<5*!,<]`9`F8]2[43.(-L5HY$I7S7<EP6FQ';]O/=G-D)
ML?*=KX8^*;?W^=/S8_.]+'\O=]^XP:ZY#RXX%-(\/9=UV[T=V6,7,OZWV_M/
MY:9YJ*O_=-LMJH;_7+L?>FVC&*.04A(E#!$ORV"4#*E`@C"+E%KTS(/0\;A\
MVIYF=`L,?H'.L7_<"<_`J6M<6`[.B5\\N@=Z_T#GH&9KH)F>!+G-',M_"-1&
M_7GC[Z8=FXL07:G[YGTD%E(7SDS"ZSYQ"PB)],AW4V^:IWZ_8'>,;X#2]7O!
M$0XPQ7Z,&&%^F$=^?C`)@UQJ:M^&G9]X%%J!N^_\>\_-3MQD6&NVD#(*DMS0
M,E5\U`:('A4XP`(CKGFZ2ETAZ8I$VZ!V(4)KQ97&_I-G1_2&EC,))"AA><R"
M)($HSS'.T6@4B:OMS&5/TI)CX;,O=F=*I]?(RC`V1FKG("S6]&Z>WE97B5+7
M/$6"EZUZJL[(Z9X61=+*]ZEL2_[#7[-Z2\MOY6/S+&SG?XM7?6P=XY,@35(?
M8T(2$B%,:<A&TSD+E)HIV+#G6`5'B-U!CA.0JDV@K%(L)V-3LZLF9A>)'0"J
M]XNRHVD2K%U1-IN<+T3?K+K4N'M$52=URT?^W8=_E76Y*QXY@&S[5-65N'9U
M7WTK!PSM`()E),J)#U.:1!&E-*5CPZPD\5&@5.S:M>RZ_.W!KL``MWM=SP'K
M2J'E"$A.DLY&ON+DIP3O(]BYI%*)RVNSE$YBLA#Y=.3<ZUE%AQ1*2ZJ="<T/
MAUYA/D8X\^*0JSR&,4VPGX0C3#X(**V038WM)RO.3?H53AYV.:5?<L05QX(+
ML0696"-_Z.<"[KZ?/0/#=G^0_;O8;5?GOR8<F[/)HN7(7!E9YGH&%C+VS.9^
MLXQ7477\*G8U'T1;;K.#^+G\>X\YJ+_6<9R%/HSR)&4>]J(DS^EPMP'-?9PK
M3?KJ6W$\IOQ6BAG%MA4#0Z\EJ@.!/G^2DCX)=6KB/&(ZL@:^"%R@`S:YM%YB
MZ)I(&K.Z%+DS=^2U<%FB1N&2Q6'"]_9>G-JK-U7Q^+%IJTX@[T0ZO]FOLX2P
M`*6,DAPRW\L((_TVM\3+,?-EYP>MV'*8]1R6.7C:>@`(1H3@RXAQ\K)7@K=K
MU:Y-VA?RYMGUZ8>;%:T3)G^1,W]NRMVNW';7._:7.?:7/*ZQE[`@\-+8\^.(
MO_Y1[I'1(J2!VA7.^F8<)P4'9/W=IJO^/%0+J@Z=ZJW-!FS*:=I$1*HIV9'#
MWWL.>US@YAT.W5S1?)&A*YIE@=:%*)4-3UY?R&R+'"-5NGW9M_NBWO)T98T2
MB$F&H@S"*(0QB;"/![,,(J*T6F%J:R9]:HX0+8B4$KGZ2N6*5SMR=2M#Z62:
M=8)&4;AT6%ZP>FFY(R%A^C3)'U?O;DW_43:CA',3D"1,,IK`/$LA1J.Y`":>
MBG[IVG"L6^3DPGBSI$J;1#F=FH(_-7T:J#L3I]4\R=0%<JX(DBF="Q$B8S=>
MGZ:W0HN^\)R*'2\C80@A-QQ!$F:QGR%_M.FE6:K8#L/$E,I+I-7UXDT9TL^=
MS'C5%"17A-I0I?ERIFLTJ>B3#KM+%2DM7]Y3*GV"I.7J\ZXLVI?=]Q.KZYBG
M8I1F2>A[*8IQDA*4'4VIY4@ZG^\X/QHAG4N3HAQI\2:G0JXI4Q.?`UMG\C.Q
MXKQ!R16A,2%P(?IBY$)C[WE2:A;T5>P8N:E94>W^+!Y?RMM[TM1[+EYEO?_(
M'Z^OQ=!-@?]S6W$&^R8E,$!<V6(4H,3/0Q0D<>[Q_\+8RU%.HG!=EP_B5HG/
MLOV"'.&0>L?2_AW[`;+\8-^A!U4-[CE^\$TX():IQ(4WFX,;X'GP8^@C]%@5
M=UUC9:5&-*X"=EWGY@^27A;6!^:F!@(SZ$"#VWMPA`U&W$/+F3/DBPB,2G>@
M!01(LS/0X0WJ+HDZ>XLNOT&;4R_^:=P62(^]-P:U28*QB'9`KGUL)GRZ5<;-
M7ZMV4S[R1[AL7MI;_LSN^A-ZP\[J-8IP$$0H9WG&?)81'/(O!ILP\.1O]C0U
MY#@O/X,'&H&/O\3=N=1?RA[BE6:9#GB5&,:FI%1MN#IGLX,&AE.^`[A)N508
M>:;D5&^$D7E2C8>0=VBX-%388F\)0X(U7QH'CY?B1$MGZ;>F;IZ[L:1^.+<*
M$2$H@4E$(^(%HFU^!`>K21HPI#+G8FC*L<S?F@B[+3;E9F(F)%)-W'L.3Y&-
MVOY+_BZA3F9HKE-U9;+&$L<+F;>QY4WCY$'46,JJ]MVUDEF]/>3'FZIL*1?1
MQZ9].=VW3)"?0ZZ>7HP@1"E+,A0,<TJ8>3E475JW:-JQI'TH'\3VX5VS*4LQ
M6=]VIZ)&![KSM6<N:"Q]V8R#_&+83"%07QZ[2#4X8IWS\(0:F>\LHCF(RD+D
MTY5W;RRT.2/1[$:-TR6_U*<HSM.`!$&<AU&4^/[0BB<G(0R4CH89&W,LH>-]
M!G([!*:[&4-R:=L6NTMY#ZWY(W.UA3Y1\H>?WCX7>CSDC+\??V0XX-R=;[Y]
M%C]XNA+_VTO7Z`!2&GDDC5B4>6$8D"SWO!$H8C17V\HS/3[G^W^ZY4;0]/AF
M?*VM4WM%!^8+XT*$8T8"7A_MFCD4<G/_@S'1K&KWK;MV@+WL>?(A]B@6G/$_
M:AXPX4!1\^2$5WT<9?6M_,C?M#6+$Y+@)&`I3*`/$YHS/.*A#,K?2.X2A.O)
MI$%>=@/V[BZ=^PY]M^59P`<O`G^W&-@[\?U_6L"M(G!P!0A?5.;#G<9-8MUA
M*2%3G+8:HC7"[NYCZ8&#$3GHH(,#]J4&26%!8RG!TEOLL/F*&2^*&%!Y:<%D
MBN@L83%E$C^;B1][I?UIQ^VUI'BN]L5COQGN(L"3>Q3$+QVV!0B`89CC"/I!
M!@.89$&"DO$^H)SX*9.JS:='Y7@T'D[S22K%L=%85RD<-T\IRORT<979V[;4
MD*K/JX['#L#@R'A@\^H(?GO_D\9697O<4F.LN6=N\EA+[J.S2//%S75SA'()
M&<$\CC=SOT7Z!_KD,*Y9ZM,TC7-$_3A/<8:0%X]`HBB%ZWW#/T5^(=2N=:4<
MX`!46DD^BU^YF@+H'_RSQ;_\`NA\U.N/U:N+`G[_HX#/=W10CM-WED+=Q&<A
MDZD.';Q\\M`)E1KWH1[[=-YL16%X7Y7;K&W+?9MM_O^EVO&OZNV'X=@+KQ_Y
M]WC>L^WNK#LNW=*81EX"88YQ%&#*08=#[RY$8`JIWDVHTV!S7:R=W#YGX>#*
M;!&4$_,E!T]-ZD_C=M)R^^@,Z+T!HSO=II@3A\#@T7!1*9AO5XSEH%Q;F)LI
M_`L9269S_^(-I7.$07H4.IP*.@'P:W>(MMS>UASZRVY7U0^X:*OVC[JY$X.D
M`'93/[_LA6?UAO]6IY[]':H$(N0SB!%)@\S+8!B-A_?%3B)?:7?WY.`<CT/'
MTY2K,Y4:?0(\KSUX!3JW5N#4,=!Y!LY=T[R%^[_L75V/V[B2_2MZW(<.(%'4
MUR-)D7<'Z)D$2>[=AWDPG+8ZT1VWU==R9]+[ZU>2)=O=;<LL?DA,L,``,68R
MKE.']*DB62Q./_)RX<OI08?%K[G&VTH$,STN(R%LMBG@2`R;S__*D=_B?%'L
M]O`^`A8\8$E(VV99D<]%D/$AXB)!,*@WS"P`?])H=JO\ALX\TV#RL&9G!K@1
MVJ0&W_7X=BOQJ,ZL\^'7BW,*'-B+=:H#,D>\8\OUW=.Z^_BQ6J]%M6TK0Q?M
MV^\"^R1+12)(V_^!9SWP,,,^:#=Q?K0_921L#S<.WGI_MOYZO<,S!D;5^3)Y
ME)Q@JK@0,M5FB>L1]/S@31-.-2?.KQ=;=0FQ%VB-#!6@/&)HF_3BU*B[Z-7O
MZO+_/)6[YX.'QRN6"TQC$J9$4-^G<>HG*$CI@$D(EBP>NS?Z/NV6VYULO81%
M.!`9?(U<6A%I\;7<;/9JM^YJK$ZFQ.3']>ILCI[<3S!(CDC.-+Z^.<^?C&"[
MO4$C1.(HIE$H?)QR@9(H&Y8*811E=.@-*E-H;0F"E"B\;`L*$X27_0R+>E<^
MM%\"Z@]Z)W>B_U,U-Y0=&"=*+6W[:**Y(8S0:3($ADCB)X%/PC!&"?/#+#AD
M+0$.@CY#X)LK$C`)&'A^,."6%@/>W4C]_]1`:WQ^A=1`VE>3J0&,8/"U++(M
M+E8<OJK\X"C.$4,1(R)GJ2!1TN\A)B*+@S12N7]ET+SEO;47US7:=Z'52GPG
M&XSQ?2Y'QD&]XMHCIT-P[IK,OM).K@'59*.B=MUIIM'1NM=4'WXH8Q<3]+M^
MJ[`D<2W)`N5.),5V/;QPT<@:F?:;$1U"<E<-V5^O+NN_Q+9HTOTFCC2+PX_-
MVG"!<9CY7-`,Q3XCC`<TP/LX'3(<LPQ4]CX[6LO!M,7DW3>@FB7V'I77Y$30
M:TKSTR1;"3\[4(NU\2WP=U]:Y-ZI=]Z)>]Z79^_T[_4N>IV/-Z>/>YSX>>-U
MLZ1UU1M\]3Z.SA*WFEG)#MY8#;TS$\>1]9M#A)AJ?F5IJ.8)C6U[Y+M=L?I7
MU9Z&M:\C==`YQT+XB(<\##$/4""0.$`/*9TM."KBM1P>CVCFC(BJ8SE#3)Q@
M&)V)BH.OWM'9GSXLGA^_J0*CYNSY%4.C+B4V@Z.1X8*%QR_7H7^!0/]<;!^"
M1411'H>4T5"(("54,$(&Q(Q%4MTD'8!I.1@>]&Y=?B]J[[^>B^6VACY>,N<H
M`N*A^P/H7AAL?9PC]ED9JVLA;]X)XE*DFYF)<P'.A<&9=]F7E]_+5;%9=0$Y
M#1*"_9S3F.2$^B3F*1N`^V$$:P0R.]JIHMRJ!^4]E\5ZY<+Z#S:H,Z[^K(VG
M>T%O</676?F=CMW4ZSZE>>-2+'2#D"G6?!I#)1T9V\W7]I&B?S8#L-TMRTW7
M#.5+O=LN[W8+G,6QG^<L0H0G&0X#ZO?U.!E+FR6GI`#J&;$G7AVNKGW1"V3>
MGP.VJ2_SC!(UHA1F"';D5V[(F<K&'%1L-U=W%;)M`_)]-=S[^Q8.?>Z./AK[
MU?98%(!#/X]21&*<L#3,$0Z2:(`2AYRHM)0S:=]R;GB`W!:=OP#=-21K`-^T
M^<3^N+2##NHS-MTP2>:&,X\0,-NS.SA6F\`!&![+R2R.ER/Z:]7%"PW;[-$)
MN49PM-_:W3?/06&**4MIDW5E%&4,\28<<!QBA&(L,@Q[=5;)A/5BW]/?<??;
M56MNILJ@G%).0!ZT0A?.FZVK$F>8&;\$H4.E(SJEZ\7;BPOZI*BK#7W^W'P#
M^5'6BSBE:9KX/&X2TKS)2REB;#`9\QQT5*9C9WK=::$UJZ\&G+;V0/A4%"!+
M5&JKD!2+TRC1D2*('"D0ZZHFJ;AR39B4Z='(A9K_/Z\>FF7S@I+&*$8IYA%%
M<4X2P0Z"B+B?ZB5$\G;F4J<]//W<","H:H)DATQ#^G25QXERI0-)H(0)3JVK
M"J7BRM74294>:87ZL*U63W>[-Y9_+[JW=+F(N<])@)(\C#)&<BS2WFI">8@@
M(J5IRK).]>B\<ZN1/4*H5.E2*Z=6$[(*$RPM0JUHUCA5([)EB&-'E,N4-Y65
MB:B__J/%YN[;PW+[5Y?9I6%,:!)$/LW:^LZ89B@:[/HDE+J`;LS8]+G6`9^Q
MY2"07N4UH3UFM1,O>5*G6AV^(`NV1%3CV1$M,^?/]<6B#E$:>C98[?/`B(8T
M\T.,_<RG'"/<9(*]W33T8TT]`QJ;5<\,+2#!!*LJFD5N32J:(^O)5W2!-$V1
M:6<U3=6?JYJF191\]<9RW3Y1^+W8/!7_J*I5_4>QZ[-"$<=1AA,L4,+3.&%Y
MF":#Q20)844:ZF9LUV*TR+P>VHTWK(QNV^<"%!>7.IQ*5E1,0R>P<.(EDQVN
M&Z]!-M>:\C)+8\4/^M0ZHE4F/'E=RF"*'&E](G=WU=-FUQB]*\JN6W-O#V=)
M3!.>!8@%*0[#F$7!8"_#$>@&NK(1R]HTX/*.P%0U29U'.46:A$*8'JFQ9T6)
M+K$SHD/:A#JB0OI^5(9G&E"!?E_^N]JRIWI7/32_X&Y]*:@0*`ORD&+BASSQ
M$<:#)9$QT%.4"E]O674Z1-X!DMKFE`IK<DICF3#@<JW',<]FTULJ1@1%@S='
MI$3'@\K8)`+*QQ_+A^+]_0M[_8H.1SYE#0U)DSKE(HCS+*2#0<0P:'VE;L6R
MF+3`VKKIEZ*BND&D0::<N$S#HZK&S+/]<Y&3$;'1Y]$1S3'@2&5ZBH$Z0_<F
MWF\.:5(4!G'$?)'EG"(49CX>K&2!CZ1JFQ2_VO:6]/!#(=!5DBI5XZ(R`4N*
M2O(>OKFE2A&D0;)5JA2;'\,HD^QQ_-K1,TJJR8@3O8G5T5=&IH6*4'[^N^JM
MA$$N8I('*/<CDOLLI2$?K##"I=I=*'[U5$))M50`0!5`*.VPI"B4#9BI*%(0
M2CM4:0JE'&4PH3PX>DTHX8RX))0*Z,\)I2H)0*%L1FX09#^G*`PBE"<,^SC@
M.8H.@LR)D'K17OG+IQ)+IJ<$$+H@<FF)*57!;.%,1Y2*:%HB3%<V)8D#"N?1
MV:O2J<"+4^*I@O^L?"H3`1-0T<R)WDS"8XI]'K(LSG*&,B)P.)C!60Y?DP.^
M>RKYS+54`4(60#TM\:0HGBV:R5A2D$Y+;&DJIR1K,.$\NGI--Q5(<4DV5>"?
M4TUE&H"B67X?M#G'.$PPHS1E-$,LC()D2&Y)%@D&%TWY[YY*-+F>'`#(@HBF
M'9Y41;-!,QE+*J)IARU=T91C#2B:!U>OBB:<%*=$4P'^6=%4I4']SL)MN2E^
MVQ4/]2*CU$=!D/LDBH(4D3SPX\$BC5)0.U\-,[:E],P5QQ:<UZ'3OJ$`H'-<
M82=F$BBVJB1.<Q_A0-'(B;0!7ATYDC;AR;7;!ZKDR"5S?SRUDE?=MR]*%MOR
M;KGNR^[K!28H1FGJ)P*G"<=Q[&=#LP^29')]@71MV"Z)Z9#MNPL.V(9[!R,O
MD)NE42+=FXA!F!(Y01X@"YR(1+5L4)%,N:3PLN>7DD,#7+F0))IPHS([A53$
M.:_J<O/UTVY;;+[NOM4+PG,>L]2/?9)E8<)I%`Q-3D@>RUT'TS(PF2SO@7D'
M9"JR`F8/(,@VB5-5XUDX4]!AF]SIBK`\AS`%?N7S-?E5I<@E[57VX9SPZA&B
MOE3_4&S;?['\6@0+D2<Y9VE`@C2/$\(YY<.>*O%3'U0LKF5H\N7ZC7>$I[M:
M!S&JN%ZW1:;NBEV.QVD6["<<09;L*M2ZNFA7\N7:LEV=(%AN^+EZ;$S=5]N'
M1A@_?%MN'Y9W95$OXHCFQ`_"D(LP3F@J.&\;224\9R3RDP"<(ZH:FBQ7;`!Z
M1X3>$:)*`J1,*R!YG()1U232#3(5LLHI2-7-+A7(A:69%TBXEF[J<N=2VJGM
MR[GTTPQ!<@(_O%7Q_O[3T\/#<OO<?"B_;LK[\FZYV?57KUL8U;IL0>S[QZ=)
MFD5IA$D0$$&3*&09WK]6@9O_@N1EWXYYR\%@`.V]O_=ZV-W'(W#OB-P;H`/?
MG[`Y.A+18_Z!@<64GWY,`$%H_K%1"TVVQD@N:BFQ=BF6V1T"%R*<90^KR>8S
MO`?W8['=/7]8M[8W*_Z?I_)Q_]CEX8&"`$<)B1&E04)"+)H_<C:83D(?]'R2
M"7N6X]T`\<;K0'9O2QY@WFB\;V*$:[E=FZEIAD4O$PS;ZM)]C;:1_1R3I#NR
MK6/4I;=-NPW3I:]ZIX\>,)^$,<DS%'.*14Q"2@;3/@Z@SP]HVW-!]=2ZFAAA
M6U/W+!%M0??F:8(B09R*\BG0[KKRJ;@DJWS*=,GM?ASLB*?MIMP];8O&N"A_
MM)_JODXW2!JQS0+2_,,%2YM<4X2#7<[D^DX:,V99\PX0NU]BA[/^UF3>M5*]
MO1%V)?8JIB86IG%'3@_P/-*RVP.<CUK`EL/4%*MM,!B@6FXO08*.2SL')IET
M89_`J#^5I2EG<T?\]E`Y3;*8-!@8"D@2,1S2-.$#&L&XL+8K+@_!T9WQ6_#]
M#-M#96&+W,XH3;--[MX`6=POMS-0T^Z92PV8G8WSVY'+.1.-APN!<0(O=3;1
M54F5;^2_7E=_+QN>1+7-JZ<ON_NG]=M6W@N$XP2%`6()IQSE@:"YWUM/?03;
M2S=DTG*0/*#T[JNMM^IQ>LL>*+3/OR&:Y;:39F`8%N!>DCM`'#3R]&F`J5\$
MD&)N9$O),/6.["J9]NKUVP$V2)-;1_R^_%$^/#W\OFP6+.7N^4.Q+:O5YXI5
MF[IL2&V0_7?Y]=OZ^;9L%CJKO/BR^VU3[[9=CE"3FBWK;\V"I_VC70E];[ZR
M^?>++$$DR@(>XSSW,Y_A)EP/2,,XD&^\-@\\R]*ZA_QNW6'V5@UHKSRB]AYZ
M9[W5\AE48CC36$HL0MP?1IA^]_YX@T/>WB/O<^4-/GF-4][>*V_OEM?ZY9TX
MYI'::WWJ=G^Z#R?>_00##UC<N#\!U!8^LTX$N861%>HO+9KF'6<7%E0S,U`Y
M\Z,#+L1^VWQOOK[:/O]1[!8\SRF.4>QG>42#D.91EATRG2@#O:(&^F++D7_`
M(G]W0(T>N662-69@P?0`HWN5<>(%SRD'(\L:):H<6;RH8:\,S!55"?B?:OO7
M;YL/V^JNJ.L%PX+Z+$E8EO.8!R@-\V"PA@,B5<:O:6(Z6;CQ_FZ0O2LW[Q[W
MV%1U`L@A4#'LT:>L'2VD9AWE]:!NO']LJS'Z[,K)"X)DA$6-4=<D1M&+2V*C
M0PI<=D39%I(4J^X)V47&$4Z0$&E(TYSQ1N;(8;<E#@/0EJ^BB2EEY[Y'YGUM
MH:FJ#I!"H.K88T]9=09(P[O2LXK."WYD1$>-4-=$1]&+2Z*C0XI^*?,_Z^+^
M:7U;WA<+3C!C$6$\2DD4T9`GR7!W)*6$2S6=,VG/=EE?O2L?EKOFM_348?+6
MY7?P.LD(KW*R-#6E,(VZ4K2\Q^BU(%TI63[2IE*RK$"Z(SIFU"79DF5ENJ05
M[M-R7=1Y6>^/L3X5V^]ED\4MHIP&*&OT5"11EHHX%9@.UE(J=S2D:<*RCC6<
M/SP^[[S'Y;.WZL'=>(_['BAMRX.O;8[@U2UXH+JI<BHG:!/0"=.P#I!W0'3C
M#9@FEJSSQ(RHE":3C@B3KA>5T>D%+>QYJ+:[\G^[XYSW][]M=LW$*K^L"U+7
MQ:Y>)!CE28XR'`<L3=(@\M%Q+<GE6@(9,F6[D.<$7:L^=TT\6)8;;WG7Q()M
MDVV5!\#>LD,,K>W19%I.G"8D&292K_D]0O/(%3KME/",$C56NF.&84?$RY0W
MKTMU3)(D+69-MO;^?E@?U8L@Y")@$2=)&B=1*M(\W:])$YH+)$!=%X%?;5FL
M&C1U^R,Z`-KOZ!:/R^WA!]:LSY>;NW*Y]C[MFK_R`*B64.533J(L4@F3I`;(
M"Q)O]B77S]Z?_9^?BQ\[CS8_E[^FOK#ZDJ,1-5(DTQ'U445?&9E1\`ZO=3,O
M5MTO;#]#V@G2S8\%YZA5LCRA*.:!3W%,V6`S32)0HJ1ER/JJK6Q$Y7&]UY\7
M2.'M737HE).:R9B$"<\+6`ZISAA=(QIDA&5'%,F,+V\[O9HB"+!S7E;;?2W3
MQ^)NW2Q9NMLC+0*R^O=3O6L3@KRH[[;E8U>8R!/ATY212/@H;1^<;K*R`4>;
MK\&VT0T;MZQJKT'"M]--DRV[MSXCSS#->XW/(=F#LCBZ[VYI0!R11WO^O=F1
MMTJD?-)WMKKSM89GOD^8G](`9PAE+/23)#IDG#@!%4&8L6A9,+OJZZ5Z/;YA
M>B6SP<F9!::%ETAU2"NE.!S+%8V.@2.J:-BIU]FC!<HT]>]C4>^VY=VN6(V!
M6Q`_IS0@6(2-!'/&!4GS/2:&0D(2?5DT!,1Z>CF@['[:1C32U!#H2.<,[!M3
MU%=C\G/JKMP`@.78\+@ZK=*F?942;RL$2VNZ6);;?RW73\7[^\,AP<F5IMYX
M2/R4B!PS$F1I'HB8,]H;#Z,X`>T'F+%H6:5;D%Z'\N7QR0E0H'(;(EI.HJ?G
M&*;%$O0ZI+=2;(X(J]G1<$1!#3M5V9S`0$W\O%VNVIYT[W??BNW;IA*]\8#2
MF+"<TR3D&4<D35@R&(]1"$IHS5BT714#:;5BDU@Y#9R>4Y@&=OBZ5+-#>*Z3
MC4,:*,7FB`::'0U'--"P4Y7-":QZP^OUWH*/TB2@A!&<!`G-,RS2@ST48:YT
MQPMJQ++2&;AS#J9-3M0F80RF8R<WNYQ1JTLTC0B4-K..:)*^'Y<N>>D1HW_-
MZ[7]),4B87GHLR`F21!@GP>#?2Y\4`)FS*AE9;K8Q]W4G2\PR;*'TS/P"].Q
M*[>_G-$V62I'3Z8-CX8CVF?>+]F[87K$26MC>[_V[W*];DR_KJ-^H\X$!RR-
M&$8D(:&(LRSS!P0!@97P&#1K61\'I-VO%W"MP#K;<C(Y$]$PH1SGV"&EE&=S
M1"LM#(DC:FG#L\KZ?`8JYL>BR5Z?BF;97'W=E.=J+AD6><R:[#5+:<`3@0,N
M!L-Y(D`+6GUKUD^?.X#>"4*@*!H@5$X+I^42)H%G:'1(]ZXR-R)WYEAW1.4,
M.E39FJ!`3:-/=;DIZII5#U_*S;Y(N=\-Q#C+L2`)%CS/HBCRJ1\>5-3'&43,
M-,Q8/XEH\NZZH[SNLY!WM^5=L6D`?P7JF0Z9<D(V$8\P!1M`>:>HW)&PRYR-
M:)<!HAT1+1.>5,9G(:1)/JNZ1TF:I?'0._?DPLMKG41^1E$41S[F+"2<9HSR
MPVHYRYET[WNC5FV731^P>B_`0KJ8FV5Y7,[F)1BF;I>X51(XV[0#>L+/1K]:
MJ_>KPZ`28"[T;(=0<R:&V*/7A0[K=ARK;,],2,#YL-QU/=@WJ_TG\OBX[B\)
ML:H>]AM>(R&)2.(\23/!4C_E0A`:'S)TR2(>B^8MAZ`>=)="[S][)[B]#CA$
M%RV-@41<FI]^X&%3SSP98=Y0L+(T*("H-?_@J(4OF9^'UEKI0BA3XNM23+-+
MO@O!S;*'U60S&=HM\MMR6]!E7:R:-=UCL:GW'9:Z*[#=AGO;/+'\7K2'E<-2
MCPLFD`@"%OEAC%+$A7_8D6(\1*!6DA;L6PYX'>1W7UK,WBEH:$])&\S+;2;-
M33HLS%WB^\;;(^XW[WK,7>&%0YM0"ER/[$[9'#E'MJVLNOBZ-:9U.@%GC'71
M_.7V[E9>?"_655<2PG^TJ(8R71)C(5+.$TXH0WF2D>"PQR:B"+0Q;\*>]7/&
M/<3N!WX"TNM10DLQC%`L>^XX+;O0D\=Q8ITZAKQ*Y.A!I+EA<$0>C;KTYC#2
M-%V`JP)WU4/Q>?GC==Z;$4P9RQ%'(6J2WXS$\:%`F&0<U+=<V8AEH=OC\AI@
M"G<%5'F3$[))*(.IUY$MAW3J$D\CXJ1-K2.*I._'F\L"1HB!].%L\[S]9O/'
MLOZ+;8M5N6L_+3(:T#S@E(1",!1E`4O2P22."*@"5L>._7/$([1])\X.F]>"
M@_?A5*=33I6F8A)\8'A$U3%W<TJC0VHUPM^(8)E@W1'-,N+*VZ:<AN@!*-?#
MX[;XUM8L?2_VLGE^]U"$&4HIR0BA2'`?B3`?&G^$/,.@SN7&C%K7M!.<WNWH
M^W"6V955M1F(A4K<*:=[C$[IFAR#HR)G>!"<43S3?KV1/RO$P9L0_5XLZZ=M
M<;Q1]::BMDD5<\8R/\$X)$2$$4*'4C7!U!H1:5NUK(8GW7).H*KV']+G6$X2
MYZ$7IHGGF75(%:5)')%%\P/AB"Y:<.Q2&R+#U$DK(U]N-^WU[@_%MCOP>&T6
MQYR@.*>^8&D@H@@WTMR;Q81EH/-<75N657"`USX+Z'4`@0JHS:6<[DU)(TSM
M#@Q^&!AT2.FNT#:B;Z8(=T35C+E3V9F7^I>5V@<-UU6KIT?K.<TSPGB:9V&6
MQVG@!_TJ.PUSDD>@LP)#)BWKV=D;./J7EY3(E5.V&7B%"=PY2KTC1+5Z<VL7
MFLYP-Z)RALEW1.Q,>W7]TI,^:?(%>G??BM73NGA_3S:[<E6NG]J"E/_C[FJ;
M([>1\U]!55(YNTI[Q1>0(,Z?"+Y<E.RM-I8NKL0?IK@C:C6YT5`9<M8K__H`
M?)FA1A*%!@&2SE6=3Z==LQ\\(!^@&XWNZWQ]V&^J35XFW]?;PVU^FW):A`M^
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MJB*AS=@\Z\0%$A#1KPU(/>L%A.$QHF^(7"W*+<WKA`I^X@LLPPI4+UI+5<8C
M)8C*1,D?\#T\;HNG/+^NBO4_FMM+?\L?ON3[51"D?(M/(]^R/,NB-&'A44:I
M1QCH:$_9BF$=:["4J"K0(_\K]UF9HW7Q\,"]]5)@1;\V.*%2-H)6R5.^21@%
MGN^UF%`-JKMB^3Z#9L[SWB)HZ"1O-*D+D2D-`SD_O=-$S53!@(^;77Y9Y0_E
MRO+C$&-J15;,7(_1R&TS_SD^&P?!A)Z_/*B9W'QP[%*,"-5#FC@X`)C?22(!
M9J96C]MO9E:7&"PXSH*YR`!\HA>R)DP_;KT^ORKQ4ZTXX8-HD+5*+>9BBEV'
M>1;%%DE9G!QCXP1[$RXWDHA,'XX**/6]L&<;ZTU9'L1A`CH\\M]5]SG*O^?[
M]89OP'^[WZSOT6_Y7ORN+UWB;ZV?RU=-#__SO)^=5RIDYTTT^Y,L1@8F?I:5
MZ`(U(_EC+4(-9G,K$'!V_W\L/]!!ZUU[E"@'%C"XYL;K!._P2UGMLW6U\ITP
MP:'/2,A7.#L*8B]J/2O+(99T[RO5QYN3A_8:_A$2^K4#-<_=^Q?<#'R\8]E<
MR.<X>ABO7KP?2XM\:ENVS<NV`<*GO%KAP**$V)$3\$<[-,(.3CHS(J,.E)L&
M?+;A_1.'@/8-&F@R&)0DR6PN@_S`=*0%<8$XC*GSIYZ3,)0`I4C70H1"&?YY
M"M(H&J2%X>JQKOR\^]H5^CHJ41RD;NS:)"4D=6(O#%AZ5**`)*"KF^I6#(M%
M4Q-6U.;*6V1_`8K&"`+EY&,:[F!"<L1TK`\WWY;D37X&-&8\IPM1&PT#*72_
M;N#"&F5U==<JW8HXE/A^XF`O\6/&7#]LVZ-S(Q:)01L3V),G4!KAM;=;$_1#
M$ZH1WU#V4.RKS>]'QWZ=[ZMLLT.9:)NTY][_YM2T,:N;\?T(+J\!XEA.F,S1
M"Q.CCMF?W]OT&:J#T6-A0'+4V%J(S"B"?U&V0IT"/<5=5Z(`AD4C*PDHMBT?
MNRYCK5&7$@QL'CG&DF&Y>59W]/8$3V<=U_?9E!.2Z8B$NDO#M5N75)]U0'GT
MT+L0)=(T&$@U5B!%\C&9?,O_].M?\QW?<8F6N^'MPV:W*>NR9M_RSCIS+!JD
M4138.(UCS\9.V^V-6W>`91$UF31]`M:@O$!?&YP7]0>8/8,*#>UHXEHRXC,]
MS3!E.S+<0JP)?@YR)I&3HVXH?*27^X7(GNY1G0>;3)`&\@!%CY;.XUP%W%`0
M8IO908`#V\,LB#H[W/_D3F!195MY)Q#T<)"X'7%(?WHWXE]!ZQ=Q)P6/#L:9
MO%-GC"ZX7]=P]'X3`F.N79^+=[P[)=H6HB_J^%_Q\480`8];-P=IHN3HRDY\
MWV46#KA3:7FI9;/XN$^+71]#9$/E^8:5XQ1TW<(+K"KQ!0Q0&Z)*-33=GIK_
M(``-!,S,!J5/G,B$HQ487(B`C!K"6R%H93JD9>13L2N>6VN%ZQCU=L+0]6@2
M>:GGL-3VHH0>]8NR!)2?.-Z:8<_KJKK/]VC3?CCMUN1'Z)&8!E+EE&=:/F$Z
MU,=VE*(6WH_SG9:]2]F`3.FC>R&BI7%`A:DW$])362CEU>Z7;+_/1/1J?<]?
M2.ZU10%.*'&C)`U]BP3$\6EGR8N<:+7+OV95?GLCV3I9S8K4ET:;+^T%('F?
MH0;#%0S=B5+!W^I2P<4=^JU!6Z+'0O0!W63;[1,J\ZK:YG52-?\7UEEY#^G3
MJTCVL+*9)EA)R@0>5.Q0BPAUD"9@"]"UV#QK:EV)._;:5U"DZ-?0_CRV[?"K
M`WY%OC6PLX2VP2-'4&A[5<#9RGPCEI?5LV5`9'1Y:1QB49*?,=]+&4E(9'?V
MB`W+P50V8GA#V>%ZL:>\0+NA'$3-3,IM)R<A$2:]1_[.=Y!SY'"^Q<_`EG$T
MI0O9*8X?QXO\;RW$R,?+A&=W]>J65%@E."11$+EQX#%;I)['^&0UL2@H=#;.
MU"3Q]UVQ^W!RSW2(TUB")6-MTW$+#+O5D8.7P;<Y]6J8K*%XG!Z6%Z)=ND9S
M'J7329)\P"ZO>E%!4?LYI2E+^']8&%+"'*LU@AU'Y*C+RQ;LR8952EQB&8[R
MFXD.]3D8B@0I<;60[T$1_'F$9P0%RNUD6%9NUB))J;G%?0PF80>+#"62^C$'
M$`4ILW%GWG934+56738->Q;=%U)?8.]NR@N\T&BU-H[E5O`YZ(4MY:_=*Z]1
M-GF0;0&!V2+8D@0.J)?N*5B(KFD?UCL-:?30IDL+5]1AE&#'96%,(A)@0E.O
M,TN935??\OV70I,*OFL-\GGV@4E_I:<OLBOIL>LK8BV%Z(=#>7OZO]!;(Z,9
MUZ*(6JDVH(3+DC]UV9/F^8\A=_+#@<D<D"9I>?LEWWR]%S+*U2#[FG\ZB&*!
M5W<UA*M#55;\E>.PSM&DD6]%7FHE#F8X\&,O]+N\".Z`):`BRH8@&-X(=J@_
M9`WL9YO!$A4GX']!7\Y%$ZB(IB9)3B@7,#\P_>P`HQ8Q:B"+`]FVRE4/]OS2
MJL;O@.(:GK"%"+'I41:3?@705MB;7;9;;[+MY8YO?^OCX?*UEF5.XOIA:OL!
M=H+$(V[BAFVZA^=[20@Z[--ET[`PO]ZL&9JXJHU@.8V=@UN8J!X1HA[$A71-
ME&1O0#)U\[\0C=0^K//&UT9HDR\%6E<E.$8``I:&&+N>Y_/=L>\R2I,DL2R;
MVP@\1F$U/6&/-JQIX?5U<G,-+94)9$=.J0P2`Q.D!LA\`<'G1`QHBR)C"Y$0
M5?3GE1W'D``4A.BPW_>+VT6V%;&08L)W8GPN@YA:7FN,!I8+:RJG9,&P/+1P
MVBHMT),(1=(@<F&2+Q75N$`=93/+QQDQ[ZJ(*I&+$A/E0;RJ*>,HD;\MG)6B
M3H/XG^1_#YMOV59L=L(JRO;[)^[XU1['BG(OCUDV(6F8^F'(F.^XG7''=D-0
M'2DM%DU+#T=7QTY$'CO*3SBA%XOUT"LG2M,S"Q.I(ZGU#SV(%RBK4(>R<7*G
MOIPL0]V`C.FE?B&RIGE0YW>;#5`&J6M5[3?K*K^5@\$\)TELU_>8XP4T\*W8
M#CH8J>N`NL_KMFU8"D]P(9=ZC!$M)X5S<@P3Q1Z]`_K8[@:FKY$%87%`'TW-
MQT*4TMCP7E;6,DBCO#^Z7HN.!.7/^3KGIK]L18YJ^XJN&$UM9E,'IX0F41)%
ME$6=39+$#L@M'6/(=/"JQ8;V1W`JF>[CN)3T5J>B$>BT=@S^W&.0(YM+[H9H
M&G)A=;"[$"'3,Y9SAU8?0=(2]7F?/V:;KG`.5\HZP?Z9:[VR<!A8+&")3Q(K
M\-,T]#K3(<86@2B5#GN&!:N%J%HC2PNC<GHU-9DPV>IX;.'5.[;FPLY9%&YB
M^9)@;4#%='*^$#'3.J3"W"LZYC1@%1,O=5/7=K'GAMPA]KRT.W((8QPSR*4=
MV)-!<J5<VN_9&<"8(X#WF5((_6LE:53(?\XXOVQ\7YJMA0B((OBA>#Z0`L!^
M1US`K9X^\W>D$A4#N5-8EUT6MP<=/W8#$EDD8C8)0C>TG*/-E*8^;*,SPI#A
M'<X12[TFWQWVNTUY+[*/51RS<8S*;G0F(A.ZPVE@7:`:6%,UM(,VQ]WC(9X&
M]S0:Z%V(%ND9RXM=C#:"Y&IJ7>ZXR75>EEV-^%Z!^%7HX]0/1#N<D$4,,Y?$
M7:P_M,+8DI&I\58,:]3E[L-C`P[MQW65T$#HL$I-RR5,HBYWJ,6%CHTEXCDH
M!-34FHQ*M=):$F_FZ"I;0Q2\(N3Z:%M"S2T]`RETOU$0_:[[*-;W`,1!Q)>#
M>,'*G\45@G(5A6D2.T%*B(V9%T?$]:S.'O&95#>@T49,!_WK=)PMVM=H(-O*
M\?1)B/54S,&TND:%POHF4@\7:H!-QA]`J:?B44VH5?F4D^B!L;^ET#KH6H)`
M:QE'H?D]TB3/_WUXW.:[WU=AX!';X_^P,'83ZO@8=[MZYK%0ZHJK+EN&Q;J%
MT8JU)IV1YG&<7)N@4*=J7Z`6X=2TZE%Q$_2:$',)FD>K>FM!0=RA+"Y<X\'#
MD91Z-9KD%/^OX<<$6_:^75-H3%(<$!(%B4=3S['"HP4WM:FTN,,>:UC'!9@/
M'(V"D`/ID=!L<\S`Y'DZ4@"*:XX<-7&5)DE.1)\-[RV]5.-@"=*HB+P8_0(`
MS[KB_+$H-U79'*Q]XB/K#MRM@$2NQYS((2GU0L?&<6?/LF#-/96-&!;##E<=
MFBOJM!.ELW%U$N6.MB;A#R:91^JZH_,3JHG/L]XB9^`L:S2?"SG'&C^.0O.+
MII1^LW)(P,+0P6Z0NLSF6SO'ZZ*K+$TIJ%BNY",G2;@9D6CS/B=RTF&`#IA0
MA.]P8#"CYMU4&FE:%O*]0U&_FCP#'+3TM_QQDWW9;#?5IG;=KJMB_8_[8LL9
M*<5)>/74NWT;N7Z"*8Z"(&2)0TC<I?*Q**6@N_;:C!K>:7R\#-GEQ\N;R^0:
MA9]B='US%?W[OUY]C).?K_^$DO_X^^7-?P%U0A_?<DHR"]4PK>E!/.;95$_S
M7>"7I6Q`J+2SOA`ITS^NPO#KJBZ'Y^4''"M-L&,SR_-8''#3*;%.KIP#JK@V
MPHQAR>O*9VQ/"*%E1\9P"!8UD_0IR]@"JI"\39&<;*GRNCRA4A[)V](TCASP
M)=//V9.X,M;E3]NA11WB<E\NL`+/2RP6.ZTUKHH>2(@439C.,>FN13XVL!0O
ME$)YD_3-S%,&]-4ZMEI$<U\>?4[,D#LWCLF%2,W84;QQ5704*1")V1_RVY?:
MMK*=R/%%$4>+>*YKNUX:I9U!S/U0H,HH6C$O-`+8\4)H+Z2\?KD1FOY[>IVU
MX4]J)-/+^:K&#N3EAZ6%&KE3:5&LN*Y`<777]H4M/Y]:15\?.T5?[D0!BU7B
M!$X:$R=@Q`FI32**PPZ"8_GR.4F:[1K^_E*]3;7ESC!A%+UUR&F(Z"6<@IH:
M6F'^/86Z^\7NZTV^?XCS+\=R#(3ZS,<ACCS?C2,G<1CK5MK8B6"5_E2>/Y&#
M_UCL12*!^.ZV'.4'_J@'=,MQ0KU]%0HEW7S#[`']^R-+`L_)Q?];5AWV<^P/
M7J%GR+<?0>9"]@2CAG#NS8^F8T1,<17'H172D#`GBKR$)#X-NZI4<>+[/N3H
M5.'QDQRC@C;0VHA3#2!JY6Q\X'#V:"$H2BA-WE*$9,0(WHT*`LD`Y'S=Y=S`
M[4WVO3D2[IG^E%>]M`]J60E-;.PFV*.>3U/F=^'(&`<L7.WRKUG%72')-"9=
M=J4^(=I\0GV(@/2F!BJJLN]'W7D"IX5IXUE.C"8F6#%QK&66@SPECXE"=3-F
MD$G2-IA2IIOZA2B<@8&]2#HS0YU<>"4J=J)+/'_\9_[&WF=E_GF_6>?\U^7F
MMFXA7^PXBJN[5I0_-][.*B(V30+BQ92Y*8V\('"[4$]LI4PJB\4H`,/>WRB%
M-,O\L%@NAG28;IX0HPXRJC&C9Z"%E**KNZ-/V0)?Q+P`+C\L87[4KDGTYNFQ
MFZ?'>I[6??#U=7<1,NF<FS:*,KHJA")S;P4G34_$$J*4QL=83/AFCXA;]E9:
MCWD.=SMLCUD>L?TT(6[7(25FM@]+45(S83HC\UFH\JW/<40($\(F/(IIB,AQ
M@<SD^WI[$"U.EQ72E-K`CR1W(;OUL:,8B&TJDZ(2WESY;FJ[`7.9'2>,8&8Q
M9K<F$N+;H6)<\]WG3A+0U!+(?)\B<`13*SO*H<OY(I9RH4IIEI:B"2K0WPY.
M`H<OWSVM>'C85'5_6-&,H]LFK85)9@=1&@78M4/?<F.7;X2.)EUL@[8C8^R8
M/E$]06L:IO7!0;NEC:%33CFF8A+J*#\G,9(CT4PKM+<9&M`:';PN1'NT#.6\
MV9DV>J2U:>#ZB)6PD#E^REP_%+?S4ROL\DD2D5("D:819@PK4Q_9G^H>CM43
M]#;'&!+E!&DB_F!Z])RZ]DI:6#6%;>ILM*I`G[-Y+WDHW4W30/="9$K'2`KM
M[R*\34\3DJ]--TW+'"]P4S>R<!1&OD?MU"/QT10.H6UYP,\W+$M'2*@4F"[0
M/UM_MKAY])BUV:`_(>^"_T;\%Y7W_"OCFX)#=5_L-[_GMS^A7=']=E.6(G^[
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M.=&9F%28#/7X%.C$5:@6WP7J2]345Q3?Y6Q`I302OA#=TCFB\]N+NLF2R[.+
M\[O->E.%Z_7AX;`5&;GQ8<]W#[TN&]GVNLJ^YBL[L%.7D@0[A(FKRB%U6&<^
M2@(JEW6LVZK4)SDFY[@'$MTVN"%I6SH)'M:Y69A53386(%&?V@8F>H83U4#G
M8AN0%S<3ZVJI<!W[6?_%;MBO[O-^+R0^`Z4`/3K[39Z?MQ+>##"\A!PW$\,J
MS+Z8P)WSS3[/RL/^J;='QT["/,KX\D5I0/G/C'5Y*BE-(PMV?47!@/$UXZ/H
M,%:UP(Z.?87615E=(+\),;2_!^Z75?B4VQ^;(E)IB>C`/'/,)][\OB1D8+,[
M@KV%;&['C*#0]BJ-/@)>8<M*8LMQ8QP%=A0&:1IW8=+4C42/3?D<-87'3Y*J
M5O9P_<L_!8Y-?FJ/?T>?_K[/G^JIKU;JC)WVSG[$"SK:E>9T(2(S9@3O'N4"
MR=!60WD5^WSC%%&<,HQ=*XB<R.X\\S1T7*:8%JMF;!(!ZN7*UF<1Y;,/3$F*
MQK,L)TR3$@R3J=<K)2^L//*`/FFC=B%JI6\\P#+(0*)&;)<^%54>;\KUMN`;
MMOPF_UZQK0@V^G$:,3_UX\@E=IJXA`0TQBX)@Y"Z3@IJ-*//ZJ3Y=.]]?:89
M5MUG34&NANV7@(E..-&O`BFJH<Z?9_<&AZ"]V=AY6(@(&AC8NSLY/=0!9#&K
M<A$,N[H3U>C2;?%;><P+3$(K9G$4,B>T8]]E7)']6HJ]./4\7[91PR@;)C_-
M%I:X9BF`H1K9G#FO;_,T^/EIH'<Q7YR.L;SXR+01)/U=?<HK8>OSOOBVN<UO
MV=/?R_SV<G?U6-^HWGT-U]7F6[,+.B)Q'$Q3B]B)'5(:)BY-VH9ZKNNF#%2=
MT8!YT^EIX@.\JS]`\5J@HH.*LB-6:(*_B4F0D[R9^8<)H:C04=/?P45?GM`/
M`C':['Y$1]#HA'H^D80S.R"=!J=I(8)J<H3%9.\\.&?M?PYE<R'KIO@Y%U1M
MMCG'=[E;%P_YQZ+DOX=B#;%C1:FX6^HY0<JLP,5VA]5./`^6Y38#0.-Y<=V8
M1$1YWPVJKF/!-[.E^*WX6=2Y1H=&7+2H_#RS+;<.+'ZB82M%;SAB.H\#JHL\
M-4-"/XA!_2C^^`^SIIB8I<'LP!E?BH6L2_-R\"(#<?8)@?3'YMJZJ1.?^,_;
M7/P0[F[#!U$@Z/<F9<O!F"2$!-CR:<S=&N8F<6>;^A2T5FDQ:'CMZ6.LCP^R
M'KBN!0J\A[8&HN66B<DYALE^']X%.@*LF>Y#G+[1]KNL#<BP5M(7(JMZQ_2R
M&;=NPN3CE")CC&5<=:/B07S.C37/=:W0BYS`M2T[CNTHB*S.6F2[H`M[BB8,
M2]NG8O>AWC+7Y\P?O@A\:-T#"#VE4212,M1KGD-@D%<`:EF+I%@S$]I]E9>A
MH.XX(A<B1V-'<1[(U4&*9!7F>_X6Y9>[7C.?WH64KJ]/<UOR<A<5NUV^%F!^
MV53W_YGM-\6A/<])-[N,;R=W7\L5<5GB1'%D!:'EV@&A2>1V.!EF=I?]^W_=
M75MSVSB6_BM\V]DJ=Q7!"T@\@B0PZZI<7$FFMG;[0:58=,(=6?204B:>7S\`
M;Y(=2<:51/:EVY5T^WSG.\1W`!S@X(MHH^8%,"H<(/ZBL!G<><8W"!Y>/*-U
M?W*'>7I32ZJ5\!)AO2Z=;H=2[69Q'[[;G=>]@M8YU/6`/KG.YXU.#5>.^7]]
M],OCCGF#9V/9_.B;\R&7Z2SM>.@5NT[+C.#Q:C^_2GO\!/[)/X$?PR?0GZOS
M'B8?]?M2F^?]3#Y?/,0NW/59U/_:D;&F/?MXW:;[18?N%8JS%`9^DB/*S!8A
M3<*AAU,8H20D1B87>A"6GCM,??!?-+[7SB6:<5&='<P0"\/)_]?W(G*7`J&;
ML^<+B.F4_.L#$2]&B)U4>Y4NJ4QJAGAG$Z4A]][,@R9I%-[7N]W=\QMS95'V
M_SZIJ0Q](*:"2I(@GV9YDM(@2V,:!MF4:",0%%+GL@V:M7TNJ@M5^ZI8WCU+
MU>V_GUQ'D2V<F^1>;'MP(=KE$M@(TOO+"/,_.?O'DO4`=;EZM3B-5W88+<3"
MD5U'&Y[5UC]D;>'$]_?U@2U?/I7W9?6#7^U<I5D8Y@$$((Z#/$4`9^%XOBJ"
M.(TD%@5&[<ZS$AB!\<-(`S)MA50A654;;1%K4A4GCC\)<#R3&/[*FY0,:M#N
MK`#J^/2F]&D3IB%ZM[L?;,I:-[S7?D#3W(]2/TQ3&",:!#D93]Q$(04R]14S
M!N>1N1-$VO(F1:>JKAFGT*2@";$YDY"=8)%2,!6"G94N)6?>U"QUBC3$ZJXI
M><O0\:5:TI]+P[O-Q_WWLNG?&E[Y!8!QG(`LA`"&,`!%'@UH8HJ.3YQKJ9@1
M)//(VP!U/,77KWIK#G-8!FN+GIFPJ*KA?*$P*9-C5`:X75`ZP,,3ZHMKIPBM
M4J)J-$[.JJU9+]^480ND&EA!WZV?NUDL(5'DL\S`K.#0CT.*23(:+M(@U]MQ
ME+5F>:-Q6LD]]7B,+96%V=1=)]L@TNPB^>XM:F=>(0]XE);'LFP[*WG*#@DO
MC-6HTA.RYE!N3A_)Y"_CIIF?X@3YB9^2*"/Q:#O-B%23?B,&[<L91W1NVC@^
MJ:W^ZJT9QC7TSB;9IB2OHW^Y9W1%>),5/E7:7=8^99]$Y$^/,`O=-E:`+?/]
ME.(8A&D1`T(!&NO8,0ESJ8:%!LU*J:%\Z\(/(A>OK777>)MT,2E<B&\Y053H
MIN%L"XTK^F@A%HZHI`W/E%ME2)*GJYA\6[2]<*$Y("$&*<&$X#P*$QB%Z5C3
M@5$JUQ?1@GG;YW!>]2>J1JCF^Q-I!4%+2>?BWZBB3J"=Z"4ASZR\R)H(D]MB
M:\1#,=$U1Z;XP\CKYZ'9!+[_QZ%JRNS05KNR9<M4!K+O4C?\S6:59!FD20YR
M&,0PHLQT0$<,)`EBN3=#C)I6*``IB&Y79WBH&R:T#%?;O17&SRW_[^%I6^[^
MY375M^_252"S(1`3W?FY5WM*>8#)6_@,<+PCTINNU\_8,7.$._<#RQ),7I%7
M*P%Q1%CM^/;ZK69[!)H0T[\V==NNBB+$!2HHI2D)$A#G"&6CW2`,"X6"NK;-
M>4KG5^7SK_@=^2/RP9OZ.?<([AA4&[5RY+L_4B7]$1^=*D2ICT@VY6(KV_WS
M'?LZ]WBWX7<HNQ?85BGU84%QT+5P2-(`LW\."!($PU!S<J-N>.:IS73QB@W,
M<@39E2P>#LVN:K]+W'JW$0;%"8YE_HU-;T:<-UZ']&9Z@J0#N[0T7F111B3U
M0^&J7!KP["WA-$6>A>VY5>I3D@<9"C)`\R3-BC`+1@0D!)F=;;DWS5K>CONE
MH'%N/\[:=MS;I)O>AC/*M_7M-V?WW(SLM0G'PA'%M.&9\MZ:)'FZBCDUZCBS
MNP?8%-</(E#DB8\A1HBFX\V\)$:QB8*&COF9"QI3:QWS!0VM(&@IZ5S\&U74
M";3+!8TKS,J+K(DPN2VV1CP4$UUS9(JO^)OZOBPW+65T\.Y)S/[+UDHKC`L4
M$II39IL@2B$NHDGU"98Z2JUO;8;)Z=,`<J@6#S!?MT"37=+K\RRXDI^58LD%
M_`MF;T^8/>TO./>B_2W"KJW5C9'MB`8:=.CURMPP54H*UQGZ^,0WTEORLVSN
M*Z:[*T!1%J4Q@CZ@,"@B']/QH$X:Q#A053@U:[,K7#E`X^.P[^Y8]Y@U)$Z1
M:'F)L\^QCL3U_5('>-Z$;T&%.\N7H,+I<>V@PFDZ=$7A3%`EUG"2C>=3PZ.Q
ML^TQ5Q&D<0(1\8,"%7'L0X#&/<\T#3,JHG3FK5I6O+N+:J?2A]HLW]<%;UFJ
MY5?&$],<Z"1W%_M'+T>[1,/(Q>A7:Q5Y/;V?[>&LW212AJ(SJ<8>S2XTAK3C
M6&W["S6QC=!\9O`^/O1]EU<T\1$@84$CBFD*0!S%XUL/:1'[B?8^@IRY69/.
MBW%WN64Z^7QWY\+J]P63LLM?M3`X.#O4]4AD`:Q#EO#@_%0^#67QCP_OZMVW
M+V7S6)1?]ZL4H2!GLU`<!TE<0!06:3;-1U%`%<[7*=N:YUS=75/M[JNG;>F-
M,#TV^+8,Z!]LD#]Z&P95<MFKSJ[8:M<NHTISO2,D/JEX-[%77&7/BGY=8N>*
M:FD3ZHA6Z?M1&_[2K!5^5XR?S(_R)/23$-("49^DDS)F*#)P]U?%K-0D0N/N
M[]-)M?%<M==:L?=MXDT7>8UR;KVXZVQ%UT@E5S@6CBBB#<^4*[>2Y`FK9G<S
M8[?A_^+3QA]L`LD;U91-56]>=W)8H2Q%N0]S3`G.(H#S&(PW-Y`?9HF,;AHU
M/(-R5E-_D\UI?Y-.4/DIX>Z'\NB)I(B:C8.8C"X6`CDAS4>*NQ].D-YX/5;O
M3.^9F:54ALHK8FHE(H[(J1W?ZAD^:2.2BIG2-\TS$_7NH965[R<D1#"@*`@S
MR(`$*!^-YS@M5D\=Z,_[=;/74519NS+C^#5$^2']6C6]]=[;?R^]K^6W:K?C
MLR.V).S-.#&B7[$I/915H^'T&%9V2FCPZE%F>-32D$VW0A]'%/F$_1N%X;AV
M107`:!BU9"=X4\V,5?DQ.P(T,V)+WE+O__4X%8W`;S5.A9U2&J=RE`F/T\^'
MIZ=MV94RMQP!W=;_O-T]U,UC5]H\MNS($@K2+$T(B!-"`H!A,9HG))(ZAF7*
MIN4JT2E,;U.U]]NZ/31]J78\Y,_6+!-NV5/]QJ@76YXLP;K<RN0%X9U"<HS>
M"<CECNL+LG=%&4WS[X@V&G>KMOO9ZM3.=TQ%RG;?/\A3;E8TI1$F08ZR($TC
M$.51-M;K41Q!7[EJ+FO(LA)V8[$9P'B;0\-7$GQ=T4]1VNZN?36`UCE[+TVP
MF/3-QJV<WKTZ<3\`\T9D2QXV>$62Z#$#56X=T3(SOEP[6J!'D$3K\M[.W;K:
MK&`&"4@`R'`19@C2HIBZK2$,J.1S"Q*_>`Y5ZEI]F%4D.?+$%,@:;W**,VD,
MQS%[X_`C!5?T1(DI1_1##?LO#;^5"9#:G>$3J0_,+_;C\3[Y;G.F6%9,:Y^3
MUU?]($]@5@00)#Y.<H"G72.09U+=,:R#66Z=N*MW?W1KQ9,V&KSYD($[X?9#
M*%[U<B9Z"I4PCOW&&]"?=-W@<3I[8_SHPG*K45W2W]C`FR6>CFCV?/Z>V?:;
MD6BQ"TMT737=?N/'A_%4^FUW(OIVET_GH?^[VG\_.;[.)K,\2AO<YG6[/YZ7
M14$<)U$:)0"F&/AI$(S//^(,Q^+7F6;$9#E3<$^\']R5TPM.5\Z<OSB:W@P^
M>>N6_46['YO:[9]E[NK,&>'K&<3EX,HEDBZNG1?\.M7HA]<[PG**=W3%X[Z\
MO'$UNN/AUN,.\=]!G(ZKQ`TM1^.K=G_+W/A=OQK!VM>\S/%\9FZP5"1=N"*V
MA-OUL@-(9L+`3&W7;5L]5/?=6)I0CL]3/?_MJ=Z-U]Y6*,[S,,AA&H<H*C*2
MH&B"@-*42%QJL6%>2$*T[[F\!GTB)J>/YWD'!GVZ(2J3"TP'12"/+Q$(Q>LQ
MK\@_9NSI5;UGCX.=[D@O2;U$JETP!&KI5&0</+\<!=IY4HZD2[G0$M4NY#M;
MKM7VOU3)3="^`\CM;L,^KLV7NLNJ3=OGRJ)L[YNJ^P^^E#_WV9;W0"H*'^1)
MEH`8$,S6V%GFIT44)CB-LAQF4I>DC1NWO'25;`MACV.Q7<E%Z95+2#U4;\#*
MVZ?W:/^C'5:!-]X)8N]/CMGK0,^]ZRA+ZI5=1FOQ<617T9Y_]4P?NFQ%B?.R
MVS>=GG^JVK\?-RR/ML,41C"E`&:0HCBDON\7O>T@HH4/I:I&)@S:K@Q5WW9=
MDF,3FOS0[NO'LNFOWIR"[UHL-N6FVGO<#]DZD!'B!6L]<W,N6<]YP2K']Z)8
MLYQPBO!VK21CDG9'!-*L3Z]+*^8)$]L->5<QNVW)3W/76_:G=0\!?VO*LG_Z
M8OV5[^DD*6`V4Q^#+,(^3!`**8G\".`89I0(ET8,V;,L@P-*#W?*=X+3.P)E
MPY-#O3(R[;$ML+VQ`-%RVN<ZQQ+[&`MPK;9_889SL7T+,5(N[5<8IM2%?0K3
M+M7VOD#)J32M=M6^?,?/A]ZR3W+WK6+&<-N6^S9[?K_^O[K)^>X)_EFUJR`!
M1905+%]E!++)!\8LI9$HR`A`&?2%BNPV[-HNI'=0_^BP>D>P7H^6=P;I\'H=
M8.]/#EE4]:Q$06QZO50`)(O=1KFW,M^6(/+*M-M&.!R9?5MQK;;_-9M3TB.`
M#^O'LJ@?U]5NA8/(!TD>)Y3D$4GX8TI9!X,BE/L8&5)3)=N+*NK-BS'-47M_
M]K@-RJI:2+2EU7HT3,JK4B#FUMASC*KIK%9LW-=:/??$]=8`C<*:6U3MOJF^
M'OJM%_X$]OOR\6O9K'RFY!$)8C9+QC`J,$JPWVM\!/PHB&7$5=F(914]Q>7U
MP+P_>VBR0JG.HY@BSD*AG/2IL6=%W2ZQ<T7&M`EU1*_T_:@-?VDR.[#O"[9J
M9P.WWN6\AW.3E_PZU60P!1!D`(,P\3,*0QBB8<$.,S\2FM_I6[&L0>^]PAO1
M>3T\K\<G*T4&"!786IV-2SDQ<HI&B=W3V>A4VS/5HE5LJ_0:`Y<V2(VPYL*V
MJ!E':M,?E(R$?VS*G_7P^S$)BCP&N*`Y"6$&0AKZX^]/0"!T=UWZEUH6Z`Z*
MDHA(,2,@O;9(D5/:F?B0T%!;O*A)IB@_8NIXXMLE,51QWP7M4\)=:\;=Z/&`
M=]6NO-V7C^T*YY2`/(8PQ1$$D4]``D?S#%=H[HB`N$TGC@EPN%Z'UVP=6X)Z
M`65=B'4YX?UM"#=Y>,`.\38/$`@%P-`I@HD=Y9,$\ORZD#ILN"5UHD"5-K'$
M@W>[PWK[?LT[(O'6`B4MRQ6"480*"C,4Q7E_``Z,AJA?B)]"4_KMEI-)C\E[
M/(+R'DJIFUQJG`GD!NMTR66!@:D3/!Z=@RD)4;?.F)I\RS(GIM'GG+VDQEK$
MN*"[>@[4IKX1J18IA_VA*=]7V[+=U[ORKG^5:U500")<X)@681"E<41B,LEV
MDF+Q=B=JO]_VKO*(9WR;K^NP=_>=/Q,2:C<O..ORI8]>DR`7/GM=%VISWXML
M/]SA$;HO-;[_QZ%JRNS0LJE+VY;MAW+_\:%K9M[_S685PCB*,9O(\*?I,HHB
MG!4C!IC(E7R-&K8\6(Z=*?D@67-4;35>]>G[-VV]IBN%S=WD58+%*[5.*\%P
MI/YIQ[?736'M$2B6Q49[^/AQ<IO_56XWV?-HF>SVO&](%$",">)]M,,@C6',
M%B:C_9`DXIV\3!JU/(0_E7SIP%O_=7T!OS.(,H/7,N$"JXREN)9;?(PHO1.8
M?>M_#M3+GKT1JM=C78QRB>7*4M2KK6(,AD!LMB=!SZ4IH`V&79@76O&KMOQI
MRJ0=TNZK1]XVZ7_*=?/QX8[]N-N3GT]5OQ^V2F-,2`##(L<^"&.V1LNFJHO/
M@`BG&EU#EM/+!,][9OAX9MGV.X0;-F_<=_N^Y0161O.T"19(+7-R*Y=.CK1R
M:+RU4P_.(\N0*9$TYB15+5%HD2N6&MX@X5(Z,,6="RG`F"^UA8]+Z?[-]MR1
M]#'7@!5&A.9QAI,D1$$*(@)!?PZ]R$GA%ZG\I1M-@Y:E?[C@L;UP?V[$J72O
M1I?JZ^*_&,MR24";8(OW9:Z3=F7'Q2CGCNRTF/7I['48HX0)U@?>-IS7.][I
MG6DP^ZFM&,V]#&<I\DF.,ASF*`HIRA-*>C@D2$D.Q&L(]C"XH8XWWA&_]\(!
MJ9[9%D,E,(]V)$I6U-7]`,DT,7<C4(I-R^T%3+"ZI\S>Q0J@_7BXL!28P\UZ
MWL]\GD0Z5%?NNK?@5ED29U%.*(0^3!D>$`6HQT9CO\!""XQ9`;F>8F^\P1_O
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MZ3I)'Z<?PSOV$_O#\8_8/[ZNVY+]R;\!4$L#!!0````(`$>'!D?(IF4A!V@`
M`+L)!0`5`!P`9V%L92TR,#$U,#8S,%]P<F4N>&UL550)``-FRL-59LK#575X
M"P`!!"4.```$.0$``.1=6W/;N))^WZK]#]Z<9T^(&T%,3?84KN>XRAF[XLR>
M4_O"HB78YD8B/225Q//K%Z1$V8YUH2B2DIVJ5$66T&!WXT.CN]$`?_O[]^GD
MY*O-\CA-/KP#OWCO3FPR2L=Q<OOAW1]7I_Q*GIV]^_M__^=__/9?IZ?_%I_.
M3U0ZFDUM4IS(S$:%'9]\BXN[DW^-;?[EY"9+IR?_2K,O\=?H]'1!=3+_-(F3
M+]=1;D^^Y_&O^>C.3J/S=!05U9/OBN+^U_?OOWW[]LOWZVSR2YK=OH>>A]XO
MJ=:V*/\ZK9N=EE^=`GB*P"_?\_&[$R=?DC?H?]'RU^_E%\_:?T-5:\`8>U_]
MNFR:QZL:NF[!^W]_/+^J1#R-D[R(DI%]YW1P<O);ED[L)WMS4O[_QZ>S9QW<
M1A.;1-=Q>G\79=/HEU$Z?5^V>\]'HVQFQ_K[O4URF_-D?%'<V4S.LLP-Q'GL
M:"9Q$=O<L59R^.M=9F\^O"O[<PH!Q/.15ZKC;SMW5#S<VP_O\GAZ/W$J>C^$
M#,H643SI3I0?^CN`1)^CZTF'8_.\N^[D$;,\3FQ>/EE$>9Q?W%QF-G?/KN;H
M-O:;40_%+1^/X_+_:'*6W*2.L/QCCH3]!&G0\5`R7J:3>-1@TN_62_?<RW1Z
M'2?5PQKSNHJF7\X:FIT&I/WRV<R8;*?LCDN9)N/29(W=A]RA:5QZ!2*:E*O>
MU9VUQ59NF_<P)->746EX[VP1CZ*M5J-E=SW+<^7FN"V=M8N;JR(=?;E+)V/G
M[.D_9W'QL#M%*R7TQ,-0FG/F4D;YG9FDW]KA>&-/0TJ13N\S>^?:Q%_M>9IW
M(,VZ'KN3J@XVW-JED\(-_Y-5=QO_36B[X]1$<?8_T61F/]HHGV5S'6UC<2-1
MS[RY42U<F.<^7LZRT9V+@2ZS>&3+P8[==*O4M&@_YH7.BWA:`F#9UT7RR8Z<
M<^KZJ-R*9M[5`5CI68_NT6DR<KYYQ>;%S;G]:B?H10#22C$[]MVSI,U<CP:D
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M\;"/<%N[ZUN>AI:P`6W'G.Z4B1XB;_SR&?O:K%T[ZU.61<!0?L\SUV%NLZ\N
M9$@S,RMFF2VG6KFWT5:Z5MWW*>\.N-]`UR&'L^O<_CES?H+^VB1%LJY]=QS]
M*\HJ*[N-DQ_;=<^!O(N26YN?)8\9X)O%;W5NM*$1;M]C]U*]?+1;T);)[C_R
M,KL]B49?KD8.@#:?+Q)EHMS]\#$=V\EN(G?\N.[U4190C6>31_YV6U]W[*9[
M_IM9E-6MN^=FB?1)E.<N*+%COK!@#=W.G3O:68:GE7ELSGUB;TLTGD?7]H<!
M7T4WR;)G9&4U("NK`8%?B;"JMPZY+/-6G3+Z8X<=\GIILS@=ZZ1CU:[NMG.^
MKXHHZUC7ZSKND/?/SFFPW7+]LLLN^4V+:-(QOR^Z[(;?%F`H7K+88.3OGY3.
MG;M6B[9EGSW5\L[9L-\+FXSM>%Y&[!AQT?XJ:2M);Z+\NA)WEI_>1M&]4Q7`
M[^VDR.MO2M..3SVPJ)/^V^+K\#)ZJ-8AQU;%:#3)^75>9-%HN3TT*77TX9U[
M?MB`*O0AT)Z&)#!&`^+[!$JD,*(\"#Q/`?%<S"J'D6:UNGN3T[&9SI*R**OB
M?#$H3[1?C\O3O?8X'TW2<DM[,5B?W:`(Q]^7#:KI]D&AQD)`P"@WTO<THXA*
MK]8F$T)MT^93^/)L=))F+I+Y\`Z\.W&_W%CWM+GEWE`Q7Z&X>&%WHFST8A(\
M)URT>']?%<*=CN[BR;BF+@\.]("I](@&PXF_M"+O?S0C0QN7E:[:J[4Q!AID
M($$!5$P$'A"4.&1@A"'#@F"TJXUYZ?R6WX1E:43YO#);X4;S;L'2"J8W-7?H
M#2@%%"OI><)HC?T`U]PJK>#/,8<;CUG:N4J?S,0=!K_:I?EHIVG.1R[<R:OD
M7)DW2.SD+"ES+FGVL)AI:R&Q2R>A$4(;*963ADFB$/,X7TA%E(*\)5#@SP"4
M'A6]&3[=V$CMG,[TP3HG>%)%K(^6>SW"&M.&$OF(:4@A8K[@`OI<^K6\`'BT
M);#0VP967_H=`D\+Q^`R2V]LGE>["L8V`=-FPA!X;J(@1:@6AG'-J2[M[UQ2
MIX"@)9+PSX&D3I7;:E6[=)HO2^3=T^?'5!TOMUDTW;*.;2$+-5%$>)KZ`>0`
M8P8-]VK.`R%,2UB0MPV+'E0[H&WYE#Y$DV8KU!J*$`6>XI0KK`/&"<<0P*"6
M#6J$6\+&?]NPZ5:KK<S(XM%+QZH^QK$!"XWH0NH63H6,BZ>-=-;0YT0KHXEO
M*)=N&K3U5.C;1D0?NFV%B_EF_L?8R56DB74R3C>@877K4&LNW((7T,#AEFGF
M";KTIH@R;7V,8%<,?+79=?K:4-")3H=81<X2-\<<DPL-;%]$5A.$$FB).$6(
M<DJT7WI/I);,\Z!LB1;VMBU&ITH=T.G8*3!>2Q,*XCQK%`BH!%?44TXN7<M'
MG>AM4W+>SJAYL3_V&E#3E6*/*D6^JB#CU6;(>2`E-!!)(Q"2A&(WB>=;%4!*
MC+W#[,(]EN:\1%"E_B8[;,T[";&G@9#8\WT70!GD<P!(K04C3-NUX95EWAMC
M(1U(T4-,^UVN)QIHEB]V(^/DMKZ#I\$D7T\4>KXA'#@5.W\.($,"9-A<Z<[7
M\\'.NV#=2'F1W49)_%>EYL>+),H)E(R?#L'%C8F3*!G%T>3QCHG'S5?7^LEI
MFI=::&(IAF8E1,:G"+NHRE>(,:2Y]FD](MC7Y.W8FRY@F;ZJT3J\T6I\0."5
MVC.M7'"*9<`!-`90BB5=K%.8"N#ICG;U'Y>UJ]ET&F4/[L-&P&S:\V_56>C"
M<$8"@MTRR8USNI%DN)8T8!`<PD[<9W&:Q<5#M5\\N-%H//;IP,H?(K;]5)Y%
MX-_C?,.\6;8)-0D8,]@%5P0"HQ3$R*OYYWA[@=TK`\\0(YUVH^O!L/+13J]M
MM@TM\U8AE53J`&,@B8O%O8!`I6L9@`D.4D(X@+%I,8BK8-!*B4,`X6.<Q-/9
M="L4GK4+G8'EQ+'N-"&HY(%V7MKCE$!OS7CL-91I=XH<!!#1]V:`>-HN)$$`
M$);8".!S[`'.'^4@*&@;LNQ5<_9:`+&'(H<`Q&66WMNL>+B<1/-+$?^<Q?=E
MM"0>/CLFMC@<#:A#@`GE/A0"4(Y*R:F2M<P4>6WW[X\5/`=P1;H?A8,BK^19
MI=,H3MH@[Y$Z%-+CR.>*05\+;'R.!*]E]C`X2$WU`&:K4S@TA5IKM;<J(5@^
MULRR)"[F&1T3?R\_Y6L7MZ:D(:!.,0QP]T\;%V\:85`M@9;DK3I`G0YNVJO.
M6Z%F5ZM\'B?VK+#352O@?AV&G/G<R2@AX)1(C$1`EXZ`D;IM+>1>Q=9O8U$<
M=&`&*6J83-)O9<VG23.5SJZ+F]FD/K/VR8YL_'5-[G&W#D*(?0H1@))JH:$"
M1J@Z`@X\V-I/.Z)]B:&@\6,A1!_Z;V4`ZV`D<H;73?3YZ?;/:7VEMF/TG_'M
MW>3A/'8&>US>MGJ6Y$4VFU]7FY<7U9<WU;G_2HO^M=RA*-8:QUX>%C(*.6%`
M^U@ICWG2!5&DUA+RP=::A9\AFF@/V:,9N&&*"Q=%L+_;S26%C\U"K93`/O0]
MIH@`2"C"V'*2$M;6,SRB0U(',I)[:'E0K)3OL3M+JHO2\TV9D=4$89GZ\22E
MDBGM:P`#I$`M&0:\[:;>$1V-.C1^]M'WH$@R<1+G3DW_2--Q(R0](PB9AIA"
M8P*G(B6UFR5\Z2[X"+1UUX[H--6AD;2/O@^:0/LCM\[%/(]O-D4%#:A#S;&4
MA$M-`DZ(0)K2.O8*!-=^2XSM=?3J[3A;_8W$$.B[<LJJ*JJJ..;*9E_CD=UD
MQU83A$0)`)F;5X82%A@_,%C4D@6BM4-_1(>Y#@2K3O0]2()CFF;%HJ;OXN;,
MC65R&Y<W\>2Y71E>-B,,*8:**LBP#V1``Q<,P\>U7].VOM;.1\3>'+(ZU?OA
M2R97O^STE=9'*BJ0A&XH@4\]IIGQM5\IGPJEE#G0F0ZWDEW<U-?(;IK2SQN&
M`&D#)-&<!CXE@0E4X-72&&C:7G9S[!LQ78QOVJ%BAU@%GE5S5V(_-"G?WT06
M:@U+"^1T!EWPYPGL"UE+&5#2=@4XUF1AC_#I4,W#A$9.R?/$Y2<[6MQ)/%H4
MR/_?+*]>;*=L/LKB^Z='?5;&2;MU%6IJ/!%(3HP'`X]PY1;`6AOETOC&MO9Z
M!%W/JA_$JJU,AN]@WIK0A\SSN/2<]XX9A$PBCU*RM.:8MLT%[955?)V0ZT/?
MA\/9)^O4$8\*.]XDU\[P:]9MR#TE!.#8(#?YM(LG>#`_KD'=R'#>]IJ6O3*4
M;PF5O0S#$&!]\I*)Y2F])UN(6U'9B#Y$W'/!K<*2`Q8HX'0MQ4)N1'S:=AT^
MUN1EC_#K0]]#X.QS%HUM?9?#RXJ+K3AK1!\"(7PNE184::8A#ZBDM=P^1&_H
M-JH>H-6'B@?=Q6ONRJTC"9VO2H'@DF,*G+H8-L%2.DCPUB.MQY^G[!%`'6GU
MH/MUS3'4M(N0!MA0J9`G@<\I`.7=&[7TVK2^(F^O"Z]>Y^+7D\J'`%RY<?TM
MGDP<US\FZ9M#KGDGH<<QD`&1&'+*D?$98UZM`<!;9SY:7)CUZE'7F]8'.7YL
MG4V>6;>,I[=)O%L^=RMM6=*C?.GL.7,!N*8&`VUJ>14U;9=+<$2%RCT"JVO]
M#H&G>OM.IM-K%W]4+_G=ZKRO)PHQ9@H;3K'1BA%"/.&AY8SQ,&N+H)]P7Z`S
M+;>J9R_?_.&D<:+7Q<E/]B>VVYR=^PBAQP0D/O%P>?6E%DP*O5SCF6I]5]Q/
ME-SO6^FM@'09%57Q>C*>?^+W]Y/%3H-,\WK-;8BH5IV%G!KJ*QHP(P,OT,9P
MX2_-;OLT`OB)DOB#:7^0^KH[I[X7+U-?O`2^]`I'3KCXJRWCDNVK88O>0FVD
M@08`23SDPP"Z(&;I"$B-6A^?_@D3^/VK?QB_?OZ"+<>Q<F[D)*WBX,6EN5LA
MV(`ZY#XV)M"::BXD5)1QL/09#"&M/;.?,&G?O;J'R:N.TJG]''W?):^ZFB1D
M'`LI%=0006?8&??]90:0,]VVLACLE9E_G6#J2,<#U9&5QG3N4'Z*\R_SM[Z5
MGS:7D:VC"ID`0@$M.#)&0L*`I$$M(R:\=5IKKP3]Z\11=VH>!DI3-T!WSF"Z
MI7D^!9H&`KMV$1K$8"`XXUQ`HSUHD%*/00YN7>GZ$V;L>]+YH)41'VU4WE/\
MN,_0''*-^PBE,]!*2N91C!'G!A$(EQD:(]L:-O@3YNO[4OH0H--1ECA=Y)<V
MJ^*4YE#;0AEB7W/H*^&YJ!HXAQ*[J;:0%7/)VD:0\">LW^]6U4,>NGF:&G[.
MQ4!';%8QTN"0S2:RT!"?*8B4(%SZ`GEN&B_.8R+E>6#KZ\<&D_3QSOLF$[I9
M!Z$2BG&I`\404WX`/+!PU9ST7)'6D=7Q[<!U`X+MFR;[:_E04WK^;H&W,[,U
M]S74P/.P8#Z5FB.R.!2)G+O(M][,UE,V>'G(<WF6\?$-YKEX>/+7NE<1M.TJ
MU!YU(/>-0-Q`P0ST-*TU@@T_R"&\`\SVQL!8^X:D7O0]Y`;\$U:W7`R\AB)4
MAOO`:1`'2@:*^"+`P5(VG[RAE]_T-^QK5I/]5'TH&)4?,[O]OM^MM*$BBG,.
M47EAI*0L4,A'M;R0'N9]*?V:J=8CW@!!^^BVU1;\_\[NG=?QU^;+>Y\U"KDR
M&%-)L,<\WP=4N*"ZYLK]<9"75@PWXBU'*.U(G8/L@=>O[I+EX<^+FZO"^<5;
M5IZU-"$DG/F>+[&10G+W1`E9+1]J\"J\/DZ#O_*UIRME#Y+-?\+BUN7F9>.0
M(E]@)@TD0GDD@$@;7DND#6A[9?,16IL.1O7'E/R^ZAQHNV>:)A6/6]^/\J)M
M2"GT/4,#S:%RMA,SGR\-L):'>6E./_#89S!?;M7LI<8#>:WG&RZ&;T(6^C`@
MU!/*]Q@G"F@*Q5)?@."V8=`172-[#&%06WT?J*9]49/_EQV?C<MRL)LX6A[Z
M6'A[8YX\?<&R^VTV71[_WGPG]S`/#K$A6"(*#01$`"$(8*+6M(+>&WJ;=C>`
MVYX:/MSH',BZE@P7#V>)&T*;%V=.&#N^R,K_2\&K758G87R;V/%N]G>'CD/M
M2Q\Q+\#"E+?8&4+AXEVCS@IYLBV.CS!8Z!7'@VC_0/;ZV=&%SUF4Y(MQ?9R)
M9\EH5GZUFSW>H6/GD2OB=`2DAU@@C:)>X->:"H`\R(MD7B%.!]'^D>&TNG,!
M=`/->5^A)RC4"@`A!0^X#LJ7BM7ZP*3UR;HCNM[^6-#82N%'!L".L`?"@!#E
M4]]7!"BC.*'5V</%-#3F#=R%?RRPVU77K;8"6CK!T2HG^%-\>[?^'47=/RG$
M5!&?E:]RJO9AD`?@<D8"K_4E"'N=8'D%6#R.X1CR5HX-QJ]NXK1H#'56G0A(
MJ0)&05+OZ&&GUS=P.7ZOAJVE'@>M]+ZX>0[F)I7=/]*$`$E/2&=]?>Q#Y#/$
M-5JBG+0^EWZ$5TCU@I.N%'NH&KPJ<_IV2O!\3#@2`?,Y9Q@#$(@Z^J>2R>T'
MC_LNP7NY)MEQ@WQ<-4I-JG`[?E*HG+/FE?LG0A`H%`,N1JCUB1AZ@W42^\%J
M;0'?(89C")OBO/UQ>2QX_'C-NQV+:%*^M/3JSCYY"\N@MF6Y#_WDWM'+=%'^
MLMW&-"$/H0+*]RG7Q$`II&8(^=IS(8E/`L'PUFLW^I%\`:H&;P)YUC`,A.$8
M(T)\3)F/!&-:U](0P0Y27CG`>9MN1_K'M]WLH^(A7,DY@[+,2"9%8\S\T#Z4
MP)/"&4;J2>*>$RCFD85<+/#00<I;ACBJU7)T5X)D/YT.4N.R\J9P7LC_9^_*
M>MRXL?5?XKX\<@T,Y,8-QW,#W!="5E?;&JBEAJ3VQ/GU]Y2DDGM32475UO(\
MS*21%*DZW_F*/!L/)ZO5C]GBZ]8*KJM[.6=\TLPRB["4T438;:T%V[F2FV!Z
MM=?V7$:"LYJ^7P9U3UUB:MO2GT^VAC,E,*="P%2`E\^55@)YK"HL(B6#%'B^
M.]IU"WHO^^&K-N)_%)L]/'7;8LVP9'7$%FO"HM3!!><T6!![*67PN2>91YAF
M;9=-+8+:3_NAYE?">XM*(1##W#!O#0V\,AE,<"2W'^T(<Y[M4N,"$/N@PLVJ
M>)C,;O<-LPY7%#R%H(8A9XQ.B!F%K+)!R("4B-'PBOY@@V;W:!]]>[U66=0^
MT+V[;.>Z:LE+'FFDF#).#=AVG,?#1^+AJ^DMM;C<3.;OE3"70-K/NG/DOH'Z
M+:EN6"+"4R4=DLYBJ0PUB!RDC#KFWN/^/@SCBWW[%J'-*H?XL(`WF!;K==72
M\4D_QV.%#75CMFT?A9*1>&,=N(]4^LIG-,CXW*SRZ)M87T:'MG'-XL+V4O>R
MI>>L]-*^/&XS'/4U+C5#DC,1[&P5I<3,<N\DY:AZ8RGL(+;K.V%">["V383]
MJ=X,/NQ')J.XQ+S,I0,L01/!6`6(Y=;DEA.,L)ZN8R;D`9I%B-_,[X$AO*I=
M"YX]E)SV,C(EI5.!Z\@),H>WHA'G5NN.L%2M#35?@MW8ZLHTU=9$:F1YYE]S
M1@4UU=LCDNU)C+XS<CL&82:,?9#`%P]EWG.]D_2/Y>Z@0JV/>6Q(0J@L2."6
M."*CYH9@Y@_2H>R^QZ-O>]P.25J"M;]HQ,DP1")266,(HRI2BV%/([RR;VV,
MV?U6FK<H'B+^T%**N"&(?:C_:<'2XG9[&/_;<@ZJ6>^.[)U14G#N%,EA1T5@
MFCFEC`UE-6X5BK,._.4KC41T6J#2$?@]4^_\^I7C@Q)!,3""+>+<>@6B1HE^
M6F7#]`#K@5[M,^`XQ2Z#O,_\[\WD1YEP/#_S^WQ`P@9I(BELSPHIS@.RGNPE
M`QSY+T"F;%T?R0)?!'!/U%D]/COJ>Q9[WAZ3,)AX`H0)2')*,>71Q4H^!B;`
ME6YVW1"H%8RS(BM/3H?\-5FM)B61E^75<K")SW_\66PV\Z*D]8=%62IS+/32
M;)84B"+12Z*L)$9CZ32K7$M'D,@-P8T]1M\B=[I'O1<+:;GX^KE8W?OBRQDU
M3&\\G<!)L8(9YKB@WI%`K*U664]<=C'F".M3.EAX+@=T&#.ZD?F<O#?(:",M
M<8X'&80V50V?#T+DYH>;Q_O[=>R[X,NEX/83)-SIY//D[UU0XLE;_U%LSHP:
MGCE'T@@%'3"C@7'-A8Y65%!ZIFSN^G.^%:1WY%H47\MC35?DE76E@RPKZ>>5
MSC>/J^FWR;JX6<VFQ;-&$O!2'^_VW\7-<E7^JV/F4N9TR4FL@Y+<:_A.M>-*
MT<H>]"C:0?HAO6>N]:B,OLVIL]:YMP<D;CF!%1USV"$D%C%(6E6?>8M%;FQ@
MW$951[&E-A#NV<HZS[Q*@D9,E:46^V`EL\A:O)<A2(%SM[YW9%=U'HYLB'$O
M9^R6]_>SS7VQNX7^L'9.ZWE3,RI9K%QTBE%L!**>PIIZD)$RG+O:C/U6[,YY
MU![F??`J*S-7@QH*UEA2=EH6IBQDB<A4P8Y0QCNNM`BD<U:U!GE/QUQVJMJ^
M]:D3F6\\G0@'JXXZQ)QQ@FL<N?0'F9C)/<8R]C1)&UI^?9;E0G3[VM[V/?M/
MGA9_\6@*E,.'Q'`0.)+@.<(_-VMC=6[E^=@S(AUPY4)H>TFFW=YN"QPF\YO)
M[+:,L#_,P`Y]\N9U6;63@Y-D-);W;%H2X?\])DS*2N+H=6[YZMA=_0[(U#K8
M61$D7]S-IK.-F4X?[Q_G9:S./Z[`('MRQ&(R_W,S^?K6DM-PAH05CE3+P,#)
M+)/01A-;R>."ZKY3\5!1R1;ITRWF?2Q1GU?;Z]I_G+6;O7XX,1(LUQ8^!JV5
MAK^MK8(48""ZW/WL?`?_"EC4&KS#^&"-?*_$$`H>$>K!J<#.J!A]9<Z!E9=]
M]&[L1W@[H,O%X(ZAM/:"DMKD!2RE3K-H&:-(.>)PM2-'0[(O'&M>GG^]P<4V
M@']"LP'[-]YLL?U6;&;3R?SY"UY1,T>C7"121U`TC1@9%]V^LR:L,A&?K&/H
M(\0"FOBXVDISN]WD;HK5GZ#.\Z,NQR8HRRDMT89KC8@73/&@4"6]MNY:ZU7;
M949M2*8EZ/N/ZVW?<FT>-]]`&__4-AFO'Y@0)67+=$DY-B26%TSS4$DJI+K6
M'FL]DNQ"R(<BU^Y"KX;$V@U*%JE("-("8;#Z`LB'7"4A]=F%TN./Y/1,JBRX
MAR+4Q\?->C-9W,X67QNRZLG(!-^'=49R0VEY/M>5UQ[N98U4ND&J7Z^16OF8
M]YRSR+"_SAB=D*&((.>B(,@C;4CPM))9@9O06ZG'%?&L?=Q[YEH#LZMF5+(.
M@6-)HE<*"4]XP+):KV-TH;^^;]?)K0OQ'H13)ZVM(R,25Z`(XL"*-%[18#2U
MLI*-4#7(C5)7QZ4LK`?AT7E&5MVP!(A11BF(RJEC1F`C<24E+,BYF;3&<<CO
MQ>K+\GHYE0]Y[XFTW0N?FTG;/9T$&(O>&\4PTE)8I9TT/V7*7IB:-Q>YHH7I
M<IP'BUX_P>5U"+[YB*%#WIFUFV>,3]1:KPV692,9$H+Q'N/(G/2>8*O1R8A<
MQ[)O+[\Z1\CM@PD[)R36S$BI/+`]$*'WTH!I+W///8_PKK*6M?LJ/7H!K/UD
MTO<O6'W2]P_+Q;82^^]9W=Y1.ZX,;4G"`";IN'6:AFA4)2<UV<WXQTR?A@H^
MQI,6X.R#-B]>TR_O)[.W#A'6/I\\85A[9ICQ09D@7?"FDHL8=D4W(K:DWV7[
MJ/;L[_Q/<?^E6)WGY.R>34AB8H-DDB(B@F5(*K*7ASH=KF@ONE"?QWV7+"0'
M+$X^R9+:<8EY[Q1W(5`4P$3W`I5=8G=R&DP&:;3_'AC3)JI]L.=3L0%QB]LP
M62W`(5^?I,W;`Y)AHFP9*RBQ0@D`R5A1288('B3Q^1[XT@J<O<=%3K+DC:=A
MZ92"PLH9HR/!21>]K2"B`)$:(H'Y'BAR.9:]>D&_5Y?8G^/Z'!X&]U!C8#K6
M&!BON##8ADHBZ\,@_53?A[^3BV$?K/BPF);L+7RQ^^>'Q>L(P:?E?!Z7J_],
M5G5IH(8S):DE+J]S-!)+;<!($PI56&@E<U>;$9J\EQ#AU4UV78+<RS+4(!GT
M.AUA,&*PSW*'.$.6<F-9]2U2A5!OU_T^%*O9LHP#KS:=4J<S?;]<JRY$>I@#
M,8#._+%\VWT7(+/9W8I2+MN?EV6'E^5B`VC#JWS]L(`/O5@W:V"0\P-)6B.$
M%I1QC`!]S@(^(&>(Z+X+V;5R=`CU]$;L72)_=Z#Q9J>YW3=97C)YBK2U@Q,M
M+[YUQE%-/4*"1V99)3'7(;=M0F/7[WG:_`K(V";L`Q)MU[4VCV<_QX*='&V0
MDF/OG/-4<L\/'Y9W/M=!&*'[.##)LC$??#%SRP4L`FM0\,>[W=^;&:S5?Q93
M>/1$M[/+)@:'W"/K*5+>.,:T,(*Z/5)@V(C<^-<(+YH;Q1+8MD*&7AX[8.YY
M\Z:`;##88(TPCX$$4%>E'H8CRDT@CO#JO#$LJVWK8_`E-]P_S)<_BF)7VU[U
M5)U/%MEK[?$9R^:_C$EMF70"_H@ZZ%AAPZ@>I,_;57*U94T,O;H>%21S53TZ
M7Z*<\8@D<4H+XG#`(E9%3DPAD^N<7W33X%4RM%4]]).F__?C>M>A\_/R2);X
M\^3O<'=73#<1X-Y^@W:RK0V]?R@6Z\F1+N,M_T)2D6$1HA0L(@>:<9Q61C^S
MQN0>TKFH?OE]<W@8S0QN&VS_X\>'[2W2X>]B-9VM:T_Z-)\L"4F#8!H)RH6U
M4K$H[1Z1\J9JGLE5C'Y=LG:NA:&M@99H>7RNQ#G@0:,PT1EDI$'@;U9X8"ZR
M&\F.,/DX!C.@#27T0<H_B@W`M;PO?E^NZ]RC9\\E0G0@-AID+<AAA'="'3XN
MAW(C2WB$E1%]D>D2@,>?Q%;4"8LLPSC8*`W8!9A7\E`IL[LG-4[([#*$87%[
M%:2Y%.C_YK!_)DFYCYQ&[3F3#'E&B#+A\,EYGUV<TSB9<V44'4([PQ^L7'^\
M*^^\C//E?];/WZW_XY&'%VEV*O+5L!0,\M8[8\%:\8):R]CN#O52.UR<3'>.
MZS`D<$D#B1UXKQ98)0T/H9)&89-MQ(S/AFE'J?5G()NAV<?&8Q_7LT6Q7ILI
M+#O[,]_UIQ^/C$CE;NJ)5-8Y%,I#-IKO;EKC`2FLK[%NLZ%2EUT`.11)RC]7
M17'R]./)L2D2)ITAEK*(P>U3DB!UD#?(WFHWNR?.Q1H_@T&78%O/I2-W)OS?
MXP-L_O\</5GR^J%DM'!,2^>QX\Q+$H0_O!5!+#OX]SXTGJFA94MPOH<S)1R\
M=VT1,TQS*AFUV)!*(NQY+D%&&#EI:2^Y&,.>PFBE976S6GZ?@6UO?_P+'(,/
MBX\/V_M;%U_-=#/[ONMZ?MH&;SY9"J2L($+@HF&CM0E4[\$5E-*8?0WTN^E.
MG<&-U_&W;D$?;S176N]MC`$+:SD6X%@37\DAJ1IDS^J!/%UJO#:XVPSOW@L!
M/A73Y6(ZFQ?/WOKSLKT%KHN?2X81Y&)Y02TG*EJD*,,5JC@,L[%>%XM'H+8^
M/@9?@,*GLRT1X.]YL67$XM;<E_'*?TZ5O)PS/!'&9)!2,22TQUY8&@Y+@`8?
MZ4J7W&$9M.Q<4;TEXIK48!TIW.&4(L,=412#800.E@(/?2^9P]D]M<>^7HZ*
M@JVH)BNTX;Y-%E^+#XLXF:UVAVONGC06^FNR6DT`H5UQPX>%6RX6Q;1\M[]F
MFV__.P$U/>ZS.?N^FHNO;]F;7?U4DM0&XKQ#RB"*E=3!T0HARVQN/OG\=/+S
MJP$__X(<'HENVV/__G[Z356T6^;U`+S5L?4U<Z:DN56"(.ET!'D\C9+N[^2C
M3$N:VT4Q]W+4_W*W*]4-T\SD@-.^B/<,?^S\29*4&D7KI(K$*AXIL8>/DV'B
M<X]FC?TRH1Z]K,Z4,0P=S72Z?(2/'3[U8O;]1(;^G.%)6;""B,"8\_(L!39@
MDU=2"Z.ZS]L?7S_[*M6YG!$G27<Q\,/0[</B.R`*RT'M\=3:<8G$LL12(:J4
MX#H2XD*UFS`:<:YQ>;YG]$L0+!_Q89AULRH>)K-;O]=@^+OTUPJSN-VV)3#K
M=;%I1KES)DS(8\&YQ)8*+*@@V#NV1X9'G9W8>2>.SB#$[$`OPVZ]-Y,?V?ON
M?FP*@3$$GR@(9RCB-)H@*WF](KG=FL=^T]^@6V\>]H-Q;04^_I/KO9O2[<7P
M9!&7"EPY`[A*I`*S@5=2*QMR;SX:^YU_0S'N,OC'56/12FU%PF".(!4-QU1Y
MCD/$NG+V>:`N]\QQ\R5O"4J_2E>W,V4,2,?2K%VW5?)3,UDB@1JL@@G!.$:E
M8%15H`NF8FXD9NSYF^Y+?MH#O0\:@I%0'>+?55]6=9G%&N3;%?SO_TOM_>$-
MIDG26A&EPTX0+E@$X4FL4`B2=)^]?NZ4#+XVML*8E]=`=Z>0@6GYVZJ^..W4
MT.0]-5[[&*,*1&+NM+:5M(32[E>^ON,SXZ!=#OB#4`UP`@MB\Z/LNK,!O[W,
M,#Z4CS0AW=%)DHI(^&C(-DLO%2E/\N\1D!HLGIY#,K_&ZM>6.L9E&;9B$2:%
M8G#$:F)Q!&_0>FI)A4"@N#]'910YN2[HV)DR!J3CH>*B#4>E9K*$85=`A&'O
M)#("',2HJC"%Y)I?:\JX>T>E/=![V:97RVE1W*[+7F)E01"\^O-JH;K=^=38
M9,`HH2&Z""*7?1^%\>SPV<'7/D1!;:_+7BMD>+D+MPQ[WS1KVE7KY-B$H[9,
M<2T0CH)XADRLPE"*<)/;[77L09>!.->&#K+J`T'>I^]1_?:;Q8W'*@.;S)&8
MB%P*'1`!WXK#VV!=&;%*49M[D<#8]\@>>-6U+@;;.E=_@F0?[W;ELTWWSF>#
M4Y1(XT!]9-%$A3%GO*HW5YZCW-Z`([S&8NC-\Q+<^V#:I^)A[WE_O/M]N?CZ
MN5C=^^)+G4=P;$A26A,'J[/A1'(O-/7*'M9I37+7M/,3N",)TW5!KI9`'Y?[
MV8K;F4!QX&(Y29&D(GH=45"'C\KJW/+0YI='C")MVP7Y.E-&'W3<YDT6M^4_
MRE7X>]G>;;/>=6Y]61A10\@FTR1ME79(.!.#L0P;QW&5GM&(VO[VUWXIV6($
MI$.XAR.=@<]HM?H!7\SV^$ECMKT8GQ"2@6I!HB;4"L"`:%?)[8S*#;0UKIAZ
M?0OC-9#M,K2OAV61PMI-D6%1EQV]C*:TLC"TQR:W+J_Q_OJR3>HU<JP9UKV<
M/G]\>)AO,9C,JUZ2'Q9WR]7]3J%G=!@];X9$K(Q8624#YC($@HVH3M[K$-@@
M%RN]+XYU@W3O`8]]"^#=0:2SX[<OAZ6H(C.!.&V)4@PSQVP5UM&<B=Q^!V-O
MN=$Z">K"')=AWD_E^NX5RWMN:BO4?SZ6A!4!2XRM\=1J<&/\(6NL#8ZYN:6Q
M!_V[9LX%&/=E394BEPW)X<^?N?[%[1N>KI^MI_/E^G%5G+$%7CIUDA(1)X7U
M1&#PW:4#)Z=""SN;6_%QT95N[VMO[%D%65FH)XT)ZCMI/,EBE!T50)FW9NV6
MZTU->J#E7TC@!G$NF6(2"V4P4H141SB--3PWVCO"!'Q_U%F.0559U(5?GD_6
MZ]G=;+K5Z.&EJR-&/_[UL%Q4>;AC]&PV2]+<.4J<4)QJYFV0^M`%Q&BE<ANK
MM%$7W,/B.`PM.U71$^H->(W'\AY^Y!L\`R;MT[ZJO5[GL>N.<WBO\YJZO#4B
M"6(",\)*XZC`3GD._V-4&H6(1*>3O1W%%4`_ZT_%]V+Q6#8#JHL?/'\R,86T
ME+CLEB8-T8X1%BIYO%#95TN-;^.Y6*,OXP,7(=F'#7XX";@_A'].A>K1,<FK
M2#W%,DH9B>=&V7C`";R7:STQUS9MV@*X%R=N:_?L.5[GD3U]+DFBI1"!,!Z$
MMY8*XV0E!Y+^BI:4%G3YTK&Z`,E^*ES6!?Q.&7SW\)+SY?84R5[\VC*7FG$)
ML/)(.Q04&#1(,$JMW<M)M63=FY[OF#%M(MM+"J387DWW6[$`).9EP^#;^]EB
M5J(`UG5QFDKG39`L05I%Y_Z?O2M;<N-&MG\T@WUYQ#JC&&UAZ\:->4)0W>46
M;[!9&BX>Z>\O0++8B[@442O9MA^LD`M%Y,E3F0D@,R$@\=922!#`E>2(JD'J
M)JZ%4YU`W`>YGC>?_O3'NZB^^</TZZPXVU_J],`033#W3&BL$++QP['4JTI2
MZESNZ<<(4SS;)U.KT/85]2Q3D>0.@3.!S_-'@XC?A%`$:B@$$9`2+4PE380N
M-_:YO.W.LURE:R%*0S![75'5NB?FP-,!.L:P!D1$W@/J`=1V[Y`M9H/D5UX+
M09KCV4O&;CDO7TZTZH%7HS[TW-B`E,)4.D,]1=I#:IS<?Q-2N]SF(6,O=6E[
M%=XVT%G;_(G`G^:['5_WXV[34?O8;O[!AX,V@CC)L7%>,<`%1TSNO:?);BPX
MWFZ^+2JN;!G=/A,P7HA^>L?WV)!`O54$15.L-:-><\<-K*3C,'OK=X2K[O9)
MTS*XO<0NJ?_J421.A3$G!P;FK(F1NDC!.Q`4&6CV'ECH[(;B8_=(W7&J5;Q[
M8]:G@[,];9I.#PR<*&Z$P590#9.#M^3I&W(@-U>Z4>''59*I+8A[*GC+N(23
M"0B\]-K%?[12DL>EXTX.@E#VX=38:X1:#XL;@-H'.=QD,4^W''TN%M7E7].[
MM/,]G:UC^%ECA57S#8$@DC;.N6<V2F^$UY!4LD/LNR^_O8UU5C=PCX!J^10+
M$FG)"<):66ZX(%QZ6LDJ-<QU:Q>?C_Y9++Z6'4?>K>O_,GY=B'4?O/K?8OKP
M+8D>X9\\%!_7CU^C@_YC,_M/Z]5R-9G?1XGJTRWOA<$;!F(T`1PBF@AF:?RZ
M*V04=[D[!Y=O1%Y=XD\O@/>1O&?+N_4&D?F]FZ^B8WE6GW!AFMZ1':[J%T[]
MT@FG??$[`HSAK)9(I:XSAA#-B4!;D!57@)]-[3_US2^+N[\]E'_^_;Z8;C_W
M^(?77WG\J["=W6_%P^;`=+[Z.'D\M+P^]F@@1@G'B'.<`DF`C]+P2@9BW""Y
MX!V&'ATJN6P5Z?K>H2Y3OBPFR5+\_O/Q:SD[0I$7SP1*XMJ?<!#G#1@A<57H
M;#5CSECNA49C3<+KAQM-(&Z?%%O93!1T,9F]BU;WQ[^*0R4H1Y\-5EOJG0;(
M0V"419YR64D`M>O^>M];)$D;4+=/%K->)&C\='DWF?V[F"Q<##ABH'.$+\<>
M#X[1^"\QPEB@D8^@6%#)8:3K_E;=6Z1,2VAW96+\=%8L3)S/0[DX;6!>/!F0
M=@!!3@G67`B6;E=_,I#:YV[XCW5KI$_ST@3H]FE2"?LEOO\(/YX_$BCEFBD$
M9?2@S!!G.:=/<IM!EI173XP&"'?'B,]5]Y@3ON;@LP%RI:A#*`(@G+24$^4K
M":23N<V\QMJ7I%^.-(&Z.[(\^3\?_^;0F<Z)IX,CW'J#I*!>*X>1Q(A44CB(
M<D]VQEJLWR]AFH'=-66V=*Y/FF?/!XT!`M%_>BPU5`+(N)K;22(PRVZ?*O^B
M30MPMT\<%:=UOYG:;/)PA"POG@G0,T&9DG':4#-JL1>PFC'2)C>*A>!-,Z0)
MQIUMI3RU=-CLT2^?;=*?WE<Y,3!X#(&*$;KP'%NK#>7"[F6C4N3RYZ]MVE:!
M[^,<9=]<Y$,Q23TA-JT/+CQ`:>=P<3^3IP85=8J^3PT+/J+-7=2C\]!SBU)&
M[!9OR@PZGPG1D:3;IAQI*R[.<T/&9UTYOD2\]>STK3@UWY!NO6+*0R8($HYR
M[+`RE?S4J1LJ9VZ'!F4?,`_V69MRGA+ITF)KO;C[-ED6GQ?3NR*U/YG>;[+L
MROGN^7NU<LO5]#$EQC_U'YK_5MRM%XO=`?'2%JO)='8SQ@)I@0E1CE/'L%;*
M175NM0@ELN;L[8X=2[JM.8Q>Z]E=[96VGFDF/O"QG"]>*.K+Y.OL5)9T:[\1
MHEOSU*CHV0P12E*I!:\PA-#GGO&--;!HEU>OK<]`6NDCDV@OF_[YS$+Y1?&?
M=3&_^ZE^3$_ES]88'0C`W#LOF4<4*NUXJM'=R4P0S;VK]6J8V!]ICM&V->7T
M2LA#<[;EXV0ZKT/(XZ-#"O<CAH@I9)BG2K)J00FE=RY[T7XMA&R##L>HUAKL
M0U%MN?\@/Q0I)>]"KKT>'K1'0EM`+<?<2`^QM&3O<Y3/W7F^&K*U08@:9&N(
M>\^>=O_'?TYCM!]7`#_?IZX[]9WMB1<$8[Q6F'/,J,%4HBC['E9D4.[AV%BS
MNT;I;]O3SV!V\%<1LISOT?<$*32$FFJD&9#6,DJJ5&8HF<[N<G(UEK$EEM0Q
MCBWIH%<NOIM_7Z^6&T!@?5?\ZZB0KG5T'&JK**4`"D"J!C`PB7_SX5Z[1#A&
MM\;`#T4NE$6NW:C@*3=(>D^,]4`C:P7=]6N%R@F=N[B]&F?;.[GR@!^*7#B+
M7+M1@7)-%<#($!J%PY9R0"L98U2;2ZZQIF`/3ZX\X'LE5X/H]GUU8T?'&]#[
MWPF`:J.%B`LPK8"($$K-*AR5P+=60S#"I<@`:NSC<]B*=6"SO\;1T]FQ`3JE
M$212,F0$--8Q#"IY$?:Y=0Q7$S'V2YK7G3Y;5D\?=#Q\D^0!&4[0LO8[@L<4
M(I&J/XCQG'F,JG(AJ+3*+IT8.SU;)$:MBT";0S^H)<RQ@($B:C5W$L0@2CLC
M.'3H*:I&_56&]ML!ISMJM05U'U1Z9NWS/&N]%P3M-7;I;,DH8`V&`+AJ7T!Q
MQ7*SJJ]FS3RH>^U$1Z?96?]JO<_E*@(YG<QF/W\O5JM9D8+@=_-DF`_0+N,M
M`3AAA4EG3O%S4\P`"_=R89=].-*P;4X/[&M;[V?NQ6M/![W$;_M\O!<I>&9W
MK5JZO6][;]^%(5V#UP;N(#$\(H,1H`YA!7AU`)#RWF]U9[$CG@Z@DCZ(F\/*
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M#5*K7=U?D$)P&=:]\JFY0[@HDZ#%GPO$.V@XUM$+60I<-`Q5,RN.O"*Y5RB.
M\+:9\;GOX?1X95^'F<SNUK/-'W\K9S-?+OX[69QJOMWY;P?!,?($*"D\]RJ:
M..1VYY8<2P(&J4(9_7>30=?NOIU6%/M6]]*)9@H+Y34`F@G`$12Z0LE[T]O^
MP_=-LZ/?5Y/%:H!SQ^%)V.9F_&4ZS3JA-)L+_-[-GYUOU>G<<.RH,O-U(4:@
MC#)-L4\WE'K$J:RL#Z94GFU'WSCH>7D]XUMF;H]Z?*NVVB#%`8<Q0L4,<1/7
M9'"O$DA@;SG#WZLVF&^9[P-H=+!CKLTRZ78Z;DD%C7!&,(H=4,1BLJNNYHHX
M+,_V4>Y&TM_OOA7WZUDTF9>F0SUEQ=?IR]7J[P3D.`(6.NV58H`92L@>2VA!
M]Q<DC^/\JC:ERO$HX\KV#FKUG.O@YX+BW&BB)2-4*VZM$[O]RH@JACAWAV#,
M.VMM4GP$.NG#<;Z/2X#9YT5Y5Q2IC>8R]=B<KC;N,R705U'"W3XII/K/(&[U
MU.PNR6N^Z#TA+CXECHM3ZQ$U!%"BC/`."JABL"/!V0"VH^3N<KE\,?-S22"'
M!P3#/.#6&44,XUI#C2#;24>]PX-T\^K&3G2D]=?YV&W`W(>3VU]]N`WT(SK?
MR_D&G-.)&2?'!:RA8189!X`C"#-O#-K)R321Z';HU%31KV.J%F'M+U-U/\VS
M21,'GP^2.:@U0\@)RX%TF,L*+>:,N:%SC);T>S`7M1FJ_6Q,[7MWG\UX^.79
MD"Z?@,@`2`5UD#."&*[D\8`-4K_;#4L:ZO.779YF2/92[WA_/TUZB6'H9'J?
M*DJ^3U>3V5F6G!P7M#8V97XXP#1RB%@C0"6GC8'_[:Q^VF5,FZCV4N+XV@G7
MR60Y/BA8+R%U0%/!`?4*2DKW$CJG;H@W+8<OK6&:=;#W\M=_?BX6=TD+#T7Y
MQV:%ZXMBF0A]["2O[OC@`=">6BHP(-9;1(#7419E+$K[[3>T<=B&0LON(>[#
MR'R>_-P>*)3J+EK;1:'7RPC&<EDL_[&(8ITP->>&!B2H8()'^\DX1L(YQ&B%
MI:$J-W_]&@Q./J$Z0K>?57<,QMXME^OBWJ[3#N+VOJS=A3:K;R=CGO.#@Y-$
M8^<MU%("QR5"?+^0(%#DKK\;=6BZ&CZUCF]>ELJL7*;?3@D'*1-A'\,?S4,Y
M-B!`#C&GPFI*H//0(H1U-5L.;6Z>5*,+G$?/AE8Q'="F;%-9\DS*T]A`!`,<
MQ-`?*,HLMTB)*B+DTKE<#C6ZV'GT'.H*WI&="7TL5P-E6`QS%*2]`E@YC2QB
M*::`B.XNSP6:6'+6NPZ(19V#Z,M>%`R'+II"#6)PA;GT0G%4H>%!]B;+"!=#
M';'DP'9=9_#W8CFBLYPO"_6P*`:\[O`?97G_W^EL%C%\%Z69/TR_SG;Y*1>9
MAHO>$X2E&%B#(%<46`N<Y3NEBW0?^]E*IFZP.#[Q.O:@QN@@M+6<.JZY1E%X
M&UFO*KG]0!<A]I#:V1$YRJX5,(@9>-I5?G8C[(!-1H:Q$$C'!:*17$&H))!0
M^6BG'0$$*FH`/ENM6W<O=(=^\B"S..ERF]K[I(UCB2(7C`Z>"^@E%4!!353T
M0%+B2A:F;[:C;D<*+[M60"])D]/Y=%6\G_Y9_(*-_OEA\G_E8I-=?J[M1_VW
M!)0*7K7U%FC'XJ248B)B@+2#4C.0VW=R1/%G)XSX]2K>CA`?F'5/<_\X>2S.
M=_6X[$U!(0(@-Y1[9TATOQ)IO<'"2QD7\_+ZV=<I0^JSL`7T^V!B=`"KQ?3K
M>E.B,WWX%B=^+H?AV)``(E;$(1J_8<6(5=&'@"V*!`*"Z)O@5C.]EYU`W0>1
M?DO5B&?<Y/Z98%4,_H4$3A'O&/=&8YCF3XE"2/H;Z*#1AQ/,Q;,W/IRU)<^>
M"LP0ZI"'3A,F%1;`8[^1@0J!U#!K\F[,1X;>#FD^"[<^=/\AFL?']>-9[;]X
M+@B*#"*"1\H+;B'$R&R<,.>6,<)NR'UD::]L#[M>.##Y48\#SY\+)OI(&1V8
MDTA`K(RR*:.8((F0`AKF]@8;D5]HE0,-L*O/@65Q][>'\L^_WQ?3K?KC'UYK
M/?Y5V)S`N?EJNOIY)`XX\%1PE$;N*DF!LM@X`0V0E>_C,+LIZU@OY^HR+&@.
M;_NDV$[EZ#+V]2,!$2R-)0!)9@`G$G.WWWUB*CL3:*Q;=(U45K:"85:VSP<;
MR1LA2BT>YG?%PD09B\518W]V3%S0",B@A@IB#K1GF.%*:*8!&61?HF.]Y^FL
M[`;1/D*"*L]QD_:XW)RMG%DP'AD1(E!6RF@:+5-6(D^QAI5L\?/)M1*-,L2N
MU&FT"_50--HFTI[?+CT[-OA-`0H17ELI.!).<5;):S4?)#VDAS.BQNJO0:<F
M0&=YJ4^+XD=YVBD]>R0HAZRA4%EO'&8:8H]!-2,.T2!E$@.I/E-592O(YA73
MG#./[T_46%WXAJ!,:L5)&1.*,$A`*DK<`V)HKI%HE%UZI?ZG6^BSJ*3F\_5D
M]B$R?U7,4V#EBZ.9!X>>#9(1(JUG6A)J4J,]`/9&TP-[`Y6_G6FM;!?;+/W[
M]6J]*#Y,9\5R5<Z+7;W.,08<?CI8#QU15E%O<32=E#CJ]A)ST=\=IM?-@5;0
M';C<[F.Q^O3'YG;?[?\YU83[DM<$S"BA*N))$:?:2Z*TK5!@//O`];KWSO()
MUX,.LNS1@0`M3>&?Q>Q>_ZPFLMU-.&:D+GA%((@IY226SF$D**,1O4HB['AN
M@M*(RJ]ZL5S=09Y%(K=<31]3X^1_%Y/%IS\^3]+-J.[']^GI;M%GA@5!5:I/
MQ=8H`#&-'ECO(WL0Q7F3D7!#YK2+^;77FF-@)5!".X:`D=IX(JJ`CSL%12;#
MV-LQ1QU!W5^BY.Q0HE5E0N$)<M49'I1TWJ36EARGDU/B&-PF9UGC++"Y!.-O
MCV`=P)VW@#L_CR.MQ(\N\K+?&'1*[XE?D\)&$NREX=YMY75(.).;UB3>#KWZ
MU4#/C-L9Y6V%=?OT>_'ZH.,2A1CG&0-,1.DA07*+A*?`JEQ3)__B8@_JR&O+
M$>>1RGK6D]FGK[/IPW8698HHIZE=VC8B2/C%I>WODV=7#_S2K^/B-P4#+596
M0\LQ4DI0B(!*X%J&!:,V^Q)1\,;XUCGT[5&KFL"7.'3YK9P=-6GU1@>&B*24
MJ!@GF+3*L1)M$MT1$])1EIT7\M;VTCN!NY>RW'+^\*58/-KBZ^KEK_=4=IM^
M^*+ZVL,#0@05*4DEP(1*[@#5PFW;Z%N`U/EMM3ZDJU->?V1$T-)SI#V/3@TH
M36-LKTPEGV&TM]OMND_=;:K@UT4^K0#:][<XY(T*;7V2(D(JJ78XK@HH!H3+
MW>5]W#-NS5GGTIUT[^9QBNMD^,]=D'#@Z8`-M]1%LL3(4B)E7%SG5'(Y3FZH
MWV=3Q1[X%)N!V<>F6/H,5[O/\$O\U3-)E(<>#\(QI``@C@*/%<=:,UA)!3V_
MH1;VC73Z2[_@QE`.09"S:9&'!P1N4]<7!C17$`@F//2DDDPKE]OF=80D::;8
M,RS)0C-S&VJQ7'U93.9WWX[77AYY,F!"M/-((H;C<M$;S)VIYH<<NR&3T%1!
M99M`CJ\X&_HX8\(TLX!!CCR%N]Y,<?[Q4^C^IM^K]`VY^(VS&)LZ)H165J<[
M7:22D)#=I6^>2\AR=XI':`PR]':B&/LRW,9;B,N]Q-33U,3>(RR(C)]!)8<6
M-K<0=ZSZOU1[)PMQ+\.NERXO+^S<^Q.9\&=&!&`9B`Z22I#J$KW&Q.YE`]CD
MAH0C[-3>IF]H!\W^F6(FB\7/Z?Q!/9;K@QG0=8:%&*;&*!4[)0A6F!CM]ZAQ
MH_0-V9+&>C[)FT:P9JTG7GT#,61^ERI,B^7JTWQV--GT]*A@@>`.<_+_[%U;
M<]LVL/Y+N%\><>UDIFTZ2=K.G!>,:M&.3A4Q(\EN<G[]`2A25FS+I"C>I'BF
M3>N8(('=;Q>+Q5Z\]P9PQRB..VZE9!UO:UI,WKQL#X?NJ3J\*JDF^V&VS8JN
M@O/'9CJ-%<MK+PD2$XB550`19JQRGAA048`#US9N>?);4]=JID,B#P^S)!?-
MO>7QX6`M@U![C#RRE`,HH=T+C@!ZE%SR2X1-"V)VL">ED'H_2UW+M]]?2=-[
M=5#@Q"GKN"42:@`Y5E7I^SAKAV5;`V6"S4)ZW)'.(VI74%BL]@$Q)V#A8%20
MAG*4ZF@QDOP!W#N'JWE[Q-H&+4THWGPH,+2G:KMXI%1T,[_].UK)LU7D25$P
M\\A^\/J`H)B1&D-@`:;4::(\W.]RWH.V&)A02'@O&.B*H$.8#<5<WU=S?;^;
MZ^_WR8'S_O9C=G._7FP7V<;,ELMLKK^7SVW*!U]SG9SYYJ`YDU!::X0&,H(<
M*+D7%4-:UT:=4,!X7P;)L)0?#:7N6[3'%YNL;//V=!FO)<2T>E\0B''EC/&&
M$,((!BGG;"^]NFUHU\EAXP_9^I_\&C#9,<6[VRY5)'$\YOTV6_^;;8O9_;G)
MYCY?_S#CDS;49J\,`@B`<#PO0(Z@,4[J*(CEBLD9;1$F%"L^W)[;"\V'B##\
M/=NF?H9_9.NB?>DHT85NMEZE#H+5)!K$%QX;$@S@$!AK&$-281`M753*L75,
MRI'Z:SV=;I.PWZ-C`F.*0)S*6'N@`17.65BM$6IWK;VTSN=YW@^%1Y#3LM-L
MT7'8?;M9WD<I];MTE/38B$VSNA1FC`AWFB(&B8=6<*T!+'N6:<6?]G@?2I@_
MWGS.YO?+:$:HU78Q7RSOMXN'[-':/>1'Y-/7^QW;W]\^PUM-I'&W'PH:QVV'
M4!&/A@1J1BT!50<XPQVXHCZ<YP/J:7_>,3DQQ+'GS&7I[R^_H"8"KL>O!F.,
M)-&85T(C*2BS1(J*QDRWOIR:(-K'`F<^56:.)S"-.HC5#0T\VAE::BQY2E-F
MTK&J8Z\P6HQ3%K4?Z$X",XUPW)H]0X"Q/(O61AS^\%P@0!"NI,4((<\(H$S0
M:AV`7%/[G^Y8FG='T"&`X;Y\7>;?L^SC-IYJWG]-G*H%R=$Q00@?]P5I&``4
M`"F=5GN)DI1?49AZ;X#IBK@78!/^VB#HM:M/!,"L(D0"`ZS&5$N#&:^H!XFX
MHA"WZ[#VVG+N`G!?&[K;R?N#!QH323#2%$@"N-?6[1D7.7JE3L#A<=<M\%MQ
M;P0'8Z$=QBDVT*4'$1!"L,'21X,?<ZXM`K*DLQ!6UU9+;7BU]ZB4RYGLR9@?
M>&I3P9<H+05I7[L!./>5`0L&N#$HZG9&N4/`E0[QN&CDT"AIQ&->$#1&03X*
M`X80[_?;S]GZW2K^G+EO7U/EH]_S[4@"?C`7M9J7T]DT$//7!P:E4T,O&4_]
M4$KC@(WV]([JW#*%:O.IAUAM\5,Y\]/*`)WTGG@65=@+0[2'ACII*5&^H@6R
MX(IRR[L"13X<N<<1^$)'C5E%J"^YY\@#X25F1F+L4EE'3!QPA`''K..U"05-
MXW<^I\35=RL_6ZS_FBWOX\[P6'3RC_OUS>=9&>?1J,)MR]<%C#@FT5A%7$!'
M.!(LKG6W6NX,[7]SESN`K;*[E*KR:6P!;\S]?'#BMPH3^RVJEVRYG*VR_'[S
M7(J/P:EF6.!4(Q1M$>^4AUX93>(/Y<PQ`E?D(>D#+]U2=P@O1C')W_-5_K7`
M[NJN#D7-!@8<[5HNL*"6&H!2M"[%Y4J%1'Z4]M$7@:->Z#NB)7%=-H1A!D&(
MG`9*,Z4(DJQTZ$,K/*E-0.D[U.AUU-2Z%,Y[81#08.(5%DH3*U+;'"XJZA"K
M1VD6/8K0-X;)T0"B'ND^A#+XN+A;+6X7-[/5UMQOMG'FZTU10WF5$I;7I=?3
M1(8NMA\6FW_'/&^D[Z?)_9E:=6]35\-%(U7QZKA@D&;&0JXMUD)@%8][R#N"
M4\UFAO1(FN('!J0%U`47OCP@I/(YVJ22/$IJ)`UR?K\ZXN4552#LB,M/LT^Z
M(.L@B4Y/)ZJ_-RAM^LJHP$2D%$_6CS66,:"1,7N2N6NJ8'4ND^LPTYJHHP"G
M4<'35T8%K>(J"1+$Q5,4LXI[LZ<;<JV/II<`G#:<KM4X;2D[!'K^6.?S^YOM
MLTG7AB6]/C`XGSPQ"B)N,95&6>)%N5*N'6Y;5.02,-2&WT\;U75)W)%V+YVM
M;CY_F:W_/7T+^V%H$)@IS2$%6CJ((-,2T6JU0.&VD143])3UOX^=0]EQ<%1-
M^/0=[<G00#76J3<%`1)H1Q")XEBN5F#`1HG0&6Q;:\GX6D2=1>,A$%7T]_F0
M/62K^^R7/)^G#M:UF]OQ0<$S1B7AQ"/N!./&8L&K%7*.6[?TN@04M67V4^=+
M5]0=)/KPYB9%B,7YWF2+AZ2/:]%S;$@@DC/-G83(0$$P9H;":G62T"L*V.X-
M.QW1=@CD_#;[WWS]Z)1[W0IZ_G#PVGLDH<6:*(`=!XB0:D6IA^?UW.QT;/><
M3<LAT)&2%][?_C#56A/GZ)A`XE9N(N%Y5*#60V8EUM7ZD*F_+KF<7>D<YN;]
MD+-=]9GRB^]7-8U*GCT89X<AHP9X:9U&"$M`JME)"-`5^6<ZX%#>(2G/8O2G
M__)FC-X_&#"TGBD+D05461!5(7;5[(QR;8,&)V@O],3HMJ0\C]'QJ88R??!H
M`%8C#"FRW*16ILXBNH>B4ZVKWDUPN^^+V:V)>1:[?7Z_;L;MQR<#=TP3X+"1
M3-K4:<,37,V/2-M6A4^PYG)/S&Y-R_-XO7AH*-F/3P9+".;$:"V,ELA@"GFE
M>I2DOFWY@`D65^Z+UVUI.8K'\M<&>;;'!P6I-4`06J`HA0+%+0NP:H6:BK9[
M_@0U0]_>[K8T;:4A=D56\]N4BI2M%S>S97F'\Q(,:D8$HA!#0@#NB4@-N1B0
MU=6CXO*J;^Y;,"WO@ZAG@<#FF\7J[N,V4N!N^[D6`4\>#]$<=<P(P("2$J<"
M6;"2`&59:Q?S!,W^OMA_'D5'V38>6XR\6K[XE6'!6VZ=$5!!85/U7*==90@I
M(%H7;9_@":)#W/1`V;-TQZ?\:_SR;;[^DE)<BVC/FT56JT..#`N,:JL`Q/&T
MBQG7PCN70@6XLT91P-L6%;H$<Z(C7=(-9:<8"SQ>QG$_D<!$6<L9P$IB%\^$
M3D86[Z*S$:$6U1;4'$C3GY9FW&1XRF\GJ5TST\Q+BCT`P%8K]Q9<D<'8$0+J
ME/_Y1)ZBP)_Z_(AY13UI"!G-?FL-1<IQ23#45>$):40\9HZC(:IDE$V1]'K(
MBEWL3OK3Q^GGZU-2BDYX6R`XY>$CQ0@W`EM$(*<571AV5W1]V!$^CJ03]4?S
M0=1)*H*G9YMLGDHF9:O-#_GR@XK_H_Y-%'V<S(=LF9+<3;[9;HIZ+_^DZ98]
MMIKHA_->'"1AR!.)@5(P6I12,+.K4L65MD".5`&]\:+TX:*:*),SWQR8YH@[
M"2B@6C&F,"CK,D9ZR9&ZJ`]0^6@HE#WM1SDHM\9326H>#93XW]GRW2H=S(J_
M'+''PE2U%7>">N:A9A#&_U?"NG*+L0QS67OX[]?<>7_[B,4?N)MJ^-YEQ5+T
M]V=X5?_-UO/FK1K._$;PE'.L.6$&2DIA/`(H6=%0RW$2,*>OP1HC[VA>]K!\
M&\+E^VFQ30M[MYHO'A;S^]FR)B3TQ><#YA80HP&2`#CCD16XK%1IHXX6HZ3^
M#X#'$8"1=\^.46#V]V+[N1#;2*;-Y\773[F+IY[M]]IPTQ/?%)B/EH/R6AF)
MF&3.2+FG!8I'J2N%YIG`J(-9IT1O=37QZ;_\?[)U\>_'E+7QKCCA+AZR/Y:S
MX_7KFPX-F#*IM3:6><X]4(("7ZV``#Q*:<0Q8-,5H_->Z3^$"ON05'G-[KA_
M)N`X6Z93%@DHHOL`196MH:%H'5]UUG7Y3[$CMF7!8!"JS=0Z>"J@>-;&1@`4
M35<>S\&6(EVMP?H!ZCB.`Z,63'P)!JV(.$@6UF*U^'+_I18*/SP7F!/0*V(<
M@<QHAITPHEJ'!JUSSB\"#*>R\FGVU1F$'"8M[ULS0!P^%R3'<<W>N4@%(QES
MRI;M":R)Y!DE)NM2`'$&(0?)$*_;/H_MGK\VB/0]_^7!"XB1Q5I;!Q0T*8"E
MVIY-M-I&">OZ*>R;P7DW:;3ONF-M?DD-UC;O5G]D$0+SO[/4;3V;E_W6BU_:
MV3;;UW'N0S3:S21$PX9`K)$@&D8=)#R">\TCN!\E;7((.1H0Q5T)T"`<'DS:
M_GE*@5V?<'6__1R9_W_9_,]51-)!"[IT.-^X;]GZ9E%6/2_VX??WV\UVMIHO
M5G<E@9Z0Y$.6/`7QUZEV>O+#W\^6G[+U%U0GA>//,/(.">\`H1H;2H`BVNTQ
MAAUO6^U@Z@;6V-)Y<9P?3VJ?,^6?(WKKKVR3%KZK5WR3FC+DZ:]*JB6;I"%Q
M7DL%F,XD0SP)4$6A`82E,G>6QK/=WJ9':)1*)3^C[%X`\UM=0+C-=O%E5DQX
M%;^;U)+/U[?98GN_CNHGF@#Y^M!D2,NI.KL>S9PXZZ7!`,^EH)XPSJ'$6J:%
M5TK+XU$2N*\3\H,S:S"(?LQ6D6&_S5:S'>VZ1.K3=Z<.E]IJBKUQ#J=B)X94
MUT<&.=36HWE6%OH;8+ODV2#5\)8%,K+YRW2M[V;3[`7!*X8D42X>X##%U#OO
M]BLGGK2]TV-O:#UF4?3"F':JM.K)GJT?XO'BY?G\N5IG-_G=*@G6X=\7@6E'
M%>G9;PY(&(DMBD1@@F)I-'&D6C^+.TQ+8/(W8+ZL1H?FV$B(?6)M[QQ>[V\_
M[$8<IF%TC^GZ;X?D);=`&2,%AM'@=VI_BV<4Y[5MFX^@7KRAOB?4=\[325]-
M[%*URXNB`]]5'Y</Q[X5K,!6T:AL+(<>RDA7;BIZ0H7:=CR0;S+2^?5"1SR<
MM$R\>(7RRSK?]');??QK@6@#!/-,2JH=!IYP!O:';RS:[AT0O`G&,/=N;=@X
M:=%X(OX/L\4R>3SCB;Q8^`"[QM-/!FJ\(08+Z@SG2'",8;496T?K,[6."<G;
MY73ON\>9O)RTI!1_I(N!5/JF4`:U-U(=?29001D03D,.N$:8(:IA147M26VI
MAF,2,<$J:)<H!.>SK-5)N_5\W;>OBUU-AMULCQVG._M`P!XS2Z5U#%*K!1>8
M/U+#ML^&>KL5??G0/!;GVA447A85"HOXB2+!]DN^*H(LCN'RZ(!`*+,8Q&DA
MJ[D55*<B`>5L,1"MP]K>KB*/5"7NB!,CED_8N_I?_/68+:*G6DE!64:!9@PA
MC*``E)@2*5SP%$]<)V1]5U)HY#$L^;XHZA+M?8<[I5<0H'E5A0Z_%U+?)I**
M+@G/#5`*4P$JVFI/V][U3;#XU%`@/%I483RV#7',>;>*BB_[&)%0Z/]?RU74
M))*^,BIHJE'<\2'CWGA('(5NOT:,KJDNVL@8R?OBR8BXJZVO\.JX(+#APCOF
MD8@&J'-:.UZMDTO0VB4T/>QUPNUF"&I%VT'RE2.SXG<^J]7<9@_9,O^:IEU&
M7=3G,=>/#M`@*234VAAA*-?6$E^MV7ET135B.^+]TS3GSFD\B.LO6\9WWOV2
MK;+U;!GGKN9?%JO%IBA0^9"5T]_4=\0]Y3W!*T.=@5C&4Q"UUL:SM"GI("!'
M5]3!H!^L]4GM(5#7C0WQ:X/\VHZ_%*#F6@%&HK1JS*S04)"*EE&81RDF\C-8
M?./R\9I"9Z5CQGADN(/2.ZZT8;I:N:?PBLXLHV&F7>CL:8P9T3VXV=Q_V04"
M[(/4RXB`^)ML_E9H]9EGQBF-L+),"@6@$T196,8-84T8J2UA-K%KWWU&]0$4
MBA+FZRQ[MXJ"G6VV*8>AC[O@IM\.A&`)G-<2,6"4<5##,JX7&\+,M1;"'`JI
M75T4]\3/28=-O+3F*M'RKSQ5^%M&D`PI02]_/3A'O`?(88<Q<1!!C_R>YECK
M,:S=-QD:CJ.33J9_;=6])<?7?C10C2S#VFCL/11*>Z-416%C:%L_VM3#.L:4
MF2DP\F(W')O*RT;C?(SMYO#;04"N"+!.,V65!HHY44'``$Q'Z6Q\Y8(S(7Z.
M=YX]*%ZC;K9Q!=OO;T?89SC31%)M/89(6"(\XI#N$GNYCH"SM6D:$].(92;#
M05FB#_ERZ?-U^F6/&3`O?S`P!K`W`A,!"`>,.U8F%D7J,LK>8EQ.AF''*2^=
M\&W2-L+SA>X2&881AMVW`J!"2&$-`%PA!"G6#N[9ZW#;2E$GR\'7PO_[<3M;
M;R\@8K4CC/8G,JVX>PG2,G[ZI*".48B=U(Y:PSW!E%0TQ9:V32L^V47SD*W_
MR2\BOGN:TG(^;P>1EV0KE]<\]^M];L\NU>W`D-Y7@'S5ECKY98$(20E!WG$D
M$'$0T+(I:J0(-:U[P31WKL@=VE?9W6SG*/B9(=\W_RYA!WBLVK47WAYW@!>^
M%BCP@$@&)%/*.0(T$OM=%9C6%UW-_28_RL3/*PZC\_82Y&7<\X6WR@'F>60N
MA-YY@1BJZ`DU:^N</[G*X>Y\X5;S7L_:5R8@Y[+S$L3CH,)N[^+Q[%O!`0$=
MEDY;5W2^B+K=5_2TRK8UKZ[\OG<LG]2Y_+L$>3B0^2<URWZL,1_5T^V0SMN&
MDPF$*V)0)#YG@!*/L>%[;#C4NAWO6;?!;T(T)$^O2,K&%ZU(>P^1-L`0A`$V
MT&NB]CM^M`3>',0C87T<L3P1#Y.0Q:/=R)IT->I,'KN;13P/:&8$%]0C*+60
M"N$*(SP5NKI2J_&:I'$T-%R$1%8+'%TH3YI(H)BFG$)+I88:66EQE6NEN9"F
MK5Q./1+Q9Y++/@%Q$:+Y@M-T+.$\<2J!`6.-!U((RI77ECA4^7:Y!ZUO;J<>
M[_@SB6>_D)B$@%[-R9(2@`%##%IO,01.1:)7M+=>MLV+/?MJX$TDIX^&2Y#$
MX[W[AI+$AC,(W#%'(\6U`X@110W759``1_!J>^==J`.U'ZY>@D0=Z))WJ^UZ
ML=HL;OIN:G[TFP$YY2W@DGDM%$<*6UYYPK@&L&T]X9;[U\">T0N5G:ZX.6RM
M[",1BV6[=75WMRXB@6IE8H19!(N8H!)1KYR2#ELF)=[OZW%C;RDE4V\<.+!\
M3)^SE["_/'/N?,JWL^5@6TV3SP>H&'-8"*$`CO]0+J"LJ*X<:'L?-_5^AQ>Z
MW_3`TE&VGJ(D?_;_[5W9DMLXLOVC&6R))>*^8)WH"+OM<'?/?61H2K2ML%ST
M2"JW^^\O*(FLQ5*)A+BJ[TMY*8)$GCP`$LA$YK*28IB5YM6/9D09234%YXVS
MUH#2E-73#X?4A67J)1#GN+!TJ<@YK"/3VJ=8O[^E[A0+R&I"C.;UR0K%,C6G
M3.LZB".<L\UTU>A*EW,8*V7)HK(H^[+.!5*4__7DD*/Y_F;T/F4:2XHX-AR\
M!\Z$(M;62SD*-UM;<:8#;2A%CY=K8Y\$]O]+QSPE&\.,"VR<LBYN8+F,?SM6
M!1)`B+Z8Q[^G>;3K[+]1RV9]NH!5[]_,G-7!2:,I-8%Q)6W`HL+8@6"I\^#-
M16$W)F/?)60253>(B5'+>GHR?WKSM9R=#Q(_)DO:SX'MQD,7'\IL7!\8D=Q9
MZ:2R3%IRK-`KM`&;ZB"8>ICFZ"-B!.6--0S.I-7:5GFUKJ)^NY=GC(#'6"I"
M=2!Q6T(5/:;O$X9QF7HR.?7HQPG1O5>%#6;#?B[64?%;_]^'V.51+-?#IQM8
MHL\?S(+&W`'!5H2@`&MGC]5%I%:8XXN7G7M,(?(,U%^+7?Y(VT;30]-W9-P%
M:WB(\R85.'@JA%05!I2$U!NM4\\"GLJ$4QD^>L!YG,&KE\M5^;K2X_&QB`^7
M_Q@QU6/JN'8H;NHMPP8PUZ"IY,""9Y01X3AF8Z5B?%P!]EO_O^QZL6U1,O2G
M5ID/+G`DC!7&>`TR4,Z/<GJET2U5*DE4\/E%^$HPFQN0V_SN'Y^*[_]<YJL#
M5^)?7E(D_E?V)H\CU=_O2CE/%]P\\53F5!08R3BW:&*8QUXI4?6:,AYNAP*=
MZ*[H"LGN]7_HRMF:ER\?R8"#=31PCQ`.@@INO*GZ2V3RY:4):?XJ+16=P);D
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M=3[TN$:9+WEQ)8Q#T.)_%V6<Q>XB)9X]%[?:5%`*5AFK<7#,8EQ;3H0XN)UU
MI4,Z7`/AT$O(FP9%HD\^GY4EV07C5IJX\W(HF/+FYU$NZTTJ-2:8NJT/DZ,+
M3(?@ROM*%_N>[IU76_VP^UQLRI"$5TCS>L,,)..<6!!R;X%C`JR65`26FMUA
MZHZ'*]5>](CQ\&R*>_5WF[V5MMR'Z;W/-WL9&K/JW`LRZ06FDE)J-2BFM82X
MHSQ('AQ2@U5]N"%V=83UP!9PBPGKE5:900)A;!6GDGL"7H?:XQ"8O]FBE=WR
MJ3N`!R91PCS5H'7F1+0<,`L<"&9.,,EQ+;-1.C7Z?.IY''HC54=`#[,.%G=Y
MOMR&B$Y9(61Q?Y?'OB_V$:+/(FE.KH&7&F?(:`(:.`%`(7"&P/A:8J13;?/6
MR0Z>5SV:`Y\Z!S?)F_#^87/W>;'-]:=-OC_"*DONGO,AG'PXXY9K%3>>*,2?
M(A#%=;TLDS@4$BEPU4W^*1.@,RB'<1Z\4EJH$N+=1[W=YKO7'0HMWI-1Y(WV
M&`0$RN)FER!5>6:"4B[U;/"JR^Q3IM00*`]V:;!1]JMC<C!#XB"QBF#G)=8@
MV*,Q%W^DNABNNNL]"YZD0CCZE/-K_N?^5\ES3?V"S&!"H_#:AVBM2:\=XZA>
M75GR)-/Z_O/LR-,'O$G&B]Z]76R^Y+O*?"J-IVV]HFYCO^[BG\7'?1''RMXZ
M9]PDO2QSTJO@'(]SJ-+11K-(UR8:8R'Y0MM5%WNGS*+!L.Z#4?N`CX>O7?#I
MU*NR0`-(,-(8)CW#FB!6K\C@5&IP!9ZX4[1?-G6`=!*7#J6@BH]'ZRO?_'&_
M.A5<?O[AC&HBA;(:*T6T14HQ2NHYE/IDW\7$O:)7\J$++`?TCAZ=N.\V'\JD
MG<]R==:_W!Y_N\6OV#U)[\L$M@)X)+W3'(PGV,;)M1H)@B1'=D_0O=KQ@>``
M<(]&P\,8BECE=]'&VZWRK5VLU_G2_/52I+:$;/[FC%EOI6000K"6<H=9'4L9
MC#,VE9I7'5S/EIJ]`9^6>>ZU7<2[,F_Q>EWLR@7\<%GUW,+9]CV9!4JTPBH$
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M1]3#P(&=S<1K%N;9[%U9B':/4MP+AZ/U8[00B%=X`*C4V(CVQQQE98/9\'(H
MO,?9-8Z8]3=U.ZA`^&BR$T4%9H)$4SXN.WM8@V)<7#P;:;_LO+:?OI@W,?UE
MF2?<Q4T*E'E6K0PZ"NXJ23F6J7&4,]L&-M;WF86D-\`'&;$/_]GF_WV([_#?
M2]?U*"/U92<:C-ES3?81S)(P81C1A`45##],OY(I;\S%16@8"1ME.CS7)I/4
M:D04<TAC(Q0RS+I*1D9P<F[_B8_;ZW7^<E_<$<)##-3*8S;*`*T^KN^7!W_=
M\UR0#<9KPS=D2D"$V&BN:`"FK-&X`MX(8".EQ#_L8'^)2/\H*S/LO5*5A>/R
M[=UFM7^@R:AN^ZK,.82M,`(#]M&RQ,8@62%BN4E-9CSUP=XY88I!]3#DE&`_
ME^=XVU_NPV*UV5\/JP^GWZQBP_5>I-FY91P.F`CO,18D@.<:J>,INI5QUWTQ
MT'5`M\RE5*?G&V7<@B!1,@K&:RR<C/^LI#0C93H=W@9OK.LFKI@48$<+>[J0
M%NULF\Q()*RC%*0C.DK'`?E*/JS\K?KPNM!X$Q(E8#P:AYKF2CO5*M.2.^^-
M15K$K2F*@ZW,Y'.0D<'-;B8Z4'H3&B6!G.3&>!M;??[]S^+WS\5#&6025A]W
M>7Y?&0D7<G4V:9Q10G`T=4!ID-9X)?&Q3$.40AHQ2F*;`=G15I=%SP"G14'F
MWW;[CSWIS.^?5YLGO7F=*HU?D"%.M.!1!J<E$=H:@^N!9(1(+?<YW:L$W=&E
M+Y"3*./RNY_Z\F>^_IXWXDNSUAD0'KP@.B#"B(O[*\UI)0<"ENH\FKI_O7/F
M]`)WVLVV"-_Z23?\.O_><(YIT#1#BG/.@@?OK=,0M_J/$KBXF;A1+WCGA.D>
MZT[,EQ9L:=`TDX1X;BWCH+VA0"F1MI)`1/MN,-_TS-G2/=:=L.7W1*J\;!>9
M3E@00B"PWH+"DI-J#ZD(IJFSRE5Q\;?`DRN!'FUK_:9Y#MDS#3.NN#$A`$"P
M5C,D)*J&@W*!WWC"QMX/:E*!3IIWZA/VHKYH^:_RY\GLBQ=:9$"1Q9()+ST/
MSE+N0]U?K6ZI-'%7BBOZ`#8M:+24J/YR<9"H[M*'8KT.Q:8,H3X;L=/T!1E8
M0A!H18@"1T"8\G[D41HD7>K.:"[;Z"MITA?.UTT?C_>T*P_=ZOPMP-=;90XK
M"DZB8)DUQ'%'$:[Z+0-)OK/<EA_?#O<S=XO-KO]5IB_=GIQANL`];9;9>W9?
M<^R^0IM&C3-FI'313@],!$FQ"U;X>J[$-M6--%7K9`C>]`'\=*:;R'IBC40<
M2<-`(1.-]9KV+#EC4.N#NL-TX^^7MT&:3E$?,OKD1,=_V?KM;O6US%;\QW9U
M_\FL%W=??KO[')MM#W$W9;*2^(NWQ3)?CQB:,F!<&\5**HFU,;@,551,'C@A
MB51$C520N^M@%H95)+MFVEC0/$1>6E-)Z82XU8#RSDG0/,JE'>+SBW(AS'#D
ML$/1Q*?,$N0?Y8N(C5(%>-S#D\8:;QSET@[C>4:Y&(6$!>P(II:*:+![8RL9
MK=>W&D7;@=);1+FT`WFJ42Y*2.ZQ%$"BD16`:>1$+055MWXLUU:7[:-<V@$\
M^2@7*L'::.4#QRY.RM:+8UPX47&0I:Y0<SF>NX8N?8$\W2@7X:@FG!+CP0F)
MD-5$5W(P9U)#HN8<Y9+$G%[@GF*4BV0Z8!\DPT%K:W&0$&H)%$K=4<TYRB6)
M,-UC/<4H%ZN0(L`M@'8R..>-HY4$/B3?%9MSE$LG=LSU6$\KRH6!4("9)Z`%
M+RL`8U598(H2EQJ2,.<HETYX<B70<XYRL49S$HTT+8&;TJ\A&*XD!?^R6/SL
M_4A#']2D`ITT[QP__=MNL_IRMCC2F2>S8()F2II@+??(2A\-]:I_EHQS260L
M(B1HK>@2W8Z\AO4M8KW=/GP]9',K<]?>[?+E:]7[VK\ITR$XP;RA05HC`UBI
MJT&C,(A4"V:6T\B5[.D=_6OFED>WX8F^_+M81P6N3Y<*37A+YFP<,!1%89R`
M0`CGQX##*)<4,)C/^@98U2ORG3/JPVK[)6SR_)?["'V^W7U8["ZM98W?DSGL
M@5()AGB0RD<4:;5?C%@F5Z*=Y=Z\1U9U@/V0\1"_W7W.EP_KQUE7W^U6W\=-
MP3%<G(,&R2DN;[&*@)2C'/G@D1>`;,"<HQN)<X#@+0<9ETE;EAD$A$PEI5`\
M=;,S=1NW<Q*TB'-HA?@,XQP0PY+S0#U@&QA(#+J63XN_51:&EAIO'N?0"N-Y
MQCE8K+RRB@($)X/7UC%5#SW!1G%>CQOGT%3I+>(<VH$\U3@'[P"5"=.D<<@@
M0Y5ROD8&@OQ[Q#DTUF7[.(=V`$\]SL&%X%6<@14+"A!82C%4TG#C1SF9F0E=
M^@)YNG$.##0.G/%@,(D_'8]K=R6')?9O=>!R#7-Z@7N*<0Z"(&/+I-@H4$85
MTP%<)8%7*M5K,,NSE&L(TSW64XQS")H"(<([Z@/1WD8YZ@VF5BCURN.<XQPZ
ML6.NQWI:<0X&I$#<`M(BN#@3>L-KI@<E4I.KSCG.H1.>7`ETVEW8XG[[L-[%
M;S;;!)U[/A/<*>?*"K'2:R*$Q(17?74*4F,PQ=^-%!T!/,0YRX?R0NZ%L[GZ
MF4PRAQQA!!O#J-<H*'X\,G!(@K_UO(77';^EPC@8#<[.&B>>RE#LL2#&V[B1
M#SP0C(VH9.#$IE)A@F<D"7H[I?DDW(;0_=O5_>KKP]>+VG_V7.:89DBS.&O1
M8(634E%;R6$9W-`969+VBNZP&X0#BQ_-./#TN4P:ST!(*<I07X.,EG%8'.4H
MP[!N9SGHA`-78#?G^%?,-0^!<1TTHI'Y$F-5SYH"IR:8G.6)5P\.O%2@T[8:
MIU)]/"F"G)K>Z_0K,HF#<CIXX)I9;IG#RE02*<%OR,CH2K47$WQU@O1HT]&3
MWK>=D)Z6H??6`:,ZCD,*5ANN,*HG7^SP8%$J$TD,=BTGFDQ3Z?!W-U%=2$CY
M6IM,:8J9-]9+3+%'`2FH;7]#[`TX^7KG1]<@=T<,_^/;:M.2&,<VF<54:L/`
M!8J))#1(4Y+9*>(($)^Z$;K*O+D98J2!//?EJ0P%UY9YJR3Q`MLX)X8*/X)"
MJL7<VN4WB41R0R].[<!/GX,>D\(=.['=DWVO-/=*,'ZCQAEVWJ$X7%@($1EA
MXBZSAD=2GQIF,%4_X(!35,?0#QF`/V+)^>'B[(GRW@DMM'02&,&*F6/)8Q&`
M7'9B-8TO.W>9X5#8O%%M^C;OR"ABQ/+@O`]<$>XQ`5?)1?G-QJ]VKO9B&`6D
M!2V^[$]YX^>@L<=;/XG<NORJ#!`-PDF-N?;**(&DPY6$B+M1SG-OCF*=ZR'-
M!&E0&;D9T=J_*7/$4"T-Q\@I$$X+AFL@K5*I>^FIGPCWRK/>U3"DH5+]N3>X
M5A]7^5+7!<C+JX*W;L,$$!)I448X&Y!.2%\56O72HLO6^X!;WBON"F(3>5?&
M<L?U$PNID7*VDE+@,$H^C'%'?F.]-[\>V`[D^5T/5$+%39SPB'CM;,#6\!HR
M0^TH%TX'=R@V5G+C&X'M8)WGC4`9X@J+F<4"',&:.V..E0.\4B$Y/^E<J--.
MSRTN`;;#=<ZA#3*`TIXJBY1@VGJ*JD(W7@DN4\_^)^04&GKR2<7VJOPH1_?3
MKP]E9$[Q\;=HE9XO`O-JHRQ$MF,:NZP0DP%C)ETUGI0S<I1LZJ-$+#16WZED
M)UU@.]J\XG_DF[O5]I"6[.?38MQVNKGTOHQP(P!K+SR38+D)[KB/B[A@0FXH
M#*]CS@T)>]($50T`M_AKJ[_GF\6G?/FQV#SKVKEYJDG;3!!`3(!"0)%3S##$
M:\2L3,[H/R'G=9_350\0#S%K-4M0=B8A6/N79)BRL,]W@T#)8'U`Q%4(,()2
M27;5#=99D*QWK,=FVYD4F4V;9HP8Z33'/EH#(+B0'NJ=1BGX&%[NFV%6`L)C
M\:EA,L.VK\@PI]@K(H6)4[<B5$HD*^FU5*DE0*^Z)3M[?G6`]-CSEEM]7RWS
M^^45:^335V1@RMN@96H3&V$()#C#*^DI\JD\N^KB[>QYU@'224;[^?+KW_+-
M?BM[SF2_W#(S##!GA!D2N!=Q#PR@JOYSGGR^(&^>*?T`?,DI^C__+!_^SV*;
MQW_\'U!+`P04````"`!'AP9'`TOR('43``"8RP``$0`<`&=A;&4M,C`Q-3`V
M,S`N>'-D550)``-FRL-59LK#575X"P`!!"4.```$.0$``.T]:W/;.J[?[\S]
M#[K^LCTSZR9.TK/;SNG9<1U[Z[E.G!N[[>Y^V6$DVN94%GU(*HGWUU^`>EMO
MV6G4L6?ZD"4`!`@2!$&0_.UOSVO;>*1",NY\[/3>GG<,ZIC<8L[R8^?+K-N?
M#<;CSM]^_^__^NU_NMU_?+J?&-?<=-?44<9`4**H93PQM3*^651^-Q:"KXUO
M7'QGCZ3;];$,[^E96A^DN:)K8A"E!'MP%1UQL;ZF"^+:ZF/'=?YPB<T6C%K`
MA4VQD`1`[+,B8DG5+5E3N2$F_=A9*;7Y<';V]/3T=DELZI`'QC<K(M;DK<G7
M9Q?GO7?GOUZ">""P(S\@3&TDFSG?$TC/#\)^R\42(,\OS_#S`Y$T`'>XX[CK
M;`1+B3.UW=`S`.H"%!7,#/'*D9(("&"I$"?.U;LS[V,<E!7(P!RIB&.&,CRG
M9'ZZU-"]]^_?G^FO(:BTL@"!;._L'S>3F59]!UJ"8>BVP-8;+I3AI'2X(/)!
MH[JRNR1D@WJXZI[WNI>]CN&UH`DWB=)--BYS)N(9M94,WG0C4F^!AXYQ5I,?
MP6TJ#\20IK4W1]@@#L61IM6(HZ*6E,-/&@5_=0.\+K[J]B[V9"/JE/78"/`.
MPL;[,R),5#=HSE1=^KRQB4,4%]L1_*[&FBU$@LHP(H(\OD<>>[_NPZ,F[=`E
M&O7J/,6Q#LM(C8H),/9G(-LP5^$CCGGK(1Z2G6:L[,%']C!2L1<%"%CRNYIE
M2FJ^7?+',Y.[CA);-%&756Q;%E[PHQL1:<J-*P2X1MO*IC83,?S5R,HFZ%J4
MU>8EP,&'_3F@S^:J-@LADG[:GPGF/%*I:C>2&)K_O'\3<0@S]5#<J\-)A.4]
M=B,"#?F0S*S-18"##P?@0&U$?18")/U4Q`1Q'*XT)?TN>+O9,&?!_5?P$L?P
M#\%`?D\7AO97/_BC:+%7>[81?$.%8N!<Q1Q[36`EZ.)C!V<,W6"*\&^3V&_!
M#PY`4@4D70P]7@&*Z=I:C$G$9$`![??'CH3ZMFD@_`^7RJ*+NE(!"G-8FX6R
MR4-=H0"%VFV59R-H77D`1<+LNEG;0PIS@#`83/CZIBE<:H$W2AU)9=^QIFI%
MQ4`/<VK"8$IM,Q2E8R#>E_MQZ;1;<UB=;LA=P%_4`G^_Z)W_VCL_-[K&-9.F
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M:M7)!/`\F-Y>#V]GPVM\FDTGX^O^''Y\ZD_ZMX.A,?L\',YG)]7MUO0=P:G4
MBBH&/!]<CTGJ94I]IWMB;:6"WQ$OYM0_40UA+4X7,\7-[RMN6U3(X1\N4]OZ
M&(=H&8=FJ:0Y75:V$;,Y_'<SO)T;TQ'\F`[^]_-T<CV\G_W)&/[?E_'\GXT1
M3TTQKD68C0R(7(UL_G20(2.;<$FSN*K?+&:HWD%_]MD83:;?3H-(JN[Y&J1<
M`0Q[I!,N#Z_<5`$E2KYHJN3IS=W]\#/`C;\.C<ET=G3*#G)`^XXU=!28V5BL
MIJ9:"TD5*?`\=/#"C-38(\8?/'KQ.-*QZ6E$F/A*;)?>4(*S%MU3:BHHFT9)
MS.%=1LP!"1F:DA$G==()5`+8-,6<)3S>N<)<$4GO!#,IFCH&SHSFVH>W^FHH
M%5NC^0MI39U[BJE%0$-'W1H%@W\D9R51D7<949&<]F.\B5@T`AX-S:21X/+/
M`9IE$&6$G,;I<L<(N?7"E\<;><YL#5`[W#&9S31_T\6$/E+[,K5H>XB&5[6H
M\I9T6;DE)<O$T+4NU;B,KR*>FD1"3XTB<4642D)Q[S)"<;D*/=)@W(1"S=\)
M;E**6WDPX+EF2M<)^%FAO32C+(MF<>_FY93TVK]>I96L"S-BI?W9B)6G/;Y$
MB89?UO$&SFNHYY:KVIVX-OD2I_&O&4YC;:6_T44=GZK!W8')<7\I:",O/XU?
MK*S>59:R/")&1.7HU7"X5(U:I(O-:^\JR[RFE'?*QDBIESO+.<4MJ0^JKOKB
MJ"6&\"]9?0OPNPH(&$CAF"N^H:N20:'$"?E+5B])J.%X78M;JC#$>D?%#"J:
MUE3&+G;)6'.9T1^`A($T#"!B:"I'K@)TB[BC'^7PV;1=BUHCP=<^6*,QIU$1
M)6//949H)ZU,C.I@8=XO:03%>4<,!/#'.Q+M:*;1)#R;1O'TNW>9,?W.4M^1
MSKQU[OG8@3JF?DYZDYE5'I42.YF5Z><EPWNTC#<^M5^.=9J4KEC=3INY%"7$
M2NQ@5N)?CK(TV>/U-7+J^4#J*K5X6;E_>;WJ2*W>C"T=MF`F<=3`E0HJ1?@A
M()A3*N%'\`>"PG3RGLGOS?I;TU)*.F+66E.L*",L*X@V1:7A"H%7GH$%'F\7
MK:N:)H-BLS)*ALRLA>JFRC_.(;6N6NK"-[+U/XBIDI$C:ZFJ8>-JVB:/=4#"
M1-!/1&>+K7%P;I*:E$.DQ*)D;7#4E`Q-RHC3.JD%21\N1EZ??HEOT+LZOZJJ
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MKX7_+=@MTVS.UJ"`DFG;>488+R@%AB&O'(,YB;U@BP`DW/QSQ'.WH+;2JI!C
M&>ZE^R)QFY]-S.\S$T8'*KVY+V[&@P\WW*+V7BWB4*67-Y>4!Q,UE\PV`JU'
MQO84:E8,S4O79R:(`_CL&)J?4X/">V$LUXXTNE>XIRK5\@:0FLE$#2`@'C<1
MI^A.4#^-?-,=Y)((SGF&1QJIYTB]T*`"PM'3)E+JZ[+ZOKO?;&6E.MWR3I6*
MG49:"Y\B^@:1_M3B.%9,?CO;O<;`?Y.\[D!?=N#?CZ8UCZK[MW\2\MA!]Y^+
M;;`37OKG('?TG0WAD<]%<,RVL0M]["B`[!@2YA:**==;*N'NYF-'7R/V@2FZ
M[AC>8?'>&YC-@YK$=@Q?4+".X;U_\([[^M@Q=6Y"\'I#!>/67!/P[GU2B7L>
MTD(ZCDOL&\(<!8T5*(XH#07+_M8Z80@P((BI`HXBX3:"V?,G/E]Q5Q+'&MH4
M=.3WBQNZ?J`BE+42:!/1O4OK/EA\#16Y*WE<1,L5?DY%H<+4#1'?J0J".#-X
M*:,=9C?DF:W=-7`CI;_'4X8R-D)]075;]"%;VP>IBCLJ,(V'+YI41BYRHR8`
M^M]X!(L:0*4.&YXT;((=E]HJXAE<GZEM?=KJE]"'O'-Z`E'KH;R&OFM)'CL<
M%$^76#KL/V!]+8"%,0Y9[TM)E0P$@\X<.VI"KQQ3ZYXM5TKN5M!!*;>V'KW)
M>2(&$(M61[-`J0>U`9@O:B+7WYA:?250F.M[*2.&HP)N(0\J\F5(O\J`4\T$
M90J\>[Q/XLR<PJHJP_S9:R)]T%&MZLA$;^_XE"'33K!-'S2?6P&9P&T7MSBX
MJ&>2<_JL/ME@$)*RU\3<PQ=3`9G]W3$]MXIB9U/AV?_A\X9YZ-=$A0YU5>#F
M.L8C'`\D%`_XY!Z;_4?H<TOJ>4VZ)WZ1>D5S^`RN#?-[9T+4QB3VJ`!?P!>J
M!*TJO,RU0,H(IKD84N_1;2Q$[HPHD^&PU]USVP9M/!%1+&$.PA[B*CP?[H5T
MIK,"2W06P?PD.INZ"ET]/,"GJM9R45JJ-SQ;HE`@'Z`=QH+C^H2V7PF?-Q(@
M'V"/*:7>&K[WG+)BLDK.X-T0N27C=\3]@&R8(K9W/$*N'-/%<+VQ^992C12Z
MIN!#9=3((6B^I$5J%%9##]RU$2_P9)*QM(+O+0B@1=.*Q$Q"WZ&T]?[-:..U
M<-K2M,OG3[=4@37RXM1W7"1F9(W16Q<@3E0)-FGLB02$NB-;Y#0N<O;G]HOD
M$GOZ8+-EH!<=SYROH/]C4MFNA*70/YG`=UQAE([8H#(=OUUXA^AHN0J%+\-L
M<45H=#"M/!'9A;FT0^UP-6IGL:HN4NO$SQ^5_#V\(_9(=\:CK"^O-Q*52\!=
MD2-!_$N+)9@Z.2J(?V@Q_V@)<R1(?FJS#$\\1X+8AQ;X8WCJWQ@ZO-#73.C[
M9(BI0WZQI>@RH-=>E<O@CSGAF%(@11*J76+@_'KL*`I>@9HZ]C9;C`RH5YR1
MYW:+:VKJ1A];XY\_4?N19J8#5(9N10=:,).IOFFZ:\ROH=:UBV&9:SQHGV\0
M&&:@BBQCO:D&QL_C`017U11=@-/WD<.JJ(?S^J&R,%)`Q2/#^_Y@BI_:MOG%
M$>'Z=?S]@,MHU?L@E-J['+6_>-\H1AFIY2];W&D6I@L_-2`^5_Y!9;71KN)Z
MO;88(U<`HZZ@T(5&[!F?=N)"U4!;8%'#K',O`PX5-N)B037/]_`A/.A`^@L'
M<QXT@:A[[4GD!7V!EZN%&748%S?$@38<]WP.1*L]=?)/2L1T<4<P>!"MWZ;$
MS05KWI672'-_20J6VF.G:^`YC"9J([86TPBS#8LTF7M=LE*18@%\-,#"PLQL
M--/31;!S/Z\J]J#8WJ$T0\R,#)92J-9YDD4"AG%!>SNC2MD461_KQ,D"@8NQ
M?H(*"-=8Y<ZR>2%$B_/2\OG>A"?METD8@WSUM=H1;H6@-GM$(P/@2Y;*2\U9
MK0KEW(="BYMP8['\^(OG<^]?2[ODVNBUCYB0:@ZMVUSMQ#DSO[3`)_=6S&^8
M3:6"EK036<O]VM[V^O?^9'AUWA.)3/3=EZU-(A\[>D^$E,%::2QV%`A3`M,V
MV7([2W!/%)Y>BSQSK[U&FT4FS-&&/51C+8Q7BRDU%W@>7S6O#%U-4$M]6&UQ
MPN8^Z"KZ42([)K?!=HL@9V<R&20M8S%("TPD7A@27=VW];<PP>R9+_2E?R-*
MY1UAX1!7`_ZU%R:0U6FP'6_X;.J$\;@<61];-Z'*;7TWU]![J)"X,0OHBP'%
M!95D\RN!:>%*Y,WDZX"_A4Y"'$MO+M2,I/I5.5@;9</QK-K6TFJ@/X&,([90
M-.1<%DN9!_P3R#FOJ,@,N!:,`OXVWAL"'C%36V\:,N?!%*5OVY_!N[2W$P:S
M&"NYEBO[$D,5.)3#?QB9>L1##"+_]*6(MR$\>,.D28$/AX)ZTU?;A%50"M;B
M:,@M[KOQ]C+C-7/!OIO,;9J!P#5Q6C?J1L*[V$NYYAN037W5LN6:,5&+()H+
MA@<H+&EAT+Z2%Q2P=TVVTE\HM!8Y&[`JPK:AXX6LZBT2,R6HLU2KE%+2G]NC
M$2_!'\SA%X>I7<9W/[Y60G^*ZSG?`%>8YX!;4_0I-68LH%\.]J(*J-9X_%7#
MW+T57]!IQN5VXC#<8HK3$?:8V*^Q'XG6;<^8"OJ\D_J7?-4")\5;$<4+@;RG
M_F9C@[D-TR$*=V,T16['M@S@F2'34C)4K@FFF"\%6>\D:I>#M3>T&7<7@D[$
M!6;4<W^Y$WP*W:N>P(O$Q#/PJ;B+1V'!P,M`9.B.X&!/%PN*X1[?M0H-TPO2
M;['O%FS#"0-K\47YO(]M&-_OJ>F?0.9UTG3>P)<-=P+/))"H-E:+5><=+N18
MT`Z58`^N-]XD(O_%(&V+E5>1[%_N!J9W_ZD@8`397CG#XR^'1#CH!P5W///8
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MJVW'$M-K8[UV@D<1PWCO]DA0&NPRO8\=J=<`KRVB^LG%R56"7;GR@%H7=?;G
M\$FKL/OR!_9_[Z!W";[VFL#/_P=02P$"'@,4````"`!'AP9':40_8,LZ`0!'
M\1$`$0`8```````!````I($`````9V%L92TR,#$U,#8S,"YX;6Q55`4``V;*
MPU5U>`L``00E#@``!#D!``!02P$"'@,4````"`!'AP9'?D:_)]47``"5YP``
M%0`8```````!````I($6.P$`9V%L92TR,#$U,#8S,%]C86PN>&UL550%``-F
MRL-5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`1X<&1UM9.YB%0@``*PP#
M`!4`&````````0```*2!.E,!`&=A;&4M,C`Q-3`V,S!?9&5F+GAM;%54!0`#
M9LK#575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`$>'!D<LIG01U:<``,?R
M"``5`!@```````$```"D@0Z6`0!G86QE+3(P,34P-C,P7VQA8BYX;6Q55`4`
M`V;*PU5U>`L``00E#@``!#D!``!02P$"'@,4````"`!'AP9'R*9E(0=H``"[
M"04`%0`8```````!````I($R/@(`9V%L92TR,#$U,#8S,%]P<F4N>&UL550%
M``-FRL-5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`1X<&1P-+\B!U$P``
MF,L``!$`&````````0```*2!B*8"`&=A;&4M,C`Q-3`V,S`N>'-D550%``-F
HRL-5=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``$BZ`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015922357984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company did not transfer any financial instruments into or out of Level 3 classification during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> or 2014. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770013424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Warrants Classified as Equity) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>May. 08, 2013</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsGrantedNumberofShares', window );">Warrants Granted, Number of Shares</a></td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofDaysAveragedforExercisePrice', window );">Number of Days Averaged for Exercise Price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">75.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueofWarrantsGrantedperShare', window );">Fair Value of Warrants Granted, per Share</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueofWarrantsGrantedperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants Granted, per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueofWarrantsGrantedperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofDaysAveragedforExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price is based on the average closing price over this many trading days up to the date of the grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofDaysAveragedforExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsGrantedNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsGrantedNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777583872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock', window );">Common Shares Excluded from Net Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Three and Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Earning Per Share To Common Shareholders Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfEarningPerShareToCommonShareholdersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777631776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Income (Expense)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766661664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Allocated Stock-based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 3,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015986210880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales to the following customers represented </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of net revenue during at least </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the periods are presented as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="40%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to concentrations in our customer base, concentrations also exist with respect to the dispensing pharmacies to which our customers sell Abstral. For example </font><font style="font-family:inherit;font-size:10pt;">47%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">57%</font><font style="font-family:inherit;font-size:10pt;"> of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> pharmacies for the three month periods ending June 30, 2015 and 2014, respectively. Additionally, </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">59%</font><font style="font-family:inherit;font-size:10pt;"> of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> pharmacies for the six months periods ending June 30, 2015 and 2014, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015759104528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents', window );">Highly-liquid debt instruments maturity days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventories, work-in-process</a></td>
<td class="nump">1,264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventories, finished goods</a></td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsServices', window );">Prompyt pay discount, percent of gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of certain acquired intangible assets</a></td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="nump">$ 588,000<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5074-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash discounts given by the entity for services rendered to customers for early payments of accounts due. For example, selling terms of "2/10, net 30" entitle a customer to a 2% discount for prompt payment within 10 days, otherwise full payment is expected in 30 days. Discounts are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=gale_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770291600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014 the Company entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (ondansetron) Oral Soluble Film (Zuplenz), an FDA approved product. The transaction was accounted for as a business combination under the acquisition method of accounting based on Accounting Standards Codification 805, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations.</font><font style="font-family:inherit;font-size:10pt;">" Accordingly, the assets acquired and liabilities assumed were recorded at fair value. As of the issuance date of the condensed consolidated financial statements for the quarter ended June 30, 2015, the Company finalized the valuation of the acquired assets and liabilities for the transaction. Specifically, more complete information for credit memos for expiring channel inventory and the anticipated gross-to-net deductions on the replacement inventory was provided in order to finalize the business combination accounting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price consideration and allocation of purchase price:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.39024390243902%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Acquisition Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase price consideration:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities assumed:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring channel inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset acquired:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above contingent consideration represents a risk adjusted net present value relating to cash payments on achievement of certain milestones.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4922-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4934-128472<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4926-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015771393424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,069<span></span>
</td>
<td class="nump">$ 6,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember', window );">Zuplenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Credit memos for expiring channel inventory</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">8,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights', window );">Zuplenz rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">$ 8,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember', window );">Zuplenz [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770147728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Schedule of Warrant Activity) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 18,  2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightExpired', window );">Class of Warrant or Right, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember', window );">Consultant Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassOfWarrantsOrRightsExpirationDate', window );">Expiration</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassOfWarrantsOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassOfWarrantsOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_ConsultantWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015756207024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 45,279<span></span>
</td>
<td class="nump">$ 23,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,122<span></span>
</td>
<td class="nump">29,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furnishings, net</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SalesAndDistributionsRights', window );">Abstral rights, net</a></td>
<td class="nump">13,946<span></span>
</td>
<td class="nump">14,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_SalesAndDistributionsRightsZuplenz', window );">Zuplenz rights</a></td>
<td class="nump">8,101<span></span>
</td>
<td class="nump">8,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_GALE401rights', window );">GALE-401 rights</a></td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,069<span></span>
</td>
<td class="nump">6,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">101,967<span></span>
</td>
<td class="nump">80,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,923<span></span>
</td>
<td class="nump">15,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsPotentiallySettleableInCash', window );">Fair value of warrants potentially settleable in cash</a></td>
<td class="nump">18,794<span></span>
</td>
<td class="nump">5,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">4,079<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,114<span></span>
</td>
<td class="nump">27,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Deferred tax liability</a></td>
<td class="nump">6,889<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">4,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 52,602<span></span>
</td>
<td class="nump">$ 43,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 275,000,000 shares authorized, 161,716,381 shares issued and 162,391,381 shares outstanding at June 30, 2015; 200,000,000 shares authorized, 130,146,341 shares issued and 129,471,341 shares outstanding at December 31, 2014</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">294,877<span></span>
</td>
<td class="nump">256,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DeficitAccumulatedDuringDevelopmentalStage', window );">Accumulated deficit</a></td>
<td class="nump">241,678<span></span>
</td>
<td class="nump">215,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury shares at cost, 675,000 shares</a></td>
<td class="num">(3,849)<span></span>
</td>
<td class="num">(3,849)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">49,365<span></span>
</td>
<td class="nump">37,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 101,967<span></span>
</td>
<td class="nump">$ 80,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DeficitAccumulatedDuringDevelopmentalStage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deficit accumulated during the developmental stage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DeficitAccumulatedDuringDevelopmentalStage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_GALE401rights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>GALE-401 rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_GALE401rights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SalesAndDistributionsRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales And Distributions Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SalesAndDistributionsRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_SalesAndDistributionsRightsZuplenz">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales And Distributions Rights, Zuplenz</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_SalesAndDistributionsRightsZuplenz</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777591264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">73.32%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
<td class="nump">78.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">5 years 9 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015756297568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,197)<span></span>
</td>
<td class="num">$ (22,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="num">(6,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(771)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">290<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(2,246)<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,415)<span></span>
</td>
<td class="num">(21,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of GALE-401 rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of equipment and furnishings</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(569)<span></span>
</td>
<td class="num">(2,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">47,416<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from exercise of stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NetProceedsFromExerciseOfCommonStockWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from common stock issued in connection with ESPP</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principle payments on long-term debt</a></td>
<td class="num">(1,914)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">45,613<span></span>
</td>
<td class="nump">14,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">21,629<span></span>
</td>
<td class="num">(8,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of period</a></td>
<td class="nump">23,650<span></span>
</td>
<td class="nump">47,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">45,279<span></span>
</td>
<td class="nump">39,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the periods for interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the periods for interest</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity', window );">Fair value of warrants issued in connection with common stock recorded as cost of equity</a></td>
<td class="nump">10,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liabilities upon exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,020)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember', window );">Zuplenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition of Zuplenz rights</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with common stock recorded as a cost of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NetProceedsFromExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NetProceedsFromExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gale_ZuplenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015771344512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">$ 5,779<span></span>
</td>
<td class="nump">$ 6,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_CreditMemosAcquisitionChannelInventoryCurrent', window );">Credit memos for expiring Zuplenz channel inventory</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatientAssistanceProgramCurrent', window );">Patient assistance programs and rebates</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AccruedInventoryPurchasesCurrent', window );">Inventory purchases</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FutureMilestonePayment', window );">Zuplenz milestone payments</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest expense</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,923<span></span>
</td>
<td class="nump">$ 15,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AccruedInventoryPurchasesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AccruedInventoryPurchasesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_CreditMemosAcquisitionChannelInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit Memos Acquisition Channel Inventory, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_CreditMemosAcquisitionChannelInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FutureMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FutureMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatientAssistanceProgramCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patient Assistance Program, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatientAssistanceProgramCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766832496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Purchase Price Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price consideration and allocation of purchase price:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.39024390243902%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="75%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Acquisition Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase price consideration:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities assumed:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring channel inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset acquired:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766715280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>May. 08, 2013</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentTermInterestOnly', window );">Term for interest only payments</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest payments at the fixed coupon rate</a></td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term for principal and interest payments</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFacilityFee', window );">Cash facility fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DebtInstrumentCashFinalPayment', window );">Cash final payment percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightTerm', window );">Warrant term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice', window );">Duration of average market price used for warrant exercise price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="nump">182,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember', window );">First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan, amount</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Average Market Price Used For Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentCashFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cash Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentCashFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DebtInstrumentTermInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Interest Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DebtInstrumentTermInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gale_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015938779280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring Zuplenz channel inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient assistance programs and rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory purchases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777618672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Business and Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Galena Biopharma, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Galena&#8221; or the &#8220;company&#8221;) is a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena&#8217;s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax&#8482; (nelipepimut-S) currently in an international, Phase 3 clinical trial. The company&#8217;s commercial drugs include Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (fentanyl) Sublingual Tablets and Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (ondansetron) Oral Soluble Film. Collectively, our clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to&#160;improve cancer care,&#160;from direct treatment of the disease to the reduction of its debilitating side-effects.&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Novel Cancer Immunotherapies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our targeted cancer immunotherapy approach is based upon preventing recurrence of cancer, which is becoming increasingly important as the number of cancer survivors continues to grow.  Once a patient&#8217;s tumor becomes metastatic, the outcome is most often fatal, making the prevention of recurrence a potentially critical component of overall patient care.  Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have undetected minimal residual disease.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our therapies utilize immunologically active peptides combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF), and work by harnessing the patient&#8217;s own immune system to target, seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system through an intradermal mode of delivery.  We are currently engaged in multiple clinical trials with NeuVax&#8482;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">(nelipepimut-S) and GALE-301, or Folate Binding Protein (FBP), targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeuVax&#8482; (nelipepimut-S)</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeuVax&#8482; (nelipepimut-S), our lead product candidate, is a targeted cancer immunotherapy and is being developed for the prevention of cancer recurrence in human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is the immunodominant nona-peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may be a predictive factor of Disease Free Survival (DFS) and Overall Survival (OS) - suggesting a dormancy of isolated micrometastases, which, over time, may lead to recurrence. After binding to the HLA A2, A3, A24 or A26 proteins on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte (CTLs). These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including undetected occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have multiple trials currently ongoing for NeuVax. For our global pivotal, fully enrolled, Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">arly-</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">reatment) trial, NeuVax is targeting the 30,000-40,000 of the 230,000 female breast cancer patients annually diagnosed in the U.S. who are at a higher risk of their breast cancer recurring, which we refer to as &#8220;disease recurrence,&#8221; after achieving &#8220;no evidence of disease&#8221; (NED) status, (or becoming a &#8220;survivor&#8221;) with standard-of-care therapy (surgery, chemotherapy, radiation). These high-risk patients have a particular molecular signature and disease status: HER2 IHC 1+/2+ (oncoprotein associated with aggressive tumor growth), node positive (disease present in the axillary lymph nodes prior to surgery), and HLA A2/A3 (human leukocyte antigen from A2/A3 patients who have the same loci of genes which represents approximately 65% of population). NeuVax has also been shown to bind to A24 and A26 which represents an additional 10-15% of the population in the U.S., but importantly, represents up to 70% of the population in Japan. Up to 25% of resectable, node-positive breast cancer patients, having no radiographic evidence of disease following surgery and adjuvant chemo/radiation therapy, are expected to relapse within three years following diagnosis. The prognosis upon recurrence is very poor.  These cancer patients presumably still had isolated, undetected tumor CTCs that led to a recurrence of cancer in the breast (local recurrence) or in another location (metastatic disease).</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographic footprint of NeuVax:</font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 3 Ongoing: Our Phase 3 PRESENT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">P</font><font style="font-family:inherit;font-size:10pt;">revention of </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">R</font><font style="font-family:inherit;font-size:10pt;">ecurrence in</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> E</font><font style="font-family:inherit;font-size:10pt;">arly- </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S</font><font style="font-family:inherit;font-size:10pt;">tage, Node-Positive Breast Cancer with Low to Intermediate HER2 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">xpression with </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuVax T</font><font style="font-family:inherit;font-size:10pt;">reatment) study has completed enrollment of 758 patients with HER2 1+ and 2+ under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA). The multinational, multicenter, randomized, double-blinded PRESENT trial is fully enrolled with trial sites in North America, Western and Eastern Europe, and Israel. Additional information on the study can be found at </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">www.neuvax.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative HLA A2/A3/A24/A26 breast cancer patients to study NeuVax in combination with trastuzumab (Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; Genentech/Roche) in the adjuvant setting. This trial is partially funded by Genentech/Roche.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:65px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Ongoing: An investigator-sponsored trial is ongoing to study NeuVax in combination with Herceptin. The study will enroll 100 patients who are neoadjuvantly treated node positive and negative HER2 IHC 3+ patients, not achieving a pathological complete response (pCR) or adjuvantly treated node positive HER2 IHC 3+ patients. Partial funding for this trial comes from the Department of Defense (DoD) through the Congressionally Directed Medical Research Program (CDMRP) which is funded through specific requests from individual members of Congress that are part of the Defense Appropriations Act. Funds are "set aside" (obligated) in entirety at the time of assistance agreement award. The grant was awarded under a Breast Cancer Research Program (BCRP) Breakthrough Award given to the lead investigator for the trial.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 2 Planned: In January 2014, we partnered with Dr.&#160;Reddy&#8217;s Laboratories, Ltd. in India for the commercialization of NeuVax in that region. Dr.&#160;Reddy&#8217;s is responsible for managing a Phase 2 gastric cancer trial of NeuVax in India in patients that express any level of HER2 (1+, 2+, and 3+). The trial  is expected to initiate in 2016. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-301 (folate binding protein or FBP)</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second immunotherapy product candidate, GALE-301, targets folate binding protein receptor-alpha, a well-validated therapeutic target, which</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">is highly over-expressed (20-80 fold) in ovarian, endometrial and breast cancers. GALE-301 is an immunogenic peptide and can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. GALE-301 consists of an FBP peptide combined with GM-CSF, and is currently in a Phase 2a clinical trial for the prevention of recurrence in patients with ovarian and endometrial cancers. Current treatments for these diseases are principally with chemotherapeutic agents and patients suffer a high recurrence rate; and, most patients relapse with an extremely poor prognosis. Although not powered for efficacy, promising preliminary results from the Phase 2a clinical trial of GALE-301 were presented in May 2015 at the American Society of Clinical Oncology conference and demonstrated the estimate for disease free survival at two years is 85.7% (1000 mcg dose group) vs. 19.2% for the control group (p = 0.09), for a 78% reduction in relative risk of recurrence, and that the agent was well-tolerated with primarily Grade 1 and 2 toxicities and elicited a strong </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;"> immune response. We expect to present a more mature data set from the Phase 2a trial this Fall at the European Society for Medical Oncology European Cancer Congress 2015.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Hematology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GALE-401 (anagrelide controlled release (CR))</font></div><div style="line-height:120%;text-align:left;padding-left:32px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we announced the acquisition of the worldwide rights to anagrelide controlled release (CR), which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC. GALE-401 contains the active ingredient anagrelide (Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Shire Pharmaceuticals), an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. Therefore, reducing the maximum concentration (C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;">) is hypothesized to reduce the side effects, but preserve efficacy. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple Phase 1 studies in 98 healthy subjects have shown GALE-401 reduces the C</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">max</sub></font><font style="font-family:inherit;font-size:10pt;"> of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the desired PK (pharmacokinetic) profile to enable the initiation of the ongoing Phase 2 proof-of-concept trial.  The Phase 2, open label, single arm trial enrolled 18 patients in the United States for the treatment of thrombocytosis, or elevated platelet counts in patients with MPNs. Phase 2 top-line safety and efficacy data was presented in June 2015 at the European Hematology Association 20th Congress. We expect to present a more mature data set from the Phase 2 trial later this year. Based on a regulatory meeting with the FDA, Galena believes a 505(b)(2) regulatory filing is an acceptable pathway for development and potential approval of GALE-401, with the reference drug Agrylin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">(anagrelide; Shire Pharmaceuticals).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Commercial Capabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Abstral</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> (fentanyl) Sublingual Tablets</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first commercial product, Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (fentanyl) Sublingual Tablets, is an important treatment option for inadequately controlled breakthrough cancer pain (BTcP), which affects more than 50% of all cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) tablet for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a convenient sublingual tablet that is designed to dissolve under the tongue in seconds and provide relief of breakthrough pain in minutes. Abstral is a transmucosal immediate release fentanyl (TIRF) product with product class oversight by the TIRF Risk Evaluation and Mitigation Strategy (REMS) access program. Abstral is manufactured for us by contract manufacturers and we distribute and sell Abstral in the U.S. through our commercial organization. </font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Zuplenz</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> (ondansetron) Oral Soluble Film</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014 we licensed our second commercial product, Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (ondansetron) Oral Soluble Film, from MonoSol Rx, LLC, which we launched on July 29, 2015. Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved in pediatric patients treated with moderately emetogenic CINV. Nausea and vomiting are two of the most common side-effects experienced by post-surgery patients and patients receiving chemotherapy or radiation. It is estimated that up to </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;"> of chemotherapy and up to 80% of radiotherapy patients will experience CINV and RINV, respectively.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The active pharmaceutical ingredient in Zuplenz, ondansetron, belongs to a class of medications called serotonin 5-HT</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">3</sub></font><font style="font-family:inherit;font-size:10pt;"> receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Ondansetron is the most widely prescribed drug in this class of anti-emetics, and used broadly across the oncology spectrum. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tables (ODT) with a safety profile equivalent to ondansetron.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz utilizes MonoSol&#8217;s proprietary PharmFilm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> technology, an oral soluble film that dissolves on the tongue in less than 30 seconds. Zuplenz eliminates the burden of swallowing pills during periods of emesis, may be advantageous for patients with oral irritation, and may increase patient adherence and the patient's ability to keep the medication down without vomiting. MonoSol will exclusively manufacture Zuplenz for us for sale in the U.S. through our commercial organization.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Unless the context otherwise indicates, references in these notes to the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Galena, our wholly owned subsidiary, Apthera, Inc., or &#8220;Apthera,&#8221; and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills."</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:inherit;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable -</font><font style="font-family:inherit;font-size:10pt;"> The company maintains credit limits for all customers based upon several factors, including but not limited to financial condition and stability, payment history, published credit reports and use of credit references. Management performs analysis to evaluate accounts receivables to ensure recorded amounts reflect estimated net realizable value. An allowance for doubtful accounts is established based on the Company's best estimate of the amount of probable credit losses in the Company's accounts receivable. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2014 the allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Inventories are stated at the lower of cost or market value and are determined using the first-in, first-out ("FIFO") method. Inventories consist of work-in-process and finished goods of our commercial products. The company has entered into manufacturing and supply agreements for the manufacture and final packaging of Abstral and Zuplenz finished goods. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company had inventories of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,426,000</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,264,000</font><font style="font-family:inherit;font-size:10pt;"> of work-in-process and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$162,000</font><font style="font-family:inherit;font-size:10pt;"> of finished goods. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the company had inventories of </font><font style="font-family:inherit;font-size:10pt;">$655,000</font><font style="font-family:inherit;font-size:10pt;"> consisting of </font><font style="font-family:inherit;font-size:10pt;">$455,000</font><font style="font-family:inherit;font-size:10pt;"> of work-in-process and </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> of finished goods.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years) of the related assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> - The company recognizes revenue from the sale of Abstral. No revenue has been recorded from the sale of Zuplenz as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell Abstral product in the United States to wholesale pharmaceutical distributors and retail pharmacies, or our "customers," subject to rights of return. We recognize Abstral product sales at the time title transfers to our customer, and provide allowances for estimated future product returns, prompt pay discounts, wholesaler discounts, rebates, chargebacks, patient assistance program benefits and other deductions as needed. The company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the company will be required to make adjustments to these allowances in the future.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Returns - The company estimates future returns based on historical return information, as well as information regarding prescription information and sell-through trends, in relation to the estimated amount of product in the sales channels and product expiration dates. The allowance for returns is recorded as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prompt Pay Discounts - As an incentive for prompt payment, the company offers a cash discount to customers, which is generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2%</font><font style="font-family:inherit;font-size:10pt;"> of gross sales. The company expects that all customers will comply with the contractual terms to earn the discount. The company records prompt pay discounts as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wholesaler Discounts - The company offers discounts on sales to wholesalers and distributors based on contractually determined rates. The company accrues the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates - The company participates in certain rebate programs, which provide discounted prescriptions to members of certain managed care organizations, group purchasing organizations and specialty pharmacies. Under these rebate programs, the company pays the rebates generally two to three months after the end of the quarter in which prescriptions subject to the rebate are filled. The company estimates and accrues these rebates based on current contract prices, historical and estimated future percentages of product sold to qualifying member pharmacies and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction to revenue in the period that the related revenue is recognized, with a corresponding liability in accrued expenses and other current liabilities.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks - The company provides discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid or Medicare contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the company the difference between the current retail price and the price the entity paid for the product. The company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historic chargeback activity. Chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient Assistance Programs - The company offers discount card programs to eligible patients for Abstral in which those patients receive discounts on their Abstral prescriptions that are reimbursed by the company. The company estimates the total amount that will be recognized based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognizes the discount as a reduction of revenue and as an other current liability (see Note 4) in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions and In-Licensing &#8212;</font><font style="font-family:inherit;font-size:10pt;"> For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:inherit;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:inherit;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:inherit;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was no income tax expense or benefit for the three and six months periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015759142560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">121,457,118<span></span>
</td>
<td class="nump">110,100,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">121,457,118<span></span>
</td>
<td class="nump">109,425,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777610720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:inherit;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the potentially dilutive common shares excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Three and Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,719</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015758962784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Galena Biopharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GALE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,862,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777599920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of its business, the company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These arrangements sometimes permit the company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the company is unlikely to cease development if the compound successfully achieves clinical testing objectives.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the acquisition of NeuVax</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, the company acquired rights and assumed obligations under a license agreement among Apthera and The University of Texas M. D. Anderson Cancer Center (&#8220;MDACC&#8221;) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (&#8220;HJF&#8221;) which grants exclusive worldwide rights to a U.S. patent covering the nelipepimut-S peptide and several U.S. and foreign patents and patent applications covering methods of using the peptide as a vaccine. Under the terms of this license, we are required to pay an annual maintenance fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$200,000</font><font style="font-family:inherit;font-size:10pt;">, a milestone payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> upon commencing the Phase 3 PRESENT trial of NeuVax and other clinical milestone payments, as well as royalty payments based on sales of NeuVax or other therapeutic products developed from the licensed technologies. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective December&#160;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#8220;ABIC&#8221;), under which we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for intradermal injection for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#8217;s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved. Under the license and supply agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase from us all supplies of NeuVax at a price determined according to a specified formula.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March&#160;18, 2013, we acquired Abstral</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (fentanyl) Sublingual Tablets, a transmucosal immediate-release fentanyl (TIRF) product, for sale and distribution in the United States from Orexo AB (ORX.ST), an emerging specialty pharmaceutical company based in Sweden, and exclusively licensed certain intellectual property from Orexo to use, distribute, market, sell, offer for sale Abstral solely in the United States and to non-exclusively manufacture Abstral for use, distribute, market, sell, offer for sale and import Abstral solely in the United States. Abstral has been approved by the U.S. Food and Drug Administration (FDA).</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our agreement with Orexo, we assumed responsibility for the U.S. commercialization of Abstral and for all regulatory and reporting matters in the U.S. We also agreed to establish and maintain through 2015 (marketing period) a specified minimum commercial field force to market, sell and distribute Abstral and to use commercially reasonable efforts to reach the specified sales milestones. Orexo is entitled to reacquire the U.S. rights to Abstral from us for no consideration if we breach our obligations to establish and maintain the requisite sales force throughout the marketing period. We expect to maintain our sales efforts beyond this date. We officially launched U.S. commercial sales of Abstral in October 2013.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In exchange for the U.S. rights to Abstral, (1)&#160;we paid Orexo </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> upfront, and a&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment in cash in October 2013 upon the approval by the FDA of a specified U.S. manufacturer of Abstral; and (2)&#160;we agreed to pay to Orexo: (a)&#160;three one-time future cash milestone payments based on our net sales of Abstral; and (b)&#160;a low double-digit royalty on future net sales. No further milestone or royalty payments will be due after the date on which all claims of the last remaining licensed patents expire (currently </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">) or become invalidated by a patent office, court, or other governmental agency of competent jurisdiction in a final and non-appealable judgment. In exchange of license, Galena agreed to pay eight-eight percent of the expenses and costs incurred to prosecute any ANDA action..</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance.</font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014, we entered into a definitive license and supply agreement with MonoSol for the U.S. commercial rights to Zuplenz</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (ondansetron) Oral Soluble Film, an FDA-approved product for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). In exchange for the U.S. rights to Zuplenz, and in connection with the effectiveness of the license and transfer to us of the New Drug Application (NDA) for Zuplenz, we paid MonoSol a total of </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and shares of our common stock in 2014 and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash in 2015. In addition to these payments, we will pay MonoSol </font><font style="font-family:inherit;font-size:10pt;">$0.25 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days after MonoSol&#8217;s payment of applicable fees relating to the notice of allowance by the United States Patent and Trademark Office of a U.S. patent with composition claims covering Zuplenz that extend beyond 2028, (ii) future cash milestone payments of up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;"> based on our achievement of specified &#8220;net sales&#8221; of Zuplenz in amounts ranging from </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">, and (iii) a low double-digit royalty on future &#8220;net sales.&#8221;</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the license agreement, we assumed responsibility for the commercialization of Zuplenz and for all regulatory and reporting matters in the U.S. We also agreed in the license and supply agreement to use our best commercial efforts to begin commercializing Zuplenz in the U.S. in accordance with a joint commercialization plan to be established by the company and MonoSol. We also agreed that, until net sales of Zuplenz exceed a specified minimum amount or a competing product has been approved by the FDA and is placed into the market for sale, we will maintain a specified minimum number of field sales force personnel on specified terms.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the license and supply agreement, MonoSol has the exclusive right to supply all of our requirements for Zuplenz, subject to certain conditions.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766495728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net revenue</a></td>
<td class="nump">$ 3,382<span></span>
</td>
<td class="nump">$ 2,331<span></span>
</td>
<td class="nump">$ 6,132<span></span>
</td>
<td class="nump">$ 4,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue (excluding amortization of certain acquired intangible assets)</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,290<span></span>
</td>
<td class="nump">8,069<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">14,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">6,451<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
<td class="nump">16,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of certain acquired intangible assets</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">14,651<span></span>
</td>
<td class="nump">18,114<span></span>
</td>
<td class="nump">28,527<span></span>
</td>
<td class="nump">32,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(15,783)<span></span>
</td>
<td class="num">(22,395)<span></span>
</td>
<td class="num">(27,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_LossOnWarrantExchange', window );">Change in fair value of warrants potentially settleable in cash</a></td>
<td class="num">(4,267)<span></span>
</td>
<td class="num">(3,353)<span></span>
</td>
<td class="num">(3,115)<span></span>
</td>
<td class="nump">6,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(491)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating income (expense), net</a></td>
<td class="num">(4,391)<span></span>
</td>
<td class="num">(4,158)<span></span>
</td>
<td class="num">(3,802)<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,660)<span></span>
</td>
<td class="num">$ (19,941)<span></span>
</td>
<td class="num">$ (26,197)<span></span>
</td>
<td class="num">$ (22,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (usd per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding: basic and diluted</a></td>
<td class="nump">161,383,398<span></span>
</td>
<td class="nump">118,083,988<span></span>
</td>
<td class="nump">148,647,581<span></span>
</td>
<td class="nump">117,154,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_LossOnWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on warrant exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_LossOnWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015779970848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings, Commitments and Contingencies (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings, Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings, Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Proceedings </font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Galena Biopharma, Inc. Stockholder Derivative Litigation and In Re Galena Biopharma, Inc. Derivative Litigation</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 23, 2015, U.S. District Court for the District of Oregon heard argument on the defendants&#8217; motion to stay and motion to dismiss.  On February 4, 2015, the District Court granted in part the motion to stay by staying any discovery until the ruling on the motion to dismiss.  On August 5, 2015, the District Court issued its decision by denying in part and granting in part defendants&#8217; motion to dismiss and granting plaintiffs leave to file an amended complaint. The court had stayed the derivative proceeding pending the outcome of the motion to dismiss in the securities class action case. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 4, 2105, plaintiffs in the voluntarily dismissed Delaware derivative action have filed a motion seeking to file under seal a derivative complaint in the District Court. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend against and seek resolution to the foregoing claims.  As of June 30, 2015, we have not recorded any</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">liabilities with respect to the claims in our consolidated financial statements.  We believe that claims are covered under our liability insurance, and we have notified our insurance carriers of the claims.  The insurers have responded by requesting additional information and by reserving their rights under the policies, including the rights to deny coverage under various policy exclusions.  Subject to their reservation of rights, we are being reimbursed by our insurer for substantially all legal fees relating to our defense of the claims. We have entered into certain undertaking agreements with our directors related to the litigation by which we have agreed to advance reasonable legal fees and costs for the litigation under certain conditions.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are aware that the Securities and Exchange Commission (SEC) is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies.  We have been in contact with the SEC staff through our counsel and are cooperating with the investigation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ANDA Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By letter dated December 23, 2014, Orexo and we received a Paragraph IV certification notice (Notice Letter) regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by Actavis Laboratories FL, Inc. (Actavis) requesting approval </font><font style="font-family:inherit;font-size:10pt;color:#404040;">to engage in the </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">an</font><font style="font-family:inherit;font-size:10pt;color:#282828;">ufacture</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">use </font><font style="font-family:inherit;font-size:10pt;color:#565656;">or sale </font><font style="font-family:inherit;font-size:10pt;color:#404040;">of generic versions of the Abstral sublingual </font><font style="font-family:inherit;font-size:10pt;color:#282828;">t</font><font style="font-family:inherit;font-size:10pt;color:#565656;">a</font><font style="font-family:inherit;font-size:10pt;color:#282828;">blets</font><font style="font-family:inherit;font-size:10pt;color:#565656;"> </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.1 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.2 </font><font style="font-family:inherit;font-size:10pt;color:#282828;">m</font><font style="font-family:inherit;font-size:10pt;color:#565656;">g </font><font style="font-family:inherit;font-size:10pt;color:#404040;">base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">E</font><font style="font-family:inherit;font-size:10pt;color:#282828;">q </font><font style="font-family:inherit;font-size:10pt;color:#404040;">0.3 mg base, </font><font style="font-family:inherit;font-size:10pt;color:#565656;">Eq 0.4 </font><font style="font-family:inherit;font-size:10pt;color:#404040;">mg base</font><font style="font-family:inherit;font-size:10pt;color:#6c6c6c;">, </font><font style="font-family:inherit;font-size:10pt;color:#404040;">Eq 0.6 mg base and Eq 0.8 mg base. In the Notice Letter, Actavis </font><font style="font-family:inherit;font-size:10pt;">contends that the patents held by Orexo for Abstral that are listed in the Orange Book (U.S. Patents 6,759,059, 6,761,910 and 7,910,132, which cover compositions, formulations and methods of using Abstral and which expire in September 2019) and which are licensed to us under the Orexo License Agreement, are invalid, unenforceable and/or will not be infringed by the manufacture, use, or sale of the product set forth in the ANDA. On February 4, 2015, Orexo filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories Fl, Inc., Andrx Corporation, Actavis, Inc., and Actavis Pharma, Inc.  All of the defendants except Actavis Laboratories FL, Inc. were subsequently dismissed. Actavis has filed an answer and counterclaim. The lawsuit claims infringement of the three patents.  Orexo filed the lawsuit within 45 days from the receipt of the Notice Letter and under the Hatch-Waxman Act, the final FDA approval of Actavis&#8217; ANDA will be stayed up to 30 months from the date of receipt of the Notice Letter.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A scheduling conference was held on July 9, 2015, in the District Court and on July 10, 2015, the District Court issued a pre-trial scheduling order. The parties are now engaged in written discovery.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated under Orexo License Agreement to pay for </font><font style="font-family:inherit;font-size:10pt;">88%</font><font style="font-family:inherit;font-size:10pt;"> of the legal costs of the patent infringement lawsuit.  We intend to work with Orexo to continue to vigorously enforce intellectual property rights related to the Abstral product.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments based on the progress of the asset through development stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency. In certain agreements, the company is required to make royalty payments based upon a percentage of the sales.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations. In addition, these arrangements often give the company the discretion to unilaterally terminate development of the product, which the company might do for clinical, business or other reasons, which would allow the company to avoid making the contingent payments. </font></div><div style="line-height:120%;text-align:left;padding-left:40px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company applies the disclosure provisions FASB ASC Topic 460 (&#8220;ASC 460&#8221;), &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guarantor&#8217;s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others</font><font style="font-family:inherit;font-size:10pt;"> &#8221;, to its agreements that contain guarantee or indemnification clauses. The company provides (i)&#160;indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims and (ii)&#160;indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us. These indemnifications give rise only to the disclosure provisions of ASC&#160;460. To date, the company has not incurred costs as a result of these obligations and does not expect to incur material costs in the future. Accordingly, the company has not accrued any liabilities in its financial statements related to these indemnifications.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015936667072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 8, 2013 we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> (the "Loan"). The Loan payment terms include </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12</font><font style="font-family:inherit;font-size:10pt;"> months of interest-only payments at the fixed coupon rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8.45%</font><font style="font-family:inherit;font-size:10pt;">, followed by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> cash facility fee and a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5.5%</font><font style="font-family:inherit;font-size:10pt;"> cash final payment and granted to the lenders </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">seven</font><font style="font-family:inherit;font-size:10pt;">-year warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">182,186</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.47</font><font style="font-family:inherit;font-size:10pt;">, which equaled a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">-day average market price of our common stock prior to the date of the grant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015756174816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,913</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;In&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants potentially settleable in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities measured and recorded at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending Level 3 liabilities for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Measurements</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Using&#160;Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in the estimated fair value of the contingent purchase price consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015922707840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Significant Customer and Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Customers and Concentration of Credit Risk</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company is engaged in the business of developing and commercializing pharmaceutical products. As of June 30, 2015, the Company had sales from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> active commercial product, Abstral, available in </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> dosing strengths, and all sales reported are in the United States.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales to the following customers represented </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of net revenue during at least </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> of the periods are presented as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="40%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following customers represented 10% or more of total accounts receivable as of at least one of the balance sheet dates presented:</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Customer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer E</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to concentrations in our customer base, concentrations also exist with respect to the dispensing pharmacies to which our customers sell Abstral. For example </font><font style="font-family:inherit;font-size:10pt;">47%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">57%</font><font style="font-family:inherit;font-size:10pt;"> of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> pharmacies for the three month periods ending June 30, 2015 and 2014, respectively. Additionally, </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">59%</font><font style="font-family:inherit;font-size:10pt;"> of our prescriptions, at wholesaler acquisition cost, were dispensed by our top </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> pharmacies for the six months periods ending June 30, 2015 and 2014, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015756591360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options to Purchase Shares of Common Stock</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company follows the provisions ASC&#160;718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For stock options and warrants granted in consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;"> per share and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.14</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company&#8217;s expected common stock price volatility assumption is based upon the company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC&#160;718-10, which averages the contractual term of the company&#8217;s options of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten years</font><font style="font-family:inherit;font-size:10pt;"> with the average vesting term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four years</font><font style="font-family:inherit;font-size:10pt;"> for an average of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six years</font><font style="font-family:inherit;font-size:10pt;">. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The company has estimated an annualized forfeiture rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15%</font><font style="font-family:inherit;font-size:10pt;"> for options granted to its employees, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">8%</font><font style="font-family:inherit;font-size:10pt;"> for options granted to senior management and zero for non-employee directors. The company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5,582,000</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the company&#8217;s operating expenses over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.54</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">26,500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were reserved for issuance under the company&#8217;s 2007 Incentive Plan, including </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">11,411,000</font><font style="font-family:inherit;font-size:10pt;"> shares subject to outstanding common stock options granted under the plan and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10,066,000</font><font style="font-family:inherit;font-size:10pt;"> shares available for future grants. The administrator of the plan determines the times when an option may become exercisable. Vesting periods of options granted to date have not exceeded </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four years</font><font style="font-family:inherit;font-size:10pt;">. The options will expire, unless previously exercised, no later than </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten years</font><font style="font-family:inherit;font-size:10pt;"> from the grant date. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic values of outstanding and exercisable options at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> were calculated based on the closing price of the company&#8217;s common stock as reported on The NASDAQ Capital Market on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.70</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the company&#8217;s common stock and the exercise price of the underlying options.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777564336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company has authorized up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of preferred stock, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">&#160;par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the company&#8217;s Board of Directors upon its issuance. To date, the company has not issued any preferred shares.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company has authorized up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">275,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">&#160;par value per share, for issuance.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">November 2014 Purchase Agreement with Lincoln Park Capital, LLC - </font><font style="font-family:inherit;font-size:10pt;">On November 18, 2014, the company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the company has the right to sell to LPC up to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of the company's common stock, subject to certain limitations and conditions over the </font><font style="font-family:inherit;font-size:10pt;">36</font><font style="font-family:inherit;font-size:10pt;"> month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased </font><font style="font-family:inherit;font-size:10pt;">2.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the company's common stock at </font><font style="font-family:inherit;font-size:10pt;">$2.00</font><font style="font-family:inherit;font-size:10pt;"> per share and the company issued </font><font style="font-family:inherit;font-size:10pt;">631,221</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the company received initial net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting commissions and other offering expenses. In addition to LPC&#8217;s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> from LPC&#8217;s subsequent purchases of a total of </font><font style="font-family:inherit;font-size:10pt;">2.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, excluding the commitment fee shares. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">At Market Issuance Sales Agreements </font><font style="font-family:inherit;font-size:10pt;">- On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with MLV &amp; Co. LLC and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds from the sale of shares, up to a total limit of </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> in gross proceeds. The ATM is available to the company until it is terminated by the Agents or the company. During the first quarter of 2015, we received </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the sale of </font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the three months ended June 30, 2015 or during the three and six months ended June 30, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">March 2015 Underwritten Public Offering</font><font style="font-family:inherit;font-size:10pt;"> - On March 18, 2015 the company closed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">24,358,974</font><font style="font-family:inherit;font-size:10pt;"> units at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$1.56</font><font style="font-family:inherit;font-size:10pt;"> per unit for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$38 million</font><font style="font-family:inherit;font-size:10pt;"> (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.50</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.08</font><font style="font-family:inherit;font-size:10pt;"> per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,826,923</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase </font><font style="font-family:inherit;font-size:10pt;">3,653,846</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for additional net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">. The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were </font><font style="font-family:inherit;font-size:10pt;">$40.8 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions and offering expenses payable by the company. </font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of common stock for future issuance are reserved for as follows (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="84%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options reserved for future issuance under the Company&#8217;s 2007 Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares reserved for future issuance under the Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total reserved for future issuance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph d<br><br><br><br> -Article 4<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Article 4<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015937261776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants classified as liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in March 2015, September 2013, December 2012,&#160;April 2011,&#160;March 2011,&#160;and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected volatility assumptions are based on the company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants classified as equity</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">182,186</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.47</font><font style="font-family:inherit;font-size:10pt;">, which equaled to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20</font><font style="font-family:inherit;font-size:10pt;">-day average market price of our common stock prior to the date of the grant. The warrants were valued using an appropriate pricing model as described in Note 9, below. The fair value assumptions for the grant included a volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">75.34%</font><font style="font-family:inherit;font-size:10pt;">, expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">seven</font><font style="font-family:inherit;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.20%</font><font style="font-family:inherit;font-size:10pt;">, and a dividend rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.00%</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the warrants granted was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.93</font><font style="font-family:inherit;font-size:10pt;"> per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Freestanding Contract<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513800<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 480<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 63<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6924035&amp;loc=d3e23176-110880<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90198-114008<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766531104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income (Expense)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) is summarized as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of the contingent purchase price liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (expense)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3,6,7,9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 3, 6, 7, 9<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770269232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">$ (490)<span></span>
</td>
<td class="num">$ (238)<span></span>
</td>
<td class="num">$ (656)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Beginning Balance Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in the estimated fair value of the contingent purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Ending Balance Liabilities</a></td>
<td class="nump">$ 6,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770164656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Customers and Concentration of Credit Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>products </div>
<div>dosing_strength </div>
<div>pharmacy</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>pharmacy</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>products </div>
<div>dosing_strength </div>
<div>pharmacy</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>pharmacy</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofCommericalProducts', window );">Number of Commerical Products | products</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofDosingStrengths', window );">Number of Dosing Strengths</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofTopPerformingPharmacies', window );">Number of Top Performing Pharmacies | pharmacy</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Product Line [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Product Line [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Product Line [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Product Line [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Product Line [Member] | Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofCommericalProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Commerical Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofCommericalProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofDosingStrengths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Dosing Strengths</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofDosingStrengths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofTopPerformingPharmacies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Top Performing Pharmacies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofTopPerformingPharmacies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=gale_CustomerFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=gale_CustomerFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015758980400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of Estimates in Preparation of Financial Statements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</font><font style="font-family:inherit;font-size:10pt;"> &#8212;&#160;The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company considers all highly liquid debt instruments with an original maturity of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#160;or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Restricted cash consists of certificates of deposit on hand with the company&#8217;s financial institutions as collateral for its corporate credit cards</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable -</font><font style="font-family:inherit;font-size:10pt;"> The company maintains credit limits for all customers based upon several factors, including but not limited to financial condition and stability, payment history, published credit reports and use of credit references. Management performs analysis to evaluate accounts receivables to ensure recorded amounts reflect estimated net realizable value. An allowance for doubtful accounts is established based on the Company's best estimate of the amount of probable credit losses in the Company's accounts receivable. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2014 the allowance for doubtful accounts was </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Inventories are stated at the lower of cost or market value and are determined using the first-in, first-out ("FIFO") method. Inventories consist of work-in-process and finished goods of our commercial products. The company has entered into manufacturing and supply agreements for the manufacture and final packaging of Abstral and Zuplenz finished goods. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company had inventories of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,426,000</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,264,000</font><font style="font-family:inherit;font-size:10pt;"> of work-in-process and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$162,000</font><font style="font-family:inherit;font-size:10pt;"> of finished goods. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment and Furnishings</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equipment and Furnishings</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years) of the related assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the company considers important that could trigger an interim review for impairment include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant changes in the manner of its use of acquired assets or the strategy for its overall business;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant negative industry or economic trends;</font></div><div style="line-height:120%;padding-left:67px;padding-bottom:8px;text-align:left;"><font style="padding-bottom:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in stock price for a sustained period; and</font></div><div style="line-height:120%;padding-left:67px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:28px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Significant decline in market capitalization relative to net book value.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The company&#8217;s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company performed its review for impairment using the qualitative assessment for both goodwill and indefinite-lived intangible assets, as well as assets not considered to be indefinite-lived, and has determined that there has been no impairment to these assets as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> - The company recognizes revenue from the sale of Abstral. No revenue has been recorded from the sale of Zuplenz as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell Abstral product in the United States to wholesale pharmaceutical distributors and retail pharmacies, or our "customers," subject to rights of return. We recognize Abstral product sales at the time title transfers to our customer, and provide allowances for estimated future product returns, prompt pay discounts, wholesaler discounts, rebates, chargebacks, patient assistance program benefits and other deductions as needed. The company is required to make significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the company will be required to make adjustments to these allowances in the future.</font></div><div style="line-height:120%;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Returns - The company estimates future returns based on historical return information, as well as information regarding prescription information and sell-through trends, in relation to the estimated amount of product in the sales channels and product expiration dates. The allowance for returns is recorded as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:66px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prompt Pay Discounts - As an incentive for prompt payment, the company offers a cash discount to customers, which is generally </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2%</font><font style="font-family:inherit;font-size:10pt;"> of gross sales. The company expects that all customers will comply with the contractual terms to earn the discount. The company records prompt pay discounts as a reduction to revenue in the period in which the revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wholesaler Discounts - The company offers discounts on sales to wholesalers and distributors based on contractually determined rates. The company accrues the discount as a reduction of receivables due from the wholesalers upon shipment to the respective wholesale distributors and retail pharmacies and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebates - The company participates in certain rebate programs, which provide discounted prescriptions to members of certain managed care organizations, group purchasing organizations and specialty pharmacies. Under these rebate programs, the company pays the rebates generally two to three months after the end of the quarter in which prescriptions subject to the rebate are filled. The company estimates and accrues these rebates based on current contract prices, historical and estimated future percentages of product sold to qualifying member pharmacies and estimated levels of inventory in the distribution channel. Rebates are recognized as a reduction to revenue in the period that the related revenue is recognized, with a corresponding liability in accrued expenses and other current liabilities.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks - The company provides discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid or Medicare contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the company the difference between the current retail price and the price the entity paid for the product. The company estimates and accrues chargebacks based on estimated wholesaler inventory levels, current contract prices and historic chargeback activity. Chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized, with a corresponding allowance against accounts receivable.</font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:65px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient Assistance Programs - The company offers discount card programs to eligible patients for Abstral in which those patients receive discounts on their Abstral prescriptions that are reimbursed by the company. The company estimates the total amount that will be recognized based on a percentage of actual redemption applied to inventory in the distribution and retail channel and recognizes the discount as a reduction of revenue and as an other current liability (see Note 4) in the same period the related revenue is recognized.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and In-Licensing</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we determined there were no variable interest entities required to be consolidated.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Purchase Price Consideration</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock', window );">Patents and Patent Application Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Patents and Patent Application Costs</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Although the company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company follows the provisions of the FASB ASC Topic 718, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#160;&#8212; Stock Compensation&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 718&#8221;), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC&#160;718 is recognized as an expense over the requisite service period.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For stock options and warrants granted as consideration for services rendered by non-employees, the company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (&#8220;ASC 505-50&#8221;), &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Based Payments to Non- Employees</font><font style="font-family:inherit;font-size:10pt;">.&#8221; Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the company&#8217;s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> &#8212; The company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC&#160;740-10, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes&#8221; (&#8220;ASC 740-10&#8221;).</font><font style="font-family:inherit;font-size:10pt;"> These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASC 740-10</font><font style="font-family:inherit;font-size:10pt;"> requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the company&#8217;s income tax provision or benefit. The recognition and measurement of benefits related to the company&#8217;s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the company&#8217;s assumptions or changes in the company&#8217;s assumptions in future periods are recorded in the period they become known.</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was no income tax expense or benefit for the three and six months periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the company&#8217;s cash equivalents were invested in money market mutual funds. The company&#8217;s investment policy does not allow investment in any debt securities rated less than &#8220;investment grade&#8221; by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Loss</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company follows ASC&#160;820, &#8220;Fair Value Measurements and Disclosures,&#8221; (&#8220;ASC 820&#8221;) for the company&#8217;s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#160;&#8212; quoted prices in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#160;&#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font></div><div style="line-height:120%;padding-left:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#160;&#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font></div><div style="line-height:120%;text-indent:106px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company categorized its cash equivalents as Level&#160;1. The valuations for Level&#160;1 were determined based on a &#8220;market approach&#8221; using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The company categorized its warrants potentially settleable in cash as Level&#160;2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC&#160;718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share.&#8221;</font><font style="font-family:inherit;font-size:10pt;"> Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. </font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents and Patent Application Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PatentsAndPatentApplicationCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)-(d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 825<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 206<br><br><br><br> -Paragraph b<br><br><br><br> -Subparagraph i, ii<br><br><br><br> -Chapter 2<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5212-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3, 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015766794128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantActivityTableTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of warrant activity for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Consultant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and Oxford Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issued</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Outstanding, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,006</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,031</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Expiration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">September 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">April 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">March 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Varies 2014-2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.68</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Strike price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility %</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">76.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free rate %</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in fair value of the warrant liability for the six months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 2015 Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2012</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">April&#160;2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2011</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2010</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of warrants issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability, June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015922209440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">33,719<span></span>
</td>
<td class="nump">19,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">22,308<span></span>
</td>
<td class="nump">9,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share</a></td>
<td class="nump">11,411<span></span>
</td>
<td class="nump">9,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015755885968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember', window );">March 2015 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">72.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember', window );">September 2013 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 2 months 19 days<span></span>
</td>
<td class="text">3 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">75.59%<span></span>
</td>
<td class="nump">75.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">1.08%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember', window );">December 2012 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 5 months 23 days<span></span>
</td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">76.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember', window );">April 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">1 year 9 months 22 days<span></span>
</td>
<td class="text">2 years 3 months 22 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">77.03%<span></span>
</td>
<td class="nump">78.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember', window );">March 2011 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">8 months 5 days<span></span>
</td>
<td class="text">1 year 2 months 5 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">63.12%<span></span>
</td>
<td class="nump">77.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember', window );">March 2010 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">8 months 27 days<span></span>
</td>
<td class="text">1 year 2 months 27 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">64.81%<span></span>
</td>
<td class="nump">77.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandFifteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_SeptemberTwoThousandThirteenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_DecemberTwoThousandTwelveWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_AprilTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandElevenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=gale_MarchTwoThousandTenWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015759023872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2015 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,146,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2014</a></td>
<td class="nump">$ 37,059<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 256,377<span></span>
</td>
<td class="num">$ (215,481)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,158,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="nump">47,416<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">47,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock warrants issued in connection with March 2015 common stock offering</a></td>
<td class="num">(10,296)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(10,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Stock-based compensation for directors and employees</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,391,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2015</a></td>
<td class="nump">$ 49,365<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 294,877<span></span>
</td>
<td class="num">$ (241,678)<span></span>
</td>
<td class="num">$ (3,849)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015770290704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit memos for expiring Zuplenz channel inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,995</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient assistance programs and rebates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory purchases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Zuplenz milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015777593936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014, respectively (in thousands):</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general, and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected lives (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes option activity of the company:</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,682</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable at June&#160;30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.2.0.727</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>260</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityCondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Legal Proceedings, Commitments and Contingencies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Other Income (Expense) (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes</Role>
      <ShortName>Other Income (Expense) (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Significant Customers and Concentration of Credit Risk (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskNotes</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Business and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>Business and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessCombinations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/Warrants</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Other Income (Expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseTables</Role>
      <ShortName>Other Income (Expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OtherIncomeExpenseNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk Significant Customers and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Business and Basis of Presentation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Business and Basis of Presentation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/BusinessCombinationsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredAtEstimatedFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/FairValueMeasurementsReconciliationOfLevel3LiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LongTermDebtDetails</Role>
      <ShortName>Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LongTermDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Legal Proceedings, Commitments and Contingencies Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesDetailsDetails</Role>
      <ShortName>Legal Proceedings, Commitments and Contingencies Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LegalProceedingsCommitmentsAndContingenciesNotes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stockholders' Equity (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockholdersEquityCommonStockAreReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Warrants (Schedule of Warrant Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsScheduleOfWarrantActivityDetail</Role>
      <ShortName>Warrants (Schedule of Warrant Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsFairValueOfWarrantsIsEstimatedUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Warrants (Changes in Fair Value of Warrant Liability) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsChangesInFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Warrants (Changes in Fair Value of Warrant Liability) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Warrants (Warrants Classified as Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/WarrantsWarrantsClassifiedAsEquityDetails</Role>
      <ShortName>Warrants (Warrants Classified as Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/WarrantsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock Based Compensation (Allocated Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAllocatedStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Allocated Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAssumptionsForOptionGrantsIssuedDetail</Role>
      <ShortName>Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock Based Compensation (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock Based Compensation (Stock Option Activity) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock Based Compensation (Stock Option Activity) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Other Income (Expense) Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/OtherIncomeExpenseTableDetails</Role>
      <ShortName>Other Income (Expense) Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/OtherIncomeExpenseTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/NetLossPerShareCommonSharesExcludedFromNetLossDetail</Role>
      <ShortName>Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - License Agreements (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/LicenseAgreements</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Significant Customers and Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskDetails</Role>
      <ShortName>Significant Customers and Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.galenabiopharma.com/role/SignificantCustomersAndConcentrationOfCreditRiskSignificantCustomersAndConcentrationOfCreditRiskTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)'', column(s) 3 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2, 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>gale-20150630.xml</File>
    <File>gale-20150630_cal.xml</File>
    <File>gale-20150630_def.xml</File>
    <File>gale-20150630_lab.xml</File>
    <File>gale-20150630_pre.xml</File>
    <File>gale-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015755366624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Nov. 18, 2014</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May. 08, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_PurchaseAgreementTerm', window );">Purchase Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,358,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_NumberofSharesPerUnit', window );">Number of Shares Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares availabe from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption', window );">Stock Issued During Period, Shares, Overallotment Option</a></td>
<td class="nump">3,653,846<span></span>
</td>
<td class="nump">1,826,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses', window );">Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember', window );">Lincoln Park Capital, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember', window );">MLV &amp; Co. LLC and Maxim Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds', window );">At Market Issuance Sales Agreements, Percent of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds', window );">At Market Issuance Sales Agreements, Maximum Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Maximum Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsMaximumGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements, Percent of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_AtMarketIssuanceSalesAgreementsPercentofGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_NumberofSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_NumberofSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gale_StockIssuedDuringPeriodSharesOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Overallotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gale_StockIssuedDuringPeriodSharesOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gale_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Subparagraph 2<br><br><br><br> -Article 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_LincolnParkCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gale_MLVCo.LLCandMaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140015758402912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company evaluated all events or transactions that occurred after </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, the company did not have any material recognizable or unrecognizable subsequent events.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
